{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": "'\\nDelta of model/method t-test\\nCompare GPT T5 and programmatic with heads up A vs B, A vs C and B vs C for the best effect\\n'"
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\"\"\"\n",
    "Delta of model/method t-test\n",
    "Compare GPT T5 and programmatic with heads up A vs B, A vs C and B vs C for the best effect\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "outputs": [],
   "source": [
    "from tqdm.notebook import tqdm\n",
    "import pingouin as pt\n",
    "import pandas as pd"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "outputs": [],
   "source": [
    "handle_gpt = \"/home/karl/PycharmProjects/DLAI_GPT/gpt-j-6b-main/final_stats/pipeline_results_graded_gpt.txt\"\n",
    "handle_t5 = \"/home/karl/PycharmProjects/DLAI_GPT/gpt-j-6b-main/final_stats/t5_pipeline_graded_results.txt\"\n",
    "handle_prog = \"/home/karl/PycharmProjects/DLAI_GPT/gpt-j-6b-main/final_stats/pipeline_results_graded_prog.txt\"\n",
    "\n",
    "prog_list = []\n",
    "t5_list = []\n",
    "\n",
    "for line1 in open(handle_t5):\n",
    "    t5_list.append(line1.lower())\n",
    "\n",
    "for line2 in open(handle_prog, 'r'):\n",
    "    prog_list.append(line2.lower())\n",
    "\n",
    "merge_prog_t5_list = list(zip(prog_list, t5_list))"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "interacting selectively and non-covalently with a ccr9 chemokine receptor. [goc:mah, goc:nln]|act selectively and non-covalently with a ccr9 chemokine organ.  [ goc : mah , goc : nln ]|1.2888636363636294|94.78197368421053|14.445909090909094|2.399210526315791|16.390128571428573|14.411166666666668|-9.450909090909093|-8.875789473684211|7.6385714285714315|1.7940000000000005|54.195869768830164|44.250742366654144|24.018181818181816|12.221052631578948\n",
      "\n",
      "interacting selectively and non-covalently with a ccr9 chemokine receptor. [goc:mah, goc:nln]|interacting selectively and not binding with a cell receptor. [goc:mah, goc:nln]|1.2888636363636294|32.05250000000001|14.445909090909094|10.155000000000001|16.390128571428573|13.006557142857146|-9.450909090909093|-15.865454545454547|7.6385714285714315|3.937857142857144|54.195869768830164|49.473833993334296|24.018181818181816|20.381818181818183\n",
      "\n",
      "the chemical reactions and pathways resulting in the formation of 2-deoxyribose 1-phosphate, the phosphorylated sugar 1-phospho-2-deoxyribose. [isbn:0198506732]|the process force and path happen in the placement of 2-deoxyribose 1-phosphate, the phosphorylated sugar 1-phospho-2-deoxyribose.  [ isbn: 0198506732]|68.81926470588238|103.625|5.772058823529413|1.2900000000000027|14.683966666666668|13.628071014492756|14.983529411764707|9.208000000000002|14.322857142857139|7.7963768115942|58.53822981607831|49.473833993334296|19.870588235294118|14.0\n",
      "\n",
      "the chemical reactions and pathways resulting in the formation of 2-deoxyribose 1-phosphate, the phosphorylated sugar 1-phospho-2-deoxyribose. [isbn:0198506732]|the chemical reactions and pathways resulting in the formation of a molecule of protein, the phosphorylated sugar 1-deoxyribose. [isbn:0198506732]|68.81926470588238|50.25565789473683|5.772058823529413|8.609736842105267|14.683966666666668|13.180157142857144|14.983529411764707|8.764210526315786|14.322857142857139|11.631428571428572|58.53822981607831|66.37611354998121|19.870588235294118|22.74736842105263\n",
      "\n",
      "any process that modulates the rate, frequency, or extent of protein deacetylation, the removal of an acetyl group from a protein amino acid. an acetyl group is ch3co-, derived from acetic [ethanoic] acid. [goc:tb]|any walk that changes the rate, ratio, or extent of protein deacetylation, the removal of an alkyl group from a protein group acid.  an alkyl group is ch3co-, make from acetic [ethnic] acid.  [ goc: tab]|41.06107843137258|75.98359649122811|10.347647058823533|5.807894736842105|12.786880952380953|11.258404864864865|5.18470588235294|2.3178947368421063|7.280476190476186|2.2556756756756755|74.48509850970193|67.59412548439398|24.533333333333335|19.803508771929824\n",
      "\n",
      "any process that modulates the rate, frequency, or extent of protein deacetylation, the removal of an acetyl group from a protein amino acid. an acetyl group is ch3co-, derived from acetic [ethanoic] acid. [goc:tb]|any process that modulates the rate, frequency, or extent of protein deacetylation, the removal of an acyl group from a protein amino acid, an enzyme that is soluble in fat globule. [goc:tb]|41.06107843137258|42.545000000000016|10.347647058823533|11.3|12.786880952380953|12.3747|5.18470588235294|10.899999999999999|7.280476190476186|8.126470588235296|74.48509850970193|85.69119412168324|24.533333333333335|25.150000000000002\n",
      "\n",
      "the core heterodimer of a condensin complex, a multisubunit protein complex that plays a central role in chromosome condensation. [goc:elh]|the cell part heterodimer of a condensing whole, a multisubunit protein, whole that plays a central role in body compression.  [ goc: eh]|27.485000000000014|64.22999999999999|11.91|7.28166666666667|13.932061904761905|10.19546231884058|5.680000000000003|3.2633333333333354|9.612857142857145|4.724637681159418|69.96656701596841|58.53822981607831|24.0|16.46666666666667\n",
      "\n",
      "the core heterodimer of a condensin complex, a multisubunit protein complex that plays a central role in chromosome condensation. [goc:elh]|the core heterodimer of a protein complex that helps chromosome condensation. [goc:elh]|27.485000000000014|31.545000000000016|11.91|10.350000000000001|13.932061904761905|14.134414285714287|5.680000000000003|-11.603333333333325|9.612857142857145|6.6292857142857144|69.96656701596841|54.195869768830164|24.0|22.400000000000002\n",
      "\n",
      "abnormally decreased blood carbon dioxide (co2) level in the cord blood. []|abnormally change blood carbon dioxide (co2) level in the cord blood.  [ ]|73.84500000000001|103.04428571428575|4.450000000000003|0.6257142857142846|11.086572727272728|10.414066666666667|-17.97333333333333|-16.665714285714287|6.582727272727272|2.942499999999999|49.473833993334296|44.250742366654144|19.06666666666667|14.228571428571428\n",
      "\n",
      "abnormally decreased blood carbon dioxide (co2) level in the cord blood. []|abnormally decreased carbon dioxide (co2) level in the cord blood. []|73.84500000000001|70.50704545454548|4.450000000000003|4.791363636363638|11.086572727272728|12.522027272727273|-17.97333333333333|-21.74545454545455|6.582727272727272|4.870000000000001|49.473833993334296|49.473833993334296|19.06666666666667|20.381818181818183\n",
      "\n",
      "a radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium ra 223, with antineoplastic activity. like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. radium ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. the radioisotope ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing dna double-strand breaks and tumor regression in the skeleton. the short range effects of alpha emission allows for localized dna damage with limited toxicity to nearby healthy bone tissue.|a pharmaceutical plan of the chloride salt of the alpha-emitting atom radium raw 223, with antineoplastic activity.  like calcium, radium aims bone tissue and preferentially increase in osteoblastic lesions, such as those seen in areas of bone metastases.  radium ra 223 forms structure with hydroxyapatite and becomes take_in into the bone mold.  the isotope ra 223 kills bone cancer cells through local flow of high energy alpha body, causing dna double-strand breaks and growth regression in the system.  the short range effects of start flow allow for stage dna change with limited toxicity to nearby healthy bone tissue.|26.236258503401388|53.5564705882353|13.657551020408164|10.012549019607842|12.8393|11.417165384615386|16.317551020408164|12.795294117647064|15.087299999999999|8.484134615384615|88.50148473330829|79.77416029015912|26.125170068027213|22.094117647058823\n",
      "\n",
      "a radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium ra 223, with antineoplastic activity. like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. radium ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. the radioisotope ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing dna double-strand breaks and tumor regression in the skeleton. the short range effects of alpha emission allows for localized dna damage with limited toxicity to nearby healthy bone tissue.|a radiopharmaceutical composed of the dichloride salt of a protein molecule, with anti-cancer activity. like calcium, radium targets bone tissue and preferentially accumulates in areas of bone metastases. radium ra 223 kills bone cancer cells through localized|26.236258503401388|22.83018018018018|13.657551020408164|13.138918918918922|12.8393|13.188479487179487|16.317551020408164|11.756756756756747|15.087299999999999|11.639230769230771|88.50148473330829|76.64453405168562|26.125170068027213|24.392792792792797\n",
      "\n",
      "national early warning score 2 (news2) escalation of care.|national early ride score 2 (news2) increase of care.|70.66750000000002|98.8675|4.520555555555557|0.5872222222222234|12.855122222222224|11.100677777777777|-33.11111111111111|-36.37777777777777|7.666666666666668|5.050000000000001|44.250742366654144|38.32226702584281|19.57777777777778|15.133333333333333\n",
      "\n",
      "national early warning score 2 (news2) escalation of care.|early warning score 2 (news2) escalation of care.|70.66750000000002|86.45000000000002|4.520555555555557|2.1950000000000003|12.855122222222224|12.631922222222224|-33.11111111111111|-42.394999999999996|7.666666666666668|1.7533333333333339|44.250742366654144|38.32226702584281|19.57777777777778|16.6\n",
      "\n",
      "a ganglioside storage disorder caused by a deficiency of enzymes b and c isoenzymes of beta-galactosidase with resulting accumulation of ganglioside mm1 in the brain and large amounts of keratosulfate-like mucopolysaccharide in the visceral organs. the affected infants appear normal at birth . locomotor ataxia, the initial symptoms with onset at about one year of life, is followed by strabismus, inability to control hand movements, slurred speech, muscle weakness of the extremities, rapidly progressive psychomotor deterioration, dullness of senses, lethargy, seizures, decerebrate rigidity, and terminal bronchopneumonia at the age of 3 to 10 years and rarely later.|a disease storage change caused by an amount of enzymes b and c isoenzymes of beta-galactosidase with happen net_income of ganglioside mm1 in the brain and large amounts of keratosulfate-like polysaccharide in the visceral meat.  the refer child appear normal at birth.  locomotor ataxia , the sign symptoms with start at about one year of life , is followed by strabismus , quality to control hand change , talk speech , muscle weakness of the region , rapidly adult psychomotor decline , shape of senses , weakness , attack , get_rid_of rigidity , and contact pneumonia at the age of 3 to 10 years and rarely later .|9.532590206185603|52.79159090909093|17.954097938144333|12.727727272727275|12.668399319727891|10.718800000000002|22.710103092783505|16.444727272727274|21.817619047619047|14.384499999999996|108.39173953766033|98.94766798666859|29.49381443298969|25.545454545454547\n",
      "\n",
      "a ganglioside storage disorder caused by a deficiency of enzymes b and c isoenzymes of beta-galactosidase with resulting accumulation of ganglioside mm1 in the brain and large amounts of keratosulfate-like mucopolysaccharide in the visceral organs. the affected infants appear normal at birth . locomotor ataxia, the initial symptoms with onset at about one year of life, is followed by strabismus, inability to control hand movements, slurred speech, muscle weakness of the extremities, rapidly progressive psychomotor deterioration, dullness of senses, lethargy, seizures, decerebrate rigidity, and terminal bronchopneumonia at the age of 3 to 10 years and rarely later.|a ganglioside storage disorder caused by a deficit of enzymes b and c isoenzymes of beta-galactosidase, the initial symptoms with onset at about one year of life, is followed by slow eye movement, slurred speech|9.532590206185603|21.447142857142865|17.954097938144333|18.962857142857143|12.668399319727891|12.299808108108108|22.710103092783505|21.44685714285714|21.817619047619047|19.21972972972973|108.39173953766033|117.07645963215661|29.49381443298969|30.0\n",
      "\n",
      "the process in which the anatomical structures of the neurocranium are generated and organized during the embryonic phase. the neurocranium is the portion of the vertebrate skull surrounding the brain. [goc:dsf, goc:jid, pmid:16049113]|the walk in which the saying system of the neurocranium are make and join during the embryonic phase.  the neurocranium is the gift of the chordate skull protect the brain.  [ goc : dsf , goc : jid , pmid:16049113 ]|44.415454545454566|99.81689922480624|9.796969696969697|2.8976744186046517|12.335738095238096|9.916961261261262|9.261818181818175|3.005581395348834|10.644761904761907|2.911981981981981|65.13532912329528|51.09635603445709|20.157575757575756|13.175193798449612\n",
      "\n",
      "the process in which the anatomical structures of the neurocranium are generated and organized during the embryonic phase. the neurocranium is the portion of the vertebrate skull surrounding the brain. [goc:dsf, goc:jid, pmid:16049113]|the process in which the anatomical structures of the brain are generated and organized during the embryonic phase. the brain's hair-like projections are the result of cellular contacts between two body parts.|44.415454545454566|47.95833333333337|9.796969696969697|9.220000000000002|12.335738095238096|9.771574509803923|9.261818181818175|5.141250000000003|10.644761904761907|8.617843137254905|65.13532912329528|67.59412548439398|20.157575757575756|21.766666666666666\n",
      "\n",
      "988\n"
     ]
    }
   ],
   "source": [
    "for i in merge_prog_t5_list[0:9]:\n",
    "    print(i[0])\n",
    "    print(i[1])\n",
    "\n",
    "\n",
    "print(len(merge_prog_t5_list))"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "outputs": [
    {
     "data": {
      "text/plain": "0it [00:00, ?it/s]",
      "application/vnd.jupyter.widget-view+json": {
       "version_major": 2,
       "version_minor": 0,
       "model_id": "d971ccbe10c6468db3af45aebae67480"
      }
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "gpt_list = []\n",
    "comb_list = []\n",
    "for line0 in tqdm(open(handle_gpt, 'r')):\n",
    "    gpt_def = line0.split('|')[1].lower()\n",
    "    #print(gpt_def)\n",
    "    for tup in merge_prog_t5_list:\n",
    "        if str(gpt_def.lower()) in str(tup[0].lower()):\n",
    "            #print('lol')\n",
    "            comb_list.append([tup[0],tup[1], '|'.join(line0.split('|')[1:])])\n",
    "\n",
    "#if def_gpt in def_t5\n",
    "#comb_defs = [line0, line1, line2]\n",
    "#comb_list.append(comb_defs)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "interacting selectively and non-covalently with a ccr9 chemokine receptor. [goc:mah, goc:nln]|act selectively and non-covalently with a ccr9 chemokine organ.  [ goc : mah , goc : nln ]|1.2888636363636294|94.78197368421053|14.445909090909094|2.399210526315791|16.390128571428573|14.411166666666668|-9.450909090909093|-8.875789473684211|7.6385714285714315|1.7940000000000005|54.195869768830164|44.250742366654144|24.018181818181816|12.221052631578948\n",
      "\n",
      "interacting selectively and non-covalently with a ccr9 chemokine receptor. [goc:mah, goc:nln]|interacting selectively and not binding with a cell receptor. [goc:mah, goc:nln]|1.2888636363636294|32.05250000000001|14.445909090909094|10.155000000000001|16.390128571428573|13.006557142857146|-9.450909090909093|-15.865454545454547|7.6385714285714315|3.937857142857144|54.195869768830164|49.473833993334296|24.018181818181816|20.381818181818183\n",
      "\n",
      "interacting selectively and non-covalently with a ccr9 chemokine receptor. [goc:mah, goc:nln]| interacting selectively and non-covalently with a membrane receptor|1.2888636363636294|-9.099999999999994|14.445909090909094|16.764444444444447|16.390128571428573|15.665736363636366|-9.450909090909093|6.964444444444446|7.6385714285714315|10.189090909090911|54.195869768830164|69.96656701596841|24.018181818181816|25.822222222222223\n",
      "\n",
      "the chemical reactions and pathways resulting in the formation of 2-deoxyribose 1-phosphate, the phosphorylated sugar 1-phospho-2-deoxyribose. [isbn:0198506732]|the process force and path happen in the placement of 2-deoxyribose 1-phosphate, the phosphorylated sugar 1-phospho-2-deoxyribose.  [ isbn: 0198506732]|68.81926470588238|103.625|5.772058823529413|1.2900000000000027|14.683966666666668|13.628071014492756|14.983529411764707|9.208000000000002|14.322857142857139|7.7963768115942|58.53822981607831|49.473833993334296|19.870588235294118|14.0\n",
      "\n",
      "the chemical reactions and pathways resulting in the formation of 2-deoxyribose 1-phosphate, the phosphorylated sugar 1-phospho-2-deoxyribose. [isbn:0198506732]|the chemical reactions and pathways resulting in the formation of a molecule of protein, the phosphorylated sugar 1-deoxyribose. [isbn:0198506732]|68.81926470588238|50.25565789473683|5.772058823529413|8.609736842105267|14.683966666666668|13.180157142857144|14.983529411764707|8.764210526315786|14.322857142857139|11.631428571428572|58.53822981607831|66.37611354998121|19.870588235294118|22.74736842105263\n",
      "\n",
      "the chemical reactions and pathways resulting in the formation of 2-deoxyribose 1-phosphate, the phosphorylated sugar 1-phospho-2-deoxyribose. [isbn:0198506732]| the chemical reactions and pathways resulting in the formation of two carbon atom molecules (dihybrid) phosphate and two carbon atom molecules (dihybrid) phosphoric acid|68.81926470588238|12.26000000000002|5.772058823529413|17.76|14.683966666666668|15.857638461538462|14.983529411764707|22.734399999999997|14.322857142857139|17.65615384615385|58.53822981607831|125.16|19.870588235294118|35.6\n",
      "\n",
      "any process that modulates the rate, frequency, or extent of protein deacetylation, the removal of an acetyl group from a protein amino acid. an acetyl group is ch3co-, derived from acetic [ethanoic] acid. [goc:tb]|any walk that changes the rate, ratio, or extent of protein deacetylation, the removal of an alkyl group from a protein group acid.  an alkyl group is ch3co-, make from acetic [ethnic] acid.  [ goc: tab]|41.06107843137258|75.98359649122811|10.347647058823533|5.807894736842105|12.786880952380953|11.258404864864865|5.18470588235294|2.3178947368421063|7.280476190476186|2.2556756756756755|74.48509850970193|67.59412548439398|24.533333333333335|19.803508771929824\n",
      "\n",
      "any process that modulates the rate, frequency, or extent of protein deacetylation, the removal of an acetyl group from a protein amino acid. an acetyl group is ch3co-, derived from acetic [ethanoic] acid. [goc:tb]|any process that modulates the rate, frequency, or extent of protein deacetylation, the removal of an acyl group from a protein amino acid, an enzyme that is soluble in fat globule. [goc:tb]|41.06107843137258|42.545000000000016|10.347647058823533|11.3|12.786880952380953|12.3747|5.18470588235294|10.899999999999999|7.280476190476186|8.126470588235296|74.48509850970193|85.69119412168324|24.533333333333335|25.150000000000002\n",
      "\n",
      "any process that modulates the rate, frequency, or extent of protein deacetylation, the removal of an acetyl group from a protein amino acid. an acetyl group is ch3co-, derived from acetic [ethanoic] acid. [goc:tb]| the acetylation (formation) of a protein, the removal of an acetyl group from a protein amino acid|41.06107843137258|38.16500000000002|10.347647058823533|12.407777777777778|12.786880952380953|12.889426315789473|5.18470588235294|10.668888888888887|7.280476190476186|8.149473684210527|74.48509850970193|88.50148473330829|24.533333333333335|24.977777777777778\n",
      "\n",
      "the core heterodimer of a condensin complex, a multisubunit protein complex that plays a central role in chromosome condensation. [goc:elh]|the cell part heterodimer of a condensing whole, a multisubunit protein, whole that plays a central role in body compression.  [ goc: eh]|27.485000000000014|64.22999999999999|11.91|7.28166666666667|13.932061904761905|10.19546231884058|5.680000000000003|3.2633333333333354|9.612857142857145|4.724637681159418|69.96656701596841|58.53822981607831|24.0|16.46666666666667\n",
      "\n",
      "the core heterodimer of a condensin complex, a multisubunit protein complex that plays a central role in chromosome condensation. [goc:elh]|the core heterodimer of a protein complex that helps chromosome condensation. [goc:elh]|27.485000000000014|31.545000000000016|11.91|10.350000000000001|13.932061904761905|14.134414285714287|5.680000000000003|-11.603333333333325|9.612857142857145|6.6292857142857144|69.96656701596841|54.195869768830164|24.0|22.400000000000002\n",
      "\n",
      "the core heterodimer of a condensin complex, a multisubunit protein complex that plays a central role in chromosome condensation. [goc:elh]| the core of a heterodimer of a protein that regulates the shape of the chromosome|27.485000000000014|58.4075|11.91|9.087500000000002|13.932061904761905|10.981464705882354|5.680000000000003|6.489999999999998|9.612857142857145|6.187058823529412|69.96656701596841|62.58|24.0|16.400000000000002\n",
      "\n",
      "abnormally decreased blood carbon dioxide (co2) level in the cord blood. []|abnormally change blood carbon dioxide (co2) level in the cord blood.  [ ]|73.84500000000001|103.04428571428575|4.450000000000003|0.6257142857142846|11.086572727272728|10.414066666666667|-17.97333333333333|-16.665714285714287|6.582727272727272|2.942499999999999|49.473833993334296|44.250742366654144|19.06666666666667|14.228571428571428\n",
      "\n",
      "abnormally decreased blood carbon dioxide (co2) level in the cord blood. []|abnormally decreased carbon dioxide (co2) level in the cord blood. []|73.84500000000001|70.50704545454548|4.450000000000003|4.791363636363638|11.086572727272728|12.522027272727273|-17.97333333333333|-21.74545454545455|6.582727272727272|4.870000000000001|49.473833993334296|49.473833993334296|19.06666666666667|20.381818181818183\n",
      "\n",
      "abnormally decreased blood carbon dioxide (co2) level in the cord blood. []| abnormally decreased blood carbon dioxide level in the cord blood|73.84500000000001|57.23363636363638|4.450000000000003|8.009090909090911|11.086572727272728|12.1267|-17.97333333333333|3.559999999999995|6.582727272727272|7.334999999999997|49.473833993334296|69.96656701596841|19.06666666666667|22.581818181818182\n",
      "\n",
      "a radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium ra 223, with antineoplastic activity. like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. radium ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. the radioisotope ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing dna double-strand breaks and tumor regression in the skeleton. the short range effects of alpha emission allows for localized dna damage with limited toxicity to nearby healthy bone tissue.|a pharmaceutical plan of the chloride salt of the alpha-emitting atom radium raw 223, with antineoplastic activity.  like calcium, radium aims bone tissue and preferentially increase in osteoblastic lesions, such as those seen in areas of bone metastases.  radium ra 223 forms structure with hydroxyapatite and becomes take_in into the bone mold.  the isotope ra 223 kills bone cancer cells through local flow of high energy alpha body, causing dna double-strand breaks and growth regression in the system.  the short range effects of start flow allow for stage dna change with limited toxicity to nearby healthy bone tissue.|26.236258503401388|53.5564705882353|13.657551020408164|10.012549019607842|12.8393|11.417165384615386|16.317551020408164|12.795294117647064|15.087299999999999|8.484134615384615|88.50148473330829|79.77416029015912|26.125170068027213|22.094117647058823\n",
      "\n",
      "a radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium ra 223, with antineoplastic activity. like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. radium ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. the radioisotope ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing dna double-strand breaks and tumor regression in the skeleton. the short range effects of alpha emission allows for localized dna damage with limited toxicity to nearby healthy bone tissue.|a radiopharmaceutical composed of the dichloride salt of a protein molecule, with anti-cancer activity. like calcium, radium targets bone tissue and preferentially accumulates in areas of bone metastases. radium ra 223 kills bone cancer cells through localized|26.236258503401388|22.83018018018018|13.657551020408164|13.138918918918922|12.8393|13.188479487179487|16.317551020408164|11.756756756756747|15.087299999999999|11.639230769230771|88.50148473330829|76.64453405168562|26.125170068027213|24.392792792792797\n",
      "\n",
      "a radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium ra 223, with antineoplastic activity. like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. radium ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. the radioisotope ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing dna double-strand breaks and tumor regression in the skeleton. the short range effects of alpha emission allows for localized dna damage with limited toxicity to nearby healthy bone tissue.| a radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium 225|26.236258503401388|23.42500000000001|13.657551020408164|13.470000000000002|12.8393|14.29885|16.317551020408164|13.717142857142857|15.087299999999999|11.003125000000004|88.50148473330829|76.64453405168562|26.125170068027213|22.742857142857144\n",
      "\n",
      "national early warning score 2 (news2) escalation of care.|national early ride score 2 (news2) increase of care.|70.66750000000002|98.8675|4.520555555555557|0.5872222222222234|12.855122222222224|11.100677777777777|-33.11111111111111|-36.37777777777777|7.666666666666668|5.050000000000001|44.250742366654144|38.32226702584281|19.57777777777778|15.133333333333333\n",
      "\n",
      "national early warning score 2 (news2) escalation of care.|early warning score 2 (news2) escalation of care.|70.66750000000002|86.45000000000002|4.520555555555557|2.1950000000000003|12.855122222222224|12.631922222222224|-33.11111111111111|-42.394999999999996|7.666666666666668|1.7533333333333339|44.250742366654144|38.32226702584281|19.57777777777778|16.6\n",
      "\n",
      "national early warning score 2 (news2) escalation of care.| escalation|70.66750000000002|35.60500000000002|4.520555555555557|8.790000000000003|12.855122222222224|19.5753|-33.11111111111111|-115.66|7.666666666666668|-1.0899999999999999|44.250742366654144|31.29|19.57777777777778|20.8\n",
      "\n",
      "a ganglioside storage disorder caused by a deficiency of enzymes b and c isoenzymes of beta-galactosidase with resulting accumulation of ganglioside mm1 in the brain and large amounts of keratosulfate-like mucopolysaccharide in the visceral organs. the affected infants appear normal at birth . locomotor ataxia, the initial symptoms with onset at about one year of life, is followed by strabismus, inability to control hand movements, slurred speech, muscle weakness of the extremities, rapidly progressive psychomotor deterioration, dullness of senses, lethargy, seizures, decerebrate rigidity, and terminal bronchopneumonia at the age of 3 to 10 years and rarely later.|a disease storage change caused by an amount of enzymes b and c isoenzymes of beta-galactosidase with happen net_income of ganglioside mm1 in the brain and large amounts of keratosulfate-like polysaccharide in the visceral meat.  the refer child appear normal at birth.  locomotor ataxia , the sign symptoms with start at about one year of life , is followed by strabismus , quality to control hand change , talk speech , muscle weakness of the region , rapidly adult psychomotor decline , shape of senses , weakness , attack , get_rid_of rigidity , and contact pneumonia at the age of 3 to 10 years and rarely later .|9.532590206185603|52.79159090909093|17.954097938144333|12.727727272727275|12.668399319727891|10.718800000000002|22.710103092783505|16.444727272727274|21.817619047619047|14.384499999999996|108.39173953766033|98.94766798666859|29.49381443298969|25.545454545454547\n",
      "\n",
      "a ganglioside storage disorder caused by a deficiency of enzymes b and c isoenzymes of beta-galactosidase with resulting accumulation of ganglioside mm1 in the brain and large amounts of keratosulfate-like mucopolysaccharide in the visceral organs. the affected infants appear normal at birth . locomotor ataxia, the initial symptoms with onset at about one year of life, is followed by strabismus, inability to control hand movements, slurred speech, muscle weakness of the extremities, rapidly progressive psychomotor deterioration, dullness of senses, lethargy, seizures, decerebrate rigidity, and terminal bronchopneumonia at the age of 3 to 10 years and rarely later.|a ganglioside storage disorder caused by a deficit of enzymes b and c isoenzymes of beta-galactosidase, the initial symptoms with onset at about one year of life, is followed by slow eye movement, slurred speech|9.532590206185603|21.447142857142865|17.954097938144333|18.962857142857143|12.668399319727891|12.299808108108108|22.710103092783505|21.44685714285714|21.817619047619047|19.21972972972973|108.39173953766033|117.07645963215661|29.49381443298969|30.0\n",
      "\n",
      "a ganglioside storage disorder caused by a deficiency of enzymes b and c isoenzymes of beta-galactosidase with resulting accumulation of ganglioside mm1 in the brain and large amounts of keratosulfate-like mucopolysaccharide in the visceral organs. the affected infants appear normal at birth . locomotor ataxia, the initial symptoms with onset at about one year of life, is followed by strabismus, inability to control hand movements, slurred speech, muscle weakness of the extremities, rapidly progressive psychomotor deterioration, dullness of senses, lethargy, seizures, decerebrate rigidity, and terminal bronchopneumonia at the age of 3 to 10 years and rarely later.| autosomal recessive disease|9.532590206185603|12.425000000000011|17.954097938144333|12.52|12.668399319727891|19.674500000000002|22.710103092783505|-35.78|21.817619047619047|6.504000000000001|108.39173953766033|54.195869768830164|29.49381443298969|31.6\n",
      "\n",
      "the process in which the anatomical structures of the neurocranium are generated and organized during the embryonic phase. the neurocranium is the portion of the vertebrate skull surrounding the brain. [goc:dsf, goc:jid, pmid:16049113]|the walk in which the saying system of the neurocranium are make and join during the embryonic phase.  the neurocranium is the gift of the chordate skull protect the brain.  [ goc : dsf , goc : jid , pmid:16049113 ]|44.415454545454566|99.81689922480624|9.796969696969697|2.8976744186046517|12.335738095238096|9.916961261261262|9.261818181818175|3.005581395348834|10.644761904761907|2.911981981981981|65.13532912329528|51.09635603445709|20.157575757575756|13.175193798449612\n",
      "\n",
      "the process in which the anatomical structures of the neurocranium are generated and organized during the embryonic phase. the neurocranium is the portion of the vertebrate skull surrounding the brain. [goc:dsf, goc:jid, pmid:16049113]|the process in which the anatomical structures of the brain are generated and organized during the embryonic phase. the brain's hair-like projections are the result of cellular contacts between two body parts.|44.415454545454566|47.95833333333337|9.796969696969697|9.220000000000002|12.335738095238096|9.771574509803923|9.261818181818175|5.141250000000003|10.644761904761907|8.617843137254905|65.13532912329528|67.59412548439398|20.157575757575756|21.766666666666666\n",
      "\n",
      "the process in which the anatomical structures of the neurocranium are generated and organized during the embryonic phase. the neurocranium is the portion of the vertebrate skull surrounding the brain. [goc:dsf, goc:jid, pmid:16049113]| the process in which the anatomical structures of the neurocranium are generated and organized during the embryonic phase|44.415454545454566|27.255263157894774|9.796969696969697|14.177894736842106|12.335738095238096|12.5235|9.261818181818175|16.91578947368421|10.644761904761907|13.532999999999994|65.13532912329528|88.50148473330829|20.157575757575756|24.442105263157895\n",
      "\n",
      "a fusion gene that results from a chromosomal translocation t(5;17)(q33-34;q11.2) which fuses exon 40 of the myo18a gene to exon 10 of the pdgfrb gene. this rearrangement is associated with eosinophilia associated with atypical myeloproliferative neoplasm.|a molecular research technique, gene that results from a chromosomal translocation t (5 ; 17) (q33-34; q11. 2) which melt exon 40 of the myo18a gene to exon 10 of the pdgfrb gene.  this arrangement is uniting with symptom associated with atypical myeloproliferative growth.|42.60000000000002|71.33625000000004|9.553333333333335|6.104166666666664|14.369505405405405|14.907166666666669|3.2077777777777783|3.611555555555551|15.443513513513516|8.991999999999997|58.53822981607831|58.53822981607831|19.15555555555556|16.944444444444446\n",
      "\n",
      "a fusion gene that results from a chromosomal translocation t(5;17)(q33-34;q11.2) which fuses exon 40 of the myo18a gene to exon 10 of the pdgfrb gene. this rearrangement is associated with eosinophilia associated with atypical myeloproliferative neoplasm.|a gene that results from a chromosomal translocation t(5;17)(q33-34;q11.2) which fuses exon 40 of the myo18a gene to the pdgfrb gene. this rearrangement is associated with eos|42.60000000000002|75.50000000000003|9.553333333333335|4.964444444444446|14.369505405405405|13.611906896551725|3.2077777777777783|-0.22222222222222143|15.443513513513516|9.694827586206895|58.53822981607831|47.79626449838941|19.15555555555556|13.97037037037037\n",
      "\n",
      "a fusion gene that results from a chromosomal translocation t(5;17)(q33-34;q11.2) which fuses exon 40 of the myo18a gene to exon 10 of the pdgfrb gene. this rearrangement is associated with eosinophilia associated with atypical myeloproliferative neoplasm.| a fusion gene that results from a chromosomal translocation fuses gene|42.60000000000002|53.655|9.553333333333335|8.756666666666668|14.369505405405405|15.212838461538462|3.2077777777777783|5.223333333333336|15.443513513513516|7.533076923076923|58.53822981607831|69.96656701596841|19.15555555555556|21.46666666666667\n",
      "\n",
      "cell-surface molecules that exhibit lineage-restricted patterns of expression during embryonic development. the antigens are useful markers in the identification of embryonic stem cells.|a cell - surface unit that walk lineage-restricted match of squeeze during embryonic section.  the substance is useful markers in the identity of embryonic stem cells.|-3.2510144927535976|59.83333333333337|15.61739130434783|7.149629629629633|11.8357|9.931048148148149|3.318260869565215|-2.1822222222222187|14.964000000000006|7.143333333333331|67.59412548439398|59.91578840339164|27.414492753623193|19.8962962962963\n",
      "\n",
      "cell-surface molecules that exhibit lineage-restricted patterns of expression during embryonic development. the antigens are useful markers in the identification of embryonic stem cells.|cell-surface molecules that exhibit lineage-restricted patterns of expression during embryonic development. the antigens are useful markers in the identification of embryonic stem cells.|-3.2510144927535976|-3.2510144927535976|15.61739130434783|15.61739130434783|12.4673|12.568674358974361|3.318260869565215|3.5739130434782567|14.964000000000006|12.069102564102565|67.59412548439398|67.59412548439398|27.414492753623193|27.414492753623193\n",
      "\n",
      "cell-surface molecules that exhibit lineage-restricted patterns of expression during embryonic development. the antigens are useful markers in the identification of embryonic stem cells.| cell-surface molecules that exhibit patterns of expression restricted to a particular cell|-3.2510144927535976|17.932307692307717|15.61739130434783|13.98769230769231|11.8357|12.801833333333335|3.318260869565215|13.415384615384614|14.964000000000006|11.189999999999998|67.59412548439398|82.78555852321104|27.414492753623193|26.738461538461536\n",
      "\n",
      "<p>indication of status as incarcerated.</p>|< p > datum of status as incarcerated.  < /p >|-15.662499999999966|109.09500000000001|16.065000000000005|-0.4666666666666668|16.36401111111111|17.092433333333332|-71.35999999999999|-32.18333333333333|4.003333333333334|-4.692500000000003|38.32226702584281|38.32226702584281|25.0|12.4\n",
      "\n",
      "<p>indication of status as incarcerated.</p>|indication of status as incarcerated.|-15.662499999999966|-15.662499999999966|16.065000000000005|16.065000000000005|16.36401111111111|14.311966666666669|-71.35999999999999|-78.416|4.003333333333334|5.975000000000001|38.32226702584281|38.32226702584281|25.0|25.0\n",
      "\n",
      "<p>indication of status as incarcerated.</p>| indication|-15.662499999999966|35.60500000000002|16.065000000000005|8.790000000000003|16.36401111111111|19.5753|-71.35999999999999|-115.66|4.003333333333334|-1.0899999999999999|38.32226702584281|31.29|25.0|20.8\n",
      "\n",
      "interacting selectively and non-covalently with a h4 histamine receptor. [goc:mah, goc:nln]|act selectively and non-covalently with an h4 amine organ.  [ goc : mah , goc : nln ]|1.2888636363636294|99.23460526315789|14.445909090909094|1.778157894736843|16.390128571428573|14.411166666666668|-10.520000000000003|-10.423157894736843|6.965714285714284|0.2240000000000002|54.195869768830164|44.250742366654144|24.018181818181816|12.221052631578948\n",
      "\n",
      "interacting selectively and non-covalently with a h4 histamine receptor. [goc:mah, goc:nln]|interacting selectively and not binding with a h4 receptor. [goc:mah, goc:nln]|1.2888636363636294|39.7434090909091|14.445909090909094|9.08227272727273|16.390128571428573|14.134414285714287|-10.520000000000003|-16.934545454545457|6.965714285714284|3.2650000000000006|54.195869768830164|49.473833993334296|24.018181818181816|20.381818181818183\n",
      "\n",
      "interacting selectively and non-covalently with a h4 histamine receptor. [goc:mah, goc:nln]| Specifically binding to a histamine h4 receptor|1.2888636363636294|40.09|14.445909090909094|9.655000000000001|16.390128571428573|14.60956666666667|-10.520000000000003|-6.130000000000003|6.965714285714284|5.573333333333334|54.195869768830164|62.58|24.018181818181816|23.200000000000003\n",
      "\n",
      "a disorder characterized by inflammation of the wall of a vein.|a change distinguishes by burning on the wall of a vein.|47.434318181818185|85.88886363636365|8.009545454545457|2.6459090909090897|9.923918181818184|7.053009090909091|-25.48727272727273|-29.229090909090914|6.335454545454546|3.3381818181818197|38.32226702584281|31.29|13.109090909090908|9.472727272727274\n",
      "\n",
      "a disorder characterized by inflammation of the wall of a vein.|a disorder characterized by inflammation of the wall of a vein.|47.434318181818185|47.434318181818185|8.009545454545457|8.009545454545457|9.923918181818184|10.513266666666667|-25.48727272727273|-24.952727272727277|6.335454545454546|2.3725000000000023|38.32226702584281|38.32226702584281|13.109090909090908|13.109090909090908\n",
      "\n",
      "a disorder characterized by inflammation of the wall of a vein.| an inflammation|47.434318181818185|62.79000000000002|8.009545454545457|5.246666666666666|9.923918181818184|15.6774|-25.48727272727273|-69.26666666666665|6.335454545454546|-0.5899999999999999|38.32226702584281|31.29|13.109090909090908|14.533333333333331\n",
      "\n",
      "the maximum blood pressure in the systemic arterial circulation during the cardiac cycle.|the maximum blood pressure in the systemic arterial spread during the cardiac ride.|31.037500000000023|57.06826923076926|10.545000000000002|6.91423076923077|12.783607692307694|10.354376923076924|-10.71076923076923|-13.424615384615386|12.605384615384615|10.431538461538462|62.58|54.195869768830164|27.21538461538462|21.06153846153846\n",
      "\n",
      "the maximum blood pressure in the systemic arterial circulation during the cardiac cycle.|the maximum blood pressure in the systemic blood vessels during the heart cycle.|31.037500000000023|63.57596153846157|10.545000000000002|6.006538461538462|12.783607692307694|9.622985714285715|-10.71076923076923|-14.329230769230772|12.605384615384615|4.947142857142854|62.58|54.195869768830164|27.21538461538462|21.06153846153846\n",
      "\n",
      "the maximum blood pressure in the systemic arterial circulation during the cardiac cycle.| the maximum blood pressure in the systemic circulation during the cardiac cycle|31.037500000000023|43.963076923076954|10.545000000000002|10.356923076923078|12.783607692307694|13.353757142857145|-10.71076923076923|8.439999999999998|12.605384615384615|9.120000000000001|62.58|82.78555852321104|27.21538461538462|26.738461538461536\n",
      "\n",
      "symptomatic; altered gi function (e.g., altered dietary habits, diarrhea, or gi fluid loss); iv fluids indicated <24 hrs|symptomatic; edit i serve (e.g., edit fare dress, diarrhea, or gi fluid loss); iv fluids inform < 24 hrs|45.64500000000001|89.09087719298246|8.383333333333333|2.4063157894736875|17.875742105263157|15.382584210526316|-15.686666666666667|-20.122105263157895|11.867894736842103|7.653684210526315|54.195869768830164|44.250742366654144|22.400000000000002|15.164912280701754\n",
      "\n",
      "symptomatic; altered gi function (e.g., altered dietary habits, diarrhea, or gi fluid loss); iv fluids indicated <24 hrs|symptomatic; altered gi function (e.g., changed dietary habits, diarrhea, or fluid loss); iv fluids indicated 24 hrs.|45.64500000000001|53.2271323529412|8.383333333333333|6.8910294117647055|17.875742105263157|16.36401111111111|-15.686666666666667|-34.367058823529405|11.867894736842103|7.666666666666668|54.195869768830164|44.250742366654144|22.400000000000002|20.523529411764706\n",
      "\n",
      "symptomatic; altered gi function (e.g., altered dietary habits, diarrhea, or gi fluid loss); iv fluids indicated <24 hrs| symptomatic; altered gastrointestinal function|45.64500000000001|-35.11999999999995|8.383333333333333|19.400000000000002|17.875742105263157|19.7241|-15.686666666666667|-7.455999999999996|11.867894736842103|16.11|54.195869768830164|62.58|22.400000000000002|34.0\n",
      "\n",
      "human cdkl5 wild-type allele is located in the vicinity of xp22 and is approximately 228 kb in length. this allele, which encodes cyclin-dependent kinase-like 5 protein, is involved in the mediation of protein phosphorylation. translocations and mutations involving the gene are associated with x-linked infantile spasm syndrome 2. rett syndrome also is associated with defects in the gene.|human cdkl5 wild-type gene is located in the section of xp22 and is approximately 228 kb in length.  this gene, which convert cyclin-dependent kinase-like 5 protein, is having in the mediation of protein phosphorylation.  translocations and change, absorb the gene are uniting with x-linked infantile spasm syndrome 2.  rett syndrome also is united with glee in the gene.|44.82306896551725|68.24544262295082|9.889172413793109|6.771278688524593|13.828364516129033|13.328148351648352|8.242068965517245|5.716065573770493|10.857580645161292|5.168703296703299|71.35217810270406|64.12541789337516|22.571034482758623|18.650491803278687\n",
      "\n",
      "human cdkl5 wild-type allele is located in the vicinity of xp22 and is approximately 228 kb in length. this allele, which encodes cyclin-dependent kinase-like 5 protein, is involved in the mediation of protein phosphorylation. translocations and mutations involving the gene are associated with x-linked infantile spasm syndrome 2. rett syndrome also is associated with defects in the gene.|normal human cdkl5 gene is located in the vicinity of chromosome location, xp22, and is about 228 kilobases in length. this gene, which encodes cyclin-dependent kinase-like 5 protein, is associated with defects in|44.82306896551725|41.39659090909092|9.889172413793109|11.584393939393944|13.828364516129033|13.740133333333334|8.242068965517245|14.489696969696972|10.857580645161292|10.465833333333332|71.35217810270406|82.78555852321104|22.571034482758623|23.56969696969697\n",
      "\n",
      "human cdkl5 wild-type allele is located in the vicinity of xp22 and is approximately 228 kb in length. this allele, which encodes cyclin-dependent kinase-like 5 protein, is involved in the mediation of protein phosphorylation. translocations and mutations involving the gene are associated with x-linked infantile spasm syndrome 2. rett syndrome also is associated with defects in the gene.| human cyclin-dependent kinase-like 5 is a cyclin-dependent kinase|44.82306896551725|9.700000000000017|9.889172413793109|14.142222222222227|13.828364516129033|16.427453846153846|8.242068965517245|5.657777777777774|10.857580645161292|5.721538461538465|71.35217810270406|69.96656701596841|22.571034482758623|25.822222222222223\n",
      "\n",
      "devices that cover the nose and mouth to maintain aseptic conditions or to administer inhaled anesthetics or other gases. they are typically composed of rubber, plastic or paper products.|an emblem that cover the nose and mouth to have aseptic conditions or to direct breathe drug or other gases.  they are typically planned of rubber, plastic or paper products.|39.49229885057474|73.54021505376345|10.152413793103449|5.569032258064517|10.345010344827585|8.223872043010754|1.6179310344827513|-1.3316129032258033|11.156551724137934|5.3115053763440905|72.26115969177356|62.58|25.935632183908048|19.617204301075272\n",
      "\n",
      "devices that cover the nose and mouth to maintain aseptic conditions or to administer inhaled anesthetics or other gases. they are typically composed of rubber, plastic or paper products.|devices that cover the nose and mouth to maintain aseptic conditions or to administer anesthetics or other gases. they are typically composed of rubber, plastic or paper products.|39.49229885057474|43.26880952380955|10.152413793103449|9.542857142857144|10.345010344827585|10.105277011494252|1.6179310344827513|0.4157142857142837|11.156551724137934|7.765402298850574|72.26115969177356|69.96656701596841|25.935632183908048|25.161904761904765\n",
      "\n",
      "devices that cover the nose and mouth to maintain aseptic conditions or to administer inhaled anesthetics or other gases. they are typically composed of rubber, plastic or paper products.| devices that cover the nose and mouth to maintain clean conditions or to administer inhaled anesthetics or gases. they are typically composed of rubber, plastic or paper products.|39.49229885057474|51.16126436781613|10.152413793103449|8.524827586206897|10.345010344827585|10.448500000000001|1.6179310344827513|0.4013793103448293|11.156551724137934|7.277000000000001|72.26115969177356|67.59412548439398|25.935632183908048|23.177011494252874\n",
      "\n",
      "the tendons that connect the muscles and bones that comprise the glenohumeral and acromioclavicular joints and enable abduction of the arm and stabilization of the shoulder.|the body part that hit the muscles and white that be the glenohumeral and acromioclavicular joints and change the motion of the arm and improvement of the thrust.|30.947692307692336|62.70357142857142|12.172307692307694|7.991428571428575|10.391869230769231|8.9728|10.701538461538458|7.2071428571428555|18.19961538461539|15.110714285714288|73.38155456243756|54.195869768830164|22.123076923076923|14.171428571428573\n",
      "\n",
      "the tendons that connect the muscles and bones that comprise the glenohumeral and acromioclavicular joints and enable abduction of the arm and stabilization of the shoulder.|the tendons that connect the muscles and bones that comprise the glenohumeral and acromioclavicular joints and enable abduction and stabilization of the shoulder.|30.947692307692336|22.2842391304348|12.172307692307694|13.008043478260873|10.391869230769231|10.810866666666666|10.701538461538458|10.307826086956517|18.19961538461539|12.044999999999995|73.38155456243756|73.38155456243756|22.123076923076923|23.730434782608697\n",
      "\n",
      "the tendons that connect the muscles and bones that comprise the glenohumeral and acromioclavicular joints and enable abduction of the arm and stabilization of the shoulder.| the tendons that connect the muscles and connect the glenohumeral joint and the acromioclavicular joint enable abduction of the arm and stabilization of the shoulder.|30.947692307692336|37.455384615384645|12.172307692307694|11.264615384615386|10.391869230769231|10.739062962962963|10.701538461538458|9.570769230769226|18.19961538461539|10.265555555555558|73.38155456243756|69.96656701596841|22.123076923076923|20.58461538461539\n",
      "\n",
      "<p>code for acuity assessment</p>|< p > code for sight act < /p >|33.57500000000002|145.925|9.57|-4.609999999999999|17.84955|15.185500000000001|-29.9|-16.663999999999998|0.2325000000000017|-6.068|44.250742366654144|0.0|21.6|4.0\n",
      "\n",
      "<p>code for acuity assessment</p>|acute lung disease|33.57500000000002|62.79000000000002|9.57|5.246666666666666|17.84955|19.6249|-29.9|-65.34666666666666|0.2325000000000017|0.5874999999999986|44.250742366654144|44.250742366654144|21.6|27.866666666666664\n",
      "\n",
      "<p>code for acuity assessment</p>| <p>code|33.57500000000002|162.505|9.57|-8.91|17.84955|19.7241|-29.9|-124.48|0.2325000000000017|-11.365|44.250742366654144|0.0|21.6|0.8\n",
      "\n",
      "molecular assay reagents intended to identify deletions or duplications of the carnitine palmitoyltransferase 1a (cpt1a) gene, located at chromosome 11q13.2, which encodes the liver isoform of carnitine o-palmitoyltransferase. genetic variants at this locus have been associated with carnitine palmitoyltransferase i deficiency.|molecular act reagents convey to identify deletions or copying of the carnitine palmitoyltransferase 1a (cpt1a) gene, located at body 11q13. 2, which convert the liver isoform of carnitine o-palmitoyltransferase.  genetic type in this set have been united with carnitine palmitoyltransferase i amount.|2.4702743902439295|32.626075581395355|15.461158536585366|11.379244186046513|14.452861904761905|13.335557575757576|12.42536585365854|7.881860465116283|20.582142857142863|12.878787878787882|75.03078418222748|69.96656701596841|26.539024390243902|22.9046511627907\n",
      "\n",
      "molecular assay reagents intended to identify deletions or duplications of the carnitine palmitoyltransferase 1a (cpt1a) gene, located at chromosome 11q13.2, which encodes the liver isoform of carnitine o-palmitoyltransferase. genetic variants at this locus have been associated with carnitine palmitoyltransferase i deficiency.|molecular assay reagents intended to identify deletions or duplications of a gene, located at chromosome 11q13.2,, which encodes the liver isoform of carnitine palmitoyltransferase i deficit.|2.4702743902439295|9.315256410256438|15.461158536585366|14.113076923076925|14.452861904761905|13.663137037037037|12.42536585365854|3.613846153846147|20.582142857142863|13.754444444444445|75.03078418222748|69.96656701596841|26.539024390243902|26.54358974358974\n",
      "\n",
      "molecular assay reagents intended to identify deletions or duplications of the carnitine palmitoyltransferase 1a (cpt1a) gene, located at chromosome 11q13.2, which encodes the liver isoform of carnitine o-palmitoyltransferase. genetic variants at this locus have been associated with carnitine palmitoyltransferase i deficiency.| molecular biology reagents intended to identify changes in the size of a gene|2.4702743902439295|35.5107142857143|15.461158536585366|11.784285714285716|14.452861904761905|11.749166666666667|12.42536585365854|6.5771428571428565|20.582142857142863|7.1080000000000005|75.03078418222748|76.64453405168562|26.539024390243902|22.742857142857144\n",
      "\n",
      "<p>lymphocyte microcytotoxicity assay</p>|< p > lymphocyte microcytotoxicity act < /p >|-162.80999999999995|66.10000000000002|36.71333333333334|6.2755555555555596|19.773699999999998|18.118455555555556|-22.22666666666666|-8.715555555555557|8.311428571428571|2.43333333333333|54.195869768830164|44.250742366654144|41.2|12.488888888888889\n",
      "\n",
      "<p>lymphocyte microcytotoxicity assay</p>|blood clot assay|-162.80999999999995|90.99000000000004|36.71333333333334|1.3133333333333361|19.773699999999998|15.6774|-22.22666666666666|-69.26666666666665|8.311428571428571|-1.7674999999999983|54.195869768830164|31.29|41.2|14.533333333333331\n",
      "\n",
      "<p>lymphocyte microcytotoxicity assay</p>| assay|-162.80999999999995|120.20500000000001|36.71333333333334|-3.01|19.773699999999998|19.5753|-22.22666666666666|-130.36|8.311428571428571|-8.94|54.195869768830164|31.29|41.2|20.8\n",
      "\n",
      "a muscle located at the posterior and medial aspect of the thigh that extends the hip joint, flexes the knee joint and assists in medially rotating the knee. (cdisc)|a muscle located on the tooth and the medial aspect of the thigh that use the hip joint, move the knee joint and help in medially grow the knee.  ( cdisc)|66.67612068965518|92.77625|7.561551724137935|4.293749999999999|11.978458620689656|9.498848387096775|7.364137931034488|4.10125|7.421034482758621|4.552258064516131|69.96656701596841|49.473833993334296|19.593103448275865|12.65\n",
      "\n",
      "a muscle located at the posterior and medial aspect of the thigh that extends the hip joint, flexes the knee joint and assists in medially rotating the knee. (cdisc)|a muscle located at the back and medial aspect of the thigh that extends the hip joint, flexes and assists in medially rotating the knee. (cdisc)|66.67612068965518|69.99384615384618|7.561551724137935|6.726153846153846|11.978458620689656|11.908692592592592|7.364137931034488|4.595384615384617|7.421034482758621|5.73|69.96656701596841|66.37611354998121|19.593103448275865|19.046153846153846\n",
      "\n",
      "a muscle located at the posterior and medial aspect of the thigh that extends the hip joint, flexes the knee joint and assists in medially rotating the knee. (cdisc)| a muscle located at the posterior and medial aspect of the thigh that flexes the hip joint, extends the knee joint and rotates the knee|66.67612068965518|63.306538461538494|7.561551724137935|10.888461538461542|11.978458620689656|12.578292592592591|7.364137931034488|13.94461538461538|7.421034482758621|11.607777777777777|69.96656701596841|88.50148473330829|19.593103448275865|22.707692307692312\n",
      "\n",
      "the division of the peripheral nervous system that comprises the afferent loop of the somatic nervous system, which functions to relay somatosensory perception, including touch, heat, and cold to the spinal cord and cns.|the division of the peripheral nervous system that include the nerve loop of the somatic nervous system, which serve to race somatosensory perception, including touch, heat, and cold to the spinal cord and cns.|40.2858823529412|52.72705882352943|11.863529411764706|10.128235294117648|12.75348823529412|11.360252941176471|14.928235294117645|13.198823529411765|20.78235294117647|19.397058823529413|85.69119412168324|76.64453405168562|24.447058823529414|20.917647058823533\n",
      "\n",
      "the division of the peripheral nervous system that comprises the afferent loop of the somatic nervous system, which functions to relay somatosensory perception, including touch, heat, and cold to the spinal cord and cns.|the division of the peripheral nervous system that comprises the somatosensory representation, including touch, heat, and cold to the spinal cord and cns.|40.2858823529412|36.997282608695684|11.863529411764706|10.955869565217395|12.75348823529412|11.468783333333334|14.928235294117645|8.262608695652176|20.78235294117647|9.88625|85.69119412168324|66.37611354998121|24.447058823529414|20.252173913043478\n",
      "\n",
      "the division of the peripheral nervous system that comprises the afferent loop of the somatic nervous system, which functions to relay somatosensory perception, including touch, heat, and cold to the spinal cord and cns.| the division of the peripheral nervous system|40.2858823529412|50.66500000000002|11.863529411764706|8.180000000000003|12.75348823529412|14.60956666666667|14.928235294117645|-7.600000000000001|20.78235294117647|4.526666666666667|85.69119412168324|62.58|24.447058823529414|23.200000000000003\n",
      "\n",
      "molecular variants of the desired biological product formed during manufacture and/or storage, which are active and have no deleterious effect on the safety and efficacy of the drug substance or drug product. these variants possess properties comparable to the desired product and are not considered impurities.|molecular type of the wish biological product formed during make and/or storage, which are active and have no deleterious effect on the safety and effectiveness of the drug substance or drug product.  these types have properties comparable to the wish product and are not considered a condition.|33.10644927536234|54.88249999999999|12.450869565217396|9.57916666666667|12.329039130434783|11.338225000000001|14.697391304347828|11.880000000000003|16.99891304347826|10.708750000000002|86.63808689023553|74.48509850970193|26.133333333333333|20.56666666666667\n",
      "\n",
      "molecular variants of the desired biological product formed during manufacture and/or storage, which are active and have no deleterious effect on the safety and efficacy of the drug substance or drug product. these variants possess properties comparable to the desired product and are not considered impurities.|molecular variants of the desired biological product formed during manufacture and/or storage, which are active and have no deleterious effect on the safety and efficacy of these substances and are not considered impurities.|33.10644927536234|26.014772727272742|12.450869565217396|13.729848484848485|12.329039130434783|11.445876470588235|14.697391304347828|16.449696969696973|16.99891304347826|13.529117647058818|86.63808689023553|88.50148473330829|26.133333333333333|25.993939393939396\n",
      "\n",
      "molecular variants of the desired biological product formed during manufacture and/or storage, which are active and have no deleterious effect on the safety and efficacy of the drug substance or drug product. these variants possess properties comparable to the desired product and are not considered impurities.| Variants of the substance|33.10644927536234|100.24000000000002|12.450869565217396|0.5199999999999996|12.329039130434783|14.460766666666668|14.697391304347828|-32.152|16.99891304347826|0.41000000000000014|86.63808689023553|44.250742366654144|26.133333333333333|18.0\n",
      "\n",
      "amino sugar derivative of galactose, substituted at the 2 position; occurs in a variety of glycosaminoglycans and complex polysaccharides, such as blood group substances, and is generally acetylated.|group sugar word of sucrose, supplant at the 2 position; occurs in a difference of glycosaminoglycans and whole carbohydrate, such as blood group matter, and is generally change.|-3.767857142857139|47.59642857142859|17.262857142857147|10.098571428571429|12.920300000000001|9.536728571428572|14.977142857142862|10.567142857142859|20.661785714285713|17.129285714285714|82.78555852321104|69.96656701596841|25.6|19.885714285714286\n",
      "\n",
      "amino sugar derivative of galactose, substituted at the 2 position; occurs in a variety of glycosaminoglycans and complex polysaccharides, such as blood group substances, and is generally acetylated.|protein building blocks, substituted at the 2 position; occurs in a variety of sugars and complex polysaccharides, such as blood group substances, and is generally acetylated.|-3.767857142857139|24.440000000000026|17.262857142857147|13.080000000000002|12.920300000000001|11.323877777777778|14.977142857142862|11.379999999999992|20.661785714285713|10.788888888888884|82.78555852321104|76.64453405168562|25.6|23.661538461538463\n",
      "\n",
      "amino sugar derivative of galactose, substituted at the 2 position; occurs in a variety of glycosaminoglycans and complex polysaccharides, such as blood group substances, and is generally acetylated.| amino sugar of glucose substituted at position 2|-3.767857142857139|47.30000000000004|17.262857142857147|8.89777777777778|12.920300000000001|15.185500000000001|14.977142857142862|-5.448888888888881|20.661785714285713|3.8230000000000004|82.78555852321104|69.96656701596841|25.6|25.822222222222223\n",
      "\n",
      "the date (and time) on which the seriousness code was assigned to the adverse event.|the date (and time) on which the trait code was transferred to the adverse event.|80.78250000000001|97.7025|3.8550000000000004|1.495000000000001|9.643833333333333|9.643833333333333|-12.026666666666664|-13.20266666666667|7.1080000000000005|6.166|44.250742366654144|38.32226702584281|13.66666666666667|11.0\n",
      "\n",
      "the date (and time) on which the seriousness code was assigned to the adverse event.|the date (and time) on which the seriousness code was assigned to a bad event.|80.78250000000001|86.42250000000001|3.8550000000000004|3.068333333333335|9.643833333333333|8.967675|-12.026666666666664|-13.986666666666672|7.1080000000000005|0.8212499999999991|44.250742366654144|38.32226702584281|13.66666666666667|11.0\n",
      "\n",
      "the date (and time) on which the seriousness code was assigned to the adverse event.| the date and time the seriousness code was assigned to the adverse event|80.78250000000001|77.81071428571428|3.8550000000000004|5.884285714285717|9.643833333333333|11.749166666666667|-12.026666666666664|4.477142857142855|7.1080000000000005|5.538000000000004|44.250742366654144|62.58|13.66666666666667|17.02857142857143\n",
      "\n",
      "an infection of any part of the eye, including the eyelid.|an ill_health of any part of the eye, including the eyelid.|78.19795454545455|85.88886363636365|3.7186363636363637|2.6459090909090897|8.488463636363637|8.488463636363637|-28.160000000000007|-27.625454545454552|3.7663636363636357|4.194545454545455|44.250742366654144|44.250742366654144|16.745454545454546|16.745454545454546\n",
      "\n",
      "an infection of any part of the eye, including the eyelid.|an infection of any part of the eye, including the lid.|78.19795454545455|85.88886363636365|3.7186363636363637|2.6459090909090897|8.488463636363637|7.8816|-28.160000000000007|-29.229090909090914|3.7663636363636357|-1.1600000000000001|44.250742366654144|38.32226702584281|16.745454545454546|13.109090909090908\n",
      "\n",
      "an infection of any part of the eye, including the eyelid.| an infection, which is also called an inflammation|78.19795454545455|66.10000000000002|3.7186363636363637|6.2755555555555596|8.488463636363637|10.448500000000001|-28.160000000000007|-4.142222222222216|3.7663636363636357|4.2940000000000005|44.250742366654144|54.195869768830164|16.745454545454546|16.933333333333334\n",
      "\n",
      "low-grade appendiceal mucinous neoplasm confined by the muscularis propria. acellular mucin or mucinous epithelium may invade into the muscularis propria. t1 and t2 are not applicable to lamn. acellular mucin or mucinous epithelium that extends into the subserosa or serosa should be classified as t3 or t4a, respectively. (from ajcc 8th ed.)|low-grade functional concept mucinous growth hold by the muscularis propria.  acellular machine or mucinous epithelium may invade into the muscularis propria.  t1 and t2 are not applicable to the loan.  acellular machine or mucinous epithelium that use into the subserosa or membrane should be assigned as t3 or t4a, respectively.  ( from ajcc 8th ed.)|36.97294871794875|59.199929378531095|10.255384615384614|7.445000000000004|13.748427044025156|12.5182206779661|-1.248461538461548|-0.8013559322033963|12.464088050314466|7.541016949152542|65.13532912329528|62.58|23.46666666666667|20.204519774011303\n",
      "\n",
      "low-grade appendiceal mucinous neoplasm confined by the muscularis propria. acellular mucin or mucinous epithelium may invade into the muscularis propria. t1 and t2 are not applicable to lamn. acellular mucin or mucinous epithelium that extends into the subserosa or serosa should be classified as t3 or t4a, respectively. (from ajcc 8th ed.)|low-grade appendiceal mucusosal tumor confined by the muscularis propria. acellular mucin or mucinous epithelium may invade into the subcutaneous tissue surrounding the intestines|36.97294871794875|-14.49836956521736|10.255384615384614|18.138478260869565|13.39792037735849|14.3621|-1.248461538461548|14.653913043478262|8.930754716981134|14.2104|65.13532912329528|91.22524239485473|23.46666666666667|34.165217391304346\n",
      "\n",
      "low-grade appendiceal mucinous neoplasm confined by the muscularis propria. acellular mucin or mucinous epithelium may invade into the muscularis propria. t1 and t2 are not applicable to lamn. acellular mucin or mucinous epithelium that extends into the subserosa or serosa should be classified as t3 or t4a, respectively. (from ajcc 8th ed.)| mucinous epithelial neoplasm|36.97294871794875|12.425000000000011|10.255384615384614|12.52|13.39792037735849|19.674500000000002|-1.248461538461548|-34.31|8.930754716981134|7.445999999999998|65.13532912329528|54.195869768830164|23.46666666666667|31.6\n",
      "\n",
      "quality of life enjoyment and satisfaction questionnaire - with regard to your physical health, during the past week how much of the time have you: been free of worry about your physical health?|quality of life pleasure and change form - to look to your physical health, during the past week how much of the time have you: been free of worry about your physical health?|47.72181818181819|65.66727272727275|14.801212121212124|12.29818181818182|8.6777625|5.9104125|19.895757575757575|16.332121212121212|17.825624999999995|6.881875000000001|98.94766798666859|82.78555852321104|25.321212121212124|21.684848484848487\n",
      "\n",
      "quality of life enjoyment and satisfaction questionnaire - with regard to your physical health, during the past week how much of the time have you: been free of worry about your physical health?|quality of life enjoyment and satisfaction questionnaire - with regard to your health, during the past week how much of the time have you been free of worry about your physical health?|47.72181818181819|52.74250000000002|14.801212121212124|13.852500000000003|8.6777625|8.6777625|19.895757575757575|19.0475|17.825624999999995|16.7953125|98.94766798666859|93.86999999999999|25.321212121212124|24.05\n",
      "\n",
      "quality of life enjoyment and satisfaction questionnaire - with regard to your physical health, during the past week how much of the time have you: been free of worry about your physical health?| quality of life|47.72181818181819|97.025|14.801212121212124|0.7199999999999989|8.6777625|13.3585|19.895757575757575|-53.42|17.825624999999995|-4.800000000000001|98.94766798666859|31.29|25.321212121212124|11.600000000000001\n",
      "\n",
      "solid preparation consisting of one or more powders, including freeze-dried powders, intended to be dissolved in the specified liquid to obtain a nebuliser solution.|solid harmony be of one or more powders, including preserving powders, convey to be a change in the choose liquid to change a dispensing solution.|25.455000000000013|62.17150000000001|12.690000000000001|7.693000000000001|11.1925|9.929300000000001|10.123333333333335|5.014399999999998|17.069200000000002|13.489600000000003|82.78555852321104|69.96656701596841|28.13333333333334|21.0\n",
      "\n",
      "solid preparation consisting of one or more powders, including freeze-dried powders, intended to be dissolved in the specified liquid to obtain a nebuliser solution.|solid preparation consisting of one or more powders, including freeze-dried powder, intended to be dissolved in the specified liquid to obtain a nebuliser solution.|25.455000000000013|25.455000000000013|12.690000000000001|12.690000000000001|11.1925|10.961684615384616|10.123333333333335|10.123333333333335|17.069200000000002|10.069230769230767|82.78555852321104|82.78555852321104|28.13333333333334|28.13333333333334\n",
      "\n",
      "solid preparation consisting of one or more powders, including freeze-dried powders, intended to be dissolved in the specified liquid to obtain a nebuliser solution.| solid preparation of one or more powders dissolved in a solvent to obtain a solution|25.455000000000013|53.120000000000005|12.690000000000001|9.825|11.1925|11.910288235294118|10.123333333333335|7.592500000000001|17.069200000000002|7.018235294117648|82.78555852321104|82.78555852321104|28.13333333333334|23.900000000000002\n",
      "\n",
      "the chemical reactions and pathways involving inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached. [goc:jl]|the process force and path absorb install salt, 1,2,3,4,5,6-cyclohexanehexol, with one or more salt groups take.  [ goc: joel]|58.8663235294118|112.08500000000001|7.160294117647062|0.11000000000000121|14.080331578947368|11.072666666666667|10.832941176470591|1.8580000000000005|14.30684210526315|5.688833333333331|62.58|38.32226702584281|22.223529411764705|10.0\n",
      "\n",
      "the chemical reactions and pathways involving inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached. [goc:jl]|the chemical reactions and pathways involving a molecule of fat and protein groups attached. [goc:jl]|58.8663235294118|58.2225|7.160294117647062|7.001666666666669|14.080331578947368|13.346335294117647|10.832941176470591|-4.970666666666666|14.30684210526315|6.092941176470589|62.58|58.53822981607831|22.223529411764705|21.666666666666668\n",
      "\n",
      "the chemical reactions and pathways involving inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached. [goc:jl]| a chemical compound|58.8663235294118|75.87500000000001|7.160294117647062|3.6700000000000017|14.080331578947368|16.5165|10.832941176470591|-47.54|14.30684210526315|-1.032|62.58|44.250742366654144|22.223529411764705|21.6\n",
      "\n",
      "a rare chromosomal anomaly syndrome resulting from a partial deletion of the long arm of chromosome 12 with a highly variable phenotype. the disorder has typical characteristics of developmental delay, learning disability, intrauterine and postnatal growth retardation, and mild facial dysmorphism that changes with age. nasal speech and hypothyroidism are also associated.|a temporal concept chromosomal position syndrome happens from a partial deletion of the long arm of body 12 with a highly symbol phenotype.  the change has the typical property of developmental delay, learning unfitness, intrauterine and postnatal growth delay, and mild facial dysmorphism that changes with age.  bone speech and hypothyroidism are also uniting.|16.30538461538464|43.06428571428572|14.214615384615389|10.730714285714289|12.998541025641027|11.805055714285714|13.641538461538463|11.092142857142857|15.858974358974358|9.654464285714283|81.29380465324526|81.29380465324526|25.969230769230776|24.885714285714286\n",
      "\n",
      "a rare chromosomal anomaly syndrome resulting from a partial deletion of the long arm of chromosome 12 with a highly variable phenotype. the disorder has typical characteristics of developmental delay, learning disability, intrauterine and postnatal growth retardation, and mild facial dysmorphism that changes with age. nasal speech and hypothyroidism are also associated.|a rare developmental delay, learning disability, intrauterine and postnatal growth retardation, and mild facial anomalies that changes with age. nasal speech and hypothyroidism are also associated.|16.30538461538464|12.569102564102593|14.214615384615389|13.65923076923077|12.998541025641027|12.855122222222224|13.641538461538463|4.970769230769228|15.858974358974358|12.376666666666672|81.29380465324526|67.59412548439398|25.969230769230776|25.005128205128205\n",
      "\n",
      "a rare chromosomal anomaly syndrome resulting from a partial deletion of the long arm of chromosome 12 with a highly variable phenotype. the disorder has typical characteristics of developmental delay, learning disability, intrauterine and postnatal growth retardation, and mild facial dysmorphism that changes with age. nasal speech and hypothyroidism are also associated.| a rare chromosomal anomaly syndrome resulting from a partial deletion of the long arm of chromosome 12|16.30538461538464|47.565|14.214615384615389|11.096666666666668|12.998541025641027|13.72047894736842|13.641538461538463|11.975555555555552|15.858974358974358|9.884736842105266|81.29380465324526|82.78555852321104|25.969230769230776|22.75555555555556\n",
      "\n",
      "the report describes a non-specific problem with the immune system. note: please use \"appropriate term /code not available\" if the report describes a specific problem but the relevant term does not exist.|the report mark a non-specific problem with the immune system.  note: please use `` assumes term /code not available '' if the reporter mark a fact problem but the relevant term does not exist.|47.95833333333337|74.13619047619049|9.220000000000002|5.8171428571428585|10.196718181818182|10.810866666666666|4.038750000000004|1.3405714285714225|10.655454545454546|4.718333333333334|67.59412548439398|59.91578840339164|21.766666666666666|17.238095238095237\n",
      "\n",
      "the report describes a non-specific problem with the immune system. note: please use \"appropriate term /code not available\" if the report describes a specific problem but the relevant term does not exist.|the report describes a non-specific problem with the immune system. note: please use \"appropriate term /code not available\" if the reported problem is specific but the relevant term does not exist.|47.95833333333337|48.978924731182815|9.220000000000002|8.99483870967742|9.923918181818184|10.26600303030303|4.038750000000004|3.2206451612903173|7.905454545454546|5.816818181818181|67.59412548439398|65.13532912329528|21.766666666666666|20.907526881720432\n",
      "\n",
      "the report describes a non-specific problem with the immune system. note: please use \"appropriate term /code not available\" if the report describes a specific problem but the relevant term does not exist.| the report describes a condition|47.95833333333337|59.745000000000005|9.220000000000002|6.416666666666668|10.196718181818182|10.750842857142857|4.038750000000004|-20.913333333333334|10.655454545454546|2.2557142857142836|67.59412548439398|54.195869768830164|21.766666666666666|22.400000000000002\n",
      "\n",
      "international physical activity questionnaire (august 2002) long last 7 days self-administered format (ipaq long last 7 days self-administered format version) how much time did you usually spend on one of those days walking as part of your work?: hours and minutes per day.|socialism physical activity form (august 2002) long last, 7 day self-administered change (ipaq long last 7 days self-administered change turn) how much time did you usually spend on one of those days walking as part of your work?  : hours and minutes per day.|45.32412790697677|63.67750000000001|12.278720930232563|9.967222222222222|10.366722222222222|9.239691304347826|17.82046511627907|14.937777777777773|13.056000000000004|11.162608695652175|82.78555852321104|69.96656701596841|21.62325581395349|17.88888888888889\n",
      "\n",
      "international physical activity questionnaire (august 2002) long last 7 days self-administered format (ipaq long last 7 days self-administered format version) how much time did you usually spend on one of those days walking as part of your work?: hours and minutes per day.|international physical activity questionnaire (august 2002) long last 7 days self-administered format) how much time did you usual spend on one of those days walking as part of your work?: hours and minutes per day.|45.32412790697677|53.712500000000034|12.278720930232563|10.115000000000002|9.994722222222222|9.216381081081082|17.82046511627907|13.661714285714286|9.306000000000001|5.472027027027028|82.78555852321104|69.96656701596841|21.62325581395349|18.428571428571427\n",
      "\n",
      "international physical activity questionnaire (august 2002) long last 7 days self-administered format (ipaq long last 7 days self-administered format version) how much time did you usually spend on one of those days walking as part of your work?: hours and minutes per day.| international physical activity questionnaire is a question|45.32412790697677|-2.2099999999999795|12.278720930232563|15.555000000000003|11.482722222222222|14.60956666666667|17.82046511627907|2.6899999999999977|24.306000000000004|11.853333333333332|82.78555852321104|69.96656701596841|21.62325581395349|28.200000000000003\n",
      "\n",
      "a species of mitosporic fungi commonly found on the body surface. it causes opportunistic infections especially in immunocompromised patients.|a kind of mitosporic fungi commonly found on the body surface.  it causes opportunistic ill_health especially in immunocompromised case.|0.03824561403510529|22.40833333333333|14.827368421052629|11.790000000000003|11.587173684210526|10.283166666666666|-8.362105263157893|-10.002000000000002|13.56315789473684|9.22133333333333|62.58|57.127462747788826|27.796491228070177|22.666666666666668\n",
      "\n",
      "a species of mitosporic fungi commonly found on the body surface. it causes opportunistic infections especially in immunocompromised patients.|a species of mitosporic fungi commonly found on the body surface. it causes infections especially in immunocompromised patients.|0.03824561403510529|12.745000000000005|14.827368421052629|12.972222222222225|11.587173684210526|11.430107017543861|-8.362105263157893|-12.746666666666663|13.56315789473684|9.005087719298249|62.58|59.91578840339164|27.796491228070177|26.84444444444445\n",
      "\n",
      "a species of mitosporic fungi commonly found on the body surface. it causes opportunistic infections especially in immunocompromised patients.| a fungus|0.03824561403510529|119.19000000000003|14.827368421052629|-2.619999999999999|11.587173684210526|15.6774|-8.362105263157893|-82.98666666666665|13.56315789473684|-8.8325|62.58|31.29|27.796491228070177|14.533333333333331\n",
      "\n",
      "tear in organ or tissue|tear in organ or tissue|83.32000000000004|83.32000000000004|2.879999999999999|2.879999999999999|7.0425|7.0425|-36.855999999999995|-36.855999999999995|-1.032|-1.032|44.250742366654144|44.250742366654144|18.0|18.0\n",
      "\n",
      "tear in organ or tissue|tear in organ or tissue surrounding the lungs|83.32000000000004|71.81500000000001|2.879999999999999|5.230000000000004|7.0425|11.100677777777777|-36.855999999999995|-8.334999999999997|-1.032|3.4800000000000004|44.250742366654144|54.195869768830164|18.0|18.2\n",
      "\n",
      "tear in organ or tissue| tear|83.32000000000004|162.505|2.879999999999999|-8.91|7.0425|14.311966666666669|-36.855999999999995|-133.3|-1.032|-10.51|44.250742366654144|0.0|18.0|0.8\n",
      "\n",
      "the fos gene family consists of 4 members: fos, fosb, fosl1, and fosl2. these genes encode leucine zipper proteins that can dimerize with proteins of the jun family, thereby forming the transcription factor complex ap-1. as such, the fos proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. (locuslink)|the gene gene family is about 4 members: fos, fosb, fosl1, and fosl2.  these genes encode leucine zipper proteins that can dimerize with proteins of the jun family, thereby change the transcription factor whole ap-1.  as such, the fish proteins have been led as control of cell increase, adaptation, and function.  ( locuslink)|52.09769230769234|80.83214285714287|9.222307692307695|5.462857142857143|13.087261538461538|12.12971212121212|11.379999999999992|7.417142857142853|11.246730769230773|5.590060606060604|73.38155456243756|68.19497397169383|22.123076923076923|19.171428571428574\n",
      "\n",
      "the fos gene family consists of 4 members: fos, fosb, fosl1, and fosl2. these genes encode leucine zipper proteins that can dimerize with proteins of the jun family, thereby forming the transcription factor complex ap-1. as such, the fos proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. (locuslink)|these proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. (lcuslink)|52.09769230769234|0.31571428571430715|9.222307692307695|14.954285714285717|13.087261538461538|12.429833333333335|11.379999999999992|3.0742857142857147|11.246730769230773|14.661999999999999|73.38155456243756|58.53822981607831|22.123076923076923|22.8\n",
      "\n",
      "the fos gene family consists of 4 members: fos, fosb, fosl1, and fosl2. these genes encode leucine zipper proteins that can dimerize with proteins of the jun family, thereby forming the transcription factor complex ap-1. as such, the fos proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. (locuslink)| the fos gene family is made up of 4 members: fos, fosb, fosl1, and fosl2. these genes encode leucine zipper proteins that can dimerize with other proteins of the jun family, thereby forming the transcription factor complex AP-1|52.09769230769234|72.07326923076926|9.222307692307695|8.050897435897436|13.087261538461538|13.313|11.379999999999992|13.617435897435898|11.246730769230773|10.471500000000002|73.38155456243756|85.69119412168324|22.123076923076923|23.184615384615388\n",
      "\n",
      "studies using excised tissues.|studies using cut_out tissues.|35.60500000000002|56.755000000000024|8.790000000000003|5.840000000000003|11.7299|11.7299|-108.31|-108.31|11.184999999999995|11.184999999999995|38.32226702584281|38.32226702584281|30.8|30.8\n",
      "\n",
      "studies using excised tissues.|studies using excised tissue.|35.60500000000002|35.60500000000002|8.790000000000003|8.790000000000003|11.7299|13.2345|-108.31|-108.31|11.184999999999995|4.312000000000001|38.32226702584281|38.32226702584281|30.8|30.8\n",
      "\n",
      "studies using excised tissues.| studies|35.60500000000002|120.20500000000001|8.790000000000003|-3.01|11.7299|14.311966666666669|-108.31|-124.48|11.184999999999995|-5.800000000000001|38.32226702584281|31.29|30.8|20.8\n",
      "\n",
      "mild increase in subarachnoid space (sas); mild ventriculomegaly; small (+/- multiple) focal t2 hyperintensities, involving periventricular white matter or <1/3 of susceptible areas of cerebrum|mild increase in the subarachnoid space (sas); mild ventriculomegaly; small (+/- product) focal t2 hyperintensities, absorb periventricular white matter or < 1/3  susceptible areas of the cerebrum|-1.275999999999982|18.27928571428575|19.648|17.665714285714284|15.857638461538462|15.739942857142859|27.908799999999996|24.918571428571433|20.55461538461538|19.652499999999996|108.39173953766033|108.39173953766033|29.200000000000003|28.342857142857145\n",
      "\n",
      "mild increase in subarachnoid space (sas); mild ventriculomegaly; small (+/- multiple) focal t2 hyperintensities, involving periventricular white matter or <1/3 of susceptible areas of cerebrum|mild increase in subarachnoid space (sas); mild ventriculomegaly; small (+/- multiple) focal t2 hyperintensities, involving periventricular white matter or 1/3 of susceptible areas of the brain.|-1.275999999999982|21.18615384615387|19.648|13.533846153846156|15.857638461538462|14.247951851851854|27.908799999999996|15.676923076923078|20.55461538461538|13.231111111111112|108.39173953766033|73.38155456243756|29.200000000000003|22.123076923076923\n",
      "\n",
      "mild increase in subarachnoid space (sas); mild ventriculomegaly; small (+/- multiple) focal t2 hyperintensities, involving periventricular white matter or <1/3 of susceptible areas of cerebrum| mild increase in subarachnoid space (sas); mild ventriculomegaly; small|-1.275999999999982|35.94500000000002|19.648|10.73|15.857638461538462|15.665736363636366|27.908799999999996|8.032|20.55461538461538|10.189090909090911|108.39173953766033|54.195869768830164|29.200000000000003|16.0\n",
      "\n",
      "interacting selectively and non-covalently with one or more specific sites on a neuromedin u receptor. [goc:jl, pmid:10899166]|act selectively and non-covalently with one or more fact sites on a neuromedin u organ.  [ goc: jl, pmid: 10899166]|29.00750000000002|75.32035714285716|11.325000000000003|5.362142857142857|14.080331578947368|12.254652380952383|3.2235294117647086|-1.5904761904761955|9.101052631578948|2.0314285714285703|54.195869768830164|44.250742366654144|17.51764705882353|11.81904761904762\n",
      "\n",
      "interacting selectively and non-covalently with one or more specific sites on a neuromedin u receptor. [goc:jl, pmid:10899166]|interacting selectively and not binding with one or more sites on a neuromedin u receptor. [goc:jl, pmid:10899166]|29.00750000000002|53.889852941176486|11.325000000000003|7.854411764705883|14.080331578947368|12.418226315789473|3.2235294117647086|-0.5811764705882325|9.101052631578948|6.622105263157895|54.195869768830164|49.473833993334296|17.51764705882353|15.164705882352942\n",
      "\n",
      "interacting selectively and non-covalently with one or more specific sites on a neuromedin u receptor. [goc:jl, pmid:10899166]| binding|29.00750000000002|120.20500000000001|11.325000000000003|-3.01|14.080331578947368|14.311966666666669|3.2235294117647086|-124.48|9.101052631578948|-5.800000000000001|54.195869768830164|31.29|17.51764705882353|20.8\n",
      "\n",
      "solitary or multiple benign hepatic vascular tumors, usually occurring in women of 20-50 years of age. the nodule, poorly encapsulated, consists of a central stellate fibrous scar and normal liver elements such as hepatocytes, small bile ducts, and kupffer cells among the intervening fibrous septa. the pale colored central scar represents large blood vessels with hyperplastic fibromuscular layer and narrowing lumen.|loner or product benign bryophyte vascular growth, usually appear in women of 20-50 years of age.  the hunk, poorly digest, be  a central stellate fibrous scar and normal liver straight_line such as hepatocytes, small bile ducts, and the kupffer cells among the happen fibrous septa.  the pale change central scar permute large blood craft  hyperplastic fibromuscular layer and tighten lumen.|27.70379098360658|61.05125000000001|13.183729508196723|8.718750000000004|13.575276344086022|13.02653076923077|15.195409836065572|11.726874999999996|15.492043010752688|8.547538461538462|91.22524239485473|84.2509034076193|28.395081967213116|24.525000000000002\n",
      "\n",
      "solitary or multiple benign hepatic vascular tumors, usually occurring in women of 20-50 years of age. the nodule, poorly encapsulated, consists of a central stellate fibrous scar and normal liver elements such as hepatocytes, small bile ducts, and kupffer cells among the intervening fibrous septa. the pale colored central scar represents large blood vessels with hyperplastic fibromuscular layer and narrowing lumen.|solitary or multiple benign hepatic tumors, usually occurring in women of 20-50 years of age. the nodule, poorly encapsulated, consists of a central scar and normal liver elements such as hepatocytes, small bile ducts, and ku|27.70379098360658|35.815|13.183729508196723|12.735555555555557|13.575276344086022|13.72047894736842|15.195409836065572|14.752222222222223|15.492043010752688|10.876315789473686|91.22524239485473|91.22524239485473|28.395081967213116|26.088888888888892\n",
      "\n",
      "solitary or multiple benign hepatic vascular tumors, usually occurring in women of 20-50 years of age. the nodule, poorly encapsulated, consists of a central stellate fibrous scar and normal liver elements such as hepatocytes, small bile ducts, and kupffer cells among the intervening fibrous septa. the pale colored central scar represents large blood vessels with hyperplastic fibromuscular layer and narrowing lumen.| Solitary or multiple benign liver disease|27.70379098360658|30.53000000000003|13.183729508196723|10.740000000000002|13.320598924731184|15.875800000000002|15.195409836065572|-11.205714285714286|15.492043010752688|4.942499999999999|91.22524239485473|69.96656701596841|28.395081967213116|31.371428571428574\n",
      "\n",
      "a gram negative, rod shaped serotype of the bacteria genus salmonella, species salmonella enterica, subspecies enterica that causes swine fever in pigs.|a bacterium negative, rod change stereotype of the bacterial kind salmonella, kind salmonella enterica, subspecies enterica that causes swine fever in pigs.|11.088181818181852|14.933636363636396|14.445454545454545|13.90909090909091|14.058154545454547|12.6227|8.103636363636358|9.172727272727268|16.759545454545453|17.615909090909092|79.77416029015912|73.38155456243756|28.03636363636364|24.400000000000002\n",
      "\n",
      "a gram negative, rod shaped serotype of the bacteria genus salmonella, species salmonella enterica, subspecies enterica that causes swine fever in pigs.|a gram negative, rod shaped serotype of the bacteria that causes swine fever in pigs.|11.088181818181852|58.2225|14.445454545454545|7.001666666666669|14.058154545454547|10.941425|8.103636363636358|-11.242666666666668|16.759545454545453|3.1762499999999996|79.77416029015912|54.195869768830164|28.03636363636364|19.0\n",
      "\n",
      "a gram negative, rod shaped serotype of the bacteria genus salmonella, species salmonella enterica, subspecies enterica that causes swine fever in pigs.| a gram negative rod shaped species of bacteria genus salmonella|11.088181818181852|34.160909090909115|14.445454545454545|11.22727272727273|14.058154545454547|16.0742|8.103636363636358|2.4909090909090885|16.759545454545453|6.550000000000001|79.77416029015912|76.64453405168562|28.03636363636364|26.218181818181815\n",
      "\n",
      "surgical removal of the rectum.|surgical procedure of the rectum.|35.097500000000025|35.097500000000025|8.985000000000003|8.985000000000003|13.3585|13.3585|-86.648|-84.29599999999999|5.562000000000001|7.445999999999998|38.32226702584281|38.32226702584281|25.0|25.0\n",
      "\n",
      "surgical removal of the rectum.|surgical removal of rectum.|35.097500000000025|14.455000000000013|8.985000000000003|11.740000000000002|13.3585|16.392500000000002|-86.648|-111.25|5.562000000000001|2.428000000000001|38.32226702584281|38.32226702584281|25.0|30.8\n",
      "\n",
      "surgical removal of the rectum.| surgical removal of the rectum|35.097500000000025|59.745000000000005|8.985000000000003|6.416666666666668|13.3585|15.262271428571431|-86.648|-22.873333333333328|5.562000000000001|0.9100000000000001|38.32226702584281|54.195869768830164|25.0|22.400000000000002\n",
      "\n",
      "a cholesteryl ester transfer protein (cetp) inhibitor that can produce an increase in serum hdl-cholesterol levels and a decrease in serum ldl-cholesterol levels. dalcetrapib is structurally dissimilar from other cetp inhibitors, including torcetrapib, and raises functional hdl by a different mechanism.|a bioactive substance ester shift protein (cetp) substance that can change, an increase in serum hdl-cholesterol levels and a change in serum ldl-cholesterol levels.  dalcetrapib is structurally dissimilar from other step substance, including torcetrapib, and end functional handle by a different device.|13.446260162601646|36.85875968992252|14.779024390243908|11.67906976744186|14.949532558139534|12.450944444444445|16.202926829268296|15.175813953488372|28.11093023255814|12.655333333333338|90.32644961471695|86.63808689023553|29.856910569105693|27.128682170542636\n",
      "\n",
      "a cholesteryl ester transfer protein (cetp) inhibitor that can produce an increase in serum hdl-cholesterol levels and a decrease in serum ldl-cholesterol levels. dalcetrapib is structurally dissimilar from other cetp inhibitors, including torcetrapib, and raises functional hdl by a different mechanism.|a protein building blocks (cetp) inhibitor that can produce an increase in serum hdl-cholesterol levels and a decrease in blood lipid molecule level. dalcetrapib is structurally dissimilar from other cetp inhibitors, including torcetrasb, and raises|13.446260162601646|22.289642857142866|14.779024390243908|14.497857142857146|13.883132558139534|12.66247837837838|16.202926829268296|19.373714285714286|17.36093023255814|14.552432432432433|90.32644961471695|98.94766798666859|29.856910569105693|29.857142857142858\n",
      "\n",
      "a cholesteryl ester transfer protein (cetp) inhibitor that can produce an increase in serum hdl-cholesterol levels and a decrease in serum ldl-cholesterol levels. dalcetrapib is structurally dissimilar from other cetp inhibitors, including torcetrapib, and raises functional hdl by a different mechanism.| A cholesterol ester transfer protein (estp) inhibitor that can produce an increase in serum high-density lipoprotein-cholesterol levels and a decrease in|13.446260162601646|11.459545454545463|14.779024390243908|17.12636363636364|13.883132558139534|14.3505|16.202926829268296|22.36|17.36093023255814|15.750400000000006|90.32644961471695|108.39173953766033|29.856910569105693|30.618181818181814\n",
      "\n",
      "a cell-based cancer vaccine composed of autologous dendritic cells (dcs) pulsed with lysates from an allogeneic glioblastoma (gbm) stem-like cell line, with potential immunostimulatory and antineoplastic activities. upon administration allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine exposes the immune system to gbm stem cell antigens, which may result in cytotoxic t lymphocyte (ctl) and antibody responses against gbm cells. this leads to gbm cell lysis. gbm stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of gbm cells. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c113296\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c113296\" nci thesaurus)|a pharmacologic substance cancer vaccine plan of autologous dendritic cells (dcs) move with lysates from an allogeneic brain_tumor (gbm) stem-like cell line, with potential immunostimulatory and antineoplastic trait.  upon justice allogeneic brain_tumor stem-like cell line lysate-pulsed autologous dendritic cell vaccine subject the immune system to gbm stem cell substance, which may result in cytotoxic t lymphocyte (steel) and protein manner against gm cells.  this leads to gbm cell lysis.  gbm stem-like cells contain a fact range of substance that are thing for the neoplastic growth and survival of gm cells.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c113296 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c113296 '' nice wordbook)|35.79307343234328|54.98000000000002|10.357846534653465|8.075|12.854653459119497|13.492334029850747|10.125148514851489|7.836000000000002|20.90654088050315|10.999253731343288|61.26237874911485|61.26237874911485|21.584488448844887|19.333333333333336\n",
      "\n",
      "a cell-based cancer vaccine composed of autologous dendritic cells (dcs) pulsed with lysates from an allogeneic glioblastoma (gbm) stem-like cell line, with potential immunostimulatory and antineoplastic activities. upon administration allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine exposes the immune system to gbm stem cell antigens, which may result in cytotoxic t lymphocyte (ctl) and antibody responses against gbm cells. this leads to gbm cell lysis. gbm stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of gbm cells. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c113296\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c113296\" nci thesaurus)|a cell-based cancer vaccine composed of autologous dendritic cells pulsed with lysates from an allogeneic glioblastoma (gbm) stem-like cell line, with potential immunostimulatory and anti-cancer activities. check for \"http|35.79307343234328|-3.3376724137930864|10.357846534653465|17.327068965517245|12.854653459119497|12.589142424242425|10.125148514851489|19.124137931034486|20.90654088050315|13.509999999999998|61.26237874911485|88.50148473330829|21.584488448844887|27.868965517241378\n",
      "\n",
      "a cell-based cancer vaccine composed of autologous dendritic cells (dcs) pulsed with lysates from an allogeneic glioblastoma (gbm) stem-like cell line, with potential immunostimulatory and antineoplastic activities. upon administration allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine exposes the immune system to gbm stem cell antigens, which may result in cytotoxic t lymphocyte (ctl) and antibody responses against gbm cells. this leads to gbm cell lysis. gbm stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of gbm cells. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c113296\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c113296\" nci thesaurus)| a|35.79307343234328|162.505|10.357846534653465|-8.91|12.854653459119497|14.311966666666669|10.125148514851489|-142.12|20.90654088050315|-15.219999999999999|61.26237874911485|0.0|21.584488448844887|0.8\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated|life-threatening result; urgent care informs|-119.71999999999994|-1.2799999999999727|31.200000000000006|14.68|16.94363333333333|14.311966666666669|6.655999999999999|-12.159999999999997|22.46|9.899999999999999|69.96656701596841|62.58|42.0|34.0\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated|life-threatening consequences; urgent intervention indicated|-119.71999999999994|-119.71999999999994|31.200000000000006|31.200000000000006|16.94363333333333|17.344385714285714|6.655999999999999|7.832000000000001|22.46|17.327142857142853|69.96656701596841|69.96656701596841|42.0|42.0\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated| life-threatening condition; urgent intervention|-119.71999999999994|-35.11999999999995|31.200000000000006|19.400000000000002|16.94363333333333|17.517985714285714|6.655999999999999|-6.279999999999994|22.46|11.675714285714285|69.96656701596841|62.58|42.0|34.0\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated|life-threatening result; urgent care informs|-119.71999999999994|-1.2799999999999727|31.200000000000006|14.68|16.94363333333333|14.311966666666669|6.655999999999999|-12.159999999999997|22.46|9.899999999999999|69.96656701596841|62.58|42.0|34.0\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated|life-threatening consequences; urgent intervention indicated|-119.71999999999994|-119.71999999999994|31.200000000000006|31.200000000000006|16.94363333333333|17.344385714285714|6.655999999999999|7.832000000000001|22.46|17.327142857142853|69.96656701596841|69.96656701596841|42.0|42.0\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated| life-threatening condition; urgent intervention|-119.71999999999994|-35.11999999999995|31.200000000000006|19.400000000000002|16.94363333333333|17.517985714285714|6.655999999999999|-6.279999999999994|22.46|11.675714285714285|69.96656701596841|62.58|42.0|34.0\n",
      "\n",
      "an abnormal endocervical or endometrial cell found in a cervical smear, not further characterized as neoplastic or non-neoplastic. it is often associated with clinically significant uterine lesions.|a finding endocervical or endometrial cell found in a cervical smear, not further distinguish  neoplastic or non-neoplastic.  it is often uniting with clinically significant uterine lesions.|6.56666666666672|28.16166666666669|14.57925925925926|11.650000000000002|12.225900000000001|12.522941379310346|4.5688888888888854|2.515714285714285|13.829999999999998|11.968620689655175|67.59412548439398|67.59412548439398|24.340740740740742|23.733333333333334\n",
      "\n",
      "an abnormal endocervical or endometrial cell found in a cervical smear, not further characterized as neoplastic or non-neoplastic. it is often associated with clinically significant uterine lesions.|an abnormal endocervical cell found in a cervical smear, not further characterized as cancer or non-cancer. it is often associated with clinically significant uterine lesions.|6.56666666666672|15.640666666666675|14.57925925925926|13.148000000000003|12.225900000000001|12.493507407407408|4.5688888888888854|0.23040000000000305|13.829999999999998|11.137777777777778|67.59412548439398|65.13532912329528|24.340740740740742|24.133333333333336\n",
      "\n",
      "an abnormal endocervical or endometrial cell found in a cervical smear, not further characterized as neoplastic or non-neoplastic. it is often associated with clinically significant uterine lesions.| an abnormal cell|6.56666666666672|97.025|14.57925925925926|0.7199999999999989|12.225900000000001|13.3585|4.5688888888888854|-51.95|13.829999999999998|-3.857999999999997|67.59412548439398|31.29|24.340740740740742|11.600000000000001\n",
      "\n",
      "formation of a blood clot (thrombus) in the lumen of the splenic vein or splenic artery.|placement of a blood clot (clot) in the lumen of the splenic vein or splenic artery.|71.81500000000001|82.39000000000001|5.230000000000004|3.7550000000000026|12.3251|12.3251|-10.172500000000003|-11.642500000000002|7.17625|5.998750000000001|54.195869768830164|49.473833993334296|18.2|15.700000000000001\n",
      "\n",
      "formation of a blood clot (thrombus) in the lumen of the splenic vein or splenic artery.|formation of a blood clot (thrombus) in the lumen of the splenic vein or artery.|71.81500000000001|75.14250000000001|5.230000000000004|4.641666666666666|12.3251|11.9283|-10.172500000000003|-13.20266666666667|7.17625|1.4100000000000001|54.195869768830164|49.473833993334296|18.2|16.333333333333332\n",
      "\n",
      "formation of a blood clot (thrombus) in the lumen of the splenic vein or splenic artery.| formation|71.81500000000001|77.90500000000002|5.230000000000004|2.890000000000004|12.3251|19.5753|-10.172500000000003|-118.6|7.17625|-2.66|54.195869768830164|31.29|18.2|20.8\n",
      "\n",
      "a subjective score of 1 on a scale that ranges from 1: strongly disagree to 6: strongly agree.|a quality score of 1 on a scale that feed from 1: strongly be  6: strongly agree.|89.60000000000004|108.40000000000002|2.9977777777777774|0.37555555555555564|12.4243|11.547077777777778|-7.735555555555553|-11.98222222222222|6.93333333333333|3.793333333333333|54.195869768830164|44.250742366654144|16.933333333333334|12.488888888888889\n",
      "\n",
      "a subjective score of 1 on a scale that ranges from 1: strongly disagree to 6: strongly agree.|a subjective score of 1 on a scale that ranges from 1: strongly disagree to 6: weakly agree.|89.60000000000004|89.60000000000004|2.9977777777777774|2.9977777777777774|12.4243|12.418226315789473|-7.735555555555553|-8.062222222222218|6.93333333333333|1.4163157894736855|54.195869768830164|54.195869768830164|16.933333333333334|16.933333333333334\n",
      "\n",
      "a subjective score of 1 on a scale that ranges from 1: strongly disagree to 6: strongly agree.| a score|89.60000000000004|147.39000000000004|2.9977777777777774|-6.553333333333333|12.4243|11.7299|-7.735555555555553|-84.94666666666666|6.93333333333333|-10.01|54.195869768830164|0.0|16.933333333333334|1.2000000000000002\n",
      "\n",
      "the joining of the lipid bilayer membrane that surround a cell with that of another cell, producing a single cell. [goc:elh, goc:mtg_muscle]|the joining of the lipid bilayer sheet that touch a cell with that of another cell, change a single cell.  [ goc : elh , goc : mtg_muscle ]|61.07909090909095|104.19000000000001|7.472727272727273|2.4533333333333367|10.810866666666666|9.102633333333333|4.896363636363631|1.8266666666666644|6.550000000000001|2.3302666666666703|69.96656701596841|54.195869768830164|22.581818181818182|14.0\n",
      "\n",
      "the joining of the lipid bilayer membrane that surround a cell with that of another cell, producing a single cell. [goc:elh, goc:mtg_muscle]|the joining of the lipid bilayer membrane that surrounds a cell with that of another cell, producing one cell. [goc:elh,goc:mtg_muscle]|61.07909090909095|57.09500000000003|7.472727272727273|7.779999999999998|10.810866666666666|11.468783333333334|4.896363636363631|4.797999999999998|6.550000000000001|6.157499999999999|69.96656701596841|62.58|22.581818181818182|20.0\n",
      "\n",
      "the joining of the lipid bilayer membrane that surround a cell with that of another cell, producing a single cell. [goc:elh, goc:mtg_muscle]| the joining of the cell's fatty acid methyl ester membrane|61.07909090909095|72.61545454545457|7.472727272727273|5.863636363636363|10.810866666666666|14.758366666666669|4.896363636363631|-0.18181818181818343|6.550000000000001|4.587499999999999|69.96656701596841|76.64453405168562|22.581818181818182|26.218181818181815\n",
      "\n",
      "a small, membrane bound vesicle circulating in the blood that was shed by a cell that expresses the coagulation protein, tissue factor (factor iii). the presence of microparticles with tissue factor in the plasma of cancer patients is associated with an increased risk for venous thrombosis.|a small, sheet bound sac move in the blood that was shed by a cell that mail the coagulation protein, tissue factor (factor iii).  the presence of microparticles with tissue factor in the plasma of cancer case is uniting with an increased risk for venous thrombosis.|47.819492753623194|68.53333333333333|10.398695652173913|7.592340425531916|12.329039130434783|10.79675815602837|12.14086956521739|8.629787234042556|14.643913043478257|7.949078014184394|80.79043260188672|69.96656701596841|23.524637681159422|19.032624113475176\n",
      "\n",
      "a small, membrane bound vesicle circulating in the blood that was shed by a cell that expresses the coagulation protein, tissue factor (factor iii). the presence of microparticles with tissue factor in the plasma of cancer patients is associated with an increased risk for venous thrombosis.|a small, membrane bound vesicle circulating in the blood that was shed by a cell that expresses the protein complex coagulation protein, tissue factor (factor iii). the presence of microparticles with protein and thrombosis.|47.819492753623194|48.525784313725495|10.398695652173913|9.306470588235296|12.329039130434783|11.884595238095239|12.14086956521739|7.087058823529411|14.643913043478257|9.433619047619047|80.79043260188672|69.96656701596841|23.524637681159422|22.180392156862748\n",
      "\n",
      "a small, membrane bound vesicle circulating in the blood that was shed by a cell that expresses the coagulation protein, tissue factor (factor iii). the presence of microparticles with tissue factor in the plasma of cancer patients is associated with an increased risk for venous thrombosis.| a small, circulating in the blood, vesicle that expresses the coagulation protein, tissue factor|47.819492753623194|39.33000000000001|10.398695652173913|11.500000000000004|12.329039130434783|13.311975|12.14086956521739|13.194666666666663|14.643913043478257|10.708750000000002|80.79043260188672|82.78555852321104|23.524637681159422|24.666666666666668\n",
      "\n",
      "a carbohydrate comprised of three to ten monosaccharides joined by ether bridges (covalent bonds centered by an oxygen).|an organic chemical include of three to ten carbohydrate joined by ether bridges (covalent bonds move by an oxygen).|28.50000000000003|50.25565789473683|11.520000000000003|8.609736842105267|10.669855555555555|11.22732105263158|0.7577777777777754|-0.8294736842105266|13.736666666666665|11.619999999999997|62.58|62.58|21.37777777777778|20.642105263157895\n",
      "\n",
      "a carbohydrate comprised of three to ten monosaccharides joined by ether bridges (covalent bonds centered by an oxygen).|a molecule composed of three to ten monosaccharides joined by ether bridges (covalent bonds centered by an oxygen).|28.50000000000003|37.900000000000034|11.520000000000003|10.208888888888893|10.669855555555555|10.75612105263158|0.7577777777777754|-0.5488888888888894|13.736666666666665|7.1178947368421035|62.58|62.58|21.37777777777778|21.37777777777778\n",
      "\n",
      "a carbohydrate comprised of three to ten monosaccharides joined by ether bridges (covalent bonds centered by an oxygen).| a carbohydrate comprising three to ten monosaccharides joined by ether bindings|28.50000000000003|32.504999999999995|11.520000000000003|11.706666666666667|10.669855555555555|12.783607692307694|0.7577777777777754|9.633333333333333|13.736666666666665|10.793846153846154|62.58|69.96656701596841|21.37777777777778|21.46666666666667\n",
      "\n",
      "the process whose specific outcome is the progression of the metanephric late distal convoluted tubule over time, from its formation to the mature structure. the metanephric late distal convoluted tubule contains metanephric dct cells and intercalated (ic) alpha and beta cells and is vasopressin-sensitive. [goc:mtg_kidney_jan10]|the walk whose fact outcome is the motion of the metanephric late distal denote tube over time, from its placement of the draw structure.  the metanephric late distal denote tube contains metanephric duct cells and add (ic) alpha and beta cells and is vasopressin-sensitive.  [ goc: mtg_kidney_jan10]|28.05000000000001|65.94646258503404|13.073333333333338|8.118775510204085|13.148460283687944|11.856457551020409|17.63733333333333|12.117551020408168|14.1622695035461|7.020000000000003|84.73372056035305|72.26115969177356|25.555555555555557|19.594557823129254\n",
      "\n",
      "the process whose specific outcome is the progression of the metanephric late distal convoluted tubule over time, from its formation to the mature structure. the metanephric late distal convoluted tubule contains metanephric dct cells and intercalated (ic) alpha and beta cells and is vasopressin-sensitive. [goc:mtg_kidney_jan10]|the process whose specific outcome is the progression of the metanephric late distal convoluted tubule over time, from its formation to the mature structure. it is vasopressin-sensitive. [goc:mtg_kidney_jan10]|28.05000000000001|40.24738095238098|13.073333333333338|9.964285714285715|13.148460283687944|12.298710752688173|17.63733333333333|6.715714285714288|14.1622695035461|10.477311827956992|84.73372056035305|65.13532912329528|25.555555555555557|22.304761904761907\n",
      "\n",
      "the process whose specific outcome is the progression of the metanephric late distal convoluted tubule over time, from its formation to the mature structure. the metanephric late distal convoluted tubule contains metanephric dct cells and intercalated (ic) alpha and beta cells and is vasopressin-sensitive. [goc:mtg_kidney_jan10]| The process whose specific outcome is the formation of|28.05000000000001|69.78500000000001|13.073333333333338|6.010000000000002|13.148460283687944|12.794827272727273|17.63733333333333|-1.9639999999999986|14.1622695035461|4.622727272727271|84.73372056035305|62.58|25.555555555555557|20.0\n",
      "\n",
      "pediatric quality of life neuromuscular module acute version 3 young adult - in the past 7 days, how much of a problem has this been for you: it is hard for my family to plan activities like vacations.|pediatrician quality of life neuromuscular module acute turn 3 young adults - in the past 7 days, how much of a problem has this been for you: it is hard for my family to plan trait like to spend.|65.10263157894738|76.4117307692308|8.898947368421055|7.445769230769233|10.592781081081082|9.676563157894737|9.797894736842107|8.642051282051282|17.43756756756757|16.657894736842103|73.38155456243756|62.58|19.178947368421053|16.005128205128205\n",
      "\n",
      "pediatric quality of life neuromuscular module acute version 3 young adult - in the past 7 days, how much of a problem has this been for you: it is hard for my family to plan activities like vacations.|pediatric quality of life module acute version 3 young adult - in the past 7 days, how much of a problem has this been for you?|65.10263157894738|76.3219230769231|8.898947368421055|9.073076923076925|10.592781081081082|10.999176923076924|9.797894736842107|11.909230769230769|17.43756756756757|9.685384615384617|73.38155456243756|82.78555852321104|19.178947368421053|21.16923076923077\n",
      "\n",
      "pediatric quality of life neuromuscular module acute version 3 young adult - in the past 7 days, how much of a problem has this been for you: it is hard for my family to plan activities like vacations.| pediatric quality of life neuromuscular module acute version 3 young adult - in the past 7 days, how much of a problem has this been for you: it is hard for my family to plan activities like vacations|65.10263157894738|47.94230769230769|8.898947368421055|16.261025641025643|10.592781081081082|11.239105128205129|9.797894736842107|17.136410256410258|17.43756756756757|17.634615384615387|73.38155456243756|103.77718969022045|19.178947368421053|26.882051282051282\n",
      "\n",
      "a condition in which an abnormal amount of a single immunoglobulin is present in the serum. this category includes igm monoclonal gammopathy of undetermined significance and non-igm monoclonal gammopathy of undetermined significance. up to 25% of cases of monoclonal gammopathy of undetermined significance progress to a b-cell malignancy or myeloma.|a shampoo in which an abnormal amount of a single antibody is present in the serum.  this category includes igm monoclonal gammopathy of undetermined message and non-igm monoclonal gammopathy of undetermined message.  up to 25 % of cases of monoclonal gammopathy of undetermined message progress to a b-cell evil or myeloma.|1.2595000000000312|28.97492924528305|16.189|12.509575471698117|12.391233333333334|11.323877777777778|11.717599999999997|7.836981132075472|13.956858974358973|8.695555555555554|79.77416029015912|79.77416029015912|25.8|24.922641509433962\n",
      "\n",
      "a condition in which an abnormal amount of a single immunoglobulin is present in the serum. this category includes igm monoclonal gammopathy of undetermined significance and non-igm monoclonal gammopathy of undetermined significance. up to 25% of cases of monoclonal gammopathy of undetermined significance progress to a b-cell malignancy or myeloma.|a condition in which an abnormal amount of a single immunoglobulin is present in the serum. this category includes igm monoclonal gammopathy of undetermined significance and not being able to make blood cells malignancy or myeloma.|1.2595000000000312|20.755000000000024|16.189|13.345555555555556|12.391233333333334|10.222827927927929|11.717599999999997|7.509999999999998|13.956858974358973|9.559639639639641|79.77416029015912|74.48509850970193|25.8|23.68888888888889\n",
      "\n",
      "a condition in which an abnormal amount of a single immunoglobulin is present in the serum. this category includes igm monoclonal gammopathy of undetermined significance and non-igm monoclonal gammopathy of undetermined significance. up to 25% of cases of monoclonal gammopathy of undetermined significance progress to a b-cell malignancy or myeloma.| a disease|1.2595000000000312|119.19000000000003|16.189|-2.619999999999999|12.391233333333334|15.6774|11.717599999999997|-81.02666666666666|13.956858974358973|-7.654999999999999|79.77416029015912|31.29|25.8|14.533333333333331\n",
      "\n",
      "life-threatening consequences (e.g. shock); requiring urgent major care changes.|life-threatening result (e.g. shock); be urgent major care changes.|7.1512500000000045|44.75125000000003|12.820833333333336|7.576388888888893|12.0275|10.448500000000001|-84.51555555555555|-93.00888888888889|15.127000000000002|9.004000000000001|38.32226702584281|34.983283507984204|27.566666666666663|23.122222222222224\n",
      "\n",
      "life-threatening consequences (e.g. shock); requiring urgent major care changes.|life-threatening consequences (e.g. shock); requiring urgent care changes.|7.1512500000000045|3.880000000000024|12.820833333333336|13.215000000000003|12.0275|13.3585|-84.51555555555555|-98.02000000000001|15.127000000000002|10.743000000000002|38.32226702584281|34.983283507984204|27.566666666666663|25.8\n",
      "\n",
      "life-threatening consequences (e.g. shock); requiring urgent major care changes.| a life-threatening condition; requiring immediate major care|7.1512500000000045|-2.2099999999999795|12.820833333333336|15.555000000000003|12.0275|13.6065|-84.51555555555555|3.424999999999997|15.127000000000002|9.004000000000001|38.32226702584281|69.96656701596841|27.566666666666663|28.200000000000003\n",
      "\n",
      "a bradyarrhythmia adverse event in a newborn characterized by life-threatening consequences (e.g. shock); requiring urgent major care changes.|a disease, adverse event in a newborn distinguishes by life-threatening result (e.g. shock); be urgent major care changes.|14.267500000000013|47.16750000000002|12.387222222222224|7.798333333333332|12.889426315789473|12.058373684210528|-24.944444444444436|-31.477777777777774|17.817368421052628|12.611578947368422|51.88859484511023|49.473833993334296|26.244444444444447|24.022222222222226\n",
      "\n",
      "a bradyarrhythmia adverse event in a newborn characterized by life-threatening consequences (e.g. shock); requiring urgent major care changes.|a rhythm abnormal event in a newborn characterized by life-threatening consequences (e.g. shock); requiring urgent major care changes.|14.267500000000013|23.667500000000018|12.387222222222224|11.07611111111111|12.889426315789473|12.817|-24.944444444444436|-27.23111111111111|17.817368421052628|10.181500000000003|51.88859484511023|49.473833993334296|26.244444444444447|24.022222222222226\n",
      "\n",
      "life-threatening consequences (e.g. shock); requiring urgent major care changes.| a life-threatening condition; requiring immediate major care|7.1512500000000045|-2.2099999999999795|12.820833333333336|15.555000000000003|12.0275|13.6065|-84.51555555555555|3.424999999999997|15.127000000000002|9.004000000000001|38.32226702584281|69.96656701596841|27.566666666666663|28.200000000000003\n",
      "\n",
      "<b>description:</b>this variant includes all attributes and associations present in the r-mim. any of non-mandatory and non-required attributes and/or associations may be present or absent, as permitted in the cardinality constraints.|< b > kindest: < /b > this type includes all abstraction and group present in the r-mim.  any  non-mandatory and non-required abstraction and/or group may be present or absent, as permit in the number constraints.|10.564999999999998|75.98359649122811|14.270000000000007|5.807894736842105|13.304952631578947|12.401927642276423|10.580000000000002|3.865263157894738|12.735526315789471|5.047479674796747|72.26115969177356|65.13532912329528|25.333333333333336|18.750877192982454\n",
      "\n",
      "<b>description:</b>this variant includes all attributes and associations present in the r-mim. any of non-mandatory and non-required attributes and/or associations may be present or absent, as permitted in the cardinality constraints.|this variant includes all attributes and associations present in the r-mim. any of non-mandatory and not-required attributes or/or associations may be present or absent, as permitted by the cardinal constraints.|10.564999999999998|21.845|14.270000000000007|12.696666666666669|13.304952631578947|10.982309523809523|10.580000000000002|6.267999999999997|12.735526315789471|8.08790476190476|72.26115969177356|72.26115969177356|25.333333333333336|25.333333333333336\n",
      "\n",
      "<b>description:</b>this variant includes all attributes and associations present in the r-mim. any of non-mandatory and non-required attributes and/or associations may be present or absent, as permitted in the cardinality constraints.| <b>description:</b>this variant may include all of the mandatory set and all of the mandatory set|10.564999999999998|53.120000000000005|14.270000000000007|9.825|13.304952631578947|12.6227|10.580000000000002|12.369999999999997|12.735526315789471|7.767727272727274|72.26115969177356|69.96656701596841|25.333333333333336|18.900000000000002\n",
      "\n",
      "a collective term for pteroylglutamic acids and their oligoglutamic acid conjugates. as a natural water-soluble substance, folic acid is involved in carbon transfer reactions of amino acid metabolism, in addition to and purine and pyrimidine synthesis, and is essential for hematopoiesis and red blood cell production. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c510\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c510\" nci thesaurus)|a collective term for pteroylglutamic acids and their oligoglutamic acid change.  as a natural water-soluble substance, folic acid is having  carbon shift force of amino acid metabolism, in addition to and base and base synthesis, and is the thing for hematopoiesis and red blood cell display.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c510 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c510 '' nice wordbook)|36.123862068965536|60.478500000000025|9.661655172413795|6.687000000000001|13.199794915254238|14.220666511627908|-0.040689655172421624|-1.8346666666666707|25.06194915254237|12.198720930232554|53.2849499389837|50.453608988852324|22.32|16.86666666666667\n",
      "\n",
      "a collective term for pteroylglutamic acids and their oligoglutamic acid conjugates. as a natural water-soluble substance, folic acid is involved in carbon transfer reactions of amino acid metabolism, in addition to and purine and pyrimidine synthesis, and is essential for hematopoiesis and red blood cell production. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c510\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c510\" nci thesaurus)|a collective term for pteroylglutamic acids and their oligoglycans. as a natural water-soluble substance, folic acid is involved in carbon transfer reactions of amino acid metabolism, in addition to and purine and pyrimidine synthesis, and|36.123862068965536|12.62107142857144|9.661655172413795|15.846428571428575|13.199794915254238|13.515991891891893|-0.040689655172421624|17.693714285714286|25.06194915254237|13.406756756756756|53.2849499389837|98.94766798666859|22.32|29.857142857142858\n",
      "\n",
      "a collective term for pteroylglutamic acids and their oligoglutamic acid conjugates. as a natural water-soluble substance, folic acid is involved in carbon transfer reactions of amino acid metabolism, in addition to and purine and pyrimidine synthesis, and is essential for hematopoiesis and red blood cell production. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c510\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c510\" nci thesaurus)| An antimetabolite|36.123862068965536|6.390000000000015|9.661655172413795|13.113333333333333|13.199794915254238|15.6774|-0.040689655172421624|-65.34666666666666|25.06194915254237|1.7650000000000006|53.2849499389837|31.29|22.32|14.533333333333331\n",
      "\n",
      "a question associated with the fact-hep version 4 questionnaire.|a question unites with the fact-hep turn 4 form.|51.867500000000035|89.46750000000003|7.142777777777777|1.8983333333333334|12.0275|8.8695|-29.191111111111105|-39.64444444444443|9.004000000000001|1.468|49.473833993334296|38.32226702584281|24.022222222222226|15.133333333333333\n",
      "\n",
      "a question associated with the fact-hep version 4 questionnaire.|a question associated with the fact-hep version 4 questionnaire.|51.867500000000035|51.867500000000035|7.142777777777777|7.142777777777777|12.0275|12.522027272727273|-29.191111111111105|-28.537777777777777|9.004000000000001|4.870000000000001|49.473833993334296|49.473833993334296|24.022222222222226|24.022222222222226\n",
      "\n",
      "a question associated with the fact-hep version 4 questionnaire.| a question associated with the fact-questionnaire|51.867500000000035|42.61571428571432|7.142777777777777|9.054285714285715|12.0275|11.100677777777777|-29.191111111111105|-4.4857142857142875|9.004000000000001|6.620000000000001|49.473833993334296|54.195869768830164|24.022222222222226|19.942857142857143\n",
      "\n",
      "reduction inexisting body weight. [hpo:probinson]|change natural process body weight.  [ hop: robinson]|-32.58249999999995|80.06750000000002|18.425|3.2094444444444434|16.94363333333333|13.637516666666667|-65.47999999999999|-36.37777777777777|12.254999999999995|4.630833333333332|44.250742366654144|44.250742366654144|33.0|19.57777777777778\n",
      "\n",
      "reduction inexisting body weight. [hpo:probinson]|reduction inexisting body weight. [hpo:probinson]|-32.58249999999995|-32.58249999999995|18.425|18.425|16.94363333333333|17.344385714285714|-65.47999999999999|-64.304|12.254999999999995|8.579999999999998|44.250742366654144|44.250742366654144|33.0|33.0\n",
      "\n",
      "reduction inexisting body weight. [hpo:probinson]| weight reduction|-32.58249999999995|90.99000000000004|18.425|1.3133333333333361|16.94363333333333|19.6249|-65.47999999999999|-67.30666666666666|12.254999999999995|0.5874999999999986|44.250742366654144|31.29|33.0|14.533333333333331\n",
      "\n",
      "the determination of the amount of calcium sulphate crystals present in a sample.|the choice of the amount of calcium salt rock present in a sample.|50.56057692307695|89.6067307692308|7.821923076923078|2.375769230769233|10.354376923076924|6.710530769230769|-14.329230769230772|-21.113846153846154|9.706923076923076|4.272307692307692|58.53822981607831|44.250742366654144|24.13846153846154|14.90769230769231\n",
      "\n",
      "the determination of the amount of calcium sulphate crystals present in a sample.|the determination of the amount of calcium ion crystals present in a sample.|50.56057692307695|57.06826923076926|7.821923076923078|6.91423076923077|10.354376923076924|10.750842857142857|-14.329230769230772|-16.13846153846154|9.706923076923076|3.6014285714285705|58.53822981607831|54.195869768830164|24.13846153846154|21.06153846153846\n",
      "\n",
      "the determination of the amount of calcium sulphate crystals present in a sample.| the determination of the presence of calcium sulphate crystals|50.56057692307695|52.86500000000001|7.821923076923078|8.370000000000001|10.354376923076924|14.230281818181819|-14.329230769230772|2.7399999999999984|9.706923076923076|8.048181818181817|58.53822981607831|69.96656701596841|24.13846153846154|24.0\n",
      "\n",
      "a unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter travelled per unit time equal to one second. (nci)|a unit of both speed (scalar) and rate (vector), choose as the distance of one centimeter travel per unit time equal to one second.  ( nice)|55.40350000000004|80.33250000000004|8.637|5.408333333333335|11.2041|9.532135897435897|4.779199999999996|2.900740740740744|6.109199999999998|2.286794871794868|73.38155456243756|66.37611354998121|22.6|18.73333333333333\n",
      "\n",
      "a unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter travelled per unit time equal to one second. (nci)|a unit of both speed (scalar) and velocity, defined as the distance of one centimeter travelled per unit time equal to one second. (nci)|55.40350000000004|57.18000000000001|8.637|8.265|11.2041|11.2041|4.779199999999996|3.2633333333333354|6.109199999999998|5.167200000000001|73.38155456243756|69.96656701596841|22.6|21.46666666666667\n",
      "\n",
      "a unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter travelled per unit time equal to one second. (nci)| a unit of measurement|55.40350000000004|83.32000000000004|8.637|2.879999999999999|11.2041|14.460766666666668|4.779199999999996|-36.855999999999995|6.109199999999998|-2.729999999999997|73.38155456243756|44.250742366654144|22.6|18.0\n",
      "\n",
      "behavioral responses or sequences associated with eating including modes of feeding, rhythmic patterns of eating, and time intervals.|behavioral manner or rate unites with spend including modes of feeding, rhythmic match of spending, and time distance.|33.20000000000002|70.80000000000003|10.864444444444448|5.6200000000000045|12.4243|11.547077777777778|5.004444444444445|0.10444444444444656|17.13833333333333|13.213333333333331|73.38155456243756|58.53822981607831|28.044444444444448|19.15555555555556\n",
      "\n",
      "behavioral responses or sequences associated with eating including modes of feeding, rhythmic patterns of eating, and time intervals.|behavioral responses or sequences associated with eating including modes of feeding, rhythms of eating, and time intervals.|33.20000000000002|38.960441176470624|10.864444444444448|9.936764705882357|14.178744444444446|13.732344444444447|5.004444444444445|2.5317647058823525|17.13833333333333|10.544999999999998|73.38155456243756|66.37611354998121|28.044444444444448|24.576470588235296\n",
      "\n",
      "behavioral responses or sequences associated with eating including modes of feeding, rhythmic patterns of eating, and time intervals.| Behavioral responses or sequences associated with eating including eating behaviors and eating habits|33.20000000000002|17.382142857142867|10.864444444444448|14.312857142857148|14.178744444444446|12.801833333333335|5.004444444444445|16.657142857142855|17.13833333333333|14.643999999999998|73.38155456243756|98.94766798666859|28.044444444444448|34.17142857142857\n",
      "\n",
      "a stratified columnar epithelial cell that surrounds a lumen in a gland such as the breast, pancreas or prostate. these cells are uniform in appearance and have uniformly sized and shaped nuclei.|a put columnar epithelial cell that touches a layman in a gland such as the breast, pancreas or prostate.  these cells are supplied in pretense and have uniformly sized and change set.|58.53333333333336|77.7427272727273|7.745000000000001|5.148484848484848|10.844787499999999|9.445433333333334|2.385000000000005|0.17454545454545567|10.267187499999999|5.47909090909091|62.58|54.195869768830164|19.266666666666666|15.309090909090907\n",
      "\n",
      "a stratified columnar epithelial cell that surrounds a lumen in a gland such as the breast, pancreas or prostate. these cells are uniform in appearance and have uniformly sized and shaped nuclei.|a stratified columnar skin cell that surrounds a lumen such as the breast, pancreas or prostate. these cells are uniform in appearance and have uniformly sized and shaped nuclei.|58.53333333333336|62.83022988505749|7.745000000000001|6.897241379310348|10.35135|9.922166666666667|2.385000000000005|-0.004137931034481568|10.267187499999999|6.806000000000001|62.58|59.91578840339164|19.266666666666666|19.039080459770116\n",
      "\n",
      "a stratified columnar epithelial cell that surrounds a lumen in a gland such as the breast, pancreas or prostate. these cells are uniform in appearance and have uniformly sized and shaped nuclei.| a stratified columnar epithelial cell that surrounds a lumen and is epithelial|58.53333333333336|37.455384615384645|7.745000000000001|11.264615384615386|10.35135|13.353757142857145|2.385000000000005|7.987692307692306|10.267187499999999|8.783571428571431|62.58|76.64453405168562|19.266666666666666|23.661538461538463\n",
      "\n",
      "<p>the relationship that links to a transportation act (target) from another act (source) indicating that the subject of the source act entered into the source act by means of the target transportation act.</p>|< p > the relation that links to a banishment act (target) from another act (source) inform that the term of the source act get_down into the source act by means of the aim banishment act.  < /p >|54.21477272727276|87.13000000000002|9.796515151515155|6.075000000000003|11.873051351351352|11.33925|13.776969696969694|8.279000000000002|19.21972972972973|6.585750000000001|69.96656701596841|62.58|18.721212121212123|16.0\n",
      "\n",
      "<p>the relationship that links to a transportation act (target) from another act (source) indicating that the subject of the source act entered into the source act by means of the target transportation act.</p>|the relationship that links to a transportation act (target) from another act(source) indicating that the subject of the source act entered into the target transportation act.|54.21477272727276|40.7092307692308|9.796515151515155|10.810769230769232|11.873051351351352|10.154248148148149|13.776969696969694|11.379999999999992|19.21972972972973|10.963333333333331|69.96656701596841|73.38155456243756|18.721212121212123|22.123076923076923\n",
      "\n",
      "<p>the relationship that links to a transportation act (target) from another act (source) indicating that the subject of the source act entered into the source act by means of the target transportation act.</p>| <p>the relationship that links to another transportation act indicating that the subject of the transportation act entered that act by means of the act.|54.21477272727276|55.40350000000004|9.796515151515155|8.637|11.873051351351352|9.800527586206897|13.776969696969694|6.895999999999997|19.21972972972973|6.933793103448274|69.96656701596841|58.53822981607831|18.721212121212123|16.2\n",
      "\n",
      "provides education and support to the patient and designated support person based on their knowledge needs.|provides upbringing and support to the case and plan support person based on their knowledge needs.|45.377500000000026|71.81500000000001|8.917500000000004|5.230000000000004|11.338225000000001|9.364474999999999|-3.1899999999999977|-6.130000000000003|13.358125000000001|11.003125000000004|62.58|54.195869768830164|23.200000000000003|18.2\n",
      "\n",
      "provides education and support to the patient and designated support person based on their knowledge needs.|provides education and support to patient and designated support person based on their knowledge needs.|45.377500000000026|41.30250000000001|8.917500000000004|9.361666666666668|11.338225000000001|11.9283|-3.1899999999999977|-4.186666666666667|13.358125000000001|8.769375|62.58|62.58|23.200000000000003|24.333333333333336\n",
      "\n",
      "provides education and support to the patient and designated support person based on their knowledge needs.| provides education and support to the patient|45.377500000000026|50.66500000000002|8.917500000000004|8.180000000000003|11.338225000000001|14.60956666666667|-3.1899999999999977|-7.600000000000001|13.358125000000001|4.526666666666667|62.58|62.58|23.200000000000003|23.200000000000003\n",
      "\n",
      "a clinical finding about one or more characteristics of lip and oral cavity cancer, following the rules of the tnm ajcc v7 classification system. the assessment of the primary tumor is based on inspection and palpation of the oral cavity and neck. additional studies may include ct, mri, or ultrasound. (from ajcc 7th ed.)|a symptom finding  one or more property of lip and oral cavity cancer, following the rules of the tnm ajcc v7 restriction system.  the act of the coil growth is based on inspection and palpation of the oral structure and neck.  additional studies may include ct, mri, or sound.  ( from ajcc 7th ed.)|54.87300000000002|85.66444827586209|8.288666666666668|4.192620689655175|11.908692592592592|11.587173684210526|1.8837037037037057|-0.9834482758620702|7.997777777777777|2.9036842105263148|64.12541789337516|55.973253612774734|19.87555555555556|15.674482758620691\n",
      "\n",
      "a clinical finding about one or more characteristics of lip and oral cavity cancer, following the rules of the tnm ajcc v7 classification system. the assessment of the primary tumor is based on inspection and palpation of the oral cavity and neck. additional studies may include ct, mri, or ultrasound. (from ajcc 7th ed.)|a clinical finding about one or more characteristics of lip and oral cavity cancer, following the rules of the ajcc 7th ed.)|54.87300000000002|61.07909090909095|8.288666666666668|7.472727272727273|11.908692592592592|11.07211739130435|1.8837037037037057|0.8872727272727268|7.997777777777777|5.003043478260871|64.12541789337516|62.58|19.87555555555556|18.94545454545455\n",
      "\n",
      "a clinical finding about one or more characteristics of lip and oral cavity cancer, following the rules of the tnm ajcc v7 classification system. the assessment of the primary tumor is based on inspection and palpation of the oral cavity and neck. additional studies may include ct, mri, or ultrasound. (from ajcc 7th ed.)| the assessment of the primary tumor is based on inspection and palpation of the oral cavity|54.87300000000002|50.2388235294118|8.288666666666668|10.47529411764706|11.908692592592592|12.4243|1.8837037037037057|9.221176470588237|7.997777777777777|7.98|64.12541789337516|82.78555852321104|19.87555555555556|23.270588235294117\n",
      "\n",
      "traumatic injury to the abducens, or sixth, cranial nerve. injury to this nerve results in lateral rectus muscle weakness or paralysis. the nerve may be damaged by closed or penetrating craniocerebral trauma or by facial trauma involving the orbit.|traumatic wrongdoing to the abducens, or sixth, cranial nerve.  wrongdoing to this nerve results in pass rectus muscle weakness or dysfunction.  the nerve may be changed by closed or penetrate craniocerebral trauma or by facial trauma absorb the path.|40.75413461538463|68.49954268292684|9.997115384615388|6.251402439024389|11.568992307692309|10.97541512195122|1.3025641025641086|1.3824390243902478|9.827692307692306|6.5646341463414615|68.19497397169383|62.58|23.387179487179488|19.709756097560977\n",
      "\n",
      "traumatic injury to the abducens, or sixth, cranial nerve. injury to this nerve results in lateral rectus muscle weakness or paralysis. the nerve may be damaged by closed or penetrating craniocerebral trauma or by facial trauma involving the orbit.|traumatic injury to the abducens, or sixth, cranial nerve. injury to this nerve results in lateral rectus muscle weakness or paralysis. the nerve may be damaged by closed or penetrating craniocerebral trauma or by facial trauma|40.75413461538463|39.55500000000001|9.997115384615388|10.723333333333333|11.568992307692309|11.503098198198199|1.3025641025641086|6.856666666666666|9.827692307692306|8.795855855855855|68.19497397169383|74.48509850970193|23.387179487179488|23.68888888888889\n",
      "\n",
      "traumatic injury to the abducens, or sixth, cranial nerve. injury to this nerve results in lateral rectus muscle weakness or paralysis. the nerve may be damaged by closed or penetrating craniocerebral trauma or by facial trauma involving the orbit.| Traumatic injury to the sixth cranial nerve resulting in muscle weakness or paralysis.|40.75413461538463|48.65857142857146|9.997115384615388|8.211428571428574|11.568992307692309|12.429833333333335|1.3025641025641086|-10.785714285714292|9.827692307692306|5.870000000000001|68.19497397169383|58.53822981607831|23.387179487179488|22.8\n",
      "\n",
      "stage i includes: t1, n0, m0. t1: solitary tumor without vascular invasion. n0: no regional lymph node metastasis. m0: no distant metastasis. (ajcc 6th and 7th eds.)|stage i includes: t1, n0, m0.  t1: loner growth without vascular spread.  n0: no regional lymph node metastasis.  m0: no distant metastasis.  ( ajcc 6th and 7th eds.)|80.06750000000002|111.53416666666669|3.2094444444444434|-0.9724999999999984|16.18545111111111|16.168536129032262|-35.50666666666666|-30.693749999999994|3.25|0.8138709677419378|40.39521630094336|36.13057984588678|16.614814814814817|12.133333333333333\n",
      "\n",
      "stage i includes: t1, n0, m0. t1: solitary tumor without vascular invasion. n0: no regional lymph node metastasis. m0: no distant metastasis. (ajcc 6th and 7th eds.)|stage i includes: t1, n0, m0. t1: tumor with no regional lymph node metastasis. (ajcc 6th and 7th eds.)|80.06750000000002|108.50848684210527|3.2094444444444434|-0.6953947368421041|16.140811111111113|15.727|-35.50666666666666|-35.701052631578946|2.8000000000000007|-0.7964999999999982|40.39521630094336|31.29|16.614814814814817|10.321052631578947\n",
      "\n",
      "stage i includes: t1, n0, m0. t1: solitary tumor without vascular invasion. n0: no regional lymph node metastasis. m0: no distant metastasis. (ajcc 6th and 7th eds.)| stage i includes: t1, n0, m0. t1: solitary tumor|80.06750000000002|108.70000000000002|3.2094444444444434|-0.6599999999999966|16.1089253968254|16.82839090909091|-35.50666666666666|-35.092|2.4785714285714278|-2.837272727272726|40.39521630094336|38.32226702584281|16.614814814814817|14.0\n",
      "\n",
      "this gene plays a role in the metabolism of a wide variety of carbonyl compounds.|this gene plays a role in the metabolism of a wide difference of compound mix.|63.86250000000001|80.78250000000001|6.215000000000003|3.8550000000000004|10.6965|8.591166666666666|-13.20266666666667|-14.378666666666668|6.7940000000000005|5.852|44.250742366654144|38.32226702584281|13.66666666666667|11.0\n",
      "\n",
      "this gene plays a role in the metabolism of a wide variety of carbonyl compounds.|this gene takes part in the metabolism of a wide variety of carbonyl compounds.|63.86250000000001|60.74428571428575|6.215000000000003|6.525714285714287|10.6965|10.3245|-13.20266666666667|-14.145714285714288|6.7940000000000005|3.0440000000000005|44.250742366654144|44.250742366654144|13.66666666666667|14.228571428571428\n",
      "\n",
      "this gene plays a role in the metabolism of a wide variety of carbonyl compounds.| This gene plays a role in the metabolism of a wide variety of carbonyl compounds.|63.86250000000001|71.81500000000001|6.215000000000003|5.230000000000004|10.6965|11.488688235294118|-13.20266666666667|-12.010000000000002|6.7940000000000005|1.6600000000000001|44.250742366654144|44.250742366654144|13.66666666666667|13.200000000000001\n",
      "\n",
      "a gland producing tears in a third eyelid in the corner of each eye, as seen in animals.|a body part change tears in a third eyelid in the turn of each eye, as seen in animals.|84.90000000000003|94.78197368421053|3.653333333333336|2.399210526315791|7.160966666666667|5.409952631578948|-9.695555555555554|-9.804210526315785|5.625|4.678947368421053|44.250742366654144|38.32226702584281|12.488888888888889|10.115789473684211\n",
      "\n",
      "a gland producing tears in a third eyelid in the corner of each eye, as seen in animals.|a gland producing tears in a third eyelid in the corner of the eye, as seen in animals.|84.90000000000003|84.90000000000003|3.653333333333336|3.653333333333336|7.160966666666667|7.431910526315789|-9.695555555555554|-9.695555555555554|5.625|0.42473684210526486|44.250742366654144|44.250742366654144|12.488888888888889|12.488888888888889\n",
      "\n",
      "a gland producing tears in a third eyelid in the corner of each eye, as seen in animals.| a gland|84.90000000000003|147.39000000000004|3.653333333333336|-6.553333333333333|7.160966666666667|15.6774|-9.695555555555554|-84.94666666666666|5.625|-10.01|44.250742366654144|0.0|12.488888888888889|1.2000000000000002\n",
      "\n",
      "the date that a specific cardiac therapeutic procedure was performed.|the date that a fact cardiac medicine software was re-create.|32.56000000000003|74.86000000000003|9.96|4.060000000000002|12.0275|9.923918181818184|-23.919999999999995|-28.624|11.359000000000002|5.47909090909091|49.473833993334296|44.250742366654144|22.0|18.0\n",
      "\n",
      "the date that a specific cardiac therapeutic procedure was performed.|the date that a specific heart rhythm procedure was performed.|32.56000000000003|66.40000000000003|9.96|5.240000000000002|12.0275|11.086572727272728|-23.919999999999995|-27.447999999999993|11.359000000000002|4.0136363636363654|49.473833993334296|38.32226702584281|22.0|14.0\n",
      "\n",
      "the date that a specific cardiac therapeutic procedure was performed.| the date that a specific cardiac therapeutic procedure was performed.|32.56000000000003|47.434318181818185|9.96|8.009545454545457|12.0275|13.144933333333334|-23.919999999999995|-21.21090909090909|11.359000000000002|5.512499999999999|49.473833993334296|49.473833993334296|22.0|20.381818181818183\n",
      "\n",
      "a standardized 30-item self-report questionnaire that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. the questionnaire, which was created by rush, et al. in 1986, originally consisted of 28 items including the nine diagnostic dsm-iv symptom domains used to characterize a major depressive episode, as well as items to address melancholic and atypical features. two additional items were later added to address leaden paralysis and interpersonal rejection sensitivity.|a measure 30-item self-report form that change a 5-point pad scale for the act of the sternness of depressive symptoms over the seven day period prior to the appraisal.  the form, which was created by the rush, et al.  in 1986, originally be of 28 fact including the nine diagnostic dsm-iv symptom class used to distinguish a major depressive episode, as well as fact to come depressive and atypical have.  two additional facts were later added to come leaden dysfunction and interpersonal speech_act ability.|25.115829268292714|61.78779310344828|13.830390243902439|8.963816091954026|13.320575968992248|10.635360073260074|16.083902439024392|11.577471264367812|18.31542635658915|7.58124542124542|89.6009242139834|74.04565456527479|26.560000000000002|19.833563218390807\n",
      "\n",
      "a standardized 30-item self-report questionnaire that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. the questionnaire, which was created by rush, et al. in 1986, originally consisted of 28 items including the nine diagnostic dsm-iv symptom domains used to characterize a major depressive episode, as well as items to address melancholic and atypical features. two additional items were later added to address leaden paralysis and interpersonal rejection sensitivity.|a standardized 30-item self-report questionnaire that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. the questionnaire, which was created by rush, et al. in 1986, originally consisted of 28 items including|25.115829268292714|39.33000000000001|13.830390243902439|11.500000000000004|13.320575968992248|13.230067346938775|16.083902439024392|13.194666666666663|18.31542635658915|14.273877551020412|89.6009242139834|80.79043260188672|26.560000000000002|23.77777777777778\n",
      "\n",
      "a standardized 30-item self-report questionnaire that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. the questionnaire, which was created by rush, et al. in 1986, originally consisted of 28 items including the nine diagnostic dsm-iv symptom domains used to characterize a major depressive episode, as well as items to address melancholic and atypical features. two additional items were later added to address leaden paralysis and interpersonal rejection sensitivity.| a standardized self-report questionnaire that utilizes a 5-point rating scale in order to assess the severity of depressive symptoms over the preceding week|25.115829268292714|27.37500000000003|13.830390243902439|15.403333333333332|12.965109302325581|12.578292592592591|16.083902439024392|20.741666666666664|14.732093023255814|15.44555555555555|89.6009242139834|108.39173953766033|26.560000000000002|29.6\n",
      "\n",
      "a unit of radioactivity equal to one millionth of a curie or 37 kilobecquerels, and corresponding to a radioactivity of 37 000 atomic disintegrations per second.|a unit of emission equal to one rank of a car or 37 kilobecquerels, and equal to an emission of 37 000 atomic destruction per second.|37.455384615384645|66.74000000000002|11.264615384615386|7.180000000000003|12.8211|11.606484615384616|7.987692307692306|1.655384615384616|15.844615384615388|10.772307692307692|69.96656701596841|66.37611354998121|20.58461538461539|19.046153846153846\n",
      "\n",
      "a unit of radioactivity equal to one millionth of a curie or 37 kilobecquerels, and corresponding to a radioactivity of 37 000 atomic disintegrations per second.|a unit of radioactivity equal to one millionth of a curie or 37 kilobases, and corresponding to an activity of 37 000 atomic breaks per second.|37.455384615384645|56.97846153846157|11.264615384615386|8.541538461538462|12.8211|11.908692592592592|7.987692307692306|4.143076923076922|15.844615384615388|5.73|69.96656701596841|66.37611354998121|20.58461538461539|19.046153846153846\n",
      "\n",
      "a unit of radioactivity equal to one millionth of a curie or 37 kilobecquerels, and corresponding to a radioactivity of 37 000 atomic disintegrations per second.| a unit of radioactivity equal to one millionth of a curie or 37 kilobecquerels, and corresponding to a radioactivity of 37 kilodaltons per second|37.455384615384645|32.56400000000002|11.264615384615386|14.928|12.8211|12.8211|7.987692307692306|17.0896|15.844615384615388|13.851923076923079|69.96656701596841|93.86999999999999|20.58461538461539|24.400000000000002\n",
      "\n",
      "the condition in which the individual does not see far distances clearly.|the condition in which the organism does not see far keep clear.|52.69500000000002|87.94500000000002|7.400000000000002|2.4833333333333343|9.495033333333335|6.863366666666667|-18.953333333333326|-23.36333333333333|8.5125|4.98|44.250742366654144|31.29|15.733333333333333|9.066666666666666\n",
      "\n",
      "the condition in which the individual does not see far distances clearly.|the condition in which the individual does not see far distances clear.|52.69500000000002|59.745000000000005|7.400000000000002|6.416666666666668|9.495033333333335|8.817361538461538|-18.953333333333326|-19.443333333333328|8.5125|3.558461538461536|44.250742366654144|38.32226702584281|15.733333333333333|12.4\n",
      "\n",
      "the condition in which the individual does not see far distances clearly.| the condition in which the individual does not see far distances clearly.|52.69500000000002|63.57596153846157|7.400000000000002|6.006538461538462|9.495033333333335|10.750842857142857|-18.953333333333326|-17.043076923076928|8.5125|3.2650000000000006|44.250742366654144|44.250742366654144|15.733333333333333|14.90769230769231\n",
      "\n",
      "the process of keeping something within particular limits or bounds.|the walk of keeping something within part limits or bounds.|49.48000000000002|83.32000000000004|7.600000000000001|2.879999999999999|12.0275|8.8695|-24.507999999999996|-29.799999999999997|10.887999999999998|6.649000000000001|54.195869768830164|44.250742366654144|26.0|18.0\n",
      "\n",
      "the process of keeping something within particular limits or bounds.|the process of keeping something within certain limits or bounds.|49.48000000000002|66.40000000000003|7.600000000000001|5.240000000000002|12.0275|11.086572727272728|-24.507999999999996|-25.683999999999997|10.887999999999998|5.298181818181817|54.195869768830164|54.195869768830164|26.0|26.0\n",
      "\n",
      "the process of keeping something within particular limits or bounds.| the process of keeping an organism within particular limits or bounds|49.48000000000002|53.655|7.600000000000001|8.756666666666668|12.0275|13.998223076923077|-24.507999999999996|4.733333333333334|10.887999999999998|7.170769230769231|54.195869768830164|76.64453405168562|26.0|24.8\n",
      "\n",
      "a measurement of the herpes simplex virus 2 igg antibody in a biological specimen.|a functional concept of the herpes simplex virus 2 egg protein in a biological sample.|36.572857142857174|52.58250000000001|9.89714285714286|7.7883333333333375|14.481614285714286|13.8545|-13.305714285714284|-11.242666666666668|8.447142857142854|8.364|58.53822981607831|62.58|22.8|24.333333333333336\n",
      "\n",
      "a measurement of the herpes simplex virus 2 igg antibody in a biological specimen.|a measurement of herpes simplex virus 2 igg antibody in a biological specimen.|36.572857142857174|31.037500000000023|9.89714285714286|10.545000000000002|14.481614285714286|15.262271428571431|-13.305714285714284|-15.233846153846155|8.447142857142854|4.274285714285714|58.53822981607831|58.53822981607831|22.8|24.13846153846154\n",
      "\n",
      "a measurement of the herpes simplex virus 2 igg antibody in a biological specimen.| a measurement of the herpes simplex virus 2 antibody in a biological specimen.|36.572857142857174|42.61571428571432|9.89714285714286|9.054285714285715|14.481614285714286|14.535166666666669|-13.305714285714284|-14.145714285714288|8.447142857142854|3.3580000000000005|58.53822981607831|58.53822981607831|22.8|22.8\n",
      "\n",
      "a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. this process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ros) derived from iron metabolism. glutathione peroxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ros production and reducing cellular iron uptake, respectively. in contrast, nadph oxidase and p53 act as positive regulators of ferroptosis by promotion of ros production and inhibition of expression of slc7a11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. misregulated ferroptosis has been implicated in multiple physiological and pathological processes. [goc:mtg_apoptosis, pmid:25236395, pmid:26794443]|a schedule, cell death distinguishes morphologically by the presence of smaller than normal mitochondria with change mitochondrial membrane spacing, change or decrease of mitochondria crista, and outer mitochondrial sheet rupture.  beginning of mitochondrial voltage-dependent anion move and mitogen-activated protein enzyme, upregulation of endoplasmic stomach stress, and action of the cystine / glutamate antiporter are having in the causing of ferroptosis.  this walk is distinguished by the net_income of lipid peroxidation products and lethal reactive oxygen kind (ros) make from iron metabolism.  glutathione oxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 serve as a negative control of ferroptosis by choosing rose display and reducing cellular iron uptake, respectively.  in contrast, nadph enzyme and p53 act as film control of ferroptosis by change of rose display and action of squeeze of slc7a11 (a fact light-chain subunit of the cystine/glutamate antiporter), respectively.  misregulated ferroptosis has been lead in product physiological and pathological transform.  [ goc : mtg_apoptosis , pmid:25236395 , pmid:26794443 ]|-8.855483870967703|30.650526315789506|19.995391705069128|15.052932330827073|15.116114109347443|12.97722549019608|28.057806451612905|22.750409356725147|20.959947089947086|12.999039215686274|111.57105673067723|103.1011095963569|31.82488479262673|27.54920634920635\n",
      "\n",
      "a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. this process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ros) derived from iron metabolism. glutathione peroxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ros production and reducing cellular iron uptake, respectively. in contrast, nadph oxidase and p53 act as positive regulators of ferroptosis by promotion of ros production and inhibition of expression of slc7a11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. misregulated ferroptosis has been implicated in multiple physiological and pathological processes. [goc:mtg_apoptosis, pmid:25236395, pmid:26794443]|a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of ferroptosis has been implicated in multiple physiological and|-8.855483870967703|-6.019038461538429|19.995391705069128|18.943205128205125|15.116114109347443|13.707749999999999|28.057806451612905|25.226666666666667|20.959947089947086|19.77375|111.57105673067723|103.77718969022045|31.82488479262673|30.364102564102566\n",
      "\n",
      "a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. this process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ros) derived from iron metabolism. glutathione peroxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ros production and reducing cellular iron uptake, respectively. in contrast, nadph oxidase and p53 act as positive regulators of ferroptosis by promotion of ros production and inhibition of expression of slc7a11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. misregulated ferroptosis has been implicated in multiple physiological and pathological processes. [goc:mtg_apoptosis, pmid:25236395, pmid:26794443]| a|-8.855483870967703|162.505|19.995391705069128|-8.91|15.116114109347443|14.311966666666669|28.057806451612905|-142.12|20.959947089947086|-15.219999999999999|111.57105673067723|0.0|31.82488479262673|0.8\n",
      "\n",
      "pediatric quality of life neuromuscular module version 3 toddler parent report - in the past one month, how much of a problem has this been for your child: i think our family has a lot of problems.|pediatrician quality of life neuromuscular module turn 3 toddler parent report - in the past one month, how much of a problem has this been for your child: i think our family has a lot of problems.|69.1602027027027|69.1602027027027|8.208783783783787|8.208783783783787|9.3696|8.930988888888889|9.585945945945948|9.585945945945948|17.110833333333332|17.110833333333332|73.38155456243756|69.96656701596841|19.291891891891893|18.210810810810813\n",
      "\n",
      "pediatric quality of life neuromuscular module version 3 toddler parent report - in the past one month, how much of a problem has this been for your child: i think our family has a lot of problems.|i think our family has a lot of problems.|69.1602027027027|89.46750000000003|8.208783783783787|1.8983333333333334|9.3696|7.0425|9.585945945945948|-43.56444444444444|17.110833333333332|-3.3870000000000005|73.38155456243756|31.29|19.291891891891893|10.68888888888889\n",
      "\n",
      "pediatric quality of life neuromuscular module version 3 toddler parent report - in the past one month, how much of a problem has this been for your child: i think our family has a lot of problems.| pediatric quality of life neuromuscular module version 3 family report - in the past one month, how much of a problem has that been for your family: i think our family has a lot of problems.|69.1602027027027|66.87371621621622|8.208783783783787|8.527702702702705|9.3696|8.821667567567568|9.585945945945948|8.791351351351349|17.110833333333332|7.2964864864864865|73.38155456243756|73.38155456243756|19.291891891891893|19.291891891891893\n",
      "\n",
      "reduced prothrombin antigen as measured by elisa assay. prothrombin is a vitamin k-dependent coagulation factor that is proteolytically cleaved to form thrombin. []|reduced immunologic factor substance as be by assay act.  prothrombin is a vitamin k-dependent coagulation factor that is proteolytically touch to form thrombin.  [ ]|22.49681159420291|50.433333333333366|12.026086956521741|8.460740740740743|13.628071014492756|13.004035384615385|-2.306086956521739|-2.3999999999999986|10.458550724637679|5.988076923076925|67.59412548439398|62.58|27.414492753623193|21.37777777777778\n",
      "\n",
      "reduced prothrombin antigen as measured by elisa assay. prothrombin is a vitamin k-dependent coagulation factor that is proteolytically cleaved to form thrombin. []|reduced fibrinogen as measured by elisa assay. prothrombin is a vitamin k-dependent protein breakdown factor that is proteolytically cleaved to form blood clot. []|22.49681159420291|36.565|12.026086956521741|10.146666666666668|13.628071014492756|13.523833333333334|-2.306086956521739|-2.4550000000000054|10.458550724637679|8.35906666666667|67.59412548439398|65.13532912329528|27.414492753623193|24.866666666666667\n",
      "\n",
      "reduced prothrombin antigen as measured by elisa assay. prothrombin is a vitamin k-dependent coagulation factor that is proteolytically cleaved to form thrombin. []| reduced coagulation factor|22.49681159420291|33.57500000000002|12.026086956521741|9.57|13.628071014492756|19.674500000000002|-2.306086956521739|-37.25|10.458550724637679|5.562000000000001|67.59412548439398|54.195869768830164|27.414492753623193|31.6\n",
      "\n",
      "any treatment designed to lessen the effects of dysphagia. treatment may include restoration of normal swallow function (rehabilitative), modifications to diet consistency and patient behavior (compensatory), or a combination of these approaches.|any care designed to change the effects of dysphagia.  care may include a model of the normal swallow function (rehabilitative), happening to diet coherence and patient trait (compensatory), or an alliance of these addresses.|5.65833333333336|42.71333333333334|15.120000000000001|10.200000000000003|14.5990125|11.271642857142858|11.756250000000005|6.716571428571427|25.0378125|12.081142857142858|82.78555852321104|74.48509850970193|30.51666666666667|24.095238095238095\n",
      "\n",
      "any treatment designed to lessen the effects of dysphagia. treatment may include restoration of normal swallow function (rehabilitative), modifications to diet consistency and patient behavior (compensatory), or a combination of these approaches.|any treatment designed to lessen the effects of dysphagia. treatment may include restoration of normal swallow function (rehabilitative), modification to diet consistency and patient behavior (compensatory), or a combination of these approaches.|5.65833333333336|5.65833333333336|15.120000000000001|15.120000000000001|13.805412500000001|13.75179696969697|11.756250000000005|11.756250000000005|17.0378125|13.614545454545457|82.78555852321104|82.78555852321104|30.51666666666667|30.51666666666667\n",
      "\n",
      "any treatment designed to lessen the effects of dysphagia. treatment may include restoration of normal swallow function (rehabilitative), modifications to diet consistency and patient behavior (compensatory), or a combination of these approaches.| Any treatment designed to lessen the effects of dysphasia.|5.65833333333336|66.40000000000003|15.120000000000001|5.240000000000002|13.805412500000001|13.957481818181819|11.756250000000005|-29.211999999999996|17.0378125|3.15727272727273|82.78555852321104|54.195869768830164|30.51666666666667|26.0\n",
      "\n",
      "any process that modulates the frequency, rate or extent of striated muscle cell differentiation. [cl:0000737, goc:ai]|any walk that changes the ratio, rate or extent of mark muscle cell adaptation.  [ cl: 0000737, goc: ai]|40.09|90.935|9.655000000000001|3.0599999999999987|13.346335294117647|11.587173684210526|0.8524999999999991|-4.609999999999999|9.694705882352942|2.9036842105263148|66.37611354998121|54.195869768830164|25.700000000000003|16.0\n",
      "\n",
      "any process that modulates the frequency, rate or extent of striated muscle cell differentiation. [cl:0000737, goc:ai]|any process that changes the frequency, rate or extent of striated muscle cell differentiation. [cl:0000737, goc:ai]|40.09|50.66500000000002|9.655000000000001|8.180000000000003|13.346335294117647|12.855122222222224|0.8524999999999991|0.48499999999999943|9.694705882352942|8.189999999999998|66.37611354998121|66.37611354998121|25.700000000000003|25.700000000000003\n",
      "\n",
      "any process that modulates the frequency, rate or extent of striated muscle cell differentiation. [cl:0000737, goc:ai]| process|40.09|120.20500000000001|9.655000000000001|-3.01|13.346335294117647|19.5753|0.8524999999999991|-124.48|9.694705882352942|-5.800000000000001|66.37611354998121|31.29|25.700000000000003|20.8\n",
      "\n",
      "international physical activity questionnaire (august 2002) - short last 7 days telephone format - how much time did you usually spend doing moderate physical activities on one of those days?: hours and minutes per day.|socialism daily activity activity form (august 2002) - short last 7 days telephone change - how much time did you usually spend doing change physical trait on one of those days?  : hours and minutes per day.|48.87821428571431|74.00789473684213|10.789285714285715|7.656842105263159|10.675203030303031|9.46707142857143|14.165714285714287|10.726315789473684|12.225454545454546|9.389714285714287|79.77416029015912|69.96656701596841|21.85714285714286|18.126315789473683\n",
      "\n",
      "international physical activity questionnaire (august 2002) - short last 7 days telephone format - how much time did you usually spend doing moderate physical activities on one of those days?: hours and minutes per day.|international physical activity questionnaire (august 2002) short last 7 days telephone format - how much time did you usually spend doing moderate physical activities on one of those days? hours and minutes per day.|48.87821428571431|45.26235294117649|10.789285714285715|11.169411764705881|11.15368787878788|11.024276470588235|14.165714285714287|14.409411764705883|12.225454545454546|7.616764705882353|79.77416029015912|79.77416029015912|21.85714285714286|22.094117647058823\n",
      "\n",
      "international physical activity questionnaire (august 2002) - short last 7 days telephone format - how much time did you usually spend doing moderate physical activities on one of those days?: hours and minutes per day.| international physical activity questionnaire|48.87821428571431|-52.039999999999964|10.789285714285715|21.76000000000001|11.493603030303031|19.7241|14.165714285714287|-8.632000000000005|20.475454545454546|16.11|79.77416029015912|62.58|21.85714285714286|34.0\n",
      "\n",
      "a colloidal mixture of nanoparticles consisting of small interfering rna (sirna) targeting the native eukaryotic translation initiation factor 5a (eif5a), plasmids expressing a pro-apoptotic mutant of elf5a under the control of a b-cell specific promoter (b29), and a synthetic cationic polymer polyethylenimine (pei) as a delivery vehicle, with potential antineoplastic activity. upon administration, the sirna component of sns01-t suppresses elf5a expression, thereby interfering with translation of eif5a and reducing levels of hypusinated elf5a in cancer cells. in turn, this inhibits activation of the transcription factor nf-kb and induces apoptosis. in addition, the b-cell specific plasmid component expresses an arginine substituted form of eif5a, eif5ak50r, which can not be hypusinated, thus leads to a selective induction of apoptosis in b-cells. the native unhypusinated form of eif5a is pro-apoptotic and can be modified at the lysine residue, by deoxyhypusine synthase (dhs) and subsequently deoxyhypusine hydroxylase (dhh), to the anti-apoptotic hypusinated form which is associated with tumor cell growth and survival. the delivery vehicle protects the sirna and plasmid from degradation. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c98288\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c98288\" nci thesaurus)|a substance mixture of nanoparticles be of small interact rna ( sirna ) aim the native eukaryotic motion causing factor 5a ( eif5a ) , plasmids mail a pro-apoptotic mutant of elf5a under the control of a b-cell fact promoter ( b29 ) , and a compound cationic polymer polyethylenimine ( pei ) as a act object , with potential antineoplastic activity .  upon justice, the soprano part of sns01-t decrease elf5a squeeze, thereby interact with motion of eif5a and reducing levels of hypusinated elf5a in cancer cells.  in turn, this suppresses beginning of the transcription factor nf-kb and produce apoptosis.  in addition, the b-cell fact plasmid part mail an arginine supplant form of eif5a, eif5ak50r, which can not be hypusinated, thus leads to a selective causing  apoptosis in b-cells.  the native unhypusinated form of eif5a is pro-apoptotic and can be added at the lysine part, by deoxyhypusine synthase (dhs) and subsequently deoxyhypusine hydroxylase (duh), to the anti-apoptotic hypusinated form which is united with tumor cell growth and survival.  the active object protects the serene and plasmid from degradation.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c98288 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c98288 '' nice wordbook)|26.465000000000003|58.57915094339626|12.762063492063493|8.850619946091644|14.291433434650456|13.483683608562691|18.52977777777777|13.15339622641509|22.738837386018233|10.207675840978592|77.0994017486517|73.38155456243756|24.03174603174603|20.58544474393531\n",
      "\n",
      "a colloidal mixture of nanoparticles consisting of small interfering rna (sirna) targeting the native eukaryotic translation initiation factor 5a (eif5a), plasmids expressing a pro-apoptotic mutant of elf5a under the control of a b-cell specific promoter (b29), and a synthetic cationic polymer polyethylenimine (pei) as a delivery vehicle, with potential antineoplastic activity. upon administration, the sirna component of sns01-t suppresses elf5a expression, thereby interfering with translation of eif5a and reducing levels of hypusinated elf5a in cancer cells. in turn, this inhibits activation of the transcription factor nf-kb and induces apoptosis. in addition, the b-cell specific plasmid component expresses an arginine substituted form of eif5a, eif5ak50r, which can not be hypusinated, thus leads to a selective induction of apoptosis in b-cells. the native unhypusinated form of eif5a is pro-apoptotic and can be modified at the lysine residue, by deoxyhypusine synthase (dhs) and subsequently deoxyhypusine hydroxylase (dhh), to the anti-apoptotic hypusinated form which is associated with tumor cell growth and survival. the delivery vehicle protects the sirna and plasmid from degradation. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c98288\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c98288\" nci thesaurus)|a colloidal mixture of nanoparticles consisting of small interfering rna (sirna) targeting the native eukaryotic translation initiation factor 5a (eif5a), plasmids expressing a cell cycle protein complex, which can be activated by|26.465000000000003|5.15500000000003|12.762063492063493|20.49|14.12491914893617|15.799966666666668|18.52977777777777|27.5|21.06026595744681|22.759090909090908|77.0994017486517|132.75222709996243|24.03174603174603|35.300000000000004\n",
      "\n",
      "a colloidal mixture of nanoparticles consisting of small interfering rna (sirna) targeting the native eukaryotic translation initiation factor 5a (eif5a), plasmids expressing a pro-apoptotic mutant of elf5a under the control of a b-cell specific promoter (b29), and a synthetic cationic polymer polyethylenimine (pei) as a delivery vehicle, with potential antineoplastic activity. upon administration, the sirna component of sns01-t suppresses elf5a expression, thereby interfering with translation of eif5a and reducing levels of hypusinated elf5a in cancer cells. in turn, this inhibits activation of the transcription factor nf-kb and induces apoptosis. in addition, the b-cell specific plasmid component expresses an arginine substituted form of eif5a, eif5ak50r, which can not be hypusinated, thus leads to a selective induction of apoptosis in b-cells. the native unhypusinated form of eif5a is pro-apoptotic and can be modified at the lysine residue, by deoxyhypusine synthase (dhs) and subsequently deoxyhypusine hydroxylase (dhh), to the anti-apoptotic hypusinated form which is associated with tumor cell growth and survival. the delivery vehicle protects the sirna and plasmid from degradation. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c98288\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c98288\" nci thesaurus)| a|26.465000000000003|162.505|12.762063492063493|-8.91|14.12491914893617|14.311966666666669|18.52977777777777|-142.12|21.06026595744681|-15.219999999999999|77.0994017486517|0.0|24.03174603174603|0.8\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated|life-threatening result; urgent care informs|-119.71999999999994|-1.2799999999999727|31.200000000000006|14.68|16.94363333333333|14.311966666666669|6.655999999999999|-12.159999999999997|22.46|9.899999999999999|69.96656701596841|62.58|42.0|34.0\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated|life-threatening consequences; urgent intervention indicated|-119.71999999999994|-119.71999999999994|31.200000000000006|31.200000000000006|16.94363333333333|17.344385714285714|6.655999999999999|7.832000000000001|22.46|17.327142857142853|69.96656701596841|69.96656701596841|42.0|42.0\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated| life-threatening condition; urgent intervention|-119.71999999999994|-35.11999999999995|31.200000000000006|19.400000000000002|16.94363333333333|17.517985714285714|6.655999999999999|-6.279999999999994|22.46|11.675714285714285|69.96656701596841|62.58|42.0|34.0\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated|life-threatening result; urgent care informs|-119.71999999999994|-1.2799999999999727|31.200000000000006|14.68|16.94363333333333|14.311966666666669|6.655999999999999|-12.159999999999997|22.46|9.899999999999999|69.96656701596841|62.58|42.0|34.0\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated|life-threatening consequences; urgent intervention indicated|-119.71999999999994|-119.71999999999994|31.200000000000006|31.200000000000006|16.94363333333333|17.344385714285714|6.655999999999999|7.832000000000001|22.46|17.327142857142853|69.96656701596841|69.96656701596841|42.0|42.0\n",
      "\n",
      "life-threatening consequences; urgent intervention indicated| life-threatening condition; urgent intervention|-119.71999999999994|-35.11999999999995|31.200000000000006|19.400000000000002|16.94363333333333|17.517985714285714|6.655999999999999|-6.279999999999994|22.46|11.675714285714285|69.96656701596841|62.58|42.0|34.0\n",
      "\n",
      "this gene plays a role in apoptosis and development.|this gene plays a role in apoptosis and section.|61.26750000000001|80.06750000000002|5.831666666666667|3.2094444444444434|11.100677777777777|11.100677777777777|-37.0311111111111|-39.64444444444443|5.573333333333334|3.4800000000000004|31.29|31.29|10.68888888888889|10.68888888888889\n",
      "\n",
      "this gene plays a role in apoptosis and development.|this gene plays a role in programmed cell death and death.|61.26750000000001|101.27068181818181|5.831666666666667|0.5004545454545486|11.100677777777777|9.197433333333334|-37.0311111111111|-27.625454545454552|5.573333333333334|0.41000000000000014|31.29|22.125371183327072|10.68888888888889|5.836363636363637\n",
      "\n",
      "this gene plays a role in apoptosis and development.| this gene is involved in cell division and development|61.26750000000001|69.78500000000001|5.831666666666667|6.010000000000002|11.100677777777777|12.794827272727273|-37.0311111111111|-1.9639999999999986|5.573333333333334|4.622727272727271|31.29|54.195869768830164|10.68888888888889|16.0\n",
      "\n",
      "a method of ultrasound imaging that uses a linear pattern of beams to produce a standard, two dimensional image.|a method of sound imaging that uses a linear match of beams to produce a standard, two dimensional image.|45.80302631578948|59.16092105263158|9.230789473684215|7.367631578947371|12.058373684210528|10.396268421052632|-2.067368421052631|-4.23368421052632|10.876315789473686|9.141052631578948|69.96656701596841|62.58|24.852631578947367|20.642105263157895\n",
      "\n",
      "a method of ultrasound imaging that uses a linear pattern of beams to produce a standard, two dimensional image.|a method of ultrasound imaging that uses a linear pattern of beams to produce standard, two dimensional image.|45.80302631578948|42.60000000000002|9.230789473684215|9.553333333333335|12.058373684210528|12.418226315789473|-2.067368421052631|-2.1822222222222187|10.876315789473686|6.126315789473683|69.96656701596841|69.96656701596841|24.852631578947367|25.822222222222223\n",
      "\n",
      "a method of ultrasound imaging that uses a linear pattern of beams to produce a standard, two dimensional image.| a method|45.80302631578948|119.19000000000003|9.230789473684215|-2.619999999999999|12.058373684210528|15.6774|-2.067368421052631|-82.98666666666665|10.876315789473686|-8.8325|69.96656701596841|31.29|24.852631578947367|14.533333333333331\n",
      "\n",
      "expanded disability rating scale - postacute interview survivor version - do you understand how to get dressed?|change unfitness pad scale - postacute interview person version - do you understand how to get dressed?|30.332941176470626|60.19176470588238|13.251764705882355|9.08705882352941|12.801833333333335|9.643833333333333|15.447058823529414|12.68|14.958000000000006|12.445999999999998|93.86999999999999|82.78555852321104|27.976470588235294|23.270588235294117\n",
      "\n",
      "expanded disability rating scale - postacute interview survivor version - do you understand how to get dressed?|disability rating scale-postacute interview survivor version - do you understand how to get dressed?|30.332941176470626|11.339285714285722|13.251764705882355|15.15571428571429|12.801833333333335|12.801833333333335|15.447058823529414|15.817142857142859|14.958000000000006|12.759999999999998|93.86999999999999|88.50148473330829|27.976470588235294|28.457142857142856\n",
      "\n",
      "expanded disability rating scale - postacute interview survivor version - do you understand how to get dressed?| expanded disability rating scale|30.332941176470626|15.640000000000015|13.251764705882355|12.320000000000004|12.801833333333335|19.7241|15.447058823529414|-23.919999999999995|14.958000000000006|5.905000000000001|93.86999999999999|54.195869768830164|27.976470588235294|26.0\n",
      "\n",
      "the application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound. this removes wound exudates, reduces build-up of inflammatory mediators, and increases the flow of nutrients to the wound thus promoting healing.|the action of a clean across the surface of a wound through a foam groom cut to fit the wound.  this kill, wound excrete, reduces build-up of inflammatory mediators, and change the flow of nutrients to the wound thus play help.|50.58772357723578|81.83928571428572|9.598536585365853|5.3223809523809535|9.189528571428571|7.652317054263566|8.315121951219513|4.89714285714286|11.947142857142858|5.562480620155043|69.96656701596841|54.195869768830164|20.100813008130082|14.171428571428573\n",
      "\n",
      "the application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound. this removes wound exudates, reduces build-up of inflammatory mediators, and increases the flow of nutrients to the wound thus promoting healing.|the application of vacuum across the surface of a wound through an elastic bandage dressing cut to fit the wound. this removes wound exudates, reduces build-up of proinflammatory mediators and increases the flow of nutrients to the wounded thus promoting healing.|50.58772357723578|42.334065040650415|9.598536585365853|10.74975609756098|9.189528571428571|9.488363565891472|8.315121951219513|10.46634146341464|11.947142857142858|9.83434108527132|69.96656701596841|76.64453405168562|20.100813008130082|23.027642276422768\n",
      "\n",
      "the application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound. this removes wound exudates, reduces build-up of inflammatory mediators, and increases the flow of nutrients to the wound thus promoting healing.| the application of a vacuum across the surface of a wound through a dressing, this removes wound exudates, reduces build-up of inflammatory mediators, and increases the flow of nutrients to the wound thus promoting healing|50.58772357723578|22.245000000000033|9.598536585365853|19.100000000000005|9.189528571428571|11.338668421052633|8.315121951219513|22.647777777777776|11.947142857142858|20.624210526315785|69.96656701596841|121.18564890283007|20.100813008130082|31.06666666666667\n",
      "\n",
      "catalysis of the reaction: diolein + mono-olein = triolein + glycerol. mono-olein, also known as mono-oleoylglycerol, is the monoglyceride formed from oleic acid, 9-octodecenoic acid; diolein is also known as dioleoylglycerol, and triolein as trioleoylglycerol and olein. [goc:ai, pmid:15364929]|the catalysis of the reaction: dylan + mono-allen = trailing + glycerol.  mono-allen, also known as mono-oleoylglycerol, is the monoglyceride formed from oleic acid, 9-octodecenoic acid; dylan is also known as dioleoylglycerol, and trailing as trioleoylglycerol and allen.  [ goc: ai, pmid: 15364929]|28.778461538461556|44.97000000000003|12.474871794871795|10.713333333333338|14.412148484848485|14.429408333333333|15.978461538461534|13.717333333333336|11.70128787878788|8.218124999999997|80.79043260188672|78.74477315987392|25.71282051282051|22.88888888888889\n",
      "\n",
      "catalysis of the reaction: diolein + mono-olein = triolein + glycerol. mono-olein, also known as mono-oleoylglycerol, is the monoglyceride formed from oleic acid, 9-octodecenoic acid; diolein is also known as dioleoylglycerol, and triolein as trioleoylglycerol and olein. [goc:ai, pmid:15364929]|starting of the reaction: diolein + mono-octadecenoic acid, also known as a molecule of fat and protein. [goc:ai, pmid:15364929]|28.778461538461556|54.70828947368423|12.474871794871795|7.988684210526319|14.412148484848485|12.794827272727273|15.978461538461534|3.193684210526321|11.70128787878788|6.121363636363636|80.79043260188672|62.58|25.71282051282051|20.642105263157895\n",
      "\n",
      "catalysis of the reaction: diolein + mono-olein = triolein + glycerol. mono-olein, also known as mono-oleoylglycerol, is the monoglyceride formed from oleic acid, 9-octodecenoic acid; diolein is also known as dioleoylglycerol, and triolein as trioleoylglycerol and olein. [goc:ai, pmid:15364929]| enzyme|28.778461538461556|120.20500000000001|12.474871794871795|-3.01|14.412148484848485|19.5753|15.978461538461534|-127.42|11.70128787878788|-7.370000000000001|80.79043260188672|31.29|25.71282051282051|20.8\n",
      "\n",
      "percutaneous transabdominal puncture of the uterus during pregnancy to obtain amniotic fluid; it is commonly used for fetal karyotype determination in order to diagnose abnormal fetal conditions.|the percutaneous transabdominal break of the uterus during pregnancy to change amniotic fluid; it is commonly used for fetal karyotype choice in order to diagnose abnormal fetal conditions.|1.9991666666667243|23.42500000000001|16.33425925925926|13.470000000000002|14.332737037037038|12.35637142857143|14.878518518518518|12.87714285714286|21.202222222222225|19.48428571428571|93.86999999999999|85.69119412168324|32.06666666666666|27.02857142857143\n",
      "\n",
      "percutaneous transabdominal puncture of the uterus during pregnancy to obtain amniotic fluid; it is commonly used for fetal karyotype determination in order to diagnose abnormal fetal conditions.|percutaneous transabdominal puncture of the uterus during pregnancy to obtain amniotic fluid; it is commonly used for fetal kilodal conditions.|1.9991666666667243|10.564999999999998|16.33425925925926|14.270000000000007|14.332737037037038|13.932061904761905|14.878518518518518|7.150000000000002|21.202222222222225|11.407142857142851|93.86999999999999|79.77416029015912|32.06666666666666|30.0\n",
      "\n",
      "percutaneous transabdominal puncture of the uterus during pregnancy to obtain amniotic fluid; it is commonly used for fetal karyotype determination in order to diagnose abnormal fetal conditions.| percutaneous transabdominal puncture of the uterus|1.9991666666667243|6.35857142857148|16.33425925925926|14.111428571428572|14.332737037037038|15.875800000000002|14.878518518518518|-3.6457142857142912|21.202222222222225|10.24125|93.86999999999999|62.58|32.06666666666666|25.65714285714286\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of d-glucose residues. [isbn:0198506732]|the process force and path happen in the breakdown of glycogen, a polydisperse, highly grow glucan plan of chains of d-glucose part.  [ isbn: 0198506732]|44.35380434782613|83.0092307692308|9.929782608695653|4.91076923076923|14.10045|11.568992307692309|13.119999999999997|6.178461538461537|13.222500000000004|7.170769230769231|79.77416029015912|62.58|27.208695652173915|17.50769230769231\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of d-glucose residues. [isbn:0198506732]|the chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched molecule composed of chains of d-glucans. [isbn:0198506732]|44.35380434782613|45.69727272727275|9.929782608695653|9.618181818181817|14.10045|14.10045|13.119999999999997|12.379999999999999|13.222500000000004|12.24125|79.77416029015912|76.64453405168562|27.208695652173915|26.218181818181815\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of d-glucose residues. [isbn:0198506732]| the chemical reactions and pathways resulting in the breakdown of glycogen, a polydiverse, highly branched glucan composed of chains of glucose residues|44.35380434782613|32.681304347826114|9.929782608695653|14.414782608695656|14.10045|14.69565|13.119999999999997|20.876521739130432|13.222500000000004|16.278749999999995|79.77416029015912|112.8176994092682|27.208695652173915|31.808695652173913\n",
      "\n",
      "an abnormal decrease of the c-reactive protein level in serum. [pmid:17852082, ucdenver:tjcallahan]|a finding change of the c-reactive protein level in serum.  [ pmid: 17852082, ucdenver: tjcallahan]|38.595|82.39000000000001|9.366666666666667|3.7550000000000026|14.134414285714287|13.769783333333333|-6.213333333333331|-6.130000000000003|9.657142857142855|4.197916666666668|58.53822981607831|58.53822981607831|25.733333333333338|20.700000000000003\n",
      "\n",
      "an abnormal decrease of the c-reactive protein level in serum. [pmid:17852082, ucdenver:tjcallahan]|an abnormal decrease of the c-reactive protein level in serum. [pmid:17852082, ucdenver:tjcallahan]|38.595|38.595|9.366666666666667|9.366666666666667|14.134414285714287|14.535166666666669|-6.213333333333331|-5.723333333333329|9.657142857142855|8.381999999999998|58.53822981607831|58.53822981607831|25.733333333333338|25.733333333333338\n",
      "\n",
      "an abnormal decrease of the c-reactive protein level in serum. [pmid:17852082, ucdenver:tjcallahan]| an abnormality|38.595|34.59000000000003|9.366666666666667|9.180000000000003|14.134414285714287|15.6774|-6.213333333333331|-71.22666666666666|9.657142857142855|-1.7674999999999983|58.53822981607831|31.29|25.733333333333338|14.533333333333331\n",
      "\n",
      "obsolete. the steps whereby the downstream processes started by a signal are brought to a conclusion. examples include destruction of camp by pde, or endocytosis resulting from receptor phosphorylation. the termination process ends when the receptor has returned to its inactive state. [goc:mtg_signal]|obsolete.  the steps whereby the downstream transform started by a tell are brought to a choice.  examples include state of camp by pride, or endocytosis happens from organ phosphorylation.  the morpheme walk ends when the organ has returned to its inactive state.  [ goc: mtg_signal]|34.80832558139534|74.30432653061226|10.540744186046513|5.32995918367347|11.250252727272727|9.568905952380952|1.1348837209302332|-1.8840816326530607|9.945454545454545|4.763571428571424|62.58|55.973253612774734|22.0446511627907|16.98122448979592\n",
      "\n",
      "obsolete. the steps whereby the downstream processes started by a signal are brought to a conclusion. examples include destruction of camp by pde, or endocytosis resulting from receptor phosphorylation. the termination process ends when the receptor has returned to its inactive state. [goc:mtg_signal]|obsolete. the steps whereby the downstream processes started by a signal are brought to an conclusion. examples include destruction of camp by pde, or endocytosis resulting from receptor phosphorylation. this process ends when the receptor has returned to its active state.|34.80832558139534|43.755902439024396|10.540744186046513|9.193365853658538|11.250252727272727|10.820282857142857|1.1348837209302332|-2.538536585365847|9.945454545454545|8.450714285714287|62.58|59.368600792001146|22.0446511627907|20.8409756097561\n",
      "\n",
      "obsolete. the steps whereby the downstream processes started by a signal are brought to a conclusion. examples include destruction of camp by pde, or endocytosis resulting from receptor phosphorylation. the termination process ends when the receptor has returned to its inactive state. [goc:mtg_signal]| obsolete. The downstream reactions that follow a biological reaction|34.80832558139534|32.56000000000003|10.540744186046513|9.96|11.250252727272727|13.957481818181819|1.1348837209302332|-23.332|9.945454545454545|7.439090909090911|62.58|54.195869768830164|22.0446511627907|26.0\n",
      "\n",
      "a taxonomic category above phylum and below subkingdom.|a functional concept category above phylum and below subkingdom.|1.8500000000000227|14.267500000000013|13.995000000000001|12.387222222222224|11.9283|12.855122222222224|-38.72|-29.191111111111105|10.24125|11.853333333333332|54.195869768830164|58.53822981607831|31.6|32.91111111111112\n",
      "\n",
      "a taxonomic category above phylum and below subkingdom.|a taxonomic category above phylum and below kingdom.|1.8500000000000227|12.425000000000011|13.995000000000001|12.52|11.9283|10.877477777777777|-38.72|-40.19|10.24125|4.370000000000001|54.195869768830164|54.195869768830164|31.6|31.6\n",
      "\n",
      "a taxonomic category above phylum and below subkingdom.| a category between kingdom and subkingdom|1.8500000000000227|42.61571428571432|13.995000000000001|9.054285714285715|11.9283|11.9283|-38.72|-11.205714285714286|10.24125|4.942499999999999|54.195869768830164|62.58|31.6|25.65714285714286\n",
      "\n",
      "semiprecision partial denture attachments designed to attach the partial denture to receptacles that are externally connected to the crown contour. these attachments are typically two-component devices that attach to each other with a lesser degree of precision than precision attachments: one component is fixed externally to the abutment tooth and a second component is an integral part of the partial denture base. rigid and resilient attachments are available that permit a slight vertical, hinging, and/or rotational movement as the patient bites.|semi-precious quantity denture joining designed to take the partial denture  fitting that is externally connected to the crown contour.  these joining are typically two-component emblem that talk to each other with a lesser state of precision than precision joining: one part is fixed externally to the support tooth and a second part is an integral part of the partial denture base.  rigid and resilient joining are available that permit a slight vertical, hinging, and/or rotational movement as the case pierces.|26.481250000000017|47.152063253012074|14.596388888888892|11.837439759036148|12.502111382113823|10.981464705882354|19.64641975308642|16.33927710843373|18.94581300813008|10.730823529411765|101.39118822659097|93.86999999999999|28.840740740740742|25.649397590361446\n",
      "\n",
      "semiprecision partial denture attachments designed to attach the partial denture to receptacles that are externally connected to the crown contour. these attachments are typically two-component devices that attach to each other with a lesser degree of precision than precision attachments: one component is fixed externally to the abutment tooth and a second component is an integral part of the partial denture base. rigid and resilient attachments are available that permit a slight vertical, hinging, and/or rotational movement as the patient bites.|these attachments are typically two-component devices that attach to each other with a lesser degree of precision than other attachment types: one component is fixed externally to the base of the crown contour and the other is an integral part of its base.|26.481250000000017|47.2915697674419|14.596388888888892|12.004302325581396|12.502111382113823|9.664944444444444|19.64641975308642|15.632558139534883|18.94581300813008|12.009333333333338|101.39118822659097|88.50148473330829|28.840740740740742|23.48372093023256\n",
      "\n",
      "semiprecision partial denture attachments designed to attach the partial denture to receptacles that are externally connected to the crown contour. these attachments are typically two-component devices that attach to each other with a lesser degree of precision than precision attachments: one component is fixed externally to the abutment tooth and a second component is an integral part of the partial denture base. rigid and resilient attachments are available that permit a slight vertical, hinging, and/or rotational movement as the patient bites.| semiprecision partial denture is denture|26.481250000000017|31.545000000000016|14.596388888888892|10.350000000000001|12.502111382113823|17.517985714285714|19.64641975308642|-13.073333333333323|18.94581300813008|7.6385714285714315|101.39118822659097|62.58|28.840740740740742|29.066666666666663\n",
      "\n",
      "replacement of sperm-specific chromosomal proteins with somatic histones, to allow the paternal genome to acquire a nucleosomal chromatin organization compatible with nuclear activity. [goc:bf, pmid:11735001]|peer of sperm-specific chromosomal proteins with somatic hailstones, to allow the paternal genome to change a nucleosomal chromatin organization compatible with nuclear activity.  [ goc: bf, pmid: 11735001]|-5.5084999999999695|22.917500000000018|17.133|13.665000000000003|15.417581481481482|15.005621839080462|19.5968|15.677241379310349|16.196666666666665|11.176091954022986|88.50148473330829|82.78555852321104|30.6|25.110344827586207\n",
      "\n",
      "replacement of sperm-specific chromosomal proteins with somatic histones, to allow the paternal genome to acquire a nucleosomal chromatin organization compatible with nuclear activity. [goc:bf, pmid:11735001]|replacement of sperm-specific proteins with somatic histones, to allow the paternal genome to acquire an organization compatible with nuclear activity. [goc:bf, pmid:11735001]|-5.5084999999999695|11.088181818181852|17.133|14.445454545454545|15.417581481481482|14.9937|19.5968|14.51818181818182|16.196666666666665|12.703200000000002|88.50148473330829|79.77416029015912|30.6|28.03636363636364\n",
      "\n",
      "replacement of sperm-specific chromosomal proteins with somatic histones, to allow the paternal genome to acquire a nucleosomal chromatin organization compatible with nuclear activity. [goc:bf, pmid:11735001]| substitution of sperm-specific chromatin proteins with somatic histones, to allow the paternal genome to acquire a nucleosomal chromatin organization compatible with nuclear activity|-5.5084999999999695|-21.974999999999937|17.133|22.286666666666665|15.417581481481482|15.857638461538462|19.5968|27.11166666666666|16.196666666666665|20.55461538461538|88.50148473330829|125.16|30.6|36.266666666666666\n",
      "\n",
      "an agent that prevents damage to the heart, thereby protecting myocardial function.|a chemical function that prevents change in the heart, thereby protecting myocardial serve.|52.69500000000002|57.06826923076926|7.400000000000002|6.91423076923077|10.810866666666666|10.354376923076924|-14.053333333333327|-9.806153846153848|12.044999999999995|12.96769230769231|58.53822981607831|54.195869768830164|25.733333333333338|21.06153846153846\n",
      "\n",
      "an agent that prevents damage to the heart, thereby protecting myocardial function.|an agent that prevents damage to the heart, thereby protecting the rhythm.|52.69500000000002|73.84500000000001|7.400000000000002|4.450000000000003|10.810866666666666|10.031976923076924|-14.053333333333327|-17.97333333333333|12.044999999999995|4.283076923076923|58.53822981607831|49.473833993334296|25.733333333333338|19.06666666666667\n",
      "\n",
      "an agent that prevents damage to the heart, thereby protecting myocardial function.| an agent that prevents damage to the heart|52.69500000000002|94.30000000000001|7.400000000000002|2.342222222222226|10.810866666666666|10.448500000000001|-14.053333333333327|-9.368888888888886|12.044999999999995|0.9969999999999999|58.53822981607831|54.195869768830164|25.733333333333338|16.933333333333334\n",
      "\n",
      "life-threatening consequences; widespread areas of mucosal ulceration; urgent intervention indicated|life-threatening result; widespread areas of mucosal lesion; urgent care inform|-65.57499999999999|10.564999999999998|24.890000000000004|14.270000000000007|16.82839090909091|15.392936363636366|23.908000000000005|11.559999999999999|19.0|10.008181818181818|93.86999999999999|88.50148473330829|40.0|36.0\n",
      "\n",
      "life-threatening consequences; widespread areas of mucosal ulceration; urgent intervention indicated|life-threatening consequences; widespread areas of mucus ulceration; urgent intervention indicated.|-65.57499999999999|-52.039999999999964|24.890000000000004|21.76000000000001|16.82839090909091|16.993233333333333|23.908000000000005|-5.691999999999993|19.0|14.717500000000001|93.86999999999999|66.37611354998121|40.0|38.0\n",
      "\n",
      "life-threatening consequences; widespread areas of mucosal ulceration; urgent intervention indicated| life-threatening consequences; widespread areas of mucosal ulceration; the need for urgent intervention.|-65.57499999999999|5.006730769230813|24.890000000000004|14.17576923076923|16.82839090909091|14.535166666666669|23.908000000000005|-3.021538461538462|19.0|10.893999999999998|93.86999999999999|62.58|40.0|27.21538461538462\n",
      "\n",
      "secretogranin-1 (677 aa, ~78 kda) is encoded by the human chgb gene. this protein may play a role in the synthesis of biologically active peptides.|secretogranin-1 (677 aa, ~78 code) is converted by the human chub gene.  this protein may play a role in the synthesis of biologically active amide.|79.93666666666668|87.40756410256414|4.18|3.220769230769232|13.7305|13.783289743589744|-6.590399999999995|-6.336923076923082|7.051199999999998|4.460641025641024|47.79626449838941|47.79626449838941|14.533333333333335|14.235897435897437\n",
      "\n",
      "secretogranin-1 (677 aa, ~78 kda) is encoded by the human chgb gene. this protein may play a role in the synthesis of biologically active peptides.|this protein may play a role in the synthesis of biologically active peptides.|79.93666666666668|50.56057692307695|4.18|7.821923076923078|13.7305|11.8787|-6.590399999999995|-15.233846153846155|7.051199999999998|4.274285714285714|47.79626449838941|49.473833993334296|14.533333333333335|17.984615384615388\n",
      "\n",
      "secretogranin-1 (677 aa, ~78 kda) is encoded by the human chgb gene. this protein may play a role in the synthesis of biologically active peptides.| secretogranin-1 is a protein|79.93666666666668|134.08000000000004|4.18|-4.199999999999999|13.7305|14.460766666666668|-6.590399999999995|-28.624|7.051199999999998|2.7650000000000006|47.79626449838941|31.29|14.533333333333335|10.0\n",
      "\n",
      "an emotional state characterized by mild to moderate elevation of mood without relevant effect on functioning.|a finding state distinguishes by mild to change increase of mood without relevant effect on serve.|18.940000000000026|66.5275|12.605000000000004|5.967500000000001|13.311975|10.35135|-2.0875000000000057|-6.497500000000002|14.24125|10.708750000000002|62.58|54.195869768830164|23.200000000000003|18.2\n",
      "\n",
      "an emotional state characterized by mild to moderate elevation of mood without relevant effect on functioning.|an emotional state characterized by mild to moderate elevation of mood without relevance to functioning.|18.940000000000026|18.742500000000007|12.605000000000004|12.508333333333336|13.311975|12.915175000000001|-2.0875000000000057|-3.7946666666666715|14.24125|9.063749999999999|62.58|58.53822981607831|23.200000000000003|21.666666666666668\n",
      "\n",
      "an emotional state characterized by mild to moderate elevation of mood without relevant effect on functioning.| an emotion|18.940000000000026|90.99000000000004|12.605000000000004|1.3133333333333361|13.311975|15.6774|-2.0875000000000057|-79.06666666666666|14.24125|-6.477499999999999|62.58|31.29|23.200000000000003|14.533333333333331\n",
      "\n",
      "an imaging technology that uses non-ionizing, millimeter-length electromagnetic waves (30ghz to 300ghz) to scan the surface of an object or body. millimeter-wave imaging (mmw) can image through non-polar and non-metallic materials such as clothing, plastic, and cardboard with relatively little energy loss. compared to microwaves and radio-frequency waves, mmw can achieve better spatial resolution due to its shorter wavelength. mmw is harmless to humans.|a biomedical training discipline that uses non-ionizing, millimeter-length electromagnetic waves (30ghz to 300ghz) to scan the surface of an be or body.  millimeter-wave imaging (mmw) can image through non-polar and non-metallic applicant such as clothing, plastic, and cardboard with relatively little good_health loss.  compared to cook and radio-frequency waves, mm can achieve better spatial decision due to its shorter distance.  mu is harmless to humans.|27.28675000000004|43.736882352941194|12.633250000000004|10.537529411764705|11.722785714285715|11.415707722007722|13.073749999999997|12.218235294117648|12.619428571428571|7.914903474903472|79.15813438933486|77.91147168421348|25.12|23.67529411764706\n",
      "\n",
      "an imaging technology that uses non-ionizing, millimeter-length electromagnetic waves (30ghz to 300ghz) to scan the surface of an object or body. millimeter-wave imaging (mmw) can image through non-polar and non-metallic materials such as clothing, plastic, and cardboard with relatively little energy loss. compared to microwaves and radio-frequency waves, mmw can achieve better spatial resolution due to its shorter wavelength. mmw is harmless to humans.|an imaging technology that uses non-ionizing, low-frequency electromagnetic waves (30ghz to 300ghz) to scan the surface of an object or body. millimeter-wave imaging (mmw) can image through polar materials such as clothing, plastic, and relatively little energy loss. mmw is|27.28675000000004|30.446666666666687|12.633250000000004|12.325000000000003|11.722785714285715|11.90010303030303|13.073749999999997|12.492|12.619428571428571|9.88151515151515|79.15813438933486|78.74477315987392|25.12|24.333333333333336\n",
      "\n",
      "an imaging technology that uses non-ionizing, millimeter-length electromagnetic waves (30ghz to 300ghz) to scan the surface of an object or body. millimeter-wave imaging (mmw) can image through non-polar and non-metallic materials such as clothing, plastic, and cardboard with relatively little energy loss. compared to microwaves and radio-frequency waves, mmw can achieve better spatial resolution due to its shorter wavelength. mmw is harmless to humans.| a technology that uses non-ionizing electromagnetic waves in the microwave or radio-frequency range to scan the surface of an object or body|27.28675000000004|25.32478260869567|12.633250000000004|15.440869565217394|11.722785714285715|11.606484615384616|13.073749999999997|17.80869565217391|12.619428571428571|13.127307692307689|79.15813438933486|93.86999999999999|25.12|24.85217391304348\n",
      "\n",
      "an active immunizing vaccine used to prevent infection by the bacterium streptococcus pneumoniae. it consists of a solution of saccharides of the capsular antigens of streptococcus serotypes individually conjugated to proteins.|an active inject vaccine used to prevent ill_health by the bacterium streptococcus pneumoniae.  it be  a success of saccharides of the capsular substance of streptococcus stereotypes individually change to proteins.|8.043440860215071|40.027083333333366|14.704516129032257|10.326250000000002|13.573687096774194|13.311975|8.721290322580646|6.060000000000006|15.947419354838708|13.652499999999996|76.64453405168562|72.26115969177356|27.35913978494624|24.266666666666666\n",
      "\n",
      "an active immunizing vaccine used to prevent infection by the bacterium streptococcus pneumoniae. it consists of a solution of saccharides of the capsular antigens of streptococcus serotypes individually conjugated to proteins.|an active vaccine used to prevent infection by the bacterium streptococcus pneumoniae. it consists of a solution of the capsular antigens individually conjugated to proteins.|8.043440860215071|25.792666666666662|14.704516129032257|11.732000000000003|13.573687096774194|13.175982051282052|8.721290322580646|-0.004799999999995919|15.947419354838708|9.895256410256408|76.64453405168562|67.59412548439398|27.35913978494624|25.733333333333338\n",
      "\n",
      "an active immunizing vaccine used to prevent infection by the bacterium streptococcus pneumoniae. it consists of a solution of saccharides of the capsular antigens of streptococcus serotypes individually conjugated to proteins.| A vaccine is substance|8.043440860215071|100.24000000000002|14.704516129032257|0.5199999999999996|13.573687096774194|14.460766666666668|8.721290322580646|-35.67999999999999|15.947419354838708|-1.9450000000000003|76.64453405168562|44.250742366654144|27.35913978494624|18.0\n",
      "\n",
      "the series of events required for an organism to detect high environmental humidity, convert this detection into a molecular signal, and recognize and characterize the signal. this is a neurological process. [pmid:18269908]|the group of events required for a system to spy high environmental wetness, change this detection into a molecular tell, and prize and distinguish the tell.  this is a neurological walk.  [ pmid: 18269908]|32.09583333333336|74.805|11.432500000000001|5.806666666666668|12.4217375|10.241833333333334|7.530000000000005|3.2633333333333354|9.946874999999999|3.825523809523812|74.48509850970193|57.127462747788826|25.516666666666666|15.911111111111111\n",
      "\n",
      "the series of events required for an organism to detect high environmental humidity, convert this detection into a molecular signal, and recognize and characterize the signal. this is a neurological process. [pmid:18269908]|the series of events required for an organism to detect high environmental humidity, convert this detection into a molecular signal, and recognize and characterize the signal. this is an abnormal process. [pmid:18269908]|32.09583333333336|37.383333333333354|11.432500000000001|10.695|12.554004166666667|12.794827272727273|7.530000000000005|7.162499999999998|11.280208333333334|10.331818181818182|74.48509850970193|74.48509850970193|25.516666666666666|25.516666666666666\n",
      "\n",
      "the series of events required for an organism to detect high environmental humidity, convert this detection into a molecular signal, and recognize and characterize the signal. this is a neurological process. [pmid:18269908]| the series of events required for an organism to detect high environmental humidity, convert this detection into a molecular signal, and recognize and characterize the signal.|32.09583333333336|30.199166666666713|11.432500000000001|12.400925925925925|12.554004166666667|13.353757142857145|7.530000000000005|10.958518518518517|11.280208333333334|10.63392857142857|74.48509850970193|85.69119412168324|25.516666666666666|27.622222222222224\n",
      "\n",
      "this gene is involved in the regulation of microtubule assemblies and chromosome stability.|this gene is have in the control of tubule whole and body order.|24.529807692307713|89.6067307692308|11.45269230769231|2.375769230769233|12.783607692307694|7.925146153846153|-9.806153846153848|-22.01846153846154|13.329999999999998|3.5476923076923086|54.195869768830164|44.250742366654144|21.06153846153846|14.90769230769231\n",
      "\n",
      "this gene is involved in the regulation of microtubule assemblies and chromosome stability.|this gene is involved in the regulation of microtubule assembly and cellular support.|24.529807692307713|37.54519230769233|11.45269230769231|9.637307692307694|12.783607692307694|13.006557142857146|-9.806153846153848|-12.067692307692312|13.329999999999998|6.6292857142857144|54.195869768830164|54.195869768830164|21.06153846153846|21.06153846153846\n",
      "\n",
      "this gene is involved in the regulation of microtubule assemblies and chromosome stability.| This gene is involved in the regulation of microtubule assemblies and chromosome structure|24.529807692307713|41.553571428571445|11.45269230769231|10.941428571428574|12.783607692307694|13.8545|-9.806153846153848|12.037142857142864|13.329999999999998|11.189999999999998|54.195869768830164|76.64453405168562|21.06153846153846|22.742857142857144\n",
      "\n",
      "a surgical procedure in which an opening is made into the mediastinum.|a procedure software in which an opening is made into the cavity.|45.64500000000001|59.745000000000005|8.383333333333333|6.416666666666668|9.495033333333335|9.495033333333335|-20.423333333333325|-22.873333333333328|7.334999999999997|5.372500000000002|49.473833993334296|49.473833993334296|19.06666666666667|19.06666666666667\n",
      "\n",
      "a surgical procedure in which an opening is made into the mediastinum.|a surgical procedure in which an opening is made into the middle ear.|45.64500000000001|63.57596153846157|8.383333333333333|6.006538461538462|9.495033333333335|8.495128571428573|-20.423333333333325|-19.30461538461539|7.334999999999997|1.24642857142857|49.473833993334296|49.473833993334296|19.06666666666667|17.984615384615388\n",
      "\n",
      "a surgical procedure in which an opening is made into the mediastinum.| a surgical procedure in which an opening is made into the mediastinum|45.64500000000001|50.470769230769264|8.383333333333333|9.44923076923077|9.495033333333335|11.098042857142858|-20.423333333333325|3.916923076923073|7.334999999999997|5.755714285714284|49.473833993334296|69.96656701596841|19.06666666666667|20.58461538461539\n",
      "\n",
      "<p>injection, hemodialysis port</p>|< p > injection, dialysis port < /p >|-50.00999999999996|113.10000000000002|20.980000000000008|-0.27999999999999936|19.773699999999998|19.8729|-33.986666666666665|-13.94222222222222|3.6014285714285705|-2.2766666666666637|44.250742366654144|44.250742366654144|27.866666666666664|12.488888888888889\n",
      "\n",
      "<p>injection, hemodialysis port</p>|blood pressure drug|-50.00999999999996|90.99000000000004|20.980000000000008|1.3133333333333361|19.773699999999998|15.6774|-33.986666666666665|-63.386666666666656|3.6014285714285705|1.7650000000000006|44.250742366654144|31.29|27.866666666666664|14.533333333333331\n",
      "\n",
      "<p>injection, hemodialysis port</p>| <p>injection, hemodialysis port|-50.00999999999996|12.425000000000011|20.980000000000008|12.52|19.773699999999998|19.823300000000003|-33.986666666666665|-29.9|3.6014285714285705|0.2325000000000017|44.250742366654144|44.250742366654144|27.866666666666664|21.6\n",
      "\n",
      "a form of diazoxide-sensitive diffuse hyperinsulinism characterised by hypoglycaemic episodes that are usually mild, escaping detection during infancy, and usually a good clinical response to diazoxide, (but some are diazoxide resistant). usually has a milder phenotype when compared to that resulting from recessive k+ channel mutations.|a form of diazoxide-sensitive spread hyperinsulinism remember by hypoglycemic film that are usually mild, issue detection during infancy, and usually a good clinical response to diazoxide, (but some are diazoxide resistant).  usually has a milder phenotype when compared to that happen from allele k+ channel change.|3.6803623188405936|27.133333333333354|16.55521739130435|13.3668085106383|12.812502836879432|12.063983333333335|18.148695652173917|14.885106382978723|14.963971631205673|16.376875000000005|90.32644961471695|84.73372056035305|27.87246376811594|24.99007092198582\n",
      "\n",
      "a form of diazoxide-sensitive diffuse hyperinsulinism characterised by hypoglycaemic episodes that are usually mild, escaping detection during infancy, and usually a good clinical response to diazoxide, (but some are diazoxide resistant). usually has a milder phenotype when compared to that resulting from recessive k+ channel mutations.|a form of diabetes-sensitive diffuse hyperinsulinism characterised by hypoglycaemic episodes that are usually mild, escaping detection during infancy, and usually a good clinical response to diabetes, (but some are diazoxide resistant).|3.6803623188405936|-10.845887096774163|16.55521739130435|18.622741935483877|13.201036170212765|13.067627272727274|18.148695652173917|20.16645161290323|18.880638297872345|15.365454545454547|90.32644961471695|91.22524239485473|27.87246376811594|28.135483870967747\n",
      "\n",
      "a form of diazoxide-sensitive diffuse hyperinsulinism characterised by hypoglycaemic episodes that are usually mild, escaping detection during infancy, and usually a good clinical response to diazoxide, (but some are diazoxide resistant). usually has a milder phenotype when compared to that resulting from recessive k+ channel mutations.| an autoimmune disease of the central nervous system|3.6803623188405936|66.10000000000002|16.55521739130435|6.2755555555555596|13.201036170212765|15.185500000000001|18.148695652173917|-3.488888888888887|18.880638297872345|5.235999999999997|90.32644961471695|69.96656701596841|27.87246376811594|25.822222222222223\n",
      "\n",
      "the literal identifier of the vendor or laboratory that performs a morphology examination.|the error symbol of the vendor or region that act a geophysics introspection.|-1.5009615384615245|57.06826923076926|15.083461538461542|6.91423076923077|12.783607692307694|11.568992307692309|-10.258461538461539|-16.13846153846154|12.96769230769231|8.25769230769231|58.53822981607831|54.195869768830164|24.13846153846154|21.06153846153846\n",
      "\n",
      "the literal identifier of the vendor or laboratory that performs a morphology examination.|the literal identifier of the vendor or laboratory that performs a morphology examination.|-1.5009615384615245|-1.5009615384615245|15.083461538461542|15.083461538461542|12.783607692307694|13.006557142857146|-10.258461538461539|-9.806153846153848|12.96769230769231|8.311428571428571|58.53822981607831|58.53822981607831|24.13846153846154|24.13846153846154\n",
      "\n",
      "the literal identifier of the vendor or laboratory that performs a morphology examination.| The name of the instrument or device|-1.5009615384615245|92.965|15.083461538461542|2.280000000000001|12.783607692307694|11.100677777777777|-10.258461538461539|-14.215|12.96769230769231|-0.18333333333333357|58.53822981607831|44.250742366654144|24.13846153846154|13.200000000000001\n",
      "\n",
      "a cgs unit of area measurement equal to a square measuring one centimeter on each side. one square centimeter is equal to 10e-4 square meter.|a quantity unit of area measurement equal to a square is one centimeter on each side.  one square centimeter is equal to 10e-4 square meters.|63.01666666666668|67.8844871794872|6.540000000000003|5.943846153846156|9.3093|9.532135897435897|-8.001599999999996|-7.920000000000009|6.485999999999997|3.736025641025641|54.195869768830164|54.195869768830164|17.733333333333334|17.31282051282051\n",
      "\n",
      "a cgs unit of area measurement equal to a square measuring one centimeter on each side. one square centimeter is equal to 10e-4 square meter.|a cgs unit of area measurement equal to a square measuring one centimeter on either side of the earth's doorstep.|63.01666666666668|57.09500000000003|6.540000000000003|7.779999999999998|9.3093|8.668728571428572|-8.001599999999996|-1.6699999999999982|6.485999999999997|4.902857142857144|54.195869768830164|62.58|17.733333333333334|20.0\n",
      "\n",
      "a cgs unit of area measurement equal to a square measuring one centimeter on each side. one square centimeter is equal to 10e-4 square meter.| a system of measurement|63.01666666666668|83.32000000000004|6.540000000000003|2.879999999999999|9.3093|14.460766666666668|-8.001599999999996|-34.50399999999999|6.485999999999997|-1.1600000000000001|54.195869768830164|44.250742366654144|17.733333333333334|18.0\n",
      "\n",
      "<p>supernumerary mandibular right second premolar</p>|< p > actor mandibular right second tooth < /p >|-68.95999999999995|103.37909090909093|24.120000000000008|1.572727272727274|16.36401111111111|15.665736363636366|-1.5760000000000005|-6.5963636363636375|8.713333333333335|0.34090909090908994|62.58|54.195869768830164|34.0|15.309090909090907\n",
      "\n",
      "<p>supernumerary mandibular right second premolar</p>|mandibular right second premolar/p>|-68.95999999999995|-8.724999999999994|24.120000000000008|15.469999999999999|16.36401111111111|15.262271428571431|-1.5760000000000005|-25.490000000000002|8.713333333333335|3.6014285714285705|62.58|54.195869768830164|34.0|31.6\n",
      "\n",
      "<p>supernumerary mandibular right second premolar</p>||-68.95999999999995|205.82000000000002|24.120000000000008|-15.2|16.36401111111111|19.476100000000002|-1.5760000000000005|-290.12|8.713333333333335|-16.22|62.58|0.0|34.0|0.4\n",
      "\n",
      "neuropsychiatric inventory - does the patient pace around the house without apparent purpose?|neuropsychiatric list - does the case pace around the house without apparent purpose?|30.947692307692336|56.97846153846157|12.172307692307694|8.541538461538462|10.810866666666666|8.1792|13.867692307692305|10.249230769230767|15.577499999999993|12.4375|82.78555852321104|69.96656701596841|26.738461538461536|20.58461538461539\n",
      "\n",
      "neuropsychiatric inventory - does the patient pace around the house without apparent purpose?|neuropsychiatric inventory - does the patient pace around the house without apparent purpose?|30.947692307692336|30.947692307692336|12.172307692307694|12.172307692307694|10.810866666666666|11.568992307692309|13.867692307692305|14.319999999999997|15.577499999999993|14.054615384615381|82.78555852321104|82.78555852321104|26.738461538461536|26.738461538461536\n",
      "\n",
      "neuropsychiatric inventory - does the patient pace around the house without apparent purpose?| neuropsychiatric inventory - does the patient pace around the house without apparent purpose?|30.947692307692336|41.553571428571445|12.172307692307694|10.941428571428574|10.810866666666666|12.225900000000001|13.867692307692305|13.297142857142855|15.577499999999993|12.820714285714281|82.78555852321104|82.78555852321104|26.738461538461536|25.6\n",
      "\n",
      "genetic loci in the vertebrate major histocompatibility complex which encode polymorphic characteristics not related to immune responsiveness or complement activity, e.g., b loci (chicken), dla (dog), gpla (guinea pig), h-2 (mouse), rt-1 (rat), hla-a, -b, and -c class i genes of man.|genetic set in the chordate major organic_phenomenon whole which encode polymorphic property not related to immune quality or balance activity, e.g., b loci (chicken), delay (dog), gpla (guinea pig), h-2 (mouse), rt-1 (rat), hula-a, -b, and -c class i genes of man.|39.06321428571431|53.163214285714304|10.419285714285714|8.452619047619049|14.949532558139534|14.215113953488373|5.829523809523813|3.1695238095238096|24.386744186046514|22.305581395348838|66.37611354998121|64.5059875127883|21.34285714285714|20.390476190476193\n",
      "\n",
      "genetic loci in the vertebrate major histocompatibility complex which encode polymorphic characteristics not related to immune responsiveness or complement activity, e.g., b loci (chicken), dla (dog), gpla (guinea pig), h-2 (mouse), rt-1 (rat), hla-a, -b, and -c class i genes of man.|gene locations in the vertebrate major histocompatibility complex which encode polymorphic characteristics not related to immune responsiveness or complement activity, e.g., loci (chicken), dla (mouse), rt-1 (rat), hla-b, and -|39.06321428571431|19.025000000000006|10.419285714285714|13.09|14.949532558139534|15.361196774193548|5.829523809523813|9.404|24.386744186046514|22.178064516129034|66.37611354998121|69.96656701596841|21.34285714285714|24.0\n",
      "\n",
      "genetic loci in the vertebrate major histocompatibility complex which encode polymorphic characteristics not related to immune responsiveness or complement activity, e.g., b loci (chicken), dla (dog), gpla (guinea pig), h-2 (mouse), rt-1 (rat), hla-a, -b, and -c class i genes of man.| genetic loci which encode polymorphic characteristics not related to immune responsiveness or complement activity, e.g., b loci (chicken), dla (dog), gpla (guinea pig), h-2 (mouse), rt-1 (rat), hla-a, -b, and -c class 1 genes of man.|39.06321428571431|60.25706081081083|10.419285714285714|7.152635135135139|14.949532558139534|14.725494871794872|5.829523809523813|-0.37513513513513885|24.386744186046514|9.937692307692306|66.37611354998121|58.53822981607831|21.34285714285714|18.835135135135136\n",
      "\n",
      "an autosomal recessive condition caused by mutation(s) in the alox12b gene, encoding arachidonate 12-lipoxygenase, 12r-type. it is characterized by dry, thickened, scaly skin.|a cell part allele condition caused by a change (s) in the alox12b gene, convert arachidonate 12-lipoxygenase , 12 r-type.  it is distinguished by dry, change, scaly skin.|44.56637681159424|92.00264367816094|8.947826086956521|2.828275862068967|13.7305|12.0275|0.5060869565217416|-1.626206896551718|11.949599999999997|4.6080000000000005|54.195869768830164|44.250742366654144|18.718840579710143|12.142528735632183\n",
      "\n",
      "an autosomal recessive condition caused by mutation(s) in the alox12b gene, encoding arachidonate 12-lipoxygenase, 12r-type. it is characterized by dry, thickened, scaly skin.|a genetic trait caused by mutation(s) in a gene, used for dna repair. it is characterized by dry, thickened, scaly skin.|44.56637681159424|66.7871428571429|8.947826086956521|5.682857142857145|13.7305|10.459778787878788|0.5060869565217416|-14.005714285714284|11.949599999999997|2.575303030303033|54.195869768830164|44.250742366654144|18.718840579710143|14.228571428571428\n",
      "\n",
      "an autosomal recessive condition caused by mutation(s) in the alox12b gene, encoding arachidonate 12-lipoxygenase, 12r-type. it is characterized by dry, thickened, scaly skin.| an autosomal recessive condition caused by mutation(s) in the alox12b gene, encoding arachidonate 12-lipoxygenase, 12r-type|44.56637681159424|47.83250000000001|8.947826086956521|10.562500000000004|13.7305|16.213636842105267|0.5060869565217416|21.924999999999997|11.949599999999997|14.346842105263157|54.195869768830164|76.64453405168562|18.718840579710143|21.400000000000002\n",
      "\n",
      "a bluish or purplish discoloration of the skin and mucous membranes resulting from a reduced concentration of oxygenated hemoglobin in the blood.|a reagent or purplish appearance of the skin and mucous sheet happen from a reduced diligence of process hemoglobin in the blood.|30.31545454545457|61.07909090909095|11.763636363636365|7.472727272727273|11.904972727272728|10.469518181818183|6.232727272727271|1.9563636363636334|15.903181818181814|12.477727272727272|66.37611354998121|66.37611354998121|20.763636363636365|20.763636363636365\n",
      "\n",
      "a bluish or purplish discoloration of the skin and mucous membranes resulting from a reduced concentration of oxygenated hemoglobin in the blood.|a bluish or purplish discoloration of the skin and mucous membrane resulting from a reduced concentration of oxygen in the blood.|30.31545454545457|51.1489285714286|11.763636363636365|8.733571428571427|11.904972727272728|11.359372727272728|6.232727272727271|2.609523809523811|15.903181818181814|7.405909090909088|66.37611354998121|62.58|20.763636363636365|19.43809523809524\n",
      "\n",
      "a bluish or purplish discoloration of the skin and mucous membranes resulting from a reduced concentration of oxygenated hemoglobin in the blood.| a blue or purple appearance of the skin and mucous membranes resulting from a reduced concentration of oxygenated hemoglobin in the blood|30.31545454545457|32.681304347826114|11.763636363636365|14.414782608695656|11.904972727272728|11.406066666666666|6.232727272727271|17.041739130434784|15.903181818181814|13.7275|66.37611354998121|93.86999999999999|20.763636363636365|24.85217391304348\n",
      "\n",
      "the chemical reactions and pathways involving a tetrahydromethanopterin. [goc:mengo_curators]|the process force and path absorb a tetrahydromethanopterin.  [ goc: mengo_curators]|-60.932499999999976|31.545000000000016|22.87611111111112|10.350000000000001|14.9375|13.866548484848485|-10.24444444444444|-13.563333333333333|19.220999999999997|10.376060606060605|54.195869768830164|44.250742366654144|28.466666666666665|15.733333333333333\n",
      "\n",
      "the chemical reactions and pathways involving a tetrahydromethanopterin. [goc:mengo_curators]|the chemical reactions and pathways involving a molecule of water. [goc:mengo_curators]|-60.932499999999976|8.979772727272717|22.87611111111112|13.373181818181823|14.9375|13.675823076923077|-10.24444444444444|-12.123636363636372|19.220999999999997|8.630769230769232|54.195869768830164|58.53822981607831|28.466666666666665|27.654545454545453\n",
      "\n",
      "the chemical reactions and pathways involving a tetrahydromethanopterin. [goc:mengo_curators]| the chemical reactions and pathways involving a tetrahydrofolate|-60.932499999999976|19.100000000000023|22.87611111111112|12.831111111111113|14.9375|15.185500000000001|-10.24444444444444|5.004444444444445|19.220999999999997|11.359000000000002|54.195869768830164|69.96656701596841|28.466666666666665|25.822222222222223\n",
      "\n",
      "a chromosome band present on 12q|a body band present on 12q|87.94500000000002|102.045|2.4833333333333343|0.5166666666666693|9.197433333333334|6.565766666666667|-22.873333333333328|-28.75333333333333|2.7650000000000006|-1.9450000000000003|44.250742366654144|44.250742366654144|15.733333333333333|15.733333333333333\n",
      "\n",
      "a chromosome band present on 12q|a chromosome band present on 12q22.3.|87.94500000000002|92.00500000000002|2.4833333333333343|0.9233333333333356|9.197433333333334|10.577242857142856|-22.873333333333328|-115.66|2.7650000000000006|1.8514285714285705|44.250742366654144|25.548178017228544|15.733333333333333|14.133333333333333\n",
      "\n",
      "a chromosome band present on 12q| a chromosome|87.94500000000002|90.99000000000004|2.4833333333333343|1.3133333333333361|9.197433333333334|15.6774|-22.873333333333328|-75.14666666666666|2.7650000000000006|-4.122500000000002|44.250742366654144|31.29|15.733333333333333|14.533333333333331\n",
      "\n",
      "a general term referring to a defect in immunity resulting from impaired antibody production. []|a general term name to a file in release happens from damage protein display.  [ ]|24.382499999999993|93.70161764705884|11.721666666666671|2.301470588235297|11.8787|8.095166666666668|-7.32266666666667|-11.995294117647056|8.647857142857145|1.1660000000000004|62.58|54.195869768830164|24.333333333333336|17.51764705882353\n",
      "\n",
      "a general term referring to a defect in immunity resulting from impaired antibody production. []|a general term referring to a defect in immunity resulting from impaired antibody production.[]|24.382499999999993|12.401428571428596|11.721666666666671|13.26857142857143|11.8787|12.429833333333335|-7.32266666666667|-7.425714285714285|8.647857142857145|7.439999999999998|62.58|62.58|24.333333333333336|25.65714285714286\n",
      "\n",
      "a general term referring to a defect in immunity resulting from impaired antibody production. []| a general term referring to a defect in immunity resulting from impaired antibody production.|24.382499999999993|24.382499999999993|11.721666666666671|11.721666666666671|11.8787|12.915175000000001|-7.32266666666667|-7.714666666666666|8.647857142857145|6.414375|62.58|62.58|24.333333333333336|24.333333333333336\n",
      "\n",
      "the part of the brain located anterior to the parietal lobes at the front of each cerebral hemisphere. (nci)|the part of the brain located tooth to the parietal throws at the front of each cerebral hemisphere.  ( nice)|63.613552631578955|87.40607142857144|6.746578947368423|3.6764285714285734|9.925068421052632|7.914666666666667|-3.3052631578947356|-3.270476190476188|4.886842105263156|2.391833333333331|54.195869768830164|44.250742366654144|16.431578947368422|11.81904761904762\n",
      "\n",
      "the part of the brain located anterior to the parietal lobes at the front of each cerebral hemisphere. (nci)|the part of the brain located anterior to the parietal lobes at the front of each brain region. (nci)|63.613552631578955|76.97144736842105|6.746578947368423|4.883421052631579|9.925068421052632|9.659|-3.3052631578947356|-5.1621052631578905|4.886842105263156|2.6454999999999984|54.195869768830164|49.473833993334296|16.431578947368422|14.326315789473682\n",
      "\n",
      "the part of the brain located anterior to the parietal lobes at the front of each cerebral hemisphere. (nci)| the neural structure located anterior to the parietal lobes|63.613552631578955|44.405|6.746578947368423|9.55|9.925068421052632|15.665736363636366|-3.3052631578947356|0.9759999999999991|4.886842105263156|6.7636363636363654|54.195869768830164|76.64453405168562|16.431578947368422|28.0\n",
      "\n",
      "<p>**description:**a suffix has a strong association to the immediately preceding name part. a suffix has no implicit leading white space (it has implicit trailing white space though).</p>|< p > * * kind: * * a suffix has a strong group to the immediately state name part.  a suffix has no implicit leading white space (it has implicit drag white space though).  < /p >|47.30000000000004|106.58666666666669|8.89777777777778|1.7049999999999983|11.433975862068966|10.223455555555555|2.3911111111111154|-1.4730000000000025|11.806206896551721|0.6016666666666666|57.127462747788826|44.250742366654144|18.414814814814815|11.333333333333336\n",
      "\n",
      "<p>**description:**a suffix has a strong association to the immediately preceding name part. a suffix has no implicit leading white space (it has implicit trailing white space though).</p>|p>**description:**a suffix has a strong association to the immediately preceding name part of the body's immediate prioritization of information about the next step in the process of preparing for an upcoming medical school entrance exam.|47.30000000000004|19.87250000000003|8.89777777777778|14.835|10.889493103448277|10.669855555555555|2.3911111111111154|17.525714285714287|11.806206896551721|14.259999999999998|57.127462747788826|88.50148473330829|18.414814814814815|25.28571428571429\n",
      "\n",
      "<p>**description:**a suffix has a strong association to the immediately preceding name part. a suffix has no implicit leading white space (it has implicit trailing white space though).</p>| <p>suffix has a strong association to the immediately preceding name part|47.30000000000004|39.55500000000001|8.89777777777778|10.723333333333333|10.889493103448277|13.311975|2.3911111111111154|6.693333333333335|11.806206896551721|5.704374999999999|57.127462747788826|62.58|18.414814814814815|18.133333333333333\n",
      "\n",
      "a unit of concentration equal to milligrams per milliliter, divided by meters squared.|a unit of diligence, equal to milligrams per milliliter, move by meter row.|24.529807692307713|50.56057692307695|11.45269230769231|7.821923076923078|11.568992307692309|11.568992307692309|-12.067692307692312|-17.043076923076928|11.156153846153849|6.808461538461536|62.58|54.195869768830164|27.21538461538462|21.06153846153846\n",
      "\n",
      "a unit of concentration equal to milligrams per milliliter, divided by meters squared.|a unit of concentration equal to grams per milliliter, divided by meters squared.|24.529807692307713|37.54519230769233|11.45269230769231|9.637307692307694|11.568992307692309|11.8787|-12.067692307692312|-13.876923076923077|11.156153846153849|4.947142857142854|62.58|58.53822981607831|27.21538461538462|24.13846153846154\n",
      "\n",
      "a unit of concentration equal to milligrams per milliliter, divided by meters squared.| a unit of concentration equal to milligrams per liter, divided by meters squared.|24.529807692307713|48.65857142857146|11.45269230769231|8.211428571428574|11.568992307692309|12.429833333333335|-12.067692307692312|-12.885714285714286|11.156153846153849|3.985999999999997|62.58|62.58|27.21538461538462|25.65714285714286\n",
      "\n",
      "absence of the tibia. [hpo:probinson]|lack of the tibia.  [ hop: robinson]|35.097500000000025|107.60000000000001|8.985000000000003|-0.754999999999999|14.311966666666669|12.775090476190478|-79.59199999999998|-52.685|2.8349999999999973|-2.7690476190476154|38.32226702584281|31.29|25.0|11.600000000000001\n",
      "\n",
      "absence of the tibia. [hpo:probinson]|absence of the tibia. [hpo:probinson]|35.097500000000025|35.097500000000025|8.985000000000003|8.985000000000003|14.311966666666669|15.08867142857143|-79.59199999999998|-78.416|2.8349999999999973|0.5057142857142836|38.32226702584281|38.32226702584281|25.0|25.0\n",
      "\n",
      "absence of the tibia. [hpo:probinson]| absence of the tibia|35.097500000000025|100.24000000000002|8.985000000000003|0.5199999999999996|14.311966666666669|14.460766666666668|-79.59199999999998|-38.032|2.8349999999999973|-3.5150000000000006|38.32226702584281|44.250742366654144|25.0|18.0\n",
      "\n",
      "a protein encoded by the il6r gene.|a bioactive substance converts by the il6r gene.|94.51107142857143|97.025|0.946428571428573|0.7199999999999989|13.006557142857146|13.902050000000001|-60.21142857142857|-43.864999999999995|0.9100000000000001|6.120000000000001|31.29|38.32226702584281|12.82857142857143|16.6\n",
      "\n",
      "a protein encoded by the il6r gene.|a protein encoded by a gene il6r.|94.51107142857143|94.51107142857143|0.946428571428573|0.946428571428573|13.006557142857146|13.902050000000001|-60.21142857142857|-61.05142857142857|0.9100000000000001|-0.9450000000000003|31.29|31.29|12.82857142857143|12.82857142857143\n",
      "\n",
      "a protein encoded by the il6r gene.| a|94.51107142857143|162.505|0.946428571428573|-8.91|13.006557142857146|14.311966666666669|-60.21142857142857|-142.12|0.9100000000000001|-15.219999999999999|31.29|0.0|12.82857142857143|0.8\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of nylon, a polymer where the main polymer chain comprises recurring amide groups; these compounds are generally formed from combinations of diamines, diacids and amino acids. [uniprotkb-kw:kw-0549]|the process force and path happen in the breakdown of nylon, a compound where the main compound chain includes use amide groups; these mixes are generally formed  an alliance of dominoes, decides and amino acids.  [ uniprotkb-kw: kw-0549]|35.815|59.63500000000003|12.735555555555557|9.910000000000004|13.72047894736842|11.63275|20.46888888888889|14.452999999999998|15.090526315789468|6.295750000000002|93.86999999999999|88.50148473330829|27.200000000000003|24.0\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of nylon, a polymer where the main polymer chain comprises recurring amide groups; these compounds are generally formed from combinations of diamines, diacids and amino acids. [uniprotkb-kw:kw-0549]|the chemical reactions and pathways resulting in the breakdown of nylon, a polymer where the main chain comprises repeated amide groups; these compounds are generally formed from combinations of diamines, diacids and amino acids. [uniprotkb-kw-0549]|35.815|39.20964285714288|12.735555555555557|12.137857142857143|13.72047894736842|13.089235135135135|20.46888888888889|19.373714285714286|15.090526315789468|14.425135135135129|93.86999999999999|91.22524239485473|27.200000000000003|26.42857142857143\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of nylon, a polymer where the main polymer chain comprises recurring amide groups; these compounds are generally formed from combinations of diamines, diacids and amino acids. [uniprotkb-kw:kw-0549]| the chemical reactions and pathways resulting in the breakdown of nylon, a polymer; these compounds are generally formed from combinations of diamines, diacids and amino acids|35.815|25.896666666666675|12.735555555555557|16.35481481481482|13.72047894736842|14.048157142857145|20.46888888888889|21.92148148148148|15.090526315789468|17.63392857142857|93.86999999999999|117.07645963215661|27.200000000000003|31.54074074074074\n",
      "\n",
      "<p>dissolve</p>|< p > change < /p >|-47.97999999999996|163.47285714285715|20.200000000000006|-7.8028571428571425|19.674500000000002|17.517985714285714|-207.8|-31.365714285714283|-4.800000000000001|-9.182857142857141|31.29|0.0|40.400000000000006|2.8000000000000003\n",
      "\n",
      "<p>dissolve</p>|dissolve/p>|-47.97999999999996|-47.97999999999996|20.200000000000006|20.200000000000006|19.674500000000002|19.6249|-207.8|-225.44|-4.800000000000001|-6.477499999999999|31.29|31.29|40.400000000000006|40.400000000000006\n",
      "\n",
      "<p>dissolve</p>| <p>break down|-47.97999999999996|147.39000000000004|20.200000000000006|-6.553333333333333|19.674500000000002|14.460766666666668|-207.8|-75.14666666666666|-4.800000000000001|-8.225|31.29|0.0|40.400000000000006|1.2000000000000002\n",
      "\n",
      "any immunoglobulin that recognizes glutamate carboxypeptidase 2 (folate hydrolase 1).|any antibody that prize salt carboxypeptidase 2 (folate hydrolase 1).|-26.659999999999968|32.56000000000003|18.220000000000002|9.96|16.7645|13.6065|-14.512|-23.919999999999995|17.952999999999996|10.417000000000002|58.53822981607831|49.473833993334296|30.0|22.0\n",
      "\n",
      "any immunoglobulin that recognizes glutamate carboxypeptidase 2 (folate hydrolase 1).|any immunoglobulin that recognizes a protein building blocks.|-26.659999999999968|1.8500000000000227|18.220000000000002|13.995000000000001|16.7645|10.877477777777777|-14.512|-33.575|17.952999999999996|9.079999999999998|58.53822981607831|49.473833993334296|30.0|26.6\n",
      "\n",
      "any immunoglobulin that recognizes glutamate carboxypeptidase 2 (folate hydrolase 1).| any immunoglobulin that recognizes glutamate carboxypeptidase 2|-26.659999999999968|-33.934999999999974|18.220000000000002|19.98|16.7645|16.36401111111111|-14.512|5.630000000000003|17.952999999999996|13.946666666666665|58.53822981607831|69.96656701596841|30.0|28.200000000000003\n",
      "\n",
      "the transport of substances that occurs outside cells. [goc:go_curators]|the move of matter that occurs outside cells.  [ goc: go_curators]|33.067500000000024|87.94500000000002|9.765|2.4833333333333343|11.7795|9.56018484848485|-23.96444444444444|-22.383333333333333|9.329999999999998|2.668787878787878|49.473833993334296|44.250742366654144|24.022222222222226|15.733333333333333\n",
      "\n",
      "the transport of substances that occurs outside cells. [goc:go_curators]|the transport of substances that occur outside cells. [goc:go_curators]|33.067500000000024|33.067500000000024|9.765|9.765|11.7795|12.522027272727273|-23.96444444444444|-23.96444444444444|9.329999999999998|7.010909090909088|49.473833993334296|49.473833993334296|24.022222222222226|24.022222222222226\n",
      "\n",
      "the transport of substances that occurs outside cells. [goc:go_curators]| the transportation of substances|33.067500000000024|49.48000000000002|9.765|7.600000000000001|11.7795|14.460766666666668|-23.96444444444444|-23.919999999999995|9.329999999999998|5.905000000000001|49.473833993334296|44.250742366654144|24.022222222222226|18.0\n",
      "\n",
      "a unit of substance content expressed in units of biological activity per 10^12 red blood cells.|a unit of substance content mail in units of biological activity per 10^12 red blood cells.|50.66500000000002|61.24000000000001|8.180000000000003|6.705000000000002|14.178744444444446|13.301522222222223|-7.232500000000002|-9.07|8.503333333333334|7.195|58.53822981607831|54.195869768830164|20.700000000000003|18.2\n",
      "\n",
      "a unit of substance content expressed in units of biological activity per 10^12 red blood cells.|a unit of substance content expressed in units of biological activity/1012 red blood cells.|50.66500000000002|60.74428571428575|8.180000000000003|6.525714285714287|14.178744444444446|12.429833333333335|-7.232500000000002|-9.105714285714278|8.503333333333334|6.812000000000001|58.53822981607831|54.195869768830164|20.700000000000003|19.942857142857143\n",
      "\n",
      "a unit of substance content expressed in units of biological activity per 10^12 red blood cells.| a unit of substance content expressed in units of chemical activity|50.66500000000002|39.55500000000001|8.180000000000003|10.723333333333333|14.178744444444446|15.212838461538462|-7.232500000000002|3.7533333333333303|8.503333333333334|6.446153846153845|58.53822981607831|82.78555852321104|20.700000000000003|28.13333333333334\n",
      "\n",
      "columbia-suicide severity rating scale children's baseline - description of active suicidal ideation with some intent to act, without specific plan.|columbia-suicide sternness pad scale children 's line - kind of active suicidal thinking with some goal to act, without a fact plan.|23.255000000000024|72.61545454545457|12.499999999999996|5.863636363636363|14.102500000000001|9.941433333333334|8.326000000000004|2.7581818181818214|18.0075|13.068571428571424|76.64453405168562|58.53822981607831|28.0|17.127272727272725\n",
      "\n",
      "columbia-suicide severity rating scale children's baseline - description of active suicidal ideation with some intent to act, without specific plan.|columbia suicide severity rating scale baseline - description of active suicidal ideation with some intent to act, without specific plan.|23.255000000000024|23.255000000000024|12.499999999999996|12.499999999999996|14.102500000000001|14.396|8.326000000000004|5.385999999999999|18.0075|10.887999999999998|76.64453405168562|76.64453405168562|28.0|28.0\n",
      "\n",
      "columbia-suicide severity rating scale children's baseline - description of active suicidal ideation with some intent to act, without specific plan.| columbia group|23.255000000000024|62.79000000000002|12.499999999999996|5.246666666666666|14.102500000000001|15.6774|8.326000000000004|-71.22666666666666|18.0075|-1.7674999999999983|76.64453405168562|31.29|28.0|14.533333333333331\n",
      "\n",
      "incomplete maturation or aberrant formation of the male gametes. [hpo:probinson, mp:0001156]|incomplete organism function or aberrant placement of the male gametes.  [ hop: robinson, mp: 0001156]|16.670681818181833|66.5275|12.300454545454546|5.967500000000001|14.460766666666668|14.411166666666668|-9.985454545454552|-5.027500000000003|11.792499999999997|6.818000000000001|54.195869768830164|58.53822981607831|24.018181818181816|20.700000000000003\n",
      "\n",
      "incomplete maturation or aberrant formation of the male gametes. [hpo:probinson, mp:0001156]|incomplete maturation or aberrant formation of the male gametes. [hpo:probinson, mp:001156]|16.670681818181833|16.670681818181833|12.300454545454546|12.300454545454546|14.460766666666668|14.890438461538462|-9.985454545454552|-9.985454545454552|11.792499999999997|9.71769230769231|54.195869768830164|54.195869768830164|24.018181818181816|24.018181818181816\n",
      "\n",
      "incomplete maturation or aberrant formation of the male gametes. [hpo:probinson, mp:0001156]| Incomplete maturation or aberrant formation of the gametes|16.670681818181833|19.100000000000023|12.300454545454546|12.831111111111113|14.460766666666668|15.185500000000001|-9.985454545454552|1.0844444444444505|11.792499999999997|8.532999999999998|54.195869768830164|69.96656701596841|24.018181818181816|25.822222222222223\n",
      "\n",
      "columbia-suicidality severity rating scale baseline (c-ssrs baseline) most recent actual attempt date.|columbia-suicidality sternness pad scale line (c-series line) most recent actual act date.|-17.805000000000007|31.545000000000016|17.233333333333338|10.350000000000001|17.865185714285715|13.353757142857145|-4.743333333333332|-10.623333333333335|14.502857142857145|10.465714285714284|62.58|49.473833993334296|29.066666666666663|19.06666666666667\n",
      "\n",
      "columbia-suicidality severity rating scale baseline (c-ssrs baseline) most recent actual attempt date.|columbia suicide severity rating scale baseline (c-ssrs basal) most recent actual attempt date.|-17.805000000000007|11.514423076923094|17.233333333333338|13.268076923076926|17.517985714285714|17.569166666666668|-4.743333333333332|-7.544615384615383|11.002857142857145|6.189999999999998|62.58|66.37611354998121|29.066666666666663|30.29230769230769\n",
      "\n",
      "columbia-suicidality severity rating scale baseline (c-ssrs baseline) most recent actual attempt date.| columbian-hissing salamander is salamander|-17.805000000000007|-35.11999999999995|17.233333333333338|19.400000000000002|17.865185714285715|17.517985714285714|-4.743333333333332|-12.159999999999997|14.502857142857145|8.984285714285715|62.58|54.195869768830164|29.066666666666663|26.0\n",
      "\n",
      "a radioimmunotherapeutic monoclonal antibody (mn-14) directed against tumor-associated carcinoembryonic antigen (cea) and chelated to the radioisotope yttrium-90 (y 90). yttrium 90 monoclonal antibody mn-14 binds to tumor cell expressing cea, delivering a cytotoxic dose of beta radiation. (nci04)|a procedure monoclonal protein (mn-14) directed against tumor-associated carcinoembryonic antigen (cea) and form to the isotope yttrium-90 (y 90).  yttrium 90 monoclonal antibody mn-14 binds to growth, cell mail queue, produce a cytotoxic dose of beta therapy.  ( nci04)|6.967807017543862|52.65113821138215|15.434210526315791|9.310731707317071|15.456510256410256|14.928314634146343|16.86315789473684|11.32682926829268|13.395769230769226|8.853292682926831|78.74477315987392|72.26115969177356|25.066666666666666|21.076422764227644\n",
      "\n",
      "a radioimmunotherapeutic monoclonal antibody (mn-14) directed against tumor-associated carcinoembryonic antigen (cea) and chelated to the radioisotope yttrium-90 (y 90). yttrium 90 monoclonal antibody mn-14 binds to tumor cell expressing cea, delivering a cytotoxic dose of beta radiation. (nci04)|a radiotherapeutic monoclonal antibody (mn-14) directed against tumor-associated carcinoembryonic antigen (cea) and chelated to the radioisotope yttrium-90 (y 90).|6.967807017543862|-7.628552631578941|15.434210526315791|16.683421052631584|15.617710256410257|15.43587142857143|16.86315789473684|14.025263157894742|15.020769230769226|14.771428571428565|78.74477315987392|69.96656701596841|25.066666666666666|24.852631578947367\n",
      "\n",
      "a radioimmunotherapeutic monoclonal antibody (mn-14) directed against tumor-associated carcinoembryonic antigen (cea) and chelated to the radioisotope yttrium-90 (y 90). yttrium 90 monoclonal antibody mn-14 binds to tumor cell expressing cea, delivering a cytotoxic dose of beta radiation. (nci04)| a radioimmunotherapy antibody targeting tumor-associated antigen|6.967807017543862|-90.3271428571428|15.434210526315791|27.597142857142853|15.617710256410257|18.118455555555556|16.86315789473684|8.114285714285714|15.020769230769226|14.470000000000006|78.74477315987392|69.96656701596841|25.066666666666666|31.371428571428574\n",
      "\n",
      "fish and shellfish used as food or suitable for food.|fish and shellfish used as food or suitable for food.|91.78000000000003|91.78000000000003|1.7000000000000028|1.7000000000000028|7.2905|7.2905|-33.327999999999996|-33.327999999999996|3.8230000000000004|3.8230000000000004|31.29|31.29|10.0|10.0\n",
      "\n",
      "fish and shellfish used as food or suitable for food.|fish and shellfish used as food or suitable for food.|91.78000000000003|91.78000000000003|1.7000000000000028|1.7000000000000028|7.2905|8.215663636363637|-33.327999999999996|-32.739999999999995|3.8230000000000004|0.16000000000000014|31.29|31.29|10.0|10.0\n",
      "\n",
      "fish and shellfish used as food or suitable for food.| seafood|91.78000000000003|120.20500000000001|1.7000000000000028|-3.01|7.2905|19.5753|-33.327999999999996|-124.48|3.8230000000000004|-5.800000000000001|31.29|31.29|10.0|20.8\n",
      "\n",
      "a unit of concentration equal to nanomoles per liter, divided by micrograms per day.|a unit of diligence, equal to nanomoles per liter, move by micrograms per day.|36.572857142857174|54.70142857142861|9.89714285714286|7.368571428571428|12.225900000000001|12.225900000000001|-12.465714285714288|-14.985714285714284|8.783571428571431|6.428571428571431|58.53822981607831|54.195869768830164|22.8|19.942857142857143\n",
      "\n",
      "a unit of concentration equal to nanomoles per liter, divided by micrograms per day.|a unit of concentration equal to nanomoles per liter, divided by micrograms/day.|36.572857142857174|17.44500000000002|9.89714285714286|12.316666666666666|12.225900000000001|11.8787|-12.465714285714288|-15.033333333333331|8.783571428571431|4.610714285714284|58.53822981607831|58.53822981607831|22.8|25.733333333333338\n",
      "\n",
      "a unit of concentration equal to nanomoles per liter, divided by micrograms per day.| a unit of concentration equal to nanomoles per liter, divided by micrograms per day.|36.572857142857174|46.942499999999995|9.89714285714286|8.575000000000003|12.225900000000001|12.915175000000001|-12.465714285714288|-11.242666666666668|8.783571428571431|3.470625000000002|58.53822981607831|58.53822981607831|22.8|21.666666666666668\n",
      "\n",
      "the process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the juxtaglomerulus cells of the kidney as it progresses from its formation to the mature state. [goc:mtg_kidney_jan10]|the walk in which relatively unspecialized cells change, evolve structural and/or functional have that distinguish the juxtaglomerulus cells of the kidney as it travels from its placement in the draw state.  [ goc: mtg_kidney_jan10]|24.03875000000002|58.54678571428573|13.881250000000005|9.440714285714286|12.589142424242425|10.700398039215688|21.189999999999998|16.349714285714285|17.078181818181818|11.111372549019606|82.78555852321104|69.96656701596841|23.900000000000002|18.428571428571427\n",
      "\n",
      "the process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the juxtaglomerulus cells of the kidney as it progresses from its formation to the mature state. [goc:mtg_kidney_jan10]|the process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the juxtaglomerulus cells that progress from its formation to the mature state. [goc:mtg_kidney_jan10]|24.03875000000002|20.40357142857144|13.881250000000005|13.891428571428573|12.589142424242425|13.328166666666666|21.189999999999998|21.69714285714286|17.078181818181818|17.470000000000006|82.78555852321104|79.77416029015912|23.900000000000002|24.171428571428574\n",
      "\n",
      "the process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the juxtaglomerulus cells of the kidney as it progresses from its formation to the mature state. [goc:mtg_kidney_jan10]| The process in which cells change by a series of complex interrelated, continuous events from a relatively unspecialized state to a specialized state|24.03875000000002|27.37500000000003|13.881250000000005|15.403333333333332|12.589142424242425|11.8241|21.189999999999998|19.026666666666667|17.078181818181818|15.185200000000002|82.78555852321104|93.86999999999999|23.900000000000002|24.6\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of tatiopterin metabolic process. [goc:mengo_curators, goc:termgenie]|any walk that changes or change the ratio, rate or extent of the tatiopterin metabolic process.  [ goc : mengo_curators , goc : termgenie ]|-5.8277941176470165|76.50153846153849|16.183823529411768|5.818461538461541|14.080331578947368|11.50274761904762|7.719999999999999|3.01230769230769|12.07578947368421|6.2928571428571445|73.38155456243756|66.37611354998121|29.28235294117647|19.046153846153846\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of tatiopterin metabolic process. [goc:mengo_curators, goc:termgenie]|any process that activates or increases the frequency, rate or extent of a metabolic process. [goc:mengo_curators, goc:termgenie]|-5.8277941176470165|9.101617647058845|16.183823529411768|14.101470588235298|14.080331578947368|13.6065|7.719999999999999|4.607058823529414|12.07578947368421|8.7685|73.38155456243756|69.96656701596841|29.28235294117647|26.929411764705886\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of tatiopterin metabolic process. [goc:mengo_curators, goc:termgenie]| any process that activates or increases the frequency, rate or extent of the tat-inducing process|-5.8277941176470165|37.25750000000002|16.183823529411768|12.037500000000005|14.080331578947368|13.301522222222223|7.719999999999999|12.369999999999997|12.07578947368421|9.28833333333333|73.38155456243756|88.50148473330829|29.28235294117647|26.400000000000002\n",
      "\n",
      "summary listings or individual subject reports provided by the laboratory or other testing facility. may include but is not limited to results of biochemical testing and histological examination. [adapted from tmf-rm]|statement name or organism term reports provided by the region or other testing service.  may include but is not limited to, results of biochemical testing and histological introspection.  [ change from tmf-rm]|13.501505376344113|60.966960784313756|13.943225806451615|7.571176470588238|12.8185375|11.404368235294118|6.824516129032258|4.4929411764705875|13.358125000000001|5.935588235294116|72.26115969177356|65.13532912329528|24.778494623655916|19.827450980392157\n",
      "\n",
      "summary listings or individual subject reports provided by the laboratory or other testing facility. may include but is not limited to results of biochemical testing and histological examination. [adapted from tmf-rm]|summary listings or individual subject reports provided by the laboratory or other testing facility. may include but is not limited to results of chemical testing and histology. [adapted from tmf-rm]|13.501505376344113|27.485000000000014|13.943225806451615|11.91|12.554004166666667|12.554004166666667|6.824516129032258|3.9160000000000004|10.691458333333337|8.336458333333333|72.26115969177356|69.96656701596841|24.778494623655916|24.0\n",
      "\n",
      "summary listings or individual subject reports provided by the laboratory or other testing facility. may include but is not limited to results of biochemical testing and histological examination. [adapted from tmf-rm]| summary|13.501505376344113|77.90500000000002|13.943225806451615|2.890000000000004|12.554004166666667|19.5753|6.824516129032258|-124.48|10.691458333333337|-5.800000000000001|72.26115969177356|31.29|24.778494623655916|20.8\n",
      "\n",
      "using homeopathic assessment methods in a detailed, subsequent, 45-minute, out-of-office meeting to assess the health status of an existing homeopathy client to reevaluate and/or develop a homeopathic treatment plan.|using procedure act methods in a detailed, subsequent, 45-minute, out-of-office meeting to charge the health status of an existing homeopathy client to measure and/or develop a homeopathic care plan.|28.7519827586207|46.2554310344828|12.851206896551727|10.409827586206898|13.1187|11.144950000000001|17.704827586206893|14.257931034482755|21.2109375|18.708750000000002|88.50148473330829|79.77416029015912|27.868965517241378|23.731034482758623\n",
      "\n",
      "using homeopathic assessment methods in a detailed, subsequent, 45-minute, out-of-office meeting to assess the health status of an existing homeopathy client to reevaluate and/or develop a homeopathic treatment plan.|using homeopathic assessment methods in a detailed, subsequent, 45-minute, out-of-office meeting to assess the health status of an existing homeopathy client to reevaluate and/or develop an herbal treatment plan.|28.7519827586207|34.58646551724141|12.851206896551727|12.03741379310345|13.1187|12.589142424242425|17.704827586206893|17.096551724137935|21.2109375|12.225454545454546|88.50148473330829|88.50148473330829|27.868965517241378|27.868965517241378\n",
      "\n",
      "using homeopathic assessment methods in a detailed, subsequent, 45-minute, out-of-office meeting to assess the health status of an existing homeopathy client to reevaluate and/or develop a homeopathic treatment plan.| Using the details of a detailed, subsequent, 45-minute out-of-office meeting to assess the health status of an existing homeopath to reassess and/or develop a homeopathy treatment plan|28.7519827586207|39.429285714285754|12.851206896551727|14.715714285714288|13.1187|12.6252625|17.704827586206893|22.81857142857143|21.2109375|17.3840625|88.50148473330829|112.8176994092682|27.868965517241378|29.771428571428572\n",
      "\n",
      "catalysis of the reaction: citronellol + nad+ = citronellal + nadh + h+. [um-bbd_reactionid:r1155]|catalysis of the reaction: citronellol + nad+ = citronella + nash + h+.  [ um-bbd_reactionid: r1155]|78.87285714285717|78.77220588235295|3.997142857142858|4.383823529411767|17.84955|17.849919607843137|-6.585714285714289|-5.769411764705879|5.825624999999999|3.2909803921568646|44.250742366654144|49.473833993334296|14.228571428571428|15.164705882352942\n",
      "\n",
      "catalysis of the reaction: citronellol + nad+ = citronellal + nadh + h+. [um-bbd_reactionid:r1155]|starting of the reaction: citronellol + nadh + h+. [um-bbd_reactionid:r1155]|78.87285714285717|100.24000000000002|3.997142857142858|0.5199999999999996|17.84955|16.105053846153847|-6.585714285714289|-19.216|5.825624999999999|4.283076923076923|44.250742366654144|31.29|14.228571428571428|10.0\n",
      "\n",
      "catalysis of the reaction: citronellol + nad+ = citronellal + nadh + h+. [um-bbd_reactionid:r1155]| acceleration|78.87285714285717|-6.694999999999993|3.997142857142858|14.690000000000001|17.717283333333334|19.5753|-6.585714285714289|-109.78|4.492291666666667|2.0500000000000007|44.250742366654144|31.29|14.228571428571428|20.8\n",
      "\n",
      "acquainted with knowledge of a subject.|inform with knowledge of a term.|62.79000000000002|90.99000000000004|5.246666666666666|1.3133333333333361|9.197433333333334|9.197433333333334|-65.34666666666666|-72.20666666666665|7.475000000000001|1.9800000000000004|38.32226702584281|31.29|21.200000000000003|14.533333333333331\n",
      "\n",
      "acquainted with knowledge of a subject.|acquainted with knowledge of a person.|62.79000000000002|62.79000000000002|5.246666666666666|5.246666666666666|9.197433333333334|10.577242857142856|-65.34666666666666|-65.34666666666666|7.475000000000001|2.524285714285714|38.32226702584281|38.32226702584281|21.200000000000003|21.200000000000003\n",
      "\n",
      "acquainted with knowledge of a subject.| be acquainted with|62.79000000000002|97.025|5.246666666666666|0.7199999999999989|9.197433333333334|13.3585|-65.34666666666666|-49.010000000000005|7.475000000000001|-1.9740000000000002|38.32226702584281|31.29|21.200000000000003|11.600000000000001\n",
      "\n",
      "a retroviral dna or mutated host gene that encodes a hyperactive form of the proto-oncogene tyrosine-protein kinase src protein. this oncogene is involved in tyrosine phosphorylation and cellular transformation.|a virus dna or change host gene that converts a hyperactive form of the gene tyrosine-protein kinase source protein.  this gene has in tyrosine phosphorylation and cellular function.|10.319885057471282|54.07850574712646|14.22137931034483|8.117931034482758|14.083041935483871|13.080166666666667|6.484137931034482|0.6041379310344865|13.516451612903225|7.4339999999999975|67.59412548439398|57.127462747788826|23.177011494252874|17.65977011494253\n",
      "\n",
      "a retroviral dna or mutated host gene that encodes a hyperactive form of the proto-oncogene tyrosine-protein kinase src protein. this oncogene is involved in tyrosine phosphorylation and cellular transformation.|a retroviral dna or mutated host gene that encodes a hyperactive form of the protein kinase src protein. this oncogene is involved in cellular transformation.|10.319885057471282|42.71266666666668|14.22137931034483|9.372000000000003|14.083041935483871|13.175982051282052|6.484137931034482|-3.7679999999999936|13.516451612903225|6.996794871794869|67.59412548439398|59.91578840339164|23.177011494252874|20.933333333333337\n",
      "\n",
      "a retroviral dna or mutated host gene that encodes a hyperactive form of the proto-oncogene tyrosine-protein kinase src protein. this oncogene is involved in tyrosine phosphorylation and cellular transformation.| a retroviral dna or mutated gene that encodes a hyperactive form of the proto-oncogene tyrosine-protein kinase src protein|10.319885057471282|13.897368421052647|14.22137931034483|16.04105263157895|14.083041935483871|15.493609090909093|6.484137931034482|17.225263157894734|13.516451612903225|12.049545454545452|67.59412548439398|88.50148473330829|23.177011494252874|24.442105263157895\n",
      "\n",
      "<p>**definition:**a patient encounter where the patient and the practitioner(s) are not in the same physical location. examples include telephone conference, email exchange, robotic surgery, and televideo conference.</p>|< p > * * distinctness: * * a case have where the case and the practitioner (s) are not in the same physical location.  examples include telephone conference, email change, robotic room, and televideo conference.  < /p >|6.56666666666672|79.47552845528456|14.57925925925926|5.569268292682931|13.611906896551725|12.630435135135135|9.36|4.15609756097561|16.51620689655173|4.835540540540542|74.48509850970193|62.58|28.785185185185185|17.173983739837396\n",
      "\n",
      "<p>**definition:**a patient encounter where the patient and the practitioner(s) are not in the same physical location. examples include telephone conference, email exchange, robotic surgery, and televideo conference.</p>|a patient encounter where the patient and the practitioner(s) are not in the same physical location. examples include telephone conference, email exchange, surgery, and televideoconference.|6.56666666666672|19.02466666666666|14.57925925925926|12.676000000000002|13.611906896551725|11.961366666666667|9.36|3.5231999999999957|16.51620689655173|11.887948717948717|74.48509850970193|67.59412548439398|28.785185185185185|25.733333333333338\n",
      "\n",
      "<p>**definition:**a patient encounter where the patient and the practitioner(s) are not in the same physical location. examples include telephone conference, email exchange, robotic surgery, and televideo conference.</p>| definition:|6.56666666666672|35.60500000000002|14.57925925925926|8.790000000000003|13.611906896551725|19.5753|9.36|-112.72|16.51620689655173|-1.0899999999999999|74.48509850970193|31.29|28.785185185185185|20.8\n",
      "\n",
      "<p>swish and swallow, oromucosal</p>|< p > swish and talk, oromucosal < /p >|12.425000000000011|112.08500000000001|12.52|0.11000000000000121|15.875800000000002|16.7645|-25.490000000000002|-11.959999999999997|1.4100000000000001|-2.771000000000001|44.250742366654144|31.29|21.6|8.0\n",
      "\n",
      "<p>swish and swallow, oromucosal</p>|swish and swallow, oromucosalp>|12.425000000000011|12.425000000000011|12.52|12.52|15.875800000000002|14.460766666666668|-25.490000000000002|-31.369999999999997|1.4100000000000001|3.5500000000000007|44.250742366654144|44.250742366654144|21.6|21.6\n",
      "\n",
      "<p>swish and swallow, oromucosal</p>||12.425000000000011|205.82000000000002|12.52|-15.2|15.875800000000002|19.476100000000002|-25.490000000000002|-290.12|1.4100000000000001|-16.22|44.250742366654144|0.0|21.6|0.4\n",
      "\n",
      "a leukemia that originates from a myeloid cell, that is the blood forming cells of the bone marrow. [hpo:probinson]|a cancer that begins from a myeloid cell, that is the blood forming cells of the bone marrow.  [ hop: robinson]|59.16092105263158|91.84272727272729|7.367631578947371|3.1818181818181834|8.8695|7.74322380952381|-1.1389473684210465|-2.8545454545454554|5.235999999999997|1.3585714285714268|54.195869768830164|54.195869768830164|16.431578947368422|15.309090909090907\n",
      "\n",
      "a leukemia that originates from a myeloid cell, that is the blood forming cells of the bone marrow. [hpo:probinson]|a leukemia that originates from a myeloid cell, that is the blood forming cells of the bone marrow. [hpo:probinson]|59.16092105263158|59.16092105263158|7.367631578947371|7.367631578947371|8.8695|9.420633333333335|-1.1389473684210465|-0.8294736842105266|5.235999999999997|4.678571428571431|54.195869768830164|54.195869768830164|16.431578947368422|16.431578947368422\n",
      "\n",
      "a leukemia that originates from a myeloid cell, that is the blood forming cells of the bone marrow. [hpo:probinson]| a leukemia|59.16092105263158|90.99000000000004|7.367631578947371|1.3133333333333361|8.8695|15.6774|-1.1389473684210465|-79.06666666666666|5.235999999999997|-6.477499999999999|54.195869768830164|31.29|16.431578947368422|14.533333333333331\n",
      "\n",
      "the chemical reactions and pathways involving keratan sulfate, a glycosaminoglycan with repeat units consisting of beta-1,4-linked d-galactopyranosyl-beta-(1,4)-n-acetyl-d-glucosamine 6-sulfate and with variable amounts of fucose, sialic acid and mannose units; keratan sulfate chains are covalently linked by a glycosidic attachment through the trisaccharide galactosyl-galactosyl-xylose to peptidyl-threonine or serine residues. [goc:go_curators]|the process force and path absorb keratan salt , a glycosaminoglycan with repeat units be of beta-1,4-linked d-galactopyranosyl-beta- ( 1,4 ) -n-acetyl-d-glucosamine 6-sulfate and with symbol amounts of fucose , sialic acid and mannose units ; keratan salt chains are covalently linked by a glycosidic joining through the trisaccharide galactosyl-galactosyl-xylose to peptidyl-threonine or serine part .  [ goc: go_curators]|-4.497806122448935|19.87500000000003|19.973163265306116|17.94|15.914333333333333|14.202226984126986|35.91836734693878|25.90333333333333|23.6355|15.012380952380951|117.07645963215661|108.39173953766033|32.65714285714286|28.0\n",
      "\n",
      "the chemical reactions and pathways involving keratan sulfate, a glycosaminoglycan with repeat units consisting of beta-1,4-linked d-galactopyranosyl-beta-(1,4)-n-acetyl-d-glucosamine 6-sulfate and with variable amounts of fucose, sialic acid and mannose units; keratan sulfate chains are covalently linked by a glycosidic attachment through the trisaccharide galactosyl-galactosyl-xylose to peptidyl-threonine or serine residues. [goc:go_curators]|the chemical reactions and pathways involving keratan sulfate, a sugar molecule with repeat units consisting of beta-1,4-linked d-galactosyl-threonine or serine residues. [goc:go_curators]|-4.497806122448935|7.242727272727308|19.973163265306116|14.98181818181818|15.914333333333333|15.417581481481482|35.91836734693878|17.99272727272727|23.6355|13.231111111111112|117.07645963215661|85.69119412168324|32.65714285714286|31.672727272727272\n",
      "\n",
      "the chemical reactions and pathways involving keratan sulfate, a glycosaminoglycan with repeat units consisting of beta-1,4-linked d-galactopyranosyl-beta-(1,4)-n-acetyl-d-glucosamine 6-sulfate and with variable amounts of fucose, sialic acid and mannose units; keratan sulfate chains are covalently linked by a glycosidic attachment through the trisaccharide galactosyl-galactosyl-xylose to peptidyl-threonine or serine residues. [goc:go_curators]| the chemical reaction pathways involving keratan sulfate protein chains|-4.497806122448935|27.485000000000014|19.973163265306116|11.91|15.914333333333333|17.10119090909091|35.91836734693878|8.032|23.6355|11.901818181818179|117.07645963215661|82.78555852321104|32.65714285714286|32.0\n",
      "\n",
      "order of dicotyledonous flowering plants consisting of 16 families, 112 genera, and nearly 2,500 species.|order of dicotyledonous growth plants be about 16 families, 112 kinds, and nearly 2,500 kinds.|41.30250000000001|75.14250000000001|9.361666666666668|4.641666666666666|12.801833333333335|9.643833333333333|-3.7946666666666715|-8.10666666666667|13.701999999999998|10.248000000000001|62.58|49.473833993334296|24.333333333333336|16.333333333333332\n",
      "\n",
      "order of dicotyledonous flowering plants consisting of 16 families, 112 genera, and nearly 2,500 species.|order of plant parts composed of 16 families, 112 genera, and nearly 2,500 species.|41.30250000000001|84.9157142857143|9.361666666666668|3.1542857142857166|12.801833333333335|11.377166666666668|-3.7946666666666715|-12.465714285714288|13.701999999999998|3.6720000000000006|62.58|54.195869768830164|24.333333333333336|19.942857142857143\n",
      "\n",
      "order of dicotyledonous flowering plants consisting of 16 families, 112 genera, and nearly 2,500 species.| order|41.30250000000001|120.20500000000001|9.361666666666668|-3.01|12.801833333333335|14.311966666666669|-3.7946666666666715|-130.36|13.701999999999998|-8.94|62.58|31.29|24.333333333333336|20.8\n",
      "\n",
      "<p>concepts representing whether a person does or does not currently have a job or is not currently in the labor pool seeking employment.</p>|< p > concepts permute whether a person does or does not currently have a job or is not currently in the labor pool seeking employment.  < /p >|59.066847826086985|87.27000000000001|7.8776086956521745|4.813333333333336|11.408662962962964|11.749166666666667|4.68347826086956|2.6106666666666634|12.82888888888889|3.968|66.37611354998121|66.37611354998121|20.252173913043478|18.0\n",
      "\n",
      "<p>concepts representing whether a person does or does not currently have a job or is not currently in the labor pool seeking employment.</p>|a person does or does not currently have a job or is currently in the labor pool seeking employment.|59.066847826086985|72.51881578947369|7.8776086956521745|5.504473684210527|11.408662962962964|8.08|4.68347826086956|-5.4715789473684175|12.82888888888889|2.8810000000000002|66.37611354998121|54.195869768830164|20.252173913043478|16.431578947368422\n",
      "\n",
      "<p>concepts representing whether a person does or does not currently have a job or is not currently in the labor pool seeking employment.</p>| <p>concepts representing whether a person does or does not currently have a job or is not currently in the labor pool seeking employment|59.066847826086985|52.05000000000001|7.8776086956521745|11.96166666666667|11.408662962962964|11.792442857142857|4.68347826086956|15.841666666666669|12.82888888888889|12.082857142857144|66.37611354998121|93.86999999999999|20.252173913043478|24.6\n",
      "\n",
      "middling or intermediate in degree, quality or extent.|put or negotiated in state, quality or extent.|23.00000000000003|54.72500000000002|11.045000000000002|6.620000000000001|13.902050000000001|9.954550000000001|-39.455000000000005|-45.334999999999994|9.063749999999999|4.353750000000002|49.473833993334296|38.32226702584281|26.6|16.6\n",
      "\n",
      "middling or intermediate in degree, quality or extent.|middling or intermediate in degree, quality or extent.|23.00000000000003|23.00000000000003|11.045000000000002|11.045000000000002|13.902050000000001|14.38636666666667|-39.455000000000005|-38.72|9.063749999999999|4.893333333333331|49.473833993334296|49.473833993334296|26.6|26.6\n",
      "\n",
      "middling or intermediate in degree, quality or extent.| middle|23.00000000000003|120.20500000000001|11.045000000000002|-3.01|11.9283|14.311966666666669|-39.455000000000005|-127.42|9.063749999999999|-7.370000000000001|49.473833993334296|31.29|26.6|20.8\n",
      "\n",
      "a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. this process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ros) derived from iron metabolism. glutathione peroxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ros production and reducing cellular iron uptake, respectively. in contrast, nadph oxidase and p53 act as positive regulators of ferroptosis by promotion of ros production and inhibition of expression of slc7a11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. misregulated ferroptosis has been implicated in multiple physiological and pathological processes. [goc:mtg_apoptosis, pmid:25236395, pmid:26794443]|a schedule, cell death distinguishes morphologically by the presence of smaller than normal mitochondria with change mitochondrial membrane spacing, change or decrease of mitochondria crista, and outer mitochondrial sheet rupture.  beginning of mitochondrial voltage-dependent anion move and mitogen-activated protein enzyme, upregulation of endoplasmic stomach stress, and action of the cystine / glutamate antiporter are having in the causing of ferroptosis.  this walk is distinguished by the net_income of lipid peroxidation products and lethal reactive oxygen kind (ros) make from iron metabolism.  glutathione oxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 serve as a negative control of ferroptosis by choosing rose display and reducing cellular iron uptake, respectively.  in contrast, nadph enzyme and p53 act as film control of ferroptosis by change of rose display and action of squeeze of slc7a11 (a fact light-chain subunit of the cystine/glutamate antiporter), respectively.  misregulated ferroptosis has been lead in product physiological and pathological transform.  [ goc : mtg_apoptosis , pmid:25236395 , pmid:26794443 ]|-8.855483870967703|30.650526315789506|19.995391705069128|15.052932330827073|15.116114109347443|12.97722549019608|28.057806451612905|22.750409356725147|20.959947089947086|12.999039215686274|111.57105673067723|103.1011095963569|31.82488479262673|27.54920634920635\n",
      "\n",
      "a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. this process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ros) derived from iron metabolism. glutathione peroxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ros production and reducing cellular iron uptake, respectively. in contrast, nadph oxidase and p53 act as positive regulators of ferroptosis by promotion of ros production and inhibition of expression of slc7a11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. misregulated ferroptosis has been implicated in multiple physiological and pathological processes. [goc:mtg_apoptosis, pmid:25236395, pmid:26794443]|a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of ferroptosis has been implicated in multiple physiological and|-8.855483870967703|-6.019038461538429|19.995391705069128|18.943205128205125|15.116114109347443|13.707749999999999|28.057806451612905|25.226666666666667|20.959947089947086|19.77375|111.57105673067723|103.77718969022045|31.82488479262673|30.364102564102566\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1); programmed death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|any chemical function that binds to any of the ligands for the organ schedule, cell death protein 1 (pd-1; pd1); schedule death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|98.76577586206898|101.37000000000002|3.0856896551724162|2.8466666666666676|14.342487096774192|14.105575|7.769655172413792|8.490666666666666|13.213870967741933|13.704374999999999|66.37611354998121|69.96656701596841|18.21379310344828|19.333333333333332\n",
      "\n",
      "any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1); programmed death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1).|98.76577586206898|85.87671052631579|3.0856896551724162|3.641315789473687|14.342487096774192|11.238|7.769655172413792|-4.23368421052632|13.213870967741933|3.116500000000002|66.37611354998121|58.53822981607831|18.21379310344828|18.53684210526316\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human b-cell maturation antigen (bcma; tnfrsf17), fused to one that is directed against the cd3 antigen found on t lymphocytes, with potential immunostimulating and antineoplastic activities. upon administration of anti-bcma/cd3 bite antibody amg 701, this bispecific antibody binds to both cd3 on cytotoxic t lymphocytes (ctls) and bcma found on bcma-expressing tumor cells. this activates and redirects ctls to bcma-expressing tumor cells, which results in the ctl-mediated cell death of bcma-expressing tumor cells. bcma, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.|a immunologic factor t-cell engager ( bite ) protein plan of two single-chain symbol break ( scfv ) , one directed against the tumor-associated substance ( taa ) human b-cell maturation antigen ( bcma ; tnfrsf17 ) , melt to one that is plan against the cd3 substance found on t leukocyte , with potential immunostimulating and antineoplastic trait .  upon justice of anti-bcma/cd3 bite protein is 701, this bispecific protein binds to both cd3 on cytotoxic t leukocyte (ctls) and become found on became-expressing growth cells.  this change and send styles to become-expressing growth cells, which results in the steel-mediated cell death of bcma-expressing tumor cells.  bcma, a member of the tumor death factor organ superfamily that is specifically overexpressed in malignant plasma cells, plays a key role in play plasma cell survival.|15.390000000000015|48.7276496350365|17.075000000000006|13.269722627737227|13.87226923076923|12.050054228855721|23.63266666666667|19.369635036496348|20.253999999999998|13.427263681592038|101.87285929039194|92.82114026448932|27.266666666666666|23.806715328467153\n",
      "\n",
      "a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human b-cell maturation antigen (bcma; tnfrsf17), fused to one that is directed against the cd3 antigen found on t lymphocytes, with potential immunostimulating and antineoplastic activities. upon administration of anti-bcma/cd3 bite antibody amg 701, this bispecific antibody binds to both cd3 on cytotoxic t lymphocytes (ctls) and bcma found on bcma-expressing tumor cells. this activates and redirects ctls to bcma-expressing tumor cells, which results in the ctl-mediated cell death of bcma-expressing tumor cells. bcma, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.|a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human protein complexes found on tumor cells, which results in the ctl-mediated cell death of|15.390000000000015|6.944285714285741|17.075000000000006|20.985714285714284|13.87226923076923|13.515500000000001|23.63266666666667|27.83085714285714|20.253999999999998|22.591|101.87285929039194|129.0119750255766|27.266666666666666|33.42857142857143\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "diagnosis of a disease or condition made before death.|diagnosis of a disease or condition made before death.|51.867500000000035|51.867500000000035|7.142777777777777|7.142777777777777|9.346233333333334|9.346233333333334|-35.724444444444444|-35.724444444444444|6.620000000000001|6.620000000000001|44.250742366654144|44.250742366654144|19.57777777777778|19.57777777777778\n",
      "\n",
      "diagnosis of a disease or condition made before death.|diagnosis of a disease or condition made before ami.|51.867500000000035|42.46750000000003|7.142777777777777|8.45388888888889|9.346233333333334|11.7795|-35.724444444444444|-36.37777777777777|6.620000000000001|1.7940000000000005|44.250742366654144|49.473833993334296|19.57777777777778|24.022222222222226\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "autologous human t-lymphocytes transduced with a retroviral vector encoding a t-cell receptor (tcr) specific for the human melanoma antigen a4 (mage-a4), with potential immunostimulatory and antineoplastic activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, mage-a4-specific tcr gene-transduced t-lymphocytes tbi-1201 binds to tumor cells expressing mage-a4. this may result in both an inhibition of growth and increased cell death for mage-a4-expressing tumor cells. the tumor-associated antigen mage-a4 is overexpressed by a variety of cancer cell types.|autologous human t-lymphocytes convert with a retroviral vector convert a t-cell, organ (tar) fact of the human skin_cancer substance a4 (mage-a4), with potential immunostimulatory and antineoplastic trait.  upon isolation, transduction, increases ex vivo, and reintroduction into the case, mage-a4-specific tcr gene-transduced t-lymphocytes tube-1201 binds to growth cells mail mage-a4.  this may result in both an action of growth and increased cell death for mage-a4-expressing tumor cells.  the tumor-associated substance mage-a4 is overexpressed by a difference of cancer cell types.|21.598000000000013|45.74997560975612|14.172|10.952341463414637|15.002372527472529|13.820375177304964|20.267341772151894|18.30682926829268|15.77236263736264|10.654822695035463|85.1180024436664|79.15813438933486|25.054177215189874|22.169756097560978\n",
      "\n",
      "autologous human t-lymphocytes transduced with a retroviral vector encoding a t-cell receptor (tcr) specific for the human melanoma antigen a4 (mage-a4), with potential immunostimulatory and antineoplastic activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, mage-a4-specific tcr gene-transduced t-lymphocytes tbi-1201 binds to tumor cells expressing mage-a4. this may result in both an inhibition of growth and increased cell death for mage-a4-expressing tumor cells. the tumor-associated antigen mage-a4 is overexpressed by a variety of cancer cell types.|t-cell receptors specific for a human melanoma antigen a4 (mage-a4), with potential immunostimulatory and anti-cancer activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, m|21.598000000000013|-3.767857142857139|14.172|17.262857142857147|15.002372527472529|15.7791625|20.267341772151894|18.96714285714285|15.77236263736264|13.063749999999999|85.1180024436664|91.22524239485473|25.054177215189874|29.885714285714286\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "any process that modulates the occurrence or rate of mesenchymal stem cell death by apoptotic process that contributes to the shaping of the nephron in the metanephros. [goc:mtg_apoptosis, goc:mtg_kidney_jan10]|any walk that changes the presence or rate of mesenchymal stem cell death by apoptosis walk that pay for the change of the nephron in the metanephros.  [ goc : mtg_apoptosis , goc : mtg_kidney_jan10 ]|34.58646551724141|82.87912162162164|12.03741379310345|6.295270270270269|11.536267741935484|9.099941666666666|16.488275862068964|10.062702702702701|13.060645161290324|7.306145833333332|76.64453405168562|62.58|22.351724137931036|16.048648648648648\n",
      "\n",
      "any process that modulates the occurrence or rate of mesenchymal stem cell death by apoptotic process that contributes to the shaping of the nephron in the metanephros. [goc:mtg_apoptosis, goc:mtg_kidney_jan10]|any process that modulates the occurrence or rate of mesenchymal stem cells death by programmed cell death that contributes to the shaping of the metanephros. [goc:mtg_apoptosis, goc:kidney_jan10]|34.58646551724141|39.59916666666669|12.03741379310345|11.089814814814819|11.536267741935484|11.222833333333334|16.488275862068964|15.314074074074071|13.060645161290324|11.975000000000001|76.64453405168562|69.96656701596841|22.351724137931036|20.214814814814815\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "cases of harm to a child caused by parents or other caregivers, defined by the federal government as: any recent act or failure to act on the part of a parent or caretaker which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act or failure to act which presents an imminent risk of serious harm.|cases of harm to a child caused by parents or other adult , choose by the agent government as : any recent act or failure to act on the part of a parent or official which results in death , serious physical or emotional harm , sexual use or mistreatment ; or an act or failure to act which greet an imminent risk of serious harm .|38.5758606557377|57.92802238805973|15.455819672131149|13.501865671641792|11.06259180327869|10.544886885245901|17.09245901639344|14.333134328358206|30.071967213114753|28.99098360655737|106.1095525859948|98.94766798666859|27.281967213114754|25.340298507462688\n",
      "\n",
      "cases of harm to a child caused by parents or other caregivers, defined by the federal government as: any recent act or failure to act on the part of a parent or caretaker which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act or failure to act which presents an imminent risk of serious harm.|any recent act or failure to act on the part of a parent or other caregiver which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act which presents an imminent risk of serious harm.|38.5758606557377|44.83000000000004|15.455819672131149|11.975000000000001|11.06259180327869|10.045007317073171|17.09245901639344|12.542|30.071967213114753|9.727804878048783|106.1095525859948|88.50148473330829|27.281967213114754|24.0\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the g2/m phase and cell death. this agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. docetaxel has been studied for use as a radiation-sensitizing agent. (nci04)|a semi-synthetic, second-generation texan make from a mix found in the european yew tree, taxus baccata.  docetaxel displays potent and broad antineoplastic properties; it binds to and change tubulin, thereby suppress tubule disassembly, which results in cell- cycle arrest at the g2/m phase and cell death.  this agent also suppresses pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by produce various mediators of the inflammatory phrase.  docetaxel has been thought to use as a radiation-sensitizing agent.  ( nci04)|7.490142857142899|28.12305617977529|16.388190476190477|13.75874157303371|14.051055555555555|13.484417730496455|20.110952380952387|17.59370786516854|17.08566666666666|11.606843971631207|91.76029239273379|86.2605770905806|27.196190476190477|24.19865168539326\n",
      "\n",
      "a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the g2/m phase and cell death. this agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. docetaxel has been studied for use as a radiation-sensitizing agent. (nci04)|a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad anti-cancer properties; it binds to and stabilizes tubulin|7.490142857142899|11.248534482758657|16.388190476190477|15.292586206896551|13.827855555555555|13.546112121212122|20.110952380952387|16.285517241379313|14.835666666666661|11.654545454545449|91.76029239273379|85.69119412168324|27.196190476190477|26.48965517241379\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "the number of days from the date of initial cancer diagnosis to the date of death.|the number of days from the date of sign cancer diagnosis to the date of death.|77.1025|87.67750000000001|4.492500000000003|3.017500000000002|7.390725|6.40385|-12.377500000000001|-13.48|5.998750000000001|5.115625000000001|44.250742366654144|38.32226702584281|13.200000000000001|10.700000000000001\n",
      "\n",
      "the number of days from the date of initial cancer diagnosis to the date of death.|the number of days from the initial cancer diagnosis to the date of death.|77.1025|72.83000000000003|4.492500000000003|4.840000000000003|7.390725|8.219166666666666|-12.377500000000001|-16.245714285714282|5.998750000000001|1.4740000000000002|44.250742366654144|44.250742366654144|13.200000000000001|14.228571428571428\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "a fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (tnf-alpha), with anti-inflammatory activity. upon administration, certolizumab binds to tnf-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering tnf-alpha inactive and inhibiting tnf-mediated inflammatory responses. tnf-alpha is a protein involved in inflammation, cell survival, and apoptosis.|a fab break of a cell, change monoclonal protein directed against the proinflammatory protein tumor death factor-alpha (tnf-alpha), with medicine activity.  upon justice, certolizumab binds to tnf-alpha, preventing the action of this protein with endogenous cell surface organ, thereby melt tnf-alpha inactive and suppress tnf-mediated inflammatory manner.  tnf-alpha is a protein involved in burning, cell survival, and apoptosis.|-22.29974137931032|26.640000000000015|19.97189655172414|13.270000000000003|15.69419230769231|13.143189696969698|23.280689655172413|16.72266666666667|24.67415384615385|10.57545454545454|97.70299368494294|91.22524239485473|32.69655172413793|28.666666666666664\n",
      "\n",
      "a fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (tnf-alpha), with anti-inflammatory activity. upon administration, certolizumab binds to tnf-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering tnf-alpha inactive and inhibiting tnf-mediated inflammatory responses. tnf-alpha is a protein involved in inflammation, cell survival, and apoptosis.|a protein complex involved in inflammation, cell survival, and apoptosis.|-22.29974137931032|24.100000000000023|19.97189655172414|11.14|15.156858974358977|13.957481818181819|23.280689655172413|-20.979999999999997|19.25748717948718|7.867272727272727|97.70299368494294|54.195869768830164|32.69655172413793|26.0\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "a monoclonal antibody directed against human hepatocyte growth factor receptor (hgfr or c-met), with potential antineoplastic activity. telisotuzumab binds to c-met, thereby preventing both c-met binding to its ligand, hgf and the subsequent activation of the hgf/c-met signaling pathway. this may cause cell death in c-met-expressing tumor cells. c-met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.|an immunologic factor protein directed against human hepatocyte growth factor organ (hgfr or c-met), with potential antineoplastic activity.  telisotuzumab binds to c-met, thereby preventing both c-met binding to its ligand, hgf and the subsequent beginning of the hgf/c-met tell path.  this may cause cell death in c-met-expressing growth cells.  c-met, an organ tyrosine kinase overexpressed or change in many growth, cell types, plays a key role in cancer cell growth, survival, growth, spread, and metastasis.|24.899486486486524|48.91638461538463|13.463081081081082|10.31194871794872|13.125982926829268|11.77366212624585|15.677297297297294|13.893333333333327|13.289024390243902|7.441345514950164|81.59433730351635|74.04565456527479|24.29837837837838|20.59897435897436\n",
      "\n",
      "a monoclonal antibody directed against human hepatocyte growth factor receptor (hgfr or c-met), with potential antineoplastic activity. telisotuzumab binds to c-met, thereby preventing both c-met binding to its ligand, hgf and the subsequent activation of the hgf/c-met signaling pathway. this may cause cell death in c-met-expressing tumor cells. c-met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.|a monoclonal antibody directed against human hepatocyte growth factor receptor, with potential anti-cancer activity. telisotuzumab binds to c-met, a protein molecule that is overexpressed or mutated in many tumor types, plays|24.899486486486524|-2.6587903225806144|13.463081081081082|17.48080645161291|12.933421951219513|13.767935294117647|15.677297297297294|18.08|13.289024390243902|13.390588235294118|81.59433730351635|93.86999999999999|24.29837837837838|29.425806451612903\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "an inhibitor of protein tyrosine phosphatase (ptp) non-receptor type 11 (shp2; src homology region 2 domain phosphatase; ptpn11), with potential antineoplastic activity. upon oral administration, shp2 inhibitor tno155 binds to and inhibits shp2. this prevents shp2-mediated signaling, inhibits mapk signaling and prevents growth of shp2-expressing tumor cells. shp2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the ras-raf-erk signaling pathway. shp2 also regulates programmed cell death 1 (pd-1)-mediated signal transduction and is involved in immune checkpoint modulation.|a substance of protein tyrosine enzyme (ptp) non-receptor type 11 (shp2; src homology region 2 domain enzyme; ptpn11), with potential antineoplastic activity.  upon oral justice, shp2 substance tno155 binds to and suppress shp2.  this prevents shp2-mediated tell, suppress map tell and prevents growth of shp2-expressing tumor cells.  shp2, an oncoprotein overexpressed in a difference of cancer cell types, restrict cell survival, adaptation and increase through the beginning of the race-raf-erk tell path.  shp2 also restrict schedule, cell death 1 (pd-1) -mediated tell transduction and is having in immune stop revision.|29.477878787878808|64.03333333333335|12.791363636363638|8.220000000000002|15.764866451612905|13.907682683982685|19.10727272727273|14.384680851063838|16.484516129032258|9.952640692640692|84.73372056035305|78.74477315987392|25.86666666666667|22.43687943262411\n",
      "\n",
      "an inhibitor of protein tyrosine phosphatase (ptp) non-receptor type 11 (shp2; src homology region 2 domain phosphatase; ptpn11), with potential antineoplastic activity. upon oral administration, shp2 inhibitor tno155 binds to and inhibits shp2. this prevents shp2-mediated signaling, inhibits mapk signaling and prevents growth of shp2-expressing tumor cells. shp2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the ras-raf-erk signaling pathway. shp2 also regulates programmed cell death 1 (pd-1)-mediated signal transduction and is involved in immune checkpoint modulation.|an inhibitor of protein tyrosine phosphatase (ptp) non-receptor type 11 (shp2), an oncoprotein that is overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the ras|29.477878787878808|-1.8514705882352587|12.791363636363638|21.964117647058824|15.764866451612905|15.071544444444447|19.10727272727273|27.265882352941176|16.484516129032258|22.736666666666665|84.73372056035305|117.07645963215661|25.86666666666667|30.070588235294117\n",
      "\n",
      "death| change|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "uptake of substances into the body via the inner mucosal surface of the cheeks.|uptake of matter into the body via the inner mucosal surface of the cheeks.|54.70142857142861|60.74428571428575|7.368571428571428|6.525714285714287|9.970185714285716|8.842328571428572|-14.565714285714286|-16.245714285714282|7.437857142857144|6.092142857142857|62.58|62.58|25.65714285714286|25.65714285714286\n",
      "\n",
      "uptake of substances into the body via the inner mucosal surface of the cheeks.|uptake of substances into the body via the inner mucus surface of the cheek.|54.70142857142861|60.74428571428575|7.368571428571428|6.525714285714287|9.970185714285716|10.3245|-14.565714285714286|-15.405714285714286|7.437857142857144|2.1020000000000003|62.58|62.58|25.65714285714286|25.65714285714286\n",
      "\n",
      "uptake of substances into the body via the inner mucosal surface of the cheeks.| the process|54.70142857142861|119.19000000000003|7.368571428571428|-2.619999999999999|9.970185714285716|15.6774|-14.565714285714286|-77.10666666666665|7.437857142857144|-5.300000000000001|62.58|31.29|25.65714285714286|14.533333333333331\n",
      "\n",
      "a plasmid encoding the protein antiangiogenic metargidin plasmid (amep), the disintegrin domain of adam-15 (metargidin), with potential antiangiogenic and antimetastatic activities. upon intratumoral electrotransfer of plasmid encoding amep, amep binds to cellular integrin receptors alpha-v-beta-3 (avb3) and alpha-5-beta-1 (a5b1), which are upregulated on activated endothelial cells and a variety of tumor cells. binding to the integrin receptors may inhibit angiogenesis and may inhibit tumor cell proliferation. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c90537\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c90537\" nci thesaurus)|a bioactive substance converts the protein antiangiogenic metargidin plasmid (amep), the disintegration class of adam-15 (metargidin), with potential antiangiogenic and antimetastatic trait.  upon intratumoral electrotransfer of plasmid convert amp, amep binds to cellular integrin organ alpha-v-beta-3 (avb3) and alpha-5-beta-1 (a5b1), which are unregulated on change endothelial cells and a difference of tumor cells.  binding to the integrin organ may suppress growth and may suppress tumor cell increase.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c90537 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c90537 '' nice wordbook)|22.845419580419588|50.808068181818214|11.834428904428908|8.340719696969696|14.582751851851853|14.742391743119267|9.894871794871797|7.610833333333339|27.07277777777778|13.167178899082572|60.408930781646994|60.408930781646994|23.862004662004665|20.574242424242424\n",
      "\n",
      "a plasmid encoding the protein antiangiogenic metargidin plasmid (amep), the disintegrin domain of adam-15 (metargidin), with potential antiangiogenic and antimetastatic activities. upon intratumoral electrotransfer of plasmid encoding amep, amep binds to cellular integrin receptors alpha-v-beta-3 (avb3) and alpha-5-beta-1 (a5b1), which are upregulated on activated endothelial cells and a variety of tumor cells. binding to the integrin receptors may inhibit angiogenesis and may inhibit tumor cell proliferation. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c90537\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c90537\" nci thesaurus)|a plasmid encoding a protein complex, with potential antiangiogenic and antimetastatic activities. upon intratumoral electrotransfer of the gene, amep binds to cellular integrins alpha-v-beta-3 (avb|22.845419580419588|1.2595000000000312|11.834428904428908|16.189|14.381871851851853|15.045542857142859|9.894871794871797|17.479999999999997|25.04777777777778|13.99821428571429|60.408930781646994|82.78555852321104|23.862004662004665|27.400000000000002\n",
      "\n",
      "a plasmid encoding the protein antiangiogenic metargidin plasmid (amep), the disintegrin domain of adam-15 (metargidin), with potential antiangiogenic and antimetastatic activities. upon intratumoral electrotransfer of plasmid encoding amep, amep binds to cellular integrin receptors alpha-v-beta-3 (avb3) and alpha-5-beta-1 (a5b1), which are upregulated on activated endothelial cells and a variety of tumor cells. binding to the integrin receptors may inhibit angiogenesis and may inhibit tumor cell proliferation. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c90537\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c90537\" nci thesaurus)| am|22.845419580419588|162.505|11.834428904428908|-8.91|14.381871851851853|14.311966666666669|9.894871794871797|-139.18|25.04777777777778|-13.65|60.408930781646994|0.0|23.862004662004665|0.8\n",
      "\n",
      "the monohydrate bromide salt form of tiotropium, a quaternary ammonium derivative of atropine and a long-acting muscarinic receptor antagonist, with bronchodilating activity. upon inhalation, tiotropium binds to and blocks mainly muscarinic m3 receptors located on smooth muscle cells, thereby preventing smooth muscle contraction.|the hydrate bromide salt form of tiotropium, a digit ammonium word of atropine and a long-acting muscarinic organ drug, with bronchodilating activity.  upon medicine, tiotropium binds to and blocks mainly muscarinic m3 organ located on smooth muscle cells, thereby preventing smooth muscle decrease.|3.41224806201555|34.284696969696995|16.34418604651163|12.120909090909091|14.431627272727273|11.749166666666667|18.867906976744187|14.029090909090911|30.756818181818183|12.236666666666665|90.32644961471695|86.63808689023553|28.98914728682171|26.775757575757577\n",
      "\n",
      "the monohydrate bromide salt form of tiotropium, a quaternary ammonium derivative of atropine and a long-acting muscarinic receptor antagonist, with bronchodilating activity. upon inhalation, tiotropium binds to and blocks mainly muscarinic m3 receptors located on smooth muscle cells, thereby preventing smooth muscle contraction.|the salt form of tiotropium, a molecule of fat and protein, which prevents smooth muscle contraction.|3.41224806201555|66.5275|16.34418604651163|5.967500000000001|13.340427272727274|10.559864705882354|18.867906976744187|-5.027500000000003|19.756818181818183|6.092941176470589|90.32644961471695|54.195869768830164|28.98914728682171|18.2\n",
      "\n",
      "the monohydrate bromide salt form of tiotropium, a quaternary ammonium derivative of atropine and a long-acting muscarinic receptor antagonist, with bronchodilating activity. upon inhalation, tiotropium binds to and blocks mainly muscarinic m3 receptors located on smooth muscle cells, thereby preventing smooth muscle contraction.| the monohydrate bromide salt form of tiotropium, a quaternary ammonium derivative of atropine and a long-acting muscarinic receptor antagonist, with bronchodilating activity. upon inhalation, tiotropium binds to and blocks mainly muscarinic receptors located on smooth muscle cells, thereby preventing smooth muscle contraction.|3.41224806201555|3.41224806201555|16.34418604651163|16.34418604651163|13.340427272727274|13.152722222222224|18.867906976744187|18.731162790697674|19.756818181818183|15.585999999999999|90.32644961471695|90.32644961471695|28.98914728682171|28.98914728682171\n",
      "\n",
      "any process that stops, prevents or reduces the frequency, rate or extent of cysteine-type endopeptidase activity involved in apoptotic signaling pathway. [goc:mtg_apoptosis]|any wall that stops, prevents or weaken the frequency, rate or extent of cysteine-type endopeptidase activity involved in apoptotic tell path.  [ goc: mtg_apoptosis]|-0.44818181818180847|38.48350000000002|16.05454545454546|10.997000000000003|14.10045|11.629033333333332|13.98363636363636|9.483199999999997|13.222500000000004|8.17066666666667|82.78555852321104|73.38155456243756|29.854545454545452|22.6\n",
      "\n",
      "any process that stops, prevents or reduces the frequency, rate or extent of cysteine-type endopeptidase activity involved in apoptotic signaling pathway. [goc:mtg_apoptosis]|any process that prevents or reduces cell membrane protein breakdown in a cell undergoin programmed cell death. [goc:mtg_apoptosis]|-0.44818181818180847|37.900000000000034|16.05454545454546|10.208888888888893|14.10045|12.817|13.98363636363636|4.677777777777784|13.222500000000004|9.7105|82.78555852321104|69.96656701596841|29.854545454545452|25.822222222222223\n",
      "\n",
      "any process that stops, prevents or reduces the frequency, rate or extent of cysteine-type endopeptidase activity involved in apoptotic signaling pathway. [goc:mtg_apoptosis]| any process that prevents or reduces cell surface molecule exposure on a cell undergoing programmed cell death|-0.44818181818180847|42.86500000000001|16.05454545454546|11.752222222222223|14.10045|12.058373684210528|13.98363636363636|14.588888888888885|13.222500000000004|11.867894736842103|82.78555852321104|93.86999999999999|29.854545454545452|27.200000000000003\n",
      "\n",
      "human ccna2 wild-type allele is located within 4q25-q31 and is approximately 6 kb in length. this allele, which encodes cyclin-a2 protein, plays a role in cell cycle g1/s and g2/m transitions.|human ccna2 wild-type gene is located within 4q25-q31 and is approximately 6 kb in length.  this gene, which convert cycling-a2 protein, plays a role in cell cycle g1/s and g2/m switch.|84.45634408602152|100.83333333333336|4.046451612903226|1.8450000000000024|14.617355555555555|14.063638738738739|2.08258064516129|0.547500000000003|7.587499999999999|3.322072072072075|59.91578840339164|51.09635603445709|18.32688172043011|14.266666666666666\n",
      "\n",
      "human ccna2 wild-type allele is located within 4q25-q31 and is approximately 6 kb in length. this allele, which encodes cyclin-a2 protein, plays a role in cell cycle g1/s and g2/m transitions.|normal human ccna2 gene is located within 4q25-q31 and is about 6 kilobases in length. this gene, which encodes cyclin-a2 protein, plays a role in cell cycle g1/s and g2/m transitions.|84.45634408602152|87.18537634408602|4.046451612903226|3.665806451612905|14.617355555555555|14.617355555555555|2.08258064516129|0.7548387096774185|7.587499999999999|6.802499999999998|59.91578840339164|57.127462747788826|18.32688172043011|17.03655913978495\n",
      "\n",
      "human ccna2 wild-type allele is located within 4q25-q31 and is approximately 6 kb in length. this allele, which encodes cyclin-a2 protein, plays a role in cell cycle g1/s and g2/m transitions.| human ccna2 gene is located within 4q25-q31|84.45634408602152|103.54|4.046451612903226|0.8049999999999997|14.617355555555555|18.3435|2.08258064516129|-9.07|7.587499999999999|1.468|59.91578840339164|54.195869768830164|18.32688172043011|18.2\n",
      "\n",
      "stage iv includes: (t3, n1, m0); (t4, n0, m0); (t4, n1, m0); (any t, any n, m1). t3: tumor of any size with local invasion, but not invading adjacent organs. t4: tumor of any size with invasion of adjacent organs. n1: metastasis in regional lymph node(s). n0: no regional lymph node metastasis. m0: no distant metastasis. m1: distant metastasis. (ajcc 7th ed.)|stage iv includes : ( t3 , n1 , m0 ) ; ( t4 , n0 , m0 ) ; ( t4 , n1 , m0 ) ; ( any t , any n , m1 ) .  t3: growth of any size with local spread, but not enter the adjacent meat.  t4: growth of any size with spread of adjacent meat.  n1: metastasis in regional lymph node (s).  n0: no regional lymph node metastasis.  m0: no distant metastasis.  m1: distant metastasis.  ( ajcc 7th ed.)|83.85890681003588|126.30150537634408|3.2740860215053758|-1.7901075268817195|14.972029032258066|14.702718466353678|-14.61096774193549|-10.120000000000001|2.272580645161291|-0.17133020344287786|51.09635603445709|43.0039916751922|18.239426523297492|11.445161290322583\n",
      "\n",
      "stage iv includes: (t3, n1, m0); (t4, n0, m0); (t4, n1, m0); (any t, any n, m1). t3: tumor of any size with local invasion, but not invading adjacent organs. t4: tumor of any size with invasion of adjacent organs. n1: metastasis in regional lymph node(s). n0: no regional lymph node metastasis. m0: no distant metastasis. m1: distant metastasis. (ajcc 7th ed.)|stage iv includes: (t3,n1, m0); t4: tumor of any size with local invasion, but not invading adjacent organs. t1: metastasis in a specific anatomical area of the muscosal node(s) t3|83.85890681003588|47.79000000000002|3.2740860215053758|10.320000000000004|14.867192668621703|14.083041935483871|-14.61096774193549|10.05866666666666|1.2157624633431112|7.894838709677423|51.09635603445709|82.78555852321104|18.239426523297492|24.666666666666668\n",
      "\n",
      "stage iv includes: (t3, n1, m0); (t4, n0, m0); (t4, n1, m0); (any t, any n, m1). t3: tumor of any size with local invasion, but not invading adjacent organs. t4: tumor of any size with invasion of adjacent organs. n1: metastasis in regional lymph node(s). n0: no regional lymph node metastasis. m0: no distant metastasis. m1: distant metastasis. (ajcc 7th ed.)| stage iv includes: (tumor of any size), (tumor of any size), (tumor of any size), (any tumour),|83.85890681003588|61.665000000000006|3.2740860215053758|9.130000000000003|14.895149032258066|11.22732105263158|-14.61096774193549|9.688888888888894|1.4975806451612925|4.926842105263159|51.09635603445709|93.86999999999999|18.239426523297492|27.200000000000003\n",
      "\n",
      "derivatives of ethylene, a simple organic gas of biological origin with many industrial and biological use.|word of alkene, a simple organic gas of biological source with many industrial and biological uses.|-7.497499999999974|24.22750000000002|16.292500000000004|11.867500000000003|11.338225000000001|10.35135|-3.1899999999999977|-6.130000000000003|13.063749999999999|10.708750000000002|66.37611354998121|62.58|25.700000000000003|23.200000000000003\n",
      "\n",
      "derivatives of ethylene, a simple organic gas of biological origin with many industrial and biological use.|derivatives of ethylene, a gas of biological origin with many industrial and biological use.|-7.497499999999974|-5.727142857142809|16.292500000000004|15.797142857142859|11.338225000000001|11.377166666666668|-3.1899999999999977|-8.685714285714283|13.063749999999999|6.812000000000001|66.37611354998121|58.53822981607831|25.700000000000003|22.8\n",
      "\n",
      "derivatives of ethylene, a simple organic gas of biological origin with many industrial and biological use.| derivatives of ethylene, a simple organic gas of biological origin|-7.497499999999974|3.3972727272727354|16.292500000000004|15.518181818181823|11.338225000000001|13.442533333333335|-3.1899999999999977|4.09454545454545|13.063749999999999|7.334999999999997|66.37611354998121|76.64453405168562|25.700000000000003|26.218181818181815\n",
      "\n",
      "an autonomic disorder characterized by excessive sweating of the forehead, upper lip, perioral region, or sternum subsequent to gustatory stimuli. the auriculotemporal syndrome features facial flushing or sweating limited to the distribution of the auriculotemporal nerve and may develop after trauma to the parotid gland, in association with parotid neoplasms, or following their surgical removal. (from ann neurol 1997 dec;42(6):973-5)|a disease change distinguishes by excessive sweating of the forehead, upper lip, perioral region, or bone subsequent to gustatory stimuli.  the auriculotemporal syndrome has facial drench or sweating, limited to the commerce of the auriculotemporal nerve and may expand after trauma to the parotid gland, in group with parotid growth, or following their surgical removal.  ( from an neurol 1997 dec; 42 (6): 973-5)|8.875000000000028|43.504999999999995|16.99|12.65666666666667|13.187164480874317|12.589142424242425|22.244|17.63818181818182|17.15109289617486|10.798181818181817|103.77718969022045|93.86999999999999|30.0|25.163636363636368\n",
      "\n",
      "an autonomic disorder characterized by excessive sweating of the forehead, upper lip, perioral region, or sternum subsequent to gustatory stimuli. the auriculotemporal syndrome features facial flushing or sweating limited to the distribution of the auriculotemporal nerve and may develop after trauma to the parotid gland, in association with parotid neoplasms, or following their surgical removal. (from ann neurol 1997 dec;42(6):973-5)|an autonomic disorder characterized by excessive sweating of the forehead, upper lip, perioral region, or sternum subsequent to gustatory stimuli. the auriculotemporal syndrome features facial flushing limited to the distribution of an ear canal. it may develop after trauma to|8.875000000000028|11.41166666666669|16.99|14.98|13.446016939890713|12.401927642276423|22.244|12.932999999999996|17.15109289617486|12.284796747967476|103.77718969022045|88.50148473330829|30.0|29.333333333333332\n",
      "\n",
      "an autonomic disorder characterized by excessive sweating of the forehead, upper lip, perioral region, or sternum subsequent to gustatory stimuli. the auriculotemporal syndrome features facial flushing or sweating limited to the distribution of the auriculotemporal nerve and may develop after trauma to the parotid gland, in association with parotid neoplasms, or following their surgical removal. (from ann neurol 1997 dec;42(6):973-5)| an allergy is hypersensitivity reaction|8.875000000000028|-10.754999999999995|16.99|16.25|13.446016939890713|15.262271428571431|22.244|-14.053333333333327|17.15109289617486|6.965714285714284|103.77718969022045|54.195869768830164|30.0|22.400000000000002\n",
      "\n",
      "penis tissue expanders designed for the expansion of the penis using constant traction. these expanders are typically a plastic device with a mechanism (e.g., consisting of a base located on the pubis bone and a penis head holder over the glans with expandable metal rods) that provides constant traction to the penis. traction penis expanders are intended for external placement on the penis, helping to correct penis curvature (i.e., straightening the penis after surgery) and/or possibly resulting in penis enlargement.|penis tissue expanders are designed for the increase of the penis using constant pull.  these expanders are typically a plastic device with a device (e.g., be  a base located on the bone bone and a penis head holder over the glans with expandable metal rods) that provides a constant pull to the penis.  pull penis expanders are conveyed for feature placement on the penis, helping to correct penis shape (i.e., arrange the penis after room) and/or possibly happen in penis photograph.|44.405|67.2632142857143|9.55|6.48595238095238|13.248916666666668|11.633219047619049|2.9604999999999997|-0.050476190476192784|17.396208333333334|11.21821428571429|73.38155456243756|67.29168940144093|26.0|21.81904761904762\n",
      "\n",
      "penis tissue expanders designed for the expansion of the penis using constant traction. these expanders are typically a plastic device with a mechanism (e.g., consisting of a base located on the pubis bone and a penis head holder over the glans with expandable metal rods) that provides constant traction to the penis. traction penis expanders are intended for external placement on the penis, helping to correct penis curvature (i.e., straightening the penis after surgery) and/or possibly resulting in penis enlargement.|these expanders are typically a plastic device that helps to correct penis curvature (i.e., straightening the penistles after surgery) and/or possibly resulting in penile enlargement.|44.405|31.29125000000002|9.55|10.447500000000002|13.248916666666668|13.998223076923077|2.9604999999999997|-9.728000000000002|17.396208333333334|13.329999999999998|73.38155456243756|60.592824451415034|26.0|26.5\n",
      "\n",
      "penis tissue expanders designed for the expansion of the penis using constant traction. these expanders are typically a plastic device with a mechanism (e.g., consisting of a base located on the pubis bone and a penis head holder over the glans with expandable metal rods) that provides constant traction to the penis. traction penis expanders are intended for external placement on the penis, helping to correct penis curvature (i.e., straightening the penis after surgery) and/or possibly resulting in penis enlargement.| penis|44.405|120.20500000000001|9.55|-3.01|13.248916666666668|19.5753|2.9604999999999997|-130.36|17.396208333333334|-8.94|73.38155456243756|31.29|26.0|20.8\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of b cell differentiation. [goc:go_curators]|any walk that changes or change the ratio, rate or extent of b cell adaptation.  [ goc: go_curators]|18.940000000000026|76.97144736842105|12.605000000000004|4.883421052631579|12.417511764705882|10.074655555555555|-0.6174999999999997|-5.781052631578945|8.863529411764706|1.9800000000000004|62.58|54.195869768830164|23.200000000000003|16.431578947368422\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of b cell differentiation. [goc:go_curators]|any process that activates or increases the frequency, rate or extent of b cell differentiation. [goc:go_cursor]|18.940000000000026|24.22750000000002|12.605000000000004|11.867500000000003|12.417511764705882|12.855122222222224|-0.6174999999999997|-0.9849999999999994|8.863529411764706|7.405000000000001|62.58|62.58|23.200000000000003|23.200000000000003\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of b cell differentiation. [goc:go_curators]| an activation process|18.940000000000026|54.72500000000002|12.605000000000004|6.620000000000001|12.417511764705882|16.5165|-0.6174999999999997|-44.6|8.863529411764706|0.8520000000000003|62.58|44.250742366654144|23.200000000000003|21.6\n",
      "\n",
      "the menstrual cycle process in which one central cavity separating the oocyte/cumulus complex from mural granulosa and theca cells is formed as part of the scattered antral spaces stage of oogenesis. [goc:dph, goc:isa_complete]|the organism function, rides walk in which one central cavity diverges the oocyte/cumulus whole from mural granulosa and theca cells is formed as part of the sow antral spaces stage of oogenesis.  [ goc : dph , goc : isa_complete ]|26.014772727272742|58.62000000000002|13.729848484848485|10.3|12.4243|11.744240350877194|16.806060606060612|12.5047619047619|12.166666666666664|7.5857017543859655|88.50148473330829|82.78555852321104|25.993939393939396|21.733333333333334\n",
      "\n",
      "the menstrual cycle process in which one central cavity separating the oocyte/cumulus complex from mural granulosa and theca cells is formed as part of the scattered antral spaces stage of oogenesis. [goc:dph, goc:isa_complete]|the menstrual cycle process in which one central cavity separating the ova/cumulus complex from mural granulosa and theca cells is formed as part of the scattered antral spaces stage of oogenesis. [goc:dph, goc:iso|26.014772727272742|33.70568181818183|13.729848484848485|12.657121212121215|12.4243|12.66247837837838|16.806060606060612|14.667878787878792|12.166666666666664|10.351621621621625|88.50148473330829|88.50148473330829|25.993939393939396|25.993939393939396\n",
      "\n",
      "the menstrual cycle process in which one central cavity separating the oocyte/cumulus complex from mural granulosa and theca cells is formed as part of the scattered antral spaces stage of oogenesis. [goc:dph, goc:isa_complete]| the menstrual cycle process in which one cavity is formed as part of the ovary's reproductive system|26.014772727272742|56.965|13.729848484848485|9.785555555555558|12.4243|12.058373684210528|16.806060606060612|11.322222222222223|12.166666666666664|9.388947368421054|88.50148473330829|82.78555852321104|25.993939393939396|22.75555555555556\n",
      "\n",
      "a chromosome band present on 8q|a body band present on 8q|87.94500000000002|102.045|2.4833333333333343|0.5166666666666693|9.197433333333334|6.565766666666667|-23.85333333333333|-29.733333333333327|1.9800000000000004|-2.729999999999997|44.250742366654144|44.250742366654144|15.733333333333333|15.733333333333333\n",
      "\n",
      "a chromosome band present on 8q|a chromosome band present on 8q21.3|87.94500000000002|90.99000000000004|2.4833333333333343|1.3133333333333361|9.197433333333334|10.750842857142857|-23.85333333333333|-68.28666666666666|1.9800000000000004|2.9285714285714306|44.250742366654144|31.29|15.733333333333333|14.533333333333331\n",
      "\n",
      "a chromosome band present on 8q| a band|87.94500000000002|147.39000000000004|2.4833333333333343|-6.553333333333333|9.197433333333334|11.7299|-23.85333333333333|-86.90666666666665|1.9800000000000004|-11.1875|44.250742366654144|0.0|15.733333333333333|1.2000000000000002\n",
      "\n",
      "a unique identifier assigned to a study.|a unique symbol transfer to a study.|34.08250000000001|70.33964285714288|9.375|4.317857142857143|10.750842857142857|10.750842857142857|-56.011428571428574|-59.37142857142857|4.274285714285714|1.5828571428571436|44.250742366654144|44.250742366654144|24.257142857142856|24.257142857142856\n",
      "\n",
      "a unique identifier assigned to a study.|a unique identifier assigned to a study.|34.08250000000001|34.08250000000001|9.375|9.375|10.750842857142857|11.7299|-56.011428571428574|-55.17142857142857|4.274285714285714|0.5874999999999986|44.250742366654144|44.250742366654144|24.257142857142856|24.257142857142856\n",
      "\n",
      "a unique identifier assigned to a study.| an identifier assigned to a study|34.08250000000001|54.70142857142861|9.375|7.368571428571428|10.750842857142857|11.9283|-56.011428571428574|-17.925714285714285|4.274285714285714|0.2325000000000017|44.250742366654144|54.195869768830164|24.257142857142856|19.942857142857143\n",
      "\n",
      "moderate symptoms; limiting instrumental adl|change functional concept; choose instrumental adl|-18.19999999999996|31.545000000000016|17.040000000000003|10.350000000000001|19.674500000000002|14.460766666666668|-12.159999999999997|-5.233333333333327|17.808|16.11|62.58|54.195869768830164|34.0|22.400000000000002\n",
      "\n",
      "moderate symptoms; limiting instrumental adl|mild symptoms; limiting instrumental adl|-18.19999999999996|15.640000000000015|17.040000000000003|12.320000000000004|19.674500000000002|19.7241|-12.159999999999997|-15.687999999999995|17.808|9.829999999999998|62.58|54.195869768830164|34.0|26.0\n",
      "\n",
      "moderate symptoms; limiting instrumental adl| moderate|-18.19999999999996|77.90500000000002|17.040000000000003|2.890000000000004|19.674500000000002|19.5753|-12.159999999999997|-121.53999999999999|17.808|-4.229999999999997|62.58|31.29|34.0|20.8\n",
      "\n",
      "a very rare hereditary neurological dysmorphic syndrome with characteristics of moyamoya disease, short stature of postnatal onset and stereotypical facial dysmorphism. the syndrome is extremely rare and has been reported in three unrelated families to date, with 10 affected individuals in several generations. these families are not from japan or asia, whereas in general the incidence of moyamoya disease is highest in japan and other asian countries, in comparison with other parts of the world. affected patients are all male (x-linked inheritance) and have moyamoya angiopathy (progressive stenosis of the terminal portion of the intracranial internal carotid arteries), short stature, hypergonadotropic hypogonadism and other variable manifestations.. the genetic cause appears to involve xq28 deletions removing mtcp1/cmc4 and brcc3 (xq28) .the specific pathophysiological mechanisms underlying this disorder remain obscure, but appear to involve alteration in dna repair.|a very rare hereditary neurological dysmorphic syndrome with property of moyamoya disease, short stature of postnatal start and stereotypical facial dysmorphism.  the syndrome is extremely rare and has been reported in three unrelated families to date, with 10 refer organism in several productions.  these families are not from japan or asia, whereas in general the incidence of moyamoya disease is highest in japan and other asian countries, in likeness with other parts of the world.  refer to the case are all male (x-linked attribute) and have moyamoya angiopathy (adult stenosis of the contact gift of the intracranial internal carotid arteries), short stature, hypergonadotropic incompetence and other symbol protest. .  the genetic cause appears to have xq28 deletions removing mtcp1/cmc4 and brcc3 (xq28). the fact pathophysiological device lies this change remain change, but appear to have changed in dna pay.|17.26970588235298|44.33942744755248|15.073823529411765|11.515515734265737|13.242700000000001|11.228572222222223|19.12205882352941|15.431048951048954|23.94347826086956|11.428333333333335|94.51962712844353|87.10767345647568|28.270588235294117|24.492657342657342\n",
      "\n",
      "a very rare hereditary neurological dysmorphic syndrome with characteristics of moyamoya disease, short stature of postnatal onset and stereotypical facial dysmorphism. the syndrome is extremely rare and has been reported in three unrelated families to date, with 10 affected individuals in several generations. these families are not from japan or asia, whereas in general the incidence of moyamoya disease is highest in japan and other asian countries, in comparison with other parts of the world. affected patients are all male (x-linked inheritance) and have moyamoya angiopathy (progressive stenosis of the terminal portion of the intracranial internal carotid arteries), short stature, hypergonadotropic hypogonadism and other variable manifestations.. the genetic cause appears to involve xq28 deletions removing mtcp1/cmc4 and brcc3 (xq28) .the specific pathophysiological mechanisms underlying this disorder remain obscure, but appear to involve alteration in dna repair.|a rare genetic disorder with characteristics of moyamoya disease, short stature of postnatal onset and stereotypical facial features. the syndrome is extremely rare and has been reported in three unrelated families to date, with 10 affected individuals in several generations. these families are not from japan or asia,|17.26970588235298|26.682500000000005|15.073823529411765|13.5125|12.6723|11.858265986394558|19.12205882352941|14.942499999999995|18.19347826086956|12.49748299319728|94.51962712844353|86.63808689023553|28.270588235294117|25.56666666666667\n",
      "\n",
      "a very rare hereditary neurological dysmorphic syndrome with characteristics of moyamoya disease, short stature of postnatal onset and stereotypical facial dysmorphism. the syndrome is extremely rare and has been reported in three unrelated families to date, with 10 affected individuals in several generations. these families are not from japan or asia, whereas in general the incidence of moyamoya disease is highest in japan and other asian countries, in comparison with other parts of the world. affected patients are all male (x-linked inheritance) and have moyamoya angiopathy (progressive stenosis of the terminal portion of the intracranial internal carotid arteries), short stature, hypergonadotropic hypogonadism and other variable manifestations.. the genetic cause appears to involve xq28 deletions removing mtcp1/cmc4 and brcc3 (xq28) .the specific pathophysiological mechanisms underlying this disorder remain obscure, but appear to involve alteration in dna repair.| a|17.26970588235298|162.505|15.073823529411765|-8.91|12.90046|14.311966666666669|19.12205882352941|-142.12|20.493478260869566|-15.219999999999999|94.51962712844353|0.0|28.270588235294117|0.8\n",
      "\n",
      "trauma symptom checklist for children - forgetting things, can't remember things.|trauma symptom list for children - lose things, can't remember things.|62.81613636363636|85.88886363636365|5.864090909090912|2.6459090909090897|10.448500000000001|8.8695|-15.865454545454547|-21.74545454545455|15.597999999999999|10.417000000000002|54.195869768830164|44.250742366654144|24.018181818181816|16.745454545454546\n",
      "\n",
      "trauma symptom checklist for children - forgetting things, can't remember things.|trauma symptom checklist for children - forging things, can't remember things.|62.81613636363636|70.50704545454548|5.864090909090912|4.791363636363638|8.8695|11.086572727272728|-15.865454545454547|-16.934545454545457|15.597999999999999|9.579999999999998|54.195869768830164|54.195869768830164|24.018181818181816|24.018181818181816\n",
      "\n",
      "trauma symptom checklist for children - forgetting things, can't remember things.| forgetting things|62.81613636363636|90.99000000000004|5.864090909090912|1.3133333333333361|8.8695|11.7299|-15.865454545454547|-65.34666666666666|15.597999999999999|1.7650000000000006|54.195869768830164|31.29|24.018181818181816|14.533333333333331\n",
      "\n",
      "the joints that connect the fingers to the hand.|the joints that hit the search to the hand.|98.8675|117.66750000000002|0.5872222222222234|-2.0349999999999984|5.837344444444444|5.837344444444444|-39.64444444444443|-42.911111111111104|3.4800000000000004|0.8633333333333333|31.29|0.0|10.68888888888889|1.8\n",
      "\n",
      "the joints that connect the fingers to the hand.|joint that connects the fingers to the hand.|98.8675|97.025|0.5872222222222234|0.7199999999999989|5.837344444444444|7.368588888888889|-39.64444444444443|-46.07|3.4800000000000004|0.18333333333333002|31.29|31.29|10.68888888888889|11.600000000000001\n",
      "\n",
      "the joints that connect the fingers to the hand.| the joints|98.8675|147.39000000000004|0.5872222222222234|-6.553333333333333|5.837344444444444|15.6774|-39.64444444444443|-79.06666666666666|3.4800000000000004|-6.477499999999999|31.29|0.0|10.68888888888889|1.2000000000000002\n",
      "\n",
      "the joints that connect the fingers to the hand.|the joints that hit the search to the hand.|98.8675|117.66750000000002|0.5872222222222234|-2.0349999999999984|5.837344444444444|5.837344444444444|-39.64444444444443|-42.911111111111104|3.4800000000000004|0.8633333333333333|31.29|0.0|10.68888888888889|1.8\n",
      "\n",
      "the joints that connect the fingers to the hand.|joint that connects the fingers to the hand.|98.8675|97.025|0.5872222222222234|0.7199999999999989|5.837344444444444|7.368588888888889|-39.64444444444443|-46.07|3.4800000000000004|0.18333333333333002|31.29|31.29|10.68888888888889|11.600000000000001\n",
      "\n",
      "the joints that connect the fingers to the hand.| the joints|98.8675|147.39000000000004|0.5872222222222234|-6.553333333333333|5.837344444444444|15.6774|-39.64444444444443|-79.06666666666666|3.4800000000000004|-6.477499999999999|31.29|0.0|10.68888888888889|1.2000000000000002\n",
      "\n",
      "an abnormal concentration of sodium. [hpo:probinson]|a finding diligence of sodium.  [ hop: robinson]|-21.809999999999945|70.66750000000002|17.04666666666667|4.520555555555557|15.08867142857143|13.637516666666667|-52.60666666666666|-39.64444444444443|9.252857142857145|1.6870833333333337|44.250742366654144|44.250742366654144|27.866666666666664|19.57777777777778\n",
      "\n",
      "an abnormal concentration of sodium. [hpo:probinson]|an abnormal concentration of sodium. [hpo:probinson]|-21.809999999999945|-21.809999999999945|17.04666666666667|17.04666666666667|15.08867142857143|15.6774|-52.60666666666666|-51.62666666666666|9.252857142857145|6.475000000000001|44.250742366654144|44.250742366654144|27.866666666666664|27.866666666666664\n",
      "\n",
      "an abnormal concentration of sodium. [hpo:probinson]| an abnormality|-21.809999999999945|34.59000000000003|17.04666666666667|9.180000000000003|15.08867142857143|15.6774|-52.60666666666666|-71.22666666666666|9.252857142857145|-1.7674999999999983|44.250742366654144|31.29|27.866666666666664|14.533333333333331\n",
      "\n",
      "the space enclosed by the double membrane of a cyanelle. [goc:rph]|the space put by the double sheet of a canal.  [ goc: rep]|70.50704545454548|115.13000000000002|4.791363636363638|-1.0599999999999987|10.513266666666667|7.602746153846153|-23.883636363636366|-23.385714285714286|1.9800000000000004|-2.9630769230769225|44.250742366654144|31.29|16.745454545454546|8.514285714285714\n",
      "\n",
      "the space enclosed by the double membrane of a cyanelle. [goc:rph]|the space enclosed by the double membrane of a cyanelle. [goc:rph]|70.50704545454548|70.50704545454548|4.791363636363638|4.791363636363638|10.513266666666667|11.246592307692307|-23.883636363636366|-23.349090909090915|1.9800000000000004|1.0223076923076917|44.250742366654144|44.250742366654144|16.745454545454546|16.745454545454546\n",
      "\n",
      "the space enclosed by the double membrane of a cyanelle. [goc:rph]| the space enclosed by the double membrane of a cyanelle|70.50704545454548|72.61545454545457|4.791363636363638|5.863636363636363|10.513266666666667|10.810866666666666|-23.883636363636366|-1.7854545454545523|1.9800000000000004|3.41|44.250742366654144|62.58|16.745454545454546|18.94545454545455\n",
      "\n",
      "a condition in which a carcinoma has spread extensively throughout the peritoneal cavity.|a shampoo in which a cancer has spread extensively throughout the peritoneal structure.|18.022115384615404|44.05288461538464|12.360384615384618|8.729615384615386|11.568992307692309|11.568992307692309|-10.71076923076923|-11.61538461538462|12.605384615384615|11.880769230769232|54.195869768830164|54.195869768830164|21.06153846153846|21.06153846153846\n",
      "\n",
      "a condition in which a carcinoma has spread extensively throughout the peritoneal cavity.|a condition in which a cancer has spread widely throughout the peritoneal cavity.|18.022115384615404|50.56057692307695|12.360384615384618|7.821923076923078|11.568992307692309|11.8787|-10.71076923076923|-13.876923076923077|12.605384615384615|5.283571428571431|54.195869768830164|54.195869768830164|21.06153846153846|21.06153846153846\n",
      "\n",
      "a condition in which a carcinoma has spread extensively throughout the peritoneal cavity.| a condition in which a cancer cell is spread through the body|18.022115384615404|89.51692307692309|12.360384615384618|4.003076923076925|11.568992307692309|8.842328571428572|-10.71076923076923|0.29846153846153456|12.605384615384615|3.0642857142857167|54.195869768830164|54.195869768830164|21.06153846153846|14.430769230769233\n",
      "\n",
      "an arbitrary unit of substance content expressed in microunit(s) per liter.|a quantitative unit of substance content mail in microunit (s) per liter.|32.05250000000001|52.69500000000002|10.155000000000001|7.400000000000002|15.665736363636366|14.758366666666669|-19.07272727272727|-18.953333333333326|11.045454545454547|7.727500000000003|58.53822981607831|54.195869768830164|27.654545454545453|22.400000000000002\n",
      "\n",
      "an arbitrary unit of substance content expressed in microunit(s) per liter.|a unit of substance content expressed in microunit(s) per liter.|32.05250000000001|49.48000000000002|10.155000000000001|7.600000000000001|15.665736363636366|15.392936363636366|-19.07272727272727|-26.272|11.045454545454547|4.441818181818181|58.53822981607831|54.195869768830164|27.654545454545453|26.0\n",
      "\n",
      "an arbitrary unit of substance content expressed in microunit(s) per liter.| an unit of measure|32.05250000000001|100.24000000000002|10.155000000000001|0.5199999999999996|15.665736363636366|11.8291|-19.07272727272727|-40.384|11.045454545454547|-5.085000000000001|58.53822981607831|44.250742366654144|27.654545454545453|18.0\n",
      "\n",
      "adult: systolic bp 120-139 mm hg or diastolic bp 80-89 mm hg; pediatric: systolic/diastolic bp >90th percentile but< 95th percentile; adolescent: bp >= 120/80 even if < 95th percentile|adult: systolic bp 120-139 mm hg or diastolic bp 80-89 mm hg; pediatrics: systolic/diastolic bp > 90th mark, but < 95th mark; juvenile: bp > = 120/80 even if < 95th mark|51.95862068965518|79.18000000000002|13.216551724137933|10.165000000000003|19.357928571428573|18.0045|21.423448275862064|16.107499999999998|15.98657142857143|13.42971428571429|98.94766798666859|82.78555852321104|25.393103448275866|21.55\n",
      "\n",
      "adult: systolic bp 120-139 mm hg or diastolic bp 80-89 mm hg; pediatric: systolic/diastolic bp >90th percentile but< 95th percentile; adolescent: bp >= 120/80 even if < 95th percentile|adult: systolic bp 120-139 mm hg or dialysis drug|51.95862068965518|75.50000000000003|13.216551724137933|4.964444444444446|18.48992857142857|18.536645454545457|21.423448275862064|-5.448888888888881|7.23657142857143|1.1972727272727255|98.94766798666859|54.195869768830164|25.393103448275866|16.933333333333334\n",
      "\n",
      "adult: systolic bp 120-139 mm hg or diastolic bp 80-89 mm hg; pediatric: systolic/diastolic bp >90th percentile but< 95th percentile; adolescent: bp >= 120/80 even if < 95th percentile| adult: systolic pressure 120-139 mm hg or diastolic pressure 80-89 mm hg; pediatric: systolic/diastolic pressure >90th percentil|51.95862068965518|42.86500000000001|13.216551724137933|11.752222222222223|18.20059523809524|19.88077826086957|21.423448275862064|20.46888888888889|4.319904761904763|12.186521739130434|98.94766798666859|93.86999999999999|25.393103448275866|27.200000000000003\n",
      "\n",
      "human tpmt*v2 allele is a variant form of the tpmt gene (tpmt family), located at chromosome 6p22.3, which encodes thiopurine s-methyltransferase. some tpmt alleles contain variable numbers of 17/18 bp tandem repeats (vntr), within the gc-rich 5'-flanking tpmt promoter region that modulate the level of tpmt enzyme activity (to a smaller extent than orf-based snp effects). tpmt*v2 contains 2 vntr. a decrease in gene expression is seen with increasing repeat numbers.|human tpmt * v2 gene is a type form of the tpmt gene (tpmt family), located at body 6p22. 3, which convert thiopurine s-methyltransferase.  some tpmt gene contains symbol numbers of 17/18 bp tandem play (venture), within the gas-rich 5'-flanking tpmt booker region that change the level of tpmt enzyme activity (to a smaller extent than off-based snap effects).  tpmt * v2 contains 2 ventures.  a change in gene squeeze is seen  change repeat numbers.|58.98754694835682|84.24045358649789|7.9714788732394375|4.780443037974685|13.84265890410959|12.684250210970463|8.029859154929582|5.281518987341773|12.406369863013701|6.497383966244726|71.12311754978124|65.13532912329528|22.198122065727702|18.43122362869198\n",
      "\n",
      "human tpmt*v2 allele is a variant form of the tpmt gene (tpmt family), located at chromosome 6p22.3, which encodes thiopurine s-methyltransferase. some tpmt alleles contain variable numbers of 17/18 bp tandem repeats (vntr), within the gc-rich 5'-flanking tpmt promoter region that modulate the level of tpmt enzyme activity (to a smaller extent than orf-based snp effects). tpmt*v2 contains 2 vntr. a decrease in gene expression is seen with increasing repeat numbers.|human tpmt*v2 gene is a variant form of the protein building blocks gene, located at chromosome 6p22.3, which encodes thiopurine s-methyltransferase. other genes contain variable numbers of 17/18 bp tandem repeat|58.98754694835682|54.43698924731183|7.9714788732394375|8.233548387096778|13.84265890410959|14.02459696969697|8.029859154929582|6.065806451612904|12.406369863013701|12.368181818181817|71.12311754978124|69.96656701596841|22.198122065727702|23.488172043010756\n",
      "\n",
      "human tpmt*v2 allele is a variant form of the tpmt gene (tpmt family), located at chromosome 6p22.3, which encodes thiopurine s-methyltransferase. some tpmt alleles contain variable numbers of 17/18 bp tandem repeats (vntr), within the gc-rich 5'-flanking tpmt promoter region that modulate the level of tpmt enzyme activity (to a smaller extent than orf-based snp effects). tpmt*v2 contains 2 vntr. a decrease in gene expression is seen with increasing repeat numbers.| human tpmt gene is a gene on chromosome 6p22.3 that encodes thiopurine s-methyltransferase|58.98754694835682|60.74428571428575|7.9714788732394375|6.525714285714287|13.84265890410959|16.2726|8.029859154929582|-9.105714285714278|12.406369863013701|9.825624999999999|71.12311754978124|49.473833993334296|22.198122065727702|17.085714285714285\n",
      "\n",
      "peroxisomal multifunctional enzyme type 2 (736 aa, ~80 kda) is encoded by the human hsd17b4 gene. this protein is involved in the peroxisomal beta-oxidation pathway for fatty acids.|peroxisomal enzyme enzyme type 2 (736 aa, ~80 code) is converted by the human hsd17b4 gene.  this protein is having in the peroxisomal beta-oxidation path for fatty acids.|46.290238095238124|65.74747126436785|9.121428571428574|6.490344827586206|15.789837931034484|14.65916666666667|0.6257142857142846|-1.626206896551718|9.857241379310349|5.235999999999997|62.58|57.127462747788826|20.876190476190477|17.65977011494253\n",
      "\n",
      "peroxisomal multifunctional enzyme type 2 (736 aa, ~80 kda) is encoded by the human hsd17b4 gene. this protein is involved in the peroxisomal beta-oxidation pathway for fatty acids.|fat cell enzyme type 2 (736 amino acids, 80 kilodaltons) is encoded by a human gene hsd17b4 protein. this protein is involved in the cell's beta-oxidation pathway for fatty acids.|46.290238095238124|64.14500000000001|9.121428571428574|6.79666666666667|15.789837931034484|14.527754166666668|0.6257142857142846|-0.003999999999997783|9.857241379310349|5.245520833333334|62.58|65.13532912329528|20.876190476190477|21.333333333333336\n",
      "\n",
      "peroxisomal multifunctional enzyme type 2 (736 aa, ~80 kda) is encoded by the human hsd17b4 gene. this protein is involved in the peroxisomal beta-oxidation pathway for fatty acids.||46.290238095238124|205.82000000000002|9.121428571428574|-15.2|15.789837931034484|19.476100000000002|0.6257142857142846|-290.12|9.857241379310349|-16.22|62.58|0.0|20.876190476190477|0.4\n",
      "\n",
      "world health organization disability assessment schedule 2.0 36-item version self-administered (whodas 2.0 36-item version self-administered) in the past 30 days, how much difficulty did you have in: walking a long distance such as a kilometre [or equivalent]?|world health organization unfitness action plan 2.0 36-item version self-administered (holds 2.0 36-item version self-administered) in the past 30 days, how much quality did you have : walking a long distance such as a kilometer [or cognition]?|43.40855855855855|59.413963963963965|10.268648648648654|8.036216216216214|13.372539024390244|12.726|11.597837837837833|9.055135135135135|23.539024390243902|21.766749999999995|67.59412548439398|62.58|20.06846846846847|17.90630630630631\n",
      "\n",
      "world health organization disability assessment schedule 2.0 36-item version self-administered (whodas 2.0 36-item version self-administered) in the past 30 days, how much difficulty did you have in: walking a long distance such as a kilometre [or equivalent]?|world health organization disability assessment schedule 2.0 36-item version self-administered) in the past 30 days, how much difficulty did you have in walking a long distance such as kilometre [or equivalent]?|43.40855855855855|41.005725806451636|10.268648648648654|11.390483870967746|12.355739024390244|11.445876470588235|11.597837837837833|15.424516129032263|13.289024390243902|11.312647058823536|67.59412548439398|73.38155456243756|20.06846846846847|20.393548387096775\n",
      "\n",
      "world health organization disability assessment schedule 2.0 36-item version self-administered (whodas 2.0 36-item version self-administered) in the past 30 days, how much difficulty did you have in: walking a long distance such as a kilometre [or equivalent]?| world health organization disability assessment schedule 2.0 36-item version self-administered (whodas 2.0 36-item version self-administered) in the past month, how much difficulty did you have in: walking a long distance such as a kilometre [or equivalent]?|43.40855855855855|43.40855855855855|10.268648648648654|10.268648648648654|13.372539024390244|13.614700000000001|11.597837837837833|11.597837837837833|23.539024390243902|23.568571428571424|67.59412548439398|67.59412548439398|20.06846846846847|20.06846846846847\n",
      "\n",
      "platelet activating factor degradation consists of conjugation, transport, and/or oxidation of a phospholipid derivative (platelet activating factor) formed by platelets, basophils, neutrophils, monocytes, and macrophages that acts as a potent agent of platelet aggregation, inflammation, neutrophil activity, prostaglandin synthesis, and systemic anaphylaxis: hypotension, thrombocytopenia, neutropenia, and bronchoconstriction.|platelet change factor degradation be of class , move , and/or oxidation of a lipid word ( platelet change factor ) formed by platelets , basophils , neutrophils , leukocyte , and phagocyte that acts as a potent agent of platelet grouping , burning , neutrophil activity , autacoid synthesis , and systemic anaphylaxis : hypotension , blood_disease , neutropenia , and bronchoconstriction .|-49.21749999999997|38.20187500000003|25.962234042553195|15.880625000000002|17.390253191489364|15.374508510638298|35.31999999999999|20.793125|38.74787234042553|33.13595744680851|127.10058084052962|114.96680107752846|37.48510638297872|29.675\n",
      "\n",
      "platelet activating factor degradation consists of conjugation, transport, and/or oxidation of a phospholipid derivative (platelet activating factor) formed by platelets, basophils, neutrophils, monocytes, and macrophages that acts as a potent agent of platelet aggregation, inflammation, neutrophil activity, prostaglandin synthesis, and systemic anaphylaxis: hypotension, thrombocytopenia, neutropenia, and bronchoconstriction.|platelet activating factor degradation consists of conjugation, transport, and/or oxidation of a molecule (also known as an activator of platelet activation).|-49.21749999999997|-1.2224999999999966|25.962234042553195|16.038333333333334|17.390253191489364|14.230281818181819|35.31999999999999|10.729523809523805|38.74787234042553|12.758181818181818|127.10058084052962|79.77416029015912|37.48510638297872|28.961904761904762\n",
      "\n",
      "platelet activating factor degradation consists of conjugation, transport, and/or oxidation of a phospholipid derivative (platelet activating factor) formed by platelets, basophils, neutrophils, monocytes, and macrophages that acts as a potent agent of platelet aggregation, inflammation, neutrophil activity, prostaglandin synthesis, and systemic anaphylaxis: hypotension, thrombocytopenia, neutropenia, and bronchoconstriction.| oxidation-reduction|-49.21749999999997|-91.29499999999996|25.962234042553195|26.490000000000006|17.390253191489364|19.6249|35.31999999999999|-89.2|38.74787234042553|4.120000000000001|127.10058084052962|31.29|37.48510638297872|20.8\n",
      "\n",
      "level 1 gestational diabetes mellitus is defined by three criteria: first, at least one of the following requirements must be met: a) absence of pre-gestational diabetes [pre-gestational diabetes is defined as a) previous diagnosis of diabetes while not pregnant or b) first trimester hemoglobin a1c level of greater than or equal to 6.5% (47.5 mmol/mol) or c) first trimester fasting blood glucose greater than or equal to 126 mg/dl (7 mmol/l)]; second, gestational age with level 1 or level 2 certainty, using the gaia definition for gestational age; third, a diagnosis of gestational diabetes as determined by a positive result from an international standard oral glucose tolerance test using venous blood samples.|level 1 gestational diabetes mellitus is choose by three ideal : first , at least one of the following duty must be met : a ) lack of pre-gestational diabetes [ pre-gestational diabetes is choose as a ) previous diagnosis of diabetes while not pregnant or b ) first school_term hemoglobin a1c level of greater than or equal to 6.5 % ( 47.5 mmol/mol ) or c ) first school_term fasting blood glucose greater than or equal to 126 mg/dl ( 7 mmol/l ) ] ; second , gestational age with level 1 or level 2 certainty , using the gaia distinctness for gestational age ; third , a diagnosis of gestational diabetes as conclude by a film result from an socialism standard oral glucose tolerance test using venous blood samples .|27.343571428571465|53.49000000000001|16.40142857142857|13.99666666666667|16.997306837606835|16.32252051282051|21.24357142857143|17.133939393939393|60.458974358974366|59.65384615384615|109.51499999999999|104.94985052395262|28.700000000000003|26.83636363636364\n",
      "\n",
      "level 1 gestational diabetes mellitus is defined by three criteria: first, at least one of the following requirements must be met: a) absence of pre-gestational diabetes [pre-gestational diabetes is defined as a) previous diagnosis of diabetes while not pregnant or b) first trimester hemoglobin a1c level of greater than or equal to 6.5% (47.5 mmol/mol) or c) first trimester fasting blood glucose greater than or equal to 126 mg/dl (7 mmol/l)]; second, gestational age with level 1 or level 2 certainty, using the gaia definition for gestational age; third, a diagnosis of gestational diabetes as determined by a positive result from an international standard oral glucose tolerance test using venous blood samples.|level 1 gdm mellitus is defined by three criteria: first, at least one of the following requirements must be met: a) absence of pre-gestational diabetes [presence of diabetes while not pregnant or b) first trimester hemoglobin a1c level of greater than|27.343571428571465|20.780975609756126|16.40142857142857|20.546341463414638|16.997306837606835|12.379067441860466|21.24357142857143|23.32780487804878|60.458974358974366|22.634186046511623|109.51499999999999|125.16|28.700000000000003|32.00975609756098\n",
      "\n",
      "level 1 gestational diabetes mellitus is defined by three criteria: first, at least one of the following requirements must be met: a) absence of pre-gestational diabetes [pre-gestational diabetes is defined as a) previous diagnosis of diabetes while not pregnant or b) first trimester hemoglobin a1c level of greater than or equal to 6.5% (47.5 mmol/mol) or c) first trimester fasting blood glucose greater than or equal to 126 mg/dl (7 mmol/l)]; second, gestational age with level 1 or level 2 certainty, using the gaia definition for gestational age; third, a diagnosis of gestational diabetes as determined by a positive result from an international standard oral glucose tolerance test using venous blood samples.| level 1 diabetes is diabetes mellitus|27.343571428571465|30.53000000000003|16.40142857142857|10.740000000000002|16.997306837606835|15.875800000000002|21.24357142857143|-14.565714285714286|60.458974358974366|2.5874999999999986|109.51499999999999|62.58|28.700000000000003|25.65714285714286\n",
      "\n",
      "a diagrammatic method to test visual acuity that utilizes the sloan optotypes and a 2.5% contrast level.|a diagrammatic method to test visual sight that change the slogan optotypes and a 2.5 % contrast level.|41.83627450980396|69.14500000000001|8.831764705882357|5.105555555555558|12.839111764705882|10.981464705882354|-21.79764705882353|-21.24|10.897058823529413|10.342941176470589|51.09635603445709|47.79626449838941|21.090196078431372|17.95555555555556\n",
      "\n",
      "a diagrammatic method to test visual acuity that utilizes the sloan optotypes and a 2.5% contrast level.|a diagrammatic method to test visual acuity that utilizes the sloan optotypes and 25% contrast level.|41.83627450980396|34.80250000000001|8.831764705882357|10.392500000000002|12.839111764705882|13.346335294117647|-21.79764705882353|-5.027500000000003|10.897058823529413|6.370000000000001|51.09635603445709|62.58|21.090196078431372|23.200000000000003\n",
      "\n",
      "a diagrammatic method to test visual acuity that utilizes the sloan optotypes and a 2.5% contrast level.| a test to determine the visual acuity|41.83627450980396|61.24000000000001|8.831764705882357|6.705000000000002|12.839111764705882|12.855122222222224|-21.79764705882353|-13.48|10.897058823529413|0.33999999999999986|51.09635603445709|54.195869768830164|21.090196078431372|18.2\n",
      "\n",
      "a comprehensive norm-referenced assessment of the adaptive skills of individuals ages 5 to 21 years that is used to evaluate children with intellectual and developmental disabilities. this form is completed by parents or others responsible for the child's primary care.|a quality norm-referenced act of the adaptive skills of individuals ages 5 to 21 years that is used to think children with person and developmental unfitness.  this form is played by parents or others responsible for the child 's coil care.|28.331666666666678|63.71071428571429|12.620000000000001|7.850952380952382|10.815251219512195|9.218280952380953|11.610000000000003|6.717142857142861|14.897317073170733|7.662142857142857|72.26115969177356|62.58|21.333333333333336|17.02857142857143\n",
      "\n",
      "a comprehensive norm-referenced assessment of the adaptive skills of individuals ages 5 to 21 years that is used to evaluate children with intellectual and developmental disabilities. this form is completed by parents or others responsible for the child's primary care.|a comprehensive normative assessment of the adaptive skills of individuals ages 5 to 21 years that is used to evaluate children with intellectual and developmental disabilities. this form is completed by parents or others responsible for the child's primary care.|28.331666666666678|32.561666666666696|12.620000000000001|12.030000000000001|10.815251219512195|10.476317886178862|11.610000000000003|10.874999999999996|14.897317073170733|11.021138211382116|72.26115969177356|72.26115969177356|21.333333333333336|21.333333333333336\n",
      "\n",
      "a comprehensive norm-referenced assessment of the adaptive skills of individuals ages 5 to 21 years that is used to evaluate children with intellectual and developmental disabilities. this form is completed by parents or others responsible for the child's primary care.| a form|28.331666666666678|147.39000000000004|12.620000000000001|-6.553333333333333|10.815251219512195|11.7299|11.610000000000003|-86.90666666666665|14.897317073170733|-11.1875|72.26115969177356|0.0|21.333333333333336|1.2000000000000002\n",
      "\n",
      "<p>criteria for specifying the entities to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). the denominator can be the same as the initial population, or it may be a subset of the initial population to further constrain it for the purpose of the emeasure. different measures within an emeasure set may have different denominators. continuous variable emeasures do not have a denominator, but instead define a measure population.</p>|< p > ideal for choosing the entities to be thought by a fact quality measure, based on a shared common set of property (within a fact measurement set to which a given measure belongs).  the divisor can be the same as the sign integer, or it may be a set of the sign integer to further constrain it for the goal of the measure.  different be within a measure set may have different divisor.  continuous symbol measures do not have a divisor, but instead choose a measure population.  < /p >|27.06304651162793|68.37825000000002|13.757534883720933|8.49175|10.542166666666667|8.508158333333334|14.241860465116279|8.77708333333333|13.474666666666671|3.704374999999999|87.38821419390602|76.64453405168562|25.01953488372093|20.180000000000003\n",
      "\n",
      "<p>criteria for specifying the entities to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). the denominator can be the same as the initial population, or it may be a subset of the initial population to further constrain it for the purpose of the emeasure. different measures within an emeasure set may have different denominators. continuous variable emeasures do not have a denominator, but instead define a measure population.</p>|acute flaccid myelitis|27.06304651162793|6.390000000000015|13.757534883720933|13.113333333333333|10.542166666666667|19.6249|14.241860465116279|-57.50666666666666|13.474666666666671|5.297499999999999|87.38821419390602|54.195869768830164|25.01953488372093|41.2\n",
      "\n",
      "<p>criteria for specifying the entities to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). the denominator can be the same as the initial population, or it may be a subset of the initial population to further constrain it for the purpose of the emeasure. different measures within an emeasure set may have different denominators. continuous variable emeasures do not have a denominator, but instead define a measure population.</p>||27.06304651162793|205.82000000000002|13.757534883720933|-15.2|10.542166666666667|19.476100000000002|14.241860465116279|-290.12|13.474666666666671|-16.22|87.38821419390602|0.0|25.01953488372093|0.4\n",
      "\n",
      "90-75% of predicted value|90-75 % of bespeak value|75.87500000000001|117.16000000000003|3.6700000000000017|-1.8399999999999999|13.3585|13.3585|-41.660000000000004|-35.67999999999999|-0.08999999999999986|-1.9740000000000002|44.250742366654144|44.250742366654144|21.6|18.0\n",
      "\n",
      "90-75% of predicted value|90-75% of predicted value|75.87500000000001|75.87500000000001|3.6700000000000017|3.6700000000000017|13.3585|14.460766666666668|-41.660000000000004|-40.19|-0.08999999999999986|-1.9450000000000003|44.250742366654144|44.250742366654144|21.6|21.6\n",
      "\n",
      "90-75% of predicted value| 90-75%|75.87500000000001|204.805|3.6700000000000017|-14.81|13.3585|19.6249|-41.660000000000004|-127.42|-0.08999999999999986|-12.365|44.250742366654144|0.0|21.6|0.8\n",
      "\n",
      "a characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles rum.|a property of a medicinal product, choose that its most predominant agreeable taste spy by the change stir of taste and olfactory organ match rum.|11.411500000000018|58.78750000000002|14.773000000000003|8.165000000000003|13.718900000000001|9.929300000000001|11.8352|5.014399999999998|19.141600000000004|13.678000000000004|79.77416029015912|58.53822981607831|25.8|16.2\n",
      "\n",
      "a characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles rum.|a characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and smell.|11.411500000000018|26.470000000000027|14.773000000000003|12.3|13.718900000000001|11.758639130434783|11.8352|7.034545454545448|19.141600000000004|9.917826086956524|79.77416029015912|69.96656701596841|25.8|22.581818181818182\n",
      "\n",
      "a characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles rum.| a property of a drug specifying that its most predominant agreeable smell resembles rum.|11.411500000000018|58.2225|14.773000000000003|7.001666666666669|13.718900000000001|12.915175000000001|11.8352|-9.674666666666674|19.141600000000004|4.942499999999999|79.77416029015912|49.473833993334296|25.8|16.333333333333332\n",
      "\n",
      "a measurement of the bicarbonate in a biological specimen.|a functional concept of the carbonate in a biological sample.|14.267500000000013|32.56000000000003|12.387222222222224|9.96|11.100677777777777|12.0275|-33.11111111111111|-28.624|8.713333333333335|7.5909999999999975|44.250742366654144|49.473833993334296|19.57777777777778|22.0\n",
      "\n",
      "a measurement of the bicarbonate in a biological specimen.|a measurement of the bicarbonate in a biological specimen.|14.267500000000013|14.267500000000013|12.387222222222224|12.387222222222224|11.100677777777777|11.7795|-33.11111111111111|-32.45777777777777|8.713333333333335|4.620000000000001|44.250742366654144|44.250742366654144|19.57777777777778|19.57777777777778\n",
      "\n",
      "a measurement of the bicarbonate in a biological specimen.| a measurement|14.267500000000013|90.99000000000004|12.387222222222224|1.3133333333333361|11.100677777777777|15.6774|-33.11111111111111|-73.18666666666667|8.713333333333335|-2.9450000000000003|44.250742366654144|31.29|19.57777777777778|14.533333333333331\n",
      "\n",
      "retroviral-like intracisternal a particles. high copy number family of repeated elements in the mouse with a typical proviral organization. expressed very early in mouse development (2-8 cell stage) and in transformed cells. mutant alleles of various genes contain newly-integrated iap genes.|retroviral-like intracisternal a body.  high copy number family of play straight_line in the mouse with a typical proviral beginning.  mail very early in mouse section (2-8 cell stage) and in change cells.  mutant gene of various genes contains newly-integrated up genes.|21.05834146341465|59.46663636363638|12.359219512195125|7.1510909090909145|11.90010303030303|10.352720060790276|0.042926829268296274|-3.167272727272728|11.915378787878787|4.17437689969605|64.12541789337516|57.69590921373889|23.767804878048782|18.974545454545456\n",
      "\n",
      "retroviral-like intracisternal a particles. high copy number family of repeated elements in the mouse with a typical proviral organization. expressed very early in mouse development (2-8 cell stage) and in transformed cells. mutant alleles of various genes contain newly-integrated iap genes.|retrovirus-like particles. high copy number family of repeated elements in the mouse with a typical proviral organization. expressed very early in mouse development (2-8 cell stage) and in transformed cells. mutant alleles of various genes contain newly-integrated iap genes.|21.05834146341465|25.379538461538488|12.359219512195125|11.657128205128206|11.718236363636365|11.77445534883721|0.042926829268296274|-2.0656410256410282|10.082045454545455|7.953488372093023|64.12541789337516|62.58|23.767804878048782|23.632820512820512\n",
      "\n",
      "retroviral-like intracisternal a particles. high copy number family of repeated elements in the mouse with a typical proviral organization. expressed very early in mouse development (2-8 cell stage) and in transformed cells. mutant alleles of various genes contain newly-integrated iap genes.| retroviral-like infectious agent|21.05834146341465|-8.724999999999994|12.359219512195125|15.469999999999999|11.90010303030303|17.092433333333332|0.042926829268296274|-28.43|11.915378787878787|5.905000000000001|64.12541789337516|54.195869768830164|23.767804878048782|31.6\n",
      "\n",
      "the anterior abdominal wall constitutes a hexagonal area defined superiorly by the costal margins and xiphoid process; and inferiorly by the iliac crests, inguinal ligament, pubis and pubic symphysis. the wall extends posteriorly and incorporates the lateral aspect of the wall until the junction with the posterior abdominal wall approximately at the mid-axillary line. the wall is covered externally by skin and subcutaneous tissue: beneath this lies the superficial fascia (between the dermis and the muscles), which is conventionally divided into a superficial fatty layer (camper's fascia) and a deep membranous layer (scarpa's fascia); deep fascia; the rectus abdominis, pyramidalis, external oblique, internal oblique and transversus abdominis; and the extraperitoneal tissue and the parietal peritoneum. these tissues also form the umbilicus and the inguinal canal, which connects the abdominal cavity to the scrotum in males and the labia majora in females.|the tooth abdominal wall constitutes a hexagonal area choose superiorly by the costal space and xiphoid process; and inferiorly by the iliac crests, inguinal ligament, bone and the pubic symphysis.  the wall uses posteriorly and take_in the pass aspect of the wall until the junction with the tooth abdominal wall approximately at the mid-axillary line.  the wall is covered externally by skin and subcutaneous tissue : beneath this lies the superficial fascia ( between the dermis and the muscles ) , which is conventionally move into a superficial fatty layer ( camper 's fascia ) and a deep membranous layer ( scarpa 's fascia ) ; deep fascia ; the rectus abdominis , pyramidalis , feature case , internal case and transversus abdominis ; and the extraperitoneal tissue and the parietal peritoneum .  these tissues also from the point and the inguinal canal, which hit the abdominal structure to the pouch in males and the labia majora in females.|6.612000000000023|34.515666666666675|19.342751773049645|16.494148148148145|13.181102816901408|11.898313150684933|23.949503546099294|19.501975308641974|22.954718309859153|17.978150684931506|123.5855977045869|113.6822154956526|33.407659574468084|29.2562962962963\n",
      "\n",
      "the anterior abdominal wall constitutes a hexagonal area defined superiorly by the costal margins and xiphoid process; and inferiorly by the iliac crests, inguinal ligament, pubis and pubic symphysis. the wall extends posteriorly and incorporates the lateral aspect of the wall until the junction with the posterior abdominal wall approximately at the mid-axillary line. the wall is covered externally by skin and subcutaneous tissue: beneath this lies the superficial fascia (between the dermis and the muscles), which is conventionally divided into a superficial fatty layer (camper's fascia) and a deep membranous layer (scarpa's fascia); deep fascia; the rectus abdominis, pyramidalis, external oblique, internal oblique and transversus abdominis; and the extraperitoneal tissue and the parietal peritoneum. these tissues also form the umbilicus and the inguinal canal, which connects the abdominal cavity to the scrotum in males and the labia majora in females.|the front abdominal wall constitutes a hexagonal area defined superiorly by the costal margins and xiphoid process; and lower mid-axillary line. the wall is covered by skin and subcutaneous tissue, which connects the abdomen to the scrotum in male|6.612000000000023|30.85788461538465|19.342751773049645|13.799615384615386|13.181102816901408|11.200373170731707|23.949503546099294|16.482051282051287|22.954718309859153|12.484878048780487|123.5855977045869|93.86999999999999|33.407659574468084|26.261538461538464\n",
      "\n",
      "the anterior abdominal wall constitutes a hexagonal area defined superiorly by the costal margins and xiphoid process; and inferiorly by the iliac crests, inguinal ligament, pubis and pubic symphysis. the wall extends posteriorly and incorporates the lateral aspect of the wall until the junction with the posterior abdominal wall approximately at the mid-axillary line. the wall is covered externally by skin and subcutaneous tissue: beneath this lies the superficial fascia (between the dermis and the muscles), which is conventionally divided into a superficial fatty layer (camper's fascia) and a deep membranous layer (scarpa's fascia); deep fascia; the rectus abdominis, pyramidalis, external oblique, internal oblique and transversus abdominis; and the extraperitoneal tissue and the parietal peritoneum. these tissues also form the umbilicus and the inguinal canal, which connects the abdominal cavity to the scrotum in males and the labia majora in females.| This|6.612000000000023|162.505|19.342751773049645|-8.91|13.181102816901408|14.311966666666669|23.949503546099294|-133.3|22.954718309859153|-10.51|123.5855977045869|0.0|33.407659574468084|0.8\n",
      "\n",
      "polycyclic aromatic hydrocarbons composed of three fused benzene rings.|polycyclic organic chemical hydrocarbons plan of three melts benzene rings.|4.867500000000007|24.100000000000023|13.698333333333334|11.14|14.60956666666667|12.0275|-24.617777777777775|-20.391999999999996|15.516666666666666|14.184999999999995|54.195869768830164|49.473833993334296|28.466666666666665|22.0\n",
      "\n",
      "polycyclic aromatic hydrocarbons composed of three fused benzene rings.|polycyclic aromatic hydrocarbons composed of three fused rings.|4.867500000000007|1.8500000000000227|13.698333333333334|13.995000000000001|14.60956666666667|14.38636666666667|-24.617777777777775|-32.105000000000004|15.516666666666666|10.126666666666669|54.195869768830164|49.473833993334296|28.466666666666665|26.6\n",
      "\n",
      "polycyclic aromatic hydrocarbons composed of three fused benzene rings.| hydrocarbon|4.867500000000007|35.60500000000002|13.698333333333334|8.790000000000003|14.60956666666667|19.5753|-24.617777777777775|-112.72|15.516666666666666|0.4800000000000004|54.195869768830164|31.29|28.466666666666665|20.8\n",
      "\n",
      "a receptor complex that consists of two identical subunits and binds growth hormone. [goc:bhf, goc:mah, goc:vk, pmid:11445442]|an organ whole that be of two identical subunits and binds growth hormone.  [ goc : bhf , goc : mah , goc : vk , pmid:11445442 ]|63.84279411764709|116.26922413793105|6.466176470588238|0.6443103448275878|15.185500000000001|13.006557142857146|3.2235294117647086|-0.137931034482758|7.355499999999999|2.7042857142857173|58.53822981607831|44.250742366654144|19.870588235294118|11.317241379310346\n",
      "\n",
      "a receptor complex that consists of two identical subunits and binds growth hormone. [goc:bhf, goc:mah, goc:vk, pmid:11445442]|a receptor complex that consists of two identical subunits and binds growth hormone. [goc:bhf, goc:mah, pmid:11445442]|63.84279411764709|61.24000000000001|6.466176470588238|6.705000000000002|15.185500000000001|14.911384210526316|3.2235294117647086|1.2199999999999989|7.355499999999999|7.365789473684213|58.53822981607831|58.53822981607831|19.870588235294118|20.700000000000003\n",
      "\n",
      "a receptor complex that consists of two identical subunits and binds growth hormone. [goc:bhf, goc:mah, goc:vk, pmid:11445442]| a receptor protein that consists of two identical subunits and binds growth hormone|63.84279411764709|53.639285714285734|6.466176470588238|9.255714285714287|15.185500000000001|13.8545|3.2235294117647086|9.09714285714286|7.355499999999999|8.991999999999997|58.53822981607831|76.64453405168562|19.870588235294118|22.742857142857144\n",
      "\n",
      "pediatric outcomes data collection instrument, pediatric parent-reported version (podci pediatric parent-reported version) if you answered \"no\" to question 52 above, was your child's activity limited by: doctor or parent instructions?|pediatric ending data grouping address, pediatric parent-reported version (podci pediatric parent-reported version) if you react `` no '' to question 52 above, was your child 's activity limited by: doctor or parent code?|-9.734999999999985|16.958181818181828|22.070000000000004|19.092121212121217|12.131825000000001|12.289076470588236|30.313333333333333|24.70666666666667|23.2715625|20.366764705882353|139.93313403193682|136.38994794338765|38.666666666666664|36.230303030303034\n",
      "\n",
      "pediatric outcomes data collection instrument, pediatric parent-reported version (podci pediatric parent-reported version) if you answered \"no\" to question 52 above, was your child's activity limited by: doctor or parent instructions?|the pediatric outcome data collection instrument, pediatric parent-reported version (podci pediatric parent-reported version) if you answered \"no\" to question 52 above, was your child's activity limited by: doctor or parent instructions?|-9.734999999999985|-4.74612903225804|22.070000000000004|21.62258064516129|11.338225000000001|11.445876470588235|30.313333333333333|29.90451612903226|15.271562500000002|14.498823529411759|139.93313403193682|139.93313403193682|38.666666666666664|38.20645161290323\n",
      "\n",
      "pediatric outcomes data collection instrument, pediatric parent-reported version (podci pediatric parent-reported version) if you answered \"no\" to question 52 above, was your child's activity limited by: doctor or parent instructions?| pediatric outcomes data collection instrument|-9.734999999999985|3.344999999999999|22.070000000000004|14.283333333333335|12.131825000000001|19.773699999999998|30.313333333333333|-8.173333333333332|23.2715625|11.002857142857145|139.93313403193682|69.96656701596841|38.666666666666664|35.73333333333334\n",
      "\n",
      "the date and time span specifying the best time for an activity or event to begin and end.|the date and time span choose the best time for an activity or event to begin and end.|80.20000000000003|89.60000000000004|4.308888888888891|2.9977777777777774|8.03818888888889|7.160966666666667|-9.042222222222218|-10.348888888888887|6.41|5.363333333333333|44.250742366654144|38.32226702584281|12.488888888888889|10.266666666666666\n",
      "\n",
      "the date and time span specifying the best time for an activity or event to begin and end.|the day and time span specifying the best time for an activity or event to begin and end.|80.20000000000003|80.20000000000003|4.308888888888891|4.308888888888891|8.03818888888889|8.262963157894736|-9.042222222222218|-9.042222222222218|6.41|1.1684210526315795|44.250742366654144|44.250742366654144|12.488888888888889|12.488888888888889\n",
      "\n",
      "the date and time span specifying the best time for an activity or event to begin and end.| the time period over which a best time is best|80.20000000000003|95.68818181818183|4.308888888888891|2.645454545454548|8.03818888888889|8.1792|-9.042222222222218|-6.5963636363636375|6.41|-0.12250000000000227|44.250742366654144|44.250742366654144|12.488888888888889|11.672727272727274\n",
      "\n",
      "refers to one of two parts of the lateral habenula of the rat ( paxinos-2009b ) and mouse ( franklin-2008 ). the other is the medial part of the lateral habenula. in this segmentation of the habenula, the medial habenula is not subdivided. \\r\\nother authors do not subdivide the lateral habenula in the rat ( swanson-2004 ) but divide the medial habenula into a dorsal part of the medial habenula and ventral part of the medial habenula. \\r\\nneither nucleus of the habenula is subdivided in the human ( carpenter-1983 ) or the macaque ( paxinos-2009a ). functionally the habenula belongs to the central gray of the behavior control column ( swanson-2004 ).|name  one of two parts of the pass habenula of the rat (paxinos-2009b) and mouse (franklin-2008).  the other is the medial part of the pass habenula.  in this segment of the habenula, the medial habenula is not divided.  \\r\\nother authors do not divide the pass habenula in the rat (swanson-2004) but move the medial habenula into a dorsal part of the medial habenula and the ventral part of the medial habenula.  \\r\\nneither set of the habenula is divided in the human (carpenter-1983) or the macaque (paxinos-2009a).  functionally the habenula belongs to the central gray of the trait control column (swanson-2004).|64.45035714285714|70.94990566037737|8.24464285714286|7.125148247978437|10.779166666666667|9.881243815513628|10.1125|8.854339622641508|11.677933333333335|6.63143605870021|74.79740637214636|67.93811816646087|20.685714285714287|18.509973045822104\n",
      "\n",
      "refers to one of two parts of the lateral habenula of the rat ( paxinos-2009b ) and mouse ( franklin-2008 ). the other is the medial part of the lateral habenula. in this segmentation of the habenula, the medial habenula is not subdivided. \\r\\nother authors do not subdivide the lateral habenula in the rat ( swanson-2004 ) but divide the medial habenula into a dorsal part of the medial habenula and ventral part of the medial habenula. \\r\\nneither nucleus of the habenula is subdivided in the human ( carpenter-1983 ) or the macaque ( paxinos-2009a ). functionally the habenula belongs to the central gray of the behavior control column ( swanson-2004 ).|refers to one of two parts of the lateral habenula of a rat ( paxinos-2009b ) and mouse ( franklin-2008 ). the other part is the medial part. rnorthophore is subdivided in the human|64.45035714285714|90.8257843137255|8.24464285714286|3.4064705882352975|10.779166666666667|9.242581720430108|10.1125|-0.34941176470588076|11.677933333333335|5.463440860215055|74.79740637214636|51.09635603445709|20.685714285714287|13.945098039215686\n",
      "\n",
      "refers to one of two parts of the lateral habenula of the rat ( paxinos-2009b ) and mouse ( franklin-2008 ). the other is the medial part of the lateral habenula. in this segmentation of the habenula, the medial habenula is not subdivided. \\r\\nother authors do not subdivide the lateral habenula in the rat ( swanson-2004 ) but divide the medial habenula into a dorsal part of the medial habenula and ventral part of the medial habenula. \\r\\nneither nucleus of the habenula is subdivided in the human ( carpenter-1983 ) or the macaque ( paxinos-2009a ). functionally the habenula belongs to the central gray of the behavior control column ( swanson-2004 ).| refers to|64.45035714285714|119.19000000000003|8.24464285714286|-2.619999999999999|10.779166666666667|15.6774|10.1125|-81.02666666666666|11.677933333333335|-7.654999999999999|74.79740637214636|31.29|20.685714285714287|14.533333333333331\n",
      "\n",
      "a plant family of the order violales, subclass dilleniidae, class magnoliopsida that are herbaceous or woody vines, shrubs, and trees, mostly of warm regions. many have tendrils in leaf axils. leaves are alternate. flowers have 3-5 sepals, petals and stamens. nearly all species have seeds that bear a fleshy appendage called an aril.|a plant family of the order violales, subclass class, class class that is herbaceous or woody vines, shrubs, and trees, mostly of warm regions.  many have tendrils in leaf axils.  leaves are active.  flowers have 3-5 sepals, petals and stamens.  nearly all kinds have seeds that bear a fleshy part called an aril.|62.1899213836478|85.87671052631579|6.779528301886796|3.641315789473687|10.020328148148149|9.400972030651342|-2.223396226415101|-4.646315789473682|7.520000000000003|2.0127394636015303|62.58|57.127462747788826|21.64654088050315|17.835087719298244\n",
      "\n",
      "a plant family of the order violales, subclass dilleniidae, class magnoliopsida that are herbaceous or woody vines, shrubs, and trees, mostly of warm regions. many have tendrils in leaf axils. leaves are alternate. flowers have 3-5 sepals, petals and stamens. nearly all species have seeds that bear a fleshy appendage called an aril.|a plant family of the order violales, subclass dilleniidae, class magnoliopsis. many have tendrils in leaf axils. leaves are alternate. nearly all species have seeds that bear a fleshy appendage called an aril.|62.1899213836478|59.135999999999996|6.779528301886796|6.65066666666667|10.020328148148149|9.546721176470589|-2.223396226415101|-12.953939393939397|7.520000000000003|5.935588235294116|62.58|54.195869768830164|21.64654088050315|20.821818181818184\n",
      "\n",
      "a plant family of the order violales, subclass dilleniidae, class magnoliopsida that are herbaceous or woody vines, shrubs, and trees, mostly of warm regions. many have tendrils in leaf axils. leaves are alternate. flowers have 3-5 sepals, petals and stamens. nearly all species have seeds that bear a fleshy appendage called an aril.| aril|62.1899213836478|120.20500000000001|6.779528301886796|-3.01|10.020328148148149|19.5753|-2.223396226415101|-133.3|7.520000000000003|-10.51|62.58|31.29|21.64654088050315|20.8\n",
      "\n",
      "any process that modulates the frequency, rate or extent of b cell differentiation. [goc:go_curators]|any walk that changes the ratio, rate or extent of b cell adaptation.  [ goc: go_curators]|18.44428571428574|73.79573529411766|12.425714285714289|5.077941176470592|12.429833333333335|10.809158333333334|-5.325714285714284|-9.228235294117649|8.381999999999998|1.8429166666666674|58.53822981607831|54.195869768830164|22.8|17.51764705882353\n",
      "\n",
      "any process that modulates the frequency, rate or extent of b cell differentiation. [goc:go_curators]|any process that changes the frequency, rate or extent of b cell differentiation. [goc:go_curators]|18.44428571428574|30.53000000000003|12.425714285714289|10.740000000000002|12.429833333333335|11.9283|-5.325714285714284|-5.7457142857142856|8.381999999999998|6.708749999999998|58.53822981607831|58.53822981607831|22.8|22.8\n",
      "\n",
      "any process that modulates the frequency, rate or extent of b cell differentiation. [goc:go_curators]| Any process that regulates the differentiation of a cell|18.44428571428574|44.405|12.425714285714289|9.55|12.429833333333335|11.359372727272728|-5.325714285714284|-0.7880000000000003|8.381999999999998|5.47909090909091|58.53822981607831|62.58|22.8|20.0\n",
      "\n",
      "telephone surveys are conducted to monitor prevalence of the major behavioral risks among adults associated with premature morbidity and mortality. the data collected is in regard to actual behaviors, rather than on attitudes or knowledge. the centers for disease control and prevention (cdc) established the behavioral risk factor surveillance system (brfss) in 1984.|telephone look performs to observe a number of the major behavioral risks among adults unite with premature quality and rate.  the data collected is  look to actual trait, rather than on cognition or knowledge.  the centers for disease control and hindrance (cdc) make the behavioral risk factor surveillance system (brfss) in 1984.|28.97492924528305|62.133295454545475|12.509575471698117|8.008863636363639|13.45050251572327|12.220645454545455|12.718490566037733|8.193454545454546|14.774654088050312|7.448727272727275|85.69119412168324|78.225|27.941509433962267|23.681818181818183\n",
      "\n",
      "telephone surveys are conducted to monitor prevalence of the major behavioral risks among adults associated with premature morbidity and mortality. the data collected is in regard to actual behaviors, rather than on attitudes or knowledge. the centers for disease control and prevention (cdc) established the behavioral risk factor surveillance system (brfss) in 1984.|telephone surveys are conducted to monitor prevalence of the major behavioral risks among adults associated with premature morbidity and mortality. the data collected is in regard to actual behaviors, rather than on attitudes or knowledge.|28.97492924528305|18.54190476190476|12.509575471698117|13.571428571428577|13.748427044025156|12.565311111111113|12.718490566037733|9.236571428571423|14.774654088050312|11.12916666666667|85.69119412168324|82.78555852321104|27.941509433962267|28.66666666666667\n",
      "\n",
      "telephone surveys are conducted to monitor prevalence of the major behavioral risks among adults associated with premature morbidity and mortality. the data collected is in regard to actual behaviors, rather than on attitudes or knowledge. the centers for disease control and prevention (cdc) established the behavioral risk factor surveillance system (brfss) in 1984.| surveys collect information|28.97492924528305|33.57500000000002|12.509575471698117|9.57|13.45050251572327|19.674500000000002|12.718490566037733|-35.78|14.774654088050312|6.504000000000001|85.69119412168324|54.195869768830164|27.941509433962267|31.6\n",
      "\n",
      "any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating redox state. redox state refers to the balance of oxidized versus reduced forms of electron donors and acceptors in an organelle, cell or organ; plastoquinone, glutathione (gsh/gssg), and nicotinamide nucleotides (nad+/nadh and nadp+/nadph) are among the most important. [goc:mah]|any walk that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme display, gene squeeze, etc..) as a result of a stimulus informs redox state.  redox state refers to the balance of change versus reduced forms of lepton donors and drawee in an organ, cell or organ; plastoquinone, glutathione (gsh/gssg), and nicotinamide ester (nad+/nash and nadp+/nadph) are among the most important.  [ goc: mah]|36.79250000000002|66.05624324324327|12.475000000000001|7.722540540540539|12.283288888888888|11.38220810810811|16.013714285714286|8.923243243243245|14.83958333333333|9.715135135135132|89.87368260508745|74.04565456527479|25.857142857142858|21.055135135135135\n",
      "\n",
      "any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating redox state. redox state refers to the balance of oxidized versus reduced forms of electron donors and acceptors in an organelle, cell or organ; plastoquinone, glutathione (gsh/gssg), and nicotinamide nucleotides (nad+/nadh and nadp+/nadph) are among the most important. [goc:mah]|any process that results in a change in state or activity of an organelle or cell (in terms of movement, secretion, enzyme production, etc.); plastoquinone, glutathione (gsh/gssg), and nicotinamide nucleoside|36.79250000000002|33.690000000000026|12.475000000000001|12.286666666666669|12.283288888888888|12.3251|16.013714285714286|15.546666666666667|14.83958333333333|11.2975|89.87368260508745|79.77416029015912|25.857142857142858|23.333333333333336\n",
      "\n",
      "any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating redox state. redox state refers to the balance of oxidized versus reduced forms of electron donors and acceptors in an organelle, cell or organ; plastoquinone, glutathione (gsh/gssg), and nicotinamide nucleotides (nad+/nadh and nadp+/nadph) are among the most important. [goc:mah]| ANY PROCESS THAT RESULTS IN A CHANGE IN STATE OR ACTIVITY OF A CELL (IN TERMS OF MOVEMENT, SECRETION, ENZYME PRODUCTION, GENE EXPRESSION, etc.) as a result of a stimulus indicating redox state. REDOX STATE REFERS TO THE BALANCE OF OX|36.79250000000002|61.696428571428584|12.475000000000001|8.131904761904764|12.283288888888888|12.047086046511629|16.013714285714286|6.017142857142854|14.83958333333333|9.803023255813951|89.87368260508745|72.26115969177356|25.857142857142858|20.83809523809524\n",
      "\n",
      "an indicator that can be set or unset in order to signal whether a particular condition is true.|a device that can be set or unset in order to tell whether a partial condition is true.|56.70000000000002|80.20000000000003|7.58666666666667|4.308888888888891|9.792633333333335|8.915411111111112|-7.082222222222221|-10.022222222222219|7.98|5.625|58.53822981607831|54.195869768830164|19.15555555555556|16.933333333333334\n",
      "\n",
      "an indicator that can be set or unset in order to signal whether a particular condition is true.|an indicator that is set or unset in order to signal whether a particular condition is true.|56.70000000000002|53.889852941176486|7.58666666666667|7.854411764705883|9.792633333333335|10.223455555555555|-7.082222222222221|-8.190588235294115|7.98|2.956666666666667|58.53822981607831|58.53822981607831|19.15555555555556|19.870588235294118\n",
      "\n",
      "an indicator that can be set or unset in order to signal whether a particular condition is true.| an indicator|56.70000000000002|62.79000000000002|7.58666666666667|5.246666666666666|9.792633333333335|15.6774|-7.082222222222221|-75.14666666666666|7.98|-4.122500000000002|58.53822981607831|31.29|19.15555555555556|14.533333333333331\n",
      "\n",
      "systems designed to dissolve high levels of oxygen into a solution, such as saline solution. typically, this system then mixes the supersaturated oxygen solution with autologous blood and delivers the hyperoxemic blood to the patient. this system can be used during therapy to treat damaged cardiac arteries.|systems designed to change high levels of oxygen into a success, such as saline solution.  typically, this system, then changes the supersaturated oxygen solution with autologous blood and produce the hyperoxemic blood in the case.  this system can be used during therapy to treat change cardiac arteries.|31.108750000000015|47.64614795918371|11.8393085106383|9.65688775510204|11.132715602836878|10.567477959183673|7.586382978723407|6.6767346938775525|12.15801418439716|7.7889795918367355|78.225|73.38155456243756|25.97659574468085|22.85918367346939\n",
      "\n",
      "systems designed to dissolve high levels of oxygen into a solution, such as saline solution. typically, this system then mixes the supersaturated oxygen solution with autologous blood and delivers the hyperoxemic blood to the patient. this system can be used during therapy to treat damaged cardiac arteries.|systems designed to dissolve high levels of oxygen into a solution, such as saline solution. typically, this system mixes the supersaturated oxygen solution with autologous blood and delivers the hyperoxemic blood to the patient. this system can be used during therapy to treat damaged heart|31.108750000000015|29.930000000000007|11.8393085106383|12.811111111111114|11.132715602836878|10.918989855072464|7.586382978723407|12.671999999999997|12.15801418439716|11.220144927536232|78.225|86.63808689023553|25.97659574468085|26.444444444444446\n",
      "\n",
      "systems designed to dissolve high levels of oxygen into a solution, such as saline solution. typically, this system then mixes the supersaturated oxygen solution with autologous blood and delivers the hyperoxemic blood to the patient. this system can be used during therapy to treat damaged cardiac arteries.| system|31.108750000000015|120.20500000000001|11.8393085106383|-3.01|11.132715602836878|19.5753|7.586382978723407|-127.42|12.15801418439716|-7.370000000000001|78.225|31.29|25.97659574468085|20.8\n",
      "\n",
      "brief (<24 hrs) episode of ischemia managed medically and without permanent deficit|brief (< 24 hrs) episode of ischemia managed medically and without wave score|25.455000000000013|63.486153846153854|12.690000000000001|7.633846153846157|16.427453846153846|13.998223076923077|10.613333333333337|6.6307692307692285|10.431538461538462|7.895384615384614|82.78555852321104|69.96656701596841|28.13333333333334|20.58461538461539\n",
      "\n",
      "brief (<24 hrs) episode of ischemia managed medically and without permanent deficit|brief (24 hrs) episode of ischemia managed medically and without permanent deficit.|25.455000000000013|31.545000000000016|12.690000000000001|10.350000000000001|16.427453846153846|16.427453846153846|10.613333333333337|-13.563333333333333|10.431538461538462|10.431538461538462|82.78555852321104|58.53822981607831|28.13333333333334|25.733333333333338\n",
      "\n",
      "brief (<24 hrs) episode of ischemia managed medically and without permanent deficit| brief (hours) episode of ischemia managed medically and without permanent deficit|25.455000000000013|25.455000000000013|12.690000000000001|12.690000000000001|16.427453846153846|15.212838461538462|10.613333333333337|10.613333333333337|10.431538461538462|10.793846153846154|82.78555852321104|82.78555852321104|28.13333333333334|28.13333333333334\n",
      "\n",
      "stage iii includes: t3, n0, m0. t3: tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. n0: no regional lymph node metastasis. m0: no distant metastasis. (ajcc 6th and 7th eds.)|stage iii includes: t3, n0, m0.  t3: tumor absorbs one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis.  n0: no regional lymph node metastasis.  m0: no distant metastasis.  ( ajcc 6th and 7th eds.)|64.44500000000002|82.28453252032523|5.761111111111113|3.4798780487804883|15.397508888888892|15.975000000000001|-16.82999999999999|-15.064390243902444|6.505000000000003|5.707000000000001|47.79626449838941|47.79626449838941|17.95555555555556|16.39186991869919\n",
      "\n",
      "stage iii includes: t3, n0, m0. t3: tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. n0: no regional lymph node metastasis. m0: no distant metastasis. (ajcc 6th and 7th eds.)|stage iii includes: t3,n0, m0. t3: tumor involves one or both both ovarian cancers with microscopically confirmed peritoneal metastasis outside of pelvis. m1: myeloma. (ajcc 6th and 7|64.44500000000002|60.74428571428575|5.761111111111113|6.525714285714287|15.33798888888889|14.885755172413795|-16.82999999999999|-9.315714285714286|5.905000000000001|6.394655172413795|47.79626449838941|54.195869768830164|17.95555555555556|19.942857142857143\n",
      "\n",
      "stage iii includes: t3, n0, m0. t3: tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. n0: no regional lymph node metastasis. m0: no distant metastasis. (ajcc 6th and 7th eds.)| This entity includes: tumor|64.44500000000002|49.48000000000002|5.761111111111113|7.600000000000001|15.295474603174606|17.092433333333332|-16.82999999999999|-29.799999999999997|5.476428571428574|1.1950000000000003|47.79626449838941|54.195869768830164|17.95555555555556|26.0\n",
      "\n",
      "the daily salt intake is deficient.|the daily salt breath is deficient.|62.79000000000002|76.89000000000003|5.246666666666666|3.2800000000000047|9.197433333333334|6.565766666666667|-69.26666666666665|-69.26666666666665|4.334999999999997|4.334999999999997|38.32226702584281|31.29|21.200000000000003|14.533333333333331\n",
      "\n",
      "the daily salt intake is deficient.|the salt intake is deficient.|62.79000000000002|68.93750000000003|5.246666666666666|4.265000000000004|9.197433333333334|11.6803|-69.26666666666665|-87.824|4.334999999999997|-0.3049999999999997|38.32226702584281|31.29|21.200000000000003|17.0\n",
      "\n",
      "the daily salt intake is deficient.| The daily salt intake is low.|62.79000000000002|106.59678571428573|5.246666666666666|-0.7392857142857139|9.197433333333334|9.756150000000002|-69.26666666666665|-63.57142857142857|4.334999999999997|-4.71125|38.32226702584281|31.29|21.200000000000003|12.82857142857143\n",
      "\n",
      "any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a l-dopa stimulus. [go_ref:0000071, goc:termgenie, pmid:25044243]|any walk that results in a change in state or activity of a cell or a system (in terms of movement, secretion, enzyme display, gene squeeze, etc..) as a result of a l-dopa stimulus.  [ go_ref:0000071 , goc : termgenie , pmid:25044243 ]|63.98693693693693|95.68818181818183|7.3983783783783785|2.645454545454548|12.296264102564102|11.403333333333332|8.260540540540543|-1.2509090909090972|11.145384615384614|6.19616666666667|67.59412548439398|54.195869768830164|20.06846846846847|15.309090909090907\n",
      "\n",
      "any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a l-dopa stimulus. [go_ref:0000071, goc:termgenie, pmid:25044243]|any process that results in a change in state or activity of eukaryotic cell or an organism (in terms of movement, secretion, enzyme production, etc.). [go_ref:0000071, goc:2544243]|63.98693693693693|66.10000000000002|7.3983783783783785|6.2755555555555596|12.296264102564102|11.66197142857143|8.260540540540543|1.0844444444444505|11.145384615384614|10.129285714285714|67.59412548439398|57.127462747788826|20.06846846846847|18.414814814814815\n",
      "\n",
      "any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a l-dopa stimulus. [go_ref:0000071, goc:termgenie, pmid:25044243]| any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.)|63.98693693693693|62.70357142857142|7.3983783783783785|7.991428571428575|12.296264102564102|11.433975862068966|8.260540540540543|6.787142857142857|11.145384615384614|6.446551724137933|67.59412548439398|69.96656701596841|20.06846846846847|19.885714285714286\n",
      "\n",
      "enzymes that catalyze reversibly the formation of an epoxide or arene oxide from a glycol or aromatic diol, respectively.|enzymes that catalyze reversing the placement of an epoxide or urine oxide from a glycol or aromatic diol, respectively.|23.53986842105263|32.44513157894738|12.336052631578948|11.093947368421052|13.72047894736842|13.72047894736842|0.717894736842112|0.4084210526315779|13.107368421052634|12.859473684210528|69.96656701596841|69.96656701596841|24.852631578947367|24.852631578947367\n",
      "\n",
      "enzymes that catalyze reversibly the formation of an epoxide or arene oxide from a glycol or aromatic diol, respectively.|enzymes that catalyze reversibly the formation of an epoxide or arene oxide from a sugar or aromatic diol, respectively.|23.53986842105263|23.53986842105263|12.336052631578948|12.336052631578948|13.72047894736842|12.817|0.717894736842112|0.717894736842112|13.107368421052634|7.355499999999999|69.96656701596841|69.96656701596841|24.852631578947367|24.852631578947367\n",
      "\n",
      "enzymes that catalyze reversibly the formation of an epoxide or arene oxide from a glycol or aromatic diol, respectively.| enzymes that form reversibly an oxygen atom bridge|23.53986842105263|47.30000000000004|12.336052631578948|8.89777777777778|13.72047894736842|13.6065|0.717894736842112|-4.142222222222216|13.107368421052634|4.765000000000001|69.96656701596841|62.58|24.852631578947367|21.37777777777778\n",
      "\n",
      "clinical, therapeutic and diagnostic approaches to optimal disease management based on individual variations in a patient's genetic profile.|clinic, medicine and diagnostic address to optimal disease management based on individual change in a case 's genetic write.|0.30000000000001137|36.89776315789476|15.453333333333337|10.472894736842104|15.055966666666668|10.669855555555555|7.291111111111114|1.6463157894736824|19.231666666666662|14.783333333333331|76.64453405168562|66.37611354998121|30.266666666666666|22.74736842105263\n",
      "\n",
      "clinical, therapeutic and diagnostic approaches to optimal disease management based on individual variations in a patient's genetic profile.|clinical, therapeutic and genetic approaches to optimal disease management based on individual variations in a patient's genetic profile.|0.30000000000001137|0.30000000000001137|15.453333333333337|15.453333333333337|15.055966666666668|14.911384210526316|7.291111111111114|6.637777777777778|19.231666666666662|12.819473684210529|76.64453405168562|76.64453405168562|30.266666666666666|30.266666666666666\n",
      "\n",
      "clinical, therapeutic and diagnostic approaches to optimal disease management based on individual variations in a patient's genetic profile.| disease management|0.30000000000001137|62.79000000000002|15.453333333333337|5.246666666666666|15.055966666666668|19.6249|7.291111111111114|-63.386666666666656|19.231666666666662|2.942499999999999|76.64453405168562|44.250742366654144|30.266666666666666|27.866666666666664\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of 3'-utr-mediated mrna stabilization. [go_ref:0000058, goc:termgenie, pmid:19737525]|any walk that changes or change the ratio, rate or extent of 3'-utr-mediated mrna improvement.  [ go_ref:0000058 , goc : termgenie , pmid:19737525 ]|52.00000000000003|116.31550000000001|8.242222222222225|0.1410000000000018|14.080331578947368|11.862166666666667|12.191111111111113|5.484799999999996|15.546315789473681|9.456833333333332|62.58|54.195869768830164|21.37777777777778|14.600000000000001\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of 3'-utr-mediated mrna stabilization. [go_ref:0000058, goc:termgenie, pmid:19737525]|any process that activates or increases the rate or helps mrna stabilization. [go_ref:0000058, goc:termgenie, pmid:19737525]|52.00000000000003|52.58250000000001|8.242222222222225|7.7883333333333375|14.080331578947368|13.346335294117647|12.191111111111113|4.045333333333332|15.546315789473681|11.911176470588238|62.58|54.195869768830164|21.37777777777778|19.0\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of 3'-utr-mediated mrna stabilization. [go_ref:0000058, goc:termgenie, pmid:19737525]| Any process that activates or increases the frequency, rate or extent of 3'-end gene regulation.|52.00000000000003|55.952500000000015|8.242222222222225|7.442500000000003|14.080331578947368|12.915175000000001|12.191111111111113|-6.497500000000002|15.546315789473681|6.708749999999998|62.58|58.53822981607831|21.37777777777778|20.700000000000003\n",
      "\n",
      "experimentally induced tumors of the liver.|experimentally functional concept growth of the liver.|6.390000000000015|9.91107142857146|13.113333333333333|12.74642857142857|11.8291|13.006557142857146|-61.42666666666666|-44.251428571428576|10.615000000000002|13.69428571428572|44.250742366654144|44.250742366654144|27.866666666666664|24.257142857142856\n",
      "\n",
      "experimentally induced tumors of the liver.|experimentally induced tumors of the liver.|6.390000000000015|6.390000000000015|13.113333333333333|13.113333333333333|11.8291|12.832957142857145|-61.42666666666666|-60.44666666666666|10.615000000000002|5.8885714285714315|44.250742366654144|44.250742366654144|27.866666666666664|27.866666666666664\n",
      "\n",
      "experimentally induced tumors of the liver.| experimentally induced hepatomas|6.390000000000015|-51.02499999999998|13.113333333333333|21.370000000000008|11.8291|19.674500000000002|-61.42666666666666|-28.43|10.615000000000002|11.214000000000006|44.250742366654144|54.195869768830164|27.866666666666664|31.6\n",
      "\n",
      "wallflower.|flower.|-47.47249999999997|37.127500000000026|20.005000000000006|8.205000000000002|19.476100000000002|0.0496|-527.32|-550.84|26.17|7.329999999999998|22.125371183327072|22.125371183327072|40.2|40.2\n",
      "\n",
      "wallflower.|a plant.|-47.47249999999997|121.22000000000003|20.005000000000006|-3.3999999999999986|19.476100000000002|8.974233333333334|-527.32|-272.48|26.17|-9.69|22.125371183327072|0.0|40.2|0.4\n",
      "\n",
      "wallflower.| flower|-47.47249999999997|120.20500000000001|20.005000000000006|-3.01|19.476100000000002|11.630700000000001|-527.32|-130.36|26.17|-3.9450000000000003|22.125371183327072|31.29|40.2|20.8\n",
      "\n",
      "reassesses genitourinary status to determine changes from baseline throughout the perioperative phase of care.|measure body system status to conclude changes from line throughout the preoperative phase of care.|6.35857142857148|58.2225|14.111428571428572|7.001666666666669|13.353757142857145|10.6965|-1.5457142857142898|-6.146666666666668|17.867142857142852|12.445999999999998|62.58|62.58|25.65714285714286|24.333333333333336\n",
      "\n",
      "reassesses genitourinary status to determine changes from baseline throughout the perioperative phase of care.|reassesses genital status to determine changes from baseline during the perioperative phase of care.|6.35857142857148|24.487142857142885|14.111428571428572|11.582857142857147|13.353757142857145|12.429833333333335|-1.5457142857142898|-5.325714285714284|17.867142857142852|9.637999999999998|62.58|62.58|25.65714285714286|25.65714285714286\n",
      "\n",
      "reassesses genitourinary status to determine changes from baseline throughout the perioperative phase of care.| reassesses the genitourinary system to determine changes from baseline|6.35857142857148|10.564999999999998|14.111428571428572|14.270000000000007|13.353757142857145|14.230281818181819|-1.5457142857142898|7.443999999999999|17.867142857142852|11.473636363636366|62.58|76.64453405168562|25.65714285714286|28.0\n",
      "\n",
      "a cell that serves to provide support and protection and perhaps contribute to the nutrition of principal or other cells of the nervous system.|a cell that serves to provide support and assets and perhaps pay for the science of wrongdoer or other cells of the nervous system.|60.70500000000001|78.33000000000001|7.773333333333333|5.315000000000001|10.090233333333334|9.432316666666667|4.733333333333334|1.7933333333333366|13.923749999999998|11.568750000000001|69.96656701596841|66.37611354998121|21.46666666666667|19.8\n",
      "\n",
      "a cell that serves to provide support and protection and perhaps contribute to the nutrition of principal or other cells of the nervous system.|a cell that serves to provide support and protection and may contribute to the nutrition of principal or other cells of the nervous system.|60.70500000000001|64.22999999999999|7.773333333333333|7.28166666666667|10.090233333333334|9.9409|4.733333333333334|3.9983333333333384|13.923749999999998|6.674399999999999|69.96656701596841|66.37611354998121|21.46666666666667|19.8\n",
      "\n",
      "a cell that serves to provide support and protection and perhaps contribute to the nutrition of principal or other cells of the nervous system.| a cell|60.70500000000001|147.39000000000004|7.773333333333333|-6.553333333333333|10.090233333333334|11.7299|4.733333333333334|-86.90666666666665|13.923749999999998|-11.1875|69.96656701596841|0.0|21.46666666666667|1.2000000000000002\n",
      "\n",
      "obsolete. catalysis of the reaction: me2+(in) + atp = me2+(out) + adp + phosphate, where me is zn2+, cd2+, co2+, ni2+ or pb2+. [tc:3.a.3.6.2]|obsolete.  the catalysis of the reaction: me2+ (in) + atp = me2+ (out) + adp + salt, where me is zn2+, cd2+, co2+, ni2+ or pb2+.  [ tc: 3.a.3.6.2]|132.85500000000002|139.57225806451612|-4.41952380952381|-5.108018433179723|16.63907011494253|15.617732432432433|-57.42333333333334|-44.83612903225806|0.7816091954022966|-3.56608108108108|23.653016720917435|20.4841133564526|8.038095238095236|5.642396313364056\n",
      "\n",
      "obsolete. catalysis of the reaction: me2+(in) + atp = me2+(out) + adp + phosphate, where me is zn2+, cd2+, co2+, ni2+ or pb2+. [tc:3.a.3.6.2]|obsolete. catalysis of the reaction: me2+(in) + adenosine triphosphate. [tc:3.a.3.6.2]|132.85500000000002|44.64500000000004|-4.41952380952381|7.387142857142859|16.519203448275864|16.737457575757574|-57.42333333333334|-161.336|-0.4267241379310356|11.232424242424244|23.653016720917435|26.444876630455283|8.038095238095236|20.571428571428573\n",
      "\n",
      "obsolete. catalysis of the reaction: me2+(in) + atp = me2+(out) + adp + phosphate, where me is zn2+, cd2+, co2+, ni2+ or pb2+. [tc:3.a.3.6.2]| out|132.85500000000002|162.505|-4.41952380952381|-8.91|16.519203448275864|14.311966666666669|-57.42333333333334|-136.24|-0.4267241379310356|-12.079999999999998|23.653016720917435|0.0|8.038095238095236|0.8\n",
      "\n",
      "biliary tract carcinoma that is resistant to treatment.|biliary tract cancer that is resistant to care.|33.57500000000002|65.30000000000001|9.57|5.145|13.902050000000001|11.9283|-38.72|-44.6|10.24125|5.53125|44.250742366654144|38.32226702584281|21.6|16.6\n",
      "\n",
      "biliary tract carcinoma that is resistant to treatment.|cancer that is resistant to treatment.|33.57500000000002|62.79000000000002|9.57|5.246666666666666|13.902050000000001|12.832957142857145|-38.72|-65.34666666666666|10.24125|2.524285714285714|44.250742366654144|38.32226702584281|21.6|21.200000000000003\n",
      "\n",
      "biliary tract carcinoma that is resistant to treatment.| gall bladder carcinoma|33.57500000000002|54.72500000000002|9.57|6.620000000000001|13.902050000000001|19.674500000000002|-38.72|-43.13|10.24125|1.7940000000000005|44.250742366654144|44.250742366654144|21.6|21.6\n",
      "\n",
      "a carcinoma that arises from the anterior two-thirds of the tongue. representative examples include squamous cell carcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.|a cancer that protest from the tooth two-thirds of the tongue.  inform examples include squamous cell cancer, adenoid cystic cancer, and mucoepidermoid cancer.|-3.2510144927535976|54.190000000000026|15.61739130434783|7.688333333333336|12.1267|12.260633333333335|1.7843478260869574|-3.6799999999999997|14.596250000000005|7.605466666666668|67.59412548439398|65.13532912329528|27.414492753623193|24.866666666666667\n",
      "\n",
      "a carcinoma that arises from the anterior two-thirds of the tongue. representative examples include squamous cell carcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.|a cancer that arises from the front two-thirds of the tongue. representative examples include squamous cell cancer, adenoid cystic carcinoma, and mucusosal cancer.|-3.2510144927535976|29.853333333333353|15.61739130434783|11.000000000000004|12.1267|11.629033333333332|1.7843478260869574|-2.306086956521739|14.596250000000005|8.547466666666669|67.59412548439398|65.13532912329528|27.414492753623193|25.675362318840584\n",
      "\n",
      "a carcinoma that arises from the anterior two-thirds of the tongue. representative examples include squamous cell carcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.| a cancer|-3.2510144927535976|119.19000000000003|15.61739130434783|-2.619999999999999|12.1267|15.6774|1.7843478260869574|-82.98666666666665|14.596250000000005|-8.8325|67.59412548439398|31.29|27.414492753623193|14.533333333333331\n",
      "\n",
      "a large vein which returns blood from the head, neck and extremities to the heart.|a large vein which pays blood from the head, neck and region of the heart.|92.06250000000001|108.9825|2.2816666666666663|-0.07833333333333137|6.485833333333334|6.485833333333334|-12.810666666666673|-15.946666666666669|6.7940000000000005|4.282|31.29|22.125371183327072|8.333333333333334|5.666666666666668\n",
      "\n",
      "a large vein which returns blood from the head, neck and extremities to the heart.|a large vein which returns blood from the head, neck, extremities to the heart.|92.06250000000001|90.95857142857145|2.2816666666666663|2.3114285714285714|6.485833333333334|7.1665|-12.810666666666673|-14.145714285714288|6.7940000000000005|2.4160000000000004|31.29|31.29|8.333333333333334|8.514285714285714\n",
      "\n",
      "a large vein which returns blood from the head, neck and extremities to the heart.| a vein which returns blood from the head, neck and extremities to the heart|92.06250000000001|90.09000000000002|2.2816666666666663|4.420000000000002|6.485833333333334|8.377600000000001|-12.810666666666673|4.962666666666667|6.7940000000000005|5.115625000000001|31.29|44.250742366654144|8.333333333333334|11.333333333333336\n",
      "\n",
      "a neoplasm that arises from mature b-lymphocytes or plasma cells. representative examples include mature b-cell non-hodgkin lymphomas, chronic lymphocytic leukemia, hairy cell leukemia, and plasma cell neoplasms.|a growth that protest from draw b-lymphocytes or plasma cells.  inform examples include mature b-cell non-hodgkin cancer, chronic lymphocytic cancer, hairy cell cancer, and plasma cell growth.|15.966666666666669|52.33309523809527|13.268148148148153|8.278571428571428|14.907166666666669|14.845484946236558|7.617777777777782|2.935714285714294|14.015999999999998|7.74247311827957|76.64453405168562|69.96656701596841|30.266666666666666|25.161904761904765\n",
      "\n",
      "a neoplasm that arises from mature b-lymphocytes or plasma cells. representative examples include mature b-cell non-hodgkin lymphomas, chronic lymphocytic leukemia, hairy cell leukemia, and plasma cell neoplasms.|a blood tumor that arises from mature b-lymphocytes or plasma cells. representative examples include mature blood cell lymphomas, adult lymph nodes, and plasma cell tumors.|15.966666666666669|42.71266666666668|13.268148148148153|9.372000000000003|14.907166666666669|13.439937037037039|7.617777777777782|-0.47520000000000095|14.015999999999998|8.189999999999998|76.64453405168562|65.13532912329528|30.266666666666666|24.133333333333336\n",
      "\n",
      "a neoplasm that arises from mature b-lymphocytes or plasma cells. representative examples include mature b-cell non-hodgkin lymphomas, chronic lymphocytic leukemia, hairy cell leukemia, and plasma cell neoplasms.| a cancerous skin tumor|15.966666666666669|83.32000000000004|13.268148148148153|2.879999999999999|14.907166666666669|14.460766666666668|7.617777777777782|-35.67999999999999|14.015999999999998|-1.9450000000000003|76.64453405168562|44.250742366654144|30.266666666666666|18.0\n",
      "\n",
      "interacting selectively and non-covalently with phosphatidylinositol-3,5-bisphosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 3' and 5' positions. [goc:bf, pmid:18397324]|act selectively and non-covalently with phosphatidylinositol-3,5-bisphosphate, a word of phosphatidylinositol in which the inositol ring is phosphorylated at the 3 ' and 5 ' positions.  [ goc: bf, pmid: 18397324]|21.563500000000005|62.837983870967776|13.357000000000003|8.345322580645163|13.353757142857145|12.553833333333335|22.419199999999996|15.424516129032263|16.85785714285715|10.574000000000005|62.58|54.195869768830164|17.8|13.94193548387097\n",
      "\n",
      "interacting selectively and non-covalently with phosphatidylinositol-3,5-bisphosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 3' and 5' positions. [goc:bf, pmid:18397324]|interacting selectively and not binding with a molecule of protein that is phosphorylated at the 3' and 5' positions. [goc:bf, pmid:18397324]|21.563500000000005|55.17750000000001|13.357000000000003|8.171666666666667|13.353757142857145|12.445160869565218|22.419199999999996|5.969523809523807|16.85785714285715|7.870000000000001|62.58|58.53822981607831|17.8|17.53333333333333\n",
      "\n",
      "interacting selectively and non-covalently with phosphatidylinositol-3,5-bisphosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 3' and 5' positions. [goc:bf, pmid:18397324]||21.563500000000005|205.82000000000002|13.357000000000003|-15.2|13.353757142857145|19.476100000000002|22.419199999999996|-290.12|16.85785714285715|-16.22|62.58|0.0|17.8|0.4\n",
      "\n",
      "this gene is involved in both drug metabolism and bilirubin clearance.|this gene is having in both drug metabolism and bilirubin room.|55.12522727272727|70.50704545454548|6.936818181818182|4.791363636363638|12.794827272727273|9.923918181818184|-21.74545454545455|-25.48727272727273|9.332727272727272|6.335454545454546|44.250742366654144|31.29|16.745454545454546|9.472727272727274\n",
      "\n",
      "this gene is involved in both drug metabolism and bilirubin clearance.|this gene is involved in drug metabolism and bilirubin clearance.|55.12522727272727|49.48000000000002|6.936818181818182|7.600000000000001|12.794827272727273|13.957481818181819|-21.74545454545455|-25.683999999999997|9.332727272727272|5.298181818181817|44.250742366654144|44.250742366654144|16.745454545454546|18.0\n",
      "\n",
      "this gene is involved in both drug metabolism and bilirubin clearance.| this gene is involved in metabolism of both drugs and bilirubin.|55.12522727272727|73.84500000000001|6.936818181818182|4.450000000000003|12.794827272727273|12.461207692307694|-21.74545454545455|-22.383333333333333|9.332727272727272|1.7469230769230784|44.250742366654144|38.32226702584281|16.745454545454546|12.4\n",
      "\n",
      "an autoimmune disease that causes pain, swelling, and stiffness in the joints, and may cause severe joint damage, loss of function, and disability. the disease may last from months to a lifetime, and symptoms may improve and worsen over time.|a disease disease that causes pain, grow, and stiffness in the joints, and may cause a severe joint change, loss of serve, and unfitness.  the disease may last for months to a lifetime, and symptoms may improve and change over time.|68.51666666666668|85.86785714285715|7.015000000000001|4.76047619047619|9.3655|8.46637619047619|7.641000000000002|5.597142857142856|11.53125|6.204285714285717|69.96656701596841|59.91578840339164|20.333333333333336|16.076190476190476\n",
      "\n",
      "an autoimmune disease that causes pain, swelling, and stiffness in the joints, and may cause severe joint damage, loss of function, and disability. the disease may last from months to a lifetime, and symptoms may improve and worsen over time.|an autoimmune disease that causes pain, swelling and rigidity in the joints, and may cause severe joint damage, loss of function and disability. the disease may last from months to a lifetime, but symptoms may improve and worsen over time.|68.51666666666668|64.28666666666669|7.015000000000001|7.605|9.3655|9.320952032520324|7.641000000000002|7.347000000000001|11.53125|7.804552845528452|69.96656701596841|69.96656701596841|20.333333333333336|20.333333333333336\n",
      "\n",
      "an autoimmune disease that causes pain, swelling, and stiffness in the joints, and may cause severe joint damage, loss of function, and disability. the disease may last from months to a lifetime, and symptoms may improve and worsen over time.| an autoimmune disease that causes pain, swelling, and stiffness in the joints, and causes severe joint damage, loss of function, and disability|68.51666666666668|51.07260869565218|7.015000000000001|11.849565217391305|9.3655|11.406066666666666|7.641000000000002|18.575652173913042|11.53125|13.923749999999998|69.96656701596841|98.94766798666859|20.333333333333336|26.59130434782609\n",
      "\n",
      "the chemical reactions and pathways involving uracil, 2,4-dioxopyrimidine, one of the pyrimidine bases occurring in rna, but not in dna. [goc:go_curators]|the process force and path absorb uracil, 2,4-dioxopyrimidine, one of the base bases appears in rna, but not in denial.  [ goc: go_curators]|43.09178571428572|81.85500000000002|9.857380952380954|4.823333333333334|13.818204347826088|11.9283|9.329523809523813|3.9983333333333384|10.122608695652175|4.157499999999999|66.37611354998121|58.53822981607831|21.34285714285714|16.46666666666667\n",
      "\n",
      "the chemical reactions and pathways involving uracil, 2,4-dioxopyrimidine, one of the pyrimidine bases occurring in rna, but not in dna. [goc:go_curators]|the chemical reactions and pathways involving uracil, 2,4-dioxopyrimidine, one of the bases occurring in rna, but not in dna. [goc:go_curators]|43.09178571428572|52.86500000000001|9.857380952380954|8.370000000000001|13.818204347826088|13.818204347826088|9.329523809523813|7.150000000000002|10.122608695652175|8.279565217391305|66.37611354998121|62.58|21.34285714285714|20.0\n",
      "\n",
      "the chemical reactions and pathways involving uracil, 2,4-dioxopyrimidine, one of the pyrimidine bases occurring in rna, but not in dna. [goc:go_curators]| a molecule|43.09178571428572|90.99000000000004|9.857380952380954|1.3133333333333361|13.818204347826088|15.6774|9.329523809523813|-79.06666666666666|10.122608695652175|-6.477499999999999|66.37611354998121|31.29|21.34285714285714|14.533333333333331\n",
      "\n",
      "lack of one or more of the normal pulmonary fissures. []|lack of one or more of the normal pulmonary crack.  [ ]|78.19795454545455|109.12980769230771|3.7186363636363637|-0.347307692307691|10.200500000000002|9.56018484848485|-29.229090909090914|-26.08923076923077|1.3230000000000004|-2.041212121212123|38.32226702584281|31.29|13.109090909090908|8.753846153846155\n",
      "\n",
      "lack of one or more of the normal pulmonary fissures. []|lack of one or two normal pulmonary fissures. []|78.19795454545455|70.66750000000002|3.7186363636363637|4.520555555555557|10.200500000000002|12.631922222222224|-29.229090909090914|-38.99111111111111|1.3230000000000004|0.706666666666667|38.32226702584281|38.32226702584281|13.109090909090908|15.133333333333333\n",
      "\n",
      "lack of one or more of the normal pulmonary fissures. []| a|78.19795454545455|162.505|3.7186363636363637|-8.91|10.200500000000002|14.311966666666669|-29.229090909090914|-142.12|1.3230000000000004|-15.219999999999999|38.32226702584281|0.0|13.109090909090908|0.8\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of myoblast proliferation. [goc:bhf]|any walk that changes or change the ratio, rate or extent of myoblast increase.  [ goc: bhf]|30.022500000000008|94.30000000000001|10.935000000000002|2.342222222222226|12.915175000000001|10.41933137254902|-3.4026666666666685|-8.388888888888882|8.180625|1.0745098039215684|62.58|54.195869768830164|24.333333333333336|16.933333333333334\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of myoblast proliferation. [goc:bhf]|any process that activates or increases the frequency, rate or extent of cellular support. [goc:bhf]|30.022500000000008|41.30250000000001|10.935000000000002|9.361666666666668|12.915175000000001|13.346335294117647|-3.4026666666666685|-5.3626666666666765|8.180625|5.538823529411765|62.58|62.58|24.333333333333336|24.333333333333336\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of myoblast proliferation. [goc:bhf]| any process that activates or increases the frequency, rate or extent of muscle cell division|30.022500000000008|42.545000000000016|10.935000000000002|11.3|12.915175000000001|12.839111764705882|-3.4026666666666685|10.899999999999999|8.180625|9.23470588235294|62.58|88.50148473330829|24.333333333333336|26.400000000000002\n",
      "\n",
      "serology reagents intended to detect antigens to human immunodeficiency virus serotype 1 (hiv-1) and/or serotype 2 (hiv-2). human immunodeficiency viruses are retroviruses of the genus lentivirus, family retroviridae, that may cause acquired immunodeficiency syndrome (aids). tests using these reagents are not widely utilized; these regents may have questionable clinical usefulness, and easier or less expensive tests may be available.|serology reagent conveys to spy substance to human immunodeficiency virus serotype 1 (hiv-1) and/or serotype 2 (hiv-2).  human immunodeficiency viruses are retroviruses of the kind lentivirus, family retroviridae, that may cause changes immunodeficiency syndrome (aids).  tests using these reagents are not widely changing; these regents may have questionable clinical quality, and easier or less expensive tests may be available.|9.758665254237314|26.316905737704957|15.562500000000004|13.377172131147542|13.443661581920905|13.187164480874317|17.70372881355932|16.255737704918033|17.62129943502825|16.45617486338798|87.10767345647568|82.78555852321104|26.916949152542372|24.46065573770492\n",
      "\n",
      "serology reagents intended to detect antigens to human immunodeficiency virus serotype 1 (hiv-1) and/or serotype 2 (hiv-2). human immunodeficiency viruses are retroviruses of the genus lentivirus, family retroviridae, that may cause acquired immunodeficiency syndrome (aids). tests using these reagents are not widely utilized; these regents may have questionable clinical usefulness, and easier or less expensive tests may be available.|these viruses are retroviruses that are not widely utilized; these regents may have questionable clinical usefulness, and easier or less expensive tests may be available.|9.758665254237314|21.563500000000005|15.562500000000004|13.357000000000003|13.711288700564973|10.961684615384616|17.70372881355932|10.894399999999997|17.62129943502825|11.156153846153849|87.10767345647568|73.38155456243756|26.916949152542372|22.6\n",
      "\n",
      "serology reagents intended to detect antigens to human immunodeficiency virus serotype 1 (hiv-1) and/or serotype 2 (hiv-2). human immunodeficiency viruses are retroviruses of the genus lentivirus, family retroviridae, that may cause acquired immunodeficiency syndrome (aids). tests using these reagents are not widely utilized; these regents may have questionable clinical usefulness, and easier or less expensive tests may be available.| serology reagents intended to detect antibodies to human immunodeficiency virus serotype 1 (hiv-1) and/or serotype 2 (hiv-2). human immunodeficiency viruses are retroviruses of the genus lentivirus, family retroviridae, that may cause acquired immunodeficiency syndrome (aids).|9.758665254237314|-0.3949999999999818|15.562500000000004|16.295555555555556|13.711288700564973|15.770665765765767|17.70372881355932|15.186666666666667|17.62129943502825|14.651531531531532|87.10767345647568|82.78555852321104|26.916949152542372|28.13333333333334\n",
      "\n",
      "functional activities questionnaire-nacc version (faq-nacc version) writing checks, paying bills, balancing checkbook.|functional trait questionnaire-neck version (faq-neck version) writing checks, paying bills, be checkbook.|-3.7049999999999557|31.545000000000016|15.266666666666666|10.350000000000001|15.60947142857143|12.225900000000001|3.096666666666671|-2.7833333333333243|19.212857142857146|15.175714285714285|69.96656701596841|62.58|35.73333333333334|29.066666666666663\n",
      "\n",
      "functional activities questionnaire-nacc version (faq-nacc version) writing checks, paying bills, balancing checkbook.|functional activities questionnaire-nacc version (faq-nac version) writing checks, paying bills, balancing checkbook.|-3.7049999999999557|-3.7049999999999557|15.266666666666666|15.266666666666666|15.60947142857143|15.463833333333334|3.096666666666671|3.096666666666671|19.212857142857146|12.470000000000006|69.96656701596841|69.96656701596841|35.73333333333334|35.73333333333334\n",
      "\n",
      "functional activities questionnaire-nacc version (faq-nacc version) writing checks, paying bills, balancing checkbook.| questionnaire-check account-writing checks, pay bills|-3.7049999999999557|31.545000000000016|15.266666666666666|10.350000000000001|15.60947142857143|9.346233333333334|3.096666666666671|-0.3333333333333215|19.212857142857146|8.189999999999998|69.96656701596841|44.250742366654144|35.73333333333334|15.733333333333333\n",
      "\n",
      "higher intake of phosphorus compared to established reference standards or recommendations based on physiological needs.|higher breath on the planet compared to make write flag or praise based on physiological needs.|18.742500000000007|82.39000000000001|12.508333333333336|3.7550000000000026|11.749166666666667|6.40385|2.085333333333324|-7.600000000000001|19.04|9.825624999999999|62.58|38.32226702584281|24.333333333333336|10.700000000000001\n",
      "\n",
      "higher intake of phosphorus compared to established reference standards or recommendations based on physiological needs.|higher intake of phosphorus compared to established reference standards or suggestions based on physiological needs.|18.742500000000007|30.022500000000008|12.508333333333336|10.935000000000002|11.749166666666667|11.9283|2.085333333333324|0.9093333333333291|19.04|12.596250000000005|62.58|62.58|24.333333333333336|24.333333333333336\n",
      "\n",
      "higher intake of phosphorus compared to established reference standards or recommendations based on physiological needs.| higher intake of phosphorus|18.742500000000007|83.32000000000004|12.508333333333336|2.879999999999999|11.749166666666667|14.460766666666668|2.085333333333324|-29.799999999999997|19.04|1.9800000000000004|62.58|44.250742366654144|24.333333333333336|18.0\n",
      "\n",
      "patient health questionnaire screener version - over the last 4 weeks, how often have you been bothered by getting tired very easily?|patient health form guard turns - over the last 4 weeks, how often have you been confused by getting tired very easily?|61.45045454545455|76.83227272727274|10.153636363636362|8.008181818181821|9.189528571428571|7.685719047619047|16.479999999999997|12.738181818181813|13.517142857142858|10.377142857142857|93.86999999999999|76.64453405168562|25.163636363636368|19.709090909090907\n",
      "\n",
      "patient health questionnaire screener version - over the last 4 weeks, how often have you been bothered by getting tired very easily?|patient health questionnaire screener version - over the last 4 weeks, how often have you been bothered by being tired very easily?|61.45045454545455|57.605000000000004|10.153636363636362|10.690000000000001|9.189528571428571|9.751790909090909|16.479999999999997|16.212727272727278|13.517142857142858|12.691818181818185|93.86999999999999|98.94766798666859|25.163636363636368|26.981818181818184\n",
      "\n",
      "patient health questionnaire screener version - over the last 4 weeks, how often have you been bothered by getting tired very easily?| patient health questionnaire screener version|61.45045454545455|59.745000000000005|10.153636363636362|6.416666666666668|9.189528571428571|17.517985714285714|16.479999999999997|-8.173333333333332|13.517142857142858|11.002857142857145|93.86999999999999|62.58|25.163636363636368|29.066666666666663\n",
      "\n",
      "structural deformities, malformations, or other abnormalities of the cranium, oral and facial bones, muscles, cartilage, etc, that exist at, and usually before, birth regardless of their causation.|structural appearance, failure, or other misbehavior of the bone, oral and facial white, muscles, cartilage, etc., that exist at, and usually before, birth regardless of their act.|20.79916666666668|50.433333333333366|13.712037037037042|8.460740740740743|13.163107407407407|11.993477777777779|15.314074074074071|0.6488888888888837|20.15555555555556|17.015555555555558|88.50148473330829|65.13532912329528|29.1037037037037|22.85925925925926\n",
      "\n",
      "structural deformities, malformations, or other abnormalities of the cranium, oral and facial bones, muscles, cartilage, etc, that exist at, and usually before, birth regardless of their causation.|structural deformities, malformations, or other abnormalities of the cranium, oral and facial bones, muscles, causation.|20.79916666666668|1.822499999999991|13.712037037037042|14.868333333333336|13.163107407407407|13.902050000000001|15.314074074074071|2.477333333333334|20.15555555555556|12.301875000000003|88.50148473330829|73.38155456243756|29.1037037037037|32.333333333333336\n",
      "\n",
      "structural deformities, malformations, or other abnormalities of the cranium, oral and facial bones, muscles, cartilage, etc, that exist at, and usually before, birth regardless of their causation.| Structural deformities, malformations, or other abnormalities of the bones of the head that exist before birth|20.79916666666668|30.332941176470626|13.712037037037042|13.251764705882355|13.163107407407407|10.669855555555555|15.314074074074071|15.792941176470588|20.15555555555556|12.428333333333335|88.50148473330829|88.50148473330829|29.1037037037037|25.623529411764707\n",
      "\n",
      "this gene is involved in both nuclear pore formation and nuclear import.|this gene is having in both nuclear pore places and nuclear import.|59.745000000000005|73.84500000000001|6.416666666666668|4.450000000000003|13.442533333333335|10.810866666666666|-19.443333333333328|-21.893333333333324|8.120000000000001|6.157499999999999|49.473833993334296|44.250742366654144|19.06666666666667|15.733333333333333\n",
      "\n",
      "this gene is involved in both nuclear pore formation and nuclear import.|this gene is involved in both nuclearpore formation and nuclear import.|59.745000000000005|55.12522727272727|6.416666666666668|6.936818181818182|13.442533333333335|13.144933333333334|-19.443333333333328|-20.67636363636364|8.120000000000001|5.512499999999999|49.473833993334296|49.473833993334296|19.06666666666667|20.381818181818183\n",
      "\n",
      "this gene is involved in both nuclear pore formation and nuclear import.| this gene is involved in both nuclear pore formation and nuclear importing|59.745000000000005|56.97846153846157|6.416666666666668|8.541538461538462|13.442533333333335|14.481614285714286|-19.443333333333328|6.178461538461537|8.120000000000001|7.437857142857144|49.473833993334296|69.96656701596841|19.06666666666667|20.58461538461539\n",
      "\n",
      "an ephemerovirus infection of cattle caused by bovine ephemeral fever virus (ephemeral fever virus, bovine). it is characterized by respiratory symptoms, increased oropharyngeal secretions and lacrimation, joint pains, tremor, and stiffness.|a disease ill_health of cattle caused by bovine insect fever viruses (insect fever virus, bovine).  it is distinguished by respiratory symptoms, increased oropharyngeal secretions and lachrymation, joint pains, shake, and stiffness.|-0.14365591397850608|32.09583333333336|15.84645161290323|11.432500000000001|13.573687096774194|12.060566666666666|11.376774193548389|9.18375|17.01096774193548|12.310520833333335|80.79043260188672|78.74477315987392|29.939784946236557|28.01666666666667\n",
      "\n",
      "an ephemerovirus infection of cattle caused by bovine ephemeral fever virus (ephemeral fever virus, bovine). it is characterized by respiratory symptoms, increased oropharyngeal secretions and lacrimation, joint pains, tremor, and stiffness.|an viral infection of cattle caused by a virus that is characterized by respiratory symptoms, increased oropharyngeal secretions and lacrimation, joint pains, and stiffness.|-0.14365591397850608|21.930000000000035|15.84645161290323|13.181666666666665|13.573687096774194|12.4673|11.376774193548389|12.328333333333333|17.01096774193548|12.514800000000001|80.79043260188672|76.64453405168562|29.939784946236557|24.8\n",
      "\n",
      "an ephemerovirus infection of cattle caused by bovine ephemeral fever virus (ephemeral fever virus, bovine). it is characterized by respiratory symptoms, increased oropharyngeal secretions and lacrimation, joint pains, tremor, and stiffness.| an ephedrine alkaloid|-0.14365591397850608|54.72500000000002|15.84645161290323|6.620000000000001|13.573687096774194|16.5165|11.376774193548389|-44.6|17.01096774193548|0.8520000000000003|80.79043260188672|44.250742366654144|29.939784946236557|21.6\n",
      "\n",
      "a non-metastasizing neoplasm that arises from the skin. representative examples include benign melanocytic skin nevus, acanthoma, sebaceous adenoma, sweat gland adenoma, lipoma, hemangioma, fibroma, and benign fibrous histiocytoma.|a neoplastic process growth that protest from the skin.  inform examples include benign melanocytic skin nevus, tumor, sebaceous adenoma, sweat gland adenoma, tumor, angina, fibroma, and benign fibrous histiocytoma.|-23.202619047619038|19.025000000000006|18.81428571428572|13.09|15.245355172413795|15.711833333333335|11.125714285714292|6.856000000000005|17.328275862068963|11.515999999999998|78.74477315987392|78.74477315987392|30.876190476190477|29.333333333333332\n",
      "\n",
      "a non-metastasizing neoplasm that arises from the skin. representative examples include benign melanocytic skin nevus, acanthoma, sebaceous adenoma, sweat gland adenoma, lipoma, hemangioma, fibroma, and benign fibrous histiocytoma.|a non-metastasizing tumor that arises from the skin. representative examples include benign melanocytic skin nevus, acanthoma, skin cancer, and benign fibrous histiocytoma.|-23.202619047619038|-4.417424242424232|18.81428571428572|15.697272727272729|15.245355172413795|13.902050000000001|11.125714285714292|0.2618181818181853|17.328275862068963|11.222500000000004|78.74477315987392|67.59412548439398|30.876190476190477|28.38787878787879\n",
      "\n",
      "a non-metastasizing neoplasm that arises from the skin. representative examples include benign melanocytic skin nevus, acanthoma, sebaceous adenoma, sweat gland adenoma, lipoma, hemangioma, fibroma, and benign fibrous histiocytoma.| a benign tumor|-23.202619047619038|97.025|18.81428571428572|0.7199999999999989|15.245355172413795|16.5165|11.125714285714292|-54.89|17.328275862068963|-5.742000000000001|78.74477315987392|44.250742366654144|30.876190476190477|21.6\n",
      "\n",
      "<p>stain, gomori-wheatly trichrome</p>|< p > stain, gomori-wheatly trichrome < /p >|-50.00999999999996|103.70000000000002|20.980000000000008|1.0311111111111124|19.823300000000003|19.9225|-28.106666666666655|-9.368888888888886|2.5874999999999986|-0.41600000000000037|44.250742366654144|44.250742366654144|27.866666666666664|12.488888888888889\n",
      "\n",
      "<p>stain, gomori-wheatly trichrome</p>|stain, gomori-wheatly triadrome/p>|-50.00999999999996|-50.00999999999996|20.980000000000008|20.980000000000008|19.823300000000003|19.773699999999998|-28.106666666666655|-33.986666666666665|2.5874999999999986|2.2557142857142836|44.250742366654144|44.250742366654144|27.866666666666664|27.866666666666664\n",
      "\n",
      "<p>stain, gomori-wheatly trichrome</p>| stain|-50.00999999999996|162.505|20.980000000000008|-8.91|19.823300000000003|19.5753|-28.106666666666655|-130.36|2.5874999999999986|-8.94|44.250742366654144|0.0|27.866666666666664|0.8\n",
      "\n",
      "a species of tick (ticks) in the family ixodidae, distributed throughout the world but abundant in southern europe. it will feed on a wide variety of mammals, but dogs are its preferred host. it transmits a large number of diseases including babesiosis; theileriasis; ehrlichiosis; and mediterranean spotted fever.|a kind of tick (ticks) in the family ixodidae, arrange throughout the world but abundant in southern europe.  it will feed on a wide difference of mammals, but dogs are its pay host.  it moves a large number of illnesses, including babesiosis; theileriasis; ehrlichiosis; and mediterranean mark fever.|43.08000000000001|60.4795|10.23166666666667|7.929000000000002|9.693433333333335|8.3619|8.040833333333339|5.955200000000001|11.788125|7.710600000000003|71.69439674758411|64.5059875127883|22.3|18.6\n",
      "\n",
      "a species of tick (ticks) in the family ixodidae, distributed throughout the world but abundant in southern europe. it will feed on a wide variety of mammals, but dogs are its preferred host. it transmits a large number of diseases including babesiosis; theileriasis; ehrlichiosis; and mediterranean spotted fever.|a species of tick (ticks) in the family ixodidae, distributed throughout the world but abundant in southern europe. it will feed on a wide variety of mammals, but dogs are its preferred host. viruses include babesiosis; theileriasis|43.08000000000001|47.981531531531516|10.23166666666667|9.63081081081081|10.35135|10.913187719298246|8.040833333333339|7.307027027027026|11.788125|8.453333333333333|71.69439674758411|69.96656701596841|22.3|21.14954954954955\n",
      "\n",
      "a species of tick (ticks) in the family ixodidae, distributed throughout the world but abundant in southern europe. it will feed on a wide variety of mammals, but dogs are its preferred host. it transmits a large number of diseases including babesiosis; theileriasis; ehrlichiosis; and mediterranean spotted fever.| a tick|43.08000000000001|147.39000000000004|10.23166666666667|-6.553333333333333|9.693433333333335|11.7299|8.040833333333339|-86.90666666666665|11.788125|-11.1875|71.69439674758411|0.0|22.3|1.2000000000000002\n",
      "\n",
      "the cascade of processes by which a signal interacts with a receptor, causing a change in the level or activity of a second messenger or other downstream target, and ultimately leading to inhibition of an innate immune response. [goc:add, isbn:0781735149, pmid:15771571]|the cascade of transforming by which a tell act with an organ, causing a change in the level or activity of a second messenger or other downstream target, and ultimately leading to the action of an innate immune response.  [ goc: add, isbn: 0781735149, pmid: 15771571]|45.71530487804881|65.98250000000002|11.975731707317074|9.894148936170215|11.069290476190476|10.23246811594203|18.546341463414635|15.177872340425534|13.965714285714284|8.046014492753624|98.94766798666859|91.22524239485473|27.712195121951222|23.86808510638298\n",
      "\n",
      "the cascade of processes by which a signal interacts with a receptor, causing a change in the level or activity of a second messenger or other downstream target, and ultimately leading to inhibition of an innate immune response. [goc:add, isbn:0781735149, pmid:15771571]|a cascade of processes by which a signal interacts with an innate immune response. [goc:add, isbn:0781735149,15771571]|45.71530487804881|66.5275|11.975731707317074|5.967500000000001|11.069290476190476|12.855122222222224|18.546341463414635|1.2199999999999989|13.965714285714284|8.975000000000001|98.94766798666859|62.58|27.712195121951222|23.200000000000003\n",
      "\n",
      "the cascade of processes by which a signal interacts with a receptor, causing a change in the level or activity of a second messenger or other downstream target, and ultimately leading to inhibition of an innate immune response. [goc:add, isbn:0781735149, pmid:15771571]| the cascade of process by which a signal is detected by a receptor, causing a change in the level or activity of a second messenger or other target, and ultimately leading to an immune system's action|45.71530487804881|34.377297297297304|11.975731707317074|17.65621621621621|11.069290476190476|11.338668421052633|18.546341463414635|18.380540540540544|13.965714285714284|18.021315789473682|98.94766798666859|129.0119750255766|27.712195121951222|33.17837837837838\n",
      "\n",
      "the component of the endoplasmic reticulum membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region. [goc:curators, goc:dos]|the part of the endoplasmic stomach sheet is being of gene products and protein structure that are loosely bound to one of its appear, but not calculate into the hydrophobic region.  [ goc: curators, god: dos]|24.03875000000002|62.30074324324326|13.881250000000005|9.16554054054054|11.910288235294118|10.372255555555554|16.228749999999998|11.492972972972971|12.28235294117647|6.419166666666669|88.50148473330829|79.77416029015912|26.400000000000002|21.454054054054055\n",
      "\n",
      "the component of the endoplasmic reticulum membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region. [goc:curators, goc:dos]|the component of the membrane consisting of gene products and protein complexes loosely bound to one of its surfaces, but not integrated into the hydrophobic region. [goc:curators, goc:dos]|24.03875000000002|32.48928571428573|13.881250000000005|12.205714285714286|11.910288235294118|12.045622580645162|16.228749999999998|13.087142857142855|12.28235294117647|10.021935483870969|88.50148473330829|82.78555852321104|26.400000000000002|25.6\n",
      "\n",
      "the component of the endoplasmic reticulum membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region. [goc:curators, goc:dos]| the component of the endoplasmic reticulum membrane consisting of gene products and protein complexes that are loosely bound to its surface|24.03875000000002|34.532272727272726|13.881250000000005|13.90818181818182|11.910288235294118|13.015560869565219|16.228749999999998|18.618181818181817|12.28235294117647|14.848695652173916|88.50148473330829|98.94766798666859|26.400000000000002|26.981818181818184\n",
      "\n",
      "squamous cell carcinoma that affects the renal pelvis.|squamous cell cancer that changes the renal pelvis.|44.150000000000006|65.30000000000001|8.094999999999999|5.145|13.902050000000001|11.9283|-39.455000000000005|-41.660000000000004|9.6525|7.88625|49.473833993334296|49.473833993334296|26.6|26.6\n",
      "\n",
      "squamous cell carcinoma that affects the renal pelvis.|cancer that affects the renal pelvis.|44.150000000000006|62.79000000000002|8.094999999999999|5.246666666666666|13.902050000000001|15.08867142857143|-39.455000000000005|-66.32666666666665|9.6525|1.8514285714285705|49.473833993334296|44.250742366654144|26.6|27.866666666666664\n",
      "\n",
      "squamous cell carcinoma that affects the renal pelvis.| squamous cell carcinoma|44.150000000000006|54.72500000000002|8.094999999999999|6.620000000000001|13.902050000000001|16.5165|-39.455000000000005|-41.660000000000004|9.6525|2.735999999999997|49.473833993334296|44.250742366654144|26.6|21.6\n",
      "\n",
      "this gene is involved in blood coagulation/hemostasis. it also plays a role in embryonic development, tissue remodeling and inflammation.|this gene is have in blood coagulation/hemostasis.  it also plays a role in embryonic section, tissue remake and burning.|22.301403508771955|60.47833333333335|11.722105263157893|6.48|12.0275|11.50274761904762|-9.909473684210525|-14.411999999999999|10.652499999999996|4.274285714285714|51.09635603445709|47.79626449838941|19.37543859649123|16.666666666666668\n",
      "\n",
      "this gene is involved in blood coagulation/hemostasis. it also plays a role in embryonic development, tissue remodeling and inflammation.|this gene is involved in blood clotting/hemolysis. it also plays a role in embryonic development, tissue remodeling and inflammation.|22.301403508771955|31.206666666666678|11.722105263157893|10.48|12.0275|12.254652380952383|-9.909473684210525|-10.837894736842102|10.652499999999996|7.189999999999998|51.09635603445709|51.09635603445709|19.37543859649123|19.37543859649123\n",
      "\n",
      "this gene is involved in blood coagulation/hemostasis. it also plays a role in embryonic development, tissue remodeling and inflammation.| this gene is involved in blood coagulation/hemostasis|22.301403508771955|40.09|11.722105263157893|9.655000000000001|12.0275|13.6065|-9.909473684210525|-1.7199999999999989|10.652499999999996|6.178000000000001|51.09635603445709|44.250742366654144|19.37543859649123|13.200000000000001\n",
      "\n",
      "visual functioning questionnaire 25-interviewer administered format version 2000 (vfq25-interviewer administered format) general heath and vision: how much of the time do you worry about your eyesight?|visual serve form 25-interviewer direct format version 2000 (vfq25-interviewer direct format) general heath and vision: how much of the time do you worry about your eyesight?|30.76807692307696|63.306538461538494|15.426923076923078|10.888461538461542|14.048157142857145|11.792442857142857|28.41846153846153|22.31230769230769|21.166428571428575|16.624642857142852|112.8176994092682|103.77718969022045|30.400000000000002|27.323076923076925\n",
      "\n",
      "visual functioning questionnaire 25-interviewer administered format version 2000 (vfq25-interviewer administered format) general heath and vision: how much of the time do you worry about your eyesight?|visual functioning questionnaire 25-interviewer administered format version 2000. how much of the time do you worry about your eyes?|30.76807692307696|59.16092105263158|15.426923076923078|7.367631578947371|14.048157142857145|11.50274761904762|28.41846153846153|4.431578947368415|21.166428571428575|7.189999999999998|112.8176994092682|62.58|30.400000000000002|20.642105263157895\n",
      "\n",
      "visual functioning questionnaire 25-interviewer administered format version 2000 (vfq25-interviewer administered format) general heath and vision: how much of the time do you worry about your eyesight?| visual functioning questionnaire 25-interviewer administered format|30.76807692307696|6.35857142857148|15.426923076923078|14.111428571428572|14.048157142857145|19.8729|28.41846153846153|10.634285714285717|21.166428571428575|16.04|112.8176994092682|69.96656701596841|30.400000000000002|31.371428571428574\n",
      "\n",
      "a response indicating that an individual doesn't know and/or remember how long it has been since they last smoked a cigarette.|a phrase informs that an organism doesn't know and/or remember how long it has been since they last smoked a cigarette.|59.20607142857145|79.34892857142859|7.609761904761903|4.800238095238097|7.685719047619047|7.685719047619047|1.4895238095238064|-0.47047619047619094|12.619999999999997|11.050000000000004|54.195869768830164|49.473833993334296|15.628571428571428|13.723809523809525\n",
      "\n",
      "a response indicating that an individual doesn't know and/or remember how long it has been since they last smoked a cigarette.|a response indicating an individual doesn't know and/or remember how long it has been since they last smoked a cigarette.|59.20607142857145|57.09500000000003|7.609761904761903|7.779999999999998|7.685719047619047|7.91682380952381|1.4895238095238064|0.6820000000000057|12.619999999999997|6.697142857142854|54.195869768830164|54.195869768830164|15.628571428571428|16.0\n",
      "\n",
      "a response indicating that an individual doesn't know and/or remember how long it has been since they last smoked a cigarette.| a response indicating that an individual does not know and/or remember how long it has been since they last smoked a cigarette|59.20607142857145|54.750869565217414|7.609761904761903|11.336521739130436|7.685719047619047|8.7744|1.4895238095238064|14.229565217391304|12.619999999999997|11.568750000000001|54.195869768830164|76.64453405168562|15.628571428571428|19.63478260869565\n",
      "\n",
      "an inhibitor of the bromodomain-containing protein 4 (brd4), with potential antineoplastic activity. upon administration, the brd4 inhibitor plx51107 binds to the acetylated lysine recognition motifs in the bromodomains of the brd4 protein, thereby preventing the binding of brd4 to acetylated lysines on histones. this disrupts chromatin remodeling and gene expression. prevention of the expression of certain growth-promoting genes may lead to an induction of apoptosis and an inhibition of proliferation in brd4-overexpressing tumor cells. brd4, a member of the human bromodomain and extra-terminal (bet) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.|a substance of the bromodomain-containing protein 4 (brd4), with potential antineoplastic activity.  upon justice, the brd4 substance plx51107 binds to the change lysine appointment theme in the bromodomains of the brd4 protein, thereby preventing the binding of brd4 to change lysines on histones.  this break chromatin remake and gene squeeze.  the hindrance of the squeeze of certain growth-promoting genes may lead to an causing  apoptosis and an action of increase in brd4-overexpressing tumor cells.  brd4, a member of the human bromodomain and extra-terminal (bet) family of proteins, is a transcriptional control that is overexpressed in certain tumor cells and plays an important role in cellular increase.|20.501446540880522|54.67912162162162|14.78867924528302|10.228603603603606|13.493712121212122|12.03854347826087|19.468301886792446|16.04864864864865|24.09287878787878|10.003760869565216|88.50148473330829|82.78555852321104|25.17987421383648|22.535135135135135\n",
      "\n",
      "an inhibitor of the bromodomain-containing protein 4 (brd4), with potential antineoplastic activity. upon administration, the brd4 inhibitor plx51107 binds to the acetylated lysine recognition motifs in the bromodomains of the brd4 protein, thereby preventing the binding of brd4 to acetylated lysines on histones. this disrupts chromatin remodeling and gene expression. prevention of the expression of certain growth-promoting genes may lead to an induction of apoptosis and an inhibition of proliferation in brd4-overexpressing tumor cells. brd4, a member of the human bromodomain and extra-terminal (bet) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.|an inhibitor of the bromodomain-containing protein 4 (brd4), with potential anti-cancer activity. upon administration, the brd4 inhibitor plx51107 binds to the lysine recognition motif in the dna of a cell's protein maker. this|20.501446540880522|36.72454545454548|14.78867924528302|10.869696969696971|12.766245454545455|13.442533333333335|19.468301886792446|8.014545454545452|16.759545454545453|9.166666666666668|88.50148473330829|67.59412548439398|25.17987421383648|21.36969696969697\n",
      "\n",
      "an inhibitor of the bromodomain-containing protein 4 (brd4), with potential antineoplastic activity. upon administration, the brd4 inhibitor plx51107 binds to the acetylated lysine recognition motifs in the bromodomains of the brd4 protein, thereby preventing the binding of brd4 to acetylated lysines on histones. this disrupts chromatin remodeling and gene expression. prevention of the expression of certain growth-promoting genes may lead to an induction of apoptosis and an inhibition of proliferation in brd4-overexpressing tumor cells. brd4, a member of the human bromodomain and extra-terminal (bet) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.||20.501446540880522|205.82000000000002|14.78867924528302|-15.2|12.766245454545455|19.476100000000002|19.468301886792446|-290.12|16.759545454545453|-16.22|88.50148473330829|0.0|25.17987421383648|0.4\n",
      "\n",
      "a clinical finding about one or more characteristics of pleural mesothelioma, following the rules of the tnm ajcc v7 classification system as they pertain to distant metastases.|a symptom finding  one or more property of pleural carcinoma, following the rules of the tnm ajcc v7 restriction system as they pertain to distant metastases.|33.33250000000004|58.3991666666667|11.963888888888892|8.467592592592595|12.578292592592591|12.578292592592591|10.958518518518517|6.820740740740746|18.062222222222225|14.922222222222224|76.64453405168562|73.38155456243756|23.177777777777777|21.696296296296296\n",
      "\n",
      "a clinical finding about one or more characteristics of pleural mesothelioma, following the rules of the tnm ajcc v7 classification system as they pertain to distant metastases.|a clinical finding about one or more characteristics of pleural mesothelioma, following the rules of the classification system for distant metastases.|33.33250000000004|14.891785714285732|11.963888888888892|13.790714285714287|12.578292592592591|11.359372727272728|10.958518518518517|8.48952380952381|18.062222222222225|11.687727272727273|76.64453405168562|73.38155456243756|23.177777777777777|25.152380952380955\n",
      "\n",
      "a clinical finding about one or more characteristics of pleural mesothelioma, following the rules of the tnm ajcc v7 classification system as they pertain to distant metastases.| a clinical finding about one or more characteristics of pleural mesothelioma|33.33250000000004|25.455000000000013|11.963888888888892|12.690000000000001|12.578292592592591|12.783607692307694|10.958518518518517|8.163333333333334|18.062222222222225|9.706923076923076|76.64453405168562|76.64453405168562|23.177777777777777|24.8\n",
      "\n",
      "moderate pain; limiting instrumental adl|change pain; choose instrumental adl|-1.2799999999999727|66.40000000000003|14.68|5.240000000000002|16.392500000000002|10.200500000000002|-16.863999999999997|-21.567999999999998|12.79|10.272000000000002|54.195869768830164|31.29|26.0|10.0\n",
      "\n",
      "moderate pain; limiting instrumental adl|mild pain; limiting instrumental adl|-1.2799999999999727|32.56000000000003|14.68|9.96|16.5165|17.092433333333332|-16.863999999999997|-20.391999999999996|14.04|6.689999999999998|54.195869768830164|44.250742366654144|26.0|18.0\n",
      "\n",
      "moderate pain; limiting instrumental adl| pain|-1.2799999999999727|162.505|14.68|-8.91|16.5165|14.311966666666669|-16.863999999999997|-133.3|14.04|-10.51|54.195869768830164|0.0|26.0|0.8\n",
      "\n",
      "a semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.|a semi-quantitative microscopic finding inform that 5 percent or less of the become cells in a bone marrow sample are immature mononuclear cells of lymphoid source.|30.947692307692336|47.21692307692311|12.172307692307694|9.903076923076924|13.163107407407407|12.578292592592591|10.249230769230767|8.666153846153843|17.189999999999998|15.968888888888891|76.64453405168562|73.38155456243756|23.661538461538463|22.123076923076923\n",
      "\n",
      "a semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.|a semi-quantitative microscopy finding indicating that 5 percent or less of the cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.|30.947692307692336|35.099500000000035|12.172307692307694|11.469000000000001|13.163107407407407|12.493507407407408|10.249230769230767|8.5424|17.189999999999998|8.870000000000001|76.64453405168562|73.38155456243756|23.661538461538463|22.6\n",
      "\n",
      "a semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.| a finding|30.947692307692336|119.19000000000003|12.172307692307694|-2.619999999999999|13.163107407407407|15.6774|10.249230769230767|-81.02666666666666|17.189999999999998|-7.654999999999999|76.64453405168562|31.29|23.661538461538463|14.533333333333331\n",
      "\n",
      "world health organization disability assessment schedule 2.0 - 36-item proxy - in the past 30 days, how much difficulty did your relative have in: his or her day-to-day work/school?|world health organization unfitness action plan 2.0 - 36-item proxy - in the past 30 days, how much quality did your person have : his or her day-to-day work/school?|63.75887931034484|84.17956896551725|7.96844827586207|5.120172413793107|10.777003225806451|9.8615|10.608275862068968|7.364137931034488|15.948709677419352|13.666000000000004|66.37611354998121|62.58|18.21379310344828|16.83448275862069\n",
      "\n",
      "world health organization disability assessment schedule 2.0 - 36-item proxy - in the past 30 days, how much difficulty did your relative have in: his or her day-to-day work/school?|world health organization disability assessment schedule 2.0 - 36-item proxy- in the past 30 days, how much difficulty your relative had in: his or her day-to-day work/school?|63.75887931034484|58.3991666666667|7.96844827586207|8.467592592592595|10.00820322580645|10.51755806451613|10.608275862068968|10.74074074074074|8.198709677419355|7.894838709677423|66.37611354998121|66.37611354998121|18.21379310344828|18.73333333333333\n",
      "\n",
      "world health organization disability assessment schedule 2.0 - 36-item proxy - in the past 30 days, how much difficulty did your relative have in: his or her day-to-day work/school?| world health organization disability assessment schedule 2.0 - 36-item proxy - in the past month, how much difficulty did your relative have in: his or her day-to-day work/school?|63.75887931034484|63.75887931034484|7.96844827586207|7.96844827586207|10.777003225806451|11.144950000000001|10.608275862068968|10.608275862068968|15.948709677419352|15.912187500000002|66.37611354998121|66.37611354998121|18.21379310344828|18.21379310344828\n",
      "\n",
      "<p>the urgency for starting a patient encounter.</p><p>*example:*routine, urgent, emergency, and elective.</p>|< p > the urgency for starting a case encounter.  < /p > < p > * example: * routine, urgent, brake, and elective.  < /p >|-12.232121212121172|118.25781609195404|15.876363636363639|-0.8337931034482757|14.907166666666669|16.002396296296297|-27.272727272727266|-11.764137931034483|16.528|0.4966666666666697|44.250742366654144|44.250742366654144|23.28484848484848|12.142528735632183\n",
      "\n",
      "<p>the urgency for starting a patient encounter.</p><p>*example:*routine, urgent, emergency, and elective.</p>|the urgency for starting a patient encounter.p>*example:*routine, urgent, emergency, elective.|-12.232121212121172|-16.508333333333297|15.876363636363639|16.390000000000004|14.907166666666669|13.957481818181819|-27.272727272727266|-38.232000000000006|16.528|16.43090909090909|44.250742366654144|44.250742366654144|23.28484848484848|25.333333333333336\n",
      "\n",
      "<p>the urgency for starting a patient encounter.</p><p>*example:*routine, urgent, emergency, and elective.</p>| <p>the urgency for starting a patient encounter.</p>|-12.232121212121172|75.87500000000001|15.876363636363639|3.6700000000000017|14.907166666666669|15.212838461538462|-27.272727272727266|-39.455000000000005|16.528|2.4607692307692304|44.250742366654144|38.32226702584281|23.28484848484848|16.6\n",
      "\n",
      "providing and responding to implicit and explicit differences of opinion or disagreement, in a contextually and socially appropriate manner.|providing and react to implicit and explicit number of opinion or speech_act, in a contextually and socially assume kind.|5.729342105263186|41.350394736842105|14.82026315789474|9.851842105263156|12.889426315789473|12.058373684210528|6.5978947368421075|0.717894736842112|17.817368421052628|13.107368421052634|73.38155456243756|69.96656701596841|26.957894736842107|24.852631578947367\n",
      "\n",
      "providing and responding to implicit and explicit differences of opinion or disagreement, in a contextually and socially appropriate manner.|providing and responding to implicit and explicit differences of opinion or disagreement, in a context and socially appropriate manner.|5.729342105263186|14.634605263157908|14.82026315789474|13.578157894736844|12.889426315789473|12.817|6.5978947368421075|5.359999999999999|17.817368421052628|10.887999999999998|73.38155456243756|73.38155456243756|26.957894736842107|26.957894736842107\n",
      "\n",
      "providing and responding to implicit and explicit differences of opinion or disagreement, in a contextually and socially appropriate manner.| expressing|5.729342105263186|77.90500000000002|14.82026315789474|2.890000000000004|12.889426315789473|19.5753|6.5978947368421075|-115.66|17.817368421052628|-1.0899999999999999|73.38155456243756|31.29|26.957894736842107|20.8\n",
      "\n",
      "human znf496 wild-type allele is located in the vicinity of 1q44 and is approximately 31 kb in length. this allele, which encodes zinc finger protein 496, plays a role in the modulation of transcription.|human znf496 wild-type gene is located in the section of 1q44 and is approximately 31 kb in length.  this gene, which convert zinc finger protein 496, plays a role in the revision of transcription.|68.43166666666669|86.22190476190477|6.530000000000005|4.131428571428572|12.62507142857143|12.565311111111113|3.2823529411764696|2.0125714285714302|9.524285714285714|5.372500000000002|62.58|57.127462747788826|18.650980392156864|16.095238095238095\n",
      "\n",
      "human znf496 wild-type allele is located in the vicinity of 1q44 and is approximately 31 kb in length. this allele, which encodes zinc finger protein 496, plays a role in the modulation of transcription.|normal human znf496 gene is located in the vicinity of 1q44 and is about 31 kilobases in length. this gene, which encodes zinc finger protein 496, plays a role in modulating transcription.|68.43166666666669|69.10833333333336|6.530000000000005|6.270000000000003|12.62507142857143|12.794827272727273|3.2823529411764696|1.2825000000000024|9.524285714285714|6.050000000000001|62.58|59.91578840339164|18.650980392156864|18.016666666666666\n",
      "\n",
      "human znf496 wild-type allele is located in the vicinity of 1q44 and is approximately 31 kb in length. this allele, which encodes zinc finger protein 496, plays a role in the modulation of transcription.| human zinc finger protein 496 wild-type allele is located near 1q44 and is approximately 31Kb in length.|68.43166666666669|84.90000000000003|6.530000000000005|3.653333333333336|12.62507142857143|13.6065|3.2823529411764696|-3.8155555555555516|9.524285714285714|4.2940000000000005|62.58|58.53822981607831|18.650980392156864|19.15555555555556\n",
      "\n",
      "sounds having similar characteristics and functional properties of natural speech but which are made by means other than natural vocalization mechanisms (e.g., computer-generated speech sounds).|sounds having similar property and functional properties of natural speech, but which are made by means other than a natural vocalization device (e.g., computer-generated speech sounds).|24.52325000000002|37.54519230769233|11.391500000000004|9.637307692307694|11.606484615384616|11.408662962962964|-7.376000000000005|-9.127692307692307|21.460384615384612|19.10888888888889|49.473833993334296|49.473833993334296|18.5|17.984615384615388\n",
      "\n",
      "sounds having similar characteristics and functional properties of natural speech but which are made by means other than natural vocalization mechanisms (e.g., computer-generated speech sounds).|sounds having similar characteristics and functional properties of natural speech but which are made by means other than natural voice mechanisms (e.g., computer-generated speech sounds).|24.52325000000002|38.05925000000002|11.391500000000004|9.503499999999999|11.606484615384616|10.739062962962963|-7.376000000000005|-8.787200000000006|21.460384615384612|13.056666666666665|49.473833993334296|46.934999999999995|18.5|16.900000000000002\n",
      "\n",
      "sounds having similar characteristics and functional properties of natural speech but which are made by means other than natural vocalization mechanisms (e.g., computer-generated speech sounds).| sounds|24.52325000000002|162.505|11.391500000000004|-8.91|11.606484615384616|14.311966666666669|-7.376000000000005|-127.42|21.460384615384612|-7.370000000000001|49.473833993334296|0.0|18.5|0.8\n",
      "\n",
      "stage iv includes: any t, any n, m1. m1: distant metastasis (excludes peritoneal metastasis). (ajcc 6th and 7th eds.)|stage i includes: any t, any n, m1.  m1: distant metastasis (expel peritoneal metastasis).  ( ajcc 6th and 7th eds.)|63.9821710526316|85.88886363636365|5.5151315789473685|2.6459090909090897|16.416422807017543|16.014176190476192|-31.677894736842102|-28.42727272727273|3.5514035087719336|1.3585714285714268|44.250742366654144|44.250742366654144|18.742105263157892|16.745454545454546\n",
      "\n",
      "stage iv includes: any t, any n, m1. m1: distant metastasis (excludes peritoneal metastasis). (ajcc 6th and 7th eds.)|stage iv includes: any t, any n, m1 (excludes peritoneal metastasis). (ajcc 6th and 7th eds.)|63.9821710526316|69.23416666666668|5.5151315789473685|4.927499999999998|16.33788947368421|15.992272549019608|-31.677894736842102|-26.467499999999994|2.7597368421052657|0.7974509803921528|44.250742366654144|44.250742366654144|18.742105263157892|17.133333333333336\n",
      "\n",
      "stage iv includes: any t, any n, m1. m1: distant metastasis (excludes peritoneal metastasis). (ajcc 6th and 7th eds.)| stage iv includes: any tumor, any distant metastasis|63.9821710526316|37.900000000000034|5.5151315789473685|10.208888888888893|16.416422807017543|15.185500000000001|-31.677894736842102|-2.8355555555555547|3.5514035087719336|4.765000000000001|44.250742366654144|76.64453405168562|18.742105263157892|30.266666666666666\n",
      "\n",
      "a vitamin that can dissolve in water. water-soluble vitamins are carried to the body's tissues but are not stored in the body. they are found in plant and animal foods or dietary supplements and must be taken in daily. vitamin c and members of the vitamin b complex are water-soluble.|a vitamin that can change in water.  water-soluble vitamins are carried to the body 's tissues, but are not stored in the body.  they are found in plant and animal foods or fare attach and must be taken in daily.  vitamin c and members of the vitamin b whole are water-soluble.|57.94100000000003|73.67300000000003|7.662000000000003|5.666444444444444|8.2288|7.758396103896104|-1.9639999999999986|-3.0162962962963|5.812115384615385|1.3385714285714272|60.99543900981449|55.973253612774734|19.200000000000003|16.17185185185185\n",
      "\n",
      "a vitamin that can dissolve in water. water-soluble vitamins are carried to the body's tissues but are not stored in the body. they are found in plant and animal foods or dietary supplements and must be taken in daily. vitamin c and members of the vitamin b complex are water-soluble.|a vitamin that can dissolve in water. water-soluble vitamins are carried to the body's tissues but are not stored in the bodies. they are found in plant and animal foods or dietary supplements and must be taken in daily. vitamin c and members of the vitamin b complex are watersoluble.|57.94100000000003|57.94100000000003|7.662000000000003|7.662000000000003|8.2288|8.403493846153847|-1.9639999999999986|-1.7287999999999961|5.812115384615385|4.783846153846152|60.99543900981449|60.99543900981449|19.200000000000003|19.200000000000003\n",
      "\n",
      "a vitamin that can dissolve in water. water-soluble vitamins are carried to the body's tissues but are not stored in the body. they are found in plant and animal foods or dietary supplements and must be taken in daily. vitamin c and members of the vitamin b complex are water-soluble.| a water-soluble nutrient found in higher plants and animals|57.94100000000003|52.86500000000001|7.662000000000003|8.370000000000001|8.2288|9.495033333333335|-1.9639999999999986|0.9759999999999991|5.812115384615385|4.98|60.99543900981449|54.195869768830164|19.200000000000003|16.0\n",
      "\n",
      "a malignant epithelial tumor with a glandular organization that originates in the ileum. [hpo:probinson]|a quality epithelial growth with a glandular beginning that begin in the ileum.  [ hop: robinson]|-5.727142857142809|58.8663235294118|15.797142857142859|7.160294117647062|13.4825|10.809158333333334|-4.065714285714286|-6.80705882352941|9.637999999999998|4.197916666666668|62.58|58.53822981607831|25.65714285714286|19.870588235294118\n",
      "\n",
      "a malignant epithelial tumor with a glandular organization that originates in the ileum. [hpo:probinson]|a cancerous skin tumor with a glandular organization that originates in the ileum. [hpo:probinson]|-5.727142857142809|12.401428571428596|15.797142857142859|13.26857142857143|13.4825|12.915175000000001|-4.065714285714286|-6.16571428571428|9.637999999999998|6.708749999999998|62.58|58.53822981607831|25.65714285714286|22.8\n",
      "\n",
      "a malignant epithelial tumor with a glandular organization that originates in the ileum. [hpo:probinson]| a malignant epithelial tumor|-5.727142857142809|32.56000000000003|15.797142857142859|9.96|13.4825|17.092433333333332|-4.065714285714286|-28.624|9.637999999999998|2.7650000000000006|62.58|54.195869768830164|25.65714285714286|26.0\n",
      "\n",
      "any process that modulates the frequency, rate or extent of l-tyrosine import into the cell. [goc:termgenie]|any walk that changes the ratio, rate or extent of l-tyrosine import into the cell.  [ goc: termini]|40.09|76.97144736842105|9.655000000000001|4.883421052631579|11.9779|10.599054385964912|-2.822499999999998|-5.781052631578945|5.834999999999997|0.8245614035087705|66.37611354998121|62.58|25.700000000000003|20.642105263157895\n",
      "\n",
      "any process that modulates the frequency, rate or extent of l-tyrosine import into the cell. [goc:termgenie]|any process that modulates the frequency, rate or extent of l-tyrosine import into the cell. [goc:termgenie]|40.09|40.09|9.655000000000001|9.655000000000001|11.9779|12.418226315789473|-2.822499999999998|-2.4550000000000054|5.834999999999997|5.134736842105266|66.37611354998121|66.37611354998121|25.700000000000003|25.700000000000003\n",
      "\n",
      "any process that modulates the frequency, rate or extent of l-tyrosine import into the cell. [goc:termgenie]| Any process that prevents or reduces l-tyrosine import into a cell|40.09|53.655|9.655000000000001|8.756666666666668|11.9779|13.353757142857145|-2.822499999999998|3.2633333333333354|5.834999999999997|4.74642857142857|66.37611354998121|82.78555852321104|25.700000000000003|28.13333333333334\n",
      "\n",
      "someone from whom an organ is removed for transplantation or other purpose.|someone from whom an organ kills for movement or other goal.|59.745000000000005|85.88886363636365|6.416666666666668|2.6459090909090897|6.863366666666667|5.617554545454546|-17.97333333333333|-27.090909090909093|9.2975|5.050909090909091|54.195869768830164|44.250742366654144|22.400000000000002|16.745454545454546\n",
      "\n",
      "someone from whom an organ is removed for transplantation or other purpose.|anyone from whom an organ is removed for transplantation or other purpose.|59.745000000000005|52.69500000000002|6.416666666666668|7.400000000000002|6.863366666666667|7.602746153846153|-17.97333333333333|-17.97333333333333|9.2975|4.645384615384614|54.195869768830164|54.195869768830164|22.400000000000002|22.400000000000002\n",
      "\n",
      "someone from whom an organ is removed for transplantation or other purpose.| someone from whom an organ is removed|59.745000000000005|92.965|6.416666666666668|2.280000000000001|6.863366666666667|7.591788888888889|-17.97333333333333|-13.48|9.2975|0.33999999999999986|54.195869768830164|54.195869768830164|22.400000000000002|18.2\n",
      "\n",
      "paced tapping test (paced tapping) total number of intertap intervals within the tone-tapping phase of trial n, that were trimmed before analysis.|paced pierce test (paced pierce) total number of intertap distance within the tone-tapping phase of trial n, that were cut before calculus.|34.160909090909115|53.388181818181835|11.22727272727273|8.545454545454547|10.269473913043479|11.642517391304349|6.4999999999999964|4.629090909090905|14.643913043478257|13.210434782608694|82.78555852321104|73.38155456243756|29.854545454545452|24.400000000000002\n",
      "\n",
      "paced tapping test (paced tapping) total number of intertap intervals within the tone-tapping phase of trial n, that were trimmed before analysis.|paced tapping test) total number of intertap intervals within the tone-tapping phase of trial n, that were trimmed before analysis.|34.160909090909115|35.94500000000002|11.22727272727273|10.73|12.445160869565218|11.895233333333334|6.4999999999999964|3.6220000000000034|8.89391304347826|5.5725757575757555|82.78555852321104|76.64453405168562|29.854545454545452|28.0\n",
      "\n",
      "paced tapping test (paced tapping) total number of intertap intervals within the tone-tapping phase of trial n, that were trimmed before analysis.| trimmed|34.160909090909115|120.20500000000001|11.22727272727273|-3.01|10.269473913043479|14.311966666666669|6.4999999999999964|-124.48|14.643913043478257|-5.800000000000001|82.78555852321104|31.29|29.854545454545452|20.8\n",
      "\n",
      "a sulfur-containing alkyl thionitrite that is one of the nitric oxide donors.|a sulfur-containing alkyl thionitrite that is one of the nitric oxide donors.|45.64500000000001|45.64500000000001|8.383333333333333|8.383333333333333|12.783607692307694|12.783607692307694|-16.993333333333332|-16.993333333333332|8.25769230769231|8.25769230769231|54.195869768830164|54.195869768830164|22.400000000000002|22.400000000000002\n",
      "\n",
      "a sulfur-containing alkyl thionitrite that is one of the nitric oxide donors.|a sulfur-containing alkyl thionitrite that is one of the noxide donors.|45.64500000000001|47.434318181818185|8.383333333333333|8.009545454545457|12.783607692307694|12.461207692307694|-16.993333333333332|-20.67636363636364|8.25769230769231|3.558461538461536|54.195869768830164|49.473833993334296|22.400000000000002|20.381818181818183\n",
      "\n",
      "a sulfur-containing alkyl thionitrite that is one of the nitric oxide donors.| a donor of nitric oxide|45.64500000000001|87.94500000000002|8.383333333333333|2.4833333333333343|12.783607692307694|15.262271428571431|-16.993333333333332|-29.733333333333327|8.25769230769231|-3.8000000000000007|54.195869768830164|54.195869768830164|22.400000000000002|22.400000000000002\n",
      "\n",
      "obsolete. the pathway by which adenine, hypoxanthine and their nucleosides from purine nucleotides breakdown are converted back to purine nucleotides. the salvage pathway is important where there is no de-novo purine nucleotide biosynthesis. [goc:pz]|obsolete.  the path by which purine, hypoxanthine and their glycoside from base ester breakdown are changing back to base ester.  the salvage path is important where there is no de-nova base ester synthesis.  [ goc: ps]|29.00750000000002|79.80028846153847|11.325000000000003|4.550961538461539|12.855122222222224|10.795663369963371|2.7047058823529397|-3.0697435897435845|10.414166666666667|2.6110989010988988|66.37611354998121|54.195869768830164|24.576470588235296|16.20769230769231\n",
      "\n",
      "obsolete. the pathway by which adenine, hypoxanthine and their nucleosides from purine nucleotides breakdown are converted back to purine nucleotides. the salvage pathway is important where there is no de-novo purine nucleotide biosynthesis. [goc:pz]|obsolete. the pathway by which adenine, hypoxanthine and their dna fragments are converted back to purine nucleotides. this salvage pathway is important where there is no de-novo dna synthesis. [goc:pz]|29.00750000000002|49.76250000000002|11.325000000000003|8.181666666666668|12.855122222222224|12.658427272727273|2.7047058823529397|-5.3626666666666765|10.414166666666667|6.387727272727272|66.37611354998121|56.4088497046341|24.576470588235296|20.333333333333336\n",
      "\n",
      "obsolete. the pathway by which adenine, hypoxanthine and their nucleosides from purine nucleotides breakdown are converted back to purine nucleotides. the salvage pathway is important where there is no de-novo purine nucleotide biosynthesis. [goc:pz]| obsolete. the pathway by which adenine, hypoxanthine and their nucleosides from purine nucleotides breakdown are converted back to purine nucleotides|29.00750000000002|26.97750000000002|11.325000000000003|12.105|12.855122222222224|13.512554545454547|2.7047058823529397|8.48952380952381|10.414166666666667|11.901818181818179|66.37611354998121|73.38155456243756|24.576470588235296|25.152380952380955\n",
      "\n",
      "interference or disruption of cognitive processes. this term encompasses a large number of problems and issues associated with intellectual functioning and information processing. 2005|obstruction or delay of cognitive transforms.  this term includes a large number of problems and issues unite with person serve and collection walk.  2005|18.940000000000026|74.39217948717952|12.605000000000004|5.036153846153844|12.586216666666667|11.246592307692307|2.444999999999993|-4.980000000000004|13.77375|5.188846153846153|65.13532912329528|59.91578840339164|24.866666666666667|20.38974358974359\n",
      "\n",
      "interference or disruption of cognitive processes. this term encompasses a large number of problems and issues associated with intellectual functioning and information processing. 2005|interference or disruption of mental processes. this term encompasses a large number of problems and issues associated with intellectual functioning and information processing.|18.940000000000026|15.140289855072496|12.605000000000004|13.052173913043479|12.586216666666667|12.586216666666667|2.444999999999993|1.017391304347825|13.77375|12.596250000000005|65.13532912329528|65.13532912329528|24.866666666666667|25.675362318840584\n",
      "\n",
      "interference or disruption of cognitive processes. this term encompasses a large number of problems and issues associated with intellectual functioning and information processing. 2005| disturbance|18.940000000000026|77.90500000000002|12.605000000000004|2.890000000000004|12.586216666666667|19.5753|2.444999999999993|-112.72|13.77375|0.4800000000000004|65.13532912329528|31.29|24.866666666666667|20.8\n",
      "\n",
      "pan-dr epitope (padre) 965.10 is a helper peptide. padre peptides have been shown the capacity to deliver help for antibody responses in vivo. they were also found to be able to provide significant helper t-cell activity in vivo. acts as an adjuvant.|pan-dr site (padre) 965.10 is a helper peptide.  padre amide have been shown the tolerance to produce help for the protein manner in vivo.  they were also found to be able to provide significant helper t-cell activity in vivo.  acts as an adjuvant.|56.71571428571431|81.3489855072464|7.08761904761905|3.817391304347826|10.823512121212122|11.020785|-13.025714285714287|-12.660000000000004|7.419469696969696|2.798750000000002|52.66891825355824|51.09635603445709|18.99047619047619|16.979710144927534\n",
      "\n",
      "pan-dr epitope (padre) 965.10 is a helper peptide. padre peptides have been shown the capacity to deliver help for antibody responses in vivo. they were also found to be able to provide significant helper t-cell activity in vivo. acts as an adjuvant.|pan-dr epitope 965.10 is a helper peptide. padres have been shown the capacity to deliver help for antibody responses in vivo. they were also found to be able to provide significant help.|56.71571428571431|60.22025000000002|7.08761904761905|6.449750000000005|10.641645454545454|10.095452941176472|-13.025714285714287|-17.401249999999997|5.5861363636363635|4.015000000000001|52.66891825355824|50.453608988852324|18.99047619047619|18.81\n",
      "\n",
      "pan-dr epitope (padre) 965.10 is a helper peptide. padre peptides have been shown the capacity to deliver help for antibody responses in vivo. they were also found to be able to provide significant helper t-cell activity in vivo. acts as an adjuvant.| pan epitope|56.71571428571431|90.99000000000004|7.08761904761905|1.3133333333333361|10.641645454545454|15.6774|-13.025714285714287|-77.10666666666665|5.5861363636363635|-5.300000000000001|52.66891825355824|31.29|18.99047619047619|14.533333333333331\n",
      "\n",
      "a surgical camera and accessories is a device intended to be used to record operative procedures.|a medical device camera and the criminal is a device convey to be used to record detective proceeding.|24.22750000000002|47.30000000000004|11.867500000000003|8.89777777777778|10.35135|11.547077777777778|-6.864999999999998|-5.12222222222222|10.414375|9.55|62.58|66.37611354998121|23.200000000000003|23.6\n",
      "\n",
      "a surgical camera and accessories is a device intended to be used to record operative procedures.|a surgical camera and accessory is a device intended to be used to record operative procedures.|24.22750000000002|24.22750000000002|11.867500000000003|11.867500000000003|10.35135|10.559864705882354|-6.864999999999998|-7.232500000000002|10.414375|4.984705882352941|62.58|62.58|23.200000000000003|23.200000000000003\n",
      "\n",
      "a surgical camera and accessories is a device intended to be used to record operative procedures.| is device|24.22750000000002|119.19000000000003|11.867500000000003|-2.619999999999999|10.35135|15.6774|-6.864999999999998|-81.02666666666666|10.414375|-7.654999999999999|62.58|31.29|23.200000000000003|14.533333333333331\n",
      "\n",
      "bai dou kou|bai dou kou|119.19000000000003|119.19000000000003|-2.619999999999999|-2.619999999999999|19.5753|19.5753|-81.02666666666666|-81.02666666666666|-5.800000000000001|-5.800000000000001|0.0|0.0|1.2000000000000002|1.2000000000000002\n",
      "\n",
      "bai dou kou|seizure drug|119.19000000000003|77.90500000000002|-2.619999999999999|2.890000000000004|19.5753|19.5753|-81.02666666666666|-112.72|-5.800000000000001|-1.0899999999999999|0.0|31.29|1.2000000000000002|20.8\n",
      "\n",
      "bai dou kou| white radish|119.19000000000003|119.19000000000003|-2.619999999999999|-2.619999999999999|19.5753|11.7299|-81.02666666666666|-75.14666666666666|-5.800000000000001|-4.122500000000002|0.0|31.29|1.2000000000000002|14.533333333333331\n",
      "\n",
      "the collection of afferent neurons that serve to connect the hair cells of the vestibular sensory end organs with the brain.|the grouping of nerve neurons that serve to hit the hair cells of the vestibular sensory end meat to the brain.|63.23464285714289|83.37750000000003|7.0478571428571435|4.238333333333333|8.43762380952381|7.685719047619047|0.9295238095238112|-2.710476190476193|12.17142857142857|9.255714285714284|58.53822981607831|44.250742366654144|17.53333333333333|11.81904761904762\n",
      "\n",
      "the collection of afferent neurons that serve to connect the hair cells of the vestibular sensory end organs with the brain.|the collection of afferent neurons that serve to connect the hair cells of the sensory end organs with the brain.|63.23464285714289|74.01500000000001|7.0478571428571435|5.419999999999998|8.43762380952381|7.91682380952381|0.9295238095238112|-1.6699999999999982|12.17142857142857|4.902857142857144|58.53822981607831|54.195869768830164|17.53333333333333|16.0\n",
      "\n",
      "the collection of afferent neurons that serve to connect the hair cells of the vestibular sensory end organs with the brain.| the collection of nerve cells that innervate the vestibular sensory end organs|63.23464285714289|50.470769230769264|7.0478571428571435|9.44923076923077|8.43762380952381|11.098042857142858|0.9295238095238112|7.987692307692306|12.17142857142857|8.783571428571431|58.53822981607831|69.96656701596841|17.53333333333333|20.58461538461539\n",
      "\n",
      "increase in size of the right atrium. [hpo:probinson]|increase in size of the right court.  [ hop: robinson]|65.30000000000001|108.96159090909092|5.145|-0.5722727272727273|10.877477777777777|8.538833333333333|-40.19|-30.29818181818182|2.8000000000000007|-0.4523333333333319|38.32226702584281|31.29|16.6|9.472727272727274\n",
      "\n",
      "increase in size of the right atrium. [hpo:probinson]|increased size of the right atrium. [hpo:probinson]|65.30000000000001|58.25392857142859|5.145|6.003571428571426|10.877477777777777|12.631922222222224|-40.19|-45.931428571428576|2.8000000000000007|2.8000000000000007|38.32226702584281|38.32226702584281|16.6|18.54285714285714\n",
      "\n",
      "increase in size of the right atrium. [hpo:probinson]| increase|65.30000000000001|120.20500000000001|5.145|-3.01|10.877477777777777|19.5753|-40.19|-121.53999999999999|2.8000000000000007|-4.229999999999997|38.32226702584281|31.29|16.6|20.8\n",
      "\n",
      "a lozenge containing an extract from the lactobacillus brevis (l. brevis) with potential anti-inflammatory activity. as l. brevis cd2 contains high levels of arginine deiminase, which catalyzes the conversion of arginine to citrulline and ammonia, administration of this lozenge leads to hydrolysis of arginine in the oral cavity. the growth of bacteria, which depends on arginine, is halted, polyamine biosynthesis is reduced and the production of nitric oxide (no) is reduced. the reduction in no generation may further prevent inflammation in the oral cavity. therefore, this agent may be able to reduce chemo- and radiotherapy-induced mucositis. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c99229\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c99229\" nci thesaurus)|a dose defends an choose from the bacteria brevis (l. brevis) with potential medicine activity.  as l.  previous cd2 contains high levels of arginine deiminase, which change_state the change of arginine to citrulline and liquid, a justice of this dose leads to hydrolysis of arginine in the oral structure.  the growth of bacteria, which trust on arginine, is checked, polyamine synthesis is reduced and the display of nitric oxide (no) is reduced.  the change in no production may further prevent burning in the oral structure.  therefore, this agent may be able to reduce chemo- and radiotherapy-induced mucositis.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c99229 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c99229 '' nice wordbook)|35.810333333333375|62.35251162790698|10.053185185185185|6.698883720930233|12.88511038961039|13.290629870129871|1.791111111111114|-0.09581395348837418|19.140233766233763|9.25742207792208|59.368600792001146|57.69590921373889|22.880000000000003|19.253953488372094\n",
      "\n",
      "a lozenge containing an extract from the lactobacillus brevis (l. brevis) with potential anti-inflammatory activity. as l. brevis cd2 contains high levels of arginine deiminase, which catalyzes the conversion of arginine to citrulline and ammonia, administration of this lozenge leads to hydrolysis of arginine in the oral cavity. the growth of bacteria, which depends on arginine, is halted, polyamine biosynthesis is reduced and the production of nitric oxide (no) is reduced. the reduction in no generation may further prevent inflammation in the oral cavity. therefore, this agent may be able to reduce chemo- and radiotherapy-induced mucositis. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c99229\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c99229\" nci thesaurus)|a lozenge containing an extract from a bacterial strain with potential anti-inflammatory activity. as l. brevis contains high levels of arginine deiminase, which catalyzes the conversion of the molecule to citrulline and ammonia,|35.810333333333375|21.342727272727302|10.053185185185185|13.015151515151516|12.88511038961039|13.527357142857145|1.791111111111114|8.370909090909091|19.140233766233763|13.426857142857138|59.368600792001146|74.48509850970193|22.880000000000003|25.006060606060608\n",
      "\n",
      "a lozenge containing an extract from the lactobacillus brevis (l. brevis) with potential anti-inflammatory activity. as l. brevis cd2 contains high levels of arginine deiminase, which catalyzes the conversion of arginine to citrulline and ammonia, administration of this lozenge leads to hydrolysis of arginine in the oral cavity. the growth of bacteria, which depends on arginine, is halted, polyamine biosynthesis is reduced and the production of nitric oxide (no) is reduced. the reduction in no generation may further prevent inflammation in the oral cavity. therefore, this agent may be able to reduce chemo- and radiotherapy-induced mucositis. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c99229\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c99229\" nci thesaurus)| a|35.810333333333375|162.505|10.053185185185185|-8.91|12.88511038961039|14.311966666666669|1.791111111111114|-142.12|19.140233766233763|-15.219999999999999|59.368600792001146|0.0|22.880000000000003|0.8\n",
      "\n",
      "leaving vocational training programme in an appropriate manner to enter the next level of school education, work, employment or other domains of adult life.|leaving activity training show in an assume a kind to enter the next level of school upbringing, work, action or other class of adult life.|39.55500000000001|65.55550000000002|10.723333333333333|7.221|10.74815|8.6661|7.9183333333333366|3.367999999999995|16.082500000000003|12.170800000000007|79.77416029015912|69.96656701596841|26.466666666666665|21.0\n",
      "\n",
      "leaving vocational training programme in an appropriate manner to enter the next level of school education, work, employment or other domains of adult life.|leaving vocational training programme in an appropriate manner to enter the next level of school education, work, or other domains of adult life.|39.55500000000001|44.35380434782613|10.723333333333333|9.929782608695653|10.74815|10.15295|7.9183333333333366|5.961739130434779|16.082500000000003|8.31625|79.77416029015912|76.64453405168562|26.466666666666665|25.469565217391306\n",
      "\n",
      "leaving vocational training programme in an appropriate manner to enter the next level of school education, work, employment or other domains of adult life.| completing|39.55500000000001|77.90500000000002|10.723333333333333|2.890000000000004|10.74815|19.5753|7.9183333333333366|-115.66|16.082500000000003|-1.0899999999999999|79.77416029015912|31.29|26.466666666666665|20.8\n",
      "\n",
      "a series of intracellular molecular signals mediated by torc1; tor (target of rapamycin) in complex with at least raptor (regulatory-associated protein of tor), or orthologs of, and other signaling components. [goc:lb]|a group of intracellular molecular tell lie by torc1; tor (target of rapamycin) in whole with at least bird (regulatory-associated protein of tor), or orthologs of, and other tell part.  [ goc: lb]|19.173467741935525|55.21529411764709|14.43564516129032|9.781176470588235|14.02459696969697|10.981464705882354|16.56258064516129|10.950588235294116|11.939999999999998|8.265|85.69119412168324|62.58|25.554838709677423|16.211764705882356\n",
      "\n",
      "a series of intracellular molecular signals mediated by torc1; tor (target of rapamycin) in complex with at least raptor (regulatory-associated protein of tor), or orthologs of, and other signaling components. [goc:lb]|a series of intracellular molecular signals mediated by torc1; tor (target of rapamycin) in complex with at least two other proteins. [goc:lb]|19.173467741935525|45.69727272727275|14.43564516129032|9.618181818181817|14.02459696969697|13.442533333333335|16.56258064516129|5.698181818181819|11.939999999999998|7.138750000000002|85.69119412168324|69.96656701596841|25.554838709677423|22.581818181818182\n",
      "\n",
      "a series of intracellular molecular signals mediated by torc1; tor (target of rapamycin) in complex with at least raptor (regulatory-associated protein of tor), or orthologs of, and other signaling components. [goc:lb]| a series of intracellular molecular signals mediated by torc1; tor (target of rapamycin) in complex with at least raptor (regulatory-associated protein of tor), or orthologs of, and other signaling components.|19.173467741935525|21.902500000000032|14.43564516129032|14.055000000000003|14.02459696969697|14.02459696969697|16.56258064516129|15.234838709677419|11.939999999999998|11.511818181818178|85.69119412168324|85.69119412168324|25.554838709677423|25.554838709677423\n",
      "\n",
      "a visual estimation of the percent or fraction of the volume of blood ejected from the left ventricle during left ventricular systole.|a functional concept, judgment of the percent or part of the volume of blood discharge from the left chamber during left ventricular pulse.|45.69727272727275|66.42336956521743|9.618181818181817|6.851521739130437|11.187245454545454|10.955995652173913|3.2927272727272765|4.17217391304348|13.548181818181817|13.619999999999997|69.96656701596841|66.37611354998121|22.581818181818182|20.252173913043478\n",
      "\n",
      "a visual estimation of the percent or fraction of the volume of blood ejected from the left ventricle during left ventricular systole.|a visual estimation of the percent or fraction of blood ejected from the left ventricle during left ventricular systole.|45.69727272727275|41.350394736842105|9.618181818181817|9.851842105263156|11.187245454545454|11.238|3.2927272727272765|0.717894736842112|13.548181818181817|7.5909999999999975|69.96656701596841|66.37611354998121|22.581818181818182|22.74736842105263\n",
      "\n",
      "a visual estimation of the percent or fraction of the volume of blood ejected from the left ventricle during left ventricular systole.| a visual estimation of the blood volume ejected at the moment of left ventricular systole|45.69727272727275|42.545000000000016|9.618181818181817|11.3|11.187245454545454|11.910288235294118|3.2927272727272765|9.43|13.548181818181817|8.403529411764705|69.96656701596841|82.78555852321104|22.581818181818182|23.900000000000002\n",
      "\n",
      "any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an anisomycin stimulus. [goc:mah]|any walk that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme display, gene squeeze, etc..) as a result of an anisomycin stimulus.  [ goc: mah]|53.245833333333366|77.09660714285717|8.482500000000002|4.679642857142859|11.632172727272728|10.700398039215688|1.833750000000002|-8.124571428571421|8.22909090909091|3.907843137254904|65.13532912329528|49.473833993334296|20.516666666666666|14.928571428571429\n",
      "\n",
      "any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an anisomycin stimulus. [goc:mah]|any process that results in a change in state or activity of cellular constituents (in terms of movement, secretion, enzyme production, etc.). [goc:mah]|53.245833333333366|51.92289855072465|8.482500000000002|7.9217391304347835|11.632172727272728|12.4673|1.833750000000002|-5.118260869565219|8.22909090909091|7.616399999999999|65.13532912329528|59.91578840339164|20.516666666666666|22.197101449275365\n",
      "\n",
      "any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an anisomycin stimulus. [goc:mah]| Any process that results in a change in state or activity of a cell as a result of an anisomycin stimulus.|53.245833333333366|64.9245454545455|8.482500000000002|6.936363636363637|11.632172727272728|9.699073913043478|1.833750000000002|-3.6563636363636363|8.22909090909091|2.1360869565217406|65.13532912329528|58.53822981607831|20.516666666666666|17.127272727272725\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism. [goc:go_curators]|any walk that changes or change the ratio, rate or extent of the chemical force and path within a cell or a system.  [ goc: go_curators]|36.03|80.33250000000004|11.215|5.408333333333335|11.8357|9.532135897435897|7.9183333333333366|2.0296296296296354|8.935200000000002|2.105641025641024|76.64453405168562|62.58|24.8|17.25185185185185\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism. [goc:go_curators]|any process that activates or increases the frequency, rate or extent of chemical reactions and pathways within a cell or an organism. [goc:go_curators]|36.03|33.31902173913048|11.215|11.468913043478263|11.8357|12.4673|7.9183333333333366|7.7513043478260855|8.935200000000002|8.558399999999999|76.64453405168562|76.64453405168562|24.8|25.469565217391306\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism. [goc:go_curators]| Any process that increases the frequency of chemical reactions|36.03|44.405|11.215|9.55|11.8357|14.230281818181819|7.9183333333333366|2.7399999999999984|8.935200000000002|8.048181818181817|76.64453405168562|76.64453405168562|24.8|28.0\n",
      "\n",
      "interacting selectively and non-covalently with phosphatidylinositol-3-phosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 3' position. [goc:bf, pmid:10209156, pmid:11395417, pmid:11557775]|act selectively and non-covalently with phosphatidylinositol-3-phosphate, a word of phosphatidylinositol in which the inositol ring is phosphorylated at the 3 ' position.  [ goc : bf , pmid:10209156 , pmid:11395417 , pmid:11557775 ]|24.94750000000002|77.60941176470591|12.885000000000002|6.657647058823532|13.917685714285716|12.827690804597701|26.4176|17.003529411764706|19.549285714285716|14.099540229885058|62.58|54.195869768830164|17.8|13.858823529411765\n",
      "\n",
      "interacting selectively and non-covalently with phosphatidylinositol-3-phosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 3' position. [goc:bf, pmid:10209156, pmid:11395417, pmid:11557775]|interacting selectively and not binding with a molecule of protein in which the inositol ring is phosphorylated at the 3' position. [goc:bf, pmid:10395417,75]|24.94750000000002|44.35380434782613|12.885000000000002|9.929782608695653|13.917685714285716|11.8357|26.4176|9.285217391304343|19.549285714285716|9.500400000000003|62.58|62.58|17.8|18.51304347826087\n",
      "\n",
      "interacting selectively and non-covalently with phosphatidylinositol-3-phosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 3' position. [goc:bf, pmid:10209156, pmid:11395417, pmid:11557775]| Interacting differently with one or more of the phospholipids|24.94750000000002|52.86500000000001|12.885000000000002|8.370000000000001|13.917685714285716|11.359372727272728|26.4176|2.1520000000000046|19.549285714285716|7.620000000000001|62.58|54.195869768830164|17.8|16.0\n",
      "\n",
      "automated brachytherapy applicators designed to deliver therapeutic radioactive sources to, retrieve them from, and/or hold them in the uterine cavity. the applicator consists of a hollow metal tube (i.e., tandem), which temporarily holds the radioactive source, and two semioval, cuplike structures (i.e., ovoids) placed on either side of the cervix. the applicator holds the radioactive source during treatment and includes tiny shields to reduce the radiation dose to the rectum and bladder. the tandem is fixed inside a hollow plastic tube (i.e., smitt sleeve) previously inserted into the uterine cavity. tandem/ovoid interstitial/intracavitary applicators are used to treat cervical cancer.|a change procedure device designed to produce medicine radioactive sources to, bring them , and/or hold them in the uterine structure.  the device is of a hollow metal tube (i.e., tandem), which temporarily holds the radioactive source, and two seminal, cuplike system (i.e., ovoids) placed on either side of the cervix.  the device holds the radioactive source during care and includes tiny shields to reduce the therapy dose to the rectum and bag.  the tandem is fixed inside a hollow plastic tube (i.e., smitt sleeve) previously add into the uterine structure.  tandem/ovoid interstitial/intracavitary device is used to treat cervical cancer.|35.24306818181819|63.00371794871796|10.393156565656568|6.624615384615385|12.924261584158417|11.734214285714286|-0.36121212121211954|-3.510000000000005|15.577623762376234|7.953333333333333|62.58|58.53822981607831|22.693939393939395|19.620512820512822\n",
      "\n",
      "automated brachytherapy applicators designed to deliver therapeutic radioactive sources to, retrieve them from, and/or hold them in the uterine cavity. the applicator consists of a hollow metal tube (i.e., tandem), which temporarily holds the radioactive source, and two semioval, cuplike structures (i.e., ovoids) placed on either side of the cervix. the applicator holds the radioactive source during treatment and includes tiny shields to reduce the radiation dose to the rectum and bladder. the tandem is fixed inside a hollow plastic tube (i.e., smitt sleeve) previously inserted into the uterine cavity. tandem/ovoid interstitial/intracavitary applicators are used to treat cervical cancer.|the applicator consists of a hollow metal tube (i.e., tandem), which temporarily holds the radioactive source to, retrieve them from, and/or hold them in the uterine cavity.|35.24306818181819|58.983750000000015|10.393156565656568|6.709166666666668|12.924261584158417|11.66197142857143|-0.36121212121211954|-11.620740740740736|15.577623762376234|9.288214285714286|62.58|49.473833993334296|22.693939393939395|17.514814814814816\n",
      "\n",
      "automated brachytherapy applicators designed to deliver therapeutic radioactive sources to, retrieve them from, and/or hold them in the uterine cavity. the applicator consists of a hollow metal tube (i.e., tandem), which temporarily holds the radioactive source, and two semioval, cuplike structures (i.e., ovoids) placed on either side of the cervix. the applicator holds the radioactive source during treatment and includes tiny shields to reduce the radiation dose to the rectum and bladder. the tandem is fixed inside a hollow plastic tube (i.e., smitt sleeve) previously inserted into the uterine cavity. tandem/ovoid interstitial/intracavitary applicators are used to treat cervical cancer.| The uterus|35.24306818181819|90.99000000000004|10.393156565656568|1.3133333333333361|12.924261584158417|15.6774|-0.36121212121211954|-79.06666666666666|15.577623762376234|-6.477499999999999|62.58|31.29|22.693939393939395|14.533333333333331\n",
      "\n",
      "orthoses designed to stabilize the hand, provide hand immobilization and/or support while keeping its functional structure and position while permitting the movement of the fingers and thumb. these orthoses typically consist of a device that is placed encircling the distal segment of the forearm and is attached to a rigid component used to support the hand. hand orthoses are used mainly in patients with severe weakness or complete paralysis of the hand muscles. static hand orthoses used for therapeutic purposes (e.g., to avoid hyperextension) and/or including attachments intended for functional activities are also available.|orthoses designed to change the hand, provide hand restraint and/or support while keeping its functional structure and position while permit the change of the search and thumb.  these orthoses typically be on a device that is placed bind the distal part of the arm and is taken  a rigid part used to support the hand.  hand orthoses are used mainly in case with severe weakness or complete dysfunction of the hand muscles.  noise hand orthoses used for medicine decide (e.g., to avoid extension) and/or including joining convey for functional trait are also available.|40.20500000000001|69.79474226804126|10.987568389057753|6.9668630338733415|12.193163829787235|10.184020471281297|11.673617021276591|7.251134020618558|16.926489361702124|8.223107511045654|80.21128224882081|69.96656701596841|24.945896656534956|19.975846833578796\n",
      "\n",
      "orthoses designed to stabilize the hand, provide hand immobilization and/or support while keeping its functional structure and position while permitting the movement of the fingers and thumb. these orthoses typically consist of a device that is placed encircling the distal segment of the forearm and is attached to a rigid component used to support the hand. hand orthoses are used mainly in patients with severe weakness or complete paralysis of the hand muscles. static hand orthoses used for therapeutic purposes (e.g., to avoid hyperextension) and/or including attachments intended for functional activities are also available.|orthoses designed to stabilize the hand, provide hand immobilization and/or support while keeping its functional structure and position while permitting the movement of the fingers and thumb. these orthoses typically consist of a device that is placed encircling the outer ring around the forearm and is attached to|40.20500000000001|37.950000000000045|10.987568389057753|13.928333333333335|12.193163829787235|11.618842857142857|11.673617021276591|20.61916666666667|16.926489361702124|16.484693877551017|80.21128224882081|103.77718969022045|24.945896656534956|27.933333333333334\n",
      "\n",
      "orthoses designed to stabilize the hand, provide hand immobilization and/or support while keeping its functional structure and position while permitting the movement of the fingers and thumb. these orthoses typically consist of a device that is placed encircling the distal segment of the forearm and is attached to a rigid component used to support the hand. hand orthoses are used mainly in patients with severe weakness or complete paralysis of the hand muscles. static hand orthoses used for therapeutic purposes (e.g., to avoid hyperextension) and/or including attachments intended for functional activities are also available.| stabilizing device|40.20500000000001|34.59000000000003|10.987568389057753|9.180000000000003|12.193163829787235|19.6249|11.673617021276591|-63.386666666666656|16.926489361702124|2.942499999999999|80.21128224882081|44.250742366654144|24.945896656534956|27.866666666666664\n",
      "\n",
      "the determination of the ratio of glutathione-s-transferase compared to creatinine present in a sample. the measurement may be expressed as a ratio or percentage.|the choice of the ratio of glutathione-s-transfers compared to creatine present in a sample.  the measurement may be mailed as a ratio or assets.|33.04000000000002|66.40066666666667|10.638333333333335|6.068000000000001|10.961684615384616|9.931048148148149|-2.9450000000000003|-7.0608|9.525769230769232|3.6544444444444437|59.91578840339164|57.127462747788826|21.53333333333333|19.333333333333336\n",
      "\n",
      "the determination of the ratio of glutathione-s-transferase compared to creatinine present in a sample. the measurement may be expressed as a ratio or percentage.|the determination of the ratio of glutathione-s-transferase compared to creatinine present in a sample. the measurement may be expressed as ratio or percentage.|33.04000000000002|29.853333333333353|10.638333333333335|11.000000000000004|10.961684615384616|11.354058974358974|-2.9450000000000003|-3.073043478260871|9.525769230769232|7.359102564102564|59.91578840339164|59.91578840339164|21.53333333333333|22.197101449275365\n",
      "\n",
      "the determination of the ratio of glutathione-s-transferase compared to creatinine present in a sample. the measurement may be expressed as a ratio or percentage.| the measurement may be expressed as a ratio or percentage.|33.04000000000002|70.50704545454548|10.638333333333335|4.791363636363638|10.961684615384616|11.8291|-2.9450000000000003|-27.090909090909093|9.525769230769232|1.1950000000000003|59.91578840339164|44.250742366654144|21.53333333333333|16.745454545454546\n",
      "\n",
      "stage 0 includes: tis, n0, m0. tis: carcinoma in situ. n0: no regional lymph node metastasis. m0: no distant metastasis. (from ajcc 7th ed.) check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c88089\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c88089\" nci thesaurus)|stage 0 includes: tis, n0, m0.  tis: cancer in situ.  n0: no regional lymph node metastasis.  m0: no distant metastasis.  ( from ajcc 7th ed.) check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c88089 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c88089 '' nice wordbook)|88.87423076923078|94.86804195804197|1.5511111111111155|1.0781818181818181|15.7766|17.109393750000002|-49.558888888888866|-32.33163636363637|24.875833333333333|6.340781249999999|28.782613742434055|33.61085161304077|13.32991452991453|12.6013986013986\n",
      "\n",
      "stage 0 includes: tis, n0, m0. tis: carcinoma in situ. n0: no regional lymph node metastasis. m0: no distant metastasis. (from ajcc 7th ed.) check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c88089\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c88089\" nci thesaurus)|stage 0 includes: tis, no regional lymph node metastasis. (from ajcc 7th ed.) check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c88089\" active|88.87423076923078|93.90164705882354|1.5511111111111155|1.0065882352941173|15.734085714285715|15.486788888888892|-49.558888888888866|-30.680000000000007|24.447261904761902|23.62833333333333|28.782613742434055|27.986626806387367|13.32991452991453|10.771764705882353\n",
      "\n",
      "stage 0 includes: tis, n0, m0. tis: carcinoma in situ. n0: no regional lymph node metastasis. m0: no distant metastasis. (from ajcc 7th ed.) check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c88089\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c88089\" nci thesaurus)| stage 0 include: tis, n0, m0. tis: carcinoma in situ. n0: no regional lymph node metastasis. m0: no distant metastasis.|88.87423076923078|85.74342857142858|1.5511111111111155|2.3432380952380996|15.702200000000001|16.711476623376626|-49.558888888888866|-42.196190476190466|24.125833333333333|-0.16220779220779136|28.782613742434055|37.022827282637394|13.32991452991453|15.013333333333334\n",
      "\n",
      "a disorder characterized by an abnormal communication between the oral cavity and another organ or anatomic site.|a change distinguishes by an abnormal connection between the oral structure and another organ or anatomic site.|4.125147058823558|33.98397058823531|14.795588235294119|10.630882352941178|11.910288235294118|10.981464705882354|-1.2729411764705887|-1.9647058823529377|13.667647058823526|13.11352941176471|69.96656701596841|66.37611354998121|26.929411764705886|24.576470588235296\n",
      "\n",
      "a disorder characterized by an abnormal communication between the oral cavity and another organ or anatomic site.|a disorder characterized by an abnormal communication between the mouth and another body part or site.|4.125147058823558|29.515000000000015|14.795588235294119|11.130000000000003|11.910288235294118|9.631041176470589|-1.2729411764705887|-4.660000000000004|13.667647058823526|6.9241176470588215|69.96656701596841|58.53822981607831|26.929411764705886|20.700000000000003\n",
      "\n",
      "a disorder characterized by an abnormal communication between the oral cavity and another organ or anatomic site.| an abnormality|4.125147058823558|34.59000000000003|14.795588235294119|9.180000000000003|11.910288235294118|15.6774|-1.2729411764705887|-71.22666666666666|13.667647058823526|-1.7674999999999983|69.96656701596841|31.29|26.929411764705886|14.533333333333331\n",
      "\n",
      "eighteen-carbon essential fatty acids that contain three double bonds.|eighteen-carbon thing fatty acids that contain three double bonds.|33.067500000000024|51.867500000000035|9.765|7.142777777777777|13.6065|12.0275|-25.271111111111104|-27.88444444444444|11.829999999999998|9.945999999999998|54.195869768830164|49.473833993334296|28.466666666666665|24.022222222222226\n",
      "\n",
      "eighteen-carbon essential fatty acids that contain three double bonds.|fat acids that contain three double bonds.|33.067500000000024|82.42535714285715|9.765|2.6321428571428562|13.6065|11.7299|-25.271111111111104|-53.49142857142857|11.829999999999998|1.7650000000000006|54.195869768830164|38.32226702584281|28.466666666666665|18.54285714285714\n",
      "\n",
      "eighteen-carbon essential fatty acids that contain three double bonds.| An eighteen-carbon fat-soluble vitamin|33.067500000000024|-1.2799999999999727|9.765|14.68|13.6065|13.902050000000001|-25.271111111111104|-16.863999999999997|11.829999999999998|3.1762499999999996|54.195869768830164|54.195869768830164|28.466666666666665|26.0\n",
      "\n",
      "a semi-quantitative microscopic finding indicating that 20 percent or less of the cells in sample are detected following staining using an anti-ki-67 antibody.|a semi-quantitative microscopic finding inform that 20 percent or less of the cells in a sample are spy following dye using an anti-ki-67 protein.|36.997282608695684|64.22999999999999|10.955869565217395|7.28166666666667|13.0873|12.8211|9.285217391304343|5.468333333333337|16.315599999999996|13.308461538461536|69.96656701596841|62.58|21.991304347826087|18.133333333333333\n",
      "\n",
      "a semi-quantitative microscopic finding indicating that 20 percent or less of the cells in sample are detected following staining using an anti-ki-67 antibody.|a semi-quantitative microscopic finding indicating that 20 percent or less of the cells in sample are detected following staining with an anti-ki-67 antibody.|36.997282608695684|36.997282608695684|10.955869565217395|10.955869565217395|13.0873|12.783607692307694|9.285217391304343|9.285217391304343|16.315599999999996|9.344615384615388|69.96656701596841|69.96656701596841|21.991304347826087|21.991304347826087\n",
      "\n",
      "a semi-quantitative microscopic finding indicating that 20 percent or less of the cells in sample are detected following staining using an anti-ki-67 antibody.| a semi-quantitative microscopic finding indicating that 20 percent or less of the cells in sample are stained following staining using an antibody against Ki-67 protein|36.997282608695684|30.76807692307696|10.955869565217395|15.426923076923078|13.0873|13.484228571428572|9.285217391304343|21.4076923076923|16.315599999999996|16.96107142857143|69.96656701596841|108.39173953766033|21.991304347826087|28.861538461538466\n",
      "\n",
      "wechsler adult intelligence scale, 4th edition. the subject either names objects presented visually or defines words that are presented visually and orally.|wechsler adult intelligence scale, 4th type.  the term either name objects presented visually or choose words that are presented visually and orally.|34.037121212121235|59.279420289855096|10.333636363636366|6.895652173913046|12.0771|11.56850579710145|-4.281818181818181|-6.140869565217393|12.329999999999998|8.001159420289856|65.13532912329528|57.127462747788826|26.56969696969697|20.457971014492756\n",
      "\n",
      "wechsler adult intelligence scale, 4th edition. the subject either names objects presented visually or defines words that are presented visually and orally.|wechsler adult intelligence scale, 4th edition. the subject either names objects presented visually or isolating them from being heard.|34.037121212121235|40.11192982456143|10.333636363636366|9.237894736842104|12.0771|11.862166666666667|-4.281818181818181|-10.218947368421055|12.329999999999998|8.985833333333332|65.13532912329528|59.91578840339164|26.56969696969697|25.69122807017544\n",
      "\n",
      "wechsler adult intelligence scale, 4th edition. the subject either names objects presented visually or defines words that are presented visually and orally.| wechsler adult intelligence scale. the ability to name objects presented visually or define words that are presented visually and orally|34.037121212121235|35.0346428571429|10.333636363636366|10.981190476190477|12.0771|12.794827272727273|-4.281818181818181|4.849523809523809|12.329999999999998|9.332727272727272|65.13532912329528|73.38155456243756|26.56969696969697|25.152380952380955\n",
      "\n",
      "a response indicating that an individual has or had an occasional cough.|a phrase informs that an organism has or had an occasional cough.|38.595|73.84500000000001|9.366666666666667|4.450000000000003|9.495033333333335|9.495033333333335|-19.443333333333328|-22.873333333333328|8.120000000000001|5.372500000000002|44.250742366654144|38.32226702584281|15.733333333333333|12.4\n",
      "\n",
      "a response indicating that an individual has or had an occasional cough.|a response indicating an individual has or had an occasional cough.|38.595|32.05250000000001|9.366666666666667|10.155000000000001|9.495033333333335|10.513266666666667|-19.443333333333328|-22.81454545454546|8.120000000000001|3.942499999999999|44.250742366654144|44.250742366654144|15.733333333333333|16.745454545454546\n",
      "\n",
      "a response indicating that an individual has or had an occasional cough.| a response indicating that an individual has or had a cough|38.595|60.70500000000001|9.366666666666667|7.773333333333333|9.495033333333335|10.354376923076924|-19.443333333333328|-0.16666666666666075|8.120000000000001|3.5476923076923086|44.250742366654144|54.195869768830164|15.733333333333333|14.8\n",
      "\n",
      "this gene plays a role in the modulation of the phosphorylation of the c-terminal domain (ctd) of dna-directed rna polymerase ii subunit rpb1 (polr2a).|this gene plays a role in the revision of the phosphorylation of the c-terminal class (ctd) of dna-directed rna enzyme ii subunit rpb1 (polr2a).|53.655|67.75500000000001|8.756666666666668|6.790000000000003|14.035715384615385|13.428407692307694|6.693333333333335|4.978333333333335|13.489615384615384|12.221538461538465|58.53822981607831|54.195869768830164|16.46666666666667|14.8\n",
      "\n",
      "this gene plays a role in the modulation of the phosphorylation of the c-terminal domain (ctd) of dna-directed rna polymerase ii subunit rpb1 (polr2a).|this gene plays a role in the modulation of the phosphorylation site on rna polymerase ii subunit rpb1 (polr2a).|53.655|68.0661842105263|8.756666666666668|6.125526315789475|14.035715384615385|13.6065|6.693333333333335|-1.757894736842104|13.489615384615384|5.235999999999997|58.53822981607831|44.250742366654144|16.46666666666667|12.221052631578948\n",
      "\n",
      "this gene plays a role in the modulation of the phosphorylation of the c-terminal domain (ctd) of dna-directed rna polymerase ii subunit rpb1 (polr2a).| This gene plays a role in the modulation of the phosphorylation of the protein CTAK domain of RNA polymerase II subunit Rpb1|53.655|54.750869565217414|8.756666666666668|11.336521739130436|14.035715384615385|14.037733333333335|6.693333333333335|13.718260869565214|13.489615384615384|11.176250000000003|58.53822981607831|76.64453405168562|16.46666666666667|19.63478260869565\n",
      "\n",
      "a appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. it is also considered to be among the safest for patients with hypertension. (from ama drug evaluations annual, 1994, p2290)|a craving depressant considered to produce less central nervous system trouble than most drugs in this medicine concept.  it is also considered to be among the safest in case with hypertension.  ( from ama drug appraisal plant, 1994, p2290)|40.36254385964915|69.15845528455286|10.776315789473689|7.008292682926832|12.418226315789473|11.238|10.209473684210526|7.024390243902435|9.472894736842104|6.649000000000001|78.74477315987392|74.48509850970193|25.066666666666666|22.052032520325202\n",
      "\n",
      "a appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. it is also considered to be among the safest for patients with hypertension. (from ama drug evaluations annual, 1994, p2290)|a appetite drug considered to produce less central nervous system disturbance than most drugs in this therapeutic category. it is also considered among the safest for patients with high blood pressure. (from ama drug evaluations annual, 1994, p2290)|40.36254385964915|49.2678070175439|10.776315789473689|9.534210526315793|12.57529298245614|12.783607692307694|10.209473684210526|9.590526315789479|11.056228070175436|10.069230769230767|78.74477315987392|76.64453405168562|25.066666666666666|24.014035087719297\n",
      "\n",
      "a appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. it is also considered to be among the safest for patients with hypertension. (from ama drug evaluations annual, 1994, p2290)| a medicine|40.36254385964915|90.99000000000004|10.776315789473689|1.3133333333333361|12.57529298245614|11.7299|10.209473684210526|-79.06666666666666|11.056228070175436|-6.477499999999999|78.74477315987392|31.29|25.066666666666666|14.533333333333331\n",
      "\n",
      "a wheel is a circular component that is intended to rotate on an axial bearing and are used to support and to provide a means of moving the wheelchair. these wheels can be rotated manually by the user or power-assisted with batteries. wheelchair wheels are typically between 22 to 26 inches (56 to 66 cm) in diameter. smaller wheels, typically between 3 and 8 inches (7 to 20 cm) in diameter and between 1 and 2 inches (2.5 to 5 cm) in width, are sometimes called casters. wheelchairs typically have two sets of wheels, 2 larger ones and 2 smaller ones. the wheels can be placed on the front, middle, or rear of the wheelchair, depending upon its design.|a wheel is an ad part that is conveyed to grow on an axial have and are used to support and to provide a means of moving the chair.  these wheels can grow manually by the user or power-assisted with assault.  chair wheels are typically between 22 to 26 inches (56 to 66 cm) in straight_line.  smaller wheels, typically between 3 and 8 inches (7 to 20 cm) in straight_line and between 1 and 2 inches (2.5 to 5 cm) in width, are sometimes called casters.  chair typically has two sets of wheels, 2 larger ones and 2 smaller ones.  the wheels can be placed on the front, middle, or rear of the chair, thrust upon its sketch.|80.83267331932774|98.37571646341463|5.680157563025212|3.3574695121951237|10.023416666666666|9.345088387096775|6.585546218487391|4.602601626016256|8.86225|3.192177419354838|65.44773057562806|54.195869768830164|17.71470588235294|13.95487804878049\n",
      "\n",
      "a wheel is a circular component that is intended to rotate on an axial bearing and are used to support and to provide a means of moving the wheelchair. these wheels can be rotated manually by the user or power-assisted with batteries. wheelchair wheels are typically between 22 to 26 inches (56 to 66 cm) in diameter. smaller wheels, typically between 3 and 8 inches (7 to 20 cm) in diameter and between 1 and 2 inches (2.5 to 5 cm) in width, are sometimes called casters. wheelchairs typically have two sets of wheels, 2 larger ones and 2 smaller ones. the wheels can be placed on the front, middle, or rear of the wheelchair, depending upon its design.|a wheel is a circular component that is intended to rotate on an axial bearing and are used to support and to move the wheelchair. these wheels can be rotated manually by the user or power-assisted with batteries. wheelchair wheels are typically between 22 to 26 inches (56 to 66 cm|80.83267331932774|66.82705882352944|5.680157563025212|8.161568627450979|10.023416666666666|10.471257232704403|6.585546218487391|9.45176470588235|8.86225|7.754088050314465|65.44773057562806|74.48509850970193|17.71470588235294|20.133333333333333\n",
      "\n",
      "a wheel is a circular component that is intended to rotate on an axial bearing and are used to support and to provide a means of moving the wheelchair. these wheels can be rotated manually by the user or power-assisted with batteries. wheelchair wheels are typically between 22 to 26 inches (56 to 66 cm) in diameter. smaller wheels, typically between 3 and 8 inches (7 to 20 cm) in diameter and between 1 and 2 inches (2.5 to 5 cm) in width, are sometimes called casters. wheelchairs typically have two sets of wheels, 2 larger ones and 2 smaller ones. the wheels can be placed on the front, middle, or rear of the wheelchair, depending upon its design.| A wheel is a mechanism that is used to move a wheelchair or vehicle.|80.83267331932774|92.06250000000001|5.680157563025212|2.2816666666666663|10.023416666666666|8.967675|6.585546218487391|-17.51466666666667|8.86225|-0.9450000000000003|65.44773057562806|38.32226702584281|17.71470588235294|11.0\n",
      "\n",
      "combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a g protein, with pharmacological characteristics of beta3-adrenergic receptors. [goc:mah, iuphar_gpcr:1274]|mix with epinephrine or norepinephrine to hash_out a change in cell activity via beginning of a g protein, with pharmacological property of the beta3-adrenergic organ.  [ goc: mah, iuphar_gpcr: 1274]|11.424615384615407|51.92185483870969|14.895384615384618|9.867903225806455|13.917685714285716|12.298710752688173|18.843076923076918|12.958709677419357|15.34392857142857|8.350215053763442|76.64453405168562|73.38155456243756|23.661538461538463|20.393548387096775\n",
      "\n",
      "combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a g protein, with pharmacological characteristics of beta3-adrenergic receptors. [goc:mah, iuphar_gpcr:1274]|combining with epinephrine or a molecule of fat or protein, with the chemical characteristics of beta3 receptors. [goc:mah, iuphar_gpcr:1274]|11.424615384615407|45.80302631578948|14.895384615384618|9.230789473684215|13.917685714285716|13.180157142857144|18.843076923076918|7.2168421052631615|15.34392857142857|10.285714285714285|76.64453405168562|62.58|23.661538461538463|20.642105263157895\n",
      "\n",
      "combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a g protein, with pharmacological characteristics of beta3-adrenergic receptors. [goc:mah, iuphar_gpcr:1274]| Combining with|11.424615384615407|90.99000000000004|14.895384615384618|1.3133333333333361|13.917685714285716|15.6774|18.843076923076918|-71.22666666666666|15.34392857142857|-1.7674999999999983|76.64453405168562|31.29|23.661538461538463|14.533333333333331\n",
      "\n",
      "a protein ternary complex that anchors microtubule minus ends to mitotic spindle pole bodies. the founding complex contains a microtubule anchoring protein (msd1 in fission yeast), a wd-repeat wdr8 family protein and and a minus end-directed kinesin. [pmid:25987607, pmid:29021344]|a bioactive substance digit whole that hook tubule minus ends to mitotic stick pole bodies.  the founding whole contains a tubule fasten protein (msd1 in fission yeast), awd-repeat wdr8 family protein and a minus end-directed kinesin.  [ pmid: 25987607, pmid: 29021344]|46.132307692307705|72.2727131782946|10.054358974358976|6.739534883720932|13.172171544715447|12.326843636363636|13.867692307692305|10.389767441860457|12.169918699186994|6.198863636363633|84.73372056035305|78.74477315987392|27.764102564102565|23.4077519379845\n",
      "\n",
      "a protein ternary complex that anchors microtubule minus ends to mitotic spindle pole bodies. the founding complex contains a microtubule anchoring protein (msd1 in fission yeast), a wd-repeat wdr8 family protein and and a minus end-directed kinesin. [pmid:25987607, pmid:29021344]|a protein complex that anchors microtubule minus ends to mitotic spindle pole bodies. the founding complex contains a protein anchoring protein (msd1 in fission yeast), a wd-repeat wdr8 family protein and plus end-directed k|46.132307692307705|45.26235294117649|10.054358974358976|11.169411764705881|13.172171544715447|13.515991891891893|13.867692307692305|15.792941176470588|12.169918699186994|11.497297297297301|84.73372056035305|96.44225707644962|27.764102564102565|29.152941176470588\n",
      "\n",
      "a protein ternary complex that anchors microtubule minus ends to mitotic spindle pole bodies. the founding complex contains a microtubule anchoring protein (msd1 in fission yeast), a wd-repeat wdr8 family protein and and a minus end-directed kinesin. [pmid:25987607, pmid:29021344]| the microtubule|46.132307692307705|62.79000000000002|10.054358974358976|5.246666666666666|13.172171544715447|15.6774|13.867692307692305|-69.26666666666665|12.169918699186994|-0.5899999999999999|84.73372056035305|31.29|27.764102564102565|14.533333333333331\n",
      "\n",
      "a unit of magnetic flux density equal to 10(e-9) tesla (one nanotesla) or 10(e-5) oersted, traditionally used in geophysics for measurement of changes in the earth's magnetic field.|a unit of magnetic flux spacing equal to 10 (e-9) tesla (one nanotesla) or 10 (e-5) oersted, traditionally used in geophysics for measurement of changes in the earth 's magnetic field.|50.61785714285716|62.837983870967776|9.677142857142858|8.345322580645163|12.35637142857143|12.493166666666667|11.197142857142854|10.113548387096774|17.465714285714284|16.491999999999997|76.64453405168562|76.64453405168562|22.742857142857144|21.68387096774194\n",
      "\n",
      "a unit of magnetic flux density equal to 10(e-9) tesla (one nanotesla) or 10(e-5) oersted, traditionally used in geophysics for measurement of changes in the earth's magnetic field.|a unit of magnetic flux density equal to 10(e-9) tela (one nanotesla) or 10 (e-5 oersted, traditionally used in geophysics for measurement of changes in the earth's magnetic field.|50.61785714285716|55.0071551724138|9.677142857142858|9.189137931034484|12.35637142857143|12.275500000000001|11.197142857142854|10.608275862068968|17.465714285714284|9.149000000000001|76.64453405168562|76.64453405168562|22.742857142857144|22.351724137931036\n",
      "\n",
      "a unit of magnetic flux density equal to 10(e-9) tesla (one nanotesla) or 10(e-5) oersted, traditionally used in geophysics for measurement of changes in the earth's magnetic field.| a unit of magnetic flux density equal to 10(-9) tesla (one ten thousandth) or 10(-5) oersted|50.61785714285716|75.12117647058825|9.677142857142858|7.004705882352944|12.35637142857143|14.178744444444446|11.197142857142854|9.567058823529408|17.465714285714284|7.195|76.64453405168562|82.78555852321104|22.742857142857144|23.270588235294117\n",
      "\n",
      "the hydrochloride salt of the synthetic imidazothiazole derivative levamisole with anthelminthic and immunomodulating activities. in immunosuppressed states, levamisole may restore immune function by: 1) stimulating antibody formation, 2) stimulating t-cell activation and proliferation, 3) potentiating monocyte and macrophage phagocytosis and chemotaxis and 4) increasing neutrophil mobility, adherence, and chemotaxis.|the complex salt of the compound imidazothiazole word levamisole with medicine and immunomodulating trait.  in immunosuppressed states, levamisole may change immune serve by: 1) challenge antibody placement, 2) challenge t-cell beginning and increase, 3) potentiating monocyte and macrophage phagocytosis and taxis and 4) increasing neutrophil mobility, support, and taxis.|-30.739251700680228|17.334333333333348|21.604489795918365|14.982000000000003|16.853700000000003|13.767935294117647|26.637551020408164|20.342400000000005|37.482|15.884117647058822|97.28456352371633|90.32644961471695|30.206802721088437|26.66666666666667\n",
      "\n",
      "the hydrochloride salt of the synthetic imidazothiazole derivative levamisole with anthelminthic and immunomodulating activities. in immunosuppressed states, levamisole may restore immune function by: 1) stimulating antibody formation, 2) stimulating t-cell activation and proliferation, 3) potentiating monocyte and macrophage phagocytosis and chemotaxis and 4) increasing neutrophil mobility, adherence, and chemotaxis.|the hydrochloride salt of a drug derivative levamisole with anthelminthic and immunomodulating activities. in immunosuppressed states, it may restore immune function by: 1) stimulating antibody formation, 2) stimulating t-cell activation and proliferation, 3) potentiating|-30.739251700680228|-11.967058823529385|21.604489795918365|19.151764705882353|15.613700000000001|14.617355555555555|26.637551020408164|24.094117647058827|24.982|17.792499999999997|97.28456352371633|91.22524239485473|30.206802721088437|26.8\n",
      "\n",
      "the hydrochloride salt of the synthetic imidazothiazole derivative levamisole with anthelminthic and immunomodulating activities. in immunosuppressed states, levamisole may restore immune function by: 1) stimulating antibody formation, 2) stimulating t-cell activation and proliferation, 3) potentiating monocyte and macrophage phagocytosis and chemotaxis and 4) increasing neutrophil mobility, adherence, and chemotaxis.| the hydrochloride salt of the synthetic imidazothiazole derivative levamisole with anthelminthic and immunomodulating activities.|-30.739251700680228|-37.65749999999997|21.604489795918365|20.374999999999996|15.613700000000001|13.902050000000001|26.637551020408164|6.397333333333329|24.982|17.011875000000003|97.28456352371633|62.58|30.206802721088437|24.333333333333336\n",
      "\n",
      "<p>a container having dimensions that adjust somewhat based on the amount and shape of the material placed within it.</p>|< p > a container having shape that change somewhat based on the amount and shape of the applicant placed within it.  < /p >|63.613552631578955|102.53230769230771|6.746578947368423|2.187692307692309|12.329039130434783|10.961684615384616|0.717894736842112|-0.38000000000000256|11.162608695652175|3.0042307692307695|58.53822981607831|49.473833993334296|18.53684210526316|12.892307692307694\n",
      "\n",
      "<p>a container having dimensions that adjust somewhat based on the amount and shape of the material placed within it.</p>|a container having dimensions that adjust somewhat based on the amount and shape of the material placed within it.|63.613552631578955|63.613552631578955|6.746578947368423|6.746578947368423|12.329039130434783|9.659|0.717894736842112|-1.1389473684210465|11.162608695652175|6.178000000000001|58.53822981607831|58.53822981607831|18.53684210526316|18.53684210526316\n",
      "\n",
      "<p>a container having dimensions that adjust somewhat based on the amount and shape of the material placed within it.</p>| &lt;p&gt;a container having dimensions that adjust somewhat based on the amount and shape of the material placed within|63.613552631578955|58.42368421052632|6.746578947368423|9.830526315789477|12.329039130434783|11.734|0.717894736842112|16.296842105263163|11.162608695652175|12.826500000000003|58.53822981607831|82.78555852321104|18.53684210526316|22.33684210526316\n",
      "\n",
      "human mir10a wild-type allele is located in the vicinity of 17q21.32 and is 109 bases in length. this allele, which encodes mir10a pre-mirna, plays a role in the regulation of gene expression. alteration in the expression of this gene is associated with development of chronic myeloid leukemia.|human mir10a wild-type gene is located in the section of 17q21. 32 and is 109 drug in length.  this gene, which convert mir10a pre-mirna, plays a role in the control of gene squeeze.  change in the squeeze of this gene is uniting with section of chronic myeloid cancer.|58.69400000000002|98.54900000000002|7.407914893617022|1.998000000000001|12.825000680272108|11.961366666666667|-0.4629787234042624|-3.727999999999998|9.902176870748299|2.286794871794868|59.368600792001146|48.47425956113202|19.079148936170213|13.600000000000001\n",
      "\n",
      "human mir10a wild-type allele is located in the vicinity of 17q21.32 and is 109 bases in length. this allele, which encodes mir10a pre-mirna, plays a role in the regulation of gene expression. alteration in the expression of this gene is associated with development of chronic myeloid leukemia.|normal human mir10a gene is located in the vicinity of chromosome location, 17q21.32, and is 109 bases in length. this gene, which encodes a protein complex, but is associated with development of chronic myeloid leukemia.|58.69400000000002|57.7594642857143|7.407914893617022|7.376785714285717|12.825000680272108|13.442533333333335|-0.4629787234042624|-2.244571428571426|9.902176870748299|8.381666666666664|59.368600792001146|60.592824451415034|19.079148936170213|20.642857142857142\n",
      "\n",
      "human mir10a wild-type allele is located in the vicinity of 17q21.32 and is 109 bases in length. this allele, which encodes mir10a pre-mirna, plays a role in the regulation of gene expression. alteration in the expression of this gene is associated with development of chronic myeloid leukemia.| human mir10a mutant allele is located in the vicinity of 17q21.32 and is 109 bases in length. this allele, which encodes mir10a pre-mirna|58.69400000000002|82.39000000000001|7.407914893617022|3.7550000000000026|12.825000680272108|13.998223076923077|-0.4629787234042624|-8.580000000000005|9.902176870748299|5.721538461538465|59.368600792001146|54.195869768830164|19.079148936170213|18.2\n",
      "\n",
      "a broad class of cell surface proteins that bind specifically to viral spike proteins found on a coronavirus. the attachment of the virus is the first step of a process that leads to coronavirus infections.|a broad class of cell surface proteins that bind specifically to viral spike proteins found on a coronavirus.  the joining of the virus is the first step of a walk that leads to coronavirus ill_health.|57.21619047619049|67.75500000000001|8.177142857142858|6.790000000000003|9.015928571428573|8.617811111111113|3.524571428571427|2.4466666666666654|10.197142857142854|6.157499999999999|59.91578840339164|57.127462747788826|17.238095238095237|15.911111111111111\n",
      "\n",
      "a broad class of cell surface proteins that bind specifically to viral spike proteins found on a coronavirus. the attachment of the virus is the first step of a process that leads to coronavirus infections.|a broad class of cell surface proteins that bind specifically to viral spike proteins found on a coronavirus. the attachment of the virus is the first step that leads to viral infection.|57.21619047619049|63.820833333333354|8.177142857142858|7.0075|9.015928571428573|8.966948484848485|3.524571428571427|0.9150000000000063|10.197142857142854|6.050000000000001|59.91578840339164|57.127462747788826|17.238095238095237|16.766666666666666\n",
      "\n",
      "a broad class of cell surface proteins that bind specifically to viral spike proteins found on a coronavirus. the attachment of the virus is the first step of a process that leads to coronavirus infections.| a protein found specifically by binding to a viral spike|57.21619047619049|64.9245454545455|8.177142857142858|6.936363636363637|9.015928571428573|10.810866666666666|3.524571428571427|-1.2509090909090972|10.197142857142854|3.8024999999999984|59.91578840339164|62.58|17.238095238095237|18.94545454545455\n",
      "\n",
      "physiologic monitoring software designed to operate hemodynamic monitors, control/monitor a limited number of their functions, and/or process data obtained while monitoring hemodynamics. this software applies a variety of algorithms to facilitate the operation and analysis of the measurements performed while monitoring hemodynamic parameters such as electrocardiographic data and waveform, blood pressure, cardiac output, central venous pressure, temperature, peripheral venous oxygen saturation, and blood gas analysis. the software usually works with many models of hemodynamic monitors; it may also work with patient information obtained from workstations and remote monitors and interact with hospital information systems. dedicated hemodynamic software is available to extend the capabilities of the parameters that can be processed [e.g., coronary flow reserve (cfr), first time derivative of pressure (dp/dt)].|physiologic observe code designed to operate hemodynamic observe, control/monitor a limited number of their serve, and/or process data exist while observing physiology.  this code give a difference of rule to cause the cognition and calculus of the measurements re-create while observe hemodynamic quantity such as electrocardiographic data and wave , blood pressure , cardiac output , central venous pressure , temperature , peripheral venous oxygen condition , and blood gas calculus .  the code usually works with many shapes of hemodynamic observe; it may also work with case collection exist from workstations and remote observe and act with hospital information systems.  assign hemodynamic code is available to use the aptitude of the quantity that can be transformed [e.g., coronary flow reserve (cfr), first time word of pressure (dp/dt)].|-4.381074380165273|37.36824427480917|18.16465171192444|12.696357688113412|14.661374796747968|13.016524146981627|21.70347107438016|16.41099236641221|23.660121951219516|15.002703412073494|100.3512511132771|90.84113440507004|30.7159386068477|25.500981461286806\n",
      "\n",
      "physiologic monitoring software designed to operate hemodynamic monitors, control/monitor a limited number of their functions, and/or process data obtained while monitoring hemodynamics. this software applies a variety of algorithms to facilitate the operation and analysis of the measurements performed while monitoring hemodynamic parameters such as electrocardiographic data and waveform, blood pressure, cardiac output, central venous pressure, temperature, peripheral venous oxygen saturation, and blood gas analysis. the software usually works with many models of hemodynamic monitors; it may also work with patient information obtained from workstations and remote monitors and interact with hospital information systems. dedicated hemodynamic software is available to extend the capabilities of the parameters that can be processed [e.g., coronary flow reserve (cfr), first time derivative of pressure (dp/dt)].|this software usually works with many models of hemodynamic monitors; it may also work with patient information obtained from workstations and remote monitoring systems, and/or process the parameters that can be processed [e.g., coronary flow reserve (cfr), first time derivative of pressure (dp/|-4.381074380165273|30.956434108527162|18.16465171192444|12.50232558139535|14.661374796747968|14.431627272727273|21.70347107438016|14.218604651162785|23.660121951219516|27.01022727272727|100.3512511132771|82.78555852321104|30.7159386068477|25.268217054263566\n",
      "\n",
      "physiologic monitoring software designed to operate hemodynamic monitors, control/monitor a limited number of their functions, and/or process data obtained while monitoring hemodynamics. this software applies a variety of algorithms to facilitate the operation and analysis of the measurements performed while monitoring hemodynamic parameters such as electrocardiographic data and waveform, blood pressure, cardiac output, central venous pressure, temperature, peripheral venous oxygen saturation, and blood gas analysis. the software usually works with many models of hemodynamic monitors; it may also work with patient information obtained from workstations and remote monitors and interact with hospital information systems. dedicated hemodynamic software is available to extend the capabilities of the parameters that can be processed [e.g., coronary flow reserve (cfr), first time derivative of pressure (dp/dt)].| software|-4.381074380165273|120.20500000000001|18.16465171192444|-3.01|14.661374796747968|19.5753|21.70347107438016|-121.53999999999999|23.660121951219516|-4.229999999999997|100.3512511132771|31.29|30.7159386068477|20.8\n",
      "\n",
      "(j0400=9)|( j0400=9)|205.82000000000002|204.805|-15.2|-14.81|19.476100000000002|19.476100000000002|-243.07999999999998|-121.53999999999999|12.04|12.04|0.0|0.0|0.4|0.8\n",
      "\n",
      "(j0400=9)|(j0400=9)|205.82000000000002|205.82000000000002|-15.2|-15.2|19.476100000000002|19.5257|-243.07999999999998|-237.2|12.04|-1.5899999999999999|0.0|0.0|0.4|0.4\n",
      "\n",
      "(j0400=9)| (j0400=9)|205.82000000000002|204.805|-15.2|-14.81|19.476100000000002|19.5753|-243.07999999999998|-118.6|12.04|-5.800000000000001|0.0|0.0|0.4|0.8\n",
      "\n",
      "prostate cancer with tumor involving both lobes. (from ajcc 7th ed.)|prostate cancer  growth absorb both throw.  ( from ajcc 7th ed.)|80.0587878787879|124.34435897435898|3.003636363636364|-3.0076923076923077|15.392936363636366|15.7766|-49.72363636363636|-44.787692307692325|4.441818181818181|1.1950000000000003|40.39521630094336|31.29|19.64848484848485|10.964102564102564\n",
      "\n",
      "prostate cancer with tumor involving both lobes. (from ajcc 7th ed.)|prostate cancer with tumor involving both lobes. (from ajcc 7th ed.)|80.0587878787879|80.0587878787879|3.003636363636364|3.003636363636364|15.392936363636366|15.7766|-49.72363636363636|-49.18909090909091|4.441818181818181|3.157499999999999|40.39521630094336|40.39521630094336|19.64848484848485|19.64848484848485\n",
      "\n",
      "prostate cancer with tumor involving both lobes. (from ajcc 7th ed.)| prostate cancer|80.0587878787879|90.99000000000004|3.003636363636364|1.3133333333333361|15.392936363636366|19.6249|-49.72363636363636|-69.26666666666665|4.441818181818181|-0.5899999999999999|40.39521630094336|44.250742366654144|19.64848484848485|27.866666666666664\n",
      "\n",
      "methods of preparing cells or tissues for examination and study of their origin, structure, function, or pathology. the methods include preservation, fixation, sectioning, staining, replica, or other technique to allow for viewing using a microscope.|methods of learning cells or tissues for introspection and study of their source, structure, serve, or ill_health.  the methods include improvement, fixation, sectioning, dye, copy, or other technique to allow for watch using a microscope.|28.210476190476186|58.35500000000002|12.222857142857148|8.101111111111113|11.722785714285715|11.547077777777778|10.916571428571423|8.653333333333336|15.041714285714285|13.082500000000003|82.78555852321104|74.48509850970193|28.66666666666667|23.68888888888889\n",
      "\n",
      "methods of preparing cells or tissues for examination and study of their origin, structure, function, or pathology. the methods include preservation, fixation, sectioning, staining, replica, or other technique to allow for viewing using a microscope.|methods of preparing cells or tissues for examination and study of their origin, structure, function, or pathology. the methods include preservation, fixation, sectioning, staining a microscope.|28.210476190476186|22.330641025641057|12.222857142857148|12.297692307692309|11.722785714285715|13.078322222222225|10.916571428571423|4.292307692307688|15.041714285714285|13.579999999999998|82.78555852321104|72.26115969177356|28.66666666666667|28.08205128205128\n",
      "\n",
      "methods of preparing cells or tissues for examination and study of their origin, structure, function, or pathology. the methods include preservation, fixation, sectioning, staining, replica, or other technique to allow for viewing using a microscope.| techniques of preparing cells or tissues for examination and study of their origin, structure, function, or pathology.|28.210476190476186|37.900000000000034|12.222857142857148|10.208888888888893|11.722785714285715|11.587173684210526|10.916571428571423|0.7577777777777754|15.041714285714285|8.109473684210528|82.78555852321104|66.37611354998121|28.66666666666667|23.6\n",
      "\n",
      "a nanodispersion containing the benzoquinone ubidecarenone (coenzyme q10), with potential protective, antioxidant and antineoplastic activities. upon administration, ubidecarenone nanodispersion bpm31510 modulates tumor cell metabolism and causes an anti-warburg effect by inducing a shift from lactate dependency towards mitochondrial oxidative phosphorylation, and induces tumor cell apoptosis. this inhibits tumor cell proliferation. bpm 31510 also induces the activation and maturation of t lymphocytes, and changes the surface expression of certain immune checkpoint modulators. in addition, as an antioxidant, ubidecarenone protects against cell damage, by preventing both the peroxidation of lipid membranes and the oxidation of ldl-cholesterol. ubidecarenone is an essential coenzyme for mitochondrial enzyme complexes involved in oxidative phosphorylation and the production of adenosine triphosphate (atp). check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c118621\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c118621\" nci thesaurus)|a spatial concept defends the compound ubidecarenone (coenzyme q10), with potential protective, antioxidant and antineoplastic trait.  upon justice, ubidecarenone nanodispersion bpm31510 modulate tumor cell metabolism and causes an anti-warburg effect by producing a shift from the lactate state towards mitochondrial oxidative phosphorylation, and produce tumor cell apoptosis.  this suppresses growth, cell increase.  bpm 31510 also produce the beginning and maturation of t leukocyte, and changes the surface squeeze of certain immune stop modulators.  in addition, as an antioxidant, ubidecarenone protects against cell change, by preventing both the peroxidation of lipid sheet and the oxidation of ldl-cholesterol.  ubidecarenone are a thing coenzyme for the mitochondrial enzyme structure involved in oxidative phosphorylation and the display of a nucleoside triphosphate (atp).  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c118621 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c118621 '' nice wordbook)|2.3142857142857736|35.78400000000002|15.172380952380955|10.929904761904762|13.91878392857143|13.806567616334284|15.597777777777779|11.690933333333334|24.951294642857142|12.944472934472934|71.45012211326164|69.96656701596841|26.774603174603183|22.952380952380953\n",
      "\n",
      "a nanodispersion containing the benzoquinone ubidecarenone (coenzyme q10), with potential protective, antioxidant and antineoplastic activities. upon administration, ubidecarenone nanodispersion bpm31510 modulates tumor cell metabolism and causes an anti-warburg effect by inducing a shift from lactate dependency towards mitochondrial oxidative phosphorylation, and induces tumor cell apoptosis. this inhibits tumor cell proliferation. bpm 31510 also induces the activation and maturation of t lymphocytes, and changes the surface expression of certain immune checkpoint modulators. in addition, as an antioxidant, ubidecarenone protects against cell damage, by preventing both the peroxidation of lipid membranes and the oxidation of ldl-cholesterol. ubidecarenone is an essential coenzyme for mitochondrial enzyme complexes involved in oxidative phosphorylation and the production of adenosine triphosphate (atp). check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c118621\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c118621\" nci thesaurus)|a nanodispersion containing a molecule of fat and protein, with potential protective, antioxidant and anti-cancer activities. upon administration, ubidecarenone is an essential coenzyme for cancer drug complexes involved in oxidative phosphorylation, and induce|2.3142857142857736|-15.003409090909088|15.172380952380955|19.45106060606061|13.805412500000001|14.429642857142857|15.597777777777779|23.04242424242424|23.808437499999997|17.464000000000006|71.45012211326164|98.94766798666859|26.774603174603183|30.842424242424244\n",
      "\n",
      "a nanodispersion containing the benzoquinone ubidecarenone (coenzyme q10), with potential protective, antioxidant and antineoplastic activities. upon administration, ubidecarenone nanodispersion bpm31510 modulates tumor cell metabolism and causes an anti-warburg effect by inducing a shift from lactate dependency towards mitochondrial oxidative phosphorylation, and induces tumor cell apoptosis. this inhibits tumor cell proliferation. bpm 31510 also induces the activation and maturation of t lymphocytes, and changes the surface expression of certain immune checkpoint modulators. in addition, as an antioxidant, ubidecarenone protects against cell damage, by preventing both the peroxidation of lipid membranes and the oxidation of ldl-cholesterol. ubidecarenone is an essential coenzyme for mitochondrial enzyme complexes involved in oxidative phosphorylation and the production of adenosine triphosphate (atp). check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c118621\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c118621\" nci thesaurus)| a|2.3142857142857736|162.505|15.172380952380955|-8.91|13.805412500000001|14.311966666666669|15.597777777777779|-142.12|23.808437499999997|-15.219999999999999|71.45012211326164|0.0|26.774603174603183|0.8\n",
      "\n",
      "a monoclonal antibody directed against the cell surface protein claudin 6 (cldn6), with potential immunostimulating and antineoplastic activities. upon administration, the anti-cldn6 monoclonal antibody imab027 binds to cldn-6 and may stimulate the immune system to exert both an antibody-dependent cellular cytotoxicity (adcc) and a complement-dependent cytotoxicity (cdc)-mediated immune response against cldn-6-expressing tumor cells. this may inhibit tumor cell growth. cldn-6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c114286\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c114286\" nci thesaurus)|an immunologic factor protein directed against the cell surface protein claudin 6 (cldn6), with potential immunostimulating and antineoplastic trait.  upon justice, the anti-cldn6 monoclonal protein imab027 binds to cldn-6 and may challenge the immune system to act both an antibody-dependent cellular toxicity (adcc) and a complement-dependent toxicity (cdc) -mediated immune response against cldn-6-expressing tumor cells.  this may suppress tumor cell growth.  cldn-6, a tight-junction protein and embryonic substance, is mailed on a difference of tumor cells, but is not mailed on normal, healthy adult cells.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c114286 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c114286 '' nice wordbook)|34.05221491228073|56.598351449275384|10.476447368421052|7.7457608695652205|13.463466666666667|14.280884615384615|10.70273684210526|8.278956521739126|22.275433333333332|13.107230769230767|61.26237874911485|63.22851473030187|22.535087719298247|20.876811594202902\n",
      "\n",
      "a monoclonal antibody directed against the cell surface protein claudin 6 (cldn6), with potential immunostimulating and antineoplastic activities. upon administration, the anti-cldn6 monoclonal antibody imab027 binds to cldn-6 and may stimulate the immune system to exert both an antibody-dependent cellular cytotoxicity (adcc) and a complement-dependent cytotoxicity (cdc)-mediated immune response against cldn-6-expressing tumor cells. this may inhibit tumor cell growth. cldn-6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c114286\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c114286\" nci thesaurus)|a monoclonal antibody directed against a protein complex, with potential immunostimulating and anti-cancer activities. upon administration, the antibody binds to cldn6 and may stimulate the immune system to exert both an antibody-dependent cellular cytotoxicity (adcc) and|34.05221491228073|-13.534999999999997|10.476447368421052|19.618888888888893|13.463466666666667|13.510879487179487|10.70273684210526|22.428888888888892|22.275433333333332|16.21769230769231|61.26237874911485|98.94766798666859|22.535087719298247|29.422222222222224\n",
      "\n",
      "a monoclonal antibody directed against the cell surface protein claudin 6 (cldn6), with potential immunostimulating and antineoplastic activities. upon administration, the anti-cldn6 monoclonal antibody imab027 binds to cldn-6 and may stimulate the immune system to exert both an antibody-dependent cellular cytotoxicity (adcc) and a complement-dependent cytotoxicity (cdc)-mediated immune response against cldn-6-expressing tumor cells. this may inhibit tumor cell growth. cldn-6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c114286\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c114286\" nci thesaurus)| a|34.05221491228073|162.505|10.476447368421052|-8.91|13.463466666666667|14.311966666666669|10.70273684210526|-142.12|22.275433333333332|-15.219999999999999|61.26237874911485|0.0|22.535087719298247|0.8\n",
      "\n",
      "stage iva includes: (t4, n0, m0); (any t, n1, m0). t4: tumor with periductal invasion. n0: no regional lymph node metastasis. n1: regional lymph node metastasis. m0: no distant metastasis. (from ajcc 7th ed.)|stage iva includes: (t4, n0, m0); (any t, n1, m0).  t4: growth with periductal spread.  n0: no regional lymph node metastasis.  n1: regional lymph node metastasis.  m0: no distant metastasis.  ( from ajcc 7th ed.)|82.46970588235294|105.86|2.963109243697481|-0.08642857142856997|16.921096078431376|16.868740293040297|-30.67647058823529|-26.22200000000001|2.5983333333333327|0.31648351648351536|40.9682267129052|37.39870318607318|16.060504201680672|12.285714285714286\n",
      "\n",
      "stage iva includes: (t4, n0, m0); (any t, n1, m0). t4: tumor with periductal invasion. n0: no regional lymph node metastasis. n1: regional lymph node metastasis. m0: no distant metastasis. (from ajcc 7th ed.)|stage iva includes: (t4, n0, m0); (from ajcc 7th ed.)|82.46970588235294|125.62000000000002|2.963109243697481|-3.0199999999999996|16.850829411764707|16.82839090909091|-30.67647058823529|-32.739999999999995|1.8900000000000006|-3.2654545454545456|40.9682267129052|31.29|16.060504201680672|10.0\n",
      "\n",
      "stage iva includes: (t4, n0, m0); (any t, n1, m0). t4: tumor with periductal invasion. n0: no regional lymph node metastasis. n1: regional lymph node metastasis. m0: no distant metastasis. (from ajcc 7th ed.)| stage iv includes: (tumor), (tumor size), (tumor stage)|82.46970588235294|75.50000000000003|2.963109243697481|4.964444444444446|16.850829411764707|15.185500000000001|-30.67647058823529|-0.8755555555555503|1.8900000000000006|2.8810000000000002|40.9682267129052|62.58|16.060504201680672|21.37777777777778\n",
      "\n",
      "the date (and time) on which an adverse event began.|the date (and time) on which an adverse event began.|91.78000000000003|91.78000000000003|1.7000000000000028|1.7000000000000028|7.2905|7.2905|-33.916|-33.916|2.41|2.41|38.32226702584281|38.32226702584281|14.0|14.0\n",
      "\n",
      "the date (and time) on which an adverse event began.|the day (and time) on which an adverse event began.|91.78000000000003|91.78000000000003|1.7000000000000028|1.7000000000000028|7.2905|8.215663636363637|-33.916|-33.916|2.41|-1.5527272727272745|38.32226702584281|38.32226702584281|14.0|14.0\n",
      "\n",
      "the date (and time) on which an adverse event began.| the time (and date) on which an adverse event begins.|91.78000000000003|101.27068181818181|1.7000000000000028|0.5004545454545486|7.2905|9.197433333333334|-33.916|-29.763636363636365|2.41|-1.5524999999999984|38.32226702584281|38.32226702584281|14.0|13.109090909090908\n",
      "\n",
      "antibody degradation consists of conjugation, transport, oxidation, and/or proteolysis of members of a class of cell-surface or secreted b lymphocyte proteins that non-covalently interact through intermolecular physical forces of attraction and spatial complementarity selectively and specifically with foreign substances (antigens), typically as part of an immune response.|protein organism function be of class , move , oxidation , and/or proteolysis of members of a class of cell-surface or hide b lymphocyte proteins that non-covalently act through intermolecular physical forces of feature and spatial complementarity selectively and specifically with foreign matter ( antigens ) , typically as part of an immune phrase .|-16.817499999999995|28.180681818181853|21.443085106382984|16.160454545454545|15.412002040816327|13.6957|28.439148936170213|20.98836363636364|33.733061224489795|30.699599999999997|117.07645963215661|106.1095525859948|33.229787234042554|27.727272727272727\n",
      "\n",
      "antibody degradation consists of conjugation, transport, oxidation, and/or proteolysis of members of a class of cell-surface or secreted b lymphocyte proteins that non-covalently interact through intermolecular physical forces of attraction and spatial complementarity selectively and specifically with foreign substances (antigens), typically as part of an immune response.|antibody degradation consists of conjugation, transport, oxidation and/or degradation of proteins that non-covalently interact through intermolecular physical forces of attraction and spatial complementarity selectively and specifically with foreign substances, typically as part of an immune response.|-16.817499999999995|-25.284999999999968|21.443085106382984|21.25777777777778|15.412002040816327|15.382584210526316|28.439148936170213|27.32888888888889|33.733061224489795|20.668157894736844|117.07645963215661|106.1095525859948|33.229787234042554|32.75555555555555\n",
      "\n",
      "antibody degradation consists of conjugation, transport, oxidation, and/or proteolysis of members of a class of cell-surface or secreted b lymphocyte proteins that non-covalently interact through intermolecular physical forces of attraction and spatial complementarity selectively and specifically with foreign substances (antigens), typically as part of an immune response.| antibody is a protein|-16.817499999999995|66.40000000000003|21.443085106382984|5.240000000000002|15.412002040816327|14.460766666666668|28.439148936170213|-36.855999999999995|33.733061224489795|-2.729999999999997|117.07645963215661|44.250742366654144|33.229787234042554|18.0\n",
      "\n",
      "the chemical reactions and pathways performed by an organism resulting in the breakdown of pectin in the cell wall of a second organism, where the two organisms are in a symbiotic interaction. [isbn:0198547684]|the process force and path re-create  a system happen in the breakdown  pectin in the cell wall of a second system, where the two systems are in a symbiotic action.  [ isbn: 0198547684]|51.65113636363637|87.515|10.154090909090915|5.524444444444445|10.40240303030303|11.249477777777777|13.776969696969694|8.05555555555556|8.904545454545453|3.8024999999999984|79.77416029015912|73.38155456243756|22.35757575757576|19.422222222222224\n",
      "\n",
      "the chemical reactions and pathways performed by an organism resulting in the breakdown of pectin in the cell wall of a second organism, where the two organisms are in a symbiotic interaction. [isbn:0198547684]|the chemical reactions and pathways performed by an organism resulting in the breakdown of a cell wall protein, where the two organisms are in an beneficial interaction. [isbn:0198547684]|51.65113636363637|50.61785714285716|10.154090909090915|9.677142857142858|10.675203030303031|11.433975862068966|13.776969696969694|12.66714285714286|11.654545454545449|11.31896551724138|79.77416029015912|73.38155456243756|22.35757575757576|21.314285714285717\n",
      "\n",
      "the chemical reactions and pathways performed by an organism resulting in the breakdown of pectin in the cell wall of a second organism, where the two organisms are in a symbiotic interaction. [isbn:0198547684]| the chemical reactions and pathways|51.65113636363637|73.84500000000001|10.154090909090915|4.450000000000003|10.675203030303031|15.262271428571431|13.776969696969694|-17.97333333333333|11.654545454545449|4.274285714285714|79.77416029015912|54.195869768830164|22.35757575757576|22.400000000000002\n",
      "\n",
      "a type of junction that attaches one cell to its neighbor. one of a number of differentiated regions which occur, for example, where the cytoplasmic membranes of adjacent epithelial cells are closely apposed. it consists of a circular region of each membrane together with associated intracellular microfilaments and an intercellular material which may include, for example, mucopolysaccharides. (from glick, glossary of biochemistry and molecular biology, 1990; singleton & sainsbury, dictionary of microbiology and molecular biology, 2d ed)|a type of junction that take one cell to its neighbor.  one of a number of dissimilate regions which occur, for example, where the cytoplasmic sheet of adjacent epithelial cells are closely put.  it be  an ad region of each sheet together with associated intracellular microfilaments and an intercellular applicant which may include, for example, polysaccharide.  ( from glick, wordbook of biochemistry and molecular collection, 1990; playing_card & sainsbury, wordbook of biology and molecular collection, 2d ed)|9.306639610389624|41.10347222222222|16.743474025974027|12.556882716049387|12.681663157894738|11.884756540084389|20.20883116883116|16.815308641975307|16.020131578947364|10.31308016877637|93.86999999999999|85.69119412168324|26.4012987012987|22.914814814814818\n",
      "\n",
      "a type of junction that attaches one cell to its neighbor. one of a number of differentiated regions which occur, for example, where the cytoplasmic membranes of adjacent epithelial cells are closely apposed. it consists of a circular region of each membrane together with associated intracellular microfilaments and an intercellular material which may include, for example, mucopolysaccharides. (from glick, glossary of biochemistry and molecular biology, 1990; singleton & sainsbury, dictionary of microbiology and molecular biology, 2d ed)|a type of junction that attaches one cell to its neighbor. one of a number of differentiated regions which occur, for example, where the cytoplasmic membranes of adjacent epithelial cells are closely surrounded by cellular microfilaments and an intercellular material which may include|9.306639610389624|25.64970930232562|16.743474025974027|15.022906976744185|12.681663157894738|11.546109090909091|20.20883116883116|19.598139534883718|16.020131578947364|15.367954545454545|93.86999999999999|93.86999999999999|26.4012987012987|25.34418604651163\n",
      "\n",
      "a type of junction that attaches one cell to its neighbor. one of a number of differentiated regions which occur, for example, where the cytoplasmic membranes of adjacent epithelial cells are closely apposed. it consists of a circular region of each membrane together with associated intracellular microfilaments and an intercellular material which may include, for example, mucopolysaccharides. (from glick, glossary of biochemistry and molecular biology, 1990; singleton & sainsbury, dictionary of microbiology and molecular biology, 2d ed)| a type of junction which connects one cell to its neighbor. one of a number of differentiated regions which occur, for example, where the cytoplasmic membranes of adjacent epithelial cells are closely apposed. it consists of a circular region of each membrane together with associated intracellular microfilaments and intercellular material which may include, for example, mucopolysaccharides.|9.306639610389624|21.687039473684223|16.743474025974027|13.774517543859652|12.681663157894738|11.433975862068966|20.20883116883116|14.198596491228066|16.020131578947364|12.861896551724136|93.86999999999999|79.77416029015912|26.4012987012987|23.94561403508772\n",
      "\n",
      "mutated forms of genes which encode proteins that are essential for the control and maintenance of normal cellular processes. inherited or somatic mutations in the wild-type form of these genes alters control of their expression, resulting in a change in control of the cell cycle. individuals who harbor cancer-predisposing genes require fewer somatic mutations for transformation of a particular cell, thereby predisposing them to the development of cancer.|change forms of genes which encode proteins that are thing for the control and wrongdoing of normal cellular transform.  receive or somatic change in the wild-type form of these genes change control of their squeeze, happen with a change in control of the cell ride.  organism who hides cancer-predisposing genes require fewer somatic change  the function of a partial cell, thereby dispose them to the section of cancer.|30.332941176470626|68.47227112676059|13.251764705882355|8.118415492957748|13.041928571428572|10.598138356164384|16.484705882352944|12.39267605633803|21.975|10.0836301369863|88.50148473330829|78.225|25.623529411764707|21.18450704225352\n",
      "\n",
      "mutated forms of genes which encode proteins that are essential for the control and maintenance of normal cellular processes. inherited or somatic mutations in the wild-type form of these genes alters control of their expression, resulting in a change in control of the cell cycle. individuals who harbor cancer-predisposing genes require fewer somatic mutations for transformation of a particular cell, thereby predisposing them to the development of cancer.|mutated forms of proteins that are essential for the control and maintenance of normal cellular processes. inherited or somatic mutations in the wild-type form of these genes alter their expression, resulting in a change in control of the cell cycle. individuals who harbor cancer-predispo|30.332941176470626|36.20742424242428|13.251764705882355|11.852727272727272|12.463261904761906|11.804630496453902|16.484705882352944|12.82636363636363|16.141666666666666|10.654822695035463|88.50148473330829|80.79043260188672|25.623529411764707|24.048484848484847\n",
      "\n",
      "mutated forms of genes which encode proteins that are essential for the control and maintenance of normal cellular processes. inherited or somatic mutations in the wild-type form of these genes alters control of their expression, resulting in a change in control of the cell cycle. individuals who harbor cancer-predisposing genes require fewer somatic mutations for transformation of a particular cell, thereby predisposing them to the development of cancer.| Protein or gene products of mutated genes|30.332941176470626|82.39000000000001|13.251764705882355|3.7550000000000026|12.463261904761906|16.36401111111111|16.484705882352944|-10.54|16.141666666666666|2.43333333333333|88.50148473330829|54.195869768830164|25.623529411764707|18.2\n",
      "\n",
      "the process in which udp-glucose is transported across a membrane. [goc:ai]|the walk in which up-glucose is moved across a sheet.  [ goc: ai]|55.12522727272727|109.08714285714288|6.936818181818182|-0.2171428571428553|12.461207692307694|8.379395238095238|-19.07272727272727|-20.445714285714285|3.558461538461536|-2.9480952380952417|54.195869768830164|31.29|24.018181818181816|8.514285714285714\n",
      "\n",
      "the process in which udp-glucose is transported across a membrane. [goc:ai]|the process in which udp-glucose is transported across a membrane. [goc]|55.12522727272727|62.81613636363636|6.936818181818182|5.864090909090912|12.461207692307694|12.461207692307694|-19.07272727272727|-20.14181818181818|3.558461538461536|3.1961538461538446|54.195869768830164|49.473833993334296|24.018181818181816|20.381818181818183\n",
      "\n",
      "the process in which udp-glucose is transported across a membrane. [goc:ai]| the process in which the transport molecule glucose moves|55.12522727272727|78.24500000000002|6.936818181818182|4.830000000000002|12.461207692307694|12.794827272727273|-19.07272727272727|-0.1999999999999993|3.558461538461536|5.90727272727273|54.195869768830164|62.58|24.018181818181816|20.0\n",
      "\n",
      "columbia-suicide severity rating scale baseline/screening version - has the subject engaged in non-suicidal self-injurious behavior. (past _ years).|columbia-suicide sternness pad scale baseline/screening version - has the term move in non-suicidal self-injurious trait.  ( past _ years).|12.745000000000005|60.47833333333335|12.972222222222225|6.48|13.6065|12.428252380952381|-6.539999999999992|-9.119999999999997|12.0655|8.715714285714284|57.127462747788826|44.250742366654144|24.622222222222224|14.666666666666666\n",
      "\n",
      "columbia-suicide severity rating scale baseline/screening version - has the subject engaged in non-suicidal self-injurious behavior. (past _ years).|columbia suicide severity rating scale baseline/screening version - has the subject engaged in non-suicidal self-injury. (past _ years).|12.745000000000005|17.44500000000002|12.972222222222225|12.316666666666666|15.185500000000001|15.020166666666666|-6.539999999999992|-10.133333333333326|12.0655|8.043833333333332|57.127462747788826|57.127462747788826|24.622222222222224|24.622222222222224\n",
      "\n",
      "columbia-suicide severity rating scale baseline/screening version - has the subject engaged in non-suicidal self-injurious behavior. (past _ years).| columbia suicide severity rating scale baseline version-has the subject engaged in non-suicidal self-injurious behavior (past years).|12.745000000000005|4.125147058823558|12.972222222222225|14.795588235294119|13.6065|14.683966666666668|-6.539999999999992|6.336470588235294|12.0655|9.388571428571431|57.127462747788826|73.38155456243756|24.622222222222224|29.28235294117647\n",
      "\n",
      "antibodies reactive with hiv antigens.|protein quality with hiv, substance.|18.17750000000001|52.01750000000001|11.345000000000006|6.6250000000000036|16.5165|16.5165|-78.416|-80.768|12.155999999999999|9.329999999999998|38.32226702584281|38.32226702584281|25.0|25.0\n",
      "\n",
      "antibodies reactive with hiv antigens.|antibodies reactive with hiv protein.|18.17750000000001|35.097500000000025|11.345000000000006|8.985000000000003|16.5165|16.94363333333333|-78.416|-78.416|12.155999999999999|5.975000000000001|38.32226702584281|38.32226702584281|25.0|25.0\n",
      "\n",
      "antibodies reactive with hiv antigens.| antiBody|18.17750000000001|35.60500000000002|11.345000000000006|8.790000000000003|16.5165|19.5753|-78.416|-121.53999999999999|12.155999999999999|-4.229999999999997|38.32226702584281|31.29|25.0|20.8\n",
      "\n",
      "mild pain not interfering with function|mild pain not interact with a serve|59.745000000000005|90.95857142857145|6.416666666666668|2.3114285714285714|11.8291|8.495128571428573|-16.01333333333333|-17.925714285714285|8.260000000000002|1.5828571428571436|44.250742366654144|31.29|15.733333333333333|8.514285714285714\n",
      "\n",
      "mild pain not interfering with function|pain not interfering with function|59.745000000000005|49.48000000000002|6.416666666666668|7.600000000000001|11.8291|11.8291|-16.01333333333333|-22.743999999999993|8.260000000000002|5.905000000000001|44.250742366654144|44.250742366654144|15.733333333333333|18.0\n",
      "\n",
      "mild pain not interfering with function| mild pain|59.745000000000005|147.39000000000004|6.416666666666668|-6.553333333333333|11.8291|15.6774|-16.01333333333333|-81.02666666666666|8.260000000000002|-7.654999999999999|44.250742366654144|0.0|15.733333333333333|1.2000000000000002\n",
      "\n",
      "blisters covering >30% bsa; associated with fluid or electrolyte abnormalities; icu care or burn unit indicated|blisters covering > 30 % base; unite with fluid or solution misbehavior; icu cares or burn unit inform|10.820000000000022|52.265000000000015|15.725000000000005|10.441111111111113|14.69675882352941|13.767935294117647|16.78|11.322222222222223|12.836470588235294|9.788823529411765|93.86999999999999|98.94766798666859|28.900000000000002|29.422222222222224\n",
      "\n",
      "blisters covering >30% bsa; associated with fluid or electrolyte abnormalities; icu care or burn unit indicated|blisters covering >30% bsa; associated with fluid abnormalities; icu care or burn unit indicated.|10.820000000000022|24.487142857142885|15.725000000000005|11.582857142857147|14.69675882352941|14.888925000000002|16.78|-6.585714285714289|12.836470588235294|6.414375|93.86999999999999|62.58|28.900000000000002|25.65714285714286\n",
      "\n",
      "blisters covering >30% bsa; associated with fluid or electrolyte abnormalities; icu care or burn unit indicated| blisters covering 30% body surface area or more|10.820000000000022|66.10000000000002|15.725000000000005|6.2755555555555596|14.69675882352941|12.0275|16.78|-6.10222222222222|12.836470588235294|2.8810000000000002|93.86999999999999|69.96656701596841|28.900000000000002|25.822222222222223\n",
      "\n",
      "a corticotroph adenoma composed of faintly basophilic or chromophobic pas-positive cells with weak or patchy positivity for acth, consistent with the scant, small secretory granules seen ultrastructurally. (who 2017)|a neoplastic process adenoma plan of faintly basophilic or chromophobic pas-positive cells with weak or patchy amount of acth, consistent with the scant, small secretory grain seen ultrastructurally.  ( who 2017)|11.248534482758657|39.901250000000005|15.292586206896551|11.66875|13.080166666666667|12.3251|17.704827586206893|14.75875|12.143999999999998|12.475000000000001|79.77416029015912|76.64453405168562|23.731034482758623|21.400000000000002\n",
      "\n",
      "a corticotroph adenoma composed of faintly basophilic or chromophobic pas-positive cells with weak or patchy positivity for acth, consistent with the scant, small secretory granules seen ultrastructurally. (who 2017)|a tumor composed of faintly basophilic or chromosome-positive cells with weak or patchy positivity for acth, consistent with the scant, small secretory granules seen ultrastructurally. (who 2017)|11.248534482758657|20.79916666666668|15.292586206896551|13.712037037037042|13.328166666666666|13.067424137931035|17.704827586206893|15.096296296296302|14.643999999999998|12.455862068965516|79.77416029015912|73.38155456243756|23.731034482758623|21.696296296296296\n",
      "\n",
      "a corticotroph adenoma composed of faintly basophilic or chromophobic pas-positive cells with weak or patchy positivity for acth, consistent with the scant, small secretory granules seen ultrastructurally. (who 2017)| a corticotroph carcinoma is a carcinoma|11.248534482758657|18.44428571428574|15.292586206896551|12.425714285714289|13.328166666666666|13.902050000000001|17.704827586206893|-12.885714285714286|14.643999999999998|3.7650000000000006|79.77416029015912|54.195869768830164|23.731034482758623|19.942857142857143\n",
      "\n",
      "the linkage of phosphoribosyl dephospho-coenzyme a to protein via peptidyl-serine, to form o-(phosphoribosyl dephospho-coenzyme a)-l-serine; it is uncertain whether the phosphoribosyl glycosidic attachment to the dephospho-coenzyme a is alpha or beta, and through the 2' or the 3' position. [resid:aa0167]|the molecule function of phosphoribosyl dephospho-coenzyme a to protein via peptidyl-serine , to form o- ( phosphoribosyl dephospho-coenzyme a ) -l-serine ; it is uncertain whether the phosphoribosyl glycosidic joining to the dephospho-coenzyme a is start or beta , and through the 2 ' or the 3 ' position .  [ reside: aa0167]|10.990000000000009|44.69666666666669|16.695000000000004|13.732592592592596|14.045343478260872|13.718900000000001|24.302000000000007|18.7637037037037|15.872608695652175|15.373600000000003|93.86999999999999|96.44225707644962|26.0|24.874074074074073\n",
      "\n",
      "the linkage of phosphoribosyl dephospho-coenzyme a to protein via peptidyl-serine, to form o-(phosphoribosyl dephospho-coenzyme a)-l-serine; it is uncertain whether the phosphoribosyl glycosidic attachment to the dephospho-coenzyme a is alpha or beta, and through the 2' or the 3' position. [resid:aa0167]|the linkage of cellular protein building blocks are alpha or beta, and through the 2' or 3' position. [resid:aa0167]|10.990000000000009|85.87671052631579|16.695000000000004|3.641315789473687|14.045343478260872|12.428252380952381|24.302000000000007|-0.5199999999999996|15.872608695652175|4.454285714285717|93.86999999999999|58.53822981607831|26.0|18.53684210526316\n",
      "\n",
      "the linkage of phosphoribosyl dephospho-coenzyme a to protein via peptidyl-serine, to form o-(phosphoribosyl dephospho-coenzyme a)-l-serine; it is uncertain whether the phosphoribosyl glycosidic attachment to the dephospho-coenzyme a is alpha or beta, and through the 2' or the 3' position. [resid:aa0167]| change|10.990000000000009|162.505|16.695000000000004|-8.91|14.045343478260872|14.311966666666669|24.302000000000007|-127.42|15.872608695652175|-7.370000000000001|93.86999999999999|0.0|26.0|0.8\n",
      "\n",
      "brief pain inventory - check yes or no if the adjective applies to your pain: aching.|brief pain list - check yes or no if the adjective give to your pain: pain.|82.39000000000001|108.82750000000001|3.7550000000000026|0.06750000000000256|8.219166666666666|6.113833333333334|-11.275000000000002|-14.95|3.3580000000000005|0.21799999999999997|44.250742366654144|22.125371183327072|13.200000000000001|5.7\n",
      "\n",
      "brief pain inventory - check yes or no if the adjective applies to your pain: aching.|brief pain inventory - check yes or no if the adjective applies to your pain: aching.|82.39000000000001|82.39000000000001|3.7550000000000026|3.7550000000000026|8.219166666666666|8.835408333333334|-11.275000000000002|-10.907499999999999|3.3580000000000005|1.2541666666666664|44.250742366654144|44.250742366654144|13.200000000000001|13.200000000000001\n",
      "\n",
      "brief pain inventory - check yes or no if the adjective applies to your pain: aching.| brief pain inventory|82.39000000000001|75.87500000000001|3.7550000000000026|3.6700000000000017|8.591166666666666|16.5165|-11.275000000000002|-46.07|7.1080000000000005|-0.08999999999999986|44.250742366654144|31.29|13.200000000000001|11.600000000000001\n",
      "\n",
      "a peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor alpha (fr alpha or folr1), including fr30, fr56, fr76, fr113, and fr238, with potential immunomodulating and antineoplastic activity. upon administration, the multi-epitope fr alpha peptide vaccine may induce a cytotoxic t-lymphocyte (ctl) response against fr alpha-overexpressing tumor cells. fr alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in a majority of ovarian cancers and in about 50% of breast cancers. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c101777\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c101777\" nci thesaurus)|an immunologic factor vaccine defends five immunogenic peptide site of the human folate organ start (for a start or folr1), including fr30, fr56, fr76, fr113, and fr238, with potential immunomodulating and antineoplastic activity.  upon justice, the multi-epitope for alpha peptide vaccine may induce a cytotoxic t-lymphocyte (ctl) response against four alpha-overexpressing tumor cells.  to start is a high-affinity folate-binding protein and a member of the folate organ family; this organ is overexpressed in an age of ovarian cancers and in about 50 % of breast cancers.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c101777 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c101777 '' nice wordbook)|35.102775119617235|52.035810276679854|10.508708133971293|8.598577075098817|14.666300000000001|13.853192801771872|11.157052631578942|8.858782608695652|24.3226|12.940797342192688|65.36267825824541|65.36267825824541|23.665071770334933|20.877470355731226\n",
      "\n",
      "a peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor alpha (fr alpha or folr1), including fr30, fr56, fr76, fr113, and fr238, with potential immunomodulating and antineoplastic activity. upon administration, the multi-epitope fr alpha peptide vaccine may induce a cytotoxic t-lymphocyte (ctl) response against fr alpha-overexpressing tumor cells. fr alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in a majority of ovarian cancers and in about 50% of breast cancers. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c101777\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c101777\" nci thesaurus)|a protein vaccine containing five immunogenic peptide epitopes of the human folate receptor alpha (fralpha or folr1), including a molecule of fat and protein building blocks, with potential immunomodulating and anti-cancer activity. check for \"http://www.|35.102775119617235|23.376190476190516|10.508708133971293|12.897142857142857|14.4183|13.94274864864865|11.157052631578942|11.924571428571419|21.8226|15.061621621621619|65.36267825824541|78.74477315987392|23.665071770334933|26.38095238095238\n",
      "\n",
      "a peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor alpha (fr alpha or folr1), including fr30, fr56, fr76, fr113, and fr238, with potential immunomodulating and antineoplastic activity. upon administration, the multi-epitope fr alpha peptide vaccine may induce a cytotoxic t-lymphocyte (ctl) response against fr alpha-overexpressing tumor cells. fr alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in a majority of ovarian cancers and in about 50% of breast cancers. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c101777\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c101777\" nci thesaurus)| a|35.102775119617235|162.505|10.508708133971293|-8.91|14.4183|14.311966666666669|11.157052631578942|-142.12|21.8226|-15.219999999999999|65.36267825824541|0.0|23.665071770334933|0.8\n",
      "\n",
      "a substance intended for administration as a solution.|a substance conveys for justice as a success.|23.00000000000003|75.87500000000001|11.045000000000002|3.6700000000000017|9.954550000000001|11.9283|-39.455000000000005|-46.07|9.6525|4.353750000000002|44.250742366654144|44.250742366654144|21.6|21.6\n",
      "\n",
      "a substance intended for administration as a solution.|a substance intended for administration as a solution.|23.00000000000003|23.00000000000003|11.045000000000002|11.045000000000002|9.954550000000001|10.877477777777777|-39.455000000000005|-38.72|9.6525|5.416666666666668|44.250742366654144|44.250742366654144|21.6|21.6\n",
      "\n",
      "a substance intended for administration as a solution.| a solution|23.00000000000003|90.99000000000004|11.045000000000002|1.3133333333333361|9.954550000000001|15.6774|-39.455000000000005|-79.06666666666666|9.6525|-6.477499999999999|44.250742366654144|31.29|21.6|14.533333333333331\n",
      "\n",
      "test names of questionnaire questions associated with the functional assessment of multiple sclerosis (fams) for the clinical data interchange standards consortium (cdisc) standard data tabulation model (sdtm).|test names of form ask associated with the functional activity of product sclerosis (farms) for the clinical data change flag consortium (disc) standard data tabulation model (sdtm).|20.79916666666668|39.59916666666669|13.712037037037042|11.089814814814819|15.502366666666669|13.163107407407407|18.14518518518519|12.047407407407412|22.946666666666665|18.062222222222225|88.50148473330829|76.64453405168562|29.1037037037037|23.177777777777777\n",
      "\n",
      "test names of questionnaire questions associated with the functional assessment of multiple sclerosis (fams) for the clinical data interchange standards consortium (cdisc) standard data tabulation model (sdtm).|test names of questionnaire items associated with the functional assessment of multiple sclerosis (fams) for the clinical data interchange standards consortium (cdisc) standard data tabulation model (sdtm).|20.79916666666668|20.79916666666668|13.712037037037042|13.712037037037042|15.502366666666669|15.60947142857143|18.14518518518519|17.491851851851848|22.946666666666665|14.839285714285715|88.50148473330829|88.50148473330829|29.1037037037037|29.1037037037037\n",
      "\n",
      "test names of questionnaire questions associated with the functional assessment of multiple sclerosis (fams) for the clinical data interchange standards consortium (cdisc) standard data tabulation model (sdtm).| test names of questionnaire questions associated with the functional assessment of multiple sclerosis|20.79916666666668|29.467857142857156|13.712037037037042|12.62714285714286|15.502366666666669|12.801833333333335|18.14518518518519|16.657142857142855|22.946666666666665|14.643999999999998|88.50148473330829|82.78555852321104|29.1037037037037|25.6\n",
      "\n",
      "a term that refers to any individual item or entity in a hierarchy or pedigree.|a term that name to any individual fact or entity in a series or breed.|46.942499999999995|69.5025|8.575000000000003|5.428333333333338|10.6965|8.591166666666666|-13.986666666666672|-17.12266666666667|6.166|3.654|58.53822981607831|44.250742366654144|21.666666666666668|13.66666666666667\n",
      "\n",
      "a term that refers to any individual item or entity in a hierarchy or pedigree.|a term that refers to any item or entity in a hierarchy or pedigree.|46.942499999999995|66.7871428571429|8.575000000000003|5.682857142857145|10.6965|10.3245|-13.986666666666672|-18.765714285714285|6.166|-0.41000000000000014|58.53822981607831|54.195869768830164|21.666666666666668|19.942857142857143\n",
      "\n",
      "a term that refers to any individual item or entity in a hierarchy or pedigree.| the term|46.942499999999995|147.39000000000004|8.575000000000003|-6.553333333333333|10.6965|11.7299|-13.986666666666672|-82.98666666666665|6.166|-8.8325|58.53822981607831|0.0|21.666666666666668|1.2000000000000002\n",
      "\n",
      "stage iv includes: (t4, n0, m0); (any t, n1, m0); (any t, n2, m0); (any t, any n, m1). t4: tumor invades adjacent organs, or through the kidney into the perinephric fat. n0: no regional lymph node metastasis. n1: metastasis in a single lymph node, 2 cm or less in greatest dimension. n2: metastasis in a single lymph node, more than 2 cm in greatest dimension; or multiple lymph nodes. m0: no distant metastasis. m1: distant metastasis. (ajcc 8th ed.)|stage i includes: (t4, n0, m0); (any t, n1, m0); (any t, n2, m0); (any t, any n, m1).  t4: tumor enters the adjacent meat, or through the kidney into the perinephric fat.  n0: no regional lymph node metastasis.  n1: metastasis in a single lymph node, 2 cm or less in greatest shape.  n2: metastasis in a single lymph node, more than 2 cm in greatest shape; or product lymph nodes.  m0: no distant metastasis.  m1: distant metastasis.  ( ajcc 8th ed.)|84.66027777777781|100.79103620474407|3.6591666666666676|1.6576779026217245|14.198625000000002|13.762298181818183|-5.9580000000000055|-6.0161797752809|3.116500000000002|0.578977272727272|52.15|48.921036374958376|16.055555555555554|13.843196004993757\n",
      "\n",
      "stage iv includes: (t4, n0, m0); (any t, n1, m0); (any t, n2, m0); (any t, any n, m1). t4: tumor invades adjacent organs, or through the kidney into the perinephric fat. n0: no regional lymph node metastasis. n1: metastasis in a single lymph node, 2 cm or less in greatest dimension. n2: metastasis in a single lymph node, more than 2 cm in greatest dimension; or multiple lymph nodes. m0: no distant metastasis. m1: distant metastasis. (ajcc 8th ed.)|stage iv includes: (t4, n0, m0); t4: tumor invades adjacent organs, or through the kidney into the tissue surrounding a single lymph node, more than 2 centimeters in greatest measurement; t1: metastasis. t2: t3|84.66027777777781|70.14470588235295|3.6591666666666676|7.698823529411765|14.033291666666669|14.429642857142857|-5.9580000000000055|13.371764705882352|1.4498333333333342|9.524285714285714|52.15|79.77416029015912|16.055555555555554|22.094117647058823\n",
      "\n",
      "stage iv includes: (t4, n0, m0); (any t, n1, m0); (any t, n2, m0); (any t, any n, m1). t4: tumor invades adjacent organs, or through the kidney into the perinephric fat. n0: no regional lymph node metastasis. n1: metastasis in a single lymph node, 2 cm or less in greatest dimension. n2: metastasis in a single lymph node, more than 2 cm in greatest dimension; or multiple lymph nodes. m0: no distant metastasis. m1: distant metastasis. (ajcc 8th ed.)| stage iv includes: (tumor invades adjacent organs,or through the kidney into the perinephric fat); (any t, no n, no m|84.66027777777781|44.52000000000001|3.6591666666666676|12.26666666666667|14.099425000000002|13.015560869565219|-5.9580000000000055|13.624761904761904|2.116500000000002|8.91|52.15|93.86999999999999|16.055555555555554|25.542857142857144\n",
      "\n",
      "a complex syndrome resulting from various genetic and epigenetic anomalies of the 11p15.5 chromosomal region, leading to dysregulated expression of imprinted genes. specific genes involved include cdkn1c, h19, igf2, and kcnq1ot1. one of the key genetic anomalies is an imbalance between the paternally expressed igf2 growth enhancer gene and the maternally expressed h19 growth suppressor gene, leading to fetal and postnatal overgrowth. the condition is typically characterized by macrosomia, macroglossia, umbilical hernia or more severe abdominal wall anomalies such as omphalocele, ear lobe indentations, and hypoglycemia associated with hyperinsulinemia due to pancreatic islet cell hyperplasia. patients with this syndrome have an increased risk for development of embryonal tumors (particularly wilms tumor and hepatoblastoma) and adrenal cortex carcinoma.|a whole syndrome happens from various genetic and epigenetic positions of the 11p15. 5 chromosomal region, leading to a dysregulated squeeze of imprinted genes.  fact genes involved include cdkn1c, h19, igf2, and kcnq1ot1.  one of the key genetic positions is an imbalance between the paternally mail igf2 growth enhancer gene and the maternally mail h19 growth gene gene, leading to fetal and postnatal overgrowth.  the condition is typically distinguished by macrosomia, birth_defect, duct hernia or more severe abdominal wall position such as hernia, ear lobe space, and symptom associated with hyperinsulinemia due to pancreatic islet cell dysplasia.  case with this syndrome have an change risk for a section of embryonal tumors (particularly wilms tumor and hepatoblastoma) and adrenal cortex cancer.|12.716153846153844|44.216290322580676|15.637973137973141|11.49276497695853|14.455580341880342|13.106248745519714|19.832136752136755|15.677741935483876|17.7474358974359|10.908082437275986|91.6077398476788|83.62604259439757|27.198534798534798|23.2147465437788\n",
      "\n",
      "a complex syndrome resulting from various genetic and epigenetic anomalies of the 11p15.5 chromosomal region, leading to dysregulated expression of imprinted genes. specific genes involved include cdkn1c, h19, igf2, and kcnq1ot1. one of the key genetic anomalies is an imbalance between the paternally expressed igf2 growth enhancer gene and the maternally expressed h19 growth suppressor gene, leading to fetal and postnatal overgrowth. the condition is typically characterized by macrosomia, macroglossia, umbilical hernia or more severe abdominal wall anomalies such as omphalocele, ear lobe indentations, and hypoglycemia associated with hyperinsulinemia due to pancreatic islet cell hyperplasia. patients with this syndrome have an increased risk for development of embryonal tumors (particularly wilms tumor and hepatoblastoma) and adrenal cortex carcinoma.|a complex syndrome resulting from various genetic and epigenetic anomalies of the 11p15.5 chromosome region, leading to dysregulated expression of imprinted genes. specific genes involved are cdkn1c, h19, and kcnq1ot1. the condition is typically characterized by|12.716153846153844|33.20000000000002|15.637973137973141|10.864444444444448|14.649020341880343|14.490395495495497|19.832136752136755|4.351111111111109|19.697435897435902|13.123963963963966|91.6077398476788|66.37611354998121|27.198534798534798|23.6\n",
      "\n",
      "a complex syndrome resulting from various genetic and epigenetic anomalies of the 11p15.5 chromosomal region, leading to dysregulated expression of imprinted genes. specific genes involved include cdkn1c, h19, igf2, and kcnq1ot1. one of the key genetic anomalies is an imbalance between the paternally expressed igf2 growth enhancer gene and the maternally expressed h19 growth suppressor gene, leading to fetal and postnatal overgrowth. the condition is typically characterized by macrosomia, macroglossia, umbilical hernia or more severe abdominal wall anomalies such as omphalocele, ear lobe indentations, and hypoglycemia associated with hyperinsulinemia due to pancreatic islet cell hyperplasia. patients with this syndrome have an increased risk for development of embryonal tumors (particularly wilms tumor and hepatoblastoma) and adrenal cortex carcinoma.| a|12.716153846153844|162.505|15.637973137973141|-8.91|14.649020341880343|14.311966666666669|19.832136752136755|-142.12|19.697435897435902|-15.219999999999999|91.6077398476788|0.0|27.198534798534798|0.8\n",
      "\n",
      "a contraceptive diaphragm is a closely fitting membrane placed between the posterior aspect of the pubic bone and the posterior vaginal fornix. the device covers the cervix completely and is used with a spermicide to prevent pregnancy. this generic type of device may include an introducer.|a device disk is a closely be sheet placed between the tooth aspect of the pubic bone and the tooth vaginal fornix.  the device covers the cervix completely and is used with a spermicide to prevent pregnancy.  this wine type of device may include an introduce.|51.71032608695654|78.33000000000001|8.903695652173912|5.315000000000001|11.948772463768117|10.362868333333335|5.5782608695652165|1.4258333333333368|11.01536231884058|4.172500000000003|73.38155456243756|62.58|23.730434782608697|18.133333333333333\n",
      "\n",
      "a contraceptive diaphragm is a closely fitting membrane placed between the posterior aspect of the pubic bone and the posterior vaginal fornix. the device covers the cervix completely and is used with a spermicide to prevent pregnancy. this generic type of device may include an introducer.|a contraceptive diaphragm is a closely fitting membrane placed between the back aspect of the pubic bone and the posterior vaginal fornix. the device covers the cervix completely and is used with spermicide to prevent pregnancy. this generic type of device may include|51.71032608695654|54.56573643410857|8.903695652173912|9.209302325581397|11.948772463768117|11.90010303030303|5.5782608695652165|10.389767441860457|11.01536231884058|9.988560606060602|73.38155456243756|80.79043260188672|23.730434782608697|24.337984496124033\n",
      "\n",
      "a contraceptive diaphragm is a closely fitting membrane placed between the posterior aspect of the pubic bone and the posterior vaginal fornix. the device covers the cervix completely and is used with a spermicide to prevent pregnancy. this generic type of device may include an introducer.| contraceptive of the diaphragm is a closely fitting membrane placed between the chest bone and the bladder|51.71032608695654|71.06500000000001|8.903695652173912|7.818888888888889|11.948772463768117|11.22732105263158|5.5782608695652165|13.28222222222222|11.01536231884058|10.876315789473686|73.38155456243756|76.64453405168562|23.730434782608697|20.53333333333333\n",
      "\n",
      "molecular assay reagents intended to identify subtypes of influenza virus type a (single-stranded rna viruses of the family orthomyxoviridae) that affect birds, by detecting the ribonucleic acid (rna) of the target virus. influenza a virus subtypes that cause avian influenza usually include the surface glycoproteins h5 or h7 (i.e., subtypes h5n1 and h7n2); these viruses may occasionally cause human influenza, a disease characterized by sudden onset of high fever, myalgia, headache, severe malaise, nonproductive cough, sore throat, and rhinitis.|molecular act reagents convey to recognize subtypes of influenza virus type a (single-stranded rna viruses of the family orthomyxoviridae) that change birds, by spy the ribonucleic acid (rna) of the target virus.  influenza a virus subtypes that cause avian influenza usually include the surface glycoproteins h5 or h7 ( i.e. , subtypes h5n1 and h7n2 ) ; these viruses may occasionally cause human influenza , a disease distinguish by sudden start of high fever , pain , ache , severe malaise , nonproductive cough , sore throat , and rhinitis .|25.881544303797483|56.66117391304351|13.574531645569625|9.927304347826087|14.502375|14.027645679012346|16.396962025316455|12.929565217391307|25.240374999999993|24.172592592592594|91.76029239273379|85.1180024436664|28.092151898734176|23.446956521739132\n",
      "\n",
      "molecular assay reagents intended to identify subtypes of influenza virus type a (single-stranded rna viruses of the family orthomyxoviridae) that affect birds, by detecting the ribonucleic acid (rna) of the target virus. influenza a virus subtypes that cause avian influenza usually include the surface glycoproteins h5 or h7 (i.e., subtypes h5n1 and h7n2); these viruses may occasionally cause human influenza, a disease characterized by sudden onset of high fever, myalgia, headache, severe malaise, nonproductive cough, sore throat, and rhinitis.|molecular assay reagents intended to identify subtypes of influenza virus type a (single-stranded rna viruses of the family orthomyxoviridae) that affect birds, by detecting the ribonucleic acid (rna) of a|25.881544303797483|-4.09499999999997|13.574531645569625|21.283333333333335|13.841041666666667|14.105575|16.396962025316455|24.825333333333333|18.57370833333333|19.739062499999996|91.76029239273379|125.16|28.092151898734176|33.333333333333336\n",
      "\n",
      "molecular assay reagents intended to identify subtypes of influenza virus type a (single-stranded rna viruses of the family orthomyxoviridae) that affect birds, by detecting the ribonucleic acid (rna) of the target virus. influenza a virus subtypes that cause avian influenza usually include the surface glycoproteins h5 or h7 (i.e., subtypes h5n1 and h7n2); these viruses may occasionally cause human influenza, a disease characterized by sudden onset of high fever, myalgia, headache, severe malaise, nonproductive cough, sore throat, and rhinitis.| molecular assay reagents intended to identify subtypes of influenza virus type a (single-stranded rna viruses of the family orthomyxoviridae) that affect birds, by detecting the ribonucleic acid (rna) of the target virus|25.881544303797483|-0.9872727272727104|13.574531645569625|21.595151515151517|14.502375|14.8465|16.396962025316455|24.884848484848483|25.240374999999993|20.965714285714284|91.76029239273379|132.75222709996243|28.092151898734176|35.018181818181816\n",
      "\n",
      "a rare carcinoma that arises from the cervix. it is characterized by the presence of cystic spaces surrounded by palisaded epithelial cells. the cystic spaces contain eosinophilic hyaline material or mucin. nuclear pleomorphism, necrotic changes, and a high mitotic rate are also present.|a temporal concept cancer that protest from the cervix.  it is distinguished by the presence of cystic spaces touch by protecting epithelial cells.  the cystic spaces contain eosinophilic hyaline applicant or machine.  nuclear pleomorphism, necrotic changes, and a high mitotic rate are also present.|28.906000000000006|47.894000000000034|11.364|8.914297872340427|11.146676744186047|11.024634954407295|-0.7795348837209275|0.2876595744680799|10.233372093023256|7.080547112462003|68.55295529734659|69.96656701596841|25.765581395348836|25.036595744680852\n",
      "\n",
      "a rare carcinoma that arises from the cervix. it is characterized by the presence of cystic spaces surrounded by palisaded epithelial cells. the cystic spaces contain eosinophilic hyaline material or mucin. nuclear pleomorphism, necrotic changes, and a high mitotic rate are also present.|a rare cancer that arises from the cervix. it is characterized by the presence of cystic spaces surrounded by palisaded epithelial cells. the cysts contain eosinophilic hyaline material or mucin. nuclear pleomorph|28.906000000000006|32.158750000000026|11.364|10.761250000000004|11.146676744186047|12.658427272727273|-0.7795348837209275|-3.373750000000001|10.233372093023256|8.385909090909088|68.55295529734659|64.5059875127883|25.765581395348836|24.450000000000003\n",
      "\n",
      "a rare carcinoma that arises from the cervix. it is characterized by the presence of cystic spaces surrounded by palisaded epithelial cells. the cystic spaces contain eosinophilic hyaline material or mucin. nuclear pleomorphism, necrotic changes, and a high mitotic rate are also present.| a rare carcinoma that arises from the female genital tract|28.906000000000006|57.23363636363638|11.364|8.009090909090911|11.146676744186047|13.442533333333335|-0.7795348837209275|-0.18181818181818343|10.233372093023256|4.587499999999999|68.55295529734659|62.58|25.765581395348836|18.94545454545455\n",
      "\n",
      "non-payable g-code for reporting functional limitation on physical therapy claim form|non-payable g-code for news functional rule on physical therapy claim form|18.77909090909094|49.54272727272729|13.372727272727271|9.081818181818182|15.212838461538462|13.998223076923077|13.181818181818176|7.301818181818181|11.518461538461537|7.533076923076923|76.64453405168562|62.58|26.218181818181815|18.94545454545455\n",
      "\n",
      "non-payable g-code for reporting functional limitation on physical therapy claim form|non-payable g-code for functional limitation on physical therapy claim form.|18.77909090909094|24.100000000000023|13.372727272727271|11.14|15.212838461538462|16.105053846153847|13.181818181818176|-19.216|11.518461538461537|5.370000000000001|76.64453405168562|49.473833993334296|26.218181818181815|22.0\n",
      "\n",
      "non-payable g-code for reporting functional limitation on physical therapy claim form| non-payable code for reporting a physical therapy report|18.77909090909094|47.30000000000004|13.372727272727271|8.89777777777778|15.212838461538462|14.230281818181819|13.181818181818176|-0.22222222222222143|11.518461538461537|5.47909090909091|76.64453405168562|69.96656701596841|26.218181818181815|25.822222222222223\n",
      "\n",
      "an elaboration of the sequence of biological or biochemical events that result in the transport of molecules from one physiological space to another.|a development of the rate of biological or biochemical events that result in the move of unit from one physiological space to another.|22.2842391304348|40.67554347826092|13.008043478260873|10.442826086956522|10.955995652173913|9.582952173913045|6.728695652173911|2.893913043478264|15.872608695652175|12.80086956521739|69.96656701596841|62.58|21.991304347826087|18.51304347826087\n",
      "\n",
      "an elaboration of the sequence of biological or biochemical events that result in the transport of molecules from one physiological space to another.|an elaboration of the sequence of molecular events that result in the transport of molecules from one physiological space to another.|22.2842391304348|31.00607142857146|13.008043478260873|11.543095238095237|10.955995652173913|10.641645454545454|6.728695652173911|3.7295238095238084|15.872608695652175|8.26227272727273|69.96656701596841|66.37611354998121|21.991304347826087|21.34285714285714\n",
      "\n",
      "an elaboration of the sequence of biological or biochemical events that result in the transport of molecules from one physiological space to another.| a development of the sequence of biological and biochemical events that result in the transport of molecules from one physiological space to another.|22.2842391304348|32.504999999999995|13.008043478260873|11.706666666666667|10.955995652173913|11.2041|6.728695652173911|6.693333333333335|15.872608695652175|8.935200000000002|69.96656701596841|69.96656701596841|21.991304347826087|21.46666666666667\n",
      "\n",
      "the term 'phyto' originated from a greek word meaning plant. phytonutrients are certain organic components of plants, and these components are thought to promote human health. fruits, vegetables, grains, legumes, nuts and teas are rich sources of phytonutrients. unlike the traditional nutrients (protein, fat, vitamins, minerals), phytonutrients are not 'essential' for life, so some people prefer the term 'phytochemical'. (usda agricultural research service)|the term 'phyto ' begins from a greek word meaning plant.  phytonutrients are certain organic part of plants, and these parts are thought to play human health.  fruits, herb, grains, pod, nuts and teas are rich sources of phytonutrients.  unlike the traditional nutrients (protein, fat, vitamins, minerals), phytonutrients are not 'essential ' for life, so some people pay the term 'phytochemical '.  ( usda agricultural research service)|36.93171428571432|69.69242253521126|11.238285714285713|7.066309859154931|10.527333015873015|10.003033901918977|13.747936507936505|9.63154929577465|12.905714285714282|7.819594882729209|75.35629887408219|67.10957353463067|23.452698412698414|18.637746478873243\n",
      "\n",
      "the term 'phyto' originated from a greek word meaning plant. phytonutrients are certain organic components of plants, and these components are thought to promote human health. fruits, vegetables, grains, legumes, nuts and teas are rich sources of phytonutrients. unlike the traditional nutrients (protein, fat, vitamins, minerals), phytonutrients are not 'essential' for life, so some people prefer the term 'phytochemical'. (usda agricultural research service)|the term 'phyto' originated from a greek word meaning plant. phytochemical substances are certain organic components of plants, and these components are thought to promote human health. fruits, vegetables, grains, legumes and teas are rich sources of phytonutrients. these nutrients are not|36.93171428571432|49.134642857142865|11.238285714285713|9.014523809523808|10.527333015873015|9.67783953488372|13.747936507936505|6.80952380952381|12.905714285714282|10.342906976744185|75.35629887408219|62.58|23.452698412698414|19.43809523809524\n",
      "\n",
      "the term 'phyto' originated from a greek word meaning plant. phytonutrients are certain organic components of plants, and these components are thought to promote human health. fruits, vegetables, grains, legumes, nuts and teas are rich sources of phytonutrients. unlike the traditional nutrients (protein, fat, vitamins, minerals), phytonutrients are not 'essential' for life, so some people prefer the term 'phytochemical'. (usda agricultural research service)| the term 'phytochem' is derived from a greek word|36.93171428571432|95.165|11.238285714285713|2.4700000000000024|10.527333015873015|11.359372727272728|13.747936507936505|-4.903999999999996|12.905714285714282|1.625454545454545|75.35629887408219|44.250742366654144|23.452698412698414|12.0\n",
      "\n",
      "a sac or recess formed by a fold of the peritoneum.|a cell part or end formed by a fold of the peritoneum.|85.88886363636365|94.995|2.6459090909090897|1.5|7.053009090909091|5.547533333333334|-31.901818181818186|-28.26333333333333|1.1972727272727255|1.0549999999999997|31.29|22.125371183327072|9.472727272727274|5.733333333333333\n",
      "\n",
      "a sac or recess formed by a fold of the peritoneum.|a sac or recessformed by a fold of the peritoneum.|85.88886363636365|66.40000000000003|2.6459090909090897|5.240000000000002|7.053009090909091|9.651118181818184|-31.901818181818186|-34.50399999999999|1.1972727272727255|-1.124545454545455|31.29|31.29|9.472727272727274|10.0\n",
      "\n",
      "a sac or recess formed by a fold of the peritoneum.| a sac|85.88886363636365|147.39000000000004|2.6459090909090897|-6.553333333333333|7.053009090909091|15.6774|-31.901818181818186|-88.86666666666666|1.1972727272727255|-12.365|31.29|0.0|9.472727272727274|1.2000000000000002\n",
      "\n",
      "primary repair of injured organ/structure indicated|coil pay of injured organ/structure informs|-38.954999999999984|31.545000000000016|20.18333333333334|10.350000000000001|13.006557142857146|13.006557142857146|-4.25333333333333|-12.093333333333334|12.348571428571425|6.965714285714284|69.96656701596841|54.195869768830164|35.73333333333334|22.400000000000002\n",
      "\n",
      "primary repair of injured organ/structure indicated|primary repair of injured organ/structure indicated.|-38.954999999999984|-35.90999999999997|20.18333333333334|19.01333333333334|13.006557142857146|13.70365|-4.25333333333333|-51.62666666666666|12.348571428571425|7.6525|69.96656701596841|49.473833993334296|35.73333333333334|34.53333333333334\n",
      "\n",
      "primary repair of injured organ/structure indicated| repair|-38.954999999999984|120.20500000000001|20.18333333333334|-3.01|13.006557142857146|14.311966666666669|-4.25333333333333|-127.42|12.348571428571425|-7.370000000000001|69.96656701596841|31.29|35.73333333333334|20.8\n",
      "\n",
      "the 1.0 version of the standard for exchange of nonclinical data (send) animal rule implementation guide.|the 1.0 turns of the standard for change of nonclinical data (send) animal rule act guide.|53.3716666666667|85.09666666666669|7.140000000000004|2.715|10.35135|8.377600000000001|-22.424999999999997|-27.937499999999993|12.180625|7.765000000000001|47.79626449838941|36.13057984588678|19.633333333333336|12.133333333333333\n",
      "\n",
      "the 1.0 version of the standard for exchange of nonclinical data (send) animal rule implementation guide.|the 1.0 version of a standard for exchange of nonclinical data (send) animal rule implementation guide.|53.3716666666667|53.3716666666667|7.140000000000004|7.140000000000004|10.35135|10.559864705882354|-22.424999999999997|-22.79249999999999|12.180625|6.6470588235294095|47.79626449838941|47.79626449838941|19.633333333333336|19.633333333333336\n",
      "\n",
      "the 1.0 version of the standard for exchange of nonclinical data (send) animal rule implementation guide.| the 1.0 version of the official animal rule implementation guide|53.3716666666667|62.81613636363636|7.140000000000004|5.864090909090912|10.35135|12.1267|-22.424999999999997|-23.883636363636366|12.180625|6.942499999999999|47.79626449838941|44.250742366654144|19.633333333333336|16.745454545454546\n",
      "\n",
      "a monoamine compound with positive inotropic activity. dopamine is a naturally occurring catecholamine formed by decarboxylation of dehydroxyphenylalanine and a precursor of norepinephrine and epinephrine. dopamine binds to alpha-1 and beta-1 adrenergic receptors. mediated through myocardial beta-1 adrenergic receptors, dopamine increase heart rate and force, thereby increasing cardiac output. alpha-1 adrenergic receptor stimulation on vascular smooth muscle, leads to vasoconstriction and results in an increase in systemic vascular resistance. stimulation of dopaminergic receptors in renal vasculature, leads to renal blood vessel dilation, and an increase in glomerular filtration rate, renal blood flow, sodium excretion, and urine output.|an amine mix with film inotropic activity.  dopamine is a naturally appear hormone formed by chemical_process of dehydroxyphenylalanine and a person of norepinephrine and epinephrine.  dopamine binds to alpha-1 and beta-1 adrenergic organ.  lie through myocardial beta-1 adrenergic organ, dopamine increase heart rate and force, thereby change cardiac output.  alpha-1 adrenergic organ arousal on vascular smooth muscle, leads to constriction and results in an increase in systemic vascular action.  arousal of the dopaminergic organ in renal vasculature, leads to renal blood craft dilation, and an increase in the glomerular change rate, renal blood flow, sodium waste, and urine output.|6.126701030927848|38.82423076923078|15.84727540500737|11.535054945054945|13.87980996563574|12.000445454545455|18.162474226804125|13.208461538461542|17.63250859106529|9.428715034965034|86.9067327656494|81.07845644806022|27.81089837997055|24.019780219780223\n",
      "\n",
      "a monoamine compound with positive inotropic activity. dopamine is a naturally occurring catecholamine formed by decarboxylation of dehydroxyphenylalanine and a precursor of norepinephrine and epinephrine. dopamine binds to alpha-1 and beta-1 adrenergic receptors. mediated through myocardial beta-1 adrenergic receptors, dopamine increase heart rate and force, thereby increasing cardiac output. alpha-1 adrenergic receptor stimulation on vascular smooth muscle, leads to vasoconstriction and results in an increase in systemic vascular resistance. stimulation of dopaminergic receptors in renal vasculature, leads to renal blood vessel dilation, and an increase in glomerular filtration rate, renal blood flow, sodium excretion, and urine output.|a monoamine compound with positive inotropic activity. dopamine is a naturally occurring catecholamine formed by decarboxylation of an amino acid, and results in an increase in systemic blood pressure. alpha-1 and beta-2 receptor stimulation on vascular smooth muscle, leads to blood vessel di|6.126701030927848|25.05410852713183|15.84727540500737|13.325581395348838|13.87980996563574|12.97669393939394|18.162474226804125|13.808372093023252|17.63250859106529|12.450606060606063|86.9067327656494|82.78555852321104|27.81089837997055|25.268217054263566\n",
      "\n",
      "a monoamine compound with positive inotropic activity. dopamine is a naturally occurring catecholamine formed by decarboxylation of dehydroxyphenylalanine and a precursor of norepinephrine and epinephrine. dopamine binds to alpha-1 and beta-1 adrenergic receptors. mediated through myocardial beta-1 adrenergic receptors, dopamine increase heart rate and force, thereby increasing cardiac output. alpha-1 adrenergic receptor stimulation on vascular smooth muscle, leads to vasoconstriction and results in an increase in systemic vascular resistance. stimulation of dopaminergic receptors in renal vasculature, leads to renal blood vessel dilation, and an increase in glomerular filtration rate, renal blood flow, sodium excretion, and urine output.| a chemical|6.126701030927848|90.99000000000004|15.84727540500737|1.3133333333333361|13.87980996563574|15.6774|18.162474226804125|-79.06666666666666|17.63250859106529|-6.477499999999999|86.9067327656494|31.29|27.81089837997055|14.533333333333331\n",
      "\n",
      "cervical carcinoma with measured stromal invasion equal or more than 3 mm and less than 5 mm in depth. (figo 2018)|cervical cancer with being stromal spread equal or more than 3 mm and less than 5 mm in depth.  ( figure 2018)|79.34892857142859|103.2059782608696|4.800238095238097|1.721086956521738|12.428252380952381|11.17750606060606|-1.8704761904761895|-3.2417391304347802|4.23|0.6484848484848484|58.53822981607831|54.195869768830164|17.53333333333333|15.03478260869565\n",
      "\n",
      "cervical carcinoma with measured stromal invasion equal or more than 3 mm and less than 5 mm in depth. (figo 2018)|cancer with measured stromal invasion equal or more than 3 mm and less than 5mm in depth. (figo 2018)|79.34892857142859|94.78197368421053|4.800238095238097|2.399210526315791|12.428252380952381|12.254652380952383|-1.8704761904761895|-5.1621052631578905|4.23|0.23714285714285666|58.53822981607831|54.195869768830164|17.53333333333333|16.431578947368422\n",
      "\n",
      "cervical carcinoma with measured stromal invasion equal or more than 3 mm and less than 5 mm in depth. (figo 2018)| cervical carcinoma|79.34892857142859|6.390000000000015|4.800238095238097|13.113333333333333|12.428252380952381|19.6249|-1.8704761904761895|-63.386666666666656|4.23|2.942499999999999|58.53822981607831|44.250742366654144|17.53333333333333|27.866666666666664\n",
      "\n",
      "determination of where in an organism (i.e., organ system) or cell (i.e., organelle) a specific protein may be found.|the choice of where in a system (i.e., organ system) or cell (i.e., organ) a fact protein may be found.|56.68399122807017|97.70166666666668|6.139736842105265|0.46000000000000085|11.22732105263158|8.576|-62.835789473684216|-64.104|10.876315789473686|6.703500000000002|33.79706274219699|28.563731373894413|16.003508771929823|11.333333333333334\n",
      "\n",
      "determination of where in an organism (i.e., organ system) or cell (i.e., organelle) a specific protein may be found.|determination of where in an organism (i.e., organ system) or cell type may be found.|56.68399122807017|73.30875|6.139736842105265|3.965833333333336|11.22732105263158|9.954550000000001|-62.835789473684216|-50.70933333333333|10.876315789473686|2.5874999999999986|33.79706274219699|31.29|16.003508771929823|12.166666666666668\n",
      "\n",
      "determination of where in an organism (i.e., organ system) or cell (i.e., organelle) a specific protein may be found.| determination|56.68399122807017|-6.694999999999993|6.139736842105265|14.690000000000001|11.22732105263158|19.5753|-62.835789473684216|-106.84|10.876315789473686|3.620000000000001|33.79706274219699|31.29|16.003508771929823|20.8\n",
      "\n",
      "positive and negative syndrome scale - uncooperativeness.|film and negative syndrome scale - uncooperativeness.|-2.1746428571428282|21.99678571428572|14.432142857142857|11.060714285714287|17.092433333333332|14.460766666666668|-41.731428571428566|-45.09142857142857|20.034999999999997|16.895000000000003|44.250742366654144|38.32226702584281|24.257142857142856|18.54285714285714\n",
      "\n",
      "positive and negative syndrome scale - uncooperativeness.|positive and negative syndrome scale - cooperativeness.|-2.1746428571428282|9.91107142857146|14.432142857142857|12.74642857142857|17.092433333333332|17.344385714285714|-41.731428571428566|-42.57142857142857|20.034999999999997|12.617142857142852|44.250742366654144|44.250742366654144|24.257142857142856|24.257142857142856\n",
      "\n",
      "positive and negative syndrome scale - uncooperativeness.| positive and negative symptoms scale|-2.1746428571428282|59.745000000000005|14.432142857142857|6.416666666666668|17.092433333333332|17.517985714285714|-41.731428571428566|-16.993333333333332|20.034999999999997|4.947142857142854|44.250742366654144|54.195869768830164|24.257142857142856|22.400000000000002\n",
      "\n",
      "immunohistochemistry test systems (ihc's) are in vitro diagnostic devices consisting of polyclonal or monoclonal antibodies labeled with directions for use and performance claims, which may be packaged with ancillary reagents in kits. their intended use is to identify, by immunological techniques, antigens in tissues or cytologic specimens. similar devices intended for use with flow cytometry devices are not considered ihc's.|assay test systems (ihc 's) are in vitro diagnostic devices of polyclonal or monoclonal protein declaring with, command for use and process claims, which may be encase with ancillary reagents  kits.  their convey use is to recognize, by immunological method, substance in tissues or cytologic sample.  similar emblem conveys for use with flow cytometry emblem are not considered is 's.|9.720000000000027|45.820178571428585|15.630000000000003|10.781071428571426|12.260333333333334|13.062743010752689|16.52666666666667|11.35301587301587|16.987000000000002|7.8184408602150555|84.2509034076193|82.78555852321104|25.333333333333336|24.07777777777778\n",
      "\n",
      "immunohistochemistry test systems (ihc's) are in vitro diagnostic devices consisting of polyclonal or monoclonal antibodies labeled with directions for use and performance claims, which may be packaged with ancillary reagents in kits. their intended use is to identify, by immunological techniques, antigens in tissues or cytologic specimens. similar devices intended for use with flow cytometry devices are not considered ihc's.|immunohistochemistry systems (ihc's) are in vitro diagnostic devices consisting of proteins or monoclonal antibodies labeled with directions for use and performance claims, which may be packaged with ancillary reagents in kits. their intended use is to identify, by|9.720000000000027|16.123684210526363|15.630000000000003|15.730526315789472|12.260333333333334|11.891392307692307|16.52666666666667|19.855789473684215|16.987000000000002|15.372307692307693|84.2509034076193|91.22524239485473|25.333333333333336|25.494736842105265\n",
      "\n",
      "immunohistochemistry test systems (ihc's) are in vitro diagnostic devices consisting of polyclonal or monoclonal antibodies labeled with directions for use and performance claims, which may be packaged with ancillary reagents in kits. their intended use is to identify, by immunological techniques, antigens in tissues or cytologic specimens. similar devices intended for use with flow cytometry devices are not considered ihc's.| Immunohistochemistry test systems are in vitro diagnostic devices consisting of antibodies labeled with direction for use and performance claims, which may be packaged with ancillary reagents in kits. their intended use is to identify, by immunological techniques, antigens in tissues or cytologic specimens|9.720000000000027|5.691363636363633|15.630000000000003|17.930909090909093|12.260333333333334|12.472055555555556|16.52666666666667|22.092727272727274|16.987000000000002|17.34733333333333|84.2509034076193|101.39118822659097|25.333333333333336|27.89090909090909\n",
      "\n",
      "the manner in which a particular genetic trait or disorder is passed from one generation to the next.|the kind in which a part genetic trait or change is passed from one production to the next.|61.400000000000034|94.30000000000001|6.9311111111111146|2.342222222222226|9.792633333333335|7.160966666666667|-5.448888888888881|-8.715555555555557|9.28833333333333|6.671666666666667|49.473833993334296|31.29|14.711111111111112|8.044444444444444\n",
      "\n",
      "the manner in which a particular genetic trait or disorder is passed from one generation to the next.|the manner in which a certain genetic trait or disorder is passed from one generation to the next.|61.400000000000034|70.80000000000003|6.9311111111111146|5.6200000000000045|9.792633333333335|9.094015789473683|-5.448888888888881|-6.10222222222222|9.28833333333333|3.399473684210527|49.473833993334296|49.473833993334296|14.711111111111112|14.711111111111112\n",
      "\n",
      "the manner in which a particular genetic trait or disorder is passed from one generation to the next.| the manner in which a particular gene is passed from one generation to the next.|61.400000000000034|82.39000000000001|6.9311111111111146|3.7550000000000026|9.792633333333335|9.631041176470589|-5.448888888888881|-12.377500000000001|9.28833333333333|1.3829411764705881|49.473833993334296|38.32226702584281|14.711111111111112|10.700000000000001\n",
      "\n",
      "aids-related kaposi sarcoma localized on the palate. the lesions are small and flat rather than raised. this stage is associated with good risk of recovery.|aids-related neoplastic process cancer stage on the palate.  the lesions are small and flat rather than raised.  this stage is uniting with good risk of an act.|51.59525000000002|85.70383620689658|7.615500000000001|3.1064655172413786|9.532135897435897|9.197433333333334|-16.313599999999997|-14.063448275862065|6.091025641025642|1.9800000000000004|46.934999999999995|44.250742366654144|16.900000000000002|13.934482758620689\n",
      "\n",
      "aids-related kaposi sarcoma localized on the palate. the lesions are small and flat rather than raised. this stage is associated with good risk of recovery.|hiv-related kaposi sarcoma localized on the palate. the lesions are small and flat rather than raised. this stage is associated with good risk of recovery.|51.59525000000002|51.59525000000002|7.615500000000001|7.615500000000001|10.139443589743589|10.404262962962964|-16.313599999999997|-16.313599999999997|6.091025641025642|4.273888888888887|46.934999999999995|46.934999999999995|16.900000000000002|16.900000000000002\n",
      "\n",
      "aids-related kaposi sarcoma localized on the palate. the lesions are small and flat rather than raised. this stage is associated with good risk of recovery.| aids-related kaposi sarcoma|51.59525000000002|-8.724999999999994|7.615500000000001|15.469999999999999|10.139443589743589|19.7241|-16.313599999999997|-35.78|6.091025641025642|1.9800000000000004|46.934999999999995|54.195869768830164|16.900000000000002|31.6\n",
      "\n",
      "a type i keratin expressed predominately in gastrointestinal epithelia, merkel cells, and the taste buds of the oral mucosa.|a type i keratin nail predominately in gastrointestinal epithelia, merkel cells, and the taste buds of the oral membrane.|23.53986842105263|36.89776315789476|12.336052631578948|10.472894736842104|12.058373684210528|11.22732105263158|1.6463157894736824|0.717894736842112|13.603157894736846|12.859473684210528|62.58|58.53822981607831|20.642105263157895|18.53684210526316\n",
      "\n",
      "a type i keratin expressed predominately in gastrointestinal epithelia, merkel cells, and the taste buds of the oral mucosa.|a type i keratin expressed predominately in gastrointestinal epithelia, merkel cells, and the taste buds of the oral mucous fluid.|23.53986842105263|27.485000000000014|12.336052631578948|11.91|13.72047894736842|14.452861904761905|1.6463157894736824|3.3279999999999994|13.603157894736846|13.517142857142858|62.58|66.37611354998121|20.642105263157895|22.0\n",
      "\n",
      "a type i keratin expressed predominately in gastrointestinal epithelia, merkel cells, and the taste buds of the oral mucosa.| an epithelial tissue|23.53986842105263|54.72500000000002|12.336052631578948|6.620000000000001|12.058373684210528|16.5165|1.6463157894736824|-46.07|13.603157894736846|-0.08999999999999986|62.58|44.250742366654144|20.642105263157895|21.6\n",
      "\n",
      "for ndas, andas, and blas, this represents an application to modify the current indications or claims for a use for which the application was previously approved/licensed. efficacy supplements may only be submitted once the original-application has been approved/licensed.|in functional concept, and as, and blas, this permute an action to add the current datum or claims for a use for which the action was previously approved/licensed.  effectiveness attaches may only be accepted once the original-application has been approved/licensed.|15.873070175438642|40.270650406504075|14.192105263157895|11.037560975609761|12.355739024390244|11.182375757575757|12.994736842105265|10.75317073170731|14.897317073170733|9.34628787878788|69.96656701596841|69.96656701596841|20.856140350877194|20.100813008130082\n",
      "\n",
      "for ndas, andas, and blas, this represents an application to modify the current indications or claims for a use for which the application was previously approved/licensed. efficacy supplements may only be submitted once the original-application has been approved/licensed.|this represents an application to modify the current indications or claims for a use for which the application was previously approved or licensed. efficacy supplements may only be submitted once the original-application has been approved/licensed.|15.873070175438642|18.54190476190476|14.192105263157895|13.571428571428577|12.355739024390244|11.744240350877194|12.994736842105265|10.74857142857143|14.897317073170733|11.056228070175436|69.96656701596841|69.96656701596841|20.856140350877194|21.80952380952381\n",
      "\n",
      "for ndas, andas, and blas, this represents an application to modify the current indications or claims for a use for which the application was previously approved/licensed. efficacy supplements may only be submitted once the original-application has been approved/licensed.| for niacin and vitamin b3, this represents an application to change the current indication or claims for a use for which the application was previously approved/licensed. efficacy supplements may only be submitted once the original-application has been approved/licensed.|15.873070175438642|22.270769230769275|14.192105263157895|13.382564102564103|12.355739024390244|12.058828682170544|12.994736842105265|12.66153846153846|14.897317073170733|10.92968992248062|69.96656701596841|69.96656701596841|20.856140350877194|20.58461538461539\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of dna endoreduplication. [goc:mah]|any walk that changes or change the ratio, rate or extent of dna endoreduplication.  [ goc: mah]|18.742500000000007|75.50000000000003|12.508333333333336|4.964444444444446|12.915175000000001|10.41933137254902|-3.7946666666666715|-7.082222222222221|7.88625|2.1827450980392165|62.58|49.473833993334296|24.333333333333336|14.711111111111112\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of dna endoreduplication. [goc:mah]|any process that activates or increases the frequency, rate or extent of dna repair. [goc:mah]|18.742500000000007|46.942499999999995|12.508333333333336|8.575000000000003|12.915175000000001|12.417511764705882|-3.7946666666666715|-7.714666666666666|7.88625|3.8764705882352963|62.58|62.58|24.333333333333336|24.333333333333336\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of dna endoreduplication. [goc:mah]| Any process that activates or increases the frequency, rate or extent of cell division|18.742500000000007|44.97000000000003|12.508333333333336|10.713333333333338|12.915175000000001|12.3251|-3.7946666666666715|9.274666666666665|7.88625|8.353750000000002|62.58|82.78555852321104|24.333333333333336|24.666666666666668\n",
      "\n",
      "a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. this process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ros) derived from iron metabolism. glutathione peroxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ros production and reducing cellular iron uptake, respectively. in contrast, nadph oxidase and p53 act as positive regulators of ferroptosis by promotion of ros production and inhibition of expression of slc7a11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. misregulated ferroptosis has been implicated in multiple physiological and pathological processes. [goc:mtg_apoptosis, pmid:25236395, pmid:26794443]|a schedule, cell death distinguishes morphologically by the presence of smaller than normal mitochondria with change mitochondrial membrane spacing, change or decrease of mitochondria crista, and outer mitochondrial sheet rupture.  beginning of mitochondrial voltage-dependent anion move and mitogen-activated protein enzyme, upregulation of endoplasmic stomach stress, and action of the cystine / glutamate antiporter are having in the causing of ferroptosis.  this walk is distinguished by the net_income of lipid peroxidation products and lethal reactive oxygen kind (ros) make from iron metabolism.  glutathione oxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 serve as a negative control of ferroptosis by choosing rose display and reducing cellular iron uptake, respectively.  in contrast, nadph enzyme and p53 act as film control of ferroptosis by change of rose display and action of squeeze of slc7a11 (a fact light-chain subunit of the cystine/glutamate antiporter), respectively.  misregulated ferroptosis has been lead in product physiological and pathological transform.  [ goc : mtg_apoptosis , pmid:25236395 , pmid:26794443 ]|-8.855483870967703|30.650526315789506|19.995391705069128|15.052932330827073|15.116114109347443|12.97722549019608|28.057806451612905|22.750409356725147|20.959947089947086|12.999039215686274|111.57105673067723|103.1011095963569|31.82488479262673|27.54920634920635\n",
      "\n",
      "a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. this process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ros) derived from iron metabolism. glutathione peroxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ros production and reducing cellular iron uptake, respectively. in contrast, nadph oxidase and p53 act as positive regulators of ferroptosis by promotion of ros production and inhibition of expression of slc7a11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. misregulated ferroptosis has been implicated in multiple physiological and pathological processes. [goc:mtg_apoptosis, pmid:25236395, pmid:26794443]|a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of ferroptosis has been implicated in multiple physiological and|-8.855483870967703|-6.019038461538429|19.995391705069128|18.943205128205125|15.116114109347443|13.707749999999999|28.057806451612905|25.226666666666667|20.959947089947086|19.77375|111.57105673067723|103.77718969022045|31.82488479262673|30.364102564102566\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1); programmed death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|any chemical function that binds to any of the ligands for the organ schedule, cell death protein 1 (pd-1; pd1); schedule death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|98.76577586206898|101.37000000000002|3.0856896551724162|2.8466666666666676|14.342487096774192|14.105575|7.769655172413792|8.490666666666666|13.213870967741933|13.704374999999999|66.37611354998121|69.96656701596841|18.21379310344828|19.333333333333332\n",
      "\n",
      "any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1); programmed death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1).|98.76577586206898|85.87671052631579|3.0856896551724162|3.641315789473687|14.342487096774192|11.238|7.769655172413792|-4.23368421052632|13.213870967741933|3.116500000000002|66.37611354998121|58.53822981607831|18.21379310344828|18.53684210526316\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human b-cell maturation antigen (bcma; tnfrsf17), fused to one that is directed against the cd3 antigen found on t lymphocytes, with potential immunostimulating and antineoplastic activities. upon administration of anti-bcma/cd3 bite antibody amg 701, this bispecific antibody binds to both cd3 on cytotoxic t lymphocytes (ctls) and bcma found on bcma-expressing tumor cells. this activates and redirects ctls to bcma-expressing tumor cells, which results in the ctl-mediated cell death of bcma-expressing tumor cells. bcma, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.|a immunologic factor t-cell engager ( bite ) protein plan of two single-chain symbol break ( scfv ) , one directed against the tumor-associated substance ( taa ) human b-cell maturation antigen ( bcma ; tnfrsf17 ) , melt to one that is plan against the cd3 substance found on t leukocyte , with potential immunostimulating and antineoplastic trait .  upon justice of anti-bcma/cd3 bite protein is 701, this bispecific protein binds to both cd3 on cytotoxic t leukocyte (ctls) and become found on became-expressing growth cells.  this change and send styles to become-expressing growth cells, which results in the steel-mediated cell death of bcma-expressing tumor cells.  bcma, a member of the tumor death factor organ superfamily that is specifically overexpressed in malignant plasma cells, plays a key role in play plasma cell survival.|15.390000000000015|48.7276496350365|17.075000000000006|13.269722627737227|13.87226923076923|12.050054228855721|23.63266666666667|19.369635036496348|20.253999999999998|13.427263681592038|101.87285929039194|92.82114026448932|27.266666666666666|23.806715328467153\n",
      "\n",
      "a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human b-cell maturation antigen (bcma; tnfrsf17), fused to one that is directed against the cd3 antigen found on t lymphocytes, with potential immunostimulating and antineoplastic activities. upon administration of anti-bcma/cd3 bite antibody amg 701, this bispecific antibody binds to both cd3 on cytotoxic t lymphocytes (ctls) and bcma found on bcma-expressing tumor cells. this activates and redirects ctls to bcma-expressing tumor cells, which results in the ctl-mediated cell death of bcma-expressing tumor cells. bcma, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.|a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human protein complexes found on tumor cells, which results in the ctl-mediated cell death of|15.390000000000015|6.944285714285741|17.075000000000006|20.985714285714284|13.87226923076923|13.515500000000001|23.63266666666667|27.83085714285714|20.253999999999998|22.591|101.87285929039194|129.0119750255766|27.266666666666666|33.42857142857143\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "diagnosis of a disease or condition made before death.|diagnosis of a disease or condition made before death.|51.867500000000035|51.867500000000035|7.142777777777777|7.142777777777777|9.346233333333334|9.346233333333334|-35.724444444444444|-35.724444444444444|6.620000000000001|6.620000000000001|44.250742366654144|44.250742366654144|19.57777777777778|19.57777777777778\n",
      "\n",
      "diagnosis of a disease or condition made before death.|diagnosis of a disease or condition made before ami.|51.867500000000035|42.46750000000003|7.142777777777777|8.45388888888889|9.346233333333334|11.7795|-35.724444444444444|-36.37777777777777|6.620000000000001|1.7940000000000005|44.250742366654144|49.473833993334296|19.57777777777778|24.022222222222226\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "autologous human t-lymphocytes transduced with a retroviral vector encoding a t-cell receptor (tcr) specific for the human melanoma antigen a4 (mage-a4), with potential immunostimulatory and antineoplastic activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, mage-a4-specific tcr gene-transduced t-lymphocytes tbi-1201 binds to tumor cells expressing mage-a4. this may result in both an inhibition of growth and increased cell death for mage-a4-expressing tumor cells. the tumor-associated antigen mage-a4 is overexpressed by a variety of cancer cell types.|autologous human t-lymphocytes convert with a retroviral vector convert a t-cell, organ (tar) fact of the human skin_cancer substance a4 (mage-a4), with potential immunostimulatory and antineoplastic trait.  upon isolation, transduction, increases ex vivo, and reintroduction into the case, mage-a4-specific tcr gene-transduced t-lymphocytes tube-1201 binds to growth cells mail mage-a4.  this may result in both an action of growth and increased cell death for mage-a4-expressing tumor cells.  the tumor-associated substance mage-a4 is overexpressed by a difference of cancer cell types.|21.598000000000013|45.74997560975612|14.172|10.952341463414637|15.002372527472529|13.820375177304964|20.267341772151894|18.30682926829268|15.77236263736264|10.654822695035463|85.1180024436664|79.15813438933486|25.054177215189874|22.169756097560978\n",
      "\n",
      "autologous human t-lymphocytes transduced with a retroviral vector encoding a t-cell receptor (tcr) specific for the human melanoma antigen a4 (mage-a4), with potential immunostimulatory and antineoplastic activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, mage-a4-specific tcr gene-transduced t-lymphocytes tbi-1201 binds to tumor cells expressing mage-a4. this may result in both an inhibition of growth and increased cell death for mage-a4-expressing tumor cells. the tumor-associated antigen mage-a4 is overexpressed by a variety of cancer cell types.|t-cell receptors specific for a human melanoma antigen a4 (mage-a4), with potential immunostimulatory and anti-cancer activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, m|21.598000000000013|-3.767857142857139|14.172|17.262857142857147|15.002372527472529|15.7791625|20.267341772151894|18.96714285714285|15.77236263736264|13.063749999999999|85.1180024436664|91.22524239485473|25.054177215189874|29.885714285714286\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "any process that modulates the occurrence or rate of mesenchymal stem cell death by apoptotic process that contributes to the shaping of the nephron in the metanephros. [goc:mtg_apoptosis, goc:mtg_kidney_jan10]|any walk that changes the presence or rate of mesenchymal stem cell death by apoptosis walk that pay for the change of the nephron in the metanephros.  [ goc : mtg_apoptosis , goc : mtg_kidney_jan10 ]|34.58646551724141|82.87912162162164|12.03741379310345|6.295270270270269|11.536267741935484|9.099941666666666|16.488275862068964|10.062702702702701|13.060645161290324|7.306145833333332|76.64453405168562|62.58|22.351724137931036|16.048648648648648\n",
      "\n",
      "any process that modulates the occurrence or rate of mesenchymal stem cell death by apoptotic process that contributes to the shaping of the nephron in the metanephros. [goc:mtg_apoptosis, goc:mtg_kidney_jan10]|any process that modulates the occurrence or rate of mesenchymal stem cells death by programmed cell death that contributes to the shaping of the metanephros. [goc:mtg_apoptosis, goc:kidney_jan10]|34.58646551724141|39.59916666666669|12.03741379310345|11.089814814814819|11.536267741935484|11.222833333333334|16.488275862068964|15.314074074074071|13.060645161290324|11.975000000000001|76.64453405168562|69.96656701596841|22.351724137931036|20.214814814814815\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "cases of harm to a child caused by parents or other caregivers, defined by the federal government as: any recent act or failure to act on the part of a parent or caretaker which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act or failure to act which presents an imminent risk of serious harm.|cases of harm to a child caused by parents or other adult , choose by the agent government as : any recent act or failure to act on the part of a parent or official which results in death , serious physical or emotional harm , sexual use or mistreatment ; or an act or failure to act which greet an imminent risk of serious harm .|38.5758606557377|57.92802238805973|15.455819672131149|13.501865671641792|11.06259180327869|10.544886885245901|17.09245901639344|14.333134328358206|30.071967213114753|28.99098360655737|106.1095525859948|98.94766798666859|27.281967213114754|25.340298507462688\n",
      "\n",
      "cases of harm to a child caused by parents or other caregivers, defined by the federal government as: any recent act or failure to act on the part of a parent or caretaker which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act or failure to act which presents an imminent risk of serious harm.|any recent act or failure to act on the part of a parent or other caregiver which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act which presents an imminent risk of serious harm.|38.5758606557377|44.83000000000004|15.455819672131149|11.975000000000001|11.06259180327869|10.045007317073171|17.09245901639344|12.542|30.071967213114753|9.727804878048783|106.1095525859948|88.50148473330829|27.281967213114754|24.0\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the g2/m phase and cell death. this agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. docetaxel has been studied for use as a radiation-sensitizing agent. (nci04)|a semi-synthetic, second-generation texan make from a mix found in the european yew tree, taxus baccata.  docetaxel displays potent and broad antineoplastic properties; it binds to and change tubulin, thereby suppress tubule disassembly, which results in cell- cycle arrest at the g2/m phase and cell death.  this agent also suppresses pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by produce various mediators of the inflammatory phrase.  docetaxel has been thought to use as a radiation-sensitizing agent.  ( nci04)|7.490142857142899|28.12305617977529|16.388190476190477|13.75874157303371|14.051055555555555|13.484417730496455|20.110952380952387|17.59370786516854|17.08566666666666|11.606843971631207|91.76029239273379|86.2605770905806|27.196190476190477|24.19865168539326\n",
      "\n",
      "a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the g2/m phase and cell death. this agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. docetaxel has been studied for use as a radiation-sensitizing agent. (nci04)|a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad anti-cancer properties; it binds to and stabilizes tubulin|7.490142857142899|11.248534482758657|16.388190476190477|15.292586206896551|13.827855555555555|13.546112121212122|20.110952380952387|16.285517241379313|14.835666666666661|11.654545454545449|91.76029239273379|85.69119412168324|27.196190476190477|26.48965517241379\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "the number of days from the date of initial cancer diagnosis to the date of death.|the number of days from the date of sign cancer diagnosis to the date of death.|77.1025|87.67750000000001|4.492500000000003|3.017500000000002|7.390725|6.40385|-12.377500000000001|-13.48|5.998750000000001|5.115625000000001|44.250742366654144|38.32226702584281|13.200000000000001|10.700000000000001\n",
      "\n",
      "the number of days from the date of initial cancer diagnosis to the date of death.|the number of days from the initial cancer diagnosis to the date of death.|77.1025|72.83000000000003|4.492500000000003|4.840000000000003|7.390725|8.219166666666666|-12.377500000000001|-16.245714285714282|5.998750000000001|1.4740000000000002|44.250742366654144|44.250742366654144|13.200000000000001|14.228571428571428\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "a fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (tnf-alpha), with anti-inflammatory activity. upon administration, certolizumab binds to tnf-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering tnf-alpha inactive and inhibiting tnf-mediated inflammatory responses. tnf-alpha is a protein involved in inflammation, cell survival, and apoptosis.|a fab break of a cell, change monoclonal protein directed against the proinflammatory protein tumor death factor-alpha (tnf-alpha), with medicine activity.  upon justice, certolizumab binds to tnf-alpha, preventing the action of this protein with endogenous cell surface organ, thereby melt tnf-alpha inactive and suppress tnf-mediated inflammatory manner.  tnf-alpha is a protein involved in burning, cell survival, and apoptosis.|-22.29974137931032|26.640000000000015|19.97189655172414|13.270000000000003|15.69419230769231|13.143189696969698|23.280689655172413|16.72266666666667|24.67415384615385|10.57545454545454|97.70299368494294|91.22524239485473|32.69655172413793|28.666666666666664\n",
      "\n",
      "a fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (tnf-alpha), with anti-inflammatory activity. upon administration, certolizumab binds to tnf-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering tnf-alpha inactive and inhibiting tnf-mediated inflammatory responses. tnf-alpha is a protein involved in inflammation, cell survival, and apoptosis.|a protein complex involved in inflammation, cell survival, and apoptosis.|-22.29974137931032|24.100000000000023|19.97189655172414|11.14|15.156858974358977|13.957481818181819|23.280689655172413|-20.979999999999997|19.25748717948718|7.867272727272727|97.70299368494294|54.195869768830164|32.69655172413793|26.0\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "a monoclonal antibody directed against human hepatocyte growth factor receptor (hgfr or c-met), with potential antineoplastic activity. telisotuzumab binds to c-met, thereby preventing both c-met binding to its ligand, hgf and the subsequent activation of the hgf/c-met signaling pathway. this may cause cell death in c-met-expressing tumor cells. c-met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.|an immunologic factor protein directed against human hepatocyte growth factor organ (hgfr or c-met), with potential antineoplastic activity.  telisotuzumab binds to c-met, thereby preventing both c-met binding to its ligand, hgf and the subsequent beginning of the hgf/c-met tell path.  this may cause cell death in c-met-expressing growth cells.  c-met, an organ tyrosine kinase overexpressed or change in many growth, cell types, plays a key role in cancer cell growth, survival, growth, spread, and metastasis.|24.899486486486524|48.91638461538463|13.463081081081082|10.31194871794872|13.125982926829268|11.77366212624585|15.677297297297294|13.893333333333327|13.289024390243902|7.441345514950164|81.59433730351635|74.04565456527479|24.29837837837838|20.59897435897436\n",
      "\n",
      "a monoclonal antibody directed against human hepatocyte growth factor receptor (hgfr or c-met), with potential antineoplastic activity. telisotuzumab binds to c-met, thereby preventing both c-met binding to its ligand, hgf and the subsequent activation of the hgf/c-met signaling pathway. this may cause cell death in c-met-expressing tumor cells. c-met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.|a monoclonal antibody directed against human hepatocyte growth factor receptor, with potential anti-cancer activity. telisotuzumab binds to c-met, a protein molecule that is overexpressed or mutated in many tumor types, plays|24.899486486486524|-2.6587903225806144|13.463081081081082|17.48080645161291|12.933421951219513|13.767935294117647|15.677297297297294|18.08|13.289024390243902|13.390588235294118|81.59433730351635|93.86999999999999|24.29837837837838|29.425806451612903\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "an inhibitor of protein tyrosine phosphatase (ptp) non-receptor type 11 (shp2; src homology region 2 domain phosphatase; ptpn11), with potential antineoplastic activity. upon oral administration, shp2 inhibitor tno155 binds to and inhibits shp2. this prevents shp2-mediated signaling, inhibits mapk signaling and prevents growth of shp2-expressing tumor cells. shp2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the ras-raf-erk signaling pathway. shp2 also regulates programmed cell death 1 (pd-1)-mediated signal transduction and is involved in immune checkpoint modulation.|a substance of protein tyrosine enzyme (ptp) non-receptor type 11 (shp2; src homology region 2 domain enzyme; ptpn11), with potential antineoplastic activity.  upon oral justice, shp2 substance tno155 binds to and suppress shp2.  this prevents shp2-mediated tell, suppress map tell and prevents growth of shp2-expressing tumor cells.  shp2, an oncoprotein overexpressed in a difference of cancer cell types, restrict cell survival, adaptation and increase through the beginning of the race-raf-erk tell path.  shp2 also restrict schedule, cell death 1 (pd-1) -mediated tell transduction and is having in immune stop revision.|29.477878787878808|64.03333333333335|12.791363636363638|8.220000000000002|15.764866451612905|13.907682683982685|19.10727272727273|14.384680851063838|16.484516129032258|9.952640692640692|84.73372056035305|78.74477315987392|25.86666666666667|22.43687943262411\n",
      "\n",
      "an inhibitor of protein tyrosine phosphatase (ptp) non-receptor type 11 (shp2; src homology region 2 domain phosphatase; ptpn11), with potential antineoplastic activity. upon oral administration, shp2 inhibitor tno155 binds to and inhibits shp2. this prevents shp2-mediated signaling, inhibits mapk signaling and prevents growth of shp2-expressing tumor cells. shp2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the ras-raf-erk signaling pathway. shp2 also regulates programmed cell death 1 (pd-1)-mediated signal transduction and is involved in immune checkpoint modulation.|an inhibitor of protein tyrosine phosphatase (ptp) non-receptor type 11 (shp2), an oncoprotein that is overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the ras|29.477878787878808|-1.8514705882352587|12.791363636363638|21.964117647058824|15.764866451612905|15.071544444444447|19.10727272727273|27.265882352941176|16.484516129032258|22.736666666666665|84.73372056035305|117.07645963215661|25.86666666666667|30.070588235294117\n",
      "\n",
      "death| termination|121.22000000000003|35.60500000000002|-3.3999999999999986|8.790000000000003|0.0496|19.5753|-266.6|-112.72|2.620000000000001|0.4800000000000004|0.0|31.29|0.4|20.8\n",
      "\n",
      "dna topoisomerases that catalyze atp-independent breakage of one of the two strands of dna, passage of the unbroken strand through the break, and rejoining of the broken strand. dna topoisomerases, type i enzymes reduce the topological stress in the dna structure by relaxing the superhelical turns and knotted rings in the dna helix.|dna enzyme that catalyzes atp-independent breakage of one of the two strands of dna, a way of the unbroken strand through the break, and answer of the broken strand.  dna topoisomerases, type i enzymes reduces the topological stress in the dna structure by decreasing the superhelical turns and tie rings in the dna curve.|42.0505031446541|54.404848484848515|11.783018867924532|10.225454545454546|12.870700000000001|11.792442857142857|14.531320754716976|12.506181818181819|16.14333333333333|14.690178571428568|74.48509850970193|67.59412548439398|19.896855345911952|17.515151515151512\n",
      "\n",
      "dna topoisomerases that catalyze atp-independent breakage of one of the two strands of dna, passage of the unbroken strand through the break, and rejoining of the broken strand. dna topoisomerases, type i enzymes reduce the topological stress in the dna structure by relaxing the superhelical turns and knotted rings in the dna helix.|dna topoisomerases that relax the superhelical turns and knotted rings in the dna helix.|42.0505031446541|42.61571428571432|11.783018867924532|9.054285714285715|12.870700000000001|12.429833333333335|14.531320754716976|-10.365714285714287|16.14333333333333|5.870000000000001|74.48509850970193|49.473833993334296|19.896855345911952|17.085714285714285\n",
      "\n",
      "dna topoisomerases that catalyze atp-independent breakage of one of the two strands of dna, passage of the unbroken strand through the break, and rejoining of the broken strand. dna topoisomerases, type i enzymes reduce the topological stress in the dna structure by relaxing the superhelical turns and knotted rings in the dna helix.| A class of enzymes that break down dna by adding enzymes to it, and rejoins|42.0505031446541|79.5575|11.783018867924532|6.137499999999999|12.870700000000001|10.052641176470589|14.531320754716976|4.285|16.14333333333333|4.247647058823528|74.48509850970193|62.58|19.896855345911952|16.400000000000002\n",
      "\n",
      "an abnormality of the larynx. [hpo:probinson]|an misbehavior of the larynx.  [ hop: robinson]|6.390000000000015|80.06750000000002|13.113333333333333|3.2094444444444434|12.832957142857145|11.663766666666668|-59.466666666666654|-40.297777777777775|4.5428571428571445|1.0983333333333327|38.32226702584281|38.32226702584281|21.200000000000003|15.133333333333333\n",
      "\n",
      "an abnormality of the larynx. [hpo:probinson]|an abnormality of the larynx. [hpo:probinson]|6.390000000000015|6.390000000000015|13.113333333333333|13.113333333333333|12.832957142857145|13.70365|-59.466666666666654|-58.48666666666666|4.5428571428571445|2.3537500000000016|38.32226702584281|38.32226702584281|21.200000000000003|21.200000000000003\n",
      "\n",
      "an abnormality of the larynx. [hpo:probinson]| an abnormality of the voice box. hyperprosine|6.390000000000015|54.72500000000002|13.113333333333333|6.620000000000001|12.832957142857145|10.877477777777777|-59.466666666666654|-44.6|4.5428571428571445|1.7533333333333339|38.32226702584281|31.29|21.200000000000003|11.600000000000001\n",
      "\n",
      "an indication that mki67 expression has been detected in a sample.|a datum that mki67 squeeze has been spied in a sample.|62.81613636363636|108.96159090909092|5.864090909090912|-0.5722727272727273|11.359372727272728|9.923918181818184|-23.883636363636366|-30.29818181818182|7.620000000000001|2.4818181818181806|44.250742366654144|31.29|16.745454545454546|9.472727272727274\n",
      "\n",
      "an indication that mki67 expression has been detected in a sample.|an indication that mki67 protein has been detected in a sample.|62.81613636363636|70.50704545454548|5.864090909090912|4.791363636363638|11.359372727272728|11.8291|-23.883636363636366|-24.952727272727277|7.620000000000001|2.3725000000000023|44.250742366654144|44.250742366654144|16.745454545454546|16.745454545454546\n",
      "\n",
      "an indication that mki67 expression has been detected in a sample.| An indication that a marker protein called mki67 is expressed in the sample|62.81613636363636|71.76785714285715|5.864090909090912|6.727142857142859|11.359372727272728|12.801833333333335|-23.883636363636366|5.737142857142857|7.620000000000001|6.48|44.250742366654144|69.96656701596841|16.745454545454546|19.885714285714286\n",
      "\n",
      "terminology associated with the contact role for clinical study codelist of the clinical data interchange standards consortium (cdisc) study data tabulation model (sdtm).|word unites with the contact role for clinical study codelist of the clinical data change flag consortium (disc) study data tabulation model (sdtm).|11.249456521739177|40.67554347826092|14.547173913043476|10.442826086956522|15.761647826086957|13.702082608695653|12.097391304347823|6.47304347826087|19.353913043478265|14.848695652173916|85.69119412168324|76.64453405168562|30.686956521739134|25.469565217391306\n",
      "\n",
      "terminology associated with the contact role for clinical study codelist of the clinical data interchange standards consortium (cdisc) study data tabulation model (sdtm).|terminology associated with the contact role for clinical study codelist of the clinical data interchange standards consortium (cdisc) study data tabulation model (sdtm)|11.249456521739177|-0.423043478260837|14.547173913043476|19.032173913043476|15.761647826086957|16.011483333333334|12.097391304347823|24.966956521739128|19.353913043478265|18.83|85.69119412168324|121.18564890283007|30.686956521739134|35.286956521739135\n",
      "\n",
      "terminology associated with the contact role for clinical study codelist of the clinical data interchange standards consortium (cdisc) study data tabulation model (sdtm).| A table|11.249456521739177|119.19000000000003|14.547173913043476|-2.619999999999999|15.761647826086957|11.7299|12.097391304347823|-84.94666666666666|19.353913043478265|-10.01|85.69119412168324|31.29|30.686956521739134|14.533333333333331\n",
      "\n",
      "catalysis of the reaction: 3-adp-2-phosphoglycerate + h(2)o = 3-adp-glycerate + phosphate. [ec:3.1.3.28, rhea:15861]|catalysis of the reaction: 3-adp-2-phosphoglycerate + h (2) o = 3-adp-glycerate + salt.  [ ec: 3.1.3.28, rhea: 15861]|132.61138461538462|140.64115789473686|-4.591384615384616|-5.413263157894738|17.99045294117647|17.637051515151516|-66.80615384615385|-47.25684210526316|9.140588235294118|0.8625757575757582|24.23712978056601|19.789533597333715|10.270769230769233|5.730526315789473\n",
      "\n",
      "catalysis of the reaction: 3-adp-2-phosphoglycerate + h(2)o = 3-adp-glycerate + phosphate. [ec:3.1.3.28, rhea:15861]|starts the reaction: 3-adp-2-phosphoglycerate + hydrogen peroxide + phosphate. [ec:3.1.3.28, rhea:15861]|132.61138461538462|104.62018181818182|-4.591384615384616|-0.7865454545454522|17.99045294117647|17.517985714285714|-66.80615384615385|-83.76363636363635|9.140588235294118|11.675714285714285|24.23712978056601|27.986626806387367|10.270769230769233|15.42545454545455\n",
      "\n",
      "catalysis of the reaction: 3-adp-2-phosphoglycerate + h(2)o = 3-adp-glycerate + phosphate. [ec:3.1.3.28, rhea:15861]| catalysis|132.61138461538462|35.60500000000002|-4.591384615384616|8.790000000000003|17.99045294117647|19.5753|-66.80615384615385|-118.6|9.140588235294118|-2.66|24.23712978056601|31.29|10.270769230769233|20.8\n",
      "\n",
      "a variability of phenotypic features. [hpo:probinson]|a changeableness of phenotypic has.  [ hop: robinson]|-50.00999999999996|61.26750000000001|20.980000000000008|5.831666666666667|15.08867142857143|11.663766666666668|-51.62666666666666|-36.37777777777777|9.925714285714285|4.630833333333332|44.250742366654144|38.32226702584281|27.866666666666664|15.133333333333333\n",
      "\n",
      "a variability of phenotypic features. [hpo:probinson]|a variability of phenotypes. [hpo:probinson]|-50.00999999999996|-49.50249999999997|20.980000000000008|20.785000000000007|15.08867142857143|15.08867142857143|-51.62666666666666|-70.184|9.925714285714285|5.215714285714284|44.250742366654144|38.32226702584281|27.866666666666664|25.0\n",
      "\n",
      "a variability of phenotypic features. [hpo:probinson]| a variability|-50.00999999999996|34.59000000000003|20.980000000000008|9.180000000000003|15.08867142857143|15.6774|-51.62666666666666|-73.18666666666667|9.925714285714285|-2.9450000000000003|44.250742366654144|31.29|27.866666666666664|14.533333333333331\n",
      "\n",
      "subdivision of anterior triangle of neck, each instance of which is bounded by anterior and posterior bellies of some digastric muscle and some; contaims some mylohyoid and hyoglossus muscle, some submandibular gland, segment of some hypoglossal nerve and some segments of lingual and facial arteries.|section in tooth shape of the neck, each instance of which is a jump by tooth and tooth swell of some digastric muscle and some; contains some mylohyoid and hyoglossus muscle, some submandibular gland, part of some cranial_nerve nerve and some part of lingual and facial arteries.|31.7175|60.58250000000001|14.425|10.647340425531919|13.588055555555556|10.671104255319149|20.425777777777775|16.67914893617021|27.445999999999998|25.01872340425532|101.39118822659097|79.77416029015912|27.666666666666664|20.463829787234047\n",
      "\n",
      "subdivision of anterior triangle of neck, each instance of which is bounded by anterior and posterior bellies of some digastric muscle and some; contaims some mylohyoid and hyoglossus muscle, some submandibular gland, segment of some hypoglossal nerve and some segments of lingual and facial arteries.|subdivision of anterior triangle of neck, each instance of which is bounded by front and back bellies of some digastric muscle and some; contaims some mylohyoid and hyoglossus muscle, some submandible glands, and|31.7175|32.34|14.425|16.94666666666667|13.588055555555556|12.289076470588236|20.425777777777775|23.281212121212114|27.445999999999998|20.089705882352938|101.39118822659097|112.8176994092682|27.666666666666664|28.957575757575757\n",
      "\n",
      "subdivision of anterior triangle of neck, each instance of which is bounded by anterior and posterior bellies of some digastric muscle and some; contaims some mylohyoid and hyoglossus muscle, some submandibular gland, segment of some hypoglossal nerve and some segments of lingual and facial arteries.| subdivision of anterior triangle of neck; each instance of which is bounded by anterior and posterior bellies of some|31.7175|46.94500000000005|14.425|11.68|13.588055555555556|12.19714761904762|20.425777777777775|14.6|27.445999999999998|11.49857142857143|101.39118822659097|88.50148473330829|27.666666666666664|24.0\n",
      "\n",
      "actions performed to give fluid rectally|actions re-create to give fluid rectally|31.545000000000016|45.64500000000001|10.350000000000001|8.383333333333333|14.460766666666668|15.262271428571431|-15.033333333333331|-15.033333333333331|9.044999999999998|4.947142857142854|62.58|62.58|29.066666666666663|29.066666666666663\n",
      "\n",
      "actions performed to give fluid rectally|actions performed to give fluid rectally|31.545000000000016|31.545000000000016|10.350000000000001|10.350000000000001|14.460766666666668|15.262271428571431|-15.033333333333331|-14.053333333333327|9.044999999999998|6.2928571428571445|62.58|62.58|29.066666666666663|29.066666666666663\n",
      "\n",
      "actions performed to give fluid rectally| act|31.545000000000016|162.505|10.350000000000001|-8.91|14.460766666666668|14.311966666666669|-15.033333333333331|-136.24|9.044999999999998|-12.079999999999998|62.58|0.0|29.066666666666663|0.8\n",
      "\n",
      "group behavior toward others by virtue of their group membership.|group trait toward others by good of their group body.|57.940000000000026|91.78000000000003|6.420000000000002|1.7000000000000028|8.8695|5.7115|-26.272|-32.739999999999995|9.475000000000001|4.2940000000000005|49.473833993334296|38.32226702584281|22.0|14.0\n",
      "\n",
      "group behavior toward others by virtue of their group membership.|group behavior toward others by virtue of the group membership.|57.940000000000026|57.940000000000026|6.420000000000002|6.420000000000002|8.8695|9.651118181818184|-26.272|-26.86|9.475000000000001|4.441818181818181|49.473833993334296|49.473833993334296|22.0|22.0\n",
      "\n",
      "group behavior toward others by virtue of their group membership.| Behavior|57.940000000000026|77.90500000000002|6.420000000000002|2.890000000000004|8.8695|19.5753|-26.272|-121.53999999999999|9.475000000000001|-4.229999999999997|49.473833993334296|31.29|22.0|20.8\n",
      "\n",
      "life threatening consequences; disabling|life bode result; injure|-29.87499999999997|75.87500000000001|18.420000000000005|3.6700000000000017|15.5782|15.5782|-19.610000000000007|-43.13|21.96|3.120000000000001|54.195869768830164|44.250742366654144|31.6|21.6\n",
      "\n",
      "life threatening consequences; disabling|life threatening consequences; disablement|-29.87499999999997|-51.02499999999998|18.420000000000005|21.370000000000008|15.6774|16.5165|-19.610000000000007|-15.200000000000003|22.96|17.808|54.195869768830164|54.195869768830164|31.6|31.6\n",
      "\n",
      "life threatening consequences; disabling| consequence|-29.87499999999997|77.90500000000002|18.420000000000005|2.890000000000004|15.6774|19.5753|-19.610000000000007|-112.72|22.96|0.4800000000000004|54.195869768830164|31.29|31.6|20.8\n",
      "\n",
      "life threatening consequences; disabling|life bode result; injure|-29.87499999999997|75.87500000000001|18.420000000000005|3.6700000000000017|15.5782|15.5782|-19.610000000000007|-43.13|21.96|3.120000000000001|54.195869768830164|44.250742366654144|31.6|21.6\n",
      "\n",
      "life threatening consequences; disabling|life threatening consequences; disablement|-29.87499999999997|-51.02499999999998|18.420000000000005|21.370000000000008|15.6774|16.5165|-19.610000000000007|-15.200000000000003|22.96|17.808|54.195869768830164|54.195869768830164|31.6|31.6\n",
      "\n",
      "life threatening consequences; disabling| consequence|-29.87499999999997|77.90500000000002|18.420000000000005|2.890000000000004|15.6774|19.5753|-19.610000000000007|-112.72|22.96|0.4800000000000004|54.195869768830164|31.29|31.6|20.8\n",
      "\n",
      "clinical chemistry reagents intended to establish points of reference (i.e., calibrate) in chemical and/or enzymatic assays used in the determination of enzyme (e.g., aldolase, creatine kinase) content in a sample of a body fluid.|clinical substance reagents convey to make points of writing (i.e., measure) in chemical and/or enzymatic act used in the choice of enzyme (e.g., aldolase, creatine kinase) content in a sample of a body fluid.|36.85980392156864|64.23039215686276|9.525882352941178|5.7082352941176495|14.611135294117647|12.75348823529412|-18.165882352941175|-21.79764705882353|21.75205882352941|18.84294117647059|55.68096308434328|51.09635603445709|24.619607843137256|21.090196078431372\n",
      "\n",
      "clinical chemistry reagents intended to establish points of reference (i.e., calibrate) in chemical and/or enzymatic assays used in the determination of enzyme (e.g., aldolase, creatine kinase) content in a sample of a body fluid.|clinical chemistry reagents intended to establish points of reference (i.e., calibrate) in chemical and/or enzymatic assays used in the determination of enzyme content in a sample of fluid.|36.85980392156864|33.5514285714286|9.525882352941178|10.318571428571431|14.611135294117647|13.611906896551725|-18.165882352941175|-8.055714285714288|21.75205882352941|11.643793103448274|55.68096308434328|60.592824451415034|24.619607843137256|24.228571428571428\n",
      "\n",
      "clinical chemistry reagents intended to establish points of reference (i.e., calibrate) in chemical and/or enzymatic assays used in the determination of enzyme (e.g., aldolase, creatine kinase) content in a sample of a body fluid.| reagents used in measuring|36.85980392156864|83.32000000000004|9.525882352941178|2.879999999999999|14.611135294117647|11.8291|-18.165882352941175|-30.975999999999996|21.75205882352941|1.1950000000000003|55.68096308434328|44.250742366654144|24.619607843137256|18.0\n",
      "\n",
      "reduced intensity of the biceps tendon reflex. []|reduced degree of the biceps tendon reflex.  [ ]|54.72500000000002|100.24000000000002|6.620000000000001|0.5199999999999996|15.08867142857143|15.6774|-43.13|-36.268|6.561428571428571|2.3537500000000016|49.473833993334296|49.473833993334296|26.6|22.0\n",
      "\n",
      "reduced intensity of the biceps tendon reflex. []|reduced intensity of the biceps tendon reflex []|54.72500000000002|50.66500000000002|6.620000000000001|8.180000000000003|15.08867142857143|15.6774|-43.13|-6.130000000000003|6.561428571428571|4.120000000000001|49.473833993334296|69.96656701596841|26.6|28.200000000000003\n",
      "\n",
      "reduced intensity of the biceps tendon reflex. []| reduced intensity of the biceps tendon reflex|54.72500000000002|50.66500000000002|6.620000000000001|8.180000000000003|15.08867142857143|16.36401111111111|-43.13|-7.600000000000001|6.561428571428571|4.526666666666667|49.473833993334296|69.96656701596841|26.6|28.200000000000003\n",
      "\n",
      "any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1); programmed death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|any chemical function that binds to any of the ligands for the organ schedule, cell death protein 1 (pd-1; pd1); schedule death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|98.76577586206898|101.37000000000002|3.0856896551724162|2.8466666666666676|14.342487096774192|14.105575|7.769655172413792|8.490666666666666|13.213870967741933|13.704374999999999|66.37611354998121|69.96656701596841|18.21379310344828|19.333333333333332\n",
      "\n",
      "any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1); programmed death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1).|98.76577586206898|85.87671052631579|3.0856896551724162|3.641315789473687|14.342487096774192|11.238|7.769655172413792|-4.23368421052632|13.213870967741933|3.116500000000002|66.37611354998121|58.53822981607831|18.21379310344828|18.53684210526316\n",
      "\n",
      "any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1); programmed death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).| Any agent that binds to a cell membrane molecule|98.76577586206898|78.24500000000002|3.0856896551724162|4.830000000000002|14.342487096774192|11.359372727272728|7.769655172413792|-5.492000000000001|13.213870967741933|2.0536363636363646|66.37611354998121|62.58|18.21379310344828|20.0\n",
      "\n",
      "monitors designed to display electronic images either in real time as they are obtained using a video camera or from a video or digital versatile disk player, a television system, or from a digital computer or computerized network. these monitors typically include electronic circuitry to process the video signal and a screen (e.g., cathode ray tube, liquid crystal or plasma display, projection sets) to display the image. video monitors may be used for many purposes, including monitoring patient activity and displaying non-diagnostic images during surgical, endoscopic, and fluoroscopic procedures. monitors that display images with a higher definition than the standard television monitors (i.e., high-definition video monitors) are also available.|observe designed to display electronic images either in real time as they are exist using a video camera or from a video or digital versatile disk player, a television system, or from a digital expert or work network.  these observe typically include electronic circuitry to walk the video tell and a screen (e.g., cathode ray tube, liquid rock or plasma display, structure sets) to display the image.  video observe may be used for many decide, including observe patient activity and woo non-diagnostic images during surgical, endoscopic, and fluoroscopic proceeding.  observe that display images with a higher distinctly than the standard television, observe (i.e., high-definition video observe) are also available.|17.580754332313973|38.60031746031751|13.815902140672783|10.966904761904761|13.974791891891893|13.027935087719298|10.40807339449541|8.081785714285711|19.05013513513513|12.44631578947368|83.43999999999998|80.11435015026959|28.33068297655454|26.04920634920635\n",
      "\n",
      "monitors designed to display electronic images either in real time as they are obtained using a video camera or from a video or digital versatile disk player, a television system, or from a digital computer or computerized network. these monitors typically include electronic circuitry to process the video signal and a screen (e.g., cathode ray tube, liquid crystal or plasma display, projection sets) to display the image. video monitors may be used for many purposes, including monitoring patient activity and displaying non-diagnostic images during surgical, endoscopic, and fluoroscopic procedures. monitors that display images with a higher definition than the standard television monitors (i.e., high-definition video monitors) are also available.|monitors designed to display electronic images either in real time as they are obtained using a video camera or their use is also possible. these monitors may be used for many purposes, including monitoring patient activity and displaying non-diagnostic images during surgery, endoscopic, and fluoroscopic procedures. monitor|17.580754332313973|10.933333333333366|13.815902140672783|15.626382978723406|13.974791891891893|12.180510884353742|10.40807339449541|16.136170212765958|19.05013513513513|13.074217687074828|83.43999999999998|95.59252899677882|28.33068297655454|30.09645390070922\n",
      "\n",
      "monitors designed to display electronic images either in real time as they are obtained using a video camera or from a video or digital versatile disk player, a television system, or from a digital computer or computerized network. these monitors typically include electronic circuitry to process the video signal and a screen (e.g., cathode ray tube, liquid crystal or plasma display, projection sets) to display the image. video monitors may be used for many purposes, including monitoring patient activity and displaying non-diagnostic images during surgical, endoscopic, and fluoroscopic procedures. monitors that display images with a higher definition than the standard television monitors (i.e., high-definition video monitors) are also available.| a device|17.580754332313973|119.19000000000003|13.815902140672783|-2.619999999999999|13.974791891891893|15.6774|10.40807339449541|-82.98666666666665|19.05013513513513|-8.8325|83.43999999999998|31.29|28.33068297655454|14.533333333333331\n",
      "\n",
      "records of sites that are evaluated, but not selected, by a clinical trial.|records of sites that are think, but not selected, by a clinical trial.|63.57596153846157|83.09903846153848|6.006538461538462|3.283461538461541|9.139761538461538|7.925146153846153|-17.043076923076928|-18.852307692307697|6.808461538461536|5.35923076923077|49.473833993334296|44.250742366654144|17.984615384615388|14.90769230769231\n",
      "\n",
      "records of sites that are evaluated, but not selected, by a clinical trial.|record sites that are evaluated, but not selected, by a clinical trial.|63.57596153846157|59.745000000000005|6.006538461538462|6.416666666666668|9.139761538461538|10.031976923076924|-17.043076923076928|-19.443333333333328|6.808461538461536|2.833846153846153|49.473833993334296|49.473833993334296|17.984615384615388|19.06666666666667\n",
      "\n",
      "records of sites that are evaluated, but not selected, by a clinical trial.| Records of sites that are evaluated, but not selected, by a clinical trial.|63.57596153846157|72.83000000000003|6.006538461538462|4.840000000000003|9.139761538461538|10.3245|-17.043076923076928|-15.405714285714286|6.808461538461536|1.7880000000000038|49.473833993334296|49.473833993334296|17.984615384615388|17.085714285714285\n",
      "\n",
      "therapeutically inactive ingredient of pharmaceutical dosage form used to improve taste of a drug. aspartame, fructose, saccharin, sorbitol, and sucrose are the most commonly used sweeteners in the united states.|therapeutically quality foodstuff of medicine, dosage form used to improve the taste of a drug.  aspartame, fructose, saccharin, sorbitol, and sucrose are the most commonly used sweeteners in the united states.|27.485000000000014|45.31458333333336|11.91|9.588750000000001|11.749166666666667|11.8316625|6.267999999999997|5.141250000000003|13.859000000000002|12.033437499999998|67.59412548439398|67.59412548439398|22.666666666666668|21.766666666666666\n",
      "\n",
      "therapeutically inactive ingredient of pharmaceutical dosage form used to improve taste of a drug. aspartame, fructose, saccharin, sorbitol, and sucrose are the most commonly used sweeteners in the united states.|theranostically inactive ingredient of pharmaceutical dosage form used to improve taste of a drug. aspartame, saccharin, sorbitol, and sucrose are the most commonly used sweeteners in the united states.|27.485000000000014|27.823333333333352|11.91|11.780000000000001|12.275500000000001|12.275500000000001|6.267999999999997|4.862068965517238|13.859000000000002|12.759999999999998|67.59412548439398|65.13532912329528|22.666666666666668|21.79770114942529\n",
      "\n",
      "therapeutically inactive ingredient of pharmaceutical dosage form used to improve taste of a drug. aspartame, fructose, saccharin, sorbitol, and sucrose are the most commonly used sweeteners in the united states.| an inactive ingredient in a medicine|27.485000000000014|42.61571428571432|11.91|9.054285714285715|12.275500000000001|11.9283|6.267999999999997|-15.405714285714286|13.859000000000002|1.9987500000000011|67.59412548439398|54.195869768830164|22.666666666666668|19.942857142857143\n",
      "\n",
      "a type of mechanical ventilation procedure that uses a non-invasive means, such as a face mask or nasal mask, to deliver oxygenated air into the lungs.|a type of mechanical discussion software that uses a non-invasive means, such as a face mask or bone mask, to produce process air into the lungs.|43.963076923076954|66.74000000000002|10.356923076923078|7.180000000000003|10.823848148148148|10.239033333333335|5.726153846153842|4.369230769230764|13.352222222222217|12.305555555555557|66.37611354998121|62.58|19.046153846153846|17.50769230769231\n",
      "\n",
      "a type of mechanical ventilation procedure that uses a non-invasive means, such as a face mask or nasal mask, to deliver oxygenated air into the lungs.|a type of ventilatory procedure that uses a non-invasive means to deliver oxygen into the lungs.|43.963076923076954|34.80250000000001|10.356923076923078|10.392500000000002|10.823848148148148|11.9779|5.726153846153842|-6.864999999999998|13.352222222222217|4.003333333333334|66.37611354998121|58.53822981607831|19.046153846153846|20.700000000000003\n",
      "\n",
      "a type of mechanical ventilation procedure that uses a non-invasive means, such as a face mask or nasal mask, to deliver oxygenated air into the lungs.| a non-invasive means, such anesthetics delivery system|43.963076923076954|18.940000000000026|10.356923076923078|12.605000000000004|10.823848148148148|15.185500000000001|5.726153846153842|-0.9849999999999994|13.352222222222217|6.178000000000001|66.37611354998121|62.58|19.046153846153846|23.200000000000003\n",
      "\n",
      "human fgf1 wild-type allele is located within 5q31 and is approximately 93 kb in length. this allele, which encodes heparin-binding growth factor 1 protein, is involved in cell migration, proliferation, organogenesis, and angiogenesis.|human fgf1 wild-type gene is located within 5q31 and is approximately 93 kb in length.  this gene, which convert heparin-binding growth factor 1 protein, is have in cell event, increase, organogenesis, and growth.|34.160909090909115|68.43166666666669|11.22727272727273|6.530000000000005|14.429642857142857|13.881144444444447|9.261818181818175|5.011764705882349|13.426857142857138|7.073333333333334|72.26115969177356|62.58|23.793939393939397|18.650980392156864\n",
      "\n",
      "human fgf1 wild-type allele is located within 5q31 and is approximately 93 kb in length. this allele, which encodes heparin-binding growth factor 1 protein, is involved in cell migration, proliferation, organogenesis, and angiogenesis.|normal human fgf1 gene is located within 5q31 and is about 93 kilobases in length. this gene, which encodes a protein complex, involved in cell migration, proliferation, and angiogenesis.|34.160909090909115|51.16126436781613|11.22727272727273|8.524827586206897|14.429642857142857|13.6065|9.261818181818175|1.8206896551724157|13.426857142857138|7.748000000000001|72.26115969177356|65.13532912329528|23.793939393939397|21.79770114942529\n",
      "\n",
      "human fgf1 wild-type allele is located within 5q31 and is approximately 93 kb in length. this allele, which encodes heparin-binding growth factor 1 protein, is involved in cell migration, proliferation, organogenesis, and angiogenesis.| human fgf1 gene is at fiveq 31 and is approximately 93 kb long|34.160909090909115|101.98214285714286|11.22727272727273|2.5128571428571433|14.429642857142857|14.907166666666669|9.261818181818175|0.27714285714285936|13.426857142857138|2.3979999999999997|72.26115969177356|54.195869768830164|23.793939393939397|14.171428571428573\n",
      "\n",
      "bacteria culture media that are available in ready-to-use tubes specially designed to transport the sample to the clinical laboratory, avoiding contamination and/or leakage.|bacteria grow media that are available in ready-to-use ride specially designed to move the sample to the clinical region, cancel soiling and/or leakage.|-3.4635869565217092|33.31902173913048|16.59934782608696|11.468913043478263|14.3505|12.4557|12.864347826086956|7.495652173913044|18.7648|14.808399999999999|85.69119412168324|76.64453405168562|30.686956521739134|25.469565217391306\n",
      "\n",
      "bacteria culture media that are available in ready-to-use tubes specially designed to transport the sample to the clinical laboratory, avoiding contamination and/or leakage.|bacterial media that are available in ready-to-use tubes specially designed to transport the sample to the clinical laboratory, avoiding contamination and/or leakage.|-3.4635869565217092|-0.44818181818180847|16.59934782608696|16.05454545454546|14.3505|13.7305|12.864347826086956|12.112727272727266|18.7648|11.572799999999994|85.69119412168324|82.78555852321104|30.686956521739134|29.854545454545452\n",
      "\n",
      "bacteria culture media that are available in ready-to-use tubes specially designed to transport the sample to the clinical laboratory, avoiding contamination and/or leakage.| laboratory equipment|-3.4635869565217092|-21.809999999999945|16.59934782608696|17.04666666666667|14.3505|19.6249|12.864347826086956|-59.466666666666654|18.7648|5.297499999999999|85.69119412168324|44.250742366654144|30.686956521739134|27.866666666666664\n",
      "\n",
      "cdh1 is an activator of the anaphase-promoting complex-cyclosome, and is involved in substrate recognition. it associates with the complex in late mitosis from anaphase through g1 to regulate activity of cyclin-dependent kinases and to prevent premature dna replication.|cdh1 is a substance of the anaphase-promoting complex-cyclosome, and is having in substrate appointment.  it unites with the whole in late mitosis from one-pass through g1 to restrict the activity of cyclin-dependent enzyme and to prevent premature dna copy.|18.0993859649123|45.251666666666694|13.881578947368421|10.260000000000002|13.51110487804878|11.541239393939394|12.685263157894735|9.992999999999999|14.897317073170733|8.70401515151515|74.48509850970193|69.96656701596841|22.96140350877193|20.333333333333336\n",
      "\n",
      "cdh1 is an activator of the anaphase-promoting complex-cyclosome, and is involved in substrate recognition. it associates with the complex in late mitosis from anaphase through g1 to regulate activity of cyclin-dependent kinases and to prevent premature dna replication.|it associates with the complex in late mitosis from anaphase through g1 to regulate activity of cyclin-dependent kinases and to prevent premature dna replication.|18.0993859649123|25.455000000000013|13.881578947368421|12.690000000000001|13.51110487804878|13.390915384615385|12.685263157894735|9.633333333333333|14.897317073170733|10.069230769230767|74.48509850970193|73.38155456243756|22.96140350877193|23.133333333333333\n",
      "\n",
      "cdh1 is an activator of the anaphase-promoting complex-cyclosome, and is involved in substrate recognition. it associates with the complex in late mitosis from anaphase through g1 to regulate activity of cyclin-dependent kinases and to prevent premature dna replication.| cdh1 is an activator of the anaphase-promoting complex|18.0993859649123|37.900000000000034|13.881578947368421|10.208888888888893|13.51110487804878|14.230281818181819|12.685263157894735|-1.5288888888888863|14.897317073170733|4.622727272727271|74.48509850970193|54.195869768830164|22.96140350877193|16.933333333333334\n",
      "\n",
      "catalysis of the reaction: atp + nucleoside diphosphate = adp + nucleoside triphosphate. [ec:2.7.4.6]|the catalysis of the reaction: atp + nucleoside diphosphate = adp + nucleoside triphosphate.  [ ec: 2.7.4.6]|65.00728571428573|85.68100000000003|4.887714285714285|2.2028888888888893|17.40225238095238|16.850829411764707|-68.75428571428571|-52.49555555555557|9.16333333333333|4.7991176470588215|34.27647764867329|34.27647764867329|18.26285714285714|14.773333333333333\n",
      "\n",
      "catalysis of the reaction: atp + nucleoside diphosphate = adp + nucleoside triphosphate. [ec:2.7.4.6]|starting of the reaction: atp + nucleoside diphosphate = adp + cellular protein. [ec:2.7.4.6]|65.00728571428573|89.17871428571428|4.887714285714285|1.516285714285715|17.40225238095238|16.5165|-68.75428571428571|-71.69428571428571|9.16333333333333|5.248000000000001|34.27647764867329|31.29|18.26285714285714|15.405714285714286\n",
      "\n",
      "catalysis of the reaction: atp + nucleoside diphosphate = adp + nucleoside triphosphate. [ec:2.7.4.6]| catalysis|65.00728571428573|35.60500000000002|4.887714285714285|8.790000000000003|17.40225238095238|19.5753|-68.75428571428571|-118.6|9.16333333333333|-2.66|34.27647764867329|31.29|18.26285714285714|20.8\n",
      "\n",
      "any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glycogen. [goc:go_curators]|any walk that changes the ratio, rate or extent of the chemical force and path happen in the breakdown of glycogen.  [ goc: go_curators]|30.31545454545457|72.32350000000002|11.763636363636365|6.277000000000001|12.445160869565218|9.954550000000001|8.370909090909091|2.662399999999998|10.327391304347824|3.7650000000000006|76.64453405168562|66.37611354998121|26.218181818181815|19.400000000000002\n",
      "\n",
      "any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glycogen. [goc:go_curators]|any process that changes the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a sugar molecule. [goc:go_curators]|30.31545454545457|39.55500000000001|11.763636363636365|10.723333333333333|12.445160869565218|11.568992307692309|8.370909090909091|8.898333333333333|10.327391304347824|8.982307692307693|76.64453405168562|79.77416029015912|26.218181818181815|26.466666666666665\n",
      "\n",
      "any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glycogen. [goc:go_curators]| Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glycogen|30.31545454545457|38.37772727272727|11.763636363636365|13.371818181818181|12.445160869565218|13.015560869565219|8.370909090909091|17.28181818181818|10.327391304347824|13.619999999999997|76.64453405168562|103.77718969022045|26.218181818181815|28.8\n",
      "\n",
      "operative procedures for the treatment of vascular disorders.|the detective is proceeding for the care of vascular change.|1.8500000000000227|66.40000000000003|13.995000000000001|5.240000000000002|13.902050000000001|8.8695|-34.31|-29.211999999999996|13.77375|7.120000000000001|49.473833993334296|38.32226702584281|26.6|14.0\n",
      "\n",
      "operative procedures for the treatment of vascular disorders.|operative procedures for the treatment of blood disorder.|1.8500000000000227|23.00000000000003|13.995000000000001|11.045000000000002|13.902050000000001|12.631922222222224|-34.31|-36.515|13.77375|6.986666666666665|49.473833993334296|44.250742366654144|26.6|21.6\n",
      "\n",
      "operative procedures for the treatment of vascular disorders.| operative procedures|1.8500000000000227|-21.809999999999945|13.995000000000001|17.04666666666667|13.902050000000001|19.6249|-34.31|-59.466666666666654|13.77375|5.297499999999999|49.473833993334296|44.250742366654144|26.6|27.866666666666664\n",
      "\n",
      "the gaps formed between myelin sheath segments along axons of certain neurons that serve to facilitate the rapid conduction of nerve impulses.|the bioactive substance formed between the myelin sheath part along axons of certain neurons that serve to cause the rapid conduction of nerve force.|53.388181818181835|71.28000000000002|8.545454545454547|6.298333333333332|11.904972727272728|10.74815|5.430909090909086|6.203333333333333|15.260909090909088|15.10125|73.38155456243756|69.96656701596841|24.400000000000002|21.46666666666667\n",
      "\n",
      "the gaps formed between myelin sheath segments along axons of certain neurons that serve to facilitate the rapid conduction of nerve impulses.|the gaps formed between myelin sheath segments along axon of certain neurons that serve to facilitate the rapid conduction of nerve impulses.|53.388181818181835|53.388181818181835|8.545454545454547|8.545454545454547|11.904972727272728|11.758639130434783|5.430909090909086|5.430909090909086|15.260909090909088|8.89391304347826|73.38155456243756|73.38155456243756|24.400000000000002|24.400000000000002\n",
      "\n",
      "the gaps formed between myelin sheath segments along axons of certain neurons that serve to facilitate the rapid conduction of nerve impulses.| the gaps formed between myelin sheath segments along a nerve fiber that serve to facilitate rapid conduction of nerve impulses.|53.388181818181835|63.23464285714289|8.545454545454547|7.0478571428571435|11.904972727272728|12.0771|5.430909090909086|2.3295238095238133|15.260909090909088|7.405909090909088|73.38155456243756|66.37611354998121|24.400000000000002|21.34285714285714\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of the addition of telomeric repeats by telomerase. [goc:mah]|any walk that changes or change the ratio, rate or extent of the addition of telomeric play by enzymes.  [ goc: mah]|27.485000000000014|77.45815217391308|11.91|5.312391304347827|11.67634761904762|9.742051515151516|3.3279999999999994|-1.7078260869565227|7.818571428571428|1.5048484848484875|73.38155456243756|58.53822981607831|26.0|16.773913043478263\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of the addition of telomeric repeats by telomerase. [goc:mah]|any process that activates or increases the frequency, rate or extent of the addition of new repeats by telomerase. [goc:mah]|27.485000000000014|40.17500000000001|11.91|10.140000000000004|11.67634761904762|11.359372727272728|3.3279999999999994|1.8580000000000005|7.818571428571428|5.90727272727273|73.38155456243756|69.96656701596841|26.0|24.0\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of the addition of telomeric repeats by telomerase. [goc:mah]| Any process that activates or increases enzyme action at the end of chromosomes, increases the rate or extent of addition of telomeric repeats|27.485000000000014|27.37500000000003|11.91|15.403333333333332|11.67634761904762|12.4557|3.3279999999999994|17.311666666666667|7.818571428571428|13.866399999999999|73.38155456243756|108.39173953766033|26.0|29.6\n",
      "\n",
      "a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human b-cell maturation antigen (bcma; tnfrsf17), fused to one that is directed against the cd3 antigen found on t lymphocytes, with potential immunostimulating and antineoplastic activities. upon administration of anti-bcma/cd3 bite antibody amg 701, this bispecific antibody binds to both cd3 on cytotoxic t lymphocytes (ctls) and bcma found on bcma-expressing tumor cells. this activates and redirects ctls to bcma-expressing tumor cells, which results in the ctl-mediated cell death of bcma-expressing tumor cells. bcma, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.|a immunologic factor t-cell engager ( bite ) protein plan of two single-chain symbol break ( scfv ) , one directed against the tumor-associated substance ( taa ) human b-cell maturation antigen ( bcma ; tnfrsf17 ) , melt to one that is plan against the cd3 substance found on t leukocyte , with potential immunostimulating and antineoplastic trait .  upon justice of anti-bcma/cd3 bite protein is 701, this bispecific protein binds to both cd3 on cytotoxic t leukocyte (ctls) and become found on became-expressing growth cells.  this change and send styles to become-expressing growth cells, which results in the steel-mediated cell death of bcma-expressing tumor cells.  bcma, a member of the tumor death factor organ superfamily that is specifically overexpressed in malignant plasma cells, plays a key role in play plasma cell survival.|15.390000000000015|48.7276496350365|17.075000000000006|13.269722627737227|13.87226923076923|12.050054228855721|23.63266666666667|19.369635036496348|20.253999999999998|13.427263681592038|101.87285929039194|92.82114026448932|27.266666666666666|23.806715328467153\n",
      "\n",
      "a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human b-cell maturation antigen (bcma; tnfrsf17), fused to one that is directed against the cd3 antigen found on t lymphocytes, with potential immunostimulating and antineoplastic activities. upon administration of anti-bcma/cd3 bite antibody amg 701, this bispecific antibody binds to both cd3 on cytotoxic t lymphocytes (ctls) and bcma found on bcma-expressing tumor cells. this activates and redirects ctls to bcma-expressing tumor cells, which results in the ctl-mediated cell death of bcma-expressing tumor cells. bcma, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.|a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human protein complexes found on tumor cells, which results in the ctl-mediated cell death of|15.390000000000015|6.944285714285741|17.075000000000006|20.985714285714284|13.87226923076923|13.515500000000001|23.63266666666667|27.83085714285714|20.253999999999998|22.591|101.87285929039194|129.0119750255766|27.266666666666666|33.42857142857143\n",
      "\n",
      "a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human b-cell maturation antigen (bcma; tnfrsf17), fused to one that is directed against the cd3 antigen found on t lymphocytes, with potential immunostimulating and antineoplastic activities. upon administration of anti-bcma/cd3 bite antibody amg 701, this bispecific antibody binds to both cd3 on cytotoxic t lymphocytes (ctls) and bcma found on bcma-expressing tumor cells. this activates and redirects ctls to bcma-expressing tumor cells, which results in the ctl-mediated cell death of bcma-expressing tumor cells. bcma, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.| An|15.390000000000015|162.505|17.075000000000006|-8.91|13.87226923076923|14.311966666666669|23.63266666666667|-139.18|20.253999999999998|-13.65|101.87285929039194|0.0|27.266666666666666|0.8\n",
      "\n",
      "a focal seizure characterized at onset by sudden loss or diminution of muscle tone without apparent preceding myoclonic or tonic activity, typically lasting more than 500 ms but less than 2 seconds. it may involve the head, trunk, jaw or limb musculature. [orcid:0000-0002-1735-8178, pmid:11580774, pmid:28276060, pmid:28276064]|a focal seizure distinguishes at start by sudden loss or statement of muscle tone without apparent state myoclonic, or note activity, typically lasting more than 500 ms but less than 2 seconds.  it may have the head, trunk, jaw or limb system.  [ orcid:0000-0002-1735-8178 , pmid:11580774 , pmid:28276060 , pmid:28276064 ]|60.69340579710146|91.53352201257863|8.603043478260872|4.881132075471701|11.977977551020409|10.869472549019608|16.8704347826087|13.199999999999996|10.648061224489801|6.6470588235294095|76.64453405168562|67.59412548439398|21.785507246376813|17.632704402515724\n",
      "\n",
      "a focal seizure characterized at onset by sudden loss or diminution of muscle tone without apparent preceding myoclonic or tonic activity, typically lasting more than 500 ms but less than 2 seconds. it may involve the head, trunk, jaw or limb musculature. [orcid:0000-0002-1735-8178, pmid:11580774, pmid:28276060, pmid:28276064]|a focal seizure coming from a specific body part or area of the brain that is characterized at onset by sudden loss or diminution of muscle tone without appreciable preceding myoclonic or tonic activity, typically lasting more than 500 ms but less than 2 seconds. it|60.69340579710146|40.03782608695653|8.603043478260872|13.388695652173912|12.180510884353742|10.849334042553192|16.8704347826087|15.507826086956523|12.689727891156465|12.3668085106383|76.64453405168562|98.94766798666859|21.785507246376813|26.59130434782609\n",
      "\n",
      "a focal seizure characterized at onset by sudden loss or diminution of muscle tone without apparent preceding myoclonic or tonic activity, typically lasting more than 500 ms but less than 2 seconds. it may involve the head, trunk, jaw or limb musculature. [orcid:0000-0002-1735-8178, pmid:11580774, pmid:28276060, pmid:28276064]| a seizure|60.69340579710146|119.19000000000003|8.603043478260872|-2.619999999999999|12.180510884353742|15.6774|16.8704347826087|-81.02666666666666|12.689727891156465|-7.654999999999999|76.64453405168562|31.29|21.785507246376813|14.533333333333331\n",
      "\n",
      "a question about how much time an individual spends thinking about the possibility that their breast cancer could recur.|a question about how much time an individual spends thinking about the option that their breast cancer could use.|50.25565789473683|68.0661842105263|8.609736842105267|6.125526315789475|7.90311052631579|7.072057894736842|0.4084210526315779|-1.757894736842104|13.107368421052634|11.372105263157898|62.58|58.53822981607831|20.642105263157895|18.53684210526316\n",
      "\n",
      "a question about how much time an individual spends thinking about the possibility that their breast cancer could recur.|a question about how much time an individual spends thinking about the possibility that their breast cancer can recur.|50.25565789473683|50.25565789473683|8.609736842105267|8.609736842105267|7.90311052631579|8.08|0.4084210526315779|0.0989473684210509|13.107368421052634|7.120000000000001|62.58|62.58|20.642105263157895|20.642105263157895\n",
      "\n",
      "a question about how much time an individual spends thinking about the possibility that their breast cancer could recur.| a question about how much time an individual spends thinking about the possibility of their cancer returning|50.25565789473683|38.16500000000002|8.609736842105267|12.407777777777778|7.90311052631579|8.734163157894738|0.4084210526315779|13.93555555555556|13.107368421052634|11.372105263157898|62.58|88.50148473330829|20.642105263157895|24.977777777777778\n",
      "\n",
      "a product elaborated and marketed by the private canadian laboratory. 714-x contains trimethylbicyclonitraminoheptane chloride, a nitrogenated camphor-derivative, and mineral salts in ethanol. it is claimed to cure cancer, multiple sclerosis, fibromyalgia, aids and other diseases by improving the body's immune function. few inconclusive animal studies and no human trials were conducted with the product. there is no scientific evidence that 714-x is effective in treating any type of disease. it has not been proven to be safe or effective for any use. 714-x is banned by fda for use in the usa. in canada 714-x is legally available on compassionate grounds only through a licensed physician.|a product develop and change by the private canadian region.  714-x contains trimethylbicyclonitraminoheptane chloride, a nitrogenated camphor-derivative, and mineral salts in ethanol.  it is claimed to cure cancer, product sclerosis, fibromyalgia, aids and other illness by change the body 's immune serve.  few inconclusive animal studies and no human trials were performed with the product.  there is no scientific inform that 714-x is effective in giving any type of disease.  it has not been printed to be safe or effective for any use.  714-x is banned by the fda for use in the usa.  in canada 714-x is legally available on grieve grounds only through a licensed physician.|36.05602725366879|59.24120772946864|11.15616352201258|8.170724637681161|11.29506036036036|11.521119004524888|7.596226415094339|5.774608695652173|9.77885135135135|5.113729799612155|72.26115969177356|67.59412548439398|22.824318658280927|19.719806763285025\n",
      "\n",
      "a product elaborated and marketed by the private canadian laboratory. 714-x contains trimethylbicyclonitraminoheptane chloride, a nitrogenated camphor-derivative, and mineral salts in ethanol. it is claimed to cure cancer, multiple sclerosis, fibromyalgia, aids and other diseases by improving the body's immune function. few inconclusive animal studies and no human trials were conducted with the product. there is no scientific evidence that 714-x is effective in treating any type of disease. it has not been proven to be safe or effective for any use. 714-x is banned by fda for use in the usa. in canada 714-x is legally available on compassionate grounds only through a licensed physician.|a product elaborated and marketed by the private canadian laboratory. 714-x contains trimethylbicyclonitraminoheptane chloride, a nitrogenated camphor-derivative, and mineral salts in ethanol. it is claimed to cure cancer, multiple|36.05602725366879|-15.935287356321822|11.15616352201258|17.88344827586207|11.437312612612612|13.540879166666668|7.596226415094339|10.742068965517241|9.77885135135135|12.899270833333333|72.26115969177356|72.26115969177356|22.824318658280927|25.935632183908048\n",
      "\n",
      "a product elaborated and marketed by the private canadian laboratory. 714-x contains trimethylbicyclonitraminoheptane chloride, a nitrogenated camphor-derivative, and mineral salts in ethanol. it is claimed to cure cancer, multiple sclerosis, fibromyalgia, aids and other diseases by improving the body's immune function. few inconclusive animal studies and no human trials were conducted with the product. there is no scientific evidence that 714-x is effective in treating any type of disease. it has not been proven to be safe or effective for any use. 714-x is banned by fda for use in the usa. in canada 714-x is legally available on compassionate grounds only through a licensed physician.| it is claimed to cure cancer, multiple sclerosis, fibromyalgia, aids and other diseases by improving the body's immune function|36.05602725366879|34.255000000000024|11.15616352201258|13.450000000000003|11.29506036036036|12.19714761904762|7.596226415094339|17.54|9.77885135135135|13.292857142857144|72.26115969177356|103.77718969022045|22.824318658280927|30.0\n",
      "\n",
      "a carcinoma that originates usually from cells on the surface of the middle and lower third of the esophagus. tumor cells exhibit typical squamous morphology and form large polypoid lesions. mutations in rnf6, lzts1, tgfbr2, dec1, and wwox1 genes are associated with this cancer.|a cancer that begins usually from cells on the surface of the middle and lower third of the esophagus.  growth cells walk typical squamous geophysics and form large polypoid lesions.  change in rnf6, lzts1, tgfbr2, dec1, and wwox1 genes are uniting with this cancer.|57.23363636363638|84.8146739130435|8.009090909090911|4.286304347826089|11.541239393939394|10.918989855072464|4.629090909090905|2.5104347826086943|10.416742424242422|8.353188405797106|64.5059875127883|58.53822981607831|19.854545454545455|16.773913043478263\n",
      "\n",
      "a carcinoma that originates usually from cells on the surface of the middle and lower third of the esophagus. tumor cells exhibit typical squamous morphology and form large polypoid lesions. mutations in rnf6, lzts1, tgfbr2, dec1, and wwox1 genes are associated with this cancer.|a cancer that originates usually from cells in the middle and lower thirds of the esophagus. tumor cells exhibit typical squamous morphology and form large polypoid lesions. mutations in rnf6, lzts1, tgfbr2, dec|57.23363636363638|52.10636363636365|8.009090909090911|8.724242424242426|11.541239393939394|12.093633333333333|4.629090909090905|5.1636363636363605|10.416742424242422|8.4793137254902|64.5059875127883|67.59412548439398|19.854545454545455|21.36969696969697\n",
      "\n",
      "a carcinoma that originates usually from cells on the surface of the middle and lower third of the esophagus. tumor cells exhibit typical squamous morphology and form large polypoid lesions. mutations in rnf6, lzts1, tgfbr2, dec1, and wwox1 genes are associated with this cancer.| A carcinoma of the esophagus|57.23363636363638|45.64500000000001|8.009090909090911|8.383333333333333|11.541239393939394|13.006557142857146|4.629090909090905|-24.833333333333325|10.416742424242422|-0.4357142857142833|64.5059875127883|44.250742366654144|19.854545454545455|15.733333333333333\n",
      "\n",
      "electrodes designed to apply electrical stimuli to nerves and/or muscles from external and/or implantable neuromuscular stimulators. these electrodes may be external devices fixed on the skin over the nerves and muscles, electrodes attached to probes appropriate for insertion in the natural cavities of the body, or implantable devices fixed directly on or around the nerves and muscles. dedicated neuromuscular stimulator electrodes are available for a variety of diagnostic and therapeutic applications, including gait, grasp, muscle strengthening, incontinence, bladder evacuation, swallowing, and ejaculation.|conductor designed to apply electrical stimuli to brace and/or muscles from feature and/or implantable neuromuscular stimulators.  these conductors may be featured emblem fixed on the skin over the brace and muscles, the conductor takes to probes assume for movement in the natural structure of the body, or implantable emblem fixed directly on or around the brace and muscles.  assign neuromuscular stimulator conductor are available for a difference of diagnostic and medicine action, including gait, grasp, muscle change, incontinence, bladder discharge, believe, and discharge.|-4.838353658536562|30.00036764705885|19.026951219512195|14.353970588235295|13.657477235772358|12.281817647058825|23.780975609756098|20.451294117647052|22.16239837398374|14.055529411764702|108.39173953766033|102.59112571270478|31.614634146341462|28.73529411764706\n",
      "\n",
      "electrodes designed to apply electrical stimuli to nerves and/or muscles from external and/or implantable neuromuscular stimulators. these electrodes may be external devices fixed on the skin over the nerves and muscles, electrodes attached to probes appropriate for insertion in the natural cavities of the body, or implantable devices fixed directly on or around the nerves and muscles. dedicated neuromuscular stimulator electrodes are available for a variety of diagnostic and therapeutic applications, including gait, grasp, muscle strengthening, incontinence, bladder evacuation, swallowing, and ejaculation.|these electrodes are available for a variety of diagnostic and therapeutic applications, including gait, grasp, muscle strengthening, bladder evacuation, and ejaculation.|-4.838353658536562|-5.251071428571407|19.026951219512195|16.6002380952381|13.850038211382113|14.948009090909093|23.780975609756098|14.089523809523811|22.16239837398374|15.113181818181822|108.39173953766033|76.64453405168562|31.614634146341462|27.057142857142857\n",
      "\n",
      "electrodes designed to apply electrical stimuli to nerves and/or muscles from external and/or implantable neuromuscular stimulators. these electrodes may be external devices fixed on the skin over the nerves and muscles, electrodes attached to probes appropriate for insertion in the natural cavities of the body, or implantable devices fixed directly on or around the nerves and muscles. dedicated neuromuscular stimulator electrodes are available for a variety of diagnostic and therapeutic applications, including gait, grasp, muscle strengthening, incontinence, bladder evacuation, swallowing, and ejaculation.| electrodes|-4.838353658536562|35.60500000000002|19.026951219512195|8.790000000000003|13.850038211382113|19.5753|23.780975609756098|-115.66|22.16239837398374|-1.0899999999999999|108.39173953766033|31.29|31.614634146341462|20.8\n",
      "\n",
      "severe pain; limiting self care adl|severe pain; choose self care ad|73.84500000000001|102.045|4.450000000000003|0.5166666666666693|11.6803|9.197433333333334|-19.93333333333333|-22.873333333333328|2.8349999999999973|1.9800000000000004|44.250742366654144|31.29|15.733333333333333|9.066666666666666\n",
      "\n",
      "severe pain; limiting self care adl|severe pain; limiting self care adl|73.84500000000001|73.84500000000001|4.450000000000003|4.450000000000003|11.8291|12.832957142857145|-19.93333333333333|-18.953333333333326|4.334999999999997|0.5057142857142836|44.250742366654144|44.250742366654144|15.733333333333333|15.733333333333333\n",
      "\n",
      "severe pain; limiting self care adl| extreme pain; limiting self care|73.84500000000001|87.94500000000002|4.450000000000003|2.4833333333333343|11.8291|13.006557142857146|-19.93333333333333|-20.913333333333334|4.334999999999997|1.5828571428571436|44.250742366654144|44.250742366654144|15.733333333333333|15.733333333333333\n",
      "\n",
      "severe pain; limiting self care adl|severe pain; choose self care ad|73.84500000000001|102.045|4.450000000000003|0.5166666666666693|11.6803|9.197433333333334|-19.93333333333333|-22.873333333333328|2.8349999999999973|1.9800000000000004|44.250742366654144|31.29|15.733333333333333|9.066666666666666\n",
      "\n",
      "severe pain; limiting self care adl|severe pain; limiting self care adl|73.84500000000001|73.84500000000001|4.450000000000003|4.450000000000003|11.8291|12.832957142857145|-19.93333333333333|-18.953333333333326|4.334999999999997|0.5057142857142836|44.250742366654144|44.250742366654144|15.733333333333333|15.733333333333333\n",
      "\n",
      "severe pain; limiting self care adl| extreme pain; limiting self care|73.84500000000001|87.94500000000002|4.450000000000003|2.4833333333333343|11.8291|13.006557142857146|-19.93333333333333|-20.913333333333334|4.334999999999997|1.5828571428571436|44.250742366654144|44.250742366654144|15.733333333333333|15.733333333333333\n",
      "\n",
      "any process that stops, prevents or reduces the frequency, rate or extent of retrograde axon cargo transport. [goc:obol]|any wall that stops, prevents or weaken the ratio, rate or extent of worsening axon cargo move.  [ goc: abel]|42.60000000000002|79.34892857142859|9.553333333333335|4.800238095238097|13.24927894736842|11.072666666666667|0.7577777777777754|-3.270476190476188|7.365789473684213|1.6853333333333325|73.38155456243756|66.37611354998121|28.044444444444448|21.34285714285714\n",
      "\n",
      "any process that stops, prevents or reduces the frequency, rate or extent of retrograde axon cargo transport. [goc:obol]|any process that stops, prevents or reduces axon cargo transport. [goc:obol]|42.60000000000002|39.7434090909091|9.553333333333335|9.08227272727273|13.24927894736842|14.890438461538462|0.7577777777777754|-18.003636363636367|7.365789473684213|4.283076923076923|73.38155456243756|62.58|28.044444444444448|31.290909090909096\n",
      "\n",
      "any process that stops, prevents or reduces the frequency, rate or extent of retrograde axon cargo transport. [goc:obol]| Any process that prevents or reduces the frequency, rate or extent of retrograde axonal transport|42.60000000000002|42.545000000000016|9.553333333333335|11.3|13.24927894736842|13.767935294117647|0.7577777777777754|12.369999999999997|7.365789473684213|10.342941176470589|73.38155456243756|93.86999999999999|28.044444444444448|28.900000000000002\n",
      "\n",
      "a question about an individual's mouth or throat sores at its worst.|a question about an organism 's mouth or throat sores at its worst.|73.84500000000001|83.09903846153848|4.450000000000003|3.283461538461541|5.547533333333334|5.547533333333334|-21.40333333333333|-20.661538461538463|6.550000000000001|5.765000000000001|44.250742366654144|44.250742366654144|15.733333333333333|14.90769230769231\n",
      "\n",
      "a question about an individual's mouth or throat sores at its worst.|a question about an individual's mouth/ throat sores at its worst.|73.84500000000001|70.50704545454548|4.450000000000003|4.791363636363638|5.547533333333334|7.8816|-21.40333333333333|-23.349090909090915|6.550000000000001|3.5500000000000007|44.250742366654144|44.250742366654144|15.733333333333333|16.745454545454546\n",
      "\n",
      "a question about an individual's mouth or throat sores at its worst.| a question about an individual's mouth or throat sores|73.84500000000001|69.78500000000001|4.450000000000003|6.010000000000002|5.547533333333334|8.488463636363637|-21.40333333333333|-1.9639999999999986|6.550000000000001|4.622727272727271|44.250742366654144|62.58|15.733333333333333|20.0\n",
      "\n",
      "follicular lymphoma grade i, ii, iii that is resistant to treatment.|follicular cancer grade i, ii, iii that is resistant to care.|55.12522727272727|70.50704545454548|6.936818181818182|4.791363636363638|12.794827272727273|11.359372727272728|-22.81454545454546|-26.55636363636364|7.620000000000001|4.622727272727271|44.250742366654144|38.32226702584281|16.745454545454546|13.109090909090908\n",
      "\n",
      "follicular lymphoma grade i, ii, iii that is resistant to treatment.|grade i, ii, iii that is resistant to treatment.|55.12522727272727|89.46750000000003|6.936818181818182|1.8983333333333334|12.794827272727273|11.7795|-22.81454545454546|-38.99111111111111|7.620000000000001|-1.032|44.250742366654144|31.29|16.745454545454546|10.68888888888889\n",
      "\n",
      "follicular lymphoma grade i, ii, iii that is resistant to treatment.| follicular lymphoma grade i, ii, iii that is treatment resistant.|55.12522727272727|62.81613636363636|6.936818181818182|5.864090909090912|12.794827272727273|14.460766666666668|-22.81454545454546|-23.349090909090915|7.620000000000001|3.157499999999999|44.250742366654144|44.250742366654144|16.745454545454546|16.745454545454546\n",
      "\n",
      "abrotanum, southernwood, old man.|abrotanum, wormwood, old man.|14.455000000000013|35.60500000000002|11.740000000000002|8.790000000000003|11.7299|11.7299|-103.9|-109.78|12.362500000000004|7.6525|31.29|31.29|20.8|20.8\n",
      "\n",
      "abrotanum, southernwood, old man.|abdomen, southernwood, old man.|14.455000000000013|35.60500000000002|11.740000000000002|8.790000000000003|11.7299|13.2345|-103.9|-105.37|12.362500000000004|4.312000000000001|31.29|31.29|20.8|20.8\n",
      "\n",
      "abrotanum, southernwood, old man.| abrotanum, southernwood, old man|14.455000000000013|49.48000000000002|11.740000000000002|7.600000000000001|11.7299|14.460766666666668|-103.9|-23.919999999999995|12.362500000000004|4.334999999999997|31.29|44.250742366654144|20.8|18.0\n",
      "\n",
      "maldi-tof mass spectroscopy of allele-specific primer extension products. can be used to determine allele dosage ratios at specific loci in samples with heterozygous genotypes. used rarely, as a validation method.|maldi-tof mass spectroscopy of allele-specific primer longness products.  can be used to conclude gene dosage ratios in fact set in samples with heterozygous genotypes.  used rarely, as a proof method.|15.922500000000014|50.66500000000002|12.901666666666667|8.180000000000003|14.7922875|13.951280392156864|-3.4026666666666685|-5.762499999999999|12.769375000000004|7.232549019607845|66.37611354998121|58.53822981607831|27.0|20.700000000000003\n",
      "\n",
      "maldi-tof mass spectroscopy of allele-specific primer extension products. can be used to determine allele dosage ratios at specific loci in samples with heterozygous genotypes. used rarely, as a validation method.|mass spectrometry of allele-specific primer extension products. can be used to determine dosage ratios at specific loci in samples with heterozygous genotypes. used rarely, as a validation method.|15.922500000000014|18.44428571428574|12.901666666666667|12.425714285714289|14.527754166666668|14.008833333333333|-3.4026666666666685|-6.585714285714289|10.102708333333332|8.225000000000001|66.37611354998121|62.58|27.0|25.65714285714286\n",
      "\n",
      "maldi-tof mass spectroscopy of allele-specific primer extension products. can be used to determine allele dosage ratios at specific loci in samples with heterozygous genotypes. used rarely, as a validation method.| mass spectroscopy|15.922500000000014|62.79000000000002|12.901666666666667|5.246666666666666|14.527754166666668|19.6249|-3.4026666666666685|-65.34666666666666|10.102708333333332|1.7650000000000006|66.37611354998121|31.29|27.0|14.533333333333331\n",
      "\n",
      "a si derived unit of specific volume, a property of materials defined as the number of cubic meters occupied by one kilogram of a particular substance. specific volume is inversely proportional to density.|a i make unit of fact volume, a property of the applicant choose as the number of cubic meters work by one kilogram of a part substance.  fact volume is inversely quantity to spacing.|26.470000000000027|66.88476190476192|12.3|6.828571428571429|13.546112121212122|9.628880952380953|3.9163636363636343|-0.33942857142857363|11.083636363636366|4.1853333333333325|78.74477315987392|65.13532912329528|27.430303030303033|19.523809523809526\n",
      "\n",
      "a si derived unit of specific volume, a property of materials defined as the number of cubic meters occupied by one kilogram of a particular substance. specific volume is inversely proportional to density.|a si unit of specific volume, a property of materials defined as the number of cubic meters occupied by one kilogram of substance. specific volume is inversely proportional to density.|26.470000000000027|30.305000000000035|12.3|11.51666666666667|13.546112121212122|13.317420430107527|3.9163636363636343|0.9759999999999991|11.083636363636366|6.982795698924733|78.74477315987392|74.48509850970193|27.430303030303033|26.666666666666664\n",
      "\n",
      "a si derived unit of specific volume, a property of materials defined as the number of cubic meters occupied by one kilogram of a particular substance. specific volume is inversely proportional to density.| a si unit of specific volume is unit of measurement|26.470000000000027|64.9245454545455|12.3|6.936363636363637|13.546112121212122|14.758366666666669|3.9163636363636343|-3.9236363636363656|11.083636363636366|1.8399999999999999|78.74477315987392|69.96656701596841|27.430303030303033|22.581818181818182\n",
      "\n",
      "virus integrated within host genome but inactive; may be reactivated by stress such as ultraviolet irradiation.|virus calculates within the host genome, but inactive; may be activated by stress such as ultraviolet therapy.|24.22750000000002|33.98397058823531|11.867500000000003|10.630882352941178|13.311975|12.839111764705882|-1.7199999999999989|-2.3105882352941123|14.24125|12.28235294117647|62.58|62.58|23.200000000000003|22.223529411764705\n",
      "\n",
      "virus integrated within host genome but inactive; may be reactivated by stress such as ultraviolet irradiation.|virus integrated within host genome but active; may be reactivated by stress such as ultraviolet irradiation.|24.22750000000002|29.515000000000015|11.867500000000003|11.130000000000003|13.311975|13.346335294117647|-1.7199999999999989|-2.0875000000000057|14.24125|8.586470588235294|62.58|62.58|23.200000000000003|23.200000000000003\n",
      "\n",
      "virus integrated within host genome but inactive; may be reactivated by stress such as ultraviolet irradiation.| virus|24.22750000000002|120.20500000000001|11.867500000000003|-3.01|13.311975|19.5009|-1.7199999999999989|-130.36|14.24125|-9.69|62.58|31.29|23.200000000000003|20.8\n",
      "\n",
      "the quantities of sodium chloride (or common salt) taken in and used by the body.|the concept of sodium chloride (or common salt) taken in and used by the body.|69.5025|75.14250000000001|5.428333333333338|4.641666666666666|8.591166666666666|8.591166666666666|-13.20266666666667|-14.378666666666668|6.166|5.224|54.195869768830164|54.195869768830164|19.0|19.0\n",
      "\n",
      "the quantities of sodium chloride (or common salt) taken in and used by the body.|the quantities of chloride (or common salt) taken in and used by the body.|69.5025|78.87285714285717|5.428333333333338|3.997142857142858|8.591166666666666|8.219166666666666|-13.20266666666667|-16.245714285714282|6.166|0.8460000000000001|54.195869768830164|49.473833993334296|19.0|17.085714285714285\n",
      "\n",
      "the quantities of sodium chloride (or common salt) taken in and used by the body.| the quantities of sodium chloride taken in and used by the body|69.5025|69.99384615384618|5.428333333333338|6.726153846153846|8.591166666666666|9.970185714285716|-13.20266666666667|1.203076923076921|6.166|3.7371428571428567|54.195869768830164|69.96656701596841|19.0|20.58461538461539\n",
      "\n",
      "compounds that include the aminobenzene structure.|a mix that includes the aminobenzene structure.|20.490000000000038|34.08250000000001|11.146666666666665|9.375|14.460766666666668|10.750842857142857|-54.566666666666656|-50.13142857142857|16.11|8.984285714285715|44.250742366654144|38.32226702584281|27.866666666666664|18.54285714285714\n",
      "\n",
      "compounds that include the aminobenzene structure.|compounds that include the aminobenzene structure.|20.490000000000038|20.490000000000038|11.146666666666665|11.146666666666665|14.460766666666668|15.08867142857143|-54.566666666666656|-53.58666666666666|16.11|10.598571428571425|44.250742366654144|44.250742366654144|27.866666666666664|27.866666666666664\n",
      "\n",
      "compounds that include the aminobenzene structure.| compounds|20.490000000000038|120.20500000000001|11.146666666666665|-3.01|14.460766666666668|19.5753|-54.566666666666656|-118.6|16.11|-2.66|44.250742366654144|31.29|27.866666666666664|20.8\n",
      "\n",
      "the short form 36 health survey standard, us version 2.0 (sf36 v2.0 standard) question 4a.|the short form 36 health look standard, us turn 2.0 (sf36 v2. 0 standard) question 4a.|118.42875000000001|134.03750000000002|-2.327499999999999|-4.442499999999999|13.8545|12.3251|-49.14133333333334|-47.9075|8.678|5.998750000000001|34.983283507984204|27.097934884415082|14.833333333333332|9.1\n",
      "\n",
      "the short form 36 health survey standard, us version 2.0 (sf36 v2.0 standard) question 4a.|the short form 36 health survey standard, us version 2, (sf36v2.0 standard) question 4a.|118.42875000000001|111.45547619047619|-2.327499999999999|-1.1271428571428554|13.8545|13.4825|-49.14133333333334|-31.508571428571425|8.678|4.614000000000001|34.983283507984204|40.39521630094336|14.833333333333332|16.152380952380952\n",
      "\n",
      "the short form 36 health survey standard, us version 2.0 (sf36 v2.0 standard) question 4a.| the short form 36 health survey standard, us version 2.0 (sf36 v2.0 standard) question 4aa|118.42875000000001|122.10916666666668|-2.327499999999999|-2.4475|13.8545|14.69675882352941|-49.14133333333334|-27.202499999999993|8.678|7.849411764705884|34.983283507984204|40.39521630094336|14.833333333333332|14.633333333333335\n",
      "\n",
      "the process of enrolling, enlisting, or adding individuals to a group.|the walk of enrolling, enroll, or adding organism to a group.|39.7434090909091|70.50704545454548|9.08227272727273|4.791363636363638|9.923918181818184|8.488463636363637|-21.74545454545455|-26.55636363636364|8.476363636363637|4.622727272727271|49.473833993334296|44.250742366654144|20.381818181818183|16.745454545454546\n",
      "\n",
      "the process of enrolling, enlisting, or adding individuals to a group.|the process of enrolling, enlisted, or adding individuals to a group.|39.7434090909091|39.7434090909091|9.08227272727273|9.08227272727273|9.923918181818184|10.513266666666667|-21.74545454545455|-21.74545454545455|8.476363636363637|3.942499999999999|49.473833993334296|49.473833993334296|20.381818181818183|20.381818181818183\n",
      "\n",
      "the process of enrolling, enlisting, or adding individuals to a group.| the process of enrolling, enlisting, or adding individuals to a group.|39.7434090909091|52.69500000000002|9.08227272727273|7.400000000000002|9.923918181818184|11.246592307692307|-21.74545454545455|-19.443333333333328|8.476363636363637|3.1961538461538446|49.473833993334296|49.473833993334296|20.381818181818183|19.06666666666667\n",
      "\n",
      "an ependymal tumor affecting the cerebellum, brain stem, and the cervical region of spinal cord.|a body region growth refers the cerebellum, brain stem, and the cervical region of the spinal cord.|41.30250000000001|63.84279411764709|9.361666666666668|6.466176470588238|11.749166666666667|10.981464705882354|-7.32266666666667|-6.115294117647053|10.875999999999998|9.23470588235294|58.53822981607831|58.53822981607831|21.666666666666668|19.870588235294118\n",
      "\n",
      "an ependymal tumor affecting the cerebellum, brain stem, and the cervical region of spinal cord.|an neural tumor affecting the cerebellum, brain stem, and the cervical region of spinal cord.|41.30250000000001|52.58250000000001|9.361666666666668|7.7883333333333375|11.749166666666667|11.9283|-7.32266666666667|-8.10666666666667|10.875999999999998|5.236875000000001|58.53822981607831|58.53822981607831|21.666666666666668|21.666666666666668\n",
      "\n",
      "an ependymal tumor affecting the cerebellum, brain stem, and the cervical region of spinal cord.| An ependymal tumor|41.30250000000001|54.72500000000002|9.361666666666668|6.620000000000001|11.749166666666667|16.5165|-7.32266666666667|-49.010000000000005|10.875999999999998|-1.9740000000000002|58.53822981607831|44.250742366654144|21.666666666666668|21.6\n",
      "\n",
      "stage ii: involvement of two or more lymph node regions on the same side of the diaphragm (ii) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (iie). note: the number of lymph node regions involved may be indicated by a subscript (e.g., ii3). (from pdq) check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c9199\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c9199\" nci thesaurus)|stage ii: involvement of two or more lymph node regions on the same side of the disk (ii) or stage involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the disk (ie).  note: the number of lymph node regions involved may be informed by a subscript (e.g., ii3).  ( from pdq) check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c9199 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c9199 '' nice wordbook)|81.28456223628693|86.79625|3.5572468354430384|3.1404166666666704|12.011416455696203|13.700957142857144|-3.8764556962025267|-3.9250000000000043|20.162974683544306|11.902285714285718|43.319043445117764|44.250742366654144|14.278902953586499|13.200000000000001\n",
      "\n",
      "stage ii: involvement of two or more lymph node regions on the same side of the diaphragm (ii) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (iie). note: the number of lymph node regions involved may be indicated by a subscript (e.g., ii3). (from pdq) check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c9199\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c9199\" nci thesaurus)|stage ii: involvement of two or more lymph node regions on the same side of the diaphragm (ii) or localized involvement of a single associated extralymphatic organ or site or its regional ly nodes with or without this agent. (from pdq|81.28456223628693|60.15920731707318|3.5572468354430384|9.961097560975613|12.011416455696203|11.445242857142857|-3.8764556962025267|13.52682926829268|20.162974683544306|10.377142857142857|43.319043445117764|76.64453405168562|14.278902953586499|19.90731707317073\n",
      "\n",
      "stage ii: involvement of two or more lymph node regions on the same side of the diaphragm (ii) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (iie). note: the number of lymph node regions involved may be indicated by a subscript (e.g., ii3). (from pdq) check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c9199\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c9199\" nci thesaurus)| stage ii: involvement of two or more lymph node regions on the same side of the diaphrag|81.28456223628693|94.565|3.5572468354430384|4.541111111111114|12.011416455696203|11.22732105263158|-3.8764556962025267|7.402222222222225|20.162974683544306|6.1663157894736855|43.319043445117764|54.195869768830164|14.278902953586499|13.866666666666667\n",
      "\n",
      "a replication incompetent adenoviral vector type 5 (ad5) encoding the tumor suppressor gene dickkopf-3 (dkk3; reduced expression in immortalized cells; reic; dickkopf wnt signaling pathway inhibitor 3), and containing the super gene expression (sge) system, composed of the triple tandem enhancer sequences of human telomerase reverse transcriptase (htert), simian virus 40 (sv40) and cytomegalovirus (cmv), with potential immunostimulating and antineoplastic activities. upon intratumoral (it) injection and transfection of ad5-sge-reic/dkk-3 mtg-201, tumor cells express reic/dkk3 protein. this may result in the activation of c-jun-nh2-kinase (jnk) and ultimately lead to apoptosis via b-cell lymphoma-2 (bcl2) suppression and caspase-3 activation. increased expression of reic/dkk3 in cancer cells may lead to an induction of tumor cell apoptosis and a reduction in tumor cell growth, while sparing normal, healthy cells expressing endogenous reic/dkk3. in addition, the tumor cell killing promotes a cytotoxic t-lymphocyte (ctl)-mediated immune response, thereby further killing any remaining reic-deficient, untransfected tumor cells. the sge system, also called c-tsc (cmv promoter driving the triple tandem enhancer sequences of htert, sv40 and cmv), enhances gene expression compared to more conventional adenoviral vectors. reic/dkk3 is expressed by healthy cells, but expression is reduced or absent in many cancer cells due to reic/dkk3 gene defects. as reic/dkk3 plays a key role in tumor cell apoptosis, the absence of the reic protein in tumor cells prevents tumor cell apoptosis.|a copy incompetent adenoviral vector type 5 ( ad5 ) convert the tumor gene gene dickkopf-3 ( dkk3 ; reduced squeeze in change cells ; reic ; dickkopf wnt tell pathway substance 3 ) , and defend the super gene squeeze ( sge ) system , plan of the hit tandem enhancer rate of human enzyme rule transcriptase ( htert ) , simian virus 40 ( sv40 ) and herpes ( cmv ) , with potential immunostimulating and antineoplastic trait .  upon intratumoral (it) injection and transfection of ad5-sage-reich/dec-3 mtg-201, tumor cells express rich/dkk3 protein.  this may result in the beginning of c-jun-nh2-kinase (junk) and ultimately lead to apoptosis via b-cell lymphoma-2 (bcl2) restraint and caspase-3 beginning.  an increased squeeze of rice/dkk3 in cancer cells may lead to an causing  tumor cell apoptosis and a change in tumor cell growth, while box normal, healthy cells mail endogenous reich/dkk3.  in addition, the tumor cell killing plays a cytotoxic t-lymphocyte (steel) -mediated immune response, thereby further killing any remaining rice-deficient, untransfected tumor cells.  the siege system, also called c-task (cmv promoter driving the hit tandem enhancer rate of the heart, sv40 and cmv), better gene squeeze compared to more conventional adenoviral vectors.  reich/dkk3 is mailed by healthy cells, but the squeeze is reduced or absent in many cancer cells due to race/dkk3 gene flee.  as reich/dkk3 plays a key role in growth, cell apoptosis, the lack of the rice protein in growth cells prevents tumor cell apoptosis.|30.890225225225237|64.2761352657005|15.078648648648652|11.27768115942029|15.340925210084036|12.703478560395428|24.39243243243243|19.126007905138337|21.51457983193277|11.205115848007416|108.39173953766033|96.15984868956481|29.326126126126127|24.68317962231006\n",
      "\n",
      "a replication incompetent adenoviral vector type 5 (ad5) encoding the tumor suppressor gene dickkopf-3 (dkk3; reduced expression in immortalized cells; reic; dickkopf wnt signaling pathway inhibitor 3), and containing the super gene expression (sge) system, composed of the triple tandem enhancer sequences of human telomerase reverse transcriptase (htert), simian virus 40 (sv40) and cytomegalovirus (cmv), with potential immunostimulating and antineoplastic activities. upon intratumoral (it) injection and transfection of ad5-sge-reic/dkk-3 mtg-201, tumor cells express reic/dkk3 protein. this may result in the activation of c-jun-nh2-kinase (jnk) and ultimately lead to apoptosis via b-cell lymphoma-2 (bcl2) suppression and caspase-3 activation. increased expression of reic/dkk3 in cancer cells may lead to an induction of tumor cell apoptosis and a reduction in tumor cell growth, while sparing normal, healthy cells expressing endogenous reic/dkk3. in addition, the tumor cell killing promotes a cytotoxic t-lymphocyte (ctl)-mediated immune response, thereby further killing any remaining reic-deficient, untransfected tumor cells. the sge system, also called c-tsc (cmv promoter driving the triple tandem enhancer sequences of htert, sv40 and cmv), enhances gene expression compared to more conventional adenoviral vectors. reic/dkk3 is expressed by healthy cells, but expression is reduced or absent in many cancer cells due to reic/dkk3 gene defects. as reic/dkk3 plays a key role in tumor cell apoptosis, the absence of the reic protein in tumor cells prevents tumor cell apoptosis.|a viral vector type 5 (ad5) encoding a tumor suppressor gene dickkopf-3 (dkk3; reduced expression in immortalized cells; reic; dickkopf wnt signaling pathway inhibitor 3), and containing the super gene expression system, also called c-tsc|30.890225225225237|31.11571428571429|15.078648648648652|17.614285714285717|15.130125210084035|17.847645945945946|24.39243243243243|25.982857142857142|19.38957983193277|21.892972972972977|108.39173953766033|129.0119750255766|29.326126126126127|33.42857142857143\n",
      "\n",
      "a replication incompetent adenoviral vector type 5 (ad5) encoding the tumor suppressor gene dickkopf-3 (dkk3; reduced expression in immortalized cells; reic; dickkopf wnt signaling pathway inhibitor 3), and containing the super gene expression (sge) system, composed of the triple tandem enhancer sequences of human telomerase reverse transcriptase (htert), simian virus 40 (sv40) and cytomegalovirus (cmv), with potential immunostimulating and antineoplastic activities. upon intratumoral (it) injection and transfection of ad5-sge-reic/dkk-3 mtg-201, tumor cells express reic/dkk3 protein. this may result in the activation of c-jun-nh2-kinase (jnk) and ultimately lead to apoptosis via b-cell lymphoma-2 (bcl2) suppression and caspase-3 activation. increased expression of reic/dkk3 in cancer cells may lead to an induction of tumor cell apoptosis and a reduction in tumor cell growth, while sparing normal, healthy cells expressing endogenous reic/dkk3. in addition, the tumor cell killing promotes a cytotoxic t-lymphocyte (ctl)-mediated immune response, thereby further killing any remaining reic-deficient, untransfected tumor cells. the sge system, also called c-tsc (cmv promoter driving the triple tandem enhancer sequences of htert, sv40 and cmv), enhances gene expression compared to more conventional adenoviral vectors. reic/dkk3 is expressed by healthy cells, but expression is reduced or absent in many cancer cells due to reic/dkk3 gene defects. as reic/dkk3 plays a key role in tumor cell apoptosis, the absence of the reic protein in tumor cells prevents tumor cell apoptosis.| A|30.890225225225237|162.505|15.078648648648652|-8.91|15.130125210084035|14.311966666666669|24.39243243243243|-142.12|19.38957983193277|-15.219999999999999|108.39173953766033|0.0|29.326126126126127|0.8\n",
      "\n",
      "a condition observed in women and children when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. it is the result of elevated androgens from the ovaries, the adrenal glands, or exogenous sources. the concept does not include hypertrichosis, which is an androgen-independent excessive hair growth.|a condition check in women and children when there is excess coarse body hair of an adult male commerce pattern, such as facial and chest areas.  it is the result of change androgens from the ovaries, the adrenal glands, or exogenous sources.  the concept does not include hypertrichosis, which is an androgen-independent excessive hair growth.|43.67511363636365|57.30809210526317|10.583409090909093|8.806096491228072|11.329509523809524|10.745653103448277|10.224727272727279|8.937543859649121|12.210297619047623|7.270344827586207|75.03078418222748|71.69439674758411|22.227272727272727|20.436842105263157\n",
      "\n",
      "a condition observed in women and children when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. it is the result of elevated androgens from the ovaries, the adrenal glands, or exogenous sources. the concept does not include hypertrichosis, which is an androgen-independent excessive hair growth.|a condition observed in women and children when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. it is the result of elevated androgens from the ovaries, the adrenal goc, or exogenous sources.|43.67511363636365|51.625|10.583409090909093|9.536666666666669|11.329509523809524|11.312667441860466|10.224727272727279|7.837142857142858|12.210297619047623|11.446046511627905|75.03078418222748|76.64453405168562|22.227272727272727|22.742857142857144\n",
      "\n",
      "a condition observed in women and children when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. it is the result of elevated androgens from the ovaries, the adrenal glands, or exogenous sources. the concept does not include hypertrichosis, which is an androgen-independent excessive hair growth.| androgenesis|43.67511363636365|-6.694999999999993|10.583409090909093|14.690000000000001|11.329509523809524|19.5753|10.224727272727279|-109.78|12.210297619047623|2.0500000000000007|75.03078418222748|31.29|22.227272727272727|20.8\n",
      "\n",
      "an autosomal recessive form of congenital glaucoma caused by mutation(s) in the cyp1b1 gene, encoding cytochrome p450 1b1.|a cell part allele form of congenital glaucoma caused by a change (s) in the cyp1b1 gene, convert cytochrome p450 1b1.|52.00000000000003|87.40607142857144|8.242222222222225|3.6764285714285734|14.178744444444446|12.19714761904762|1.4111111111111114|-0.750476190476185|14.259999999999998|10.152857142857144|58.53822981607831|49.473833993334296|19.15555555555556|13.723809523809525\n",
      "\n",
      "an autosomal recessive form of congenital glaucoma caused by mutation(s) in the cyp1b1 gene, encoding cytochrome p450 1b1.|a genetic trait of mental impairment and brittle hair caused by mutation(s) in a gene, used for dna repair.|52.00000000000003|72.51881578947369|8.242222222222225|5.504473684210527|14.178744444444446|11.238|1.4111111111111114|-3.3052631578947356|14.259999999999998|4.058499999999999|58.53822981607831|54.195869768830164|19.15555555555556|16.431578947368422\n",
      "\n",
      "an autosomal recessive form of congenital glaucoma caused by mutation(s) in the cyp1b1 gene, encoding cytochrome p450 1b1.| an autosomal recessive congenital disease of the eye disease that can be caused by mutation(s) in the cyp1b1 gene|52.00000000000003|59.63500000000003|8.242222222222225|9.910000000000004|14.178744444444446|12.19714761904762|1.4111111111111114|13.424000000000001|14.259999999999998|10.60142857142857|58.53822981607831|76.64453405168562|19.15555555555556|20.0\n",
      "\n",
      "the menstrual cycle involves regularly recurring hormonal changes and physiologic endometrial changes during the reproductive period in human females, and some primates, and culminates in partial sloughing of the endometrium (menstruation) in the absence of fertilization. for most women, one cycle takes 28 days. (nci)|the organism function ride absorbs regularly use hormonal changes and physiologic endometrial changes during the reproductive period in human females, and some priest, and a form of partial shade of the endometrium (discharge) in the lack of enrichment.  for most women, one ride takes 28 days.  ( nice)|20.53000000000003|54.558333333333366|14.122222222222224|9.790000000000003|12.450944444444445|10.688997959183673|16.199999999999996|12.110399999999998|13.911333333333339|8.437244897959182|90.32644961471695|78.74477315987392|28.222222222222225|21.86666666666667\n",
      "\n",
      "the menstrual cycle involves regularly recurring hormonal changes and physiologic endometrial changes during the reproductive period in human females, and some primates, and culminates in partial sloughing of the endometrium (menstruation) in the absence of fertilization. for most women, one cycle takes 28 days. (nci)|the menstrual cycle involves regularly recurring hormonal changes and physiologic changes during the reproductive period in human females, and some primates. it culminates in partial sloughing of the endometrium (menstruation) in the absence of fertilization. for most women,|20.53000000000003|13.646754385964925|14.122222222222224|14.50263157894737|12.450944444444445|12.378735897435899|16.199999999999996|13.613684210526312|13.911333333333339|13.209230769230771|90.32644961471695|86.63808689023553|28.222222222222225|29.277192982456143\n",
      "\n",
      "the menstrual cycle involves regularly recurring hormonal changes and physiologic endometrial changes during the reproductive period in human females, and some primates, and culminates in partial sloughing of the endometrium (menstruation) in the absence of fertilization. for most women, one cycle takes 28 days. (nci)| the menstrual cycle is a time period.|20.53000000000003|86.45000000000002|14.122222222222224|2.1950000000000003|12.450944444444445|12.631922222222224|16.199999999999996|-50.480000000000004|13.911333333333339|-2.4333333333333336|90.32644961471695|38.32226702584281|28.222222222222225|16.6\n",
      "\n",
      "an accessory for a telephone that is worn on the head and designed to allow hands free conversation.|a criminal for a telephone that is worn on the head and designed to allow hands free speech.|66.10000000000002|84.90000000000003|6.2755555555555596|3.653333333333336|7.160966666666667|6.283744444444444|-5.775555555555556|-8.388888888888882|9.026666666666667|6.93333333333333|49.473833993334296|44.250742366654144|14.711111111111112|12.488888888888889\n",
      "\n",
      "an accessory for a telephone that is worn on the head and designed to allow hands free conversation.|an accessory phone that is worn on the head and designed to allow hands free conversation.|66.10000000000002|71.81500000000001|6.2755555555555596|5.230000000000004|7.160966666666667|7.773394117647059|-5.775555555555556|-9.07|9.026666666666667|3.5994117647058843|49.473833993334296|44.250742366654144|14.711111111111112|13.200000000000001\n",
      "\n",
      "an accessory for a telephone that is worn on the head and designed to allow hands free conversation.| An accessory for a telephone that is worn on the head and designed to allow hands free conversation.|66.10000000000002|72.51881578947369|6.2755555555555596|5.504473684210527|7.160966666666667|8.08|-5.775555555555556|-5.1621052631578905|9.026666666666667|3.3520000000000003|49.473833993334296|49.473833993334296|14.711111111111112|14.326315789473682\n",
      "\n",
      "any mixing operation not elsewhere described.|any change cognition not elsewhere mark.|20.490000000000038|62.79000000000002|11.146666666666665|5.246666666666666|9.197433333333334|6.565766666666667|-59.466666666666654|-64.36666666666666|12.184999999999995|8.260000000000002|49.473833993334296|38.32226702584281|34.53333333333334|21.200000000000003\n",
      "\n",
      "any mixing operation not elsewhere described.|any mixing operation not elsewhere described.|20.490000000000038|20.490000000000038|11.146666666666665|11.146666666666665|6.565766666666667|8.321528571428573|-59.466666666666654|-58.48666666666666|12.184999999999995|7.234285714285715|49.473833993334296|49.473833993334296|34.53333333333334|34.53333333333334\n",
      "\n",
      "any mixing operation not elsewhere described.| any operation|20.490000000000038|34.59000000000003|11.146666666666665|9.180000000000003|6.565766666666667|15.6774|-59.466666666666654|-73.18666666666667|12.184999999999995|-2.9450000000000003|49.473833993334296|44.250742366654144|34.53333333333334|27.866666666666664\n",
      "\n",
      "candidiasis of the esophagus.|candidiasis of the esophagus.|-6.694999999999993|-6.694999999999993|14.690000000000001|14.690000000000001|11.7299|11.7299|-109.78|-109.78|10.0075|10.0075|31.29|31.29|20.8|20.8\n",
      "\n",
      "candidiasis of the esophagus.|intestinal infection of the esophagus.|-6.694999999999993|-15.662499999999966|14.690000000000001|16.065000000000005|11.7299|14.311966666666669|-109.78|-77.24|10.0075|6.760000000000002|31.29|38.32226702584281|20.8|25.0\n",
      "\n",
      "candidiasis of the esophagus.| candida|-6.694999999999993|77.90500000000002|14.690000000000001|2.890000000000004|11.7299|19.5753|-109.78|-124.48|10.0075|-5.800000000000001|31.29|31.29|20.8|20.8\n",
      "\n",
      "the reemergence of lip and/or oral cavity cancer after a period of remission. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c8037\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c8037\" nci thesaurus)|the reemergence of lip and/or oral cavity cancer after a period of payment.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c8037 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c8037 '' nice wordbook)|68.65555555555557|71.19388888888889|4.373333333333335|4.433333333333337|13.523833333333334|15.817100000000002|-36.70559999999999|-22.647000000000013|37.184266666666666|9.8518|34.59239656340682|40.39521630094336|18.711111111111112|16.77777777777778\n",
      "\n",
      "the reemergence of lip and/or oral cavity cancer after a period of remission. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c8037\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c8037\" nci thesaurus)|the reappearance of lip and/or oral cavity cancer after a period of remission. check for \"http://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c8037\" active clinical trials using this agent. (http|68.65555555555557|55.03556521739131|4.373333333333335|6.7257391304347856|13.523833333333334|13.244133333333336|-36.70559999999999|-14.239999999999995|37.184266666666666|20.05375|34.59239656340682|46.41057013224466|18.711111111111112|20.9704347826087\n",
      "\n",
      "the reemergence of lip and/or oral cavity cancer after a period of remission. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c8037\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c8037\" nci thesaurus)| the reappearance of lip and/or oral cavity cancer|68.65555555555557|66.10000000000002|4.373333333333335|6.2755555555555596|13.523833333333334|15.185500000000001|-36.70559999999999|-4.795555555555556|37.184266666666666|4.2940000000000005|34.59239656340682|62.58|18.711111111111112|21.37777777777778\n",
      "\n",
      "mini-mental state examination - what were those three words i asked you to remember: word 1?|mini-mental state introspection - what were those three words i asked you to remember: word 1?|68.9825|74.27000000000001|7.612500000000001|6.8750000000000036|8.377600000000001|8.377600000000001|9.7975|10.532499999999999|8.059375|8.648125|54.195869768830164|54.195869768830164|13.9|13.9\n",
      "\n",
      "mini-mental state examination - what were those three words i asked you to remember: word 1?|mini-mental state examination - what were those three words i asked you to remember? word 1?|68.9825|68.9825|7.612500000000001|7.612500000000001|8.377600000000001|8.702217647058824|9.7975|10.165000000000003|8.059375|3.3223529411764687|54.195869768830164|54.195869768830164|13.9|13.9\n",
      "\n",
      "mini-mental state examination - what were those three words i asked you to remember: word 1?| mini-mental state examination - what were those three words i asked you to remember|68.9825|67.53000000000003|7.612500000000001|7.566666666666666|8.377600000000001|9.364474999999999|9.7975|8.098666666666666|8.059375|7.17625|54.195869768830164|54.195869768830164|13.9|14.0\n",
      "\n",
      "any nematode parasite that can be assigned to the species anisakis simplex.|any worm parasite that can be transferred to the kind anisakis simplex.|31.545000000000016|59.745000000000005|10.350000000000001|6.416666666666668|12.1267|9.495033333333335|-17.97333333333333|-19.93333333333333|9.2975|7.727500000000003|58.53822981607831|49.473833993334296|25.733333333333338|19.06666666666667\n",
      "\n",
      "any nematode parasite that can be assigned to the species anisakis simplex.|any parasitic parasite that can be assigned to the species anisakis simplex.|31.545000000000016|24.495000000000005|10.350000000000001|11.333333333333336|12.1267|12.461207692307694|-17.97333333333333|-16.993333333333332|9.2975|5.370000000000001|58.53822981607831|58.53822981607831|25.733333333333338|25.733333333333338\n",
      "\n",
      "any nematode parasite that can be assigned to the species anisakis simplex.| any nematode|31.545000000000016|62.79000000000002|10.350000000000001|5.246666666666666|12.1267|15.6774|-17.97333333333333|-75.14666666666666|9.2975|-4.122500000000002|58.53822981607831|44.250742366654144|25.733333333333338|27.866666666666664\n",
      "\n",
      "name of the pulse sequence that is used for the acquisition. example(s): other name(s): note(s): this is usually a vendor-specific name.|name of the pulse rate that is used for the acquiring.  example (s): other name (s): note (s): this is usually a vendor-specific name.|54.70142857142861|79.93666666666668|7.368571428571428|4.18|10.641645454545454|10.139443589743589|-9.805714285714288|-9.647999999999996|6.977727272727272|0.8375641025641016|51.09635603445709|40.39521630094336|18.038095238095238|11.333333333333336\n",
      "\n",
      "name of the pulse sequence that is used for the acquisition. example(s): other name(s): note(s): this is usually a vendor-specific name.|name of the pulse sequence that is used for the acquisition. it is usually a vendor-specific name.|54.70142857142861|66.71862745098042|7.368571428571428|5.361176470588237|10.641645454545454|9.768001754385967|-9.805714285714288|-23.52705882352941|6.977727272727272|1.5682456140350887|51.09635603445709|36.13057984588678|18.038095238095238|11.67843137254902\n",
      "\n",
      "name of the pulse sequence that is used for the acquisition. example(s): other name(s): note(s): this is usually a vendor-specific name.| name|54.70142857142861|162.505|7.368571428571428|-8.91|10.641645454545454|14.311966666666669|-9.805714285714288|-133.3|6.977727272727272|-10.51|51.09635603445709|0.0|18.038095238095238|0.8\n",
      "\n",
      "the aggregation, arrangement and bonding together of a set of components to form a postsynapse. [goc:bf, goc:dos, gocl:parl]|the grouping, structure and bonding together of a set of part to form a postsynapse.  [ goc : bf , goc : dos , gocl : parl ]|47.30000000000004|110.43474137931035|8.89777777777778|1.458103448275864|11.67634761904762|11.359372727272728|2.0644444444444474|-0.9489655172413798|5.800000000000001|2.91|62.58|49.473833993334296|21.37777777777778|12.696551724137933\n",
      "\n",
      "the aggregation, arrangement and bonding together of a set of components to form a postsynapse. [goc:bf, goc:dos, gocl:parl]|the aggregation, arrangement and bonding together a set of components to form an postsynapse. [goc:bf, goc:dos, parl]|47.30000000000004|48.9133823529412|8.89777777777778|8.548529411764708|11.67634761904762|12.0275|2.0644444444444474|0.4564705882352982|5.800000000000001|5.707000000000001|62.58|58.53822981607831|21.37777777777778|19.870588235294118\n",
      "\n",
      "the aggregation, arrangement and bonding together of a set of components to form a postsynapse. [goc:bf, goc:dos, gocl:parl]| the gathering together, arrangement and bonding together of a set of components to form a chemical bond|47.30000000000004|47.565|8.89777777777778|11.096666666666668|11.67634761904762|11.22732105263158|2.0644444444444474|12.302222222222227|5.800000000000001|9.884736842105266|62.58|82.78555852321104|21.37777777777778|22.75555555555556\n",
      "\n",
      "delivery of health services via remote telecommunications. this includes interactive consultative and diagnostic services.|act of health services via remote medium.  this includes interactive consultative and diagnostic services.|-33.57309523809522|21.28000000000003|19.101428571428574|11.533333333333335|13.006557142857146|12.429833333333335|-17.648571428571422|-23.135999999999996|18.067857142857143|10.893999999999998|57.127462747788826|54.195869768830164|30.438095238095244|26.0\n",
      "\n",
      "delivery of health services via remote telecommunications. this includes interactive consultative and diagnostic services.|delivery of health services via remote telecommunications. this includes interactive consulting and diagnostic services.|-33.57309523809522|-27.530238095238104|19.101428571428574|18.258571428571432|13.006557142857146|13.3585|-17.648571428571422|-18.068571428571424|18.067857142857143|14.354|57.127462747788826|57.127462747788826|30.438095238095244|30.438095238095244\n",
      "\n",
      "delivery of health services via remote telecommunications. this includes interactive consultative and diagnostic services.| delivery of health care services via remote telecommunications. this includes interactive consultative and diagnostic services|-33.57309523809522|-12.784999999999997|19.101428571428574|17.029999999999998|13.006557142857146|13.346335294117647|-17.648571428571422|4.527500000000003|18.067857142857143|14.127647058823534|57.127462747788826|69.96656701596841|30.438095238095244|28.200000000000003\n",
      "\n",
      "a traditional unit of volume used for measuring liquids and dry matter. gallons of various sizes (predominantly in the range of 3.5 - 4.75 liters) have been used in different countries since roman times.|a traditional unit of volume used for be liquids and dry matter.  gallons of various sizes (predominantly in the range of 3.5 - 4.75 liters) have been used in different countries since roman times.|68.05652941176473|76.45571428571432|5.456117647058825|4.334285714285716|9.718233333333334|9.771574509803923|-14.129411764705885|-14.90171428571428|10.370000000000001|6.2628431372549045|52.35818446050245|50.453608988852324|19.190588235294115|17.65714285714286\n",
      "\n",
      "a traditional unit of volume used for measuring liquids and dry matter. gallons of various sizes (predominantly in the range of 3.5 - 4.75 liters) have been used in different countries since roman times.|a traditional unit of volume used for measuring liquids and dry matter. large volumes (predominantly in the range of 3.5 - 4.75 liters) have been used in different countries since roman times.|68.05652941176473|70.79525000000001|5.456117647058825|4.974750000000004|9.718233333333334|10.086816666666667|-14.129411764705885|-16.4825|10.370000000000001|7.011770833333333|52.35818446050245|48.47425956113202|19.190588235294115|17.56\n",
      "\n",
      "a traditional unit of volume used for measuring liquids and dry matter. gallons of various sizes (predominantly in the range of 3.5 - 4.75 liters) have been used in different countries since roman times.| a unit of volume|68.05652941176473|100.24000000000002|5.456117647058825|0.5199999999999996|9.718233333333334|14.460766666666668|-14.129411764705885|-42.736|10.370000000000001|-6.654999999999999|52.35818446050245|44.250742366654144|19.190588235294115|18.0\n",
      "\n",
      "diagnosis of a disease or condition made before death.|diagnosis of a disease or condition made before death.|51.867500000000035|51.867500000000035|7.142777777777777|7.142777777777777|9.346233333333334|9.346233333333334|-35.724444444444444|-35.724444444444444|6.620000000000001|6.620000000000001|44.250742366654144|44.250742366654144|19.57777777777778|19.57777777777778\n",
      "\n",
      "diagnosis of a disease or condition made before death.|diagnosis of a disease or condition made before ami.|51.867500000000035|42.46750000000003|7.142777777777777|8.45388888888889|9.346233333333334|11.7795|-35.724444444444444|-36.37777777777777|6.620000000000001|1.7940000000000005|44.250742366654144|49.473833993334296|19.57777777777778|24.022222222222226\n",
      "\n",
      "diagnosis of a disease or condition made before death.| a diagnosis|51.867500000000035|62.79000000000002|7.142777777777777|5.246666666666666|9.346233333333334|15.6774|-35.724444444444444|-77.10666666666665|6.620000000000001|-5.300000000000001|44.250742366654144|31.29|19.57777777777778|14.533333333333331\n",
      "\n",
      "a subspecies of facultatively anaerobic, gram positive, cocci shaped bacteria in the phylum firmicutes. this subspecies is positive for lancefield group g, beta hemolysis, arginine deamination, esculin hydrolysis, beta glucuronidase, and growth in 6.5% nacl and negative for alpha and beta galactosidase, catalase, and pyrrolidonylarylamidase. it can ferment trehalose, and ribose but not sorbitol, or glycogen. s. dysgalactiae subsp. equisimilis is found in the human respiratory tract and vagina and is pathogenic, causing pharyngitis, impetigo, cellulitis, septicemia, glomerulonephritis, and toxic shock.|a classification of facultatively anaerobic, gram film, cocci change bacteria in the phylum firmicutes.  this subspecies is a film for lancefield group g, beta lysis, arginine domination, esculin hydrolysis, beta glucuronidase, and growth in 6.5 % nucleus and negative for start and beta galactosidase, enzyme, and pyrrolidonylarylamidase.  it can seethe trehalose, and ribs, but not subtle, or glycogen.  s.  dysgalactiae subsp.  equisimilis is found in the human respiratory tract and duct and is pathogenic, causing pharyngitis, skin_disease, cellulites, blood_disease, nephritis, and toxic shock.|-0.8418749999999875|29.354090909090957|15.892083333333336|11.897727272727273|14.186933580246915|13.372173563218391|9.094320987654317|7.368636363636359|16.034814814814816|10.147471264367816|73.38155456243756|68.19497397169383|25.778395061728396|21.672727272727272\n",
      "\n",
      "a subspecies of facultatively anaerobic, gram positive, cocci shaped bacteria in the phylum firmicutes. this subspecies is positive for lancefield group g, beta hemolysis, arginine deamination, esculin hydrolysis, beta glucuronidase, and growth in 6.5% nacl and negative for alpha and beta galactosidase, catalase, and pyrrolidonylarylamidase. it can ferment trehalose, and ribose but not sorbitol, or glycogen. s. dysgalactiae subsp. equisimilis is found in the human respiratory tract and vagina and is pathogenic, causing pharyngitis, impetigo, cellulitis, septicemia, glomerulonephritis, and toxic shock.|a subspecies of bacteria that ferment trehalose, and ribose but not sorbitol, or toxic shock. s. dysgalactiae subsp. equisimilis is found in the human respiratory tract and vagina and is path|-0.8418749999999875|46.14294354838711|15.892083333333336|8.748629032258066|14.186933580246915|12.060566666666666|9.094320987654317|-7.465806451612899|16.034814814814816|7.158958333333331|73.38155456243756|54.195869768830164|25.778395061728396|18.583870967741937\n",
      "\n",
      "a subspecies of facultatively anaerobic, gram positive, cocci shaped bacteria in the phylum firmicutes. this subspecies is positive for lancefield group g, beta hemolysis, arginine deamination, esculin hydrolysis, beta glucuronidase, and growth in 6.5% nacl and negative for alpha and beta galactosidase, catalase, and pyrrolidonylarylamidase. it can ferment trehalose, and ribose but not sorbitol, or glycogen. s. dysgalactiae subsp. equisimilis is found in the human respiratory tract and vagina and is pathogenic, causing pharyngitis, impetigo, cellulitis, septicemia, glomerulonephritis, and toxic shock.| a subspecies|-0.8418749999999875|90.99000000000004|15.892083333333336|1.3133333333333361|14.186933580246915|15.6774|9.094320987654317|-75.14666666666666|16.034814814814816|-4.122500000000002|73.38155456243756|31.29|25.778395061728396|14.533333333333331\n",
      "\n",
      "an antihistamine with mast-cell stabilizing properties used as eye drops in the treatment of allergic conjunctivitis.|a medicine with mast-cell change properties used as eye drops in the care of allergic inflammation.|24.22750000000002|61.24000000000001|11.867500000000003|6.705000000000002|10.052641176470589|7.266170588235294|0.48499999999999943|-6.130000000000003|14.775882352941174|9.788823529411765|58.53822981607831|49.473833993334296|20.700000000000003|15.700000000000001\n",
      "\n",
      "an antihistamine with mast-cell stabilizing properties used as eye drops in the treatment of allergic conjunctivitis.|an antibiotic with mast-cell stabilizing properties used as eye drops in the treatment of allergic conjunctivitis.|24.22750000000002|29.515000000000015|11.867500000000003|11.130000000000003|10.052641176470589|10.223455555555555|0.48499999999999943|-0.25|14.775882352941174|8.713333333333335|58.53822981607831|58.53822981607831|20.700000000000003|20.700000000000003\n",
      "\n",
      "an antihistamine with mast-cell stabilizing properties used as eye drops in the treatment of allergic conjunctivitis.| an antihistamine|24.22750000000002|34.59000000000003|11.867500000000003|9.180000000000003|10.052641176470589|15.6774|0.48499999999999943|-67.30666666666666|14.775882352941174|0.5874999999999986|58.53822981607831|31.29|20.700000000000003|14.533333333333331\n",
      "\n",
      "a sulfonamide antibiotic used in the treatment of urinary tract infections.|an antibiotic antibiotic used in the care of urinary tract ill_health.|24.36159090909092|39.7434090909091|11.227727272727272|9.08227272727273|12.794827272727273|11.359372727272728|-19.07272727272727|-21.74545454545455|11.473636363636366|9.332727272727272|49.473833993334296|44.250742366654144|20.381818181818183|16.745454545454546\n",
      "\n",
      "a sulfonamide antibiotic used in the treatment of urinary tract infections.|a sulfur drug used in the treatment of urinary tract infections.|24.36159090909092|62.81613636363636|11.227727272727272|5.864090909090912|12.794827272727273|13.144933333333334|-19.07272727272727|-24.41818181818182|11.473636363636366|2.7650000000000006|49.473833993334296|44.250742366654144|20.381818181818183|16.745454545454546\n",
      "\n",
      "a sulfonamide antibiotic used in the treatment of urinary tract infections.| a sulfonamide antibiotic used in the treatment of urinary tract infections|24.36159090909092|32.504999999999995|11.227727272727272|11.706666666666667|12.794827272727273|13.998223076923077|-19.07272727272727|7.183333333333337|11.473636363636366|8.982307692307693|49.473833993334296|69.96656701596841|20.381818181818183|21.46666666666667\n",
      "\n",
      "administration of a veterinary medicinal product through the shell into an embryonated egg.|justice of a doctor, medicinal product through the shell into an embryonated egg.|11.514423076923094|50.56057692307695|13.268076923076926|7.821923076923078|10.354376923076924|9.139761538461538|-9.806153846153848|-14.329230769230772|13.329999999999998|9.344615384615388|54.195869768830164|54.195869768830164|21.06153846153846|21.06153846153846\n",
      "\n",
      "administration of a veterinary medicinal product through the shell into an embryonated egg.|administration of a vet medicinal product through the shell into an embryonated egg.|11.514423076923094|37.54519230769233|13.268076923076926|9.637307692307694|10.354376923076924|10.750842857142857|-9.806153846153848|-12.520000000000003|13.329999999999998|6.2928571428571445|54.195869768830164|49.473833993334296|21.06153846153846|17.984615384615388\n",
      "\n",
      "administration of a veterinary medicinal product through the shell into an embryonated egg.| administration|11.514423076923094|-6.694999999999993|13.268076923076926|14.690000000000001|10.354376923076924|19.5753|-9.806153846153848|-103.9|13.329999999999998|5.189999999999998|54.195869768830164|31.29|21.06153846153846|20.8\n",
      "\n",
      "indicates that a toxicity adverse effect has been experienced by a patient, and it is severe enough for the patient to discontinue the treatment.|inform that a toxicity adverse effect has been changed by a case, and it is severe enough for the patient to end the care.|46.60500000000002|78.33000000000001|9.740000000000002|5.315000000000001|11.406066666666666|8.7744|5.223333333333336|-0.4116666666666653|14.119999999999997|9.606250000000003|73.38155456243756|58.53822981607831|23.133333333333333|16.46666666666667\n",
      "\n",
      "indicates that a toxicity adverse effect has been experienced by a patient, and it is severe enough for the patient to discontinue the treatment.|indicates that an adverse effect has been experienced by a patient, and it is severe enough for the patient to discontinue the treatment.|46.60500000000002|55.38858695652178|9.740000000000002|8.390652173913043|11.406066666666666|10.810866666666666|5.223333333333336|3.9165217391304346|14.119999999999997|6.942499999999999|73.38155456243756|69.96656701596841|23.133333333333333|21.991304347826087\n",
      "\n",
      "indicates that a toxicity adverse effect has been experienced by a patient, and it is severe enough for the patient to discontinue the treatment.| indicates that a toxicity adverse effect has been experienced by a patient, and it is severe enough for the patient to discontinue the therapy.|46.60500000000002|48.63550000000001|9.740000000000002|9.581|11.406066666666666|12.213792307692307|5.223333333333336|4.779199999999996|14.119999999999997|13.308461538461536|73.38155456243756|73.38155456243756|23.133333333333333|22.6\n",
      "\n",
      "a device, with a light source, which allows the clear visualization of the structure of the eye at any depth, in order to detect abnormalities within the eye.|a medical device, with a light source, which allows the clear image of the structure of the eye at any depth, in order to spy misbehavior within the eye.|62.70357142857142|72.51060344827589|7.991428571428575|6.747758620689655|9.536728571428572|9.975244827586206|6.367142857142859|4.931034482758623|13.933214285714286|12.722068965517245|66.37611354998121|66.37611354998121|18.45714285714286|18.21379310344828\n",
      "\n",
      "a device, with a light source, which allows the clear visualization of the structure of the eye at any depth, in order to detect abnormalities within the eye.|a device, with a light source, which allows the clear visualization of the structure of eye at any depth, in order to detect abnormalities within the eye.|62.70357142857142|61.53250000000003|7.991428571428575|8.030555555555559|9.536728571428572|9.406257142857143|6.367142857142859|6.167407407407406|13.933214285714286|6.596785714285716|66.37611354998121|66.37611354998121|18.45714285714286|18.73333333333333\n",
      "\n",
      "a device, with a light source, which allows the clear visualization of the structure of the eye at any depth, in order to detect abnormalities within the eye.| a medical instrument, which uses light, to allow the clear visualization of the structure of the body part being examined|62.70357142857142|40.4914285714286|7.991428571428575|12.828571428571426|9.536728571428572|9.751790909090909|6.367142857142859|14.744761904761905|13.933214285714286|11.407272727272733|66.37611354998121|93.86999999999999|18.45714285714286|25.542857142857144\n",
      "\n",
      "chuan xiong|chuan xiong|120.20500000000001|120.20500000000001|-3.01|-3.01|19.5257|19.5257|-118.6|-118.6|3.120000000000001|3.120000000000001|0.0|0.0|0.8|0.8\n",
      "\n",
      "chuan xiong|blood xiong|120.20500000000001|120.20500000000001|-3.01|-3.01|19.5257|14.311966666666669|-118.6|-115.66|3.120000000000001|-2.66|0.0|0.0|0.8|0.8\n",
      "\n",
      "chuan xiong| chuan xiong|120.20500000000001|147.39000000000004|-3.01|-6.553333333333333|19.5257|19.6249|-118.6|-77.10666666666665|3.120000000000001|-5.300000000000001|0.0|0.0|0.8|1.2000000000000002\n",
      "\n",
      "air pollutants which affect environmental conditions.|air waste which affect environmental conditions.|6.390000000000015|34.59000000000003|13.113333333333333|9.180000000000003|14.460766666666668|11.8291|-51.62666666666666|-56.52666666666666|18.464999999999996|14.54|44.250742366654144|38.32226702584281|27.866666666666664|21.200000000000003\n",
      "\n",
      "air pollutants which affect environmental conditions.|air pollutants which affect the environment.|6.390000000000015|34.59000000000003|13.113333333333333|9.180000000000003|14.460766666666668|12.832957142857145|-51.62666666666666|-59.466666666666654|18.464999999999996|6.561428571428571|44.250742366654144|38.32226702584281|27.866666666666664|21.200000000000003\n",
      "\n",
      "air pollutants which affect environmental conditions.| gaseous pollutants|6.390000000000015|62.79000000000002|13.113333333333333|5.246666666666666|14.460766666666668|19.6249|-51.62666666666666|-63.386666666666656|18.464999999999996|2.942499999999999|44.250742366654144|44.250742366654144|27.866666666666664|27.866666666666664\n",
      "\n",
      "interacting selectively and non-covalently with a 30-bp purine-rich negative regulatory element; the best characterized such element is found in the first intronic region of the rat cardiac alpha-myosin heavy chain gene, and contains two palindromic high-affinity ets-binding sites (cttccctggaag). the presence of this element restricts expression of the gene containing it to cardiac myocytes. [goc:mah, pmid:9819411]|act selectively and non-covalently with a 30-bp purine-rich negative regulatory straight_line ; the best distinguish such straight_line is found in the first intronic region of the rat cardiac alpha-myosin heavy chain gene , and contains two palindromic high-affinity ets-binding sites ( cttccctggaag ) .  the presence of this straight_line restricts squeeze of the gene defend it to cardiac myocytes.  [ goc: mah, pmid: 9819411]|21.709761904761933|56.32318181818184|14.868571428571432|10.86878787878788|13.450322222222225|12.664704848484849|22.257857142857148|18.974545454545456|15.012380952380951|10.075909090909093|92.11526583579942|86.63808689023553|26.03809523809524|22.739393939393942\n",
      "\n",
      "interacting selectively and non-covalently with a 30-bp purine-rich negative regulatory element; the best characterized such element is found in the first intronic region of the rat cardiac alpha-myosin heavy chain gene, and contains two palindromic high-affinity ets-binding sites (cttccctggaag). the presence of this element restricts expression of the gene containing it to cardiac myocytes. [goc:mah, pmid:9819411]|interacting selectively and not binding with a dna element; the best characterized such element is found in the first region of the rat heart alpha-myosin heavy chain gene, and contains two palindromic high-affinity ets-binding sites. the presence of|21.709761904761933|31.70789473684212|14.868571428571432|13.556842105263158|13.450322222222225|11.069290476190476|22.257857142857148|17.534736842105264|15.012380952380951|12.395714285714284|92.11526583579942|82.78555852321104|26.03809523809524|22.33684210526316\n",
      "\n",
      "interacting selectively and non-covalently with a 30-bp purine-rich negative regulatory element; the best characterized such element is found in the first intronic region of the rat cardiac alpha-myosin heavy chain gene, and contains two palindromic high-affinity ets-binding sites (cttccctggaag). the presence of this element restricts expression of the gene containing it to cardiac myocytes. [goc:mah, pmid:9819411]| Binding|21.709761904761933|120.20500000000001|14.868571428571432|-3.01|13.450322222222225|19.5753|22.257857142857148|-124.48|15.012380952380951|-5.800000000000001|92.11526583579942|31.29|26.03809523809524|20.8\n",
      "\n",
      "catalysis of the reaction: alpha-n-peptidyl-l-glutamine + h2o = alpha-n-peptidyl-l-glutamate + nh3. [ec:3.5.1.43, metacyc:peptidyl-glutaminase-rxn]|the catalysis of the reaction: alpha-n-peptidyl-l-glutamine + h2o = alpha-n-peptidyl-l-glutamate + nh3.  [ ec:3.5.1.43 , metacyc : peptidyl-glutaminase-rxn ]|-30.080923076923057|46.265000000000015|18.100923076923085|7.800000000000001|18.50746666666667|18.249376923076923|-52.78461538461537|-33.428|5.923749999999998|7.351923076923079|31.29|34.27647764867329|16.42461538461539|13.600000000000001\n",
      "\n",
      "catalysis of the reaction: alpha-n-peptidyl-l-glutamine + h2o = alpha-n-peptidyl-l-glutamate + nh3. [ec:3.5.1.43, metacyc:peptidyl-glutaminase-rxn]|starting of the reaction: alpha-n-peptidyl-l-glutamine + hydrogen peroxide + nh3. [ec:3.5.1.43, metacyc]|-30.080923076923057|42.248999999999995|18.100923076923085|7.962666666666667|18.70586666666667|17.061629411764706|-52.78461538461537|-77.27333333333334|7.923749999999998|6.370000000000001|31.29|31.29|16.42461538461539|17.62666666666667\n",
      "\n",
      "catalysis of the reaction: alpha-n-peptidyl-l-glutamine + h2o = alpha-n-peptidyl-l-glutamate + nh3. [ec:3.5.1.43, metacyc:peptidyl-glutaminase-rxn]| catalepsy is hypersensitivity|-30.080923076923057|-51.02499999999998|18.100923076923085|21.370000000000008|18.50746666666667|16.5165|-52.78461538461537|-32.84|5.923749999999998|8.387999999999998|31.29|44.250742366654144|16.42461538461539|21.6\n",
      "\n",
      "invasive intervention indicated|invasive care informs|-106.40999999999997|34.59000000000003|28.846666666666668|9.180000000000003|19.5753|14.311966666666669|-41.82666666666667|-61.42666666666666|25.599999999999994|9.899999999999999|54.195869768830164|44.250742366654144|41.2|27.866666666666664\n",
      "\n",
      "invasive intervention indicated|blood clot that travels|-106.40999999999997|97.025|28.846666666666668|0.7199999999999989|19.5753|13.3585|-41.82666666666667|-43.13|25.599999999999994|0.8520000000000003|54.195869768830164|31.29|41.2|11.600000000000001\n",
      "\n",
      "invasive intervention indicated| intervention|-106.40999999999997|35.60500000000002|28.846666666666668|8.790000000000003|19.5753|19.5753|-41.82666666666667|-109.78|25.599999999999994|2.0500000000000007|54.195869768830164|31.29|41.2|20.8\n",
      "\n",
      "invasive intervention indicated|invasive care informs|-106.40999999999997|34.59000000000003|28.846666666666668|9.180000000000003|19.5753|14.311966666666669|-41.82666666666667|-61.42666666666666|25.599999999999994|9.899999999999999|54.195869768830164|44.250742366654144|41.2|27.866666666666664\n",
      "\n",
      "invasive intervention indicated|blood clot that travels|-106.40999999999997|97.025|28.846666666666668|0.7199999999999989|19.5753|13.3585|-41.82666666666667|-43.13|25.599999999999994|0.8520000000000003|54.195869768830164|31.29|41.2|11.600000000000001\n",
      "\n",
      "invasive intervention indicated| intervention|-106.40999999999997|35.60500000000002|28.846666666666668|8.790000000000003|19.5753|19.5753|-41.82666666666667|-109.78|25.599999999999994|2.0500000000000007|54.195869768830164|31.29|41.2|20.8\n",
      "\n",
      "vulvar cancer with tumor of any size with extension to any of the following: upper/proximal 2/3 urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone. (from ajcc 7th ed.)|vulvar cancer  the growth of any size with longness in any of the following: upper/proximal 2/3 urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone.  ( from ajcc 7th ed.)|46.97909090909093|63.05500000000001|9.439393939393941|7.445555555555558|12.62507142857143|13.089235135135135|4.272727272727266|3.7533333333333303|9.389714285714287|8.824054054054056|72.26115969177356|69.96656701596841|23.793939393939397|21.46666666666667\n",
      "\n",
      "vulvar cancer with tumor of any size with extension to any of the following: upper/proximal 2/3 urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone. (from ajcc 7th ed.)|cancer below vocal cords with tumor of any size with extension to any of the following: upper/proximal 2/3 urine retention time (from ajcc 7th ed.)|46.97909090909093|58.78750000000002|9.439393939393941|8.165000000000003|12.62507142857143|11.323877777777778|4.272727272727266|5.484799999999996|9.389714285714287|6.078888888888891|72.26115969177356|73.38155456243756|23.793939393939397|22.6\n",
      "\n",
      "vulvar cancer with tumor of any size with extension to any of the following: upper/proximal 2/3 urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone. (from ajcc 7th ed.)| Vulvar cancer is cancer|46.97909090909093|83.32000000000004|9.439393939393941|2.879999999999999|12.62507142857143|17.092433333333332|4.272727272727266|-34.50399999999999|9.389714285714287|-1.1600000000000001|72.26115969177356|54.195869768830164|23.793939393939397|26.0\n",
      "\n",
      "assistance in promoting continence and maintaining perineal skin integrity|resource in playful restraint and confirm perineal skin honesty|-9.099999999999994|37.900000000000034|16.764444444444447|10.208888888888893|14.60956666666667|14.60956666666667|10.231111111111112|3.0444444444444443|17.61|11.853333333333332|76.64453405168562|76.64453405168562|30.266666666666666|30.266666666666666\n",
      "\n",
      "assistance in promoting continence and maintaining perineal skin integrity|assistance in promoting continence and maintaining skin integrity.|-9.099999999999994|1.8500000000000227|16.764444444444447|13.995000000000001|14.60956666666667|14.38636666666667|10.231111111111112|-29.9|17.61|11.696666666666665|76.64453405168562|49.473833993334296|30.266666666666666|26.6\n",
      "\n",
      "assistance in promoting continence and maintaining perineal skin integrity| assistance|-9.099999999999994|77.90500000000002|16.764444444444447|2.890000000000004|14.60956666666667|19.5753|10.231111111111112|-115.66|17.61|-1.0899999999999999|76.64453405168562|31.29|30.266666666666666|20.8\n",
      "\n",
      "the process in which a protrusion or bulge is formed at the site of plant root hair outgrowth. [goc:jid, pmid:12468740]|the walk in which a protrusion or bulge is formed at the site of plant root hair outgrowth.  [ goc: jid, pmid: 12468740]|95.165|110.055|2.4700000000000024|0.8900000000000006|10.172538095238096|10.19546231884058|-0.1999999999999993|-0.9016666666666637|5.127142857142857|1.2433333333333323|44.250742366654144|31.29|12.0|8.133333333333333\n",
      "\n",
      "the process in which a protrusion or bulge is formed at the site of plant root hair outgrowth. [goc:jid, pmid:12468740]|the process in which a bulge is formed at the site of plant root hair outgrowth. [goc:jid, pmid:12468740]|95.165|103.70000000000002|2.4700000000000024|1.0311111111111124|10.172538095238096|10.448500000000001|-0.1999999999999993|-3.8155555555555516|5.127142857142857|3.3520000000000003|44.250742366654144|38.32226702584281|12.0|10.266666666666666\n",
      "\n",
      "the process in which a protrusion or bulge is formed at the site of plant root hair outgrowth. [goc:jid, pmid:12468740]| root hair outgrowth|95.165|118.17500000000001|2.4700000000000024|-2.2299999999999986|10.172538095238096|13.3585|-0.1999999999999993|-47.54|5.127142857142857|-1.032|44.250742366654144|31.29|12.0|11.600000000000001\n",
      "\n",
      "enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucose(out) + h(out)+ = glucose(in) + h(in)+, in response to a stimulus by insulin. symporter activity enables the active transport of a solute across a membrane by a mechanism whereby two or more species are transported together in the same direction in a tightly coupled process not directly linked to a form of energy other than chemiosmotic energy. [goc:mtg_transport]|change the shift of a solute or matter from one side of a sheet to the other according to the reaction: glucose (out) + h (out) + = glucose (in) + h (in) +, in phrase to a stimulus by hormone.  symporter activity changes the active move of a solute across a sheet by a device whereby two or more kinds are moving together in the same command in a tightly join process not directly linked to a form of good_health other than charismatic good_health.  [ goc: mtg_transport]|34.890833333333376|63.585000000000036|15.017500000000002|11.843333333333337|12.383354320987655|10.551514831460675|18.741|15.090666666666664|15.154814814814813|6.9979775280898835|106.8756964889586|93.86999999999999|28.16666666666667|24.0\n",
      "\n",
      "enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucose(out) + h(out)+ = glucose(in) + h(in)+, in response to a stimulus by insulin. symporter activity enables the active transport of a solute across a membrane by a mechanism whereby two or more species are transported together in the same direction in a tightly coupled process not directly linked to a form of energy other than chemiosmotic energy. [goc:mtg_transport]|enables the transfer of a solute or two side membranes according to the reaction: glucose(out) + hydrogen peroxide (also known as chemiosmotic energy). [goc:mtg_transport]|34.890833333333376|25.455000000000013|15.017500000000002|12.690000000000001|11.847674320987656|13.175982051282052|18.741|11.838333333333331|9.754814814814814|8.446025641025642|106.8756964889586|79.77416029015912|28.16666666666667|26.466666666666665\n",
      "\n",
      "enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucose(out) + h(out)+ = glucose(in) + h(in)+, in response to a stimulus by insulin. symporter activity enables the active transport of a solute across a membrane by a mechanism whereby two or more species are transported together in the same direction in a tightly coupled process not directly linked to a form of energy other than chemiosmotic energy. [goc:mtg_transport]| enables the passive or active transportation of a solute across a membrane by a mechanism whereby two or more species are transported together in the same direction in a loosely coupled process not directly linked to a form of energy other than chemiosmotic energy.|34.890833333333376|35.47750000000002|15.017500000000002|13.90055555555556|12.048554320987655|11.642517391304349|18.741|15.983111111111112|11.779814814814813|12.903260869565216|106.8756964889586|101.39118822659097|28.16666666666667|27.666666666666664\n",
      "\n",
      "<p>a person becomes eligible for a program based on more than one criterion.</p><i>examples:</i>in the u.s., a child whose familiy income meets medicaid financial thresholds and whose age is less than 18 is eligible for the early and periodic screening, diagnostic, and treatment program (epsdt). a person whose family income meets medicaid financial thresholds and whose age is 65 years or older is eligible for medicaid and medicare, and are referred to as dual eligibles.|< p > a person becomes eligible for a program based on more than one criterion.  < /p > < i > examples: < /i > in the u.s., a child whose family income meets health_care financial sill and whose age is less than 18 is eligible for the early and periodic sift, diagnosis, and care program (epsdt).  a person whose family income meets health_care financial sill and whose age is 65 years or older is eligible for health_care and health_care, and are named to as dual eligibles.|47.981531531531516|76.93000000000002|9.63081081081081|6.255555555555556|11.883324691358025|10.893055555555556|7.8632432432432395|5.485333333333333|21.614074074074075|9.549666666666667|69.96656701596841|65.13532912329528|21.14954954954955|17.555555555555554\n",
      "\n",
      "<p>a person becomes eligible for a program based on more than one criterion.</p><i>examples:</i>in the u.s., a child whose familiy income meets medicaid financial thresholds and whose age is less than 18 is eligible for the early and periodic screening, diagnostic, and treatment program (epsdt). a person whose family income meets medicaid financial thresholds and whose age is 65 years or older is eligible for medicaid and medicare, and are referred to as dual eligibles.|a person becomes eligible for a program based on more than one criterion./p>i>examples: a child whose family income meets medicaid financial thresholds and his age is less than 18 years old. these are referred to as dual eligibles.|47.981531531531516|56.93460526315789|9.63081081081081|7.678157894736845|11.213724691358024|9.488363565891472|7.8632432432432395|-0.9842105263157883|14.922222222222224|6.767364341085273|69.96656701596841|56.4088497046341|21.14954954954955|17.48421052631579\n",
      "\n",
      "<p>a person becomes eligible for a program based on more than one criterion.</p><i>examples:</i>in the u.s., a child whose familiy income meets medicaid financial thresholds and whose age is less than 18 is eligible for the early and periodic screening, diagnostic, and treatment program (epsdt). a person whose family income meets medicaid financial thresholds and whose age is 65 years or older is eligible for medicaid and medicare, and are referred to as dual eligibles.| a person|47.981531531531516|119.19000000000003|9.63081081081081|-2.619999999999999|11.883324691358025|11.7299|7.8632432432432395|-82.98666666666665|21.614074074074075|-8.8325|69.96656701596841|31.29|21.14954954954955|14.533333333333331\n",
      "\n",
      "a chromosome band present on 11p|a body band present on 11p|87.94500000000002|102.045|2.4833333333333343|0.5166666666666693|9.197433333333334|6.565766666666667|-22.873333333333328|-28.75333333333333|2.7650000000000006|-1.9450000000000003|44.250742366654144|44.250742366654144|15.733333333333333|15.733333333333333\n",
      "\n",
      "a chromosome band present on 11p|a dna band present on 11p.|87.94500000000002|119.19000000000003|2.4833333333333343|-2.619999999999999|9.197433333333334|10.577242857142856|-22.873333333333328|-77.10666666666665|2.7650000000000006|-5.550000000000001|44.250742366654144|22.125371183327072|15.733333333333333|7.866666666666666\n",
      "\n",
      "a chromosome band present on 11p| a band|87.94500000000002|147.39000000000004|2.4833333333333343|-6.553333333333333|9.197433333333334|11.7299|-22.873333333333328|-86.90666666666665|2.7650000000000006|-11.1875|44.250742366654144|0.0|15.733333333333333|1.2000000000000002\n",
      "\n",
      "columbia-suicide severity rating scale baseline - description of non-specific active suicidal thoughts.|columbia-suicide sternness pad scale line - kind of non-specific active suicidal thoughts.|-3.7049999999999557|45.64500000000001|15.266666666666666|8.383333333333333|17.64206923076923|13.998223076923077|-4.25333333333333|-10.623333333333335|16.953076923076928|12.24307692307692|62.58|49.473833993334296|29.066666666666663|19.06666666666667\n",
      "\n",
      "columbia-suicide severity rating scale baseline - description of non-specific active suicidal thoughts.|columbia suicide severity rating scale baseline - description of non-specific active suicide thoughts.|-3.7049999999999557|-1.5009615384615245|15.266666666666666|15.083461538461542|17.64206923076923|17.517985714285714|-4.25333333333333|-4.3784615384615435|16.953076923076928|11.675714285714285|62.58|66.37611354998121|29.066666666666663|30.29230769230769\n",
      "\n",
      "columbia-suicide severity rating scale baseline - description of non-specific active suicidal thoughts.| columbia-suicide severity rating scale baseline|-3.7049999999999557|-10.754999999999995|15.266666666666666|16.25|17.64206923076923|19.823300000000003|-4.25333333333333|-6.213333333333331|16.953076923076928|8.475000000000001|62.58|62.58|29.066666666666663|29.066666666666663\n",
      "\n",
      "any process that modulates the frequency, rate or extent of interleukin-17a biosynthetic process. [goc:aruk, pmid:27901018]|any walk that changes the ratio, rate or extent of interleukin-17a biosynthetic process.  [ goc: ark, pmid: 27901018]|46.942499999999995|94.78197368421053|8.575000000000003|2.399210526315791|13.902050000000001|12.706322222222223|3.261333333333333|-0.5199999999999996|12.890625|5.905000000000001|62.58|54.195869768830164|24.333333333333336|16.431578947368422\n",
      "\n",
      "any process that modulates the frequency, rate or extent of interleukin-17a biosynthetic process. [goc:aruk, pmid:27901018]|any process that modulates the frequency, rate or extent of an il-17a biosynthetic process. [goc:aruk, pmid:27901018]|46.942499999999995|50.66500000000002|8.575000000000003|8.180000000000003|13.902050000000001|13.732344444444447|3.261333333333333|0.8524999999999991|12.890625|8.451666666666668|62.58|62.58|24.333333333333336|23.200000000000003\n",
      "\n",
      "any process that modulates the frequency, rate or extent of interleukin-17a biosynthetic process. [goc:aruk, pmid:27901018]| any process that is involved in modulation of the frequency, rate or extent of a cytokine|46.942499999999995|55.21529411764709|8.575000000000003|9.781176470588235|13.902050000000001|11.547077777777778|3.261333333333333|8.529411764705884|12.890625|7.195|62.58|82.78555852321104|24.333333333333336|23.270588235294117\n",
      "\n",
      "specifies whether the entity is active.|choose whether the entity is active.|34.59000000000003|62.79000000000002|9.180000000000003|5.246666666666666|14.460766666666668|11.8291|-65.34666666666666|-68.28666666666666|7.475000000000001|5.120000000000001|44.250742366654144|38.32226702584281|27.866666666666664|21.200000000000003\n",
      "\n",
      "specifies whether the entity is active.|specifies whether an entity is active.|34.59000000000003|34.59000000000003|9.180000000000003|9.180000000000003|14.460766666666668|15.08867142857143|-65.34666666666666|-65.34666666666666|7.475000000000001|2.524285714285714|44.250742366654144|44.250742366654144|27.866666666666664|27.866666666666664\n",
      "\n",
      "specifies whether the entity is active.| specifies whether the entity is an active agent|34.59000000000003|56.70000000000002|9.180000000000003|7.58666666666667|14.460766666666668|15.185500000000001|-65.34666666666666|-6.10222222222222|7.475000000000001|3.3520000000000003|44.250742366654144|69.96656701596841|27.866666666666664|25.822222222222223\n",
      "\n",
      "an anatomical qualifier that describes the arrangement or apportioning of an entity within a body part, region or organ.|a saying qualifier that marks the structure or distribute of an entity within a body part, region or organ.|27.992500000000007|59.16092105263158|11.715|7.367631578947371|10.396268421052632|10.396268421052632|0.4084210526315779|-3.6147368421052626|12.859473684210528|9.636842105263156|69.96656701596841|66.37611354998121|24.852631578947367|22.74736842105263\n",
      "\n",
      "an anatomical qualifier that describes the arrangement or apportioning of an entity within a body part, region or organ.|anatomical qualifier that describes the arrangement or apportioning of a body part, region or organ.|27.992500000000007|24.382499999999993|11.715|11.721666666666671|10.396268421052632|9.954550000000001|0.4084210526315779|-5.3626666666666765|12.859473684210528|7.591875000000002|69.96656701596841|62.58|24.852631578947367|24.333333333333336\n",
      "\n",
      "an anatomical qualifier that describes the arrangement or apportioning of an entity within a body part, region or organ.| an anatomical description|27.992500000000007|12.425000000000011|11.715|12.52|10.396268421052632|16.5165|0.4084210526315779|-38.72|12.859473684210528|4.620000000000001|69.96656701596841|44.250742366654144|24.852631578947367|21.6\n",
      "\n",
      "<p>every racial or ethnic group has specific health concerns. differences in the health of groups can result from</p> <ul> <li>genetics</li> <li>environmental factors</li> <li>access to care</li> <li>cultural factors</li> </ul> <p>on this page, you'll find links to health issues that affect latino and hispanic americans.</p>|< p > every racial or ethnic group has fact health concerns.  number in the health of groups can result from < /p > < ul > < li > genetics < /li > < li > environmental factors < /li > < li > reach to care < /li > < li > cultural factors < /li > < /ul > < p > on this page, you'll find links to health issues that affect latino and hispanic americans.  < /p >|28.988992248062033|99.44843137254904|12.776744186046514|6.427058823529414|16.294623943661975|16.704617647058825|18.184186046511627|8.507294117647058|15.027323943661976|14.947411764705883|78.74477315987392|72.26115969177356|23.4077519379845|18.862745098039216\n",
      "\n",
      "<p>every racial or ethnic group has specific health concerns. differences in the health of groups can result from</p> <ul> <li>genetics</li> <li>environmental factors</li> <li>access to care</li> <li>cultural factors</li> </ul> <p>on this page, you'll find links to health issues that affect latino and hispanic americans.</p>|every race or ethnic group has specific health concerns. differences in the health of groups can result from/p> ul>|28.988992248062033|72.51881578947369|12.776744186046514|5.504473684210527|15.238143943661973|10.385595652173913|18.184186046511627|-0.8294736842105266|4.37732394366197|3.9791304347826078|78.74477315987392|54.195869768830164|23.4077519379845|16.431578947368422\n",
      "\n",
      "<p>every racial or ethnic group has specific health concerns. differences in the health of groups can result from</p> <ul> <li>genetics</li> <li>environmental factors</li> <li>access to care</li> <li>cultural factors</li> </ul> <p>on this page, you'll find links to health issues that affect latino and hispanic americans.</p>| every racial or ethnic group has specific health issues. differences in the health of groups can result from|28.988992248062033|72.51881578947369|12.776744186046514|5.504473684210527|15.238143943661973|9.659|18.184186046511627|-2.6863157894736815|4.37732394366197|5.235999999999997|78.74477315987392|58.53822981607831|23.4077519379845|18.53684210526316\n",
      "\n",
      "therapeutic wrist orthoses designed for external modification of the functional characteristics of the wrist joint. this permits a limited and adjustable limited range of flexion motion of the joint. these orthoses are prefabricated devices typically consisting of semi-rigid articulated devices that include forearm and hand straps, and an adjustable mechanical joint placed at the wrist to regulate the range of the joint flexion. flexion dynamic therapy wrist orthoses are used to treat patients suffering from hyperextension deformity of the wrist.|medicine procedure orthoses designed for feature happening with the functional property of the wrist joint.  this permits a limited and adjustable limited range of flexion change of the joint.  these outhouses are producing devices typically be  semi-rigid state devices that include arm and hand straps, and an adjustable mechanical joint placed at the wrist to restrict the range of the joint flexion.  flexion dynamic therapy wrist orthoses are used to treat case worsen  the extension appearance of the wrist.|24.567500000000024|52.811571428571455|13.807500000000001|10.066761904761904|13.608060493827162|12.598197478991596|16.265499999999996|12.480952380952381|15.85018518518519|8.413075630252102|82.78555852321104|77.91147168421348|23.900000000000002|21.481904761904765\n",
      "\n",
      "therapeutic wrist orthoses designed for external modification of the functional characteristics of the wrist joint. this permits a limited and adjustable limited range of flexion motion of the joint. these orthoses are prefabricated devices typically consisting of semi-rigid articulated devices that include forearm and hand straps, and an adjustable mechanical joint placed at the wrist to regulate the range of the joint flexion. flexion dynamic therapy wrist orthoses are used to treat patients suffering from hyperextension deformity of the wrist.|these orthoses are prefabricated devices typically consisting of semi-rigid articulated devices that include forearm and hand straps, and an adjustable range of the joint flexion.|24.567500000000024|18.17950000000002|13.807500000000001|13.829000000000004|13.608060493827162|14.332737037037038|16.265499999999996|13.011200000000002|15.85018518518519|18.759999999999998|82.78555852321104|76.64453405168562|23.900000000000002|24.200000000000003\n",
      "\n",
      "therapeutic wrist orthoses designed for external modification of the functional characteristics of the wrist joint. this permits a limited and adjustable limited range of flexion motion of the joint. these orthoses are prefabricated devices typically consisting of semi-rigid articulated devices that include forearm and hand straps, and an adjustable mechanical joint placed at the wrist to regulate the range of the joint flexion. flexion dynamic therapy wrist orthoses are used to treat patients suffering from hyperextension deformity of the wrist.| therapeutic braces|24.567500000000024|34.59000000000003|13.807500000000001|9.180000000000003|13.608060493827162|19.6249|16.265499999999996|-63.386666666666656|15.85018518518519|2.942499999999999|82.78555852321104|44.250742366654144|23.900000000000002|27.866666666666664\n",
      "\n",
      "the reported name of an exposure treatment vehicle.|the reported name of a danger care object.|44.150000000000006|75.87500000000001|8.094999999999999|3.6700000000000017|9.954550000000001|6.00705|-41.660000000000004|-48.275000000000006|7.88625|2.5874999999999986|44.250742366654144|38.32226702584281|21.6|16.6\n",
      "\n",
      "the reported name of an exposure treatment vehicle.|the reported name of a treatment vehicle.|44.150000000000006|58.25392857142859|8.094999999999999|6.003571428571426|11.9283|11.7299|-41.660000000000004|-54.33142857142857|7.88625|1.1762499999999996|44.250742366654144|38.32226702584281|21.6|18.54285714285714\n",
      "\n",
      "the reported name of an exposure treatment vehicle.| the name of a chemical element|44.150000000000006|78.87285714285717|8.094999999999999|3.997142857142858|11.9283|11.9283|-41.660000000000004|-20.445714285714285|7.88625|-1.5337499999999977|44.250742366654144|44.250742366654144|21.6|14.228571428571428\n",
      "\n",
      "a condition in which the gastrointestinal tract is inflamed over a long period of time. crohn disease usually affects the small intestine and colon. symptoms include fever, diarrhea, stomach cramps, vomiting, and weight loss. crohn disease increases the risk of colorectal cancer and small intestine cancer. it is a type of inflammatory bowel disease (ibd).|a shampoo in which the gastrointestinal tract worsens over a long period of time.  crohn disease usually changes the small intestine and colon.  symptoms include fever, diarrhea, stomach cramps, excrete, and weight loss.  crohn disease change the risk of colorectal cancer and small intestine cancer.  it is a type of inflammatory bowel disease (ibd).|49.8653787878788|65.74747126436785|8.581363636363637|6.490344827586206|12.794827272727273|12.667868582375478|0.10254545454544939|-0.8151724137931033|9.075818181818185|5.098601532567049|63.87044504307137|62.58|21.848484848484848|20.418390804597703\n",
      "\n",
      "a condition in which the gastrointestinal tract is inflamed over a long period of time. crohn disease usually affects the small intestine and colon. symptoms include fever, diarrhea, stomach cramps, vomiting, and weight loss. crohn disease increases the risk of colorectal cancer and small intestine cancer. it is a type of inflammatory bowel disease (ibd).|a condition in which the gastrointestinal tract is inflamed over a long period of time. crohn disease usually affects the small intestine and colon. symptoms include fever, diarrhea, stomach cramps, vomiting, and weight loss.|49.8653787878788|51.40161764705883|8.581363636363637|8.201470588235296|12.794827272727273|12.191071428571428|0.10254545454544939|-1.445882352941176|9.075818181818185|7.9752857142857145|63.87044504307137|62.58|21.848484848484848|22.223529411764705\n",
      "\n",
      "a condition in which the gastrointestinal tract is inflamed over a long period of time. crohn disease usually affects the small intestine and colon. symptoms include fever, diarrhea, stomach cramps, vomiting, and weight loss. crohn disease increases the risk of colorectal cancer and small intestine cancer. it is a type of inflammatory bowel disease (ibd).| a disease|49.8653787878788|119.19000000000003|8.581363636363637|-2.619999999999999|12.794827272727273|15.6774|0.10254545454544939|-81.02666666666666|9.075818181818185|-7.654999999999999|63.87044504307137|31.29|21.848484848484848|14.533333333333331\n",
      "\n",
      "any viral organism that can be assigned to the species rubella virus.|any being system that can be transferred to the kind measles virus.|45.64500000000001|73.84500000000001|8.383333333333333|4.450000000000003|12.1267|9.495033333333335|-20.913333333333334|-21.893333333333324|6.942499999999999|6.157499999999999|58.53822981607831|54.195869768830164|25.733333333333338|22.400000000000002\n",
      "\n",
      "any viral organism that can be assigned to the species rubella virus.|any viral organism that can be assigned to the family rubella virus.|45.64500000000001|38.595|8.383333333333333|9.366666666666667|12.1267|11.246592307692307|-20.913333333333334|-20.913333333333334|6.942499999999999|2.471538461538465|58.53822981607831|58.53822981607831|25.733333333333338|25.733333333333338\n",
      "\n",
      "any viral organism that can be assigned to the species rubella virus.| any viral organism|45.64500000000001|54.72500000000002|8.383333333333333|6.620000000000001|12.1267|16.5165|-20.913333333333334|-49.010000000000005|6.942499999999999|-1.9740000000000002|58.53822981607831|54.195869768830164|25.733333333333338|31.6\n",
      "\n",
      "a neoplasm that arises from the vagina and is characterized by the proliferation of nests of benign melanocytes.|a growth that protest from the duct and is distinguished by the increase of nests of benign melanocytes.|28.50000000000003|66.10000000000002|11.520000000000003|6.2755555555555596|9.792633333333335|10.669855555555555|-1.8555555555555578|-4.468888888888891|12.166666666666664|10.073333333333334|58.53822981607831|49.473833993334296|19.15555555555556|14.711111111111112\n",
      "\n",
      "a neoplasm that arises from the vagina and is characterized by the proliferation of nests of benign melanocytes.|a tumor that arises from the vagina and is characterized by the proliferation of nests of benign melanocytes.|28.50000000000003|28.50000000000003|11.520000000000003|11.520000000000003|9.792633333333335|9.925068421052632|-1.8555555555555578|-2.508888888888883|12.166666666666664|6.126315789473683|58.53822981607831|58.53822981607831|19.15555555555556|19.15555555555556\n",
      "\n",
      "a neoplasm that arises from the vagina and is characterized by the proliferation of nests of benign melanocytes.| a cancer that arises from the vagina|28.50000000000003|71.81500000000001|11.520000000000003|5.230000000000004|9.792633333333335|11.100677777777777|-1.8555555555555578|-14.215|12.166666666666664|-0.18333333333333357|58.53822981607831|54.195869768830164|19.15555555555556|18.2\n",
      "\n",
      "an imaging agent composed of a heptapeptide targeting human epithelial growth factor receptor type 2 (egfr2; her2; erbb2) conjugated, via a five-amino acid linker, to the near-infrared (nir) fluorescent dye irdye800cw, that can potentially be used for the imaging of her2-expressing tumors. upon oral administration of the irdye800cw-labeled heptapeptide ksp-910638g, the peptide moiety targets and binds to her2 expressed on tumor cells in the gastrointestinal (gi) tract. upon fluorescence imaging of the fluorophore irdye800cw, the tumor cells can be detected.|a reagent agent plan of a heptapeptide aim human epithelial growth factor organ type 2 (egfr2; her2; erbb2) change, via a five-amino acid linker, to the near-infrared (nir) fluorescent dye irdye800cw, that can potentially be used for the imaging of her2-expressing growth.  upon oral justice of the irdye800cw-labeled heptapeptide ksp-910638g, the peptide moiety aim and binds to her2 mail on growth cells in the gastrointestinal (gi) tract.  upon light imaging of the fluorophore irdye800cw, the growth cells can be a spy.|42.71500000000003|67.53760542168676|12.270000000000003|8.994066265060244|14.701598039215687|12.942755454545456|20.774|16.976867469879522|18.447725490196078|10.010113636363638|92.55706820659348|78.225|25.5|20.34819277108434\n",
      "\n",
      "an imaging agent composed of a heptapeptide targeting human epithelial growth factor receptor type 2 (egfr2; her2; erbb2) conjugated, via a five-amino acid linker, to the near-infrared (nir) fluorescent dye irdye800cw, that can potentially be used for the imaging of her2-expressing tumors. upon oral administration of the irdye800cw-labeled heptapeptide ksp-910638g, the peptide moiety targets and binds to her2 expressed on tumor cells in the gastrointestinal (gi) tract. upon fluorescence imaging of the fluorophore irdye800cw, the tumor cells can be detected.|an imaging agent composed of a molecule targeting her2 expressed on tumor cells in the gastrointestinal tract. upon oral administration of the irdye800cw-labeled peptide moiety targets and binds to specific genetic markers.|42.71500000000003|40.027083333333366|12.270000000000003|10.326250000000002|14.701598039215687|14.23234705882353|20.774|7.713750000000001|18.447725490196078|13.390588235294118|92.55706820659348|74.48509850970193|25.5|25.516666666666666\n",
      "\n",
      "an imaging agent composed of a heptapeptide targeting human epithelial growth factor receptor type 2 (egfr2; her2; erbb2) conjugated, via a five-amino acid linker, to the near-infrared (nir) fluorescent dye irdye800cw, that can potentially be used for the imaging of her2-expressing tumors. upon oral administration of the irdye800cw-labeled heptapeptide ksp-910638g, the peptide moiety targets and binds to her2 expressed on tumor cells in the gastrointestinal (gi) tract. upon fluorescence imaging of the fluorophore irdye800cw, the tumor cells can be detected.| a substance|42.71500000000003|119.19000000000003|12.270000000000003|-2.619999999999999|14.701598039215687|15.6774|20.774|-77.10666666666665|18.447725490196078|-5.300000000000001|92.55706820659348|31.29|25.5|14.533333333333331\n",
      "\n",
      "sheehan disability scale (sds) the symptoms have disrupted your social life/leisure activities.|sheehan unfitness scale (seeds) the symptoms have broken your social life/leisure trait.|10.39500000000001|52.69500000000002|13.3|7.400000000000002|15.212838461538462|12.783607692307694|-8.173333333333332|-11.603333333333325|14.054615384615381|11.518461538461537|58.53822981607831|54.195869768830164|25.733333333333338|22.400000000000002\n",
      "\n",
      "sheehan disability scale (sds) the symptoms have disrupted your social life/leisure activities.|the symptoms have disrupted your social life/leisure activities.|10.39500000000001|12.425000000000011|13.3|12.52|14.890438461538462|13.3585|-8.173333333333332|-31.369999999999997|10.804615384615381|7.445999999999998|58.53822981607831|49.473833993334296|25.733333333333338|26.6\n",
      "\n",
      "sheehan disability scale (sds) the symptoms have disrupted your social life/leisure activities.| sheehan disability scale (sds) the symptoms have disrupted your social/leisure life|10.39500000000001|39.55500000000001|13.3|10.723333333333333|15.212838461538462|15.60947142857143|-8.173333333333332|11.59333333333334|14.054615384615381|9.792857142857144|58.53822981607831|69.96656701596841|25.733333333333338|21.46666666666667\n",
      "\n",
      "a partial or complete breakage of the humerus. []|a quantity or complete breakage of the arm_bone.  [ ]|80.06750000000002|101.27068181818181|3.2094444444444434|0.5004545454545486|11.7299|12.631922222222224|-38.99111111111111|-30.832727272727276|2.942499999999999|2.2766666666666673|44.250742366654144|44.250742366654144|19.57777777777778|16.745454545454546\n",
      "\n",
      "a partial or complete breakage of the humerus. []|a partial or complete breakage of the humerus. []|80.06750000000002|80.06750000000002|3.2094444444444434|3.2094444444444434|11.7299|12.631922222222224|-38.99111111111111|-38.33777777777777|2.942499999999999|1.2300000000000004|44.250742366654144|44.250742366654144|19.57777777777778|19.57777777777778\n",
      "\n",
      "a partial or complete breakage of the humerus. []| a partial or complete breakage of the humerus|80.06750000000002|75.50000000000003|3.2094444444444434|4.964444444444446|11.7299|13.6065|-38.99111111111111|-7.408888888888889|2.942499999999999|2.41|44.250742366654144|62.58|19.57777777777778|21.37777777777778\n",
      "\n",
      "subcutaneous tissue including some tissue of finger and some additional non finger tissue|subcutaneous tissue, including some tissue of search and some additional non finger tissue|30.947692307692336|37.455384615384645|12.172307692307694|11.264615384615386|12.783607692307694|12.783607692307694|12.05846153846154|12.510769230769231|12.96769230769231|12.96769230769231|88.50148473330829|82.78555852321104|29.81538461538462|26.738461538461536\n",
      "\n",
      "subcutaneous tissue including some tissue of finger and some additional non finger tissue|subcutaneous tissue including some tissue of finger and some additional non finger tissue.|30.947692307692336|37.54519230769233|12.172307692307694|9.637307692307694|12.783607692307694|13.006557142857146|12.05846153846154|-9.806153846153848|12.96769230769231|8.311428571428571|88.50148473330829|62.58|29.81538461538462|27.21538461538462\n",
      "\n",
      "subcutaneous tissue including some tissue of finger and some additional non finger tissue| subcutaneous tissue|30.947692307692336|34.59000000000003|12.172307692307694|9.180000000000003|12.783607692307694|19.6249|12.05846153846154|-61.42666666666666|12.96769230769231|4.120000000000001|88.50148473330829|44.250742366654144|29.81538461538462|27.866666666666664\n",
      "\n",
      "an enzyme deficiency in the androgen biosynthesis pathway, resulting in the underproduction of one or more androgens by the adrenal glands and/or gonads.|a disease amount in the androgen synthesis path, happen in the production of one or more androgens by the adrenal glands and/or gonads.|33.31902173913048|59.066847826086985|11.468913043478263|7.8776086956521745|13.015560869565219|10.955995652173913|7.7513043478260855|3.1495652173913022|16.48695652173913|12.80086956521739|69.96656701596841|66.37611354998121|21.991304347826087|20.252173913043478\n",
      "\n",
      "an enzyme deficiency in the androgen biosynthesis pathway, resulting in the underproduction of one or more androgens by the adrenal glands and/or gonads.|an enzyme deficit in the androgen biosynthesis pathway, resulting in a shortage of one or more steroid hormones by the adrenal glands and/or gonads.|33.31902173913048|46.60500000000002|11.468913043478263|9.740000000000002|13.015560869565219|13.0989|7.7513043478260855|6.203333333333333|16.48695652173913|8.1816|69.96656701596841|73.38155456243756|21.991304347826087|23.133333333333333\n",
      "\n",
      "an enzyme deficiency in the androgen biosynthesis pathway, resulting in the underproduction of one or more androgens by the adrenal glands and/or gonads.| an enzyme deficiency in the androgen synthesis pathway, resulting in the underproduction of one or more androgens|33.31902173913048|28.765000000000015|11.468913043478263|13.718888888888891|13.015560869565219|12.889426315789473|7.7513043478260855|15.568888888888893|16.48695652173913|12.363684210526316|69.96656701596841|88.50148473330829|21.991304347826087|24.977777777777778\n",
      "\n",
      "peruvian bark.|peruvian organism trait.|36.62000000000003|7.912499999999994|8.400000000000002|12.528333333333336|11.630700000000001|19.5753|-257.78|-154.2133333333333|7.829999999999998|13.04|22.125371183327072|31.29|20.400000000000002|27.266666666666666\n",
      "\n",
      "peruvian bark.|a plant.|36.62000000000003|121.22000000000003|8.400000000000002|-3.3999999999999986|11.630700000000001|8.974233333333334|-257.78|-272.48|7.829999999999998|-9.69|22.125371183327072|0.0|20.400000000000002|0.4\n",
      "\n",
      "peruvian bark.| bark|36.62000000000003|162.505|8.400000000000002|-8.91|11.630700000000001|14.311966666666669|-257.78|-133.3|7.829999999999998|-10.51|22.125371183327072|0.0|20.400000000000002|0.8\n",
      "\n",
      "a nevus that recurs after incomplete surgical removal, biopsy, or trauma. (who 2018)|a nevus that uses after incomplete surgical removal, biopsy, or trauma.  ( who 2018)|50.56057692307695|69.5025|7.821923076923078|5.428333333333338|13.675823076923077|13.006557142857146|-12.972307692307695|-12.026666666666664|6.094615384615388|4.274285714285714|62.58|62.58|27.21538461538462|24.333333333333336\n",
      "\n",
      "a nevus that recurs after incomplete surgical removal, biopsy, or trauma. (who 2018)|a skin tumor that recurs after incomplete surgical removal, biopsy, or trauma.|50.56057692307695|38.595|7.821923076923078|9.366666666666667|13.675823076923077|13.675823076923077|-12.972307692307695|-16.01333333333333|6.094615384615388|5.370000000000001|62.58|62.58|27.21538461538462|29.066666666666663\n",
      "\n",
      "a nevus that recurs after incomplete surgical removal, biopsy, or trauma. (who 2018)| a nevus|50.56057692307695|119.19000000000003|7.821923076923078|-2.619999999999999|13.675823076923077|15.6774|-12.972307692307695|-84.94666666666666|6.094615384615388|-10.01|62.58|31.29|27.21538461538462|14.533333333333331\n",
      "\n",
      "surgery intended to reduce the risk of ovarian cancer by removing the ovaries before disease develops.|room conveys to reduce the risk of ovarian cancer by killing the ovaries before disease expand.|29.515000000000015|55.952500000000015|11.130000000000003|7.442500000000003|12.3251|12.3251|-5.027500000000003|-7.600000000000001|11.886249999999997|9.825624999999999|69.96656701596841|66.37611354998121|28.200000000000003|25.700000000000003\n",
      "\n",
      "surgery intended to reduce the risk of ovarian cancer by removing the ovaries before disease develops.|surgery intended to reduce the risk of ovarian cancer by removing the ovaries before disease begins.|29.515000000000015|34.80250000000001|11.130000000000003|10.392500000000002|12.3251|11.488688235294118|-5.027500000000003|-5.395|11.886249999999997|6.370000000000001|69.96656701596841|69.96656701596841|28.200000000000003|28.200000000000003\n",
      "\n",
      "surgery intended to reduce the risk of ovarian cancer by removing the ovaries before disease develops.| major abdominal surgery, intended to reduce the risk of ovarian cancer by removal of the ovaries|29.515000000000015|30.332941176470626|11.130000000000003|13.251764705882355|12.3251|13.301522222222223|-5.027500000000003|10.950588235294116|11.886249999999997|9.026666666666667|69.96656701596841|93.86999999999999|28.200000000000003|27.976470588235294\n",
      "\n",
      "any of various immunohistochemical procedures for visualizing and/or quantitating sox11 transcription factor expression in a sample. dysregulation of sox11 is associated with several types of cancer and has diagnostic and prognostic value.|any of various immunohistochemical proceeding to change and/or quantitating sox11 transcription factor squeeze in a sample.  dysregulation of sox11 is united with several types of cancer and has diagnostic and prognostic value.|10.945833333333354|34.160909090909115|14.3825|11.22727272727273|13.311975|12.589142424242425|10.470000000000002|7.8363636363636395|16.890625|14.509090909090908|74.48509850970193|69.96656701596841|25.516666666666666|22.581818181818182\n",
      "\n",
      "any of various immunohistochemical procedures for visualizing and/or quantitating sox11 transcription factor expression in a sample. dysregulation of sox11 is associated with several types of cancer and has diagnostic and prognostic value.|any of various immunohistochemical procedures for visualizing and/or quantitating sox11 transcription factor expression in a sample. dysregulation is associated with several types of cancer and has diagnostic and prognostic value.|10.945833333333354|2.105000000000018|14.3825|15.45|13.311975|13.317420430107527|10.470000000000002|9.992|16.890625|14.123763440860216|74.48509850970193|74.48509850970193|25.516666666666666|26.666666666666664\n",
      "\n",
      "any of various immunohistochemical procedures for visualizing and/or quantitating sox11 transcription factor expression in a sample. dysregulation of sox11 is associated with several types of cancer and has diagnostic and prognostic value.| any of various immunohistochemical procedures for visualizing and/or quantitating protein expression in a sample.|10.945833333333354|-9.45750000000001|14.3825|16.441666666666666|13.311975|14.888925000000002|10.470000000000002|0.1253333333333302|16.890625|12.301875000000003|74.48509850970193|66.37611354998121|25.516666666666666|27.0\n",
      "\n",
      "an indication of the first year that a particular event or status was noted.|a datum of the first year that a part event or state was noted.|60.74428571428575|97.0014285714286|6.525714285714287|1.4685714285714297|8.842328571428572|6.586614285714286|-15.825714285714284|-21.285714285714285|6.428571428571431|2.0549999999999997|49.473833993334296|38.32226702584281|17.085714285714285|11.371428571428572\n",
      "\n",
      "an indication of the first year that a particular event or status was noted.|an indication of the first year a particular event or status was noted.|60.74428571428575|57.06826923076926|6.525714285714287|6.91423076923077|8.842328571428572|9.622985714285715|-15.825714285714284|-18.400000000000006|6.428571428571431|1.9192857142857136|49.473833993334296|49.473833993334296|17.085714285714285|17.984615384615388\n",
      "\n",
      "an indication of the first year that a particular event or status was noted.| a year|60.74428571428575|147.39000000000004|6.525714285714287|-6.553333333333333|8.842328571428572|11.7299|-15.825714285714284|-86.90666666666665|6.428571428571431|-11.1875|49.473833993334296|0.0|17.085714285714285|1.2000000000000002\n",
      "\n",
      "a disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. the rhythm disturbance originates in the atria.|a change distinguishes by a dysrhythmia with abrupt starts and sudden morpheme of atrial decrease with a rate of 150-250 beats per minute.  the rhythm trouble begins in the court.|44.405|81.727311827957|9.55|4.427096774193547|12.045622580645162|9.593379166666667|2.7399999999999984|-0.383225806451609|10.93354838709677|5.539895833333333|65.13532912329528|57.127462747788826|21.333333333333336|17.03655913978495\n",
      "\n",
      "a disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. the rhythm disturbance originates in the atria.|a disorder characterized by a rhythm disturbance with abrupt onset and sudden termination of irregular heart rhythm with sudden initiation and abrupt removal of the pacemaker. the rhythm disorder originates in the ear canal.|44.405|26.13166666666669|9.55|12.430000000000003|12.045622580645162|11.884595238095239|2.7399999999999984|7.087058823529411|10.93354838709677|9.971904761904764|65.13532912329528|72.26115969177356|21.333333333333336|23.35686274509804\n",
      "\n",
      "a disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. the rhythm disturbance originates in the atria.| a disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 bpm. the rhythm disturbance originates in the atria.|44.405|48.244022988505776|9.55|8.931724137931035|12.045622580645162|12.80806559139785|2.7399999999999984|0.8068965517241402|10.93354838709677|6.982795698924733|65.13532912329528|62.58|21.333333333333336|20.418390804597703\n",
      "\n",
      "expanded disability rating scale - postacute interview survivor version (expanded drs-pi survivor version) do you need 24-hour care and are not able to help with your own care at all?|change unfitness pad scale - postacute interview person version (change drs-pi person version) do you need 24-hour care and are not able to help with your own car at all?|41.025000000000034|66.40500000000003|14.990000000000006|11.450000000000003|12.305067741935485|9.758293548387096|20.317333333333334|17.769333333333332|16.556451612903224|14.581290322580642|103.77718969022045|88.50148473330829|26.666666666666664|22.66666666666667\n",
      "\n",
      "expanded disability rating scale - postacute interview survivor version (expanded drs-pi survivor version) do you need 24-hour care and are not able to help with your own care at all?|do you need 24-hour care and are not able to help with your own care at all?|41.025000000000034|104.98000000000002|14.990000000000006|2.84|11.536267741935484|6.241005263157895|20.317333333333334|3.687058823529412|8.806451612903228|2.695789473684208|103.77718969022045|31.29|26.666666666666664|9.15294117647059\n",
      "\n",
      "expanded disability rating scale - postacute interview survivor version (expanded drs-pi survivor version) do you need 24-hour care and are not able to help with your own care at all?| expanded disability scale - postacute interview survivor version - is the|41.025000000000034|39.55500000000001|14.990000000000006|10.723333333333333|11.536267741935484|17.10119090909091|20.317333333333334|6.693333333333335|8.806451612903228|11.045454545454547|103.77718969022045|76.64453405168562|26.666666666666664|24.8\n",
      "\n",
      "an alteration in body temperature outside the normal range.|a change in body temperature outside the normal range.|33.067500000000024|61.26750000000001|9.765|5.831666666666667|11.100677777777777|9.346233333333334|-32.45777777777777|-35.724444444444444|9.236666666666665|6.620000000000001|49.473833993334296|44.250742366654144|24.022222222222226|19.57777777777778\n",
      "\n",
      "an alteration in body temperature outside the normal range.|an alteration in body temperature out of the normal range.|33.067500000000024|49.48000000000002|9.765|7.600000000000001|11.100677777777777|11.086572727272728|-32.45777777777777|-29.799999999999997|9.236666666666665|2.300909090909091|49.473833993334296|44.250742366654144|24.022222222222226|18.0\n",
      "\n",
      "an alteration in body temperature outside the normal range.| an alteration in body temperature|33.067500000000024|31.545000000000016|9.765|10.350000000000001|11.100677777777777|13.006557142857146|-32.45777777777777|-19.93333333333333|9.236666666666665|2.9285714285714306|49.473833993334296|54.195869768830164|24.022222222222226|22.400000000000002\n",
      "\n",
      "any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a blue light stimulus. blue light is electromagnetic radiation with a wavelength of between 440 and 500nm. [goc:ai, goc:mtg_far_red]|any walk that results in a change in state or activity of a cell or a system (in terms of movement, secretion, enzyme display, gene squeeze, etc..) as a result of a blue light stimulus.  blue light is electromagnetic therapy with a distance of between 440 and 500nm.  [ goc : ai , goc : mtg_far_red ]|57.095500000000015|88.74952542372883|8.401000000000003|3.812000000000001|11.365030817610062|10.785190909090911|6.543199999999995|-0.9667796610169503|8.998238993710693|3.6807272727272746|66.37611354998121|54.195869768830164|19.400000000000002|14.889491525423729\n",
      "\n",
      "any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a blue light stimulus. blue light is electromagnetic radiation with a wavelength of between 440 and 500nm. [goc:ai, goc:mtg_far_red]|any process that results in a change in state or activity of eukaryotic cells or an organism (in terms of movement, secretion, enzyme production, etc.). blue light is an electromagnetic radiation of between 440 and 500nm. [goc:ai, goc:|57.095500000000015|56.93460526315789|8.401000000000003|7.678157894736845|11.365030817610062|11.6316837398374|6.543199999999995|-0.36526315789473784|8.998238993710693|6.88552845528455|66.37611354998121|58.53822981607831|19.400000000000002|18.53684210526316\n",
      "\n",
      "any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a blue light stimulus. blue light is electromagnetic radiation with a wavelength of between 440 and 500nm. [goc:ai, goc:mtg_far_red]| process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a blue light stimulus. blue light is electromagnetic radiation with a wavelength of between 440 and 500nm.|57.095500000000015|64.22999999999999|8.401000000000003|7.28166666666667|11.365030817610062|11.094966666666666|6.543199999999995|3.630833333333335|8.998238993710693|7.909933333333335|66.37611354998121|60.592824451415034|19.400000000000002|17.3\n",
      "\n",
      "<p>proposed therapy is outside of the standard practice for an adult patient.</p>|< p > choose therapy is outside of the standard practice for an adult patient.  < /p >|52.69500000000002|103.68723684210525|7.400000000000002|1.1571052631578986|14.29885|14.551531578947367|-15.033333333333331|-10.113684210526312|7.17625|4.926842105263159|58.53822981607831|54.195869768830164|25.733333333333338|16.431578947368422\n",
      "\n",
      "<p>proposed therapy is outside of the standard practice for an adult patient.</p>|proposed therapy is outside the standard practice for an adult patient.|52.69500000000002|55.12522727272727|7.400000000000002|6.936818181818182|14.29885|13.144933333333334|-15.033333333333331|-20.67636363636364|7.17625|5.512499999999999|58.53822981607831|58.53822981607831|25.733333333333338|27.654545454545453\n",
      "\n",
      "<p>proposed therapy is outside of the standard practice for an adult patient.</p>| proposed therapy is outside of the standard practice for an adult patient.|52.69500000000002|70.08365384615385|7.400000000000002|5.098846153846157|14.29885|13.006557142857146|-15.033333333333331|-16.590769230769233|7.17625|3.6014285714285705|58.53822981607831|58.53822981607831|25.733333333333338|24.13846153846154\n",
      "\n",
      "a substance formed by chemical union of two or more elements or ingredients in definite proportion by weight.|a substance formed by chemical union of two or more straight_line or foodstuff in definite adjust by weight.|56.70000000000002|70.80000000000003|7.58666666666667|5.6200000000000045|11.547077777777778|11.547077777777778|-2.8355555555555547|-3.1622222222222227|11.381666666666668|11.119999999999997|58.53822981607831|58.53822981607831|19.15555555555556|19.15555555555556\n",
      "\n",
      "a substance formed by chemical union of two or more elements or ingredients in definite proportion by weight.|a substance formed by chemical union of two or more elements or ingredients definite proportion by weight.|56.70000000000002|53.889852941176486|7.58666666666667|7.854411764705883|11.547077777777778|11.9779|-2.8355555555555547|-3.3482352941176465|11.381666666666668|6.620000000000001|58.53822981607831|58.53822981607831|19.15555555555556|19.870588235294118\n",
      "\n",
      "a substance formed by chemical union of two or more elements or ingredients in definite proportion by weight.| a substance formed by chemical union of two or more elements or ingredients in definite proportion by weight.|56.70000000000002|63.613552631578955|7.58666666666667|6.746578947368423|11.547077777777778|12.0275|-2.8355555555555547|-2.376842105263158|11.381666666666668|5.4715000000000025|58.53822981607831|58.53822981607831|19.15555555555556|18.53684210526316\n",
      "\n",
      "a congenital birth defect characterized by the absence of a normal vaginal opening.|a birth defect birth flees distinguish by the lack of a normal vaginal opening.|24.529807692307713|66.7871428571429|11.45269230769231|5.682857142857145|12.783607692307694|12.225900000000001|-13.424615384615386|-14.565714285714286|10.431538461538462|7.437857142857144|58.53822981607831|49.473833993334296|24.13846153846154|17.085714285714285\n",
      "\n",
      "a congenital birth defect characterized by the absence of a normal vaginal opening.|a genetic birth defect characterized by the absence of a normal vaginal opening.|24.529807692307713|31.037500000000023|11.45269230769231|10.545000000000002|12.783607692307694|13.006557142857146|-13.424615384615386|-14.329230769230772|10.431538461538462|4.947142857142854|58.53822981607831|58.53822981607831|24.13846153846154|24.13846153846154\n",
      "\n",
      "a congenital birth defect characterized by the absence of a normal vaginal opening.| a congenital birth defect characterized by the absence of a normal vagina|24.529807692307713|37.455384615384645|11.45269230769231|11.264615384615386|12.783607692307694|13.353757142857145|-13.424615384615386|5.726153846153842|10.431538461538462|7.1014285714285705|58.53822981607831|76.64453405168562|24.13846153846154|23.661538461538463\n",
      "\n",
      "the cell cycle phase following cytokinesis which begins with g1 phase, proceeds through s phase and g2 phase and ends when prophase of meiosis or mitosis begins. during interphase the cell readies itself for meiosis or mitosis and the replication of its dna occurs. [goc:mtg_cell_cycle]|the cell cycle phase following cytokinesis, which act with g1 phase, act through s phase and g2 phase and ends when prophase of meiosis or mitosis act.  during interphase the cell change itself for meiosis or mitosis and the copy of its dna occurs.  [ goc: mtg_cell_cycle]|56.25000000000003|76.30564625850343|9.140000000000004|6.673877551020407|11.605511594202898|11.020785|11.888000000000002|8.757551020408165|10.401014492753625|4.859375|76.64453405168562|67.59412548439398|22.0|17.96190476190476\n",
      "\n",
      "the cell cycle phase following cytokinesis which begins with g1 phase, proceeds through s phase and g2 phase and ends when prophase of meiosis or mitosis begins. during interphase the cell readies itself for meiosis or mitosis and the replication of its dna occurs. [goc:mtg_cell_cycle]|the cell cycle phase following cellular replication which begins with g1 phase, proceeds through g2 phase and ends when prophase of dna replication begins.|56.25000000000003|64.22999999999999|9.140000000000004|7.28166666666667|11.605511594202898|12.4673|11.888000000000002|7.9183333333333366|10.401014492753625|9.500400000000003|76.64453405168562|66.37611354998121|22.0|19.8\n",
      "\n",
      "the cell cycle phase following cytokinesis which begins with g1 phase, proceeds through s phase and g2 phase and ends when prophase of meiosis or mitosis begins. during interphase the cell readies itself for meiosis or mitosis and the replication of its dna occurs. [goc:mtg_cell_cycle]| the phase following cell division which initiates with phase one, proceeds through phase two and phase three and ends when phase four of meiosis or phase one of mitosis begins|56.25000000000003|60.750645161290336|9.140000000000004|12.48709677419355|11.605511594202898|11.6383875|11.888000000000002|18.3341935483871|10.401014492753625|16.206562499999997|76.64453405168562|82.78555852321104|22.0|21.43225806451613\n",
      "\n",
      "autologous human t-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric t-cell receptor (chimeric antigen receptor or car) consisting of an anti-cd22 single chain variable fragment (scfv) derived from the monoclonal antibody (moab) 971 (m971), and the co-stimulatory domain 4-1bb (cd137) coupled to the zeta chain of the tcr/cd3 complex (cd3-zeta), with potential immunostimulating and antineoplastic activities. autologous peripheral blood lymphocytes (pbls) from a patient with cd22-positive cancer are transduced with this lentiviral vector that encodes the car gene specific for cd22. after expansion in culture and reintroduction into the patient, the anti-cd22-car m971-bbz lentiviral vector-transduced autologous t-lymphocytes express anti-cd22-car on their cell surfaces and bind to the cd22 antigen on tumor cell surfaces. subsequently, cd22-expressing tumor cells are lysed. cd22, a b-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant b-cells. m971 binds to a membrane proximal epitope on cd22 and has a higher binding affinity compared to any other anti-cd22 moab. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c120035\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c120035\" nci thesaurus)|autologous human t-lymphocytes convert with a cell lentiviral vector convert a chimeric t-cell organ ( chimeric antigen organ or car ) be of an anti-cd22 single chain symbol break ( scfv ) make from the monoclonal protein ( moab ) 971 ( m971 ) , and the co-stimulatory class 4-1bb ( cd137 ) join to the zeta chain of the tcr/cd3 whole ( cd3-zeta ) , with potential immunostimulating and antineoplastic trait .  autologous peripheral blood leukocyte (pebbles) from a case with cd22-positive cancer are converted with this lentiviral vector that convert the car gene fact for cd22.  after an increase in grow and reintroduction into the case, the anti-cd22-car m971-bbz lentiviral vector-transduced autologous t-lymphocytes express anti-cd22-car on their cell appear and bind to the cd22 substance of tumor cell appear.  subsequently, cd22-expressing tumor cells are lysed.  cd22, a b-lineage-restricted, transmembrane phosphoglycoprotein, is mailed on malignant b-cells.  m971 binds to a sheet proximal site on cd22 and has a higher binding attraction compared to any other anti-cd22 moab.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c120035 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c120035 '' nice wordbook)|40.18890243902442|70.51100000000002|10.563937282229965|6.973428571428574|14.090218357487922|13.490156529516995|18.401463414634147|13.2664|18.588091787439616|10.827370304114488|71.93784191925693|67.42147098662265|22.734494773519167|18.714285714285715\n",
      "\n",
      "autologous human t-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric t-cell receptor (chimeric antigen receptor or car) consisting of an anti-cd22 single chain variable fragment (scfv) derived from the monoclonal antibody (moab) 971 (m971), and the co-stimulatory domain 4-1bb (cd137) coupled to the zeta chain of the tcr/cd3 complex (cd3-zeta), with potential immunostimulating and antineoplastic activities. autologous peripheral blood lymphocytes (pbls) from a patient with cd22-positive cancer are transduced with this lentiviral vector that encodes the car gene specific for cd22. after expansion in culture and reintroduction into the patient, the anti-cd22-car m971-bbz lentiviral vector-transduced autologous t-lymphocytes express anti-cd22-car on their cell surfaces and bind to the cd22 antigen on tumor cell surfaces. subsequently, cd22-expressing tumor cells are lysed. cd22, a b-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant b-cells. m971 binds to a membrane proximal epitope on cd22 and has a higher binding affinity compared to any other anti-cd22 moab. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c120035\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c120035\" nci thesaurus)|autologous human t-cell receptors are transduced with a viral vector that encodes an anti-cd22 protein complex. subsequently, tumor cells are lysed.|40.18890243902442|42.61571428571432|10.563937282229965|9.054285714285715|14.216973913043478|14.55996666666667|18.401463414634147|-6.16571428571428|19.865869565217388|6.905000000000001|71.93784191925693|62.58|22.734494773519167|25.65714285714286\n",
      "\n",
      "autologous human t-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric t-cell receptor (chimeric antigen receptor or car) consisting of an anti-cd22 single chain variable fragment (scfv) derived from the monoclonal antibody (moab) 971 (m971), and the co-stimulatory domain 4-1bb (cd137) coupled to the zeta chain of the tcr/cd3 complex (cd3-zeta), with potential immunostimulating and antineoplastic activities. autologous peripheral blood lymphocytes (pbls) from a patient with cd22-positive cancer are transduced with this lentiviral vector that encodes the car gene specific for cd22. after expansion in culture and reintroduction into the patient, the anti-cd22-car m971-bbz lentiviral vector-transduced autologous t-lymphocytes express anti-cd22-car on their cell surfaces and bind to the cd22 antigen on tumor cell surfaces. subsequently, cd22-expressing tumor cells are lysed. cd22, a b-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant b-cells. m971 binds to a membrane proximal epitope on cd22 and has a higher binding affinity compared to any other anti-cd22 moab. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c120035\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c120035\" nci thesaurus)| Aut|40.18890243902442|162.505|10.563937282229965|-8.91|14.216973913043478|19.5753|18.401463414634147|-136.24|19.865869565217388|-12.079999999999998|71.93784191925693|0.0|22.734494773519167|0.8\n",
      "\n",
      "palpation of the part of the chest wall that is located anterior to the heart. (acc-aha)|palpation of the part of the chest wall that is located tooth in the heart.  ( ac-aha)|71.81500000000001|94.30000000000001|5.230000000000004|2.342222222222226|8.702217647058824|8.469011111111111|-10.172500000000003|-10.348888888888887|1.9370588235294122|0.33999999999999986|44.250742366654144|38.32226702584281|13.200000000000001|10.266666666666666\n",
      "\n",
      "palpation of the part of the chest wall that is located anterior to the heart. (acc-aha)|part of the chest wall that is located anterior to the heart. (acc-aha)|71.81500000000001|76.59134615384617|5.230000000000004|4.191153846153846|8.702217647058824|9.271833333333333|-10.172500000000003|-18.400000000000006|1.9370588235294122|-0.09600000000000009|44.250742366654144|38.32226702584281|13.200000000000001|11.830769230769231\n",
      "\n",
      "palpation of the part of the chest wall that is located anterior to the heart. (acc-aha)| examination|71.81500000000001|-6.694999999999993|5.230000000000004|14.690000000000001|8.702217647058824|19.5753|-10.172500000000003|-112.72|1.9370588235294122|0.4800000000000004|44.250742366654144|31.29|13.200000000000001|20.8\n",
      "\n",
      "autologous human t-lymphocytes transduced with a retroviral vector encoding a t-cell receptor (tcr) specific for the human melanoma antigen a4 (mage-a4), with potential immunostimulatory and antineoplastic activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, mage-a4-specific tcr gene-transduced t-lymphocytes tbi-1201 binds to tumor cells expressing mage-a4. this may result in both an inhibition of growth and increased cell death for mage-a4-expressing tumor cells. the tumor-associated antigen mage-a4 is overexpressed by a variety of cancer cell types.|autologous human t-lymphocytes convert with a retroviral vector convert a t-cell, organ (tar) fact of the human skin_cancer substance a4 (mage-a4), with potential immunostimulatory and antineoplastic trait.  upon isolation, transduction, increases ex vivo, and reintroduction into the case, mage-a4-specific tcr gene-transduced t-lymphocytes tube-1201 binds to growth cells mail mage-a4.  this may result in both an action of growth and increased cell death for mage-a4-expressing tumor cells.  the tumor-associated substance mage-a4 is overexpressed by a difference of cancer cell types.|21.598000000000013|45.74997560975612|14.172|10.952341463414637|15.002372527472529|13.820375177304964|20.267341772151894|18.30682926829268|15.77236263736264|10.654822695035463|85.1180024436664|79.15813438933486|25.054177215189874|22.169756097560978\n",
      "\n",
      "autologous human t-lymphocytes transduced with a retroviral vector encoding a t-cell receptor (tcr) specific for the human melanoma antigen a4 (mage-a4), with potential immunostimulatory and antineoplastic activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, mage-a4-specific tcr gene-transduced t-lymphocytes tbi-1201 binds to tumor cells expressing mage-a4. this may result in both an inhibition of growth and increased cell death for mage-a4-expressing tumor cells. the tumor-associated antigen mage-a4 is overexpressed by a variety of cancer cell types.|t-cell receptors specific for a human melanoma antigen a4 (mage-a4), with potential immunostimulatory and anti-cancer activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, m|21.598000000000013|-3.767857142857139|14.172|17.262857142857147|15.002372527472529|15.7791625|20.267341772151894|18.96714285714285|15.77236263736264|13.063749999999999|85.1180024436664|91.22524239485473|25.054177215189874|29.885714285714286\n",
      "\n",
      "autologous human t-lymphocytes transduced with a retroviral vector encoding a t-cell receptor (tcr) specific for the human melanoma antigen a4 (mage-a4), with potential immunostimulatory and antineoplastic activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, mage-a4-specific tcr gene-transduced t-lymphocytes tbi-1201 binds to tumor cells expressing mage-a4. this may result in both an inhibition of growth and increased cell death for mage-a4-expressing tumor cells. the tumor-associated antigen mage-a4 is overexpressed by a variety of cancer cell types.| autologous transduced human t-lymphocytes specific for the human melanoma antigen a4 binds to tumor cells expressing the antigen|21.598000000000013|13.897368421052647|14.172|16.04105263157895|15.002372527472529|15.95667142857143|20.267341772151894|19.08210526315789|15.77236263736264|14.189999999999998|85.1180024436664|103.77718969022045|25.054177215189874|30.757894736842104\n",
      "\n",
      "a membrane-bounded, cytoplasmic secretory granule found in enzyme-secreting cells and visible by light microscopy. contain zymogen, an inactive enzyme precursor, often of a digestive enzyme. [goc:jl, isbn:0198506732]|a cell part, cytoplasmic secretory grain found in enzyme-secreting cells and visible by light research.  contain zymogen, an inactive enzyme person, often of a substance enzyme.  [ goc: jl, isbn: 0198506732]|12.833333333333371|59.79727272727277|13.705185185185186|7.651515151515152|14.132833333333334|12.658427272727273|8.488888888888894|4.272727272727266|11.673000000000002|6.387727272727272|69.96656701596841|65.13532912329528|25.822222222222223|20.157575757575756\n",
      "\n",
      "a membrane-bounded, cytoplasmic secretory granule found in enzyme-secreting cells and visible by light microscopy. contain zymogen, an inactive enzyme precursor, often of a digestive enzyme. [goc:jl, isbn:0198506732]|a membrane-bounded, cellular secretory granule found in enzyme-secreting cells and visible by light. contain zymogen, an active enzyme precursor, often of a digestive enzyme. [goc:jl, isbn:0198506732]|12.833333333333371|25.584487179487212|13.705185185185186|11.843846153846155|14.132833333333334|14.132833333333334|8.488888888888894|5.649230769230755|11.673000000000002|9.475000000000001|69.96656701596841|67.59412548439398|25.822222222222223|25.005128205128205\n",
      "\n",
      "a membrane-bounded, cytoplasmic secretory granule found in enzyme-secreting cells and visible by light microscopy. contain zymogen, an inactive enzyme precursor, often of a digestive enzyme. [goc:jl, isbn:0198506732]| a membrane-bound, cytoplasmic hormone|12.833333333333371|15.640000000000015|13.705185185185186|12.320000000000004|14.132833333333334|15.262271428571431|8.488888888888894|-18.04|11.673000000000002|4.947142857142854|69.96656701596841|54.195869768830164|25.822222222222223|26.0\n",
      "\n",
      "pandrug resistance (pdr) is defined as non-susceptibility to all agents in all epidemiologically significant antimicrobial categories (i.e. no agents tested as susceptible for that organism). non-susceptibility refers to either a resistant, intermediate or non-susceptible result obtained from in vitro antimicrobial susceptibility testing. (doi: 10.1111/j.1469-0691.2011.03570.x)|pandering action (pdr) is chosen  a non-susceptibility to all agents in all epidemiological significant agent concept (i.e. no agents take as susceptible for that system).  non-susceptibility name to either a resistant, negotiated or non-susceptible result exist from in vitro agent condition testing.  ( doi: 10.1111/j. 1469-0691.2011.03570. x)|-7.208272727272686|44.404000000000025|15.357818181818182|8.308000000000003|14.758470068027211|14.406439259259258|-22.237272727272725|-24.3904|17.688095238095237|8.653888888888886|48.47425956113202|46.41057013224466|23.578181818181818|19.6\n",
      "\n",
      "pandrug resistance (pdr) is defined as non-susceptibility to all agents in all epidemiologically significant antimicrobial categories (i.e. no agents tested as susceptible for that organism). non-susceptibility refers to either a resistant, intermediate or non-susceptible result obtained from in vitro antimicrobial susceptibility testing. (doi: 10.1111/j.1469-0691.2011.03570.x)|pandrug resistance (pdr) is defined as non-susceptibility to all agents in all epidemiologically significant antimicrobial categories (i.e. no agents tested as susceptible for that organism). mic: 10.1111/j.1469-0691.2011.03570|-7.208272727272686|12.276041666666714|15.357818181818182|12.385509259259258|14.758470068027211|14.59239677419355|-22.237272727272725|-43.71259259259258|17.688095238095237|15.643548387096779|48.47425956113202|39.88708014507956|23.578181818181818|20.60925925925926\n",
      "\n",
      "pandrug resistance (pdr) is defined as non-susceptibility to all agents in all epidemiologically significant antimicrobial categories (i.e. no agents tested as susceptible for that organism). non-susceptibility refers to either a resistant, intermediate or non-susceptible result obtained from in vitro antimicrobial susceptibility testing. (doi: 10.1111/j.1469-0691.2011.03570.x)| resistance is the nature of a substance to act as an agent which increases the probability of a reaction|-7.208272727272686|51.17500000000004|15.357818181818182|11.090000000000003|14.758470068027211|11.445242857142857|-22.237272727272725|10.777999999999997|17.688095238095237|8.807142857142857|48.47425956113202|82.78555852321104|23.578181818181818|22.0\n",
      "\n",
      "feces|feces|36.62000000000003|36.62000000000003|8.400000000000002|8.400000000000002|19.476100000000002|19.476100000000002|-266.6|-266.6|2.620000000000001|2.620000000000001|31.29|31.29|40.400000000000006|40.400000000000006\n",
      "\n",
      "feces|female feces|36.62000000000003|35.60500000000002|8.400000000000002|8.790000000000003|19.476100000000002|19.5753|-266.6|-112.72|2.620000000000001|-1.0899999999999999|31.29|44.250742366654144|40.400000000000006|40.800000000000004\n",
      "\n",
      "feces| matter|36.62000000000003|120.20500000000001|8.400000000000002|-3.01|19.476100000000002|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|31.29|31.29|40.400000000000006|20.8\n",
      "\n",
      "immunoassay reagents intended to perform qualitative and/or quantitative analyses on a body fluid sample (typically serum or feces) to determine the serine proteinase trypsin. there are two types of trypsin: trypsin i, which is cationic and is found in serum either as its precursor trypsinogen or in complexed forms, and trypsin ii, which is anionic and is only found in healthy people as its precursor trypsinogen ii. trypsin is used as an indicator of the type and severity of pancreatitis. the level of trypsin in feces and duodenal content is used as an aid in the diagnosis of chronic pancreatitis and cystic fibrosis in neonates and children.|bioassay reagent conveys to act qualitative and/or quantitative treat on a body fluid sample (typically serum or feces) to conclude the serine enzyme trypsin.  there are two types of trypsin: trypsin i, which is cationic and is found in serum either as its person trypsin or in complexed forms, and trypsin ii, which is anionic and is only found in healthy people as its person trypsin ii.  trypsin is used as a device of the type and sternness of pancreatitis.  the level of trypsin in feces and duodenal thing is used as an aid in the diagnosis of chronic pancreatitis and cystic fibrosis in baby and children.|35.68035514018692|55.29772727272726|13.598990654205611|11.011818181818182|11.603954205607476|10.731928571428572|16.00785046728972|13.433090909090902|15.406962616822433|7.664961038961039|96.94851912226405|93.86999999999999|26.503925233644864|25.163636363636368\n",
      "\n",
      "immunoassay reagents intended to perform qualitative and/or quantitative analyses on a body fluid sample (typically serum or feces) to determine the serine proteinase trypsin. there are two types of trypsin: trypsin i, which is cationic and is found in serum either as its precursor trypsinogen or in complexed forms, and trypsin ii, which is anionic and is only found in healthy people as its precursor trypsinogen ii. trypsin is used as an indicator of the type and severity of pancreatitis. the level of trypsin in feces and duodenal content is used as an aid in the diagnosis of chronic pancreatitis and cystic fibrosis in neonates and children.|immunoassay reagents intended to perform qualitative and/or quantitative analyses on a body fluid sample (typically serum or feces) to determine the protein building blocks used in the diagnosis of pancreatitis and cystic fibrosis. the level of tryp|35.68035514018692|18.857500000000016|13.598990654205611|15.225000000000001|11.603954205607476|12.889426315789473|16.00785046728972|18.008648648648645|15.406962616822433|14.2228947368421|96.94851912226405|101.39118822659097|26.503925233644864|30.102702702702704\n",
      "\n",
      "feces| matter|36.62000000000003|120.20500000000001|8.400000000000002|-3.01|19.476100000000002|14.311966666666669|-266.6|-127.42|2.620000000000001|-7.370000000000001|31.29|31.29|40.400000000000006|20.8\n",
      "\n",
      "a primary or metastatic malignant neoplasm that affects the penile urethra.|a coil or metastatic malignant growth that changes the penile duct.|24.36159090909092|62.81613636363636|11.227727272727272|5.864090909090912|14.230281818181819|12.794827272727273|-19.07272727272727|-23.349090909090915|11.473636363636366|8.048181818181817|58.53822981607831|44.250742366654144|27.654545454545453|16.745454545454546\n",
      "\n",
      "a primary or metastatic malignant neoplasm that affects the penile urethra.|a primary or metastatic cancer that affects the penile artery.|24.36159090909092|32.56000000000003|11.227727272727272|9.96|14.230281818181819|13.957481818181819|-19.07272727272727|-27.447999999999993|11.473636363636366|4.0136363636363654|58.53822981607831|54.195869768830164|27.654545454545453|26.0\n",
      "\n",
      "a primary or metastatic malignant neoplasm that affects the penile urethra.| a cancer|24.36159090909092|119.19000000000003|11.227727272727272|-2.619999999999999|14.230281818181819|15.6774|-19.07272727272727|-82.98666666666665|11.473636363636366|-8.8325|58.53822981607831|31.29|27.654545454545453|14.533333333333331\n",
      "\n",
      "part of the chromosome bands present on the long (q) arm of chromosome 2.|part of the body bands present on the long (q) arm of body 2.|90.95857142857145|103.04428571428575|2.3114285714285714|0.6257142857142846|8.842328571428572|6.586614285714286|-17.085714285714285|-22.125714285714288|4.74642857142857|0.7092857142857127|38.32226702584281|38.32226702584281|11.371428571428572|11.371428571428572\n",
      "\n",
      "part of the chromosome bands present on the long (q) arm of chromosome 2.|part of the dna strands present on the long arm of chromosome 2.|90.95857142857145|102.62211538461541|2.3114285714285714|0.560384615384617|8.842328571428572|9.622985714285715|-17.085714285714285|-21.56615384615385|4.74642857142857|-0.4357142857142833|38.32226702584281|31.29|11.371428571428572|8.753846153846155\n",
      "\n",
      "part of the chromosome bands present on the long (q) arm of chromosome 2.| part of a chromosome|90.95857142857145|100.24000000000002|2.3114285714285714|0.5199999999999996|8.842328571428572|11.8291|-17.085714285714285|-38.032|4.74642857142857|-3.5150000000000006|38.32226702584281|31.29|11.371428571428572|10.0\n",
      "\n",
      "increased megakaryocyte number, i.e., of platelet precursor cells, present in the bone marrow. [hpo:probinson]|increased bone_cell number, i.e., of platelet person cells, present in the bone marrow.  [ hop: robinson]|28.039642857142866|73.13301470588237|10.217857142857145|4.114558823529411|12.429833333333335|10.809158333333334|-43.831428571428575|-38.8635294117647|10.579999999999998|5.669791666666669|44.250742366654144|44.250742366654144|24.257142857142856|20.523529411764706\n",
      "\n",
      "increased megakaryocyte number, i.e., of platelet precursor cells, present in the bone marrow. [hpo:probinson]|increased megakaryocyte number, i.e., of platelet precursor cells, present in the bone marrow.|28.039642857142866|40.843942307692316|10.217857142857145|8.369807692307692|12.429833333333335|11.8787|-43.831428571428575|-53.535384615384615|10.579999999999998|8.647857142857145|44.250742366654144|41.39277926160552|24.257142857142856|22.83846153846154\n",
      "\n",
      "increased megakaryocyte number, i.e., of platelet precursor cells, present in the bone marrow. [hpo:probinson]| increase|28.039642857142866|120.20500000000001|10.217857142857145|-3.01|12.429833333333335|19.5753|-43.831428571428575|-121.53999999999999|10.579999999999998|-4.229999999999997|44.250742366654144|31.29|24.257142857142856|20.8\n",
      "\n",
      "the incorporation of a metal and exogenous sulfur into a metallo-sulfur cluster. [goc:jl, goc:mah, goc:pde, goc:vw]|the inclusion of a metal and exogenous sulfur into a metallic-sulfur form.  [ goc : jl , goc : mah , goc : pde , goc : vw ]|29.515000000000015|101.37000000000002|11.130000000000003|2.8466666666666676|14.683966666666668|14.048415151515153|-0.25|-1.3093333333333348|3.7814285714285703|0.22030303030303244|62.58|54.195869768830164|23.200000000000003|14.0\n",
      "\n",
      "the incorporation of a metal and exogenous sulfur into a metallo-sulfur cluster. [goc:jl, goc:mah, goc:pde, goc:vw]|the incorporation of metal and exogenous sulfur into a metallo-sulfur cluster. [goc:mah, goc:pde, groupw]|29.515000000000015|18.44428571428574|11.130000000000003|12.425714285714289|14.683966666666668|14.60956666666667|-0.25|-3.2257142857142824|3.7814285714285703|5.311666666666667|62.58|62.58|23.200000000000003|25.65714285714286\n",
      "\n",
      "the incorporation of a metal and exogenous sulfur into a metallo-sulfur cluster. [goc:jl, goc:mah, goc:pde, goc:vw]| the incorporation of an atom|29.515000000000015|59.745000000000005|11.130000000000003|6.416666666666668|14.683966666666668|13.006557142857146|-0.25|-24.833333333333325|3.7814285714285703|-0.4357142857142833|62.58|44.250742366654144|23.200000000000003|15.733333333333333\n",
      "\n",
      "<h3>what is stuttering?</h3> <p>stuttering is a <a href=\"https://medlineplus.gov/speechandcommunicationdisorders.html\">speech disorder</a>. it involves interruptions in the flow of speech. these interruptions are called disfluencies. they may involve</p> <ul> <li>repeating sounds, syllables, or words</li> <li>stretching out a sound</li> <li>suddenly stopping in the middle of a syllable or word</li> </ul> <p>sometimes, along with the stuttering, there may be nodding, rapid blinking, or trembling lips. the stuttering may be worse when you are stressed, excited, or tired.</p> <p>stuttering can be frustrating, because you know exactly what you want to say, but you have trouble saying it. it can make it difficult to communicate with people. this can cause problems with school, work, and relationships.</p> <h3>what causes stuttering?</h3> <p>there are two main types of stuttering, and they have different causes:</p> <ul> <li><strong>developmental stuttering</strong> is the more common type. it starts in young children while they are still learning speech and language skills. many children stutter when they first start talking. most of them will outgrow it. but some continue to stutter, and the exact cause is unknown. there are differences in the brains of people who continue to stutter. genetics may also play a role, since this type of stuttering can run in families.</li> <li><strong>neurogenic stuttering</strong> can happen after someone has a <a href=\"https://medlineplus.gov/stroke.html\">stroke</a>, <a href=\"https://medlineplus.gov/headinjuries.html\">head trauma</a>, or other type of <a href=\"https://medlineplus.gov/traumaticbraininjury.html\">brain injury</a>. because of the injury, the brain has trouble coordinating the different parts of the brain involved in speech.</li> </ul> <h3>who is at risk for stuttering?</h3> <p>stuttering can affect anyone, but it is much more common in boys than girls. younger children are most likely to stutter. about 75 percent of children who stutter will get better. for the rest, stuttering can continue their whole lives.</p> <h3>how is stuttering diagnosed?</h3> <p>stuttering is usually diagnosed by a speech-language pathologist. this is a health professional who is trained to test and treat people with voice, speech, and language disorders. if you or your child stutters, your regular health care provider may give you a referral to a speech-language pathologist. or in some cases, a child's teacher may make a referral.</p> <p>to make a diagnosis, the speech-language pathologist will</p> <ul> <li>look at the case history, such as when the stuttering was first noticed, how often it happens, and in what situations it happens</li> <li>listen to you or your child speak and analyze the stuttering</li> <li>evaluate you or your child's speech and language abilities, including the ability to understand and use language</li> <li>ask about the impact of stuttering on you or your child's life</li> <li>ask whether stuttering runs in the family</li> <li>for a child, consider how likely it is that he or she will outgrow it</li> </ul> <h3>what are the treatments for stuttering?</h3> <p>there are different treatments that can help with stuttering. some of these may help one person but not another. you need to work with the speech-language pathologist to figure out the best plan for you or your child.</p> <p>the plan should take into account how long the stuttering has been going on and whether there are any other speech or language problems. for a child, the plan should also take into account your child's age and whether he or she is likely to outgrow the stuttering.</p> <p>younger children may not need therapy right away. their parents and teachers can learn strategies to help the child practice speaking. that can help some children. as a parent, it's important to be calm and relaxed when your child is speaking. if your child feels pressured, it can make it harder for them to talk. the speech-language pathologist will probably want to evaluate your child regularly, to see whether treatment is needed.</p> <p>speech therapy can help children and adults minimize stuttering. some techniques include</p> <ul> <li>speaking more slowly</li> <li>controlling breathing</li> <li>gradually working up from single-syllable responses to longer words and more complex sentences</li> </ul> <p>for adults, self-help groups can help you find resources and support as you face the challenges of stuttering.</p> <p>there are electronic devices to help with fluency, but more research is needed to see whether they really help over the long term. some people have tried medicines that usually treat other health problems such as epilepsy, anxiety, or depression. but these medicines are not approved for stuttering, and they often have side effects.</p> <p class=\"\">nih: national institute on deafness and other communication disorders</p>|< h3 > what is talk?  < /h3 > < p > talk is a < a href= '' https: //medlineplus.gov/speechandcommunicationdisorders.html '' > speech change < /a >.  it absorbs happening in the flow of speech.  these happenings are called disfluencies.  they may have < /p > < ul > < li > play sounds, syllables, or words < /li > < li > move out a sound < /li > < li > suddenly catch in the middle of a syllable or word < /li > < /ul > < p > sometimes, along with the talk, there may be drowsy, rapid blinking, or shake lips.  the talk may be worse when you are stressed, excited, or tired.  < /p > < p > talk can be harassed, because you know exactly what you want to say, but you have trouble saying it.  it can make it difficult to covenant with the people.  this can cause problems with school, work, and relationships.  < /p > < h3 > what causes talk?  < /h3 > < p > there are two main types of talk, and they have different causes: < /p > < ul > < li > < strong > developmental talk < /strong > is the more common type.  it starts in young children while they are still learning, speech and language skills.  many children talk when they first start talking.  most of them will outgrow it.  but some continue to talk, and the claim, cause is unknown.  there are numbered in the brains of people who continue to talk.  genetics may also play a role, since this type of talk can run in families.  < /li > < li > < strong > neurogenic talk < /strong > can happen after someone has a < a href= '' https : //medlineplus.gov/stroke.html '' > stroke < /a > , < a href= '' https : //medlineplus.gov/headinjuries.html '' > head trauma < /a > , or other type of < a href= '' https : //medlineplus.gov/traumaticbraininjury.html '' > brain injury < /a > .  because of the wrongdoing, the brain has trouble adjust the different parts of the brain have in speech.  < /li > < /ul > < h3 > who is at risk for talk?  < /h3 > < p > talk can affect anyone, but it is much more common in boys than girls.  younger children are most likely to talk.  about 75 percent of children who talk will get better.  for the rest, talk can continue their whole lives.  < /p > < h3 > how is talk diagnosed?  < /h3 > < p > talk is usually diagnosed by a speech-language specialist.  this is a healthy athlete who is trained to test and treat people with voice, speech, and language change.  if you or your child talk, your size health care provider may give you a case of a speech-language specialist.  or in some cases , a child 's teacher may make a referral. < /p > < p > to make a diagnosis , the speech-language specialist will < /p > < ul > < li > look at the case history , such as when the talk was first note , how often it chance , and in what state it chance < /li > < li > listen to you or your child speak and treat the talk < /li > < li > think you or your child 's speech and language cognition , including the ability to understand and use language < /li > < li > ask about the change of talk on you or your child 's life < /li > < li > ask whether talk runs in the family < /li > < li > for a child , consider how likely it is that he or she will outgrow it < /li > < /ul > < h3 > what are the care for talk ? < /h3 > < p > there are different care that can help with talk . some of these may help one person but not another . you need to work with the speech-language specialist to figure out the best plan for you or your child. < /p > < p > the plan should take into account how long the talk has been going on and whether there are any other speech or language problems . for a child , the plan should also take into account your child 's age and whether he or she is likely to outgrow the stuttering. < /p > < p > younger children may not need therapy right away . their parents and teachers can learn strategies to help the child practice speaking . that can help some children . as a parent , it 's important to be calm and decrease when your child is speaking . if your child feels compel , it can make it harder for them to talk . the speech-language specialist will probably want to think your child regularly , to see whether care is needed. < /p > < p > speech therapy can help children and adults inform talk . some method include < /p > < ul > < li > speaking more slowly < /li > < li > know breathing < /li > < li > gradually working up from single-syllable manner to longer words and more whole sentences < /li > < /ul > < p > for adults , self-help groups can help you find asset and support as you face the object of stuttering. < /p > < p > there are electronic emblem to help with fluency , but more research is needed to see whether they really help over the long term . some people have tried treat that usually treat other health problems such as epilepsy , emotion , or push . but these treat are not approved for talk , and they often have side effects. < /p > < p class= '' '' > nih : national institute on deafness and other connection change < /p >|53.45904289693593|97.29015876777251|9.37028857938719|4.931132701421802|11.068580123266564|10.691622908047512|13.717214484679658|7.674616113744079|13.857972265023115|4.787039570265584|70.52407835626069|60.83471293595458|19.89441782729805|15.605876777251186\n",
      "\n",
      "<h3>what is stuttering?</h3> <p>stuttering is a <a href=\"https://medlineplus.gov/speechandcommunicationdisorders.html\">speech disorder</a>. it involves interruptions in the flow of speech. these interruptions are called disfluencies. they may involve</p> <ul> <li>repeating sounds, syllables, or words</li> <li>stretching out a sound</li> <li>suddenly stopping in the middle of a syllable or word</li> </ul> <p>sometimes, along with the stuttering, there may be nodding, rapid blinking, or trembling lips. the stuttering may be worse when you are stressed, excited, or tired.</p> <p>stuttering can be frustrating, because you know exactly what you want to say, but you have trouble saying it. it can make it difficult to communicate with people. this can cause problems with school, work, and relationships.</p> <h3>what causes stuttering?</h3> <p>there are two main types of stuttering, and they have different causes:</p> <ul> <li><strong>developmental stuttering</strong> is the more common type. it starts in young children while they are still learning speech and language skills. many children stutter when they first start talking. most of them will outgrow it. but some continue to stutter, and the exact cause is unknown. there are differences in the brains of people who continue to stutter. genetics may also play a role, since this type of stuttering can run in families.</li> <li><strong>neurogenic stuttering</strong> can happen after someone has a <a href=\"https://medlineplus.gov/stroke.html\">stroke</a>, <a href=\"https://medlineplus.gov/headinjuries.html\">head trauma</a>, or other type of <a href=\"https://medlineplus.gov/traumaticbraininjury.html\">brain injury</a>. because of the injury, the brain has trouble coordinating the different parts of the brain involved in speech.</li> </ul> <h3>who is at risk for stuttering?</h3> <p>stuttering can affect anyone, but it is much more common in boys than girls. younger children are most likely to stutter. about 75 percent of children who stutter will get better. for the rest, stuttering can continue their whole lives.</p> <h3>how is stuttering diagnosed?</h3> <p>stuttering is usually diagnosed by a speech-language pathologist. this is a health professional who is trained to test and treat people with voice, speech, and language disorders. if you or your child stutters, your regular health care provider may give you a referral to a speech-language pathologist. or in some cases, a child's teacher may make a referral.</p> <p>to make a diagnosis, the speech-language pathologist will</p> <ul> <li>look at the case history, such as when the stuttering was first noticed, how often it happens, and in what situations it happens</li> <li>listen to you or your child speak and analyze the stuttering</li> <li>evaluate you or your child's speech and language abilities, including the ability to understand and use language</li> <li>ask about the impact of stuttering on you or your child's life</li> <li>ask whether stuttering runs in the family</li> <li>for a child, consider how likely it is that he or she will outgrow it</li> </ul> <h3>what are the treatments for stuttering?</h3> <p>there are different treatments that can help with stuttering. some of these may help one person but not another. you need to work with the speech-language pathologist to figure out the best plan for you or your child.</p> <p>the plan should take into account how long the stuttering has been going on and whether there are any other speech or language problems. for a child, the plan should also take into account your child's age and whether he or she is likely to outgrow the stuttering.</p> <p>younger children may not need therapy right away. their parents and teachers can learn strategies to help the child practice speaking. that can help some children. as a parent, it's important to be calm and relaxed when your child is speaking. if your child feels pressured, it can make it harder for them to talk. the speech-language pathologist will probably want to evaluate your child regularly, to see whether treatment is needed.</p> <p>speech therapy can help children and adults minimize stuttering. some techniques include</p> <ul> <li>speaking more slowly</li> <li>controlling breathing</li> <li>gradually working up from single-syllable responses to longer words and more complex sentences</li> </ul> <p>for adults, self-help groups can help you find resources and support as you face the challenges of stuttering.</p> <p>there are electronic devices to help with fluency, but more research is needed to see whether they really help over the long term. some people have tried medicines that usually treat other health problems such as epilepsy, anxiety, or depression. but these medicines are not approved for stuttering, and they often have side effects.</p> <p class=\"\">nih: national institute on deafness and other communication disorders</p>|asd can affect anyone, but it is much more common in boys than girls. these medicines are not approved for stuttering, and they often have side effects.|53.45904289693593|75.50000000000003|9.37028857938719|4.964444444444446|10.566624720179085|8.046933333333333|13.717214484679658|-5.231111111111112|8.797937959705791|3.9270238095238135|70.52407835626069|51.09635603445709|19.89441782729805|15.45185185185185\n",
      "\n",
      "<h3>what is stuttering?</h3> <p>stuttering is a <a href=\"https://medlineplus.gov/speechandcommunicationdisorders.html\">speech disorder</a>. it involves interruptions in the flow of speech. these interruptions are called disfluencies. they may involve</p> <ul> <li>repeating sounds, syllables, or words</li> <li>stretching out a sound</li> <li>suddenly stopping in the middle of a syllable or word</li> </ul> <p>sometimes, along with the stuttering, there may be nodding, rapid blinking, or trembling lips. the stuttering may be worse when you are stressed, excited, or tired.</p> <p>stuttering can be frustrating, because you know exactly what you want to say, but you have trouble saying it. it can make it difficult to communicate with people. this can cause problems with school, work, and relationships.</p> <h3>what causes stuttering?</h3> <p>there are two main types of stuttering, and they have different causes:</p> <ul> <li><strong>developmental stuttering</strong> is the more common type. it starts in young children while they are still learning speech and language skills. many children stutter when they first start talking. most of them will outgrow it. but some continue to stutter, and the exact cause is unknown. there are differences in the brains of people who continue to stutter. genetics may also play a role, since this type of stuttering can run in families.</li> <li><strong>neurogenic stuttering</strong> can happen after someone has a <a href=\"https://medlineplus.gov/stroke.html\">stroke</a>, <a href=\"https://medlineplus.gov/headinjuries.html\">head trauma</a>, or other type of <a href=\"https://medlineplus.gov/traumaticbraininjury.html\">brain injury</a>. because of the injury, the brain has trouble coordinating the different parts of the brain involved in speech.</li> </ul> <h3>who is at risk for stuttering?</h3> <p>stuttering can affect anyone, but it is much more common in boys than girls. younger children are most likely to stutter. about 75 percent of children who stutter will get better. for the rest, stuttering can continue their whole lives.</p> <h3>how is stuttering diagnosed?</h3> <p>stuttering is usually diagnosed by a speech-language pathologist. this is a health professional who is trained to test and treat people with voice, speech, and language disorders. if you or your child stutters, your regular health care provider may give you a referral to a speech-language pathologist. or in some cases, a child's teacher may make a referral.</p> <p>to make a diagnosis, the speech-language pathologist will</p> <ul> <li>look at the case history, such as when the stuttering was first noticed, how often it happens, and in what situations it happens</li> <li>listen to you or your child speak and analyze the stuttering</li> <li>evaluate you or your child's speech and language abilities, including the ability to understand and use language</li> <li>ask about the impact of stuttering on you or your child's life</li> <li>ask whether stuttering runs in the family</li> <li>for a child, consider how likely it is that he or she will outgrow it</li> </ul> <h3>what are the treatments for stuttering?</h3> <p>there are different treatments that can help with stuttering. some of these may help one person but not another. you need to work with the speech-language pathologist to figure out the best plan for you or your child.</p> <p>the plan should take into account how long the stuttering has been going on and whether there are any other speech or language problems. for a child, the plan should also take into account your child's age and whether he or she is likely to outgrow the stuttering.</p> <p>younger children may not need therapy right away. their parents and teachers can learn strategies to help the child practice speaking. that can help some children. as a parent, it's important to be calm and relaxed when your child is speaking. if your child feels pressured, it can make it harder for them to talk. the speech-language pathologist will probably want to evaluate your child regularly, to see whether treatment is needed.</p> <p>speech therapy can help children and adults minimize stuttering. some techniques include</p> <ul> <li>speaking more slowly</li> <li>controlling breathing</li> <li>gradually working up from single-syllable responses to longer words and more complex sentences</li> </ul> <p>for adults, self-help groups can help you find resources and support as you face the challenges of stuttering.</p> <p>there are electronic devices to help with fluency, but more research is needed to see whether they really help over the long term. some people have tried medicines that usually treat other health problems such as epilepsy, anxiety, or depression. but these medicines are not approved for stuttering, and they often have side effects.</p> <p class=\"\">nih: national institute on deafness and other communication disorders</p>||53.45904289693593|205.82000000000002|9.37028857938719|-15.2|10.736034668721109|19.476100000000002|13.717214484679658|-290.12|10.505699537750388|-16.22|70.52407835626069|0.0|19.89441782729805|0.4\n",
      "\n",
      "the small airways branching off the tertiary bronchi. terminal bronchioles lead into several orders of respiratory bronchioles which in turn lead into alveolar ducts and then into pulmonary alveoli.|the small line grows off the tertiary bronchi.  contact duct leads into the several sects of respiratory duct, which in turn lead into alveolar ducts and then into pulmonary socket.|30.740574712643706|62.62408602150538|11.373103448275863|7.091612903225808|10.345010344827585|10.51755806451613|3.8482758620689665|-0.0038709677419390687|13.10551724137931|8.958387096774196|72.26115969177356|59.91578840339164|25.935632183908048|18.32688172043011\n",
      "\n",
      "the small airways branching off the tertiary bronchi. terminal bronchioles lead into several orders of respiratory bronchioles which in turn lead into alveolar ducts and then into pulmonary alveoli.|the small airways branching off the tertiary bronchi. terminal bronchioles lead into several orders of respiratory tracts which in turn lead to alveolar ducts and then into pulmonary alveoli.|30.740574712643706|39.49229885057474|11.373103448275863|10.152413793103449|10.345010344827585|10.448500000000001|3.8482758620689665|2.6317241379310374|13.10551724137931|9.004000000000001|72.26115969177356|67.59412548439398|25.935632183908048|23.177011494252874\n",
      "\n",
      "the small airways branching off the tertiary bronchi. terminal bronchioles lead into several orders of respiratory bronchioles which in turn lead into alveolar ducts and then into pulmonary alveoli.| the bronchial tubes|30.740574712643706|97.025|11.373103448275863|0.7199999999999989|10.345010344827585|16.5165|3.8482758620689665|-47.54|13.10551724137931|-1.032|72.26115969177356|44.250742366654144|25.935632183908048|21.6\n",
      "\n",
      "molecular assay reagents intended to identify mutations in genes associated with diamond-blackfan anemia, a bone marrow disorder that leads to reduced numbers of red blood cells. genetic variants at multiple loci have been associated with diamond-blackfan anemia. these reagents are intended to detect mutations in multiple diamond-blackfan anemia-associated loci simultaneously.|molecular act reagents convey to identify changes in genes unite with diamond-blackfan symptom, a bone marrow change that leads to reduced numbers of red blood cells.  genetic type at product loci have been united with diamond-blackfan symptom.  these reagents are conveying to detect change in product diamond-blackfan anemia-associated loci simultaneously.|6.335499999999996|39.08230769230772|15.481000000000005|11.03769230769231|12.716707407407407|12.225900000000001|15.128|11.945384615384615|15.655555555555559|10.886249999999997|84.2509034076193|78.225|28.200000000000003|24.430769230769233\n",
      "\n",
      "molecular assay reagents intended to identify mutations in genes associated with diamond-blackfan anemia, a bone marrow disorder that leads to reduced numbers of red blood cells. genetic variants at multiple loci have been associated with diamond-blackfan anemia. these reagents are intended to detect mutations in multiple diamond-blackfan anemia-associated loci simultaneously.|molecular assay reagents intended to identify mutations in genes associated with diamond-blackfan anemia, a bone marrow disorder that leads to reduced numbers of red blood cells. genetic variants at multiple locations have been associated w i thy disease. these loci are|6.335499999999996|32.01699186991871|15.481000000000005|12.18878048780488|12.716707407407407|12.058828682170544|15.128|11.47024390243902|15.655555555555559|10.601085271317828|84.2509034076193|80.79043260188672|28.200000000000003|24.978861788617888\n",
      "\n",
      "molecular assay reagents intended to identify mutations in genes associated with diamond-blackfan anemia, a bone marrow disorder that leads to reduced numbers of red blood cells. genetic variants at multiple loci have been associated with diamond-blackfan anemia. these reagents are intended to detect mutations in multiple diamond-blackfan anemia-associated loci simultaneously.| molecular assay reagents intended to identify mutations in genes associated with diamond blackfan anemia, a bone marrow disorder that leads to reduced numbers of red blood cells|6.335499999999996|24.322142857142893|15.481000000000005|16.822857142857142|12.716707407407407|12.697658620689655|15.128|21.348571428571425|15.655555555555559|17.756896551724132|84.2509034076193|117.07645963215661|28.200000000000003|31.200000000000003\n",
      "\n",
      "an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin sv with antibacterial activity. rifaximin binds to the beta-subunit of bacterial dna-dependent rna polymerase, inhibiting bacterial rna synthesis and bacterial cell growth. as rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract.|an orally direct, semi-synthetic, nonsystemic antibiotic make from rifamycin save with medicine activity.  rifaximin binds to the beta-subunit of bacterial dna-dependent rna enzyme, suppress bacterial rna synthesis and bacterial cell growth.  as rifaximin is not well receive, its medicine activity is largely staged to the gastrointestinal tract.|-17.49124999999998|16.568596938775528|18.618031914893617|13.991581632653062|14.884566666666666|12.654647692307694|15.5931914893617|11.716734693877555|16.67053333333334|10.127884615384612|78.225|76.64453405168562|25.97659574468085|24.491836734693877\n",
      "\n",
      "an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin sv with antibacterial activity. rifaximin binds to the beta-subunit of bacterial dna-dependent rna polymerase, inhibiting bacterial rna synthesis and bacterial cell growth. as rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract.|an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin sv with antibacterial activity. rifaximin binds to a beta-subunit of bacterial dna-dependent rna polymerase, which is largely localized|-17.49124999999998|-35.6008333333333|18.618031914893617|21.578703703703706|14.884566666666666|15.611106451612905|15.5931914893617|20.75851851851852|16.67053333333334|15.035806451612906|78.225|88.50148473330829|25.97659574468085|29.1037037037037\n",
      "\n",
      "an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin sv with antibacterial activity. rifaximin binds to the beta-subunit of bacterial dna-dependent rna polymerase, inhibiting bacterial rna synthesis and bacterial cell growth. as rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract.| an antibiotic|-17.49124999999998|62.79000000000002|18.618031914893617|5.246666666666666|14.884566666666666|15.6774|15.5931914893617|-73.18666666666667|16.67053333333334|-2.9450000000000003|78.225|31.29|25.97659574468085|14.533333333333331\n",
      "\n",
      "physicians specializing in the diagnosis, and treatment of diseases of the urinary tract in both sexes, and the genital tract in the male.|physicians evolve in the diagnosis, and care of illness of the urinary tract in both classes, and the genital tract in the male.|48.032065217391334|62.74510869565219|9.416739130434784|7.364565217391306|11.642517391304349|10.269473913043479|3.9165217391304346|1.3599999999999994|13.210434782608694|11.162608695652175|62.58|58.53822981607831|18.51304347826087|16.773913043478263\n",
      "\n",
      "physicians specializing in the diagnosis, and treatment of diseases of the urinary tract in both sexes, and the genital tract in the male.|physicians specialized in the diagnosis, and treatment of diseases of the urinary tract in both sexes, as well as the genital tract.|48.032065217391334|45.69727272727275|9.416739130434784|9.618181818181817|11.642517391304349|11.758639130434783|3.9165217391304346|3.0254545454545436|13.210434782608694|6.641304347826086|62.58|62.58|18.51304347826087|18.94545454545455\n",
      "\n",
      "physicians specializing in the diagnosis, and treatment of diseases of the urinary tract in both sexes, and the genital tract in the male.| doctors|48.032065217391334|120.20500000000001|9.416739130434784|-3.01|11.642517391304349|14.311966666666669|3.9165217391304346|-124.48|13.210434782608694|-5.800000000000001|62.58|31.29|18.51304347826087|20.8\n",
      "\n",
      "a coronary vasodilator agent.|a pharmacologic substance dilator agent.|-48.994999999999976|-15.662499999999966|20.590000000000007|16.065000000000005|15.6774|16.5165|-109.78|-76.064|10.0075|14.04|38.32226702584281|44.250742366654144|30.8|33.0\n",
      "\n",
      "a coronary vasodilator agent.|blood vessel spasm drug.|-48.994999999999976|99.055|20.590000000000007|-0.0600000000000005|15.6774|13.2345|-109.78|-115.66|10.0075|-0.3979999999999997|38.32226702584281|22.125371183327072|30.8|10.8\n",
      "\n",
      "a coronary vasodilator agent.| a vasodilator|-48.994999999999976|34.59000000000003|20.590000000000007|9.180000000000003|15.6774|15.6774|-109.78|-73.18666666666667|10.0075|-2.9450000000000003|38.32226702584281|31.29|30.8|14.533333333333331\n",
      "\n",
      "a category of juvenile idiopathic arthritis defined by the presence of arthritis affecting five or more separate joints during the first six months of disease, with positive serologic testing for rheumatoid factor.|a concept of person idiopathic arthritis choose by the presence of arthritis refer five or more diverge joints during the first six months of disease, with film serologic testing for rheumatoid factor.|31.97|53.120000000000005|12.775000000000002|9.825|12.6252625|11.6383875|15.126249999999999|12.7375|21.2109375|19.2975|85.69119412168324|79.77416029015912|25.150000000000002|22.650000000000002\n",
      "\n",
      "a category of juvenile idiopathic arthritis defined by the presence of arthritis affecting five or more separate joints during the first six months of disease, with positive serologic testing for rheumatoid factor.|a category of juvenile joint disease defined by the presence of arthritis affecting five or more separate joints during the first six months of disease, with positive serologic testing for rheumatoid factor.|31.97|42.545000000000016|12.775000000000002|11.3|12.6252625|12.110657575757577|15.126249999999999|14.02375|21.2109375|11.797272727272727|85.69119412168324|82.78555852321104|25.150000000000002|23.900000000000002\n",
      "\n",
      "a category of juvenile idiopathic arthritis defined by the presence of arthritis affecting five or more separate joints during the first six months of disease, with positive serologic testing for rheumatoid factor.| a category of juvenile rheumatoid arthritis|31.97|18.44428571428574|12.775000000000002|12.425714285714289|12.6252625|15.875800000000002|15.126249999999999|-9.525714285714287|21.2109375|6.120000000000001|85.69119412168324|62.58|25.150000000000002|25.65714285714286\n",
      "\n",
      "a usually aggressive malignant neoplasm arising from the deep soft tissue. it is characterized by the presence of poorly-differentiated spindle-shaped fibroblasts, collagenous stroma formation and increased mitotic activity.|a usually aggressive malignant growth protest from the deep soft tissue.  it is distinguished by the presence of poorly-differentiated spindle-shaped fibroblasts, collagenous stroma placement and increased mitotic activity.|-2.0526190476190322|16.15436781609199|15.864285714285717|13.40758620689655|13.328166666666666|13.826775268817205|9.655714285714286|8.917241379310347|16.214000000000006|12.756344086021507|74.48509850970193|72.26115969177356|28.019047619047615|25.935632183908048\n",
      "\n",
      "a usually aggressive malignant neoplasm arising from the deep soft tissue. it is characterized by the presence of poorly-differentiated spindle-shaped fibroblasts, collagenous stroma formation and increased mitotic activity.|a usually aggressive cancerous tumor arising from the deep soft tissue. it is characterized by the presence of poorly differentiated spindle-shaped fibroblasts, collagenous stroma formation and increased mitotic activity.|-2.0526190476190322|4.485402298850573|15.864285714285717|15.035172413793106|13.328166666666666|13.317420430107527|9.655714285714286|8.71448275862069|16.214000000000006|12.604408602150535|74.48509850970193|76.64453405168562|28.019047619047615|28.694252873563222\n",
      "\n",
      "a usually aggressive malignant neoplasm arising from the deep soft tissue. it is characterized by the presence of poorly-differentiated spindle-shaped fibroblasts, collagenous stroma formation and increased mitotic activity.| An usually aggressive malignant neoplasm arising from the deep soft tissue|-2.0526190476190322|46.60500000000002|15.864285714285717|9.740000000000002|13.328166666666666|12.783607692307694|9.655714285714286|7.183333333333337|16.214000000000006|8.982307692307693|74.48509850970193|76.64453405168562|28.019047619047615|24.8\n",
      "\n",
      "information learned before age 12 and less subject to disruption than intermediate memory.|collection learned before age 12 and less term to delay than negotiated hardware.|37.54519230769233|70.08365384615385|9.637307692307694|5.098846153846157|10.354376923076924|9.139761538461538|-10.258461538461539|-14.329230769230772|12.96769230769231|9.706923076923076|54.195869768830164|49.473833993334296|21.06153846153846|17.984615384615388\n",
      "\n",
      "information learned before age 12 and less subject to disruption than intermediate memory.|information learned before age 12 and less subject to disruption than intermediate memory.|37.54519230769233|37.54519230769233|9.637307692307694|9.637307692307694|10.354376923076924|10.750842857142857|-10.258461538461539|-9.806153846153848|12.96769230769231|8.311428571428571|54.195869768830164|54.195869768830164|21.06153846153846|21.06153846153846\n",
      "\n",
      "information learned before age 12 and less subject to disruption than intermediate memory.| information|37.54519230769233|35.60500000000002|9.637307692307694|8.790000000000003|10.354376923076924|19.5753|-10.258461538461539|-112.72|12.96769230769231|0.4800000000000004|54.195869768830164|31.29|21.06153846153846|20.8\n",
      "\n",
      "a white blood cell that is derived from a lymphocyte stem cell matured in the thymus and characterized by a cd8 marker on the surface and an antigen-specific t cell receptor which recognizes antigens in the context of mhc class i.|a white blood cell that is made with a lymphocyte stem cell draw in the thymus and distinguish by a cd8 marker on the surface and an antigen-specific t cell organ which prize substance in the context of mhc class me.|51.905548780487806|72.53969512195123|11.112317073170736|8.23426829268293|11.734938095238094|9.85517619047619|12.809756097560975|10.801951219512198|20.765|19.082857142857144|76.64453405168562|66.37611354998121|19.90731707317073|16.98048780487805\n",
      "\n",
      "a white blood cell that is derived from a lymphocyte stem cell matured in the thymus and characterized by a cd8 marker on the surface and an antigen-specific t cell receptor which recognizes antigens in the context of mhc class i.|a white blood cell that is derived from a lymphocyte stem cell population matured in the thymus and characterized by an immunoglobulin class i.|51.905548780487806|46.60500000000002|11.112317073170736|9.740000000000002|11.734938095238094|10.5609|12.809756097560975|4.978333333333335|20.765|13.866399999999999|76.64453405168562|58.53822981607831|19.90731707317073|16.46666666666667\n",
      "\n",
      "a white blood cell that is derived from a lymphocyte stem cell matured in the thymus and characterized by a cd8 marker on the surface and an antigen-specific t cell receptor which recognizes antigens in the context of mhc class i.| a white blood cell that is derived from a lymphocyte stem cell and has a memory cell|51.905548780487806|85.16499999999999|11.112317073170736|5.852222222222224|11.734938095238094|8.734163157894738|12.809756097560975|6.095555555555556|20.765|5.422631578947367|76.64453405168562|54.195869768830164|19.90731707317073|13.866666666666667\n",
      "\n",
      "using midwifery assessment methods in a usual, subsequent, 30-minute, out-of-office meeting to assess the health status of an existing midwifery client to develop a midwifery treatment plan.|using medicine act methods in a usual, subsequent, 30-minute, out-of-office meeting to charge the health status of an existing medicine client to expand a medical care plan.|27.06583333333336|52.13250000000002|12.837962962962965|9.341666666666669|12.493166666666667|9.8615|13.78962962962963|10.087407407407412|18.219|15.550000000000004|85.69119412168324|76.64453405168562|27.622222222222224|23.177777777777777\n",
      "\n",
      "using midwifery assessment methods in a usual, subsequent, 30-minute, out-of-office meeting to assess the health status of an existing midwifery client to develop a midwifery treatment plan.|using midwifery assessment methods in a usual, followed, 30-minute, out-of-office meeting to assess the health status of an existing midwives treatment plan.|27.06583333333336|38.00636363636366|12.837962962962965|10.690909090909091|12.493166666666667|10.961684615384616|13.78962962962963|9.707272727272727|18.219|8.620000000000001|85.69119412168324|76.64453405168562|27.622222222222224|26.218181818181815\n",
      "\n",
      "using midwifery assessment methods in a usual, subsequent, 30-minute, out-of-office meeting to assess the health status of an existing midwifery client to develop a midwifery treatment plan.| using assessment methods in midwifery care to assess the health status of an existing client to develop a midwife's treatment plan|27.06583333333336|46.06863636363636|12.837962962962965|12.29909090909091|12.493166666666667|13.015560869565219|13.78962962962963|16.212727272727278|18.219|13.005652173913042|85.69119412168324|98.94766798666859|27.622222222222224|26.981818181818184\n",
      "\n",
      "general mental functions of the state of awareness and alertness, including the clarity and continuity of the wakeful state.|general mental serve in the state of knowing and alertness, including the clarity and lastingness of the wakeful state.|41.350394736842105|54.70828947368423|9.851842105263156|7.988684210526319|11.22732105263158|9.565215789473683|1.6463157894736824|0.0989473684210509|13.851052631578945|12.611578947368422|66.37611354998121|62.58|22.74736842105263|20.642105263157895\n",
      "\n",
      "general mental functions of the state of awareness and alertness, including the clarity and continuity of the wakeful state.|general mental functions of the state of awareness and alertness, including the clarity and continuity of this state.|41.350394736842105|47.30000000000004|9.851842105263156|8.89777777777778|11.22732105263158|10.75612105263158|1.6463157894736824|0.10444444444444656|13.851052631578945|7.861578947368422|66.37611354998121|62.58|22.74736842105263|21.37777777777778\n",
      "\n",
      "general mental functions of the state of awareness and alertness, including the clarity and continuity of the wakeful state.| general mental functions of the state of awareness and alertness, including the clarity and continuity of the wakeful state.|41.350394736842105|48.63500000000002|9.851842105263156|8.960000000000004|11.22732105263158|11.67634761904762|1.6463157894736824|1.8580000000000005|13.851052631578945|7.594285714285714|66.37611354998121|66.37611354998121|22.74736842105263|22.0\n",
      "\n",
      "a representation of the sequence of biological or biochemical events that are involved in the regulation of the cell cycle.|an activity of the rate of biological or biochemical events that are have in the control of the cell ride.|35.94500000000002|61.32500000000002|10.73|7.190000000000001|10.944500000000001|8.576|0.9759999999999991|-4.022000000000002|12.826500000000003|8.823|62.58|49.473833993334296|20.0|14.0\n",
      "\n",
      "a representation of the sequence of biological or biochemical events that are involved in the regulation of the cell cycle.|a sequence of biological or chemical events that are involved in the regulation of the cell cycle.|35.94500000000002|48.9133823529412|10.73|8.548529411764708|10.944500000000001|11.100677777777777|0.9759999999999991|-6.115294117647053|12.826500000000003|4.526666666666667|62.58|58.53822981607831|20.0|19.870588235294118\n",
      "\n",
      "a representation of the sequence of biological or biochemical events that are involved in the regulation of the cell cycle.| a representation|35.94500000000002|34.59000000000003|10.73|9.180000000000003|10.944500000000001|15.6774|0.9759999999999991|-67.30666666666666|12.826500000000003|0.5874999999999986|62.58|31.29|20.0|14.533333333333331\n",
      "\n",
      "a unit of spoken language larger than a phoneme.|a unit of spoken language larger than a phone.|80.06750000000002|89.46750000000003|3.2094444444444434|1.8983333333333334|9.346233333333334|7.591788888888889|-39.64444444444443|-40.9511111111111|3.4800000000000004|2.43333333333333|44.250742366654144|38.32226702584281|19.57777777777778|15.133333333333333\n",
      "\n",
      "a unit of spoken language larger than a phoneme.|a unit of spoken language larger than a phoneme.|80.06750000000002|80.06750000000002|3.2094444444444434|3.2094444444444434|9.346233333333334|10.200500000000002|-39.64444444444443|-38.99111111111111|3.4800000000000004|-0.08999999999999986|44.250742366654144|44.250742366654144|19.57777777777778|19.57777777777778\n",
      "\n",
      "a unit of spoken language larger than a phoneme.| A unit of spoken language|80.06750000000002|87.94500000000002|3.2094444444444434|2.4833333333333343|9.346233333333334|13.006557142857146|-39.64444444444443|-27.77333333333333|3.4800000000000004|-2.4542857142857173|44.250742366654144|54.195869768830164|19.57777777777778|22.400000000000002\n",
      "\n",
      "a genetic syndrome caused by mutations in the ptpn11 and raf1 genes. it is characterized by the following abnormalities: multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormalities in genitalia, growth retardation, and deafness.|a disease syndrome caused by changes in the ptpn11 and raf1 genes.  it is distinguished by the following misbehavior: product molecule, electrocardiographies conduction misbehavior, ocular hypertelorism, pulmonary stenosis, misbehavior in genitalia, growth delay, and deafness.|-15.298095238095215|13.705000000000013|18.291428571428572|14.32888888888889|14.429642857142857|13.881144444444447|17.97257142857142|14.86|20.828285714285713|15.184999999999995|78.74477315987392|78.74477315987392|26.38095238095238|25.91111111111111\n",
      "\n",
      "a genetic syndrome caused by mutations in the ptpn11 and raf1 genes. it is characterized by the following abnormalities: multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormalities in genitalia, growth retardation, and deafness.|a genetic syndrome caused by mutations in the ptpn11 and raf1 genes. it is characterized by the following abnormalities: multiple lentigines, electrical heart rhythm, pulmonary stenosis, and deafness.|-15.298095238095215|31.183095238095262|18.291428571428572|11.228571428571431|14.429642857142857|12.827690804597701|17.97257142857142|4.825714285714287|20.828285714285713|10.688850574712646|78.74477315987392|62.58|26.38095238095238|20.876190476190477\n",
      "\n",
      "a genetic syndrome caused by mutations in the ptpn11 and raf1 genes. it is characterized by the following abnormalities: multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormalities in genitalia, growth retardation, and deafness.| a syndrome;autoimmune disease|-15.298095238095215|12.425000000000011|18.291428571428572|12.52|14.429642857142857|16.5165|17.97257142857142|-32.84|20.828285714285713|8.387999999999998|78.74477315987392|44.250742366654144|26.38095238095238|21.6\n",
      "\n",
      "a finding of no distension of pharyngoesophageal segment opening during swallowing with total obstruction of flow.|a finding of no distension of pharyngoesophageal part opening during believe with the total hindrance of flow.|24.22750000000002|43.93691176470591|11.867500000000003|9.242647058823533|11.338225000000001|10.052641176470589|-0.6174999999999997|-2.3105882352941123|15.418749999999996|12.836470588235294|66.37611354998121|62.58|25.700000000000003|22.223529411764705\n",
      "\n",
      "a finding of no distension of pharyngoesophageal segment opening during swallowing with total obstruction of flow.|a finding of no distension of the pharyngeal segment opening during swallowing with total obstruction of flow.|24.22750000000002|43.93691176470591|11.867500000000003|9.242647058823533|11.338225000000001|11.100677777777777|-0.6174999999999997|-1.9647058823529377|15.418749999999996|7.666666666666668|66.37611354998121|66.37611354998121|25.700000000000003|24.576470588235296\n",
      "\n",
      "a finding of no distension of pharyngoesophageal segment opening during swallowing with total obstruction of flow.| the finding no esophageal opening during swallowing|24.22750000000002|29.515000000000015|11.867500000000003|11.130000000000003|11.338225000000001|12.855122222222224|-0.6174999999999997|-3.1899999999999977|15.418749999999996|7.666666666666668|66.37611354998121|69.96656701596841|25.700000000000003|28.200000000000003\n",
      "\n",
      "health insurance plans for employees, and generally including their dependents, usually on a cost-sharing basis with the employer paying a percentage of the premium.|health contract plans for worker, and generally including their dependents, usually on a cost-sharing part with the leader paying an asset of the reward.|32.504999999999995|53.655|11.706666666666667|8.756666666666668|11.8241|8.6661|10.123333333333335|7.183333333333337|17.069200000000002|14.808399999999999|76.64453405168562|73.38155456243756|24.8|23.133333333333333\n",
      "\n",
      "health insurance plans for employees, and generally including their dependents, usually on a cost-sharing basis with the employer paying a percentage of the premium.|health insurance plans for employees, and generally including their dependents, usually on a cost-sharing basis with the employer paying % of the premium.|32.504999999999995|40.67554347826092|11.706666666666667|10.442826086956522|11.8241|11.468783333333334|10.123333333333335|8.262608695652176|17.069200000000002|9.689999999999998|76.64453405168562|73.38155456243756|24.8|23.730434782608697\n",
      "\n",
      "health insurance plans for employees, and generally including their dependents, usually on a cost-sharing basis with the employer paying a percentage of the premium.| health insurance|32.504999999999995|90.99000000000004|11.706666666666667|1.3133333333333361|11.8241|15.6774|10.123333333333335|-67.30666666666666|17.069200000000002|0.5874999999999986|76.64453405168562|31.29|24.8|14.533333333333331\n",
      "\n",
      "<b>description:</b>a telephone number served by a fax device \\[http://www.ietf.org/rfc/rfc3966.txt and http://www.ietf.org/rfc/rfc2806.txt\\]|< b > kindest: < /b > a telephone number served by a fax device \\ [http: //www.ietf.org/rfc/rfc3966.txt and protocol: //www.ietf.org/rfc/rfc2806.txt\\]|82.18545454545456|107.10428571428575|2.1864935064935054|-0.9342857142857142|14.178744444444446|15.35356666666667|-118.87272727272725|-62.26666666666666|20.801666666666662|14.119999999999997|23.653016720917435|28.96891092188313|15.174025974025975|12.628571428571428\n",
      "\n",
      "<b>description:</b>a telephone number served by a fax device \\[http://www.ietf.org/rfc/rfc3966.txt and http://www.ietf.org/rfc/rfc2806.txt\\]|a telephone number served by a fax device.|82.18545454545456|75.87500000000001|2.1864935064935054|3.6700000000000017|14.178744444444446|9.123033333333336|-118.87272727272725|-47.54|20.801666666666662|-0.8633333333333333|23.653016720917435|38.32226702584281|15.174025974025975|16.6\n",
      "\n",
      "<b>description:</b>a telephone number served by a fax device \\[http://www.ietf.org/rfc/rfc3966.txt and http://www.ietf.org/rfc/rfc2806.txt\\]| description: a telephone number served by a fax device|82.18545454545456|69.78500000000001|2.1864935064935054|6.010000000000002|14.178744444444446|11.359372727272728|-118.87272727272725|-1.9639999999999986|20.801666666666662|4.194545454545455|23.653016720917435|62.58|15.174025974025975|20.0\n",
      "\n",
      "used in pharmacokinetics and bioequivalence to indicate maximum plasma concentration for a drug.|used in pharmacology and bioequivalence to inform maximum plasma diligence for a drug.|11.514423076923094|31.037500000000023|13.268076923076926|10.545000000000002|12.783607692307694|12.783607692307694|-7.544615384615383|-12.067692307692312|15.141538461538467|11.518461538461537|54.195869768830164|54.195869768830164|21.06153846153846|21.06153846153846\n",
      "\n",
      "used in pharmacokinetics and bioequivalence to indicate maximum plasma concentration for a drug.|use in pharmacokinetics and bioequivalence to indicate maximum plasma concentration for a drug.|11.514423076923094|11.514423076923094|13.268076923076926|13.268076923076926|12.783607692307694|13.006557142857146|-7.544615384615383|-7.544615384615383|15.141538461538467|9.993571428571428|54.195869768830164|54.195869768830164|21.06153846153846|21.06153846153846\n",
      "\n",
      "used in pharmacokinetics and bioequivalence to indicate maximum plasma concentration for a drug.| used in pharmacokinetics and pharmacodynamics to indicate maximum plasma concentration for a drug.|11.514423076923094|12.401428571428596|13.268076923076926|13.26857142857143|12.783607692307694|13.4825|-7.544615384615383|-5.7457142857142856|15.141538461538467|9.637999999999998|54.195869768830164|54.195869768830164|21.06153846153846|19.942857142857143\n",
      "\n",
      "any process that modulates the frequency, rate or extent of insulin receptor signaling. [goc:bf]|any walk that changes the ratio, rate or extent of hormone organ tells.  [ goc: bf]|30.53000000000003|93.70161764705884|10.740000000000002|2.301470588235297|13.4825|9.822283333333335|-7.425714285714285|-11.649411764705881|6.812000000000001|-0.21770833333333073|62.58|54.195869768830164|25.65714285714286|17.51764705882353\n",
      "\n",
      "any process that modulates the frequency, rate or extent of insulin receptor signaling. [goc:bf]|any process that modulates the rate or extent of insulin receptor signaling. [goc:bf]|30.53000000000003|37.54519230769233|10.740000000000002|9.637307692307694|13.4825|13.4825|-7.425714285714285|-12.067692307692312|6.812000000000001|4.300000000000001|62.58|58.53822981607831|25.65714285714286|24.13846153846154\n",
      "\n",
      "any process that modulates the frequency, rate or extent of insulin receptor signaling. [goc:bf]| any process that modulates how well the receptor molecule of insulin receptor is able to signal|30.53000000000003|35.309411764705914|10.740000000000002|12.55764705882353|13.4825|12.4243|-7.425714285714285|10.604705882352942|6.812000000000001|9.026666666666667|62.58|93.86999999999999|25.65714285714286|27.976470588235294\n",
      "\n",
      "the manifestation of psychotic symptoms, such as hallucinations or delusions, in the presence of a mood disorder.|the protest of psychotic symptoms, such as object or delusions, in the presence of a mood change.|33.98397058823531|73.79573529411766|10.630882352941178|5.077941176470592|11.910288235294118|10.981464705882354|-1.2729411764705887|-6.80705882352941|13.11352941176471|8.680588235294117|58.53822981607831|54.195869768830164|19.870588235294118|17.51764705882353\n",
      "\n",
      "the manifestation of psychotic symptoms, such as hallucinations or delusions, in the presence of a mood disorder.|the manifestation of psychotic symptoms, such as hallucinations or delusions, in the presence of mood disorder.|33.98397058823531|29.515000000000015|10.630882352941178|11.130000000000003|11.910288235294118|12.417511764705882|-1.2729411764705887|-1.3524999999999991|13.11352941176471|8.863529411764706|58.53822981607831|58.53822981607831|19.870588235294118|20.700000000000003\n",
      "\n",
      "the manifestation of psychotic symptoms, such as hallucinations or delusions, in the presence of a mood disorder.| psychotic manifestation in the presence of a mood disorder|33.98397058823531|44.405|10.630882352941178|9.55|11.910288235294118|14.230281818181819|-1.2729411764705887|0.3880000000000017|13.11352941176471|6.335454545454546|58.53822981607831|62.58|19.870588235294118|20.0\n",
      "\n",
      "a multi-organ, animal-based dietary supplement used to help strengthen, support and improve the function of the female reproductive system.|a diseased function, animal-based diets attach used to help change, support and improve the serve of the female reproductive system.|23.53986842105263|48.63500000000002|12.336052631578948|8.960000000000004|11.445242857142857|10.693338095238095|6.288421052631584|3.6220000000000034|15.087142857142858|13.517142857142858|73.38155456243756|66.37611354998121|26.957894736842107|22.0\n",
      "\n",
      "a multi-organ, animal-based dietary supplement used to help strengthen, support and improve the function of the female reproductive system.|a multi-organ, animal-based supplement used to help strengthen, support and improve the function of the female reproductive system.|23.53986842105263|28.50000000000003|12.336052631578948|11.520000000000003|11.445242857142857|10.924442857142857|6.288421052631584|4.677777777777784|15.087142857142858|8.491428571428571|73.38155456243756|69.96656701596841|26.957894736842107|25.822222222222223\n",
      "\n",
      "a multi-organ, animal-based dietary supplement used to help strengthen, support and improve the function of the female reproductive system.| a dietary supplement|23.53986842105263|54.72500000000002|12.336052631578948|6.620000000000001|11.445242857142857|16.5165|6.288421052631584|-46.07|15.087142857142858|-0.08999999999999986|73.38155456243756|44.250742366654144|26.957894736842107|21.6\n",
      "\n",
      "a thymic epithelial neoplasm characterized by the presence of a lymphocyte-poor component similar to that seen in type a thymoma and a lymphocyte-rich component which contains neoplastic small polygonal epithelial cells. it may be associated with myasthenia gravis and pure red cell aplasia. the majority of cases occur in the anterior mediastinum as masaoka stage i tumors. a minority of the cases occur as stage ii or stage iii tumors. the overall survival is reported to be 80-100% at 5 and 10 years.|a neoplastic process epithelial growth is distinguished by the presence of a lymphocyte-poor part similar to that seen in type a thymoma and a lymphocyte-rich part which contains neoplastic small polygonal epithelial cells.  it may unite with myasthenia gravis and pure red cell aplasia.  the age of cases occurs in the tooth cavity as masaoka stage i growth.  at the age of the cases occur as stage ii or stage iii growth.  the overall survival is reported to be 80-100 % at 5 and 10 years.|41.94115461847392|66.59000000000002|10.845963855421687|7.69777777777778|11.282992093023257|10.493848309178745|8.427469879518068|6.530666666666665|9.734186046511624|4.005785024154587|73.38155456243756|65.13532912329528|21.43694779116466|17.555555555555554\n",
      "\n",
      "a thymic epithelial neoplasm characterized by the presence of a lymphocyte-poor component similar to that seen in type a thymoma and a lymphocyte-rich component which contains neoplastic small polygonal epithelial cells. it may be associated with myasthenia gravis and pure red cell aplasia. the majority of cases occur in the anterior mediastinum as masaoka stage i tumors. a minority of the cases occur as stage ii or stage iii tumors. the overall survival is reported to be 80-100% at 5 and 10 years.|a cancerous skin tumor characterized by the presence of a lymphocyte-poor component similar to that seen in type a thymoma. a minority of the cases occur as stage ii or stage iii tumors. the overall survival is reported to be 80-100% at 5 and 10|41.94115461847392|56.25000000000003|10.845963855421687|9.140000000000004|11.282992093023257|11.338225000000001|8.427469879518068|6.6613333333333316|9.734186046511624|5.900625000000002|73.38155456243756|69.96656701596841|21.43694779116466|19.333333333333332\n",
      "\n",
      "a thymic epithelial neoplasm characterized by the presence of a lymphocyte-poor component similar to that seen in type a thymoma and a lymphocyte-rich component which contains neoplastic small polygonal epithelial cells. it may be associated with myasthenia gravis and pure red cell aplasia. the majority of cases occur in the anterior mediastinum as masaoka stage i tumors. a minority of the cases occur as stage ii or stage iii tumors. the overall survival is reported to be 80-100% at 5 and 10 years.| A thymic epithelial neoplasm|41.94115461847392|49.48000000000002|10.845963855421687|7.600000000000001|11.282992093023257|17.092433333333332|8.427469879518068|-28.624|9.734186046511624|2.7650000000000006|73.38155456243756|54.195869768830164|21.43694779116466|26.0\n",
      "\n",
      "a propoxyphene test system is a device intended to measure propoxyphene, a pain-relieving drug, in serum, plasma, and urine. measurements obtained by this device are used in the diagnosis and treatment of propoxyphene use or overdose or in monitoring levels of propoxyphene to ensure appropriate therapy.|a pharmacologic substance test system is a device convey to measure propoxyphene, a pain-relieving drug, in serum, plasma, and urine.  measurements exist by this device are used in the diagnosis and care of propoxyphene use or drug or in observe levels of propoxyphene to ensure assume therapy.|23.910797101449305|40.78250000000003|13.733478260869568|11.54583333333333|11.857206382978724|11.858265986394558|13.802608695652172|11.757499999999997|15.573617021276597|9.902176870748299|86.63808689023553|84.73372056035305|26.133333333333333|24.733333333333334\n",
      "\n",
      "a propoxyphene test system is a device intended to measure propoxyphene, a pain-relieving drug, in serum, plasma, and urine. measurements obtained by this device are used in the diagnosis and treatment of propoxyphene use or overdose or in monitoring levels of propoxyphene to ensure appropriate therapy.|a propoxyphene test system is a device intended to measure the drug of choice for the treatment of pain and fever drug, in serum, plasma, and urine. measurements obtained by this device are used in the diagnosis and treatment to ensure appropriate therapy.|23.910797101449305|50.630852713178314|13.733478260869568|9.758139534883725|11.857206382978724|10.823512121212122|13.802608695652172|8.748837209302323|15.573617021276597|8.382878787878784|86.63808689023553|76.64453405168562|26.133333333333333|22.477519379844964\n",
      "\n",
      "a propoxyphene test system is a device intended to measure propoxyphene, a pain-relieving drug, in serum, plasma, and urine. measurements obtained by this device are used in the diagnosis and treatment of propoxyphene use or overdose or in monitoring levels of propoxyphene to ensure appropriate therapy.| a propoxyphene test is a diagnostic test|23.910797101449305|71.81500000000001|13.733478260869568|5.230000000000004|11.857206382978724|11.100677777777777|13.802608695652172|-11.275000000000002|15.573617021276597|1.9100000000000001|86.63808689023553|44.250742366654144|26.133333333333333|13.200000000000001\n",
      "\n",
      "an indication that somatostatin receptor type 2 expression has been detected in a sample.|a datum that somatostatin organ type 2 squeeze has been spied in a sample.|36.572857142857174|78.87285714285717|9.89714285714286|3.997142857142858|13.353757142857145|11.098042857142858|-10.365714285714287|-16.665714285714287|10.802142857142854|5.755714285714284|54.195869768830164|44.250742366654144|19.942857142857143|14.228571428571428\n",
      "\n",
      "an indication that somatostatin receptor type 2 expression has been detected in a sample.|an indication that somatostatin receptor type 2 has been detected in a sample.|36.572857142857174|44.05288461538464|9.89714285714286|8.729615384615386|13.353757142857145|13.006557142857146|-10.365714285714287|-15.233846153846155|10.802142857142854|4.274285714285714|54.195869768830164|49.473833993334296|19.942857142857143|17.984615384615388\n",
      "\n",
      "an indication that somatostatin receptor type 2 expression has been detected in a sample.| an indicator|36.572857142857174|62.79000000000002|9.89714285714286|5.246666666666666|13.353757142857145|15.6774|-10.365714285714287|-75.14666666666666|10.802142857142854|-4.122500000000002|54.195869768830164|31.29|19.942857142857143|14.533333333333331\n",
      "\n",
      "this gene is involved in cellular signaling. it is also involved in the immune response and host defense in leprosy.|this gene has in cellular tell.  it is also have in the immune response and host defense in leprosy.|64.70833333333334|85.85833333333333|5.890000000000004|2.9400000000000013|10.448500000000001|8.704166666666666|-15.881999999999998|-20.586|5.942499999999999|0.7433333333333323|54.195869768830164|44.250742366654144|20.666666666666668|14.666666666666666\n",
      "\n",
      "this gene is involved in cellular signaling. it is also involved in the immune response and host defense in leprosy.|this gene is involved cellular signaling. it is also involved in the immune response and host defense in leprosy.|64.70833333333334|62.37508771929825|5.890000000000004|6.132631578947368|10.448500000000001|11.072666666666667|-15.881999999999998|-17.027368421052632|5.942499999999999|4.040333333333333|54.195869768830164|54.195869768830164|20.666666666666668|21.480701754385965\n",
      "\n",
      "this gene is involved in cellular signaling. it is also involved in the immune response and host defense in leprosy.| this gene is involved in cellular signaling. it is also involved in the immune response and host defense in leprosy|64.70833333333334|67.2632142857143|5.890000000000004|6.48595238095238|10.448500000000001|11.359372727272728|-15.881999999999998|-1.0304761904761932|5.942499999999999|4.836818181818181|54.195869768830164|66.37611354998121|20.666666666666668|21.34285714285714\n",
      "\n",
      "cell surface receptors for interleukin-18 found on a variety of cell types including macrophages; neutrophils; nk cells; endothelial cells; and smooth muscle cells. they are formed as a heterodimer of alpha and beta subunits.|cell receptor organ for interleukin-18 found on a difference of cell types including phagocyte; neutrophils; no cells; endothelial cells; and smooth muscle cells.  they are formed as a heterodimer of start and beta subunits.|53.50225490196081|64.46761904761905|8.612352941176475|7.165714285714287|10.981464705882354|9.628880952380953|7.087058823529411|6.5485714285714245|12.836470588235294|9.299047619047617|62.58|59.91578840339164|18.650980392156864|17.238095238095237\n",
      "\n",
      "cell surface receptors for interleukin-18 found on a variety of cell types including macrophages; neutrophils; nk cells; endothelial cells; and smooth muscle cells. they are formed as a heterodimer of alpha and beta subunits.|cell surface receptors for interleukin-18 are formed as a heterodimer of alpha and beta subunits.|53.50225490196081|58.2225|8.612352941176475|7.001666666666669|11.445876470588235|10.941425|7.087058823529411|-6.538666666666671|12.836470588235294|7.003125000000001|62.58|54.195869768830164|18.650980392156864|19.0\n",
      "\n",
      "cell surface receptors for interleukin-18 found on a variety of cell types including macrophages; neutrophils; nk cells; endothelial cells; and smooth muscle cells. they are formed as a heterodimer of alpha and beta subunits.| cell surface receptors;|53.50225490196081|75.87500000000001|8.612352941176475|3.6700000000000017|10.981464705882354|13.3585|7.087058823529411|-41.660000000000004|12.836470588235294|1.7940000000000005|62.58|44.250742366654144|18.650980392156864|21.6\n",
      "\n",
      "this gene is involved in signaling.|this gene has to tell.|76.89000000000003|119.69750000000002|3.2800000000000047|-2.8149999999999995|11.8291|7.0425|-69.26666666666665|-97.232|4.334999999999997|-2.9160000000000004|31.29|0.0|14.533333333333331|1.0\n",
      "\n",
      "this gene is involved in signaling.|this gene is involved in signaling.|76.89000000000003|76.89000000000003|3.2800000000000047|3.2800000000000047|11.8291|12.832957142857145|-69.26666666666665|-68.28666666666666|4.334999999999997|0.5057142857142836|31.29|31.29|14.533333333333331|14.533333333333331\n",
      "\n",
      "this gene is involved in signaling.| this gene is involved in signalling|76.89000000000003|90.95857142857145|3.2800000000000047|2.3114285714285714|11.8291|13.902050000000001|-69.26666666666665|-16.245714285714282|4.334999999999997|1.4100000000000001|31.29|44.250742366654144|14.533333333333331|14.228571428571428\n",
      "\n",
      "the process in which the anatomical structures of a mesonephric nephron tubule are generated and organized. a mesonephric nephron tubule is an epithelial tube that is part of the mesonephric nephron, the functional part of the mesonephros. [goc:mtg_kidney_jan10]|the walk in which the saying system of a mesonephric neoprene tube is made and join.  a mesonephric neoprene tube is an epithelial tube that is part of the mesonephric nephron, the functional part of the mesonephros.  [ goc: mtg_kidney_jan10]|35.909912280701775|71.76785714285715|11.397368421052636|6.727142857142859|11.973864102564102|10.590293170731707|11.447368421052634|6.997142857142855|11.518461538461537|5.300975609756094|72.26115969177356|59.91578840339164|21.90877192982456|16.076190476190476\n",
      "\n",
      "the process in which the anatomical structures of a mesonephric nephron tubule are generated and organized. a mesonephric nephron tubule is an epithelial tube that is part of the mesonephric nephron, the functional part of the mesonephros. [goc:mtg_kidney_jan10]|the process in which the anatomical structures of a renal cell's kidney are generated and organized. a mesonephric nephron tubule is an epithelial tube that is part of the renal pelvis. [goc:mtg_kid|35.909912280701775|45.31458333333336|11.397368421052636|9.588750000000001|11.973864102564102|12.093633333333333|11.447368421052634|3.120000000000001|11.518461538461537|6.955490196078433|72.26115969177356|67.59412548439398|21.90877192982456|21.766666666666666\n",
      "\n",
      "the process in which the anatomical structures of a mesonephric nephron tubule are generated and organized. a mesonephric nephron tubule is an epithelial tube that is part of the mesonephric nephron, the functional part of the mesonephros. [goc:mtg_kidney_jan10]| the process in which the structure of an epithelial tube is generated and organized.|35.909912280701775|63.86250000000001|11.397368421052636|6.215000000000003|11.973864102564102|11.9283|11.447368421052634|-11.242666666666668|11.518461538461537|3.7650000000000006|72.26115969177356|49.473833993334296|21.90877192982456|16.333333333333332\n",
      "\n",
      "the determination of the amount of chenodeoxycholate in a sample.|the choice of the amount of chenodeoxycholate in a sample.|24.100000000000023|57.940000000000026|11.14|6.420000000000002|8.8695|7.2905|-26.272|-30.387999999999998|9.475000000000001|6.178000000000001|44.250742366654144|38.32226702584281|18.0|14.0\n",
      "\n",
      "the determination of the amount of chenodeoxycholate in a sample.|the determination of the amount of chenodeoxycholate in a sample.|24.100000000000023|24.100000000000023|11.14|11.14|8.8695|9.651118181818184|-26.272|-25.683999999999997|9.475000000000001|5.298181818181817|44.250742366654144|44.250742366654144|18.0|18.0\n",
      "\n",
      "the determination of the amount of chenodeoxycholate in a sample.| the determination of the amount of bile salt in a sample|24.100000000000023|74.805|11.14|5.806666666666668|8.8695|10.354376923076924|-26.272|-1.6366666666666667|9.475000000000001|2.4607692307692304|44.250742366654144|54.195869768830164|18.0|14.8\n",
      "\n",
      "any process that modulates the occurrence or rate of mesenchymal stem cell death by apoptotic process that contributes to the shaping of the nephron in the metanephros. [goc:mtg_apoptosis, goc:mtg_kidney_jan10]|any walk that changes the presence or rate of mesenchymal stem cell death by apoptosis walk that pay for the change of the nephron in the metanephros.  [ goc : mtg_apoptosis , goc : mtg_kidney_jan10 ]|34.58646551724141|82.87912162162164|12.03741379310345|6.295270270270269|11.536267741935484|9.099941666666666|16.488275862068964|10.062702702702701|13.060645161290324|7.306145833333332|76.64453405168562|62.58|22.351724137931036|16.048648648648648\n",
      "\n",
      "any process that modulates the occurrence or rate of mesenchymal stem cell death by apoptotic process that contributes to the shaping of the nephron in the metanephros. [goc:mtg_apoptosis, goc:mtg_kidney_jan10]|any process that modulates the occurrence or rate of mesenchymal stem cells death by programmed cell death that contributes to the shaping of the metanephros. [goc:mtg_apoptosis, goc:kidney_jan10]|34.58646551724141|39.59916666666669|12.03741379310345|11.089814814814819|11.536267741935484|11.222833333333334|16.488275862068964|15.314074074074071|13.060645161290324|11.975000000000001|76.64453405168562|69.96656701596841|22.351724137931036|20.214814814814815\n",
      "\n",
      "any process that modulates the occurrence or rate of mesenchymal stem cell death by apoptotic process that contributes to the shaping of the nephron in the metanephros. [goc:mtg_apoptosis, goc:mtg_kidney_jan10]||34.58646551724141|205.82000000000002|12.03741379310345|-15.2|11.536267741935484|19.476100000000002|16.488275862068964|-290.12|13.060645161290324|-16.22|76.64453405168562|0.0|22.351724137931036|0.4\n",
      "\n",
      "a 30-item, self-report questionnaire designed to measure physical and social function along with symptom impact associated with musculoskeletal disorders of the upper limb.|a 30-item, self-report form designed to measure physical and social serve along with symptom change associated with the musculoskeletal change of the upper limb.|25.962500000000034|50.130000000000024|12.495000000000001|9.248333333333335|12.4557|9.784561538461539|12.608695652173907|9.143333333333338|18.5764|15.844615384615388|82.78555852321104|69.96656701596841|28.947826086956525|21.46666666666667\n",
      "\n",
      "a 30-item, self-report questionnaire designed to measure physical and social function along with symptom impact associated with musculoskeletal disorders of the upper limb.|a 30-item, self-report questionnaire designed to measure physical and social function along with symptom impact associated with upper limb disorders.|25.962500000000034|35.94500000000002|12.495000000000001|10.73|12.4557|12.445160869565218|12.608695652173907|8.913999999999998|18.5764|10.327391304347824|82.78555852321104|79.77416029015912|28.947826086956525|30.0\n",
      "\n",
      "a 30-item, self-report questionnaire designed to measure physical and social function along with symptom impact associated with musculoskeletal disorders of the upper limb.| a questionnaire designed to measure physical and social function as well as symptom impact associated with musculoskeletal disorders of the upper limb|25.962500000000034|25.32478260869567|12.495000000000001|15.440869565217394|12.4557|12.7219|12.608695652173907|20.36521739130435|18.5764|16.278749999999995|82.78555852321104|108.39173953766033|28.947826086956525|30.0695652173913\n",
      "\n",
      "a cytogenetic abnormality that refers to the loss of all or part of the short arm of chromosome 12 (12p).|a cell dysfunction misbehavior that name for the loss of all or part of the short arm of body 12 (12p).|74.01500000000001|95.4632142857143|5.419999999999998|2.55261904761905|9.3655|7.685719047619047|-4.3160000000000025|-4.950476190476191|8.116500000000002|7.012857142857143|44.250742366654144|38.32226702584281|12.0|9.914285714285715\n",
      "\n",
      "a cytogenetic abnormality that refers to the loss of all or part of the short arm of chromosome 12 (12p).|a dna abnormality that refers to the loss of all or part of the short arm of chromosome 12 (12p).|74.01500000000001|90.935|5.419999999999998|3.0599999999999987|9.3655|9.420633333333335|-4.3160000000000025|-6.373999999999999|8.116500000000002|0.8657142857142865|44.250742366654144|38.32226702584281|12.0|10.0\n",
      "\n",
      "a cytogenetic abnormality that refers to the loss of all or part of the short arm of chromosome 12 (12p).| An altered gene|74.01500000000001|97.025|5.419999999999998|0.7199999999999989|9.3655|16.5165|-4.3160000000000025|-53.42|8.116500000000002|-4.800000000000001|44.250742366654144|31.29|12.0|11.600000000000001\n",
      "\n",
      "catalysis of the reaction: a hydroxyjasmonate + 3'-phosphoadenosine-5'-phosphosulfate = a hydroxyjasmonate sulfate + adenosine-3',5'-diphosphate. [ec:2.8.2.-, goc:pmn_curators, metacyc:rxn-10451, metacyc:rxn-10453, pmid:12637544]|catalysis of the reaction: a hydroxyjasmonate + 3'-phosphoadenosine-5'-phosphosulfate = a hydroxyjasmonate salt + adenosine-3', 5'-diphosphate.  [ ec:2.8.2.- , goc : pmn_curators , metacyc : rxn-10451 , metacyc : rxn-10453 , pmid:12637544 ]|73.85168421052632|112.97236363636364|3.9025263157894763|-0.8584242424242419|16.7645|16.929063636363637|-12.59578947368422|-7.786666666666669|30.67|31.53181818181818|34.27647764867329|37.022827282637394|14.15157894736842|11.124848484848485\n",
      "\n",
      "catalysis of the reaction: a hydroxyjasmonate + 3'-phosphoadenosine-5'-phosphosulfate = a hydroxyjasmonate sulfate + adenosine-3',5'-diphosphate. [ec:2.8.2.-, goc:pmn_curators, metacyc:rxn-10451, metacyc:rxn-10453, pmid:12637544]|increasing the rate of the reaction: a hydroxyjasmonate + 3'-phosphoadenosine-5' phosphosulfate is formed. [ec:2.8.2.-, goc:pmn_curators, metacyc:rxn-10|73.85168421052632|60.82450000000003|3.9025263157894763|5.570500000000003|16.7645|13.732344444444447|-12.59578947368422|-41.785000000000004|30.67|17.086666666666666|34.27647764867329|31.29|14.15157894736842|13.780000000000001\n",
      "\n",
      "catalysis of the reaction: a hydroxyjasmonate + 3'-phosphoadenosine-5'-phosphosulfate = a hydroxyjasmonate sulfate + adenosine-3',5'-diphosphate. [ec:2.8.2.-, goc:pmn_curators, metacyc:rxn-10451, metacyc:rxn-10453, pmid:12637544]| catalysis|73.85168421052632|35.60500000000002|3.9025263157894763|8.790000000000003|16.7645|19.5753|-12.59578947368422|-118.6|30.67|-2.66|34.27647764867329|31.29|14.15157894736842|20.8\n",
      "\n",
      "visual field deficit within the central 10 degrees of the visual field in the affected eye|visual field scores within the central 10 degrees of the visual field in the refer eye|53.120000000000005|68.9825|9.825|7.612500000000001|12.3251|11.338225000000001|9.0625|7.592500000000001|8.648125|7.470625000000002|82.78555852321104|76.64453405168562|23.900000000000002|21.400000000000002\n",
      "\n",
      "visual field deficit within the central 10 degrees of the visual field in the affected eye|visual field deficit within the central 10 degrees of visual field in the affected eye.|53.120000000000005|58.2225|9.825|7.001666666666669|12.3251|12.915175000000001|9.0625|-10.45866666666667|8.648125|4.059374999999999|82.78555852321104|58.53822981607831|23.900000000000002|21.666666666666668\n",
      "\n",
      "visual field deficit within the central 10 degrees of the visual field in the affected eye| visual impairment|53.120000000000005|34.59000000000003|9.825|9.180000000000003|12.3251|19.6249|9.0625|-65.34666666666666|8.648125|1.7650000000000006|82.78555852321104|44.250742366654144|23.900000000000002|27.866666666666664\n",
      "\n",
      "immunoassay reagents intended to perform qualitative and/or quantitative analyses on a body fluid sample (typically serum or feces) to determine the serine proteinase trypsin. there are two types of trypsin: trypsin i, which is cationic and is found in serum either as its precursor trypsinogen or in complexed forms, and trypsin ii, which is anionic and is only found in healthy people as its precursor trypsinogen ii. trypsin is used as an indicator of the type and severity of pancreatitis. the level of trypsin in feces and duodenal content is used as an aid in the diagnosis of chronic pancreatitis and cystic fibrosis in neonates and children.|bioassay reagent conveys to act qualitative and/or quantitative treat on a body fluid sample (typically serum or feces) to conclude the serine enzyme trypsin.  there are two types of trypsin: trypsin i, which is cationic and is found in serum either as its person trypsin or in complexed forms, and trypsin ii, which is anionic and is only found in healthy people as its person trypsin ii.  trypsin is used as a device of the type and sternness of pancreatitis.  the level of trypsin in feces and duodenal thing is used as an aid in the diagnosis of chronic pancreatitis and cystic fibrosis in baby and children.|35.68035514018692|55.29772727272726|13.598990654205611|11.011818181818182|11.603954205607476|10.731928571428572|16.00785046728972|13.433090909090902|15.406962616822433|7.664961038961039|96.94851912226405|93.86999999999999|26.503925233644864|25.163636363636368\n",
      "\n",
      "immunoassay reagents intended to perform qualitative and/or quantitative analyses on a body fluid sample (typically serum or feces) to determine the serine proteinase trypsin. there are two types of trypsin: trypsin i, which is cationic and is found in serum either as its precursor trypsinogen or in complexed forms, and trypsin ii, which is anionic and is only found in healthy people as its precursor trypsinogen ii. trypsin is used as an indicator of the type and severity of pancreatitis. the level of trypsin in feces and duodenal content is used as an aid in the diagnosis of chronic pancreatitis and cystic fibrosis in neonates and children.|immunoassay reagents intended to perform qualitative and/or quantitative analyses on a body fluid sample (typically serum or feces) to determine the protein building blocks used in the diagnosis of pancreatitis and cystic fibrosis. the level of tryp|35.68035514018692|18.857500000000016|13.598990654205611|15.225000000000001|11.603954205607476|12.889426315789473|16.00785046728972|18.008648648648645|15.406962616822433|14.2228947368421|96.94851912226405|101.39118822659097|26.503925233644864|30.102702702702704\n",
      "\n",
      "immunoassay reagents intended to perform qualitative and/or quantitative analyses on a body fluid sample (typically serum or feces) to determine the serine proteinase trypsin. there are two types of trypsin: trypsin i, which is cationic and is found in serum either as its precursor trypsinogen or in complexed forms, and trypsin ii, which is anionic and is only found in healthy people as its precursor trypsinogen ii. trypsin is used as an indicator of the type and severity of pancreatitis. the level of trypsin in feces and duodenal content is used as an aid in the diagnosis of chronic pancreatitis and cystic fibrosis in neonates and children.| immunoassay reagent|35.68035514018692|34.59000000000003|13.598990654205611|9.180000000000003|11.603954205607476|19.6249|16.00785046728972|-61.42666666666666|15.406962616822433|4.120000000000001|96.94851912226405|44.250742366654144|26.503925233644864|27.866666666666664\n",
      "\n",
      "this gene plays a role in transcription and proliferation.|this gene plays a role in transcription and increase.|61.26750000000001|89.46750000000003|5.831666666666667|1.8983333333333334|11.100677777777777|11.100677777777777|-33.11111111111111|-36.37777777777777|8.713333333333335|6.096666666666668|31.29|31.29|10.68888888888889|10.68888888888889\n",
      "\n",
      "this gene plays a role in transcription and proliferation.|this gene has a role in transcription and proliferation.|61.26750000000001|61.26750000000001|5.831666666666667|5.831666666666667|11.100677777777777|11.7795|-33.11111111111111|-33.764444444444436|8.713333333333335|3.678000000000001|31.29|31.29|10.68888888888889|10.68888888888889\n",
      "\n",
      "this gene plays a role in transcription and proliferation.| this gene plays a role in transcription and cell division.|61.26750000000001|93.57977272727274|5.831666666666667|1.5731818181818191|11.100677777777777|11.8291|-33.11111111111111|-27.090909090909093|8.713333333333335|1.1950000000000003|31.29|31.29|10.68888888888889|9.472727272727274\n",
      "\n",
      "ensuring physical comfort, health and physical and mental well-being, such as by maintaining a balanced diet, and an appropriate level of physical activity, keeping warm or cool, avoiding harms to health, following safe sex practices, including using condoms, getting immunizations and regular physical examinations.|ensuring physical aid, health and physical and mental well-being, such as by confirming a be dieting, and an assume level of physical activity, keeping warm or cool, cancel harms to health, following safe sex perform, including using condoms, getting protection and size physical introspection.|17.227727272727265|38.37772727272727|16.321818181818184|13.371818181818181|12.535388888888889|11.83361111111111|23.028181818181814|20.088181818181816|28.59733333333333|26.294666666666664|106.1095525859948|98.94766798666859|29.709090909090914|26.981818181818184\n",
      "\n",
      "ensuring physical comfort, health and physical and mental well-being, such as by maintaining a balanced diet, and an appropriate level of physical activity, keeping warm or cool, avoiding harms to health, following safe sex practices, including using condoms, getting immunizations and regular physical examinations.|ensuring physical comfort, health and physical and mental well-being, such as by maintaining a balanced diet, and an appropriate level of physical activity, keeping warm or cool, avoiding harms to health, including condoms and regular physical examinations.|17.227727272727265|23.43047297297298|16.321818181818184|14.587162162162166|12.535388888888889|11.486520512820514|23.028181818181814|19.28|28.59733333333333|14.16461538461538|106.1095525859948|98.94766798666859|29.709090909090914|29.021621621621627\n",
      "\n",
      "ensuring physical comfort, health and physical and mental well-being, such as by maintaining a balanced diet, and an appropriate level of physical activity, keeping warm or cool, avoiding harms to health, following safe sex practices, including using condoms, getting immunizations and regular physical examinations.||17.227727272727265|205.82000000000002|16.321818181818184|-15.2|12.535388888888889|19.476100000000002|23.028181818181814|-290.12|28.59733333333333|-16.22|106.1095525859948|0.0|29.709090909090914|0.4\n",
      "\n",
      "yellow, white or greyish lesions in the retina that are well-defined/distinct, individual and mostly uniform in size. [umanchester:psergouniotis]|yellow, white or grayish lesions in the membrane that are well-defined/distinct, individual and mostly supply in size.  [ manchester: psergouniotis]|5.000000000000028|43.09178571428572|14.797777777777782|9.857380952380954|9.998938095238096|11.17750606060606|8.924444444444447|7.6495238095238065|8.984285714285715|8.14166666666667|62.58|66.37611354998121|21.37777777777778|21.34285714285714\n",
      "\n",
      "yellow, white or greyish lesions in the retina that are well-defined/distinct, individual and mostly uniform in size. [umanchester:psergouniotis]|yellow, white or greyish lesions in the retina that are well-defined/distinct, individual and mostly uniform in size. [umanchester:pserotis]|5.000000000000028|9.700000000000017|14.797777777777782|14.142222222222227|10.172538095238096|10.641645454545454|8.924444444444447|7.617777777777782|10.734285714285711|8.904545454545453|62.58|62.58|21.37777777777778|21.37777777777778\n",
      "\n",
      "yellow, white or greyish lesions in the retina that are well-defined/distinct, individual and mostly uniform in size. [umanchester:psergouniotis]| yellow, white or greyish spots in the retina that are well-defined/distinct, individual and mostly uniform in size|5.000000000000028|38.16500000000002|14.797777777777782|12.407777777777778|10.172538095238096|9.941433333333334|8.924444444444447|15.895555555555553|10.734285714285711|10.60142857142857|62.58|76.64453405168562|21.37777777777778|20.53333333333333\n",
      "\n",
      "a drug used together with other drugs to treat early breast cancer that has spread to lymph nodes. it is also being studied in the treatment of other types of cancer. epirubicin is a type of anthracycline antibiotic.|a drug used together with other drugs to treat early breast cancer that has spread to lymph nodes.  it is also being think in the care of other types of cancer.  epirubicin is a type of anthracycline antibiotic.|65.83986842105264|76.13000000000001|6.436052631578949|5.1250000000000036|9.25108245614035|9.16505|-3.4599999999999973|-4.3160000000000025|6.718070175438598|2.705250000000003|56.4088497046341|51.88859484511023|17.48421052631579|15.0\n",
      "\n",
      "a drug used together with other drugs to treat early breast cancer that has spread to lymph nodes. it is also being studied in the treatment of other types of cancer. epirubicin is a type of anthracycline antibiotic.|a drug that has spread to lymph nodes. it is also being studied in the treatment of other types of cancer.|65.83986842105264|90.95857142857145|6.436052631578949|2.3114285714285714|9.25108245614035|9.024324242424242|-3.4599999999999973|-17.925714285714285|6.718070175438598|0.4343939393939422|56.4088497046341|44.250742366654144|17.48421052631579|14.228571428571428\n",
      "\n",
      "a drug used together with other drugs to treat early breast cancer that has spread to lymph nodes. it is also being studied in the treatment of other types of cancer. epirubicin is a type of anthracycline antibiotic.| an anthracycline antibiotic|65.83986842105264|12.425000000000011|6.436052631578949|12.52|9.25108245614035|16.5165|-3.4599999999999973|-35.78|6.718070175438598|6.504000000000001|56.4088497046341|44.250742366654144|17.48421052631579|21.6\n",
      "\n",
      "this gene is involved in second messenger molecule metabolism.|this gene is have in second messenger unit metabolism.|33.067500000000024|51.867500000000035|9.765|7.142777777777777|12.855122222222224|11.100677777777777|-30.49777777777777|-35.724444444444444|10.806666666666665|6.620000000000001|49.473833993334296|44.250742366654144|24.022222222222226|19.57777777777778\n",
      "\n",
      "this gene is involved in second messenger molecule metabolism.|this gene is involved in second messenger molecule metabolism.|33.067500000000024|33.067500000000024|9.765|9.765|12.855122222222224|13.3585|-30.49777777777777|-29.84444444444444|10.806666666666665|6.504000000000001|49.473833993334296|49.473833993334296|24.022222222222226|24.022222222222226\n",
      "\n",
      "this gene is involved in second messenger molecule metabolism.| This gene is involved in metabolism of messenger molecules|33.067500000000024|44.405|9.765|9.55|12.855122222222224|14.230281818181819|-30.49777777777777|0.3880000000000017|10.806666666666665|6.335454545454546|49.473833993334296|62.58|24.022222222222226|20.0\n",
      "\n",
      "cases of harm to a child caused by parents or other caregivers, defined by the federal government as: any recent act or failure to act on the part of a parent or caretaker which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act or failure to act which presents an imminent risk of serious harm.|cases of harm to a child caused by parents or other adult , choose by the agent government as : any recent act or failure to act on the part of a parent or official which results in death , serious physical or emotional harm , sexual use or mistreatment ; or an act or failure to act which greet an imminent risk of serious harm .|38.5758606557377|57.92802238805973|15.455819672131149|13.501865671641792|11.06259180327869|10.544886885245901|17.09245901639344|14.333134328358206|30.071967213114753|28.99098360655737|106.1095525859948|98.94766798666859|27.281967213114754|25.340298507462688\n",
      "\n",
      "cases of harm to a child caused by parents or other caregivers, defined by the federal government as: any recent act or failure to act on the part of a parent or caretaker which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act or failure to act which presents an imminent risk of serious harm.|any recent act or failure to act on the part of a parent or other caregiver which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act which presents an imminent risk of serious harm.|38.5758606557377|44.83000000000004|15.455819672131149|11.975000000000001|11.06259180327869|10.045007317073171|17.09245901639344|12.542|30.071967213114753|9.727804878048783|106.1095525859948|88.50148473330829|27.281967213114754|24.0\n",
      "\n",
      "cases of harm to a child caused by parents or other caregivers, defined by the federal government as: any recent act or failure to act on the part of a parent or caretaker which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act or failure to act which presents an imminent risk of serious harm.| A situation in which harm is done to a child|38.5758606557377|95.68818181818183|15.455819672131149|2.645454545454548|11.06259180327869|8.1792|17.09245901639344|-7.665454545454544|30.071967213114753|-0.9074999999999989|106.1095525859948|31.29|27.281967213114754|8.036363636363637\n",
      "\n",
      "the non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle. [goc:bhf, goc:mah]|the molecular function graphing and structure of proteins and lipids in the liver to form a very-low-density lipoprotein body.  [ goc : bhf , goc : mah ]|19.025000000000006|72.51060344827589|13.09|6.747758620689655|12.4673|11.961366666666667|8.326000000000004|4.931034482758623|7.428000000000001|4.279487179487177|69.96656701596841|69.96656701596841|24.0|19.593103448275865\n",
      "\n",
      "the non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle. [goc:bhf, goc:mah]|the non-covalent aggregation and arrangement of proteins and lipids in the liver to form very-low-density lipoprotein particle. [goc:bhf, goc:mah]|19.025000000000006|14.634605263157908|13.09|13.578157894736844|12.4673|13.0989|8.326000000000004|8.764210526315786|7.428000000000001|7.428000000000001|69.96656701596841|69.96656701596841|24.0|24.852631578947367\n",
      "\n",
      "the non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle. [goc:bhf, goc:mah]| the non-covalent aggregation and arrangement of proteins and lipids in the liver to form molecules (VLDL)|19.025000000000006|40.2858823529412|13.09|11.863529411764706|12.4673|12.889426315789473|8.326000000000004|14.063529411764705|7.428000000000001|10.132631578947368|69.96656701596841|82.78555852321104|24.0|23.270588235294117\n",
      "\n",
      "a pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of type 2 diabetes.|a medicine, harmony of sitagliptin salt and metformin complex that is used in the care of type 2 diabetes.|27.992500000000007|59.16092105263158|11.715|7.367631578947371|12.889426315789473|10.396268421052632|3.812631578947368|-3.924210526315786|15.834210526315793|9.388947368421054|62.58|54.195869768830164|20.642105263157895|16.431578947368422\n",
      "\n",
      "a pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of type 2 diabetes.|a pharmaceutical preparation of a drug that treats type 2 diabetes.|27.992500000000007|47.434318181818185|11.715|8.009545454545457|12.889426315789473|13.144933333333334|3.812631578947368|-22.81454545454546|15.834210526315793|3.942499999999999|62.58|38.32226702584281|20.642105263157895|13.109090909090908\n",
      "\n",
      "a pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of type 2 diabetes.| an antidiabetic|27.992500000000007|34.59000000000003|11.715|9.180000000000003|12.889426315789473|15.6774|3.812631578947368|-69.26666666666665|15.834210526315793|-0.5899999999999999|62.58|31.29|20.642105263157895|14.533333333333331\n",
      "\n",
      "severe pain; limiting self care adl|severe pain; choose self care ad|73.84500000000001|102.045|4.450000000000003|0.5166666666666693|11.6803|9.197433333333334|-19.93333333333333|-22.873333333333328|2.8349999999999973|1.9800000000000004|44.250742366654144|31.29|15.733333333333333|9.066666666666666\n",
      "\n",
      "severe pain; limiting self care adl|severe pain; limiting self care adl|73.84500000000001|73.84500000000001|4.450000000000003|4.450000000000003|11.8291|12.832957142857145|-19.93333333333333|-18.953333333333326|4.334999999999997|0.5057142857142836|44.250742366654144|44.250742366654144|15.733333333333333|15.733333333333333\n",
      "\n",
      "severe pain; limiting self care adl| extreme pain; limiting self care ability|73.84500000000001|54.70142857142861|4.450000000000003|7.368571428571428|11.8291|13.902050000000001|-19.93333333333333|-12.045714285714283|4.334999999999997|3.7650000000000006|44.250742366654144|54.195869768830164|15.733333333333333|19.942857142857143\n",
      "\n",
      "severe pain; limiting self care adl|severe pain; choose self care ad|73.84500000000001|102.045|4.450000000000003|0.5166666666666693|11.6803|9.197433333333334|-19.93333333333333|-22.873333333333328|2.8349999999999973|1.9800000000000004|44.250742366654144|31.29|15.733333333333333|9.066666666666666\n",
      "\n",
      "severe pain; limiting self care adl|severe pain; limiting self care adl|73.84500000000001|73.84500000000001|4.450000000000003|4.450000000000003|11.8291|12.832957142857145|-19.93333333333333|-18.953333333333326|4.334999999999997|0.5057142857142836|44.250742366654144|44.250742366654144|15.733333333333333|15.733333333333333\n",
      "\n",
      "severe pain; limiting self care adl| extreme pain; limiting self care ability|73.84500000000001|54.70142857142861|4.450000000000003|7.368571428571428|11.8291|13.902050000000001|-19.93333333333333|-12.045714285714283|4.334999999999997|3.7650000000000006|44.250742366654144|54.195869768830164|15.733333333333333|19.942857142857143\n",
      "\n",
      "a lymph node located above the collar bone and between the center of the body and a line drawn through the nipple to the shoulder.|a body part node located above the seize bone and between the center of the body and a line drawn through the cap to the thrust.|79.09150000000001|86.26307692307695|5.333000000000002|4.456923076923079|7.4029|7.355330769230769|1.2512000000000008|0.5246153846153838|10.851999999999997|10.047692307692309|62.58|54.195869768830164|17.8|14.430769230769233\n",
      "\n",
      "a lymph node located above the collar bone and between the center of the body and a line drawn through the nipple to the shoulder.|a lymph node located above the collar bone and between the center of the body and a line drawn through the nipple to the shoulder.|79.09150000000001|79.09150000000001|5.333000000000002|5.333000000000002|7.4029|7.317838461538462|1.2512000000000008|1.4863999999999997|10.851999999999997|4.272307692307692|62.58|62.58|17.8|17.8\n",
      "\n",
      "a lymph node located above the collar bone and between the center of the body and a line drawn through the nipple to the shoulder.| a lymph node|79.09150000000001|139.32500000000002|5.333000000000002|-5.179999999999998|7.4029|16.5165|1.2512000000000008|-57.83|10.851999999999997|-7.6259999999999994|62.58|0.0|17.8|1.6\n",
      "\n",
      "this gene is involved in g protein-coupled receptor signal transduction and the regulation of growth factor release.|this gene has in g protein-coupled organ tell transduction and the control of growth factor release.|43.93691176470591|66.5275|9.242647058823533|5.967500000000001|15.055966666666668|12.839111764705882|-0.235294117647058|-5.762499999999999|13.213333333333331|10.065882352941177|62.58|54.195869768830164|22.223529411764705|18.2\n",
      "\n",
      "this gene is involved in g protein-coupled receptor signal transduction and the regulation of growth factor release.|this gene is involved in protein-coupled receptor signal transduction and the regulation of growth factor release.|43.93691176470591|40.09|9.242647058823533|9.655000000000001|15.055966666666668|15.055966666666668|-0.235294117647058|-0.25|13.213333333333331|13.213333333333331|62.58|62.58|22.223529411764705|23.200000000000003\n",
      "\n",
      "this gene is involved in g protein-coupled receptor signal transduction and the regulation of growth factor release.| this protein is involved in transmembrane signaling and the regulation of growth factor release|43.93691176470591|50.610000000000014|9.242647058823533|9.92666666666667|15.055966666666668|14.29885|-0.235294117647058|12.802666666666667|13.213333333333331|11.2975|62.58|82.78555852321104|22.223529411764705|24.666666666666668\n",
      "\n",
      "fountains that spray a controlled stream of water for an extended period of time into the eyes and face. these fountains are usually used for decontamination in emergency situations (e.g., contact with corrosive chemicals or materials). these fountains are usually installed at eye or waist level. they may be wall-mounted hoses with a spray nozzle or consist of a stand-alone sink/basin with one or two nozzles or cups for the eyes and face.|flow that spray a know stream of water for an increase period of time into the eyes and face.  these flows are usually used for removal on brake state (e.g., contact with compound chemicals or applicant).  these flows are usually put on the eye or waist level.  they may be wall-mounted tube with a spray nose or be of a stand-alone sink/basin with one or two noses or cups for the eyes and face.|60.65821917808219|86.89857142857144|7.389471624266147|3.8714285714285737|8.734163157894738|7.558732142857143|1.419178082191781|-2.472727272727276|10.38052631578947|2.712160714285716|60.30359690764722|47.30603344183487|18.418003913894324|12.711688311688313\n",
      "\n",
      "fountains that spray a controlled stream of water for an extended period of time into the eyes and face. these fountains are usually used for decontamination in emergency situations (e.g., contact with corrosive chemicals or materials). these fountains are usually installed at eye or waist level. they may be wall-mounted hoses with a spray nozzle or consist of a stand-alone sink/basin with one or two nozzles or cups for the eyes and face.|fountains that spray a controlled stream of water for an extended period of time into the eyes and face. these fountains are usually used for decontamination in emergency situations (e.g., contact with corrosive chemicals or materials). they may be wall-mounted hoses with one or|60.65821917808219|51.775727272727295|7.389471624266147|8.223818181818185|8.734163157894738|9.202685507246377|1.419178082191781|-1.9645454545454477|10.38052631578947|9.889057971014491|60.30359690764722|57.69590921373889|18.418003913894324|18.974545454545456\n",
      "\n",
      "fountains that spray a controlled stream of water for an extended period of time into the eyes and face. these fountains are usually used for decontamination in emergency situations (e.g., contact with corrosive chemicals or materials). these fountains are usually installed at eye or waist level. they may be wall-mounted hoses with a spray nozzle or consist of a stand-alone sink/basin with one or two nozzles or cups for the eyes and face.| fountain|60.65821917808219|120.20500000000001|7.389471624266147|-3.01|8.734163157894738|14.311966666666669|1.419178082191781|-121.53999999999999|10.38052631578947|-4.229999999999997|60.30359690764722|31.29|18.418003913894324|20.8\n",
      "\n",
      "bifunctional cross-linking agent that links covalently free amino groups of proteins or polypeptides, including those in cell membranes. it is used as reagent or fixative in immunohistochemistry and is a proposed antisickling agent.|bifunctional join agent that links covalently free group groups of proteins or peptide, including those in cell sheet.  it is used as reagent or varnish in assay and is a choose antisickling agent.|23.906363636363665|70.91990196078433|12.657575757575756|6.182941176470592|11.910288235294118|10.235986274509806|8.727272727272723|2.244705882352939|14.221764705882357|6.678431372549021|69.96656701596841|59.91578840339164|22.581818181818182|17.47450980392157\n",
      "\n",
      "bifunctional cross-linking agent that links covalently free amino groups of proteins or polypeptides, including those in cell membranes. it is used as reagent or fixative in immunohistochemistry and is a proposed antisickling agent.|bifunctional cross-linker that links covalently free amino groups of proteins or polypeptides, including those in cell membranes. it is used as reagent or fixative in immunohistochemistry and is a proposed antisickling agent.|23.906363636363665|24.164583333333354|12.657575757575756|12.53875|11.910288235294118|11.629221568627452|8.727272727272723|8.08125|14.221764705882357|10.69578431372549|69.96656701596841|67.59412548439398|22.581818181818182|21.766666666666666\n",
      "\n",
      "bifunctional cross-linking agent that links covalently free amino groups of proteins or polypeptides, including those in cell membranes. it is used as reagent or fixative in immunohistochemistry and is a proposed antisickling agent.| bifunctional cross-linking agent that links to covalently free amino groups of proteins or polypeptides, including those in cell membranes. it is used as a reagent or fixative in immunohistochemistry and is a proposed antisickling agent.|23.906363636363665|32.504999999999995|12.657575757575756|11.706666666666667|11.910288235294118|11.744240350877194|8.727272727272723|8.653333333333336|14.221764705882357|9.816754385964913|69.96656701596841|69.96656701596841|22.581818181818182|21.46666666666667\n",
      "\n",
      "an insertion of the amino acid histidine between the asparagine at position 771 and the proline at position 772 of the epidermal growth factor receptor protein.|a movement of the group acid histidine between the asparagine at position 771 and the proline at position 772 of the epidermal growth factor organ protein.|40.7092307692308|53.72461538461542|10.810769230769232|8.995384615384616|14.035715384615385|12.8211|7.761538461538464|6.6307692307692285|15.844615384615388|14.93884615384615|79.77416029015912|76.64453405168562|25.200000000000003|23.661538461538463\n",
      "\n",
      "an insertion of the amino acid histidine between the asparagine at position 771 and the proline at position 772 of the epidermal growth factor receptor protein.|an insertion of protein building blocks between the asparagine and the proline at position 771 of a protein.|40.7092307692308|61.400000000000034|10.810769230769232|6.9311111111111146|14.035715384615385|10.75612105263158|7.761538461538464|-2.8355555555555547|15.844615384615388|5.87842105263158|79.77416029015912|62.58|25.200000000000003|21.37777777777778\n",
      "\n",
      "an insertion of the amino acid histidine between the asparagine at position 771 and the proline at position 772 of the epidermal growth factor receptor protein.| an insertion of the amino acid histidine between the asparagine at position 771 of the protein and the proline at position 772|40.7092307692308|47.39434782608697|10.810769230769232|12.362608695652174|14.035715384615385|13.379816666666667|7.761538461538464|14.229565217391304|15.844615384615388|11.568750000000001|79.77416029015912|98.94766798666859|25.200000000000003|26.59130434782609\n",
      "\n",
      "a dose calculation unit expressed in milligrams per milliliter, divided by milligram per kilogram.|a quantity planning unit mail in milligrams per milliliter, move by milligram per kilogram.|12.401428571428596|36.572857142857174|13.26857142857143|9.89714285714286|15.60947142857143|14.481614285714286|-6.585714285714289|-9.525714285714287|13.493571428571428|11.138571428571431|62.58|58.53822981607831|25.65714285714286|22.8\n",
      "\n",
      "a dose calculation unit expressed in milligrams per milliliter, divided by milligram per kilogram.|a dose calculation unit expressed in micrograms per milliliter, divided by millium per kilogram.|12.401428571428596|18.44428571428574|13.26857142857143|12.425714285714289|15.60947142857143|15.587833333333334|-6.585714285714289|-7.005714285714284|13.493571428571428|8.068000000000001|62.58|62.58|25.65714285714286|25.65714285714286\n",
      "\n",
      "a dose calculation unit expressed in milligrams per milliliter, divided by milligram per kilogram.| a dose calculation unit expressed in milligrams per milliliter per kilogram;divided by milligram per kilogram.|12.401428571428596|13.652500000000003|13.26857142857143|13.342500000000001|15.60947142857143|17.061629411764706|-6.585714285714289|-1.3524999999999991|13.493571428571428|9.694705882352942|62.58|62.58|25.65714285714286|23.200000000000003\n",
      "\n",
      "the formation of daughter actin filament branches at an angle on the sides of preexisting mother filaments. [goc:ascb_2009, goc:dph, goc:tb]|the placement of daughter actin wire branches at a fish on the sides of existing mother wore.  [ goc : ascb_2009 , goc : dph , goc : tb ]|61.32500000000002|114.68959677419357|7.190000000000001|1.1130645161290325|12.445160869565218|10.612466666666666|5.974|1.1987096774193589|7.460434782608694|2.1950000000000003|66.37611354998121|54.195869768830164|22.0|13.94193548387097\n",
      "\n",
      "the formation of daughter actin filament branches at an angle on the sides of preexisting mother filaments. [goc:ascb_2009, goc:dph, goc:tb]|the formation of daughter filament branches at an angle on the sides of preexisting mother filaments. [goc:dph, goc:tb]|61.32500000000002|56.70000000000002|7.190000000000001|7.58666666666667|12.445160869565218|11.67634761904762|5.974|0.7577777777777754|7.460434782608694|5.575714285714284|66.37611354998121|62.58|22.0|21.37777777777778\n",
      "\n",
      "the formation of daughter actin filament branches at an angle on the sides of preexisting mother filaments. [goc:ascb_2009, goc:dph, goc:tb]| actin filament branching|61.32500000000002|54.72500000000002|7.190000000000001|6.620000000000001|12.445160869565218|19.674500000000002|5.974|-40.19|7.460434782608694|3.678000000000001|66.37611354998121|54.195869768830164|22.0|31.6\n",
      "\n",
      "the presence of microorganisms that normally reside at an anatomical site and that under normal circumstances do not cause disease.|the finding of organism that normally reside at a saying site and that under normal condition do not cause disease.|40.17500000000001|61.32500000000002|10.140000000000004|7.190000000000001|11.734|10.944500000000001|3.3279999999999994|-1.3759999999999977|14.710500000000003|10.942500000000003|66.37611354998121|66.37611354998121|22.0|22.0\n",
      "\n",
      "the presence of microorganisms that normally reside at an anatomical site and that under normal circumstances do not cause disease.|the presence of microorganisms that normally reside at a body site and that under normal circumstances do not cause disease.|40.17500000000001|52.86500000000001|10.140000000000004|8.370000000000001|11.734|10.924442857142857|3.3279999999999994|1.564|14.710500000000003|7.370000000000001|66.37611354998121|66.37611354998121|22.0|22.0\n",
      "\n",
      "the presence of microorganisms that normally reside at an anatomical site and that under normal circumstances do not cause disease.| the presence of microorganism that normally resides and that does not cause disease|40.17500000000001|59.68214285714288|10.140000000000004|8.412857142857145|11.734|11.749166666666667|3.3279999999999994|9.09714285714286|14.710500000000003|8.991999999999997|66.37611354998121|69.96656701596841|22.0|19.885714285714286\n",
      "\n",
      "any process that modulates the frequency, rate or extent of mesenchymal cell apoptotic process. [goc:mtg_apoptosis, goc:obol]|any walk that changes the ratio, rate or extent of the mesenchymal cell apoptotic process.  [ goc : mtg_apoptosis , goc : obol ]|3.077500000000015|79.09150000000001|14.817500000000003|5.333000000000002|13.732344444444447|11.862166666666667|3.424999999999997|0.7807999999999993|10.021666666666668|4.982333333333333|69.96656701596841|66.37611354998121|28.200000000000003|19.400000000000002\n",
      "\n",
      "any process that modulates the frequency, rate or extent of mesenchymal cell apoptotic process. [goc:mtg_apoptosis, goc:obol]|any process that modulates cell death. [goc:mtg_apoptosis, goc:obol]|3.077500000000015|1.8500000000000227|14.817500000000003|13.995000000000001|13.732344444444447|13.957481818181819|3.424999999999997|-28.43|10.021666666666668|5.298181818181817|69.96656701596841|49.473833993334296|28.200000000000003|26.6\n",
      "\n",
      "any process that modulates the frequency, rate or extent of mesenchymal cell apoptotic process. [goc:mtg_apoptosis, goc:obol]| modulation of frequency changes|3.077500000000015|32.56000000000003|14.817500000000003|9.96|13.732344444444447|14.460766666666668|3.424999999999997|-25.096000000000004|10.021666666666668|5.120000000000001|69.96656701596841|54.195869768830164|28.200000000000003|26.0\n",
      "\n",
      "an abnormality of a blood vessel of the head, including branches of the arterial and venous systems of the head. [goc:termgenie, orcid:0000-0001-5889-4463]|an misbehavior of a blood craft of the head, including branches of the arterial and venous systems of the head.  [ goc: termgenie, orchid: 0000-0001-5889-4463]|64.9245454545455|83.0092307692308|6.936363636363637|4.91076923076923|10.961684615384616|11.994433333333333|8.905454545454543|7.535384615384615|7.714230769230767|4.263452380952383|62.58|62.58|18.94545454545455|17.50769230769231\n",
      "\n",
      "an abnormality of a blood vessel of the head, including branches of the arterial and venous systems of the head. [goc:termgenie, orcid:0000-0001-5889-4463]|an abnormality of a blood vessel on the head, including branches of the arterial and venous systems ofthe head. [goc:termgenie, orcid:000-0001-5889-4463]|64.9245454545455|63.23464285714289|6.936363636363637|7.0478571428571435|10.961684615384616|12.1763|8.905454545454543|9.329523809523813|7.714230769230767|7.714230769230767|62.58|62.58|18.94545454545455|19.43809523809524\n",
      "\n",
      "an abnormality of a blood vessel of the head, including branches of the arterial and venous systems of the head. [goc:termgenie, orcid:0000-0001-5889-4463]| A blood vessel anomaly of the head|64.9245454545455|82.39000000000001|6.936363636363637|3.7550000000000026|10.961684615384616|9.346233333333334|8.905454545454543|-15.684999999999999|7.714230769230767|-1.2299999999999969|62.58|44.250742366654144|18.94545454545455|13.200000000000001\n",
      "\n",
      "an array of expression measurement objects.|a stand of squeeze measurement objects.|34.59000000000003|76.89000000000003|9.180000000000003|3.2800000000000047|14.460766666666668|9.197433333333334|-61.42666666666666|-65.34666666666666|10.615000000000002|7.475000000000001|44.250742366654144|31.29|27.866666666666664|14.533333333333331\n",
      "\n",
      "an array of expression measurement objects.|an array of expression measurement object.|34.59000000000003|34.59000000000003|9.180000000000003|9.180000000000003|14.460766666666668|15.08867142857143|-61.42666666666666|-61.42666666666666|10.615000000000002|5.215714285714284|44.250742366654144|44.250742366654144|27.866666666666664|27.866666666666664\n",
      "\n",
      "an array of expression measurement objects.| a collection|34.59000000000003|90.99000000000004|9.180000000000003|1.3133333333333361|14.460766666666668|14.311966666666669|-61.42666666666666|-77.10666666666665|10.615000000000002|-1.0899999999999999|44.250742366654144|31.29|27.866666666666664|14.533333333333331\n",
      "\n",
      "a recombinant form of naturally-occurring gc (group-specific component) protein-derived macrophage-activating factor (gc-maf). gc is also known as vitamin d binding protein (vdbp). gc-maf promotes macrophage activation.|a cellular form of naturally-occurring gas (group-specific component) protein-derived macrophage-activating factor (gc-maf).  gas is also known as vitamin d binding protein (vdbp).  gc-may play macrophage beginning.|-8.008653846153834|18.44428571428574|15.99115384615385|12.425714285714289|15.514629166666667|13.262015294117647|-1.664615384615388|-2.805714285714288|10.249895833333333|6.212647058823531|58.53822981607831|56.4088497046341|24.13846153846154|21.371428571428574\n",
      "\n",
      "a recombinant form of naturally-occurring gc (group-specific component) protein-derived macrophage-activating factor (gc-maf). gc is also known as vitamin d binding protein (vdbp). gc-maf promotes macrophage activation.|a recombinant form of protein-derived macrophage activation factor. gc is also known as vitamin d binding protein (vdbp).|-8.008653846153834|31.545000000000016|15.99115384615385|10.350000000000001|15.514629166666667|13.441166666666666|-1.664615384615388|-15.033333333333331|10.249895833333333|5.453333333333333|58.53822981607831|54.195869768830164|24.13846153846154|22.400000000000002\n",
      "\n",
      "a recombinant form of naturally-occurring gc (group-specific component) protein-derived macrophage-activating factor (gc-maf). gc is also known as vitamin d binding protein (vdbp). gc-maf promotes macrophage activation.| a recombinant form of macrophage-activating factor|-8.008653846153834|-5.727142857142809|15.99115384615385|15.797142857142859|15.514629166666667|14.60956666666667|-1.664615384615388|-3.6457142857142912|10.249895833333333|7.143333333333331|58.53822981607831|54.195869768830164|24.13846153846154|19.942857142857143\n",
      "\n",
      "derived from a spontaneous mutation in the leptin receptor that appeared in a 13m rat colony bred at the zucker laboratory of comparative pathology (stow, ma), genotype leprfa. the zucker rat may come in four principal color variants, including brown, brown and white, black, and black and white. the mutation causes severe obesity, diabetes, abnormal heart function, hypertriglyceridemia, and hypercholesterolemia. the zucker rat is utilized in biomedical research to study insulin resistance, glucose intolerance, metabolic syndromes, and obesity.|make  a spontaneous change in the leptin organ that perform in a 13m rat colony bred in the zucker region of adjective ill_health (stow, ma), genotype leprfa.  the zucker rat may come in four wrongdoer color type, including brown, brown and white, black, and black and white.  the change causes severe fatness, diabetes, abnormal heart serves, hypertriglyceridemia, and symptom.  the zucker rat is change in biomedical research to study hormone action, glucose attitude, metabolic symptom, and fatness.|16.377923076923082|57.74755555555555|14.85041025641026|9.229234567901234|12.41116329113924|11.767257073170732|16.607179487179483|12.36246913580247|15.452974683544305|10.147682926829269|87.38821419390602|80.38546547728637|26.24|22.776296296296294\n",
      "\n",
      "derived from a spontaneous mutation in the leptin receptor that appeared in a 13m rat colony bred at the zucker laboratory of comparative pathology (stow, ma), genotype leprfa. the zucker rat may come in four principal color variants, including brown, brown and white, black, and black and white. the mutation causes severe obesity, diabetes, abnormal heart function, hypertriglyceridemia, and hypercholesterolemia. the zucker rat is utilized in biomedical research to study insulin resistance, glucose intolerance, metabolic syndromes, and obesity.|the zucker rat is utilized in biomedical research to study insulin resistance, glucose intolerance, and obesity.|16.377923076923082|8.365000000000009|14.85041025641026|14.080000000000002|12.41116329113924|13.346335294117647|16.607179487179483|-0.9849999999999994|15.452974683544305|9.140588235294118|87.38821419390602|69.96656701596841|26.24|28.200000000000003\n",
      "\n",
      "derived from a spontaneous mutation in the leptin receptor that appeared in a 13m rat colony bred at the zucker laboratory of comparative pathology (stow, ma), genotype leprfa. the zucker rat may come in four principal color variants, including brown, brown and white, black, and black and white. the mutation causes severe obesity, diabetes, abnormal heart function, hypertriglyceridemia, and hypercholesterolemia. the zucker rat is utilized in biomedical research to study insulin resistance, glucose intolerance, metabolic syndromes, and obesity.| is used in biomedical research to study insulin resistance, abnormal heart function, hypertriglyceridemia, and hypercholesterolemia|16.377923076923082|-26.192499999999995|14.85041025641026|20.8875|12.41116329113924|13.767935294117647|16.607179487179483|24.864999999999995|15.452974683544305|19.208823529411767|87.38821419390602|93.86999999999999|26.24|28.900000000000002\n",
      "\n",
      "faces pain scale - revised test code.|faces pain scale - revised test code.|106.59678571428573|106.59678571428573|-0.7392857142857139|-0.7392857142857139|11.8291|11.8291|-58.53142857142856|-58.53142857142856|4.334999999999997|4.334999999999997|31.29|31.29|12.82857142857143|12.82857142857143\n",
      "\n",
      "faces pain scale - revised test code.|faces pain scale- revised test code.|106.59678571428573|90.99000000000004|-0.7392857142857139|1.3133333333333361|11.8291|12.832957142857145|-58.53142857142856|-67.30666666666666|4.334999999999997|1.1785714285714306|31.29|31.29|12.82857142857143|14.533333333333331\n",
      "\n",
      "faces pain scale - revised test code.| face|106.59678571428573|162.505|-0.7392857142857139|-8.91|11.8291|14.311966666666669|-58.53142857142856|-133.3|4.334999999999997|-10.51|31.29|0.0|12.82857142857143|0.8\n",
      "\n",
      "a fully human monoclonal antibody that targets the neonatal crystallizable fragment receptor (fcrn), with potential immunomodulating activity. upon administration, nipocalimab targets and binds to fcrn at the immunoglobulin g (igg) binding site, thereby preventing the interaction between fcrn and the serum protein igg. by preventing fcrn/igg binding, nipocalimab blocks the fcrn-mediated rescue of igg, enables igg degradation and prevents igg-mediated inflammation. igg plays a key role in many autoimmune diseases and is an important factor in inflammatory processes.|a fully human monoclonal protein that aim the neonatal crystallizable break organ (fcrn), with potential immunomodulating activity.  upon justice, nipocalimab aim and binds to fcrn at the antibody g (igg) binding site, thereby preventing the action between fern and the serum protein egg.  by preventing fcrn/egg binding, nipocalimab blocks the fcrn-mediated take off if, change if degradation and prevents egg-mediated burning.  egg plays a key role in many autoimmune illnesses and is an important factor in inflammatory transform.|8.785615384615397|34.76977777777779|15.909384615384617|12.434172839506171|14.722613580246914|11.93872380952381|18.26564102564102|14.612839506172836|19.864814814814814|9.241428571428571|89.6009242139834|83.9598804191621|27.265641025641028|24.25777777777778\n",
      "\n",
      "a fully human monoclonal antibody that targets the neonatal crystallizable fragment receptor (fcrn), with potential immunomodulating activity. upon administration, nipocalimab targets and binds to fcrn at the immunoglobulin g (igg) binding site, thereby preventing the interaction between fcrn and the serum protein igg. by preventing fcrn/igg binding, nipocalimab blocks the fcrn-mediated rescue of igg, enables igg degradation and prevents igg-mediated inflammation. igg plays a key role in many autoimmune diseases and is an important factor in inflammatory processes.|a fully human monoclonal antibody that targets a neonatal crystallizable fragment receptor, with potential immunomodulating activity. upon administration, nipocalimab targets and binds to fcrn at the immunoglobulin g (igg) binding|8.785615384615397|-19.889999999999986|15.909384615384617|19.76|14.582751851851853|14.59239677419355|18.26564102564102|19.858666666666664|16.547962962962963|16.251290322580644|89.6009242139834|93.86999999999999|27.265641025641028|30.0\n",
      "\n",
      "a fully human monoclonal antibody that targets the neonatal crystallizable fragment receptor (fcrn), with potential immunomodulating activity. upon administration, nipocalimab targets and binds to fcrn at the immunoglobulin g (igg) binding site, thereby preventing the interaction between fcrn and the serum protein igg. by preventing fcrn/igg binding, nipocalimab blocks the fcrn-mediated rescue of igg, enables igg degradation and prevents igg-mediated inflammation. igg plays a key role in many autoimmune diseases and is an important factor in inflammatory processes.| a human antibody|8.785615384615397|54.72500000000002|15.909384615384617|6.620000000000001|14.582751851851853|16.5165|18.26564102564102|-51.95|16.489814814814814|-3.857999999999997|89.6009242139834|44.250742366654144|27.265641025641028|21.6\n",
      "\n",
      "a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. this process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ros) derived from iron metabolism. glutathione peroxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ros production and reducing cellular iron uptake, respectively. in contrast, nadph oxidase and p53 act as positive regulators of ferroptosis by promotion of ros production and inhibition of expression of slc7a11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. misregulated ferroptosis has been implicated in multiple physiological and pathological processes. [goc:mtg_apoptosis, pmid:25236395, pmid:26794443]|a schedule, cell death distinguishes morphologically by the presence of smaller than normal mitochondria with change mitochondrial membrane spacing, change or decrease of mitochondria crista, and outer mitochondrial sheet rupture.  beginning of mitochondrial voltage-dependent anion move and mitogen-activated protein enzyme, upregulation of endoplasmic stomach stress, and action of the cystine / glutamate antiporter are having in the causing of ferroptosis.  this walk is distinguished by the net_income of lipid peroxidation products and lethal reactive oxygen kind (ros) make from iron metabolism.  glutathione oxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 serve as a negative control of ferroptosis by choosing rose display and reducing cellular iron uptake, respectively.  in contrast, nadph enzyme and p53 act as film control of ferroptosis by change of rose display and action of squeeze of slc7a11 (a fact light-chain subunit of the cystine/glutamate antiporter), respectively.  misregulated ferroptosis has been lead in product physiological and pathological transform.  [ goc : mtg_apoptosis , pmid:25236395 , pmid:26794443 ]|-8.855483870967703|30.650526315789506|19.995391705069128|15.052932330827073|15.116114109347443|12.97722549019608|28.057806451612905|22.750409356725147|20.959947089947086|12.999039215686274|111.57105673067723|103.1011095963569|31.82488479262673|27.54920634920635\n",
      "\n",
      "a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. this process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ros) derived from iron metabolism. glutathione peroxidase 4 (gpx4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ros production and reducing cellular iron uptake, respectively. in contrast, nadph oxidase and p53 act as positive regulators of ferroptosis by promotion of ros production and inhibition of expression of slc7a11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. misregulated ferroptosis has been implicated in multiple physiological and pathological processes. [goc:mtg_apoptosis, pmid:25236395, pmid:26794443]|a programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. activation of ferroptosis has been implicated in multiple physiological and|-8.855483870967703|-6.019038461538429|19.995391705069128|18.943205128205125|15.116114109347443|13.707749999999999|28.057806451612905|25.226666666666667|20.959947089947086|19.77375|111.57105673067723|103.77718969022045|31.82488479262673|30.364102564102566\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1); programmed death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|any chemical function that binds to any of the ligands for the organ schedule, cell death protein 1 (pd-1; pd1); schedule death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|98.76577586206898|101.37000000000002|3.0856896551724162|2.8466666666666676|14.342487096774192|14.105575|7.769655172413792|8.490666666666666|13.213870967741933|13.704374999999999|66.37611354998121|69.96656701596841|18.21379310344828|19.333333333333332\n",
      "\n",
      "any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1); programmed death ligand 1 (pd-l1; cd274) and 2 (pd-l2; cd273).|any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (pd-1; pd1).|98.76577586206898|85.87671052631579|3.0856896551724162|3.641315789473687|14.342487096774192|11.238|7.769655172413792|-4.23368421052632|13.213870967741933|3.116500000000002|66.37611354998121|58.53822981607831|18.21379310344828|18.53684210526316\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human b-cell maturation antigen (bcma; tnfrsf17), fused to one that is directed against the cd3 antigen found on t lymphocytes, with potential immunostimulating and antineoplastic activities. upon administration of anti-bcma/cd3 bite antibody amg 701, this bispecific antibody binds to both cd3 on cytotoxic t lymphocytes (ctls) and bcma found on bcma-expressing tumor cells. this activates and redirects ctls to bcma-expressing tumor cells, which results in the ctl-mediated cell death of bcma-expressing tumor cells. bcma, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.|a immunologic factor t-cell engager ( bite ) protein plan of two single-chain symbol break ( scfv ) , one directed against the tumor-associated substance ( taa ) human b-cell maturation antigen ( bcma ; tnfrsf17 ) , melt to one that is plan against the cd3 substance found on t leukocyte , with potential immunostimulating and antineoplastic trait .  upon justice of anti-bcma/cd3 bite protein is 701, this bispecific protein binds to both cd3 on cytotoxic t leukocyte (ctls) and become found on became-expressing growth cells.  this change and send styles to become-expressing growth cells, which results in the steel-mediated cell death of bcma-expressing tumor cells.  bcma, a member of the tumor death factor organ superfamily that is specifically overexpressed in malignant plasma cells, plays a key role in play plasma cell survival.|15.390000000000015|48.7276496350365|17.075000000000006|13.269722627737227|13.87226923076923|12.050054228855721|23.63266666666667|19.369635036496348|20.253999999999998|13.427263681592038|101.87285929039194|92.82114026448932|27.266666666666666|23.806715328467153\n",
      "\n",
      "a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human b-cell maturation antigen (bcma; tnfrsf17), fused to one that is directed against the cd3 antigen found on t lymphocytes, with potential immunostimulating and antineoplastic activities. upon administration of anti-bcma/cd3 bite antibody amg 701, this bispecific antibody binds to both cd3 on cytotoxic t lymphocytes (ctls) and bcma found on bcma-expressing tumor cells. this activates and redirects ctls to bcma-expressing tumor cells, which results in the ctl-mediated cell death of bcma-expressing tumor cells. bcma, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.|a bispecific t-cell engager (bite) antibody composed of two single-chain variable fragments (scfv), one directed against the tumor-associated antigen (taa) human protein complexes found on tumor cells, which results in the ctl-mediated cell death of|15.390000000000015|6.944285714285741|17.075000000000006|20.985714285714284|13.87226923076923|13.515500000000001|23.63266666666667|27.83085714285714|20.253999999999998|22.591|101.87285929039194|129.0119750255766|27.266666666666666|33.42857142857143\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "diagnosis of a disease or condition made before death.|diagnosis of a disease or condition made before death.|51.867500000000035|51.867500000000035|7.142777777777777|7.142777777777777|9.346233333333334|9.346233333333334|-35.724444444444444|-35.724444444444444|6.620000000000001|6.620000000000001|44.250742366654144|44.250742366654144|19.57777777777778|19.57777777777778\n",
      "\n",
      "diagnosis of a disease or condition made before death.|diagnosis of a disease or condition made before ami.|51.867500000000035|42.46750000000003|7.142777777777777|8.45388888888889|9.346233333333334|11.7795|-35.724444444444444|-36.37777777777777|6.620000000000001|1.7940000000000005|44.250742366654144|49.473833993334296|19.57777777777778|24.022222222222226\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "autologous human t-lymphocytes transduced with a retroviral vector encoding a t-cell receptor (tcr) specific for the human melanoma antigen a4 (mage-a4), with potential immunostimulatory and antineoplastic activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, mage-a4-specific tcr gene-transduced t-lymphocytes tbi-1201 binds to tumor cells expressing mage-a4. this may result in both an inhibition of growth and increased cell death for mage-a4-expressing tumor cells. the tumor-associated antigen mage-a4 is overexpressed by a variety of cancer cell types.|autologous human t-lymphocytes convert with a retroviral vector convert a t-cell, organ (tar) fact of the human skin_cancer substance a4 (mage-a4), with potential immunostimulatory and antineoplastic trait.  upon isolation, transduction, increases ex vivo, and reintroduction into the case, mage-a4-specific tcr gene-transduced t-lymphocytes tube-1201 binds to growth cells mail mage-a4.  this may result in both an action of growth and increased cell death for mage-a4-expressing tumor cells.  the tumor-associated substance mage-a4 is overexpressed by a difference of cancer cell types.|21.598000000000013|45.74997560975612|14.172|10.952341463414637|15.002372527472529|13.820375177304964|20.267341772151894|18.30682926829268|15.77236263736264|10.654822695035463|85.1180024436664|79.15813438933486|25.054177215189874|22.169756097560978\n",
      "\n",
      "autologous human t-lymphocytes transduced with a retroviral vector encoding a t-cell receptor (tcr) specific for the human melanoma antigen a4 (mage-a4), with potential immunostimulatory and antineoplastic activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, mage-a4-specific tcr gene-transduced t-lymphocytes tbi-1201 binds to tumor cells expressing mage-a4. this may result in both an inhibition of growth and increased cell death for mage-a4-expressing tumor cells. the tumor-associated antigen mage-a4 is overexpressed by a variety of cancer cell types.|t-cell receptors specific for a human melanoma antigen a4 (mage-a4), with potential immunostimulatory and anti-cancer activities. upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, m|21.598000000000013|-3.767857142857139|14.172|17.262857142857147|15.002372527472529|15.7791625|20.267341772151894|18.96714285714285|15.77236263736264|13.063749999999999|85.1180024436664|91.22524239485473|25.054177215189874|29.885714285714286\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "any process that modulates the occurrence or rate of mesenchymal stem cell death by apoptotic process that contributes to the shaping of the nephron in the metanephros. [goc:mtg_apoptosis, goc:mtg_kidney_jan10]|any walk that changes the presence or rate of mesenchymal stem cell death by apoptosis walk that pay for the change of the nephron in the metanephros.  [ goc : mtg_apoptosis , goc : mtg_kidney_jan10 ]|34.58646551724141|82.87912162162164|12.03741379310345|6.295270270270269|11.536267741935484|9.099941666666666|16.488275862068964|10.062702702702701|13.060645161290324|7.306145833333332|76.64453405168562|62.58|22.351724137931036|16.048648648648648\n",
      "\n",
      "any process that modulates the occurrence or rate of mesenchymal stem cell death by apoptotic process that contributes to the shaping of the nephron in the metanephros. [goc:mtg_apoptosis, goc:mtg_kidney_jan10]|any process that modulates the occurrence or rate of mesenchymal stem cells death by programmed cell death that contributes to the shaping of the metanephros. [goc:mtg_apoptosis, goc:kidney_jan10]|34.58646551724141|39.59916666666669|12.03741379310345|11.089814814814819|11.536267741935484|11.222833333333334|16.488275862068964|15.314074074074071|13.060645161290324|11.975000000000001|76.64453405168562|69.96656701596841|22.351724137931036|20.214814814814815\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "cases of harm to a child caused by parents or other caregivers, defined by the federal government as: any recent act or failure to act on the part of a parent or caretaker which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act or failure to act which presents an imminent risk of serious harm.|cases of harm to a child caused by parents or other adult , choose by the agent government as : any recent act or failure to act on the part of a parent or official which results in death , serious physical or emotional harm , sexual use or mistreatment ; or an act or failure to act which greet an imminent risk of serious harm .|38.5758606557377|57.92802238805973|15.455819672131149|13.501865671641792|11.06259180327869|10.544886885245901|17.09245901639344|14.333134328358206|30.071967213114753|28.99098360655737|106.1095525859948|98.94766798666859|27.281967213114754|25.340298507462688\n",
      "\n",
      "cases of harm to a child caused by parents or other caregivers, defined by the federal government as: any recent act or failure to act on the part of a parent or caretaker which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act or failure to act which presents an imminent risk of serious harm.|any recent act or failure to act on the part of a parent or other caregiver which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act which presents an imminent risk of serious harm.|38.5758606557377|44.83000000000004|15.455819672131149|11.975000000000001|11.06259180327869|10.045007317073171|17.09245901639344|12.542|30.071967213114753|9.727804878048783|106.1095525859948|88.50148473330829|27.281967213114754|24.0\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the g2/m phase and cell death. this agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. docetaxel has been studied for use as a radiation-sensitizing agent. (nci04)|a semi-synthetic, second-generation texan make from a mix found in the european yew tree, taxus baccata.  docetaxel displays potent and broad antineoplastic properties; it binds to and change tubulin, thereby suppress tubule disassembly, which results in cell- cycle arrest at the g2/m phase and cell death.  this agent also suppresses pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by produce various mediators of the inflammatory phrase.  docetaxel has been thought to use as a radiation-sensitizing agent.  ( nci04)|7.490142857142899|28.12305617977529|16.388190476190477|13.75874157303371|14.051055555555555|13.484417730496455|20.110952380952387|17.59370786516854|17.08566666666666|11.606843971631207|91.76029239273379|86.2605770905806|27.196190476190477|24.19865168539326\n",
      "\n",
      "a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the g2/m phase and cell death. this agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. docetaxel has been studied for use as a radiation-sensitizing agent. (nci04)|a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad anti-cancer properties; it binds to and stabilizes tubulin|7.490142857142899|11.248534482758657|16.388190476190477|15.292586206896551|13.827855555555555|13.546112121212122|20.110952380952387|16.285517241379313|14.835666666666661|11.654545454545449|91.76029239273379|85.69119412168324|27.196190476190477|26.48965517241379\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "the number of days from the date of initial cancer diagnosis to the date of death.|the number of days from the date of sign cancer diagnosis to the date of death.|77.1025|87.67750000000001|4.492500000000003|3.017500000000002|7.390725|6.40385|-12.377500000000001|-13.48|5.998750000000001|5.115625000000001|44.250742366654144|38.32226702584281|13.200000000000001|10.700000000000001\n",
      "\n",
      "the number of days from the date of initial cancer diagnosis to the date of death.|the number of days from the initial cancer diagnosis to the date of death.|77.1025|72.83000000000003|4.492500000000003|4.840000000000003|7.390725|8.219166666666666|-12.377500000000001|-16.245714285714282|5.998750000000001|1.4740000000000002|44.250742366654144|44.250742366654144|13.200000000000001|14.228571428571428\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "a fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (tnf-alpha), with anti-inflammatory activity. upon administration, certolizumab binds to tnf-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering tnf-alpha inactive and inhibiting tnf-mediated inflammatory responses. tnf-alpha is a protein involved in inflammation, cell survival, and apoptosis.|a fab break of a cell, change monoclonal protein directed against the proinflammatory protein tumor death factor-alpha (tnf-alpha), with medicine activity.  upon justice, certolizumab binds to tnf-alpha, preventing the action of this protein with endogenous cell surface organ, thereby melt tnf-alpha inactive and suppress tnf-mediated inflammatory manner.  tnf-alpha is a protein involved in burning, cell survival, and apoptosis.|-22.29974137931032|26.640000000000015|19.97189655172414|13.270000000000003|15.69419230769231|13.143189696969698|23.280689655172413|16.72266666666667|24.67415384615385|10.57545454545454|97.70299368494294|91.22524239485473|32.69655172413793|28.666666666666664\n",
      "\n",
      "a fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (tnf-alpha), with anti-inflammatory activity. upon administration, certolizumab binds to tnf-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering tnf-alpha inactive and inhibiting tnf-mediated inflammatory responses. tnf-alpha is a protein involved in inflammation, cell survival, and apoptosis.|a protein complex involved in inflammation, cell survival, and apoptosis.|-22.29974137931032|24.100000000000023|19.97189655172414|11.14|15.156858974358977|13.957481818181819|23.280689655172413|-20.979999999999997|19.25748717948718|7.867272727272727|97.70299368494294|54.195869768830164|32.69655172413793|26.0\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "a monoclonal antibody directed against human hepatocyte growth factor receptor (hgfr or c-met), with potential antineoplastic activity. telisotuzumab binds to c-met, thereby preventing both c-met binding to its ligand, hgf and the subsequent activation of the hgf/c-met signaling pathway. this may cause cell death in c-met-expressing tumor cells. c-met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.|an immunologic factor protein directed against human hepatocyte growth factor organ (hgfr or c-met), with potential antineoplastic activity.  telisotuzumab binds to c-met, thereby preventing both c-met binding to its ligand, hgf and the subsequent beginning of the hgf/c-met tell path.  this may cause cell death in c-met-expressing growth cells.  c-met, an organ tyrosine kinase overexpressed or change in many growth, cell types, plays a key role in cancer cell growth, survival, growth, spread, and metastasis.|24.899486486486524|48.91638461538463|13.463081081081082|10.31194871794872|13.125982926829268|11.77366212624585|15.677297297297294|13.893333333333327|13.289024390243902|7.441345514950164|81.59433730351635|74.04565456527479|24.29837837837838|20.59897435897436\n",
      "\n",
      "a monoclonal antibody directed against human hepatocyte growth factor receptor (hgfr or c-met), with potential antineoplastic activity. telisotuzumab binds to c-met, thereby preventing both c-met binding to its ligand, hgf and the subsequent activation of the hgf/c-met signaling pathway. this may cause cell death in c-met-expressing tumor cells. c-met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.|a monoclonal antibody directed against human hepatocyte growth factor receptor, with potential anti-cancer activity. telisotuzumab binds to c-met, a protein molecule that is overexpressed or mutated in many tumor types, plays|24.899486486486524|-2.6587903225806144|13.463081081081082|17.48080645161291|12.933421951219513|13.767935294117647|15.677297297297294|18.08|13.289024390243902|13.390588235294118|81.59433730351635|93.86999999999999|24.29837837837838|29.425806451612903\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "death|death|121.22000000000003|121.22000000000003|-3.3999999999999986|-3.3999999999999986|0.0496|0.0496|-266.6|-266.6|2.620000000000001|2.620000000000001|0.0|0.0|0.4|0.4\n",
      "\n",
      "death|sudden death|121.22000000000003|77.90500000000002|-3.3999999999999986|2.890000000000004|0.0496|9.048633333333335|-266.6|-112.72|2.620000000000001|-1.0899999999999999|0.0|31.29|0.4|20.8\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "an inhibitor of protein tyrosine phosphatase (ptp) non-receptor type 11 (shp2; src homology region 2 domain phosphatase; ptpn11), with potential antineoplastic activity. upon oral administration, shp2 inhibitor tno155 binds to and inhibits shp2. this prevents shp2-mediated signaling, inhibits mapk signaling and prevents growth of shp2-expressing tumor cells. shp2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the ras-raf-erk signaling pathway. shp2 also regulates programmed cell death 1 (pd-1)-mediated signal transduction and is involved in immune checkpoint modulation.|a substance of protein tyrosine enzyme (ptp) non-receptor type 11 (shp2; src homology region 2 domain enzyme; ptpn11), with potential antineoplastic activity.  upon oral justice, shp2 substance tno155 binds to and suppress shp2.  this prevents shp2-mediated tell, suppress map tell and prevents growth of shp2-expressing tumor cells.  shp2, an oncoprotein overexpressed in a difference of cancer cell types, restrict cell survival, adaptation and increase through the beginning of the race-raf-erk tell path.  shp2 also restrict schedule, cell death 1 (pd-1) -mediated tell transduction and is having in immune stop revision.|29.477878787878808|64.03333333333335|12.791363636363638|8.220000000000002|15.764866451612905|13.907682683982685|19.10727272727273|14.384680851063838|16.484516129032258|9.952640692640692|84.73372056035305|78.74477315987392|25.86666666666667|22.43687943262411\n",
      "\n",
      "an inhibitor of protein tyrosine phosphatase (ptp) non-receptor type 11 (shp2; src homology region 2 domain phosphatase; ptpn11), with potential antineoplastic activity. upon oral administration, shp2 inhibitor tno155 binds to and inhibits shp2. this prevents shp2-mediated signaling, inhibits mapk signaling and prevents growth of shp2-expressing tumor cells. shp2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the ras-raf-erk signaling pathway. shp2 also regulates programmed cell death 1 (pd-1)-mediated signal transduction and is involved in immune checkpoint modulation.|an inhibitor of protein tyrosine phosphatase (ptp) non-receptor type 11 (shp2), an oncoprotein that is overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the ras|29.477878787878808|-1.8514705882352587|12.791363636363638|21.964117647058824|15.764866451612905|15.071544444444447|19.10727272727273|27.265882352941176|16.484516129032258|22.736666666666665|84.73372056035305|117.07645963215661|25.86666666666667|30.070588235294117\n",
      "\n",
      "death| death|121.22000000000003|162.505|-3.3999999999999986|-8.91|0.0496|14.311966666666669|-266.6|-130.36|2.620000000000001|-8.94|0.0|0.0|0.4|0.8\n",
      "\n",
      "chemical and/or pharmacological reactions of drugs in combination, including agonistic and antagonistic interactions.|chemical and/or pharmacological force of drugs in alliance, including agonistic and antagonistic action.|-27.531730769230762|-1.5009615384615245|18.71423076923077|15.083461538461542|16.427453846153846|16.427453846153846|1.9538461538461505|-3.926153846153852|22.387692307692312|17.67769230769231|62.58|58.53822981607831|27.21538461538462|24.13846153846154\n",
      "\n",
      "chemical and/or pharmacological reactions of drugs in combination, including agonistic and antagonistic interactions.|chemical and/or drug reactions of drugs in combination, including agonistic and antagonistic interactions.|-27.531730769230762|5.006730769230813|18.71423076923077|14.17576923076923|16.427453846153846|16.390128571428573|1.9538461538461505|-2.569230769230778|22.387692307692312|13.35785714285715|62.58|58.53822981607831|27.21538461538462|24.13846153846154\n",
      "\n",
      "chemical and/or pharmacological reactions of drugs in combination, including agonistic and antagonistic interactions.| chemical and/or pharmacological reactions of drugs|-27.531730769230762|30.53000000000003|18.71423076923077|10.740000000000002|16.427453846153846|17.84955|1.9538461538461505|-3.6457142857142912|22.387692307692312|10.24125|62.58|54.195869768830164|27.21538461538462|19.942857142857143\n",
      "\n",
      "the presenting findings of chd.|the greet findings of the child.|68.93750000000003|105.09000000000002|4.265000000000004|-0.6533333333333324|10.200500000000002|6.565766666666667|-86.648|-72.20666666666665|5.562000000000001|1.9800000000000004|31.29|22.125371183327072|17.0|7.866666666666666\n",
      "\n",
      "the presenting findings of chd.|the presenting findings of chd.|68.93750000000003|68.93750000000003|4.265000000000004|4.265000000000004|10.200500000000002|11.6803|-86.648|-85.472|5.562000000000001|1.2650000000000006|31.29|31.29|17.0|17.0\n",
      "\n",
      "the presenting findings of chd.| the presenting findings of a disease|68.93750000000003|78.87285714285717|4.265000000000004|3.997142857142858|10.200500000000002|11.9283|-86.648|-15.405714285714286|5.562000000000001|1.9987500000000011|31.29|54.195869768830164|17.0|19.942857142857143\n",
      "\n",
      "a pathologic stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site plus nodes on both sides of the diaphragm (iiie), or lymph nodes on both sides of the diaphragm plus spleen (iiis).|a clinical trait stage that name for cancer absorb node regions on both sides of the disk, or an extralymphatic organ or site plus nodes on both sides of the disk (eye), or lymph nodes on both sides of the disk plus spleen (yes).|66.96598837209305|80.67772727272727|9.260116279069766|7.471818181818183|12.746276744186048|11.919581818181818|14.401860465116275|11.401818181818184|21.867441860465114|19.73113636363636|69.96656701596841|54.195869768830164|17.90232558139535|14.254545454545454\n",
      "\n",
      "a pathologic stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site plus nodes on both sides of the diaphragm (iiie), or lymph nodes on both sides of the diaphragm plus spleen (iiis).|a pathologic stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site or more than one side of a body part.|66.96598837209305|62.837983870967776|9.260116279069766|8.345322580645163|12.746276744186048|9.364474999999999|14.401860465116275|7.647741935483875|21.867441860465114|7.029062499999998|69.96656701596841|66.37611354998121|17.90232558139535|17.81290322580645\n",
      "\n",
      "a pathologic stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site plus nodes on both sides of the diaphragm (iiie), or lymph nodes on both sides of the diaphragm plus spleen (iiis).| an|66.96598837209305|162.505|9.260116279069766|-8.91|12.746276744186048|14.311966666666669|14.401860465116275|-139.18|21.867441860465114|-13.65|69.96656701596841|0.0|17.90232558139535|0.8\n",
      "\n",
      "a response of 5 on a scale for the subject scoring of upset that ranges from 1: it does not upset me at all to 6: it makes me extremely upset.|a phrase of 5 on a scale for the term notch  shape that feed from 1: it does not shape me at all to 6: it makes me extremely upset.|90.12830645161293|109.23153225806453|4.538870967741939|1.874354838709678|9.24893870967742|9.24893870967742|2.1470967741935496|0.06064516129032427|10.630967741935486|9.111612903225804|62.58|31.29|16.52258064516129|8.780645161290323\n",
      "\n",
      "a response of 5 on a scale for the subject scoring of upset that ranges from 1: it does not upset me at all to 6: it makes me extremely upset.|a response of 5 on a scale for the subject scoring of upset that ranges from 1: it does not upset me at all to 6: i makes me extremely upset.|90.12830645161293|90.12830645161293|4.538870967741939|4.538870967741939|9.24893870967742|8.8710375|2.1470967741935496|2.1470967741935496|10.630967741935486|2.6134375|62.58|62.58|16.52258064516129|16.52258064516129\n",
      "\n",
      "a response of 5 on a scale for the subject scoring of upset that ranges from 1: it does not upset me at all to 6: it makes me extremely upset.| a response of 5 to a score of upset|90.12830645161293|112.08500000000001|4.538870967741939|0.11000000000000121|9.24893870967742|9.923918181818184|2.1470967741935496|-13.136|10.630967741935486|-3.5127272727272754|62.58|44.250742366654144|16.52258064516129|12.0\n",
      "\n",
      "an injury to the spinal cord occurring during labor and/or delivery. injury may include compression, partial or complete disruption of the cord.|an wrongdoing to the spinal cord appear during labor and/or act.  wrongdoing may include press, partial or complete delay of the cord.|41.72803030303032|81.3489855072464|9.260909090909092|3.817391304347826|13.340427272727274|11.56850579710145|-7.489090909090912|-9.97565217391304|15.260909090909088|4.92942028985507|62.58|57.127462747788826|24.75151515151515|20.457971014492756\n",
      "\n",
      "an injury to the spinal cord occurring during labor and/or delivery. injury may include compression, partial or complete disruption of the cord.|an injury to the spinal cord occurring during labor and/or delivery. injury may include compression, partial or total disruption of the cord.|41.72803030303032|41.72803030303032|9.260909090909092|9.260909090909092|12.794827272727273|12.94154927536232|-7.489090909090912|-8.023636363636363|9.760909090909088|6.567681159420289|62.58|62.58|24.75151515151515|24.75151515151515\n",
      "\n",
      "an injury to the spinal cord occurring during labor and/or delivery. injury may include compression, partial or complete disruption of the cord.| An injury to the spinal cord occurring during labor and/or delivery.|41.72803030303032|52.69500000000002|9.260909090909092|7.400000000000002|12.794827272727273|13.675823076923077|-7.489090909090912|-20.423333333333325|9.760909090909088|3.1961538461538446|62.58|54.195869768830164|24.75151515151515|22.400000000000002\n",
      "\n",
      "a pathologic finding about one or more characteristics of eyelid carcinoma, following the rules of the tnm ajcc v8 classification system as they pertain to staging of regional lymph nodes.|a finding finding about one or more property of eyelid cancer, following the rules of the tnm ajcc v8 restriction system as they pertain to staging of regional lymph nodes.|42.150000000000034|64.71000000000002|11.10666666666667|7.960000000000004|12.493166666666667|12.493166666666667|11.430666666666664|8.294666666666664|18.219|15.707|76.64453405168562|76.64453405168562|22.0|22.0\n",
      "\n",
      "a pathologic finding about one or more characteristics of eyelid carcinoma, following the rules of the tnm ajcc v8 classification system as they pertain to staging of regional lymph nodes.|a pathologic finding about one or more characteristics of eyelid cancer, following the rules of the cancer staging classification system as they pertain to staging of lymph nodes.|42.150000000000034|41.553571428571445|11.10666666666667|10.941428571428574|12.493166666666667|10.889493103448277|11.430666666666664|10.987142857142853|18.219|10.344482758620689|76.64453405168562|79.77416029015912|22.0|24.171428571428574\n",
      "\n",
      "a pathologic finding about one or more characteristics of eyelid carcinoma, following the rules of the tnm ajcc v8 classification system as they pertain to staging of regional lymph nodes.| a finding|42.150000000000034|119.19000000000003|11.10666666666667|-2.619999999999999|12.493166666666667|15.6774|11.430666666666664|-81.02666666666666|18.219|-7.654999999999999|76.64453405168562|31.29|22.0|14.533333333333331\n",
      "\n",
      "difficulty releasing one's grip associated with prolonged first handgrip relaxation times. [pmid:22987687, utoronto:htrang]|quality issue one 's grip unite with lengthen first handgrip easing times.  [ pmid: 22987687, utoronto: htrang]|-1.5009615384615245|80.20000000000003|15.083461538461542|4.308888888888891|15.262271428571431|15.743533333333334|4.667692307692306|-2.1822222222222187|17.731428571428573|7.436041666666668|62.58|58.53822981607831|27.21538461538462|19.15555555555556\n",
      "\n",
      "difficulty releasing one's grip associated with prolonged first handgrip relaxation times. [pmid:22987687, utoronto:htrang]|difficulty releasing one's grip associated with prolonged first handgrip relaxation times. [pmid:22987687, utoronto:htr]|-1.5009615384615245|5.006730769230813|15.083461538461542|14.17576923076923|15.262271428571431|15.587833333333334|4.667692307692306|3.763076923076923|17.731428571428573|14.975999999999999|62.58|62.58|27.21538461538462|27.21538461538462\n",
      "\n",
      "difficulty releasing one's grip associated with prolonged first handgrip relaxation times. [pmid:22987687, utoronto:htrang]| difficulty releasing one's grip associated with prolonged first handgrip relaxation times|-1.5009615384615245|11.355000000000018|15.083461538461542|14.656666666666666|15.262271428571431|15.212838461538462|4.667692307692306|14.533333333333339|17.731428571428573|14.416923076923077|62.58|82.78555852321104|27.21538461538462|28.13333333333334\n",
      "\n",
      "the attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules that contributes to the shaping of the heart. [goc:dph, goc:mtg_heart, pmid:16860783]|the joining of a cell, either to another cell or to a lie substrate such as the extracellular mold, via cell support unit that pay for the change of the heart.  [ goc : dph , goc : mtg_heart , pmid:16860783 ]|45.26235294117649|92.54273255813956|11.169411764705881|5.69267441860465|11.108466666666667|9.796071171171171|15.965882352941176|8.932093023255817|11.64333333333333|4.849639639639641|79.77416029015912|62.58|22.094117647058823|16.041860465116283\n",
      "\n",
      "the attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules that contributes to the shaping of the heart. [goc:dph, goc:mtg_heart, pmid:16860783]|the attachment of a cell, either to another cell or to an underlying substrate such as the matrix outside of cells. [goc:dph, goc:mtg_heart, pmid:16860783]|45.26235294117649|71.28000000000002|11.169411764705881|6.298333333333332|11.108466666666667|10.154248148148149|15.965882352941176|7.9183333333333366|11.64333333333333|7.125555555555557|79.77416029015912|62.58|22.094117647058823|18.133333333333333\n",
      "\n",
      "the attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules that contributes to the shaping of the heart. [goc:dph, goc:mtg_heart, pmid:16860783]| the attachment of a cell to another cell or to an underlying substrate|45.26235294117649|65.72500000000001|11.169411764705881|7.570000000000004|11.108466666666667|9.643833333333333|15.965882352941176|3.6371428571428552|11.64333333333333|4.91|79.77416029015912|62.58|22.094117647058823|17.02857142857143\n",
      "\n",
      "a country in western south america, bordering the pacific ocean at the equator, between colombia and peru. (nci)|a country in western south america, touch the pacific ocean at the circle, between colombia and peru.  ( nice)|33.20000000000002|61.32500000000002|10.864444444444448|7.190000000000001|10.223455555555555|8.262963157894736|-1.8555555555555578|-2.8459999999999965|6.620000000000001|4.886842105263156|69.96656701596841|66.37611354998121|25.822222222222223|22.0\n",
      "\n",
      "a country in western south america, bordering the pacific ocean at the equator, between colombia and peru. (nci)|a country in western south america, bordering the pacific ocean at the equator, between colombia and peru.|33.20000000000002|29.00750000000002|10.864444444444448|11.325000000000003|10.223455555555555|10.223455555555555|-1.8555555555555578|-3.3482352941176465|6.620000000000001|6.096666666666668|69.96656701596841|69.96656701596841|25.822222222222223|26.929411764705886\n",
      "\n",
      "a country in western south america, bordering the pacific ocean at the equator, between colombia and peru. (nci)| a|33.20000000000002|162.505|10.864444444444448|-8.91|10.223455555555555|14.311966666666669|-1.8555555555555578|-142.12|6.620000000000001|-15.219999999999999|69.96656701596841|0.0|25.822222222222223|0.8\n",
      "\n",
      "<2.5 - 2.0 mg/dl <0.8 - 0.6 mmol/l|< 2.5-2.0 mg/del < 0.8-0.6 mmol/l|184.061|177.41700000000003|-12.016|-11.188666666666666|19.9225|19.674500000000002|-165.155|-219.2266666666667|-5.597000000000001|-7.6259999999999994|0.0|0.0|0.6400000000000001|0.48\n",
      "\n",
      "<2.5 - 2.0 mg/dl <0.8 - 0.6 mmol/l|2.5-2.0 mg/dl 0.8 -0.6 mmol/l|184.061|171.98000000000002|-12.016|-10.48|19.9225|19.8729|-165.155|-265.424|-5.597000000000001|-4.893333333333334|0.0|0.0|0.6400000000000001|0.4\n",
      "\n",
      "<2.5 - 2.0 mg/dl <0.8 - 0.6 mmol/l| small;light|184.061|120.20500000000001|-12.016|-3.01|19.9225|19.5753|-165.155|-112.72|-5.597000000000001|0.4800000000000004|0.0|31.29|0.6400000000000001|20.8\n",
      "\n",
      "a collection of logically related observations with a common, specific topic that are normally collected for all subjects in a clinical investigation. note: the logic of the relationship may pertain to the scientific subject matter of the data or to its role in the trial. example domains include laboratory test results (lb), adverse events (ae), concomitant medications (cm). [after sdtm implementation guide version 3.2, cdisc.org] see also general observation class.|a grouping of logically related attention with a common, fact topic that are normally collected for all term in a clinical work.  note: the logic of the relation may pertain to the scientific term matter of the data or to its role in the trial.  example class includes region test results (lb), adverse events (ae), happening therapy (cm).  [ after sdtm act guide version 3.2, cdisc.org] see also general attention class.|32.31928571428574|64.63202702702705|11.235714285714284|6.8706949806949815|12.62507142857143|11.161610502283105|4.084|-0.3481081081081143|13.157714285714285|6.203196347031962|70.9590501627523|64.77645405546679|24.57142857142857|20.444787644787645\n",
      "\n",
      "a collection of logically related observations with a common, specific topic that are normally collected for all subjects in a clinical investigation. note: the logic of the relationship may pertain to the scientific subject matter of the data or to its role in the trial. example domains include laboratory test results (lb), adverse events (ae), concomitant medications (cm). [after sdtm implementation guide version 3.2, cdisc.org] see also general observation class.|a collection of logically related observations with a common, specific topic that are normally collected for all subjects in an clinical investigation. note: the logic of the relationship may pertain to the scientific subject matter or the role in the trial. example domains include laboratory test results (lb), adverse events (ae),|32.31928571428574|27.015294117647073|11.235714285714284|13.714509803921569|12.451471428571429|12.479953846153846|4.084|15.331764705882353|11.407714285714285|9.888076923076923|70.9590501627523|92.11526583579942|24.57142857142857|27.192156862745094\n",
      "\n",
      "a collection of logically related observations with a common, specific topic that are normally collected for all subjects in a clinical investigation. note: the logic of the relationship may pertain to the scientific subject matter of the data or to its role in the trial. example domains include laboratory test results (lb), adverse events (ae), concomitant medications (cm). [after sdtm implementation guide version 3.2, cdisc.org] see also general observation class.| a collection|32.31928571428574|90.99000000000004|11.235714285714284|1.3133333333333361|12.62507142857143|15.6774|4.084|-75.14666666666666|13.157714285714285|-4.122500000000002|70.9590501627523|31.29|24.57142857142857|14.533333333333331\n",
      "\n",
      "a neuroendocrine tumor arising from the wall of the appendix, producing glucagon-like peptides. morphologically, it is characterized by the presence of neoplastic cells forming tubular or trabecular patterns.|a neoplastic process growth protest from the wall of the process, change glucagon-like amide.  morphologically, it is distinguished by the presence of neoplastic cells forming tubular or trabecular match.|10.033095238095257|41.58500000000001|14.17857142857143|9.943333333333332|11.433975862068966|11.536267741935484|6.295714285714286|4.699999999999999|14.404827586206899|12.300967741935487|69.96656701596841|65.13532912329528|25.161904761904765|21.333333333333336\n",
      "\n",
      "a neuroendocrine tumor arising from the wall of the appendix, producing glucagon-like peptides. morphologically, it is characterized by the presence of neoplastic cells forming tubular or trabecular patterns.|a neuroendocrine tumor arising from the wall of the appendix, producing a molecule of protein building blocks. morphologically, it is characterized by the presence of certain genetic markers.|10.033095238095257|28.16166666666669|14.17857142857143|11.650000000000002|11.433975862068966|10.649759770114944|6.295714285714286|2.935714285714294|14.404827586206899|9.551954022988507|69.96656701596841|67.59412548439398|25.161904761904765|23.733333333333334\n",
      "\n",
      "a neuroendocrine tumor arising from the wall of the appendix, producing glucagon-like peptides. morphologically, it is characterized by the presence of neoplastic cells forming tubular or trabecular patterns.| a skin tumor of the outer lining of the front of the pituitary gland|10.033095238095257|78.81000000000003|14.17857142857143|5.993333333333336|11.433975862068966|11.338225000000001|6.295714285714286|2.218666666666664|14.404827586206899|3.3493749999999984|69.96656701596841|62.58|25.161904761904765|16.666666666666668\n",
      "\n",
      "epithelial discoidin domain-containing receptor 1 (913 aa, ~101 kda) is encoded by the human ddr1 gene. this protein plays a role in tyrosine phosphorylation, extracellular matrix catabolism and signal transduction.|epithelial receptor domain-containing organ 1 (913 aa, ~101 code) is converted by the human ddr1 gene.  this protein plays a role in tyrosine phosphorylation, extracellular matrix catabolism and tell transduction.|33.125|43.52086021505377|11.123333333333338|9.756129032258066|16.12046129032258|15.021191666666668|6.856000000000005|6.065806451612904|13.516451612903225|9.955520833333331|67.59412548439398|65.13532912329528|22.666666666666668|20.907526881720432\n",
      "\n",
      "epithelial discoidin domain-containing receptor 1 (913 aa, ~101 kda) is encoded by the human ddr1 gene. this protein plays a role in tyrosine phosphorylation, extracellular matrix catabolism and signal transduction.|this protein plays a role in tyrosine phosphorylation, matrix chemistry and signal transduction.|33.125|31.037500000000023|11.123333333333338|10.545000000000002|16.12046129032258|14.134414285714287|6.856000000000005|-7.092307692307692|13.516451612903225|9.993571428571428|67.59412548439398|58.53822981607831|22.666666666666668|24.13846153846154\n",
      "\n",
      "epithelial discoidin domain-containing receptor 1 (913 aa, ~101 kda) is encoded by the human ddr1 gene. this protein plays a role in tyrosine phosphorylation, extracellular matrix catabolism and signal transduction.| This protein is encoded by the human ddr1 gene. It plays a role in tyrosine phosphorylation.|33.125|76.671568627451|11.123333333333338|3.9729411764705915|16.12046129032258|12.706322222222223|6.856000000000005|-25.2564705882353|13.516451612903225|1.7183333333333337|67.59412548439398|40.39521630094336|22.666666666666668|14.031372549019608\n",
      "\n",
      "a collection of classification entities in a digital content archive.|a grouping of restriction entities in a digital content archive.|15.640000000000015|41.02000000000004|12.320000000000004|8.780000000000001|13.6065|13.6065|-23.919999999999995|-26.86|11.359000000000002|9.004000000000001|54.195869768830164|54.195869768830164|26.0|26.0\n",
      "\n",
      "a collection of classification entities in a digital content archive.|a collection of class entities in a digital content archive.|15.640000000000015|49.48000000000002|12.320000000000004|7.600000000000001|13.6065|12.522027272727273|-23.919999999999995|-28.624|11.359000000000002|3.15727272727273|54.195869768830164|49.473833993334296|26.0|22.0\n",
      "\n",
      "a collection of classification entities in a digital content archive.| class|15.640000000000015|162.505|12.320000000000004|-8.91|13.6065|14.311966666666669|-23.919999999999995|-130.36|11.359000000000002|-8.94|54.195869768830164|0.0|26.0|0.8\n",
      "\n",
      "a potency unit for measuring infectious activity of a biologic product or an infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent embryo infective dose.(nci)|a power unit for being an infectious activity of a biologic product or an infectious agent harmony, equal to the power at which one dose of infectious material contains one 50 percent plant infective dose.  ( nice)|22.868235294117653|49.518421052631595|14.292941176470588|11.07263157894737|14.146723529411764|11.503098198198199|14.755294117647058|11.809473684210527|21.197941176470586|6.886396396396396|96.44225707644962|91.22524239485473|29.152941176470588|25.494736842105265\n",
      "\n",
      "a potency unit for measuring infectious activity of a biologic product or an infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent embryo infective dose.(nci)|a unit for measuring infectious activity of a biologic product or an infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent embryo infective dose.(nci)|22.868235294117653|26.014772727272742|14.292941176470588|13.729848484848485|14.146723529411764|14.146723529411764|14.755294117647058|14.133333333333333|21.197941176470586|20.366764705882353|96.44225707644962|93.86999999999999|29.152941176470588|28.418181818181814\n",
      "\n",
      "a potency unit for measuring infectious activity of a biologic product or an infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent embryo infective dose.(nci)| a unit of measurement for measuring infectious activity of a biological product or an infectious agent preparation equal to the unit of measurement at which one dose of infectious material contains one 50 percent embryo infective dose|22.868235294117653|10.196578947368437|14.292941176470588|21.277368421052632|14.146723529411764|14.478079487179487|14.755294117647058|23.003157894736837|21.197941176470586|22.22384615384616|96.44225707644962|136.38994794338765|29.152941176470588|35.2\n",
      "\n",
      "information collected directly from a patient that typically includes subjective feelings regarding symptoms, functions in daily life, physical, mental, emotional, spiritual, and social well being, and satisfaction with his/her health care.|collection collected directly from a case that typically includes subjective feelings refer symptoms, serve in daily life, physical, mental, emotional, spiritual, and social well being, and change with his/her health care.|10.986370967741976|30.08959677419358|15.577580645161287|12.913064516129037|13.6121375|12.131825000000001|20.735483870967748|17.321290322580644|24.1546875|21.505312499999995|98.94766798666859|91.22524239485473|32.00645161290323|28.135483870967747\n",
      "\n",
      "information collected directly from a patient that typically includes subjective feelings regarding symptoms, functions in daily life, physical, mental, emotional, spiritual, and social well being, and satisfaction with his/her health care.|information collected directly from a patient that typically includes subjective feelings regarding symptoms, functions in daily life, physical, mental, emotional, spiritual, and satisfaction with his/her health care.|10.986370967741976|5.132500000000022|15.577580645161287|15.897222222222226|13.6121375|13.611906896551725|20.735483870967748|19.88740740740741|24.1546875|15.704137931034488|98.94766798666859|93.86999999999999|32.00645161290323|32.06666666666666\n",
      "\n",
      "information collected directly from a patient that typically includes subjective feelings regarding symptoms, functions in daily life, physical, mental, emotional, spiritual, and social well being, and satisfaction with his/her health care.| information|10.986370967741976|35.60500000000002|15.577580645161287|8.790000000000003|13.6121375|19.5753|20.735483870967748|-112.72|24.1546875|0.4800000000000004|98.94766798666859|31.29|32.00645161290323|20.8\n",
      "\n",
      "the nci term type designation for the us brand name of a drug. a brand name may be trademarked.|the nazi term type decision for the us brand name of a drug.  a brand name may be filed.|89.09087719298246|107.00833333333333|2.4063157894736875|-0.00999999999999801|9.925068421052632|9.493666666666666|-22.907368421052634|-24.113999999999997|1.912105263157894|-2.082666666666668|25.548178017228544|25.548178017228544|6.7438596491228076|6.666666666666668\n",
      "\n",
      "the nci term type designation for the us brand name of a drug. a brand name may be trademarked.|the nci term type designation for the us brand name of a drug. a brandname may be trademarked.|89.09087719298246|83.24500000000002|2.4063157894736875|3.1388888888888893|9.925068421052632|10.599054385964912|-22.907368421052634|-23.85333333333333|1.912105263157894|0.576666666666668|25.548178017228544|31.29|6.7438596491228076|9.066666666666666\n",
      "\n",
      "the nci term type designation for the us brand name of a drug. a brand name may be trademarked.| the national science foundation term type designation for the u.s. government agency|89.09087719298246|46.2520512820513|2.4063157894736875|7.884615384615387|9.925068421052632|14.481614285714286|-22.907368421052634|-34.83692307692309|1.912105263157894|10.465714285714284|25.548178017228544|44.250742366654144|6.7438596491228076|20.194871794871798\n",
      "\n",
      "theoretical representations that simulate the behavior or activity of the neurological system, processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment.|a theoretical activity that re-create the trait or activity of the neurological system, transform, or process; includes the use of mathematical status, computers, and other electronic equipment.|-24.367692307692295|5.132500000000022|19.88769230769231|15.897222222222226|14.035715384615385|14.048157142857145|17.938461538461535|14.660740740740742|23.27192307692308|19.652499999999996|88.50148473330829|85.69119412168324|29.81538461538462|27.622222222222224\n",
      "\n",
      "theoretical representations that simulate the behavior or activity of the neurological system, processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment.|theoretical representations that simulate the behavior or activity of the brain system, processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment.|-24.367692307692295|-11.352307692307647|19.88769230769231|18.072307692307692|14.035715384615385|13.078322222222225|17.938461538461535|16.58153846153846|23.27192307692308|14.801111111111112|88.50148473330829|85.69119412168324|29.81538461538462|28.276923076923072\n",
      "\n",
      "theoretical representations that simulate the behavior or activity of the neurological system, processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment.| representations|-24.367692307692295|-6.694999999999993|19.88769230769231|14.690000000000001|14.035715384615385|19.5753|17.938461538461535|-100.96000000000001|23.27192307692308|6.760000000000002|88.50148473330829|31.29|29.81538461538462|20.8\n",
      "\n",
      "human nr1h4 wild-type allele is located in the vicinity of 12q23.1 and is approximately 91 kb in length. this allele, which encodes bile acid receptor protein, plays a role in both the metabolism of bile acids and ligand-dependent transcriptional regulation.|human nr1h4 wild-type gene is located in the section of 12q23. 1 and is approximately 91 kb in length.  this gene, which convert bile acid organ protein, plays a role in both the metabolism of bile acids and ligand-dependent transcriptional control.|50.75|73.30607142857146|8.665000000000003|5.643095238095238|13.700957142857144|13.15369090909091|2.593|0.9295238095238112|12.956428571428567|5.693181818181817|62.58|58.53822981607831|20.0|17.53333333333333\n",
      "\n",
      "human nr1h4 wild-type allele is located in the vicinity of 12q23.1 and is approximately 91 kb in length. this allele, which encodes bile acid receptor protein, plays a role in both the metabolism of bile acids and ligand-dependent transcriptional regulation.|normal human nr1h4 gene is located in the vicinity of chromosome location, 12q23.1, and is about 91 kilobases in length. this gene, which encodes bile acid receptor protein, plays a role in both the metabolism of amino acids and|50.75|56.97846153846157|8.665000000000003|8.541538461538462|13.700957142857144|13.313|2.593|6.0276923076923055|12.956428571428567|10.471500000000002|62.58|69.96656701596841|20.0|20.58461538461539\n",
      "\n",
      "human nr1h4 wild-type allele is located in the vicinity of 12q23.1 and is approximately 91 kb in length. this allele, which encodes bile acid receptor protein, plays a role in both the metabolism of bile acids and ligand-dependent transcriptional regulation.| human nr1h4 wild-type allele is located in the vicinity of 12q23.1 and is approximately 91 kb in length. This allele, which encodes the bile acid receptor protein is involved in the metabolism of bile acids and ligand-dependent transcriptional regulation|50.75|47.366666666666674|8.665000000000003|9.965000000000003|13.700957142857144|14.250341860465117|2.593|9.699000000000002|12.956428571428567|12.760465116279072|62.58|74.48509850970193|20.0|22.333333333333336\n",
      "\n",
      "a characterization of the extent of any localized or abnormal change in the structure of part of an organ or tissue. example(s): typically provided as a set of two measurements (two longest perpendicular measurements) and/or volume measurement. other name(s): note(s):|an acting of the extent of any stage or abnormal change in the structure of part of an organ or tissue.  example (s): typically provided as a set of two measurements (two longest face measurements) and/or volume measurement.  other name (s): note (s):|28.331666666666678|63.770000000000024|12.620000000000001|8.091111111111115|11.008583333333334|10.5105|11.462999999999997|7.31466666666666|11.023916666666665|4.709666666666664|80.79043260188672|72.26115969177356|25.333333333333336|20.222222222222225\n",
      "\n",
      "a characterization of the extent of any localized or abnormal change in the structure of part of an organ or tissue. example(s): typically provided as a set of two measurements (two longest perpendicular measurements) and/or volume measurement. other name(s): note(s):|a characterization of the extent of any localized or abnormal change in the structure of part of an organ or tissue. example(s): typically provided as a set of two measurements (two longest measurements) and/or volume measurement.|28.331666666666678|37.20500000000001|12.620000000000001|11.051111111111112|11.008583333333334|10.649584684684685|11.462999999999997|7.346666666666671|11.023916666666665|8.923153153153155|80.79043260188672|72.26115969177356|25.333333333333336|22.57777777777778\n",
      "\n",
      "a characterization of the extent of any localized or abnormal change in the structure of part of an organ or tissue. example(s): typically provided as a set of two measurements (two longest perpendicular measurements) and/or volume measurement. other name(s): note(s):| a characterization of the extent of any localized or abnormal change in the structure of part of a human organ or tissue|28.331666666666678|43.716086956521764|12.620000000000001|12.875652173913043|11.008583333333334|10.74815|11.462999999999997|12.69565217391304|11.023916666666665|10.39125|80.79043260188672|93.86999999999999|25.333333333333336|24.85217391304348\n",
      "\n",
      "a term coined from a contraction of nutrition and pharmaceutical to mean a component of food that has bioactive effects. it is used in marketing and has no regulatory definition.|a term coined from a decrease of science and medicine to mean a part of food that has bioactive effects.  it is used to change and has no regulatory distinctness.|55.685|84.45634408602152|7.97666666666667|4.046451612903226|9.1175|7.7145172043010755|-0.39599999999999724|-3.6077419354838725|9.149000000000001|3.6402150537634412|57.127462747788826|51.09635603445709|17.333333333333332|14.455913978494625\n",
      "\n",
      "a term coined from a contraction of nutrition and pharmaceutical to mean a component of food that has bioactive effects. it is used in marketing and has no regulatory definition.|a term coined from a contraction of nutrition and pharmaceutical terms that have active effects. it is used in marketing and has no regulatory definition.|55.685|52.864666666666665|7.97666666666667|7.9559999999999995|9.1175|9.532135897435897|-0.39599999999999724|-4.7087999999999965|9.149000000000001|6.272179487179486|57.127462747788826|54.195869768830164|17.333333333333332|17.733333333333334\n",
      "\n",
      "a term coined from a contraction of nutrition and pharmaceutical to mean a component of food that has bioactive effects. it is used in marketing and has no regulatory definition.| a made up term|55.685|134.08000000000004|7.97666666666667|-4.199999999999999|9.1175|9.197433333333334|-0.39599999999999724|-45.087999999999994|9.149000000000001|-8.225|57.127462747788826|0.0|17.333333333333332|2.0\n",
      "\n",
      "a question about how often an individual has or had problems with sexual interest or activity.|a question about how often an organism has or had problems with sexual interest or activity.|34.80250000000001|45.377500000000026|10.392500000000002|8.917500000000004|9.364474999999999|9.364474999999999|-7.967500000000001|-8.7025|9.53125|8.942499999999999|62.58|62.58|23.200000000000003|23.200000000000003\n",
      "\n",
      "a question about how often an individual has or had problems with sexual interest or activity.|a question about how often an individual has/had problems with sexual interest or activity.|34.80250000000001|18.44428571428574|10.392500000000002|12.425714285714289|9.364474999999999|9.954550000000001|-7.967500000000001|-9.105714285714278|9.53125|5.236875000000001|62.58|66.37611354998121|23.200000000000003|28.51428571428572\n",
      "\n",
      "a question about how often an individual has or had problems with sexual interest or activity.||34.80250000000001|205.82000000000002|10.392500000000002|-15.2|9.364474999999999|19.476100000000002|-7.967500000000001|-290.12|9.53125|-16.22|62.58|0.0|23.200000000000003|0.4\n",
      "\n",
      "a phenobarbitol test system is a device intended to measure phenobarbital, an antiepileptic and sedative-hypnotic drug, in human specimens. measurements obtained by this device are used in the diagnosis and treatment of phenobarbital use or overdose and in monitoring levels of phenobarbital to ensure appropriate therapy.|a pharmacologic substance test system is a device convey to measure barbiturate, a medicine and sedative drug, in human samples.  measurements exist by this device are used in the diagnosis and care of barbiturate use or drug and in observe levels of barbiturate to ensure assume therapy.|3.6803623188405936|40.78250000000003|16.55521739130435|11.54583333333333|12.193163829787235|11.667183333333334|16.10347826086956|11.022499999999997|17.577872340425536|9.923749999999998|86.63808689023553|84.73372056035305|26.133333333333333|24.733333333333334\n",
      "\n",
      "a phenobarbitol test system is a device intended to measure phenobarbital, an antiepileptic and sedative-hypnotic drug, in human specimens. measurements obtained by this device are used in the diagnosis and treatment of phenobarbital use or overdose and in monitoring levels of phenobarbital to ensure appropriate therapy.|a drug test system is a device intended to measure phenobarbital, an antiepileptic and sedative-hypnotic drug, in human specimens. measurements obtained by this device are used in the diagnosis and treatment of this drug's use or overdose and in|3.6803623188405936|28.68865384615387|16.55521739130435|14.102179487179487|12.193163829787235|11.58549512195122|16.10347826086956|16.180512820512824|17.577872340425536|12.255121951219515|86.63808689023553|85.69119412168324|26.133333333333333|23.184615384615388\n",
      "\n",
      "a phenobarbitol test system is a device intended to measure phenobarbital, an antiepileptic and sedative-hypnotic drug, in human specimens. measurements obtained by this device are used in the diagnosis and treatment of phenobarbital use or overdose and in monitoring levels of phenobarbital to ensure appropriate therapy.| a drug test system is a device intended to measure a drug in bodily fluid|3.6803623188405936|68.9825|16.55521739130435|7.612500000000001|12.193163829787235|11.910288235294118|16.10347826086956|3.5500000000000007|17.577872340425536|3.9705882352941195|86.63808689023553|76.64453405168562|26.133333333333333|21.400000000000002\n",
      "\n",
      "a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the g2/m phase and cell death. this agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. docetaxel has been studied for use as a radiation-sensitizing agent. (nci04)|a semi-synthetic, second-generation texan make from a mix found in the european yew tree, taxus baccata.  docetaxel displays potent and broad antineoplastic properties; it binds to and change tubulin, thereby suppress tubule disassembly, which results in cell- cycle arrest at the g2/m phase and cell death.  this agent also suppresses pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by produce various mediators of the inflammatory phrase.  docetaxel has been thought to use as a radiation-sensitizing agent.  ( nci04)|7.490142857142899|28.12305617977529|16.388190476190477|13.75874157303371|14.051055555555555|13.484417730496455|20.110952380952387|17.59370786516854|17.08566666666666|11.606843971631207|91.76029239273379|86.2605770905806|27.196190476190477|24.19865168539326\n",
      "\n",
      "a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the g2/m phase and cell death. this agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. docetaxel has been studied for use as a radiation-sensitizing agent. (nci04)|a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad anti-cancer properties; it binds to and stabilizes tubulin|7.490142857142899|11.248534482758657|16.388190476190477|15.292586206896551|13.827855555555555|13.546112121212122|20.110952380952387|16.285517241379313|14.835666666666661|11.654545454545449|91.76029239273379|85.69119412168324|27.196190476190477|26.48965517241379\n",
      "\n",
      "a semi-synthetic, second-generation taxane derived from a compound found in the european yew tree, taxus baccata. docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the g2/m phase and cell death. this agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (vegf) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. docetaxel has been studied for use as a radiation-sensitizing agent. (nci04)| a semi-synthetic antineoplastic|7.490142857142899|-29.87499999999997|16.388190476190477|18.420000000000005|13.827855555555555|17.092433333333332|20.110952380952387|-29.9|14.835666666666661|5.120000000000001|91.76029239273379|44.250742366654144|27.196190476190477|21.6\n",
      "\n",
      "a glucose-induced hyperinsulinemia, a marker of insulin-resistant state. it is a mechanism to compensate for reduced sensitivity to insulin.|a glucose-induced hyperinsulinemia, a marker of insulin-resistant state.  it is a device to pay for the reduced ability to hormone.|-8.867017543859646|26.50142857142862|16.06947368421053|11.301904761904762|12.428252380952381|11.56850579710145|-8.981052631578947|-11.205714285714286|10.061428571428571|4.315072463768114|54.195869768830164|51.09635603445709|21.480701754385965|18.038095238095238\n",
      "\n",
      "a glucose-induced hyperinsulinemia, a marker of insulin-resistant state. it is a mechanism to compensate for reduced sensitivity to insulin.|a glucose-induced hyperinsulinemia, a marker of insulin-resistant state. it isa mechanism to compensate for reduced sensitivity to insulin.|-8.867017543859646|-20.154999999999973|16.06947368421053|17.561111111111114|12.428252380952381|13.758461904761907|-8.981052631578947|-9.153333333333329|10.061428571428571|8.535714285714285|54.195869768830164|57.127462747788826|21.480701754385965|24.622222222222224\n",
      "\n",
      "a glucose-induced hyperinsulinemia, a marker of insulin-resistant state. it is a mechanism to compensate for reduced sensitivity to insulin.| hyperinsulinemia is a state|-8.867017543859646|32.56000000000003|16.06947368421053|9.96|12.428252380952381|11.8291|-8.981052631578947|-29.799999999999997|10.061428571428571|1.9800000000000004|54.195869768830164|31.29|21.480701754385965|10.0\n",
      "\n",
      "lim/homeobox protein lhx2 (406 aa, ~44 kda) is encoded by the human lhx2 gene. this protein plays a role in both dna binding and transcriptional regulation.|lim/homeobox bioactive substance lhx2 (406 aa, ~44 code) is converted by the human lhx2 gene.  this protein plays a role in both dna binding and transcriptional control.|77.64602564102567|85.56880952380955|4.582307692307694|3.6428571428571423|14.83276666666667|15.005621839080462|-4.527692307692313|-1.894285714285715|7.125555555555557|5.654022988505748|51.09635603445709|54.195869768830164|15.774358974358975|16.590476190476192\n",
      "\n",
      "lim/homeobox protein lhx2 (406 aa, ~44 kda) is encoded by the human lhx2 gene. this protein plays a role in both dna binding and transcriptional regulation.|lim/homeobox protein lhx2 (406 amino acids, 44 kilodaltons) is encoded by a human gene lhx2 protein. this protein is involved in both dna binding and transcription.|77.64602564102567|64.63064102564107|4.582307692307694|6.3976923076923065|14.247951851851854|14.814076190476193|-4.527692307692313|-2.4923076923076977|7.125555555555557|5.777380952380952|51.09635603445709|62.58|15.774358974358975|21.92820512820513\n",
      "\n",
      "lim/homeobox protein lhx2 (406 aa, ~44 kda) is encoded by the human lhx2 gene. this protein plays a role in both dna binding and transcriptional regulation.| lim/homeobox protein lhx2 (376 aa, 44 kda) is encoded by the human lhx2 gene. It plays a role in both dna binding and transcriptional regulation.|77.64602564102567|84.15371794871797|4.582307692307694|3.674615384615386|14.247951851851854|14.25014761904762|-4.527692307692313|-6.563076923076931|7.125555555555557|2.9177380952380965|51.09635603445709|47.79626449838941|15.774358974358975|14.235897435897437\n",
      "\n",
      "obsolete. (was not defined before being made obsolete). [goc:go_curators]|obsolete.  ( was not choose before being made obsolete).  [ goc: go_curators]|15.79000000000002|87.28404761904761|11.802222222222223|2.2442857142857164|11.696833333333334|11.6803|-56.199999999999996|-36.54857142857142|7.554666666666666|3.2275000000000027|44.250742366654144|40.39521630094336|27.866666666666664|16.152380952380952\n",
      "\n",
      "obsolete. (was not defined before being made obsolete). [goc:go_curators]|obsolete. (was not defined before being made obsolete)|15.79000000000002|44.150000000000006|11.802222222222223|8.094999999999999|11.696833333333334|10.877477777777777|-56.199999999999996|-38.72|7.554666666666666|4.370000000000001|44.250742366654144|49.473833993334296|27.866666666666664|26.6\n",
      "\n",
      "obsolete. (was not defined before being made obsolete). [goc:go_curators]| obsolete|15.79000000000002|77.90500000000002|11.802222222222223|2.890000000000004|11.696833333333334|19.5753|-56.199999999999996|-121.53999999999999|7.554666666666666|-4.229999999999997|44.250742366654144|31.29|27.866666666666664|20.8\n",
      "\n",
      "<p>codes representing a service or product that is being invoiced (billed). the code can represent such concepts as \"office visit\", \"drug x\", \"wheelchair\" and other billable items such as taxes, service charges and discounts.</p>|< p > codes permute a service or product that is being charged (post).  the code can permute such concepts as `` office visit '', `` drug x '', `` chair '' and other billable fact such as taxes, service charges and discounts.  < /p >|51.01401960784315|100.70750000000001|8.959411764705884|3.1875000000000036|12.058373684210528|12.455658333333334|7.778823529411767|4.285|10.876315789473686|1.7418750000000003|78.74477315987392|67.59412548439398|26.886274509803926|18.06666666666667\n",
      "\n",
      "<p>codes representing a service or product that is being invoiced (billed). the code can represent such concepts as \"office visit\", \"drug x\", \"wheelchair\" and other billable items such as taxes, service charges and discounts.</p>|a service or product that is being invoiced (billed). the code can represent such concepts as \"office visit), \"drug x\", \"wheelchair\" and other billable items such as taxes, service charges and discounts.|51.01401960784315|58.53333333333336|8.959411764705884|7.745000000000001|12.058373684210528|10.40240303030303|7.778823529411767|4.038750000000004|10.876315789473686|6.906363636363636|78.74477315987392|74.48509850970193|26.886274509803926|25.516666666666666\n",
      "\n",
      "<p>codes representing a service or product that is being invoiced (billed). the code can represent such concepts as \"office visit\", \"drug x\", \"wheelchair\" and other billable items such as taxes, service charges and discounts.</p>| codes representing a service or product|51.01401960784315|66.7871428571429|8.959411764705884|5.682857142857145|12.058373684210528|13.902050000000001|7.778823529411767|-12.885714285714286|10.876315789473686|3.7650000000000006|78.74477315987392|54.195869768830164|26.886274509803926|19.942857142857143\n",
      "\n",
      "any process involved in the transition from the initiation to the elongation phases of transcription by rna polymerase ii, generally including a conformational change from the initiation conformation to the elongation conformation. promoter clearance often involves breaking contact with transcription factors involved only in the initiation phase and making contacts with elongation specific factors. [goc:txnoh, pmid:15020047]|any walk have in the switch from the casing  the addition stage of transcription by rna enzyme ii, generally including a conformational change from the causing balance to the addition balance.  booker room often absorbs breaking contact with transcription lend involved only in the causing phase and making lenses with addition fact lend.  [ goc: txnoh, pmid: 15020047]|11.134761904761916|61.376994535519145|16.343571428571433|9.749836065573774|13.72047894736842|11.3372|23.307857142857145|15.228196721311473|18.31315789473684|8.433999999999997|103.77718969022045|88.50148473330829|31.03809523809524|23.871038251366123\n",
      "\n",
      "any process involved in the transition from the initiation to the elongation phases of transcription by rna polymerase ii, generally including a conformational change from the initiation conformation to the elongation conformation. promoter clearance often involves breaking contact with transcription factors involved only in the initiation phase and making contacts with elongation specific factors. [goc:txnoh, pmid:15020047]|any process involved in the transition from initiation to the elongation phases of transcription by rna polymerase ii, generally including a conformational change from the initial state of the cell's protein maker. promoter clearance often involves breaking contact with transcription factors involved only in one or two phases|11.134761904761916|22.087500000000034|16.343571428571433|16.140833333333333|13.72047894736842|12.907822448979593|23.307857142857145|22.089166666666667|18.31315789473684|17.638163265306126|103.77718969022045|112.8176994092682|31.03809523809524|31.266666666666666\n",
      "\n",
      "any process involved in the transition from the initiation to the elongation phases of transcription by rna polymerase ii, generally including a conformational change from the initiation conformation to the elongation conformation. promoter clearance often involves breaking contact with transcription factors involved only in the initiation phase and making contacts with elongation specific factors. [goc:txnoh, pmid:15020047]| the process of going from initiation to elongation|11.134761904761916|47.30000000000004|16.343571428571433|8.89777777777778|13.72047894736842|12.0275|23.307857142857145|-4.142222222222216|18.31315789473684|4.765000000000001|103.77718969022045|62.58|31.03809523809524|21.37777777777778\n",
      "\n",
      "the anterior portion of a deep fissure or furrow on the medial surface of the cerebral cortex.|the tooth gift of a deep crack or cut on the medial surface of the cerebral cortex.|63.84279411764709|88.72514705882354|6.466176470588238|2.995588235294118|10.981464705882354|7.266170588235294|-7.844705882352944|-11.649411764705881|8.403529411764705|5.355882352941176|62.58|44.250742366654144|22.223529411764705|12.811764705882354\n",
      "\n",
      "the anterior portion of a deep fissure or furrow on the medial surface of the cerebral cortex.|the front portion of a deep fissure or furrow on the medial surface of the brain.|63.84279411764709|87.67750000000001|6.466176470588238|3.017500000000002|10.981464705882354|8.702217647058824|-7.844705882352944|-12.377500000000001|8.403529411764705|1.105882352941176|62.58|49.473833993334296|22.223529411764705|15.700000000000001\n",
      "\n",
      "the anterior portion of a deep fissure or furrow on the medial surface of the cerebral cortex.| the front of the brain|63.84279411764709|130.245|6.466176470588238|-3.416666666666666|10.981464705882354|8.495128571428573|-7.844705882352944|-30.71333333333333|8.403529411764705|-4.472857142857144|62.58|0.0|22.223529411764705|2.4000000000000004\n",
      "\n",
      "a preparation of autologous human t-lymphocytes engineered to express a chimeric t-cell receptor (chimeric antigen receptor or car) consisting of one or more binding domains targeting the tumor-associated antigens (taas) cd19 and cd22 and fused to one or more co-stimulatory tcr-signaling domains, with potential immunostimulating and antineoplastic activities. upon administration, the autologous cd19/cd22 car t-cells bind to cd19 and cd22 on the surface of, and induce selective toxicity against, tumor cells expressing cd19 and cd22. cd19 and cd22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the b lineage, are overexpressed on malignant b-cells.|a harmony of autologous human t-lymphocytes plan to mail a chimeric t-cell organ ( chimeric antigen organ or car ) be of one or more binding class aim the tumor-associated substance ( taas ) cd19 and cd22 and melt to one or more co-stimulatory tcr-signaling class , with potential immunostimulating and antineoplastic trait .  upon justice, the autologous cd19/cd22 cart-cells bind to cd19 and cd22 on the surface , and induce selective toxicity against, tumor cells mail cd19 and cd22.  cd19 and cd22, both transmembrane phosphoglycoproteins mail on the surface of cells in the b rate, are overexpressed on malignant b-cells.|20.325000000000017|51.7453519417476|16.386666666666667|12.438907766990294|14.718007692307694|11.758311538461538|23.74291666666667|18.418640776699032|30.293846153846154|14.440673076923076|101.39118822659097|88.50148473330829|27.1|22.72718446601942\n",
      "\n",
      "a preparation of autologous human t-lymphocytes engineered to express a chimeric t-cell receptor (chimeric antigen receptor or car) consisting of one or more binding domains targeting the tumor-associated antigens (taas) cd19 and cd22 and fused to one or more co-stimulatory tcr-signaling domains, with potential immunostimulating and antineoplastic activities. upon administration, the autologous cd19/cd22 car t-cells bind to cd19 and cd22 on the surface of, and induce selective toxicity against, tumor cells expressing cd19 and cd22. cd19 and cd22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the b lineage, are overexpressed on malignant b-cells.|a preparation of autologous human t-cell receptors engineered to express a chimeric tcr consisting of one or more binding domains targeting the tumor-associated antigens (taas) cd19 and cd22 on the surface of, and induce selective toxicity against, tumor|20.325000000000017|5.7439473684210895|16.386666666666667|21.89842105263158|13.858274358974361|14.52790487804878|23.74291666666667|25.943157894736835|21.627179487179482|23.42414634146342|101.39118822659097|136.38994794338765|27.1|35.2\n",
      "\n",
      "a preparation of autologous human t-lymphocytes engineered to express a chimeric t-cell receptor (chimeric antigen receptor or car) consisting of one or more binding domains targeting the tumor-associated antigens (taas) cd19 and cd22 and fused to one or more co-stimulatory tcr-signaling domains, with potential immunostimulating and antineoplastic activities. upon administration, the autologous cd19/cd22 car t-cells bind to cd19 and cd22 on the surface of, and induce selective toxicity against, tumor cells expressing cd19 and cd22. cd19 and cd22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the b lineage, are overexpressed on malignant b-cells.| a preparation of autologous human t-lymphocytes engineered to express a chimeric t-cell receptor (chimeric antigen receptor|20.325000000000017|-9.478823529411756|16.386666666666667|18.804705882352945|13.858274358974361|15.681500000000002|23.74291666666667|20.289411764705886|21.627179487179482|13.768499999999996|101.39118822659097|103.77718969022045|27.1|32.68235294117647\n",
      "\n",
      "the determination of the amount of factor xii present in a sample.|the choice of the amount of factor xi present in a sample.|59.745000000000005|87.94500000000002|6.416666666666668|2.4833333333333343|9.495033333333335|8.1792|-22.383333333333333|-26.30333333333333|5.765000000000001|2.625|49.473833993334296|44.250742366654144|19.06666666666667|15.733333333333333\n",
      "\n",
      "the determination of the amount of factor xii present in a sample.|the determination the amount of factor xii present in a sample.|59.745000000000005|55.12522727272727|6.416666666666668|6.936818181818182|9.495033333333335|10.513266666666667|-22.383333333333333|-24.952727272727277|5.765000000000001|2.3725000000000023|49.473833993334296|49.473833993334296|19.06666666666667|20.381818181818183\n",
      "\n",
      "the determination of the amount of factor xii present in a sample.| the determination of the factor present in a sample|59.745000000000005|61.32500000000002|6.416666666666668|7.190000000000001|9.495033333333335|11.359372727272728|-22.383333333333333|-3.727999999999998|5.765000000000001|3.3381818181818197|49.473833993334296|62.58|19.06666666666667|20.0\n",
      "\n",
      "the rationale or explanation for why each study endpoint was chosen.|the concept or speech_act for why each study end was chosen.|55.12522727272727|85.88886363636365|6.936818181818182|2.6459090909090897|8.488463636363637|7.053009090909091|-22.81454545454546|-27.090909090909093|8.476363636363637|5.050909090909091|49.473833993334296|44.250742366654144|20.381818181818183|16.745454545454546\n",
      "\n",
      "the rationale or explanation for why each study endpoint was chosen.|the rationale or explanation why each study endpoint was chosen.|55.12522727272727|49.48000000000002|6.936818181818182|7.600000000000001|8.488463636363637|9.651118181818184|-22.81454545454546|-26.272|8.476363636363637|4.870000000000001|49.473833993334296|49.473833993334296|20.381818181818183|22.0\n",
      "\n",
      "the rationale or explanation for why each study endpoint was chosen.| the rationale or explanation for why each study's objective was chosen|55.12522727272727|53.655|6.936818181818182|8.756666666666668|8.488463636363637|10.354376923076924|-22.81454545454546|5.223333333333336|8.476363636363637|7.533076923076923|49.473833993334296|69.96656701596841|20.381818181818183|21.46666666666667\n",
      "\n",
      "the point at the base of the skull where the brainstem and cervical spine intersect.|the point at the base of the skull where the brainstem and cervical spine meet.|86.42250000000001|97.7025|3.068333333333335|1.495000000000001|9.643833333333333|8.591166666666666|-12.026666666666664|-13.986666666666672|7.735999999999997|6.166|38.32226702584281|31.29|11.0|8.333333333333334\n",
      "\n",
      "the point at the base of the skull where the brainstem and cervical spine intersect.|the point at the base of the skull where the brainstem and neck bone intersect.|86.42250000000001|97.7025|3.068333333333335|1.495000000000001|9.643833333333333|7.9808|-12.026666666666664|-13.594666666666669|7.735999999999997|1.7043749999999989|38.32226702584281|31.29|11.0|8.333333333333334\n",
      "\n",
      "the point at the base of the skull where the brainstem and cervical spine intersect.| the point at the base of a person's skull where the brainstem and spinal cord meet.|86.42250000000001|103.65455882352943|3.068333333333335|0.9132352941176478|9.643833333333333|8.469011111111111|-12.026666666666664|-10.957647058823529|7.735999999999997|1.125|38.32226702584281|38.32226702584281|11.0|10.458823529411767\n",
      "\n",
      ">uln - 1.5 x uln|> uln - 1.5 x uln|153.53750000000002|161.49|-7.535|-8.52|19.5505|19.5505|-104.288|-86.90666666666665|-9.818|-9.818|0.0|0.0|1.0|1.2000000000000002\n",
      "\n",
      ">uln - 1.5 x uln|grade ln - 1.5 x uln greater than or equal to 12 months of life.|153.53750000000002|122.80000000000003|-7.535|-2.626666666666665|19.674500000000002|10.3245|-104.288|-39.208|-8.568|-2.2940000000000005|0.0|25.548178017228544|1.0|7.333333333333335\n",
      "\n",
      ">uln - 1.5 x uln| >multiply|153.53750000000002|77.90500000000002|-7.535|2.890000000000004|19.674500000000002|15.6774|-104.288|-118.6|-8.568|-6.477499999999999|0.0|31.29|1.0|20.8\n",
      "\n",
      "a response indicating that an individual is in extreme agreement with something.|a phrase informs that an organism is in extreme speech_act with something.|31.545000000000016|73.84500000000001|10.350000000000001|4.450000000000003|10.810866666666666|10.810866666666666|-15.523333333333326|-18.46333333333333|11.259999999999998|8.905000000000001|54.195869768830164|49.473833993334296|22.400000000000002|19.06666666666667\n",
      "\n",
      "a response indicating that an individual is in extreme agreement with something.|a response that an individual is in extreme agreement with something.|31.545000000000016|47.434318181818185|10.350000000000001|8.009545454545457|10.810866666666666|10.513266666666667|-15.523333333333326|-21.74545454545455|11.259999999999998|4.727500000000003|54.195869768830164|49.473833993334296|22.400000000000002|20.381818181818183\n",
      "\n",
      "a response indicating that an individual is in extreme agreement with something.| an agreement|31.545000000000016|90.99000000000004|10.350000000000001|1.3133333333333361|10.810866666666666|15.6774|-15.523333333333326|-75.14666666666666|11.259999999999998|-4.122500000000002|54.195869768830164|31.29|22.400000000000002|14.533333333333331\n",
      "\n",
      "a feeling of tension or tightness in one or more muscles.|a feeling of stress or lack in one or more passages.|85.88886363636365|93.57977272727274|2.6459090909090897|1.5731818181818191|9.923918181818184|9.923918181818184|-28.694545454545462|-31.36727272727273|3.7663636363636357|1.625454545454545|44.250742366654144|31.29|16.745454545454546|9.472727272727274\n",
      "\n",
      "a feeling of tension or tightness in one or more muscles.|a sense of tension or tightness in one or more muscles.|85.88886363636365|93.57977272727274|2.6459090909090897|1.5731818181818191|9.923918181818184|9.197433333333334|-28.694545454545462|-29.229090909090914|3.7663636363636357|-0.7674999999999983|44.250742366654144|38.32226702584281|16.745454545454546|13.109090909090908\n",
      "\n",
      "a feeling of tension or tightness in one or more muscles.| a feeling of tension|85.88886363636365|100.24000000000002|2.6459090909090897|0.5199999999999996|9.923918181818184|14.460766666666668|-28.694545454545462|-38.032|3.7663636363636357|-3.5150000000000006|44.250742366654144|44.250742366654144|16.745454545454546|18.0\n",
      "\n",
      "<p>you can help prevent medical errors by being an active member of your health care team. research shows that patients who are more involved with their care tend to get better results. to reduce the risk of medical errors, you can</p> <ul> <li>ask questions if you have doubts or concerns. take a relative or friend to your doctor appointment to help you ask questions and understand answers.</li> <li>make sure you understand what will happen if you need surgery</li> <li>tell your health care providers about all the medicines you take, including over-the-counter drugs and dietary supplements. tell them if you have any allergies or bad reactions to anesthesia. make sure you know how to <a href=\"https://medlineplus.gov/medicationerrors.html\">take your medications correctly</a>. </li> <li>get a second opinion about treatment options</li> <li>keep a copy of your own <a href=\"https://medlineplus.gov/personalhealthrecords.html\">medical history</a></li> </ul> <p class=\"\">agency for healthcare research and quality</p>|< p > you can help prevent medical errors from being an active member of your health care team.  research shows that case who are more have with their care tend to get better results.  to reduce the risk of medical errors, you can < /p > < ul > < li > ask questions if you have doubts or concerns.  take a person or a friend to your doctor person to help you ask questions and understand the answers.  < /li > < li > make sure you understand what will happen if you need surgery < /li > < li > tell your health care providers about all the treat you take, including over-the-counter drugs and dietary attach.  tell them if you have any allergies or bad force to anesthesia.  make sure you know how to < a href= '' https: //medlineplus.gov/medicationerrors.html '' > take your therapy correctly < /a >.  < /li > < li > get a second judgment about care options < /li > < li > keep a copy of your own < a href= '' https: //medlineplus.gov/personalhealthrecords.html '' > medical history < /a > < /li > < /ul > < p class= '' '' > agency for care research and quality < /p >|43.879443473193504|92.50851027397262|10.099458041958044|4.8900570776255705|11.898019810576164|12.182530330959363|11.386573426573428|6.62958904109589|14.11177584846093|6.470548806032678|67.59412548439398|61.26237874911485|20.431002331002333|15.701826484018264\n",
      "\n",
      "<p>you can help prevent medical errors by being an active member of your health care team. research shows that patients who are more involved with their care tend to get better results. to reduce the risk of medical errors, you can</p> <ul> <li>ask questions if you have doubts or concerns. take a relative or friend to your doctor appointment to help you ask questions and understand answers.</li> <li>make sure you understand what will happen if you need surgery</li> <li>tell your health care providers about all the medicines you take, including over-the-counter drugs and dietary supplements. tell them if you have any allergies or bad reactions to anesthesia. make sure you know how to <a href=\"https://medlineplus.gov/medicationerrors.html\">take your medications correctly</a>. </li> <li>get a second opinion about treatment options</li> <li>keep a copy of your own <a href=\"https://medlineplus.gov/personalhealthrecords.html\">medical history</a></li> </ul> <p class=\"\">agency for healthcare research and quality</p>|you can help prevent medical errors by being an active member of your health care team. research shows that patients who are more involved with their care tend to get better results. to reduce the risk of medical error, you can/p> li>alkhurma href|43.879443473193504|70.3052713178295|10.099458041958044|7.013953488372092|11.513265524861879|11.009266666666665|11.386573426573428|7.518139534883716|10.233204419889503|6.391249999999999|67.59412548439398|69.96656701596841|20.431002331002333|19.686821705426357\n",
      "\n",
      "<p>you can help prevent medical errors by being an active member of your health care team. research shows that patients who are more involved with their care tend to get better results. to reduce the risk of medical errors, you can</p> <ul> <li>ask questions if you have doubts or concerns. take a relative or friend to your doctor appointment to help you ask questions and understand answers.</li> <li>make sure you understand what will happen if you need surgery</li> <li>tell your health care providers about all the medicines you take, including over-the-counter drugs and dietary supplements. tell them if you have any allergies or bad reactions to anesthesia. make sure you know how to <a href=\"https://medlineplus.gov/medicationerrors.html\">take your medications correctly</a>. </li> <li>get a second opinion about treatment options</li> <li>keep a copy of your own <a href=\"https://medlineplus.gov/personalhealthrecords.html\">medical history</a></li> </ul> <p class=\"\">agency for healthcare research and quality</p>||43.879443473193504|205.82000000000002|10.099458041958044|-15.2|11.513265524861879|19.476100000000002|11.386573426573428|-290.12|10.233204419889503|-16.22|67.59412548439398|0.0|20.431002331002333|0.4\n",
      "\n",
      "organized plans for care or training in psychiatric hospitals.|jain plans for care or training in psychiatric hospitals.|51.867500000000035|70.66750000000002|7.142777777777777|4.520555555555557|9.346233333333334|9.346233333333334|-30.49777777777777|-33.764444444444436|10.806666666666665|8.189999999999998|44.250742366654144|38.32226702584281|19.57777777777778|15.133333333333333\n",
      "\n",
      "organized plans for care or training in psychiatric hospitals.|arrangements for care or training in psychiatric hospitals.|51.867500000000035|33.57500000000002|7.142777777777777|9.57|9.346233333333334|10.877477777777777|-30.49777777777777|-35.045|10.806666666666665|8.033333333333331|44.250742366654144|44.250742366654144|19.57777777777778|21.6\n",
      "\n",
      "organized plans for care or training in psychiatric hospitals.| organized|51.867500000000035|77.90500000000002|7.142777777777777|2.890000000000004|9.346233333333334|19.5753|-30.49777777777777|-118.6|10.806666666666665|-2.66|44.250742366654144|31.29|19.57777777777778|20.8\n",
      "\n",
      "invasive intervention indicated|invasive care informs|-106.40999999999997|34.59000000000003|28.846666666666668|9.180000000000003|19.5753|14.311966666666669|-41.82666666666667|-61.42666666666666|25.599999999999994|9.899999999999999|54.195869768830164|44.250742366654144|41.2|27.866666666666664\n",
      "\n",
      "invasive intervention indicated|blood clot that travels|-106.40999999999997|97.025|28.846666666666668|0.7199999999999989|19.5753|13.3585|-41.82666666666667|-43.13|25.599999999999994|0.8520000000000003|54.195869768830164|31.29|41.2|11.600000000000001\n",
      "\n",
      "invasive intervention indicated| intervention|-106.40999999999997|35.60500000000002|28.846666666666668|8.790000000000003|19.5753|19.5753|-41.82666666666667|-109.78|25.599999999999994|2.0500000000000007|54.195869768830164|31.29|41.2|20.8\n",
      "\n",
      "invasive intervention indicated|invasive care informs|-106.40999999999997|34.59000000000003|28.846666666666668|9.180000000000003|19.5753|14.311966666666669|-41.82666666666667|-61.42666666666666|25.599999999999994|9.899999999999999|54.195869768830164|44.250742366654144|41.2|27.866666666666664\n",
      "\n",
      "invasive intervention indicated|blood clot that travels|-106.40999999999997|97.025|28.846666666666668|0.7199999999999989|19.5753|13.3585|-41.82666666666667|-43.13|25.599999999999994|0.8520000000000003|54.195869768830164|31.29|41.2|11.600000000000001\n",
      "\n",
      "invasive intervention indicated| intervention|-106.40999999999997|35.60500000000002|28.846666666666668|8.790000000000003|19.5753|19.5753|-41.82666666666667|-109.78|25.599999999999994|2.0500000000000007|54.195869768830164|31.29|41.2|20.8\n",
      "\n",
      "a response indicating that an individual has or had severe pain or discomfort that prevented most activities.|a phrase informs that an organism has or had severe pain or discomfort that prevented most trait.|33.98397058823531|73.79573529411766|10.630882352941178|5.077941176470592|10.981464705882354|10.981464705882354|-2.656470588235294|-6.80705882352941|12.559411764705885|9.23470588235294|58.53822981607831|49.473833993334296|19.870588235294118|15.164705882352942\n",
      "\n",
      "a response indicating that an individual has or had severe pain or discomfort that prevented most activities.|a response that an individual has or had severe pain or discomfort that prevented most activities.|33.98397058823531|45.377500000000026|10.630882352941178|8.917500000000004|10.981464705882354|10.559864705882354|-2.656470588235294|-6.130000000000003|12.559411764705885|5.815882352941177|58.53822981607831|54.195869768830164|19.870588235294118|18.2\n",
      "\n",
      "a response indicating that an individual has or had severe pain or discomfort that prevented most activities.| a response indicating that an individual has or had severe pain or discomfort that prevented them from their activities|33.98397058823531|38.48500000000004|10.630882352941178|12.860000000000003|10.981464705882354|11.445242857142857|-2.656470588235294|15.188|12.559411764705885|12.17142857142857|58.53822981607831|82.78555852321104|19.870588235294118|22.0\n",
      "\n",
      "a terminology codelist relevant to a comparator against which the study treatment is evaluated.|a word codelist relevant to a comparator against which the study care is thought.|12.401428571428596|60.74428571428575|13.26857142857143|6.525714285714287|11.098042857142858|7.714471428571429|-7.845714285714287|-13.72571428571429|12.820714285714281|8.110714285714284|62.58|49.473833993334296|25.65714285714286|17.085714285714285\n",
      "\n",
      "a terminology codelist relevant to a comparator against which the study treatment is evaluated.|a vocabulary list relevant to a comparator against which the study treatment is evaluated.|12.401428571428596|24.487142857142885|13.26857142857143|11.582857142857147|11.098042857142858|10.3245|-7.845714285714287|-9.525714285714287|12.820714285714281|6.498000000000001|62.58|58.53822981607831|25.65714285714286|22.8\n",
      "\n",
      "a terminology codelist relevant to a comparator against which the study treatment is evaluated.| a terminology|12.401428571428596|34.59000000000003|13.26857142857143|9.180000000000003|11.098042857142858|15.6774|-7.845714285714287|-73.18666666666667|12.820714285714281|-2.9450000000000003|62.58|31.29|25.65714285714286|14.533333333333331\n",
      "\n",
      "abnormal behavioral or physiologic events that are associated with rem sleep, including rem sleep behavior disorder.|abnormal mental illness or physiologic events that are united with rem sleep, including rem sleep trait change.|29.515000000000015|58.8663235294118|11.130000000000003|7.160294117647062|14.29885|13.767935294117647|0.11749999999999972|-1.9647058823529377|15.713124999999998|12.836470588235294|62.58|58.53822981607831|23.200000000000003|19.870588235294118\n",
      "\n",
      "abnormal behavioral or physiologic events that are associated with rem sleep, including rem sleep behavior disorder.|abnormal behavioral or physiological events that are associated with rem sleep, including slow eye movement disorder.|29.515000000000015|29.515000000000015|11.130000000000003|11.130000000000003|14.29885|13.346335294117647|0.11749999999999972|0.8524999999999991|15.713124999999998|10.80294117647059|62.58|62.58|23.200000000000003|23.200000000000003\n",
      "\n",
      "abnormal behavioral or physiologic events that are associated with rem sleep, including rem sleep behavior disorder.| abnormal behavioral or physiologic events that are associated with dreaming|29.515000000000015|26.470000000000027|11.130000000000003|12.3|14.29885|13.442533333333335|0.11749999999999972|8.905454545454543|15.713124999999998|11.259999999999998|62.58|76.64453405168562|23.200000000000003|26.218181818181815\n",
      "\n",
      "a group of congenital disorders of lipid metabolism, caused by loss of the normal peroxisomes. signs and symptoms include developmental delays, mental retardation, facial abnormalities, hepatomegaly, and hypotonia.|a group of congenital change of lipid metabolism, caused by the loss of the normal peroxisomes.  signs and symptoms include developmental delays, mental delay, facial misbehavior, abnormality, and hypotonia.|0.96880952380954|27.485000000000014|15.442857142857147|11.91|14.048157142857145|12.553833333333335|7.555714285714284|5.288000000000007|22.848571428571425|10.574000000000005|72.26115969177356|69.96656701596841|26.59047619047619|24.0\n",
      "\n",
      "a group of congenital disorders of lipid metabolism, caused by loss of the normal peroxisomes. signs and symptoms include developmental delays, mental retardation, facial abnormalities, hepatomegaly, and hypotonia.|a group of genetic disorders of lipid metabolism, caused by loss of the normal cell membranes. signs and symptoms include developmental delays, mental retardation, facial abnormalities, and hypotonia.|0.96880952380954|25.140238095238118|15.442857142857147|12.071428571428573|13.353757142857145|12.827690804597701|7.555714285714284|4.825714285714287|15.848571428571425|10.688850574712646|72.26115969177356|69.96656701596841|26.59047619047619|25.161904761904765\n",
      "\n",
      "a group of congenital disorders of lipid metabolism, caused by loss of the normal peroxisomes. signs and symptoms include developmental delays, mental retardation, facial abnormalities, hepatomegaly, and hypotonia.| a group of diseases that result from the loss of the normal peroxisomes and which cause delays.|0.96880952380954|75.50000000000003|15.442857142857147|4.964444444444446|13.353757142857145|9.925068421052632|7.555714285714284|-6.755555555555549|15.848571428571425|3.151578947368421|72.26115969177356|49.473833993334296|26.59047619047619|14.711111111111112\n",
      "\n",
      "a kind of antidote for arsenic, mercury, gold, and lead poisoning|a kind of antidote for trioxide, mercury, gold, and lead drug|49.54272727272729|72.61545454545457|9.081818181818182|5.863636363636363|9.923918181818184|9.923918181818184|2.4909090909090885|0.35272727272727167|6.335454545454546|4.622727272727271|62.58|54.195869768830164|18.94545454545455|15.309090909090907\n",
      "\n",
      "a kind of antidote for arsenic, mercury, gold, and lead poisoning|antidote for arsenic, mercury, gold, and lead poisoning.|49.54272727272729|33.57500000000002|9.081818181818182|9.57|9.923918181818184|12.631922222222224|2.4909090909090885|-37.25|6.335454545454546|4.893333333333331|62.58|44.250742366654144|18.94545454545455|21.6\n",
      "\n",
      "a kind of antidote for arsenic, mercury, gold, and lead poisoning| an antidote for poisons|49.54272727272729|83.32000000000004|9.081818181818182|2.879999999999999|9.923918181818184|11.8291|2.4909090909090885|-34.50399999999999|6.335454545454546|-1.1600000000000001|62.58|44.250742366654144|18.94545454545455|18.0\n",
      "\n",
      "a descriptive adjective assigned to the computed amount of blood ejected during a ventricular contraction of the heart.|a descriptive adjective transfer in the reason amount of blood discharge during a ventricular decrease of the heart.|33.20000000000002|52.00000000000003|10.864444444444448|8.242222222222225|10.669855555555555|9.792633333333335|0.43111111111111455|-0.5488888888888894|13.998333333333328|13.213333333333331|66.37611354998121|66.37611354998121|23.6|23.6\n",
      "\n",
      "a descriptive adjective assigned to the computed amount of blood ejected during a ventricular contraction of the heart.|a descriptive adjective assigned to the computed amount of blood ejected during a heart rhythm.|33.20000000000002|46.942499999999995|10.864444444444448|8.575000000000003|10.669855555555555|10.941425|0.43111111111111455|-7.32266666666667|13.998333333333328|6.414375|66.37611354998121|58.53822981607831|23.6|21.666666666666668\n",
      "\n",
      "a descriptive adjective assigned to the computed amount of blood ejected during a ventricular contraction of the heart.| a descriptive adjective assigned to the amount of blood ejected during a heart contraction|33.20000000000002|44.97000000000003|10.864444444444448|10.713333333333338|10.669855555555555|11.338225000000001|0.43111111111111455|10.842666666666663|13.998333333333328|9.825624999999999|66.37611354998121|82.78555852321104|23.6|24.666666666666668\n",
      "\n",
      "a natural pyrrolizidine alkaloid with antineoplastic properties. indicine-n-oxide alkylates and crosslinks dna. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c1134\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c1134\" nci thesaurus)|a natural pyrrolizidine alkaloid with antineoplastic properties.  indicine-n-oxide alkyls and crosslinks dna.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c1134 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c1134 '' nice wordbook)|24.624000000000024|50.495000000000005|10.421000000000003|7.210000000000001|15.497746153846155|17.123482051282053|-41.99333333333334|-25.049000000000007|39.97038461538462|11.07275641025641|34.27647764867329|39.57906719466743|20.96|17.6\n",
      "\n",
      "a natural pyrrolizidine alkaloid with antineoplastic properties. indicine-n-oxide alkylates and crosslinks dna. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c1134\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c1134\" nci thesaurus)|a natural molecule of fat and protein building blocks with anti-cancer properties. indicine-n-oxide alkylates and crosslinks dna. check for \"http://ncit.nih.gov/content.jsp?dictionary=nci%20the|24.624000000000024|38.48166666666668|10.421000000000003|8.720000000000002|15.497746153846155|13.244133333333336|-41.99333333333334|-37.35|39.97038461538462|15.736249999999998|34.27647764867329|38.32226702584281|20.96|19.333333333333336\n",
      "\n",
      "a natural pyrrolizidine alkaloid with antineoplastic properties. indicine-n-oxide alkylates and crosslinks dna. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c1134\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c1134\" nci thesaurus)| a pyrrolizidine alkaloid|24.624000000000024|12.425000000000011|10.421000000000003|12.52|15.497746153846155|16.5165|-41.99333333333334|-40.19|39.97038461538462|3.678000000000001|34.27647764867329|44.250742366654144|20.96|21.6\n",
      "\n",
      "carcinoma, miscellaneous is an nci cancer therapeutic evaluation program (ctep) simplified disease classification (sdc) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard medical dictionary for drug regulatory reporting (meddra) terminology.|cancer, miscellaneous is a nice cancer medicine appraisal program (step) change the disease, restriction (sdc) category used to join cancer-related disease mock that change with and supports reporting based on the global standard medical wordbook for drug regulatory reporting (madras) word.|-12.274999999999977|33.33481707317074|19.94|13.70256097560976|17.223758536585365|14.366604761904762|26.36|21.55804878048781|30.20195121951219|26.596428571428568|110.62685591663536|98.94766798666859|33.0|27.712195121951222\n",
      "\n",
      "carcinoma, miscellaneous is an nci cancer therapeutic evaluation program (ctep) simplified disease classification (sdc) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard medical dictionary for drug regulatory reporting (meddra) terminology.|cancer drug classification (sdc) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard medical dictionary for drug regulatory reporting system (meddra) terminology.|-12.274999999999977|5.528306451612963|19.94|16.338870967741936|17.223758536585365|16.756936363636363|26.36|20.735483870967748|30.20195121951219|24.186363636363637|110.62685591663536|96.44225707644962|33.0|30.716129032258063\n",
      "\n",
      "carcinoma, miscellaneous is an nci cancer therapeutic evaluation program (ctep) simplified disease classification (sdc) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard medical dictionary for drug regulatory reporting (meddra) terminology.| carcinoma|-12.274999999999977|35.60500000000002|19.94|8.790000000000003|17.223758536585365|19.5753|26.36|-118.6|30.20195121951219|-2.66|110.62685591663536|31.29|33.0|20.8\n",
      "\n",
      "a radioimmunoconjugate comprised of a recombinant scfv dimer diabody of a monoclonal antibody against human carcinoembryonic antigen (cea) labeled with iodine i 123 (i-123) with potential radioimmunolocalization applications. the antibody moiety of iodine i 123 anti-cea recombinant diabody t84.66 binds to cells expressing cea, selectively delivering i-123 upon cellular internalization and allowing the scintigraphic imaging of cea-expressing tumor cells. cea, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers. compared to whole monoclonal antibodies, diabody fragments offer the advantages of rapid tumor targeting, rapid blood clearance, more uniform tumor distribution, and a lower potential for eliciting an immune response. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c77911\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c77911\" nci thesaurus)|an immunologic factor include of a cell scfv dimmer diabody of a monoclonal protein against human carcinoembryonic substance (ca) declare with iodine i 123 (i-123) with potential radioimmunolocalization action.  the protein moiety of iodine i 123 anti-ca cell diabody t84. 66 binds to cells mail queue, selectively produce i-123 upon cellular learning and allowing the scintigraphic imaging of ca-expressing tumor cells.  sea, a growth associated substance, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.  compared to whole monoclonal protein, diabody break offer the prefer of rapid tumor aim, rapid blood room, more supply tumor commerce, and a lower potential for deduce an immune phrase.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c77911 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c77911 '' nice wordbook)|17.00091544818818|50.62615384615387|13.200330578512396|8.89248226950355|14.67166064516129|14.635925396825398|14.412231404958675|9.657304964539009|25.991129032258065|13.030555555555559|71.56296786209171|69.96656701596841|26.202415766052134|22.778177850518276\n",
      "\n",
      "a radioimmunoconjugate comprised of a recombinant scfv dimer diabody of a monoclonal antibody against human carcinoembryonic antigen (cea) labeled with iodine i 123 (i-123) with potential radioimmunolocalization applications. the antibody moiety of iodine i 123 anti-cea recombinant diabody t84.66 binds to cells expressing cea, selectively delivering i-123 upon cellular internalization and allowing the scintigraphic imaging of cea-expressing tumor cells. cea, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers. compared to whole monoclonal antibodies, diabody fragments offer the advantages of rapid tumor targeting, rapid blood clearance, more uniform tumor distribution, and a lower potential for eliciting an immune response. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c77911\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c77911\" nci thesaurus)|a radioimmunoconjugate comprised of a recombinant scfv monoclonal antibody against human carcinoembryonic antigen (cea) labeled with iodine i 123 after cellular internalization and potential radio|17.00091544818818|-35.115999999999985|13.200330578512396|24.368|14.466647311827957|15.25033076923077|14.412231404958675|28.8496|23.924462365591403|22.54730769230769|71.56296786209171|125.16|26.202415766052134|35.6\n",
      "\n",
      "a radioimmunoconjugate comprised of a recombinant scfv dimer diabody of a monoclonal antibody against human carcinoembryonic antigen (cea) labeled with iodine i 123 (i-123) with potential radioimmunolocalization applications. the antibody moiety of iodine i 123 anti-cea recombinant diabody t84.66 binds to cells expressing cea, selectively delivering i-123 upon cellular internalization and allowing the scintigraphic imaging of cea-expressing tumor cells. cea, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers. compared to whole monoclonal antibodies, diabody fragments offer the advantages of rapid tumor targeting, rapid blood clearance, more uniform tumor distribution, and a lower potential for eliciting an immune response. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c77911\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c77911\" nci thesaurus)| a|17.00091544818818|162.505|13.200330578512396|-8.91|14.466647311827957|14.311966666666669|14.412231404958675|-142.12|23.924462365591403|-15.219999999999999|71.56296786209171|0.0|26.202415766052134|0.8\n",
      "\n",
      "an indication as to whether a continuous audio recording is made during the assessment.|a datum as to whether a continuous audio remind is made during the act.|30.53000000000003|60.74428571428575|10.740000000000002|6.525714285714287|11.098042857142858|8.842328571428572|-11.205714285714286|-17.925714285714285|10.129285714285714|4.74642857142857|58.53822981607831|54.195869768830164|22.8|19.942857142857143\n",
      "\n",
      "an indication as to whether a continuous audio recording is made during the assessment.|an indication as to whether a continuous hearing aid is made during the assessment.|30.53000000000003|48.65857142857146|10.740000000000002|8.211428571428574|11.098042857142858|9.271833333333333|-11.205714285714286|-12.465714285714288|10.129285714285714|4.300000000000001|58.53822981607831|54.195869768830164|22.8|19.942857142857143\n",
      "\n",
      "an indication as to whether a continuous audio recording is made during the assessment.| a clue|30.53000000000003|147.39000000000004|10.740000000000002|-6.553333333333333|11.098042857142858|15.6774|-11.205714285714286|-86.90666666666665|10.129285714285714|-11.1875|58.53822981607831|0.0|22.8|1.2000000000000002\n",
      "\n",
      "a monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; cd73; 5'-nt; ecto-5'-nucleotidase; nt5e), with potential immunomodulating and antineoplastic activities. upon administration, anti-cd73 monoclonal antibody bms-986179 targets and binds to cd73, leading to clustering and internalization of cd73. this prevents cd73-mediated conversion of extracellular adenosine monophosphate (amp) to adenosine and decreases the amount of free adenosine. this prevents adenosine-mediated suppression of lymphocyte activity and increases the activity of cd8-positive effector cells. this also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (mdscs) and regulatory t lymphocytes. by abrogating the inhibitory effect on the immune system and enhancing the cytotoxic t-cell-mediated immune response against cancer cells, tumor cell growth is decreased. cd73, a plasma membrane protein belonging to the 5'-nucleotidase (ntase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as amp, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c132266\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c132266\" nci thesaurus)|an immunologic factor protein aims the ectoenzyme 5'-ecto-nucleotidase (a form of adaptation 73; cd73; 5'-nt; ecto-5'-nucleotides; nt5e), with potential immunomodulating and antineoplastic trait.  upon justice, anti-cd73 monoclonal antibody bms-986179 aim and binds to cd73, leading to form and learning of cd73.  this prevents cd73-mediated change of extracellular nucleoside monophosphate (amp) to nucleoside and change the amount of free nucleoside.  this prevents adenosine-mediated restraint of lymphocyte activity and change the activity of cd8-positive organ cells.  this also changes phagocyte, and weaken the activity of both myeloid-derived gene cells (mdscs) and regulatory t leukocyte.  by abolishing the inhibitory effect on the immune system and better the cytotoxic t-cell-mediated immune response against cancer cells, tumor cell growth is change.  cd73 , a plasma sheet protein belonging to the 5'-nucleotidase ( ntase ) family , is upregulated on a number of cancer cell types and change_state the change of extracellular ester , such as amp , to membrane-permeable glycoside , such as nucleoside ; it plays a key role in adenosine-mediated immunosuppression within the growth microenvironment .  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c132266 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c132266 '' nice wordbook)|20.02651724137931|54.0859579288026|13.347793103448279|9.127165048543691|14.122761904761907|13.310726103286385|20.002068965517243|14.83980582524272|25.443809523809527|12.691690140845068|73.15884826868175|69.49855797065143|23.490574712643678|19.862265372168288\n",
      "\n",
      "a monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; cd73; 5'-nt; ecto-5'-nucleotidase; nt5e), with potential immunomodulating and antineoplastic activities. upon administration, anti-cd73 monoclonal antibody bms-986179 targets and binds to cd73, leading to clustering and internalization of cd73. this prevents cd73-mediated conversion of extracellular adenosine monophosphate (amp) to adenosine and decreases the amount of free adenosine. this prevents adenosine-mediated suppression of lymphocyte activity and increases the activity of cd8-positive effector cells. this also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (mdscs) and regulatory t lymphocytes. by abrogating the inhibitory effect on the immune system and enhancing the cytotoxic t-cell-mediated immune response against cancer cells, tumor cell growth is decreased. cd73, a plasma membrane protein belonging to the 5'-nucleotidase (ntase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as amp, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c132266\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c132266\" nci thesaurus)|a monoclonal antibody targeting a protein building block, which prevents the inhibitory effect on the immune system and enhancing the cellular response against cancer cells. tumor cell growth is decreased.|20.02651724137931|33.125|13.347793103448279|11.123333333333338|13.839333333333334|12.80806559139785|20.002068965517243|5.092000000000002|22.586666666666666|10.173440860215056|73.15884826868175|74.48509850970193|23.490574712643678|26.666666666666664\n",
      "\n",
      "a monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; cd73; 5'-nt; ecto-5'-nucleotidase; nt5e), with potential immunomodulating and antineoplastic activities. upon administration, anti-cd73 monoclonal antibody bms-986179 targets and binds to cd73, leading to clustering and internalization of cd73. this prevents cd73-mediated conversion of extracellular adenosine monophosphate (amp) to adenosine and decreases the amount of free adenosine. this prevents adenosine-mediated suppression of lymphocyte activity and increases the activity of cd8-positive effector cells. this also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (mdscs) and regulatory t lymphocytes. by abrogating the inhibitory effect on the immune system and enhancing the cytotoxic t-cell-mediated immune response against cancer cells, tumor cell growth is decreased. cd73, a plasma membrane protein belonging to the 5'-nucleotidase (ntase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as amp, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c132266\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c132266\" nci thesaurus)| A|20.02651724137931|162.505|13.347793103448279|-8.91|13.839333333333334|14.311966666666669|20.002068965517243|-142.12|22.586666666666666|-15.219999999999999|73.15884826868175|0.0|23.490574712643678|0.8\n",
      "\n",
      "an autoimmune diseases affecting multiple endocrine organs|a disease, illness refers product gland organs|-17.812857142857126|54.70142857142861|17.482857142857146|7.368571428571428|15.262271428571431|15.262271428571431|1.394285714285715|-8.685714285714283|17.058571428571433|8.311428571428571|76.64453405168562|69.96656701596841|37.08571428571428|31.371428571428574\n",
      "\n",
      "an autoimmune diseases affecting multiple endocrine organs|an autoimmune disease affecting multiple body parts.|-17.812857142857126|21.99678571428572|17.482857142857146|11.060714285714287|15.262271428571431|13.70365|1.394285714285715|-45.09142857142857|17.058571428571433|7.6525|76.64453405168562|49.473833993334296|37.08571428571428|29.971428571428575\n",
      "\n",
      "an autoimmune diseases affecting multiple endocrine organs| an autoimmune disease|-17.812857142857126|75.87500000000001|17.482857142857146|3.6700000000000017|15.262271428571431|16.5165|1.394285714285715|-44.6|17.058571428571433|0.8520000000000003|76.64453405168562|44.250742366654144|37.08571428571428|21.6\n",
      "\n",
      "suicidal ideation questionnaire (siq) i thought if i had the chance i would kill myself.|suicidal thinking form (sic) i thought if i had the chance i would kill myself.|75.14250000000001|92.06250000000001|4.641666666666666|2.2816666666666663|8.219166666666666|7.1665|-10.45866666666667|-13.986666666666672|4.614000000000001|1.7880000000000038|44.250742366654144|38.32226702584281|13.66666666666667|11.0\n",
      "\n",
      "suicidal ideation questionnaire (siq) i thought if i had the chance i would kill myself.|suicide severity rating scale i thought if i had the chance i would kill myself.|75.14250000000001|75.14250000000001|4.641666666666666|4.641666666666666|8.219166666666666|8.967675|-10.45866666666667|-13.20266666666667|4.614000000000001|1.9987500000000011|44.250742366654144|44.250742366654144|13.66666666666667|13.66666666666667\n",
      "\n",
      "suicidal ideation questionnaire (siq) i thought if i had the chance i would kill myself.| siq|75.14250000000001|162.505|4.641666666666666|-8.91|8.219166666666666|19.5753|-10.45866666666667|-136.24|4.614000000000001|-12.079999999999998|44.250742366654144|0.0|13.66666666666667|0.8\n",
      "\n",
      "a standardized 17-item scale that was developed by elaine scott and michelle eagle in 2011 to measure functional motor ability in ambulant children and adolescents with duchenne muscular dystrophy. the instrument, which is partly based on the hammersmith motor ability scale (2003), utilizes a 3-point rating scale to grade activities ranging from standing to running, as well as abilities that are necessary for a patient to remain functionally ambulant and that are known to progressively deteriorate in untreated dmd.|a measurement 17-item scale that was expanded by elaine scott and michelle score in 2011 to measure functional motor ability in ambulant children and juvenile with duchenne muscular dystrophy.  the address , which is partly based on the hammersmith motor ability scale ( 2003 ) , change a 3-point pad scale to grade trait feed from standing to running , as well as cognition that are necessary for a case to remain functionally ambulant and that are known to progressively worsen in untreated dmd .|28.040843881856574|53.78949612403103|15.890126582278484|12.878372093023255|12.663077777777778|11.832051219512195|21.65772151898734|17.91209302325581|23.998148148148147|22.332804878048783|106.8756964889586|97.28456352371633|28.254852320675106|24.955038759689923\n",
      "\n",
      "a standardized 17-item scale that was developed by elaine scott and michelle eagle in 2011 to measure functional motor ability in ambulant children and adolescents with duchenne muscular dystrophy. the instrument, which is partly based on the hammersmith motor ability scale (2003), utilizes a 3-point rating scale to grade activities ranging from standing to running, as well as abilities that are necessary for a patient to remain functionally ambulant and that are known to progressively deteriorate in untreated dmd.|a standardized 17-item scale that was developed by elaine scott and michelle eagle in 2011 to measure functional motor ability in ambulant children and adolescents with muscle and nerve birth defect. the instrument, which is partly based on the hammersmith motor ability scale (2003), utilizes a 3-|28.040843881856574|42.58250000000004|15.890126582278484|13.15797872340426|12.663077777777778|12.263332653061225|21.65772151898734|19.056170212765956|23.998148148148147|14.562244897959182|106.8756964889586|98.94766798666859|28.254852320675106|26.42127659574468\n",
      "\n",
      "a standardized 17-item scale that was developed by elaine scott and michelle eagle in 2011 to measure functional motor ability in ambulant children and adolescents with duchenne muscular dystrophy. the instrument, which is partly based on the hammersmith motor ability scale (2003), utilizes a 3-point rating scale to grade activities ranging from standing to running, as well as abilities that are necessary for a patient to remain functionally ambulant and that are known to progressively deteriorate in untreated dmd.| a standardized scale that measures the degree to which a person is able to perform daily living activities|28.040843881856574|45.06578947368425|15.890126582278484|11.693684210526317|12.663077777777778|10.155000000000001|21.65772151898734|12.273684210526316|23.998148148148147|10.000499999999999|106.8756964889586|93.86999999999999|28.254852320675106|26.54736842105263\n",
      "\n",
      "a person who has a license that gives them the legal power to witness the signing of documents, to certify that documents are real, and to take statements made under oath.|a person who has a license that gives them the legal power to watch the signing of documents, to declare that the documents are real, and to take code made under oath.|65.56701612903228|74.27000000000001|7.964677419354839|6.8750000000000036|9.758293548387096|9.171199999999999|7.647741935483875|6.489999999999998|15.03709677419355|14.145937499999995|76.64453405168562|69.96656701596841|21.68387096774194|18.900000000000002\n",
      "\n",
      "a person who has a license that gives them the legal power to witness the signing of documents, to certify that documents are real, and to take statements made under oath.|a person who has a license that gives them the power to witness the signing of documents, to certify that documents are real, and to take statements made under oath.|65.56701612903228|67.53000000000003|7.964677419354839|7.566666666666666|9.758293548387096|8.989493548387095|7.647741935483875|7.1186666666666625|15.03709677419355|6.679354838709678|76.64453405168562|73.38155456243756|21.68387096774194|20.666666666666668\n",
      "\n",
      "a person who has a license that gives them the legal power to witness the signing of documents, to certify that documents are real, and to take statements made under oath.| a witness|65.56701612903228|119.19000000000003|7.964677419354839|-2.619999999999999|9.758293548387096|15.6774|7.647741935483875|-81.02666666666666|15.03709677419355|-7.654999999999999|76.64453405168562|31.29|21.68387096774194|14.533333333333331\n",
      "\n",
      "any factor that lessens or improves the chief complaint.|any factor that changes or change the chief cry.|61.26750000000001|89.46750000000003|5.831666666666667|1.8983333333333334|9.346233333333334|5.837344444444444|-34.41777777777777|-39.64444444444443|7.666666666666668|3.4800000000000004|49.473833993334296|38.32226702584281|24.022222222222226|15.133333333333333\n",
      "\n",
      "any factor that lessens or improves the chief complaint.|any factor that lessens or improves chief complaint.|61.26750000000001|54.72500000000002|5.831666666666667|6.620000000000001|9.346233333333334|10.877477777777777|-34.41777777777777|-40.19|7.666666666666668|4.370000000000001|49.473833993334296|49.473833993334296|24.022222222222226|26.6\n",
      "\n",
      "any factor that lessens or improves the chief complaint.| any factor that degrades or makes better the chief complaint.|61.26750000000001|78.19795454545455|5.831666666666667|3.7186363636363637|9.346233333333334|10.513266666666667|-34.41777777777777|-25.48727272727273|7.666666666666668|2.3725000000000023|49.473833993334296|49.473833993334296|24.022222222222226|20.381818181818183\n",
      "\n",
      "a person who determines the significance of a tumor identification assessment.|a person who concludes the message of a growth identity act.|1.2888636363636294|62.81613636363636|14.445909090909094|5.864090909090912|11.359372727272728|8.488463636363637|-17.46909090909091|-27.090909090909093|12.758181818181818|5.050909090909091|54.195869768830164|44.250742366654144|24.018181818181816|16.745454545454546\n",
      "\n",
      "a person who determines the significance of a tumor identification assessment.|a person who determines the significance of a tumor identification test.|1.2888636363636294|16.670681818181833|14.445909090909094|12.300454545454546|11.359372727272728|10.513266666666667|-17.46909090909091|-20.14181818181818|12.758181818181818|5.905000000000001|54.195869768830164|49.473833993334296|24.018181818181816|20.381818181818183\n",
      "\n",
      "a person who determines the significance of a tumor identification assessment.| a person who determines the significance of a tumor identification assessment.|1.2888636363636294|17.44500000000002|14.445909090909094|12.316666666666666|11.359372727272728|12.461207692307694|-17.46909090909091|-15.523333333333326|12.758181818181818|6.819230769230767|54.195869768830164|54.195869768830164|24.018181818181816|22.400000000000002\n",
      "\n",
      "a ring-like band of skeletal muscle on the palpebrae, temple, cheeks, and surrounding the orbit, which originates on the frontal bone, medial palpebral ligament, and lacrimal bone with insertion on the lateral palpebral raphe, that functions to close the eyelid.|a ringlike band of skeletal muscle on the paper, temple, cheeks, and protect the path, which begin on the front bone, medial palpebral ligament, and lacrimal bone with movement on the pass palpebral raphe, that serve to close the eyelid.|40.60000000000002|61.75000000000003|12.565000000000005|9.615000000000002|12.60229512195122|10.3575|17.981|14.306|23.653902439024392|20.942500000000003|93.86999999999999|82.78555852321104|26.0|22.0\n",
      "\n",
      "a ring-like band of skeletal muscle on the palpebrae, temple, cheeks, and surrounding the orbit, which originates on the frontal bone, medial palpebral ligament, and lacrimal bone with insertion on the lateral palpebral raphe, that functions to close the eyelid.|a ring-like band of muscle on the palpebrae, temple, cheeks, and surrounding the orbit, which originates on a body part, that functions to close the eyelid.|40.60000000000002|63.486153846153854|12.565000000000005|7.633846153846157|12.60229512195122|9.406257142857143|17.981|7.08307692307692|23.653902439024392|6.596785714285716|93.86999999999999|69.96656701596841|26.0|20.58461538461539\n",
      "\n",
      "a ring-like band of skeletal muscle on the palpebrae, temple, cheeks, and surrounding the orbit, which originates on the frontal bone, medial palpebral ligament, and lacrimal bone with insertion on the lateral palpebral raphe, that functions to close the eyelid.| a ring-shaped band of skeletal muscle|40.60000000000002|66.7871428571429|12.565000000000005|5.682857142857145|12.60229512195122|11.100677777777777|17.981|-14.565714285714286|23.653902439024392|0.33999999999999986|93.86999999999999|54.195869768830164|26.0|19.942857142857143\n",
      "\n",
      "any process involved in the maintenance of an internal steady state of water within an organism or cell. [goc:dph, goc:mah, goc:tb]|any walk have in the wrongdoing of an internal steady state of water within a system or cell.  [ goc : dph , goc : mah , goc : tb ]|59.20607142857145|105.995|7.609761904761903|2.4499999999999993|12.784616666666667|11.629033333333332|2.8895238095238085|-0.125|4.783750000000001|0.25786666666666846|69.96656701596841|58.53822981607831|23.247619047619047|15.15\n",
      "\n",
      "any process involved in the maintenance of an internal steady state of water within an organism or cell. [goc:dph, goc:mah, goc:tb]|any process involved in the maintenance of an internal steady state of water within an organism or cell. [goc:dph, goc:m,tb]|59.20607142857145|61.32500000000002|7.609761904761903|7.190000000000001|12.784616666666667|12.784616666666667|2.8895238095238085|1.564|4.783750000000001|3.998750000000001|69.96656701596841|66.37611354998121|23.247619047619047|22.0\n",
      "\n",
      "any process involved in the maintenance of an internal steady state of water within an organism or cell. [goc:dph, goc:mah, goc:tb]| a process|59.20607142857145|119.19000000000003|7.609761904761903|-2.619999999999999|12.784616666666667|15.6774|2.8895238095238085|-81.02666666666666|4.783750000000001|-7.654999999999999|69.96656701596841|31.29|23.247619047619047|14.533333333333331\n",
      "\n",
      "a measurement of the streptococcus pneumoniae serotype 5 igg antibody in a biological specimen.|a functional concept of the streptococcus pneumonia serotype 5 egg protein in a biological sample.|18.44428571428574|30.022500000000008|12.425714285714289|10.935000000000002|14.481614285714286|13.8545|-7.845714285714287|-6.538666666666671|12.820714285714281|12.131999999999998|58.53822981607831|62.58|22.8|24.333333333333336\n",
      "\n",
      "a measurement of the streptococcus pneumoniae serotype 5 igg antibody in a biological specimen.|a measurement of the streptococcus pneumoniae protein complex in a biological specimen.|18.44428571428574|17.44500000000002|12.425714285714289|12.316666666666666|14.481614285714286|13.675823076923077|-7.845714285714287|-11.603333333333325|12.820714285714281|9.355384615384615|58.53822981607831|58.53822981607831|22.8|25.733333333333338\n",
      "\n",
      "a measurement of the streptococcus pneumoniae serotype 5 igg antibody in a biological specimen.| a measurement of the antibody molecule streptococcus pneumoniae serotype 5|18.44428571428574|26.470000000000027|12.425714285714289|12.3|14.481614285714286|16.0742|-7.845714285714287|8.370909090909091|12.820714285714281|10.8675|58.53822981607831|76.64453405168562|22.8|26.218181818181815\n",
      "\n",
      "the fifth and smallest finger from the radial side of the hand. (nci)|the fifth and smallest search from the radial side of the hand.  ( nice)|102.62211538461541|120.2625|0.560384615384617|-1.6516666666666655|6.388130769230769|6.123680952380953|-19.75692307692308|-16.730666666666668|1.3846153846153868|-0.2566666666666677|31.29|22.125371183327072|8.753846153846155|5.666666666666668\n",
      "\n",
      "the fifth and smallest finger from the radial side of the hand. (nci)|the fifth and smallest finger from the base side of the hand. (nci)|102.62211538461541|109.12980769230771|0.560384615384617|-0.347307692307691|6.388130769230769|6.239414285714286|-19.75692307692308|-20.209230769230775|1.3846153846153868|-0.09928571428571331|31.29|22.125371183327072|8.753846153846155|5.676923076923078\n",
      "\n",
      "the fifth and smallest finger from the radial side of the hand. (nci)| finger|102.62211538461541|120.20500000000001|0.560384615384617|-3.01|6.388130769230769|14.311966666666669|-19.75692307692308|-127.42|1.3846153846153868|-7.370000000000001|31.29|31.29|8.753846153846155|20.8\n",
      "\n",
      "walking on sloping, uneven, or moving surfaces, such as on grass, gravel or ice and snow, or walking aboard a ship, train or other vehicle.|walking on feed, uneven, or moving appear, such as on grass, rock or ice and snow, or walking aboard a ship, train or other object.|65.55550000000002|79.09150000000001|7.221|5.333000000000002|6.7713|6.1396999999999995|3.367999999999995|1.4863999999999997|11.417200000000001|9.91|69.96656701596841|62.58|21.0|17.8\n",
      "\n",
      "walking on sloping, uneven, or moving surfaces, such as on grass, gravel or ice and snow, or walking aboard a ship, train or other vehicle.|walking on sloping, uneven or moving surfaces, such as on grass, gravel or ice and snow, or walking aboard a ship, train or other vehicle.|65.55550000000002|65.55550000000002|7.221|7.221|6.7713|6.710530769230769|3.367999999999995|3.367999999999995|11.417200000000001|4.815769230769231|69.96656701596841|69.96656701596841|21.0|21.0\n",
      "\n",
      "walking on sloping, uneven, or moving surfaces, such as on grass, gravel or ice and snow, or walking aboard a ship, train or other vehicle.| Walking|65.55550000000002|120.20500000000001|7.221|-3.01|6.7713|19.5753|3.367999999999995|-124.48|11.417200000000001|-5.800000000000001|69.96656701596841|31.29|21.0|20.8\n",
      "\n",
      "any process that stops, prevents or reduces the rate or extent of mast cell proliferation. [goc:add, goc:mah]|any wall that stops, prevents or weaken the rate or extent of the mast cell increase.  [ goc: add, god: mah]|53.889852941176486|99.53363636363638|7.854411764705883|2.109090909090913|10.75612105263158|8.495128571428573|-2.656470588235294|-3.6563636363636363|4.638947368421054|0.23714285714285666|62.58|49.473833993334296|22.223529411764705|13.490909090909092\n",
      "\n",
      "any process that stops, prevents or reduces the rate or extent of mast cell proliferation. [goc:add, goc:mah]|any process that stops, prevents or reduces cell proliferation. [goc:add, goc:mah]|53.889852941176486|32.05250000000001|7.854411764705883|10.155000000000001|10.75612105263158|13.006557142857146|-2.656470588235294|-14.796363636363644|4.638947368421054|4.274285714285714|62.58|58.53822981607831|22.223529411764705|27.654545454545453\n",
      "\n",
      "any process that stops, prevents or reduces the rate or extent of mast cell proliferation. [goc:add, goc:mah]| Any process that prevents or reduces cell division|53.889852941176486|56.70000000000002|7.854411764705883|7.58666666666667|10.75612105263158|13.6065|-2.656470588235294|-4.142222222222216|4.638947368421054|4.765000000000001|62.58|69.96656701596841|22.223529411764705|25.822222222222223\n",
      "\n",
      "a person having origins in any of the black racial groups of africa. terms such as \"haitian\" or \"negro\" can be used in addition to \"black or african american\". (omb)|a person having source in any of the black racial groups of africa.  terms such as `` haitian '' or `` negro '' can be used in addition to `` black or person american ''.  ( omb)|66.965|100.36307692307693|6.4033333333333395|2.4902564102564106|8.8695|10.75612105263158|-2.9440000000000026|-1.6615384615384627|3.3520000000000003|-0.3189473684210533|57.127462747788826|54.195869768830164|17.333333333333332|14.430769230769233\n",
      "\n",
      "a person having origins in any of the black racial groups of africa. terms such as \"haitian\" or \"negro\" can be used in addition to \"black or african american\". (omb)|a person having origins in any of the black racial groups of africa. terms such as \"haitian\" or \"negro\" can be used in addition to \"black or african american\" (omb)|66.965|61.890000000000015|6.4033333333333395|8.353333333333339|8.8695|9.498848387096775|-2.9440000000000026|6.922666666666661|3.3520000000000003|5.6158064516129045|57.127462747788826|69.96656701596841|17.333333333333332|19.333333333333332\n",
      "\n",
      "a person having origins in any of the black racial groups of africa. terms such as \"haitian\" or \"negro\" can be used in addition to \"black or african american\". (omb)| a person having origins in any of the racial groups|66.965|80.30636363636367|6.4033333333333395|4.790909090909089|8.8695|9.495033333333335|-2.9440000000000026|-3.9236363636363656|3.3520000000000003|1.8399999999999999|57.127462747788826|62.58|17.333333333333332|18.94545454545455\n",
      "\n",
      "a reduced ability to synthesize postvaccination antibodies against a haemophilus influenzae type b (hib) antigen, as measured by antibody titer determination following vaccination. []|a reduced ability to change postvaccination protein against a haemophilus influenzae type b (hib) substance, as be by protein titer choice following scar.  [ ]|-6.269999999999982|56.97846153846157|17.115|8.541538461538462|14.31459275362319|13.244133333333336|14.533333333333339|7.535384615384615|13.939855072463772|7.88625|85.69119412168324|73.38155456243756|29.8|22.123076923076923\n",
      "\n",
      "a reduced ability to synthesize postvaccination antibodies against a haemophilus influenzae type b (hib) antigen, as measured by antibody titer determination following vaccination. []|a reduced ability to synthesize antibodies against a viral protein, as measured by antibody titer determination following vaccination. []|-6.269999999999982|1.2767105263157816|17.115|15.441315789473688|14.504726086956522|13.24927894736842|14.533333333333339|5.9789473684210535|15.856521739130436|12.07578947368421|85.69119412168324|79.77416029015912|29.8|31.16842105263158\n",
      "\n",
      "a reduced ability to synthesize postvaccination antibodies against a haemophilus influenzae type b (hib) antigen, as measured by antibody titer determination following vaccination. []| a reduced ability to synthesize antibody following vaccination|-6.269999999999982|-9.099999999999994|17.115|16.764444444444447|14.504726086956522|15.185500000000001|14.533333333333339|3.6977777777777803|15.856521739130436|10.417000000000002|85.69119412168324|76.64453405168562|29.8|30.266666666666666\n",
      "\n",
      "breathing that requires observed effort or an increased amount of energy.|pause that requires check effort or a change amount of good_health.|47.434318181818185|78.19795454545455|8.009545454545457|3.7186363636363637|11.359372727272728|9.923918181818184|-20.14181818181818|-23.349090909090915|10.617272727272727|8.048181818181817|58.53822981607831|44.250742366654144|27.654545454545453|16.745454545454546\n",
      "\n",
      "breathing that requires observed effort or an increased amount of energy.|breathing that requires observed effort or a higher amount of energy.|47.434318181818185|55.12522727272727|8.009545454545457|6.936818181818182|11.359372727272728|10.513266666666667|-20.14181818181818|-21.74545454545455|10.617272727272727|4.727500000000003|58.53822981607831|54.195869768830164|27.654545454545453|24.018181818181816\n",
      "\n",
      "breathing that requires observed effort or an increased amount of energy.| breathing requiring observed effort or effort|47.434318181818185|54.70142857142861|8.009545454545457|7.368571428571428|12.794827272727273|17.84955|-20.14181818181818|-7.845714285714287|10.617272727272727|7.297499999999999|58.53822981607831|69.96656701596841|27.654545454545453|31.371428571428574\n",
      "\n",
      "prostate cancer limited to one-half or less of one lobe of the prostate gland. (from ajcc 6th and 7th eds.)|prostate cancer limited to one-half or less of one lobe of the prostate gland.  ( from ajcc 6th and 7th eds.)|94.31833333333333|103.25530303030304|1.7600000000000016|0.6790909090909132|11.50274761904762|12.0771|-18.528|-16.84363636363636|0.6857142857142868|2.0536363636363646|40.39521630094336|40.39521630094336|12.666666666666668|12.024242424242424\n",
      "\n",
      "prostate cancer limited to one-half or less of one lobe of the prostate gland. (from ajcc 6th and 7th eds.)|prostate cancer limited to one-half or less of one lobe of the prostate gland. (from ajcc 6th and 7th eds.)|94.31833333333333|94.31833333333333|1.7600000000000016|1.7600000000000016|11.67634761904762|12.0771|-18.528|-18.233999999999998|2.435714285714287|2.0536363636363646|40.39521630094336|40.39521630094336|12.666666666666668|12.666666666666668\n",
      "\n",
      "prostate cancer limited to one-half or less of one lobe of the prostate gland. (from ajcc 6th and 7th eds.)| prostate cancer|94.31833333333333|90.99000000000004|1.7600000000000016|1.3133333333333361|11.67634761904762|19.6249|-18.528|-69.26666666666665|2.435714285714287|-0.5899999999999999|40.39521630094336|44.250742366654144|12.666666666666668|27.866666666666664\n",
      "\n",
      "the joints that connect the fingers to the hand.|the joints that hit the search to the hand.|98.8675|117.66750000000002|0.5872222222222234|-2.0349999999999984|5.837344444444444|5.837344444444444|-39.64444444444443|-42.911111111111104|3.4800000000000004|0.8633333333333333|31.29|0.0|10.68888888888889|1.8\n",
      "\n",
      "the joints that connect the fingers to the hand.|joint that connects the fingers to the hand.|98.8675|97.025|0.5872222222222234|0.7199999999999989|5.837344444444444|7.368588888888889|-39.64444444444443|-46.07|3.4800000000000004|0.18333333333333002|31.29|31.29|10.68888888888889|11.600000000000001\n",
      "\n",
      "the joints that connect the fingers to the hand.| the joints that connect the fingers to the hand.|98.8675|108.70000000000002|0.5872222222222234|-0.6599999999999966|5.837344444444444|8.215663636363637|-39.64444444444443|-35.092|3.4800000000000004|-1.124545454545455|31.29|31.29|10.68888888888889|10.0\n",
      "\n",
      "the joints that connect the fingers to the hand.|the joints that hit the search to the hand.|98.8675|117.66750000000002|0.5872222222222234|-2.0349999999999984|5.837344444444444|5.837344444444444|-39.64444444444443|-42.911111111111104|3.4800000000000004|0.8633333333333333|31.29|0.0|10.68888888888889|1.8\n",
      "\n",
      "the joints that connect the fingers to the hand.|joint that connects the fingers to the hand.|98.8675|97.025|0.5872222222222234|0.7199999999999989|5.837344444444444|7.368588888888889|-39.64444444444443|-46.07|3.4800000000000004|0.18333333333333002|31.29|31.29|10.68888888888889|11.600000000000001\n",
      "\n",
      "the joints that connect the fingers to the hand.| the joints that connect the fingers to the hand.|98.8675|108.70000000000002|0.5872222222222234|-0.6599999999999966|5.837344444444444|8.215663636363637|-39.64444444444443|-35.092|3.4800000000000004|-1.124545454545455|31.29|31.29|10.68888888888889|10.0\n",
      "\n",
      "a eukaryotically conserved histone deacetylase complex which deacetylates histones across gene coding regions. composed of a catalytic histone deacetylase subunit, a chromodomain protein, a sin3 family co-repressor, and a wd repeat protein (clr6p, alp13p, pst2p, and prw1p respectively in schizosaccharomyces; rpd3p, sin3p, ume1p, rco1p and eaf3 in saccharomyces; homologs thereof in other species). [goc:vw, pmid:12773392, pmid:17450151]|a eukaryotically preserve histone deacetylase whole which distillates historians across gene mock regions.  the plan of a catalytic histone deacetylase subunit, a chromodomain protein, a sin3 family, co-repressor, and a wed repeat protein (clr6p, alp13p, pst2p, and prw1p respectively in fungus_genus; rpd3p, sin3p, ume1p, rco1p and eaf3 in fungus_genus; homologs thereof in other kind).  [ goc : vw , pmid:12773392 , pmid:17450151 ]|30.77404761904765|59.89564102564103|13.604285714285716|10.287692307692314|15.757329885057471|14.438636774193549|24.35785714285715|19.718769230769233|17.633563218390805|11.28274193548387|95.59252899677882|88.50148473330829|27.46666666666667|23.435897435897438\n",
      "\n",
      "a eukaryotically conserved histone deacetylase complex which deacetylates histones across gene coding regions. composed of a catalytic histone deacetylase subunit, a chromodomain protein, a sin3 family co-repressor, and a wd repeat protein (clr6p, alp13p, pst2p, and prw1p respectively in schizosaccharomyces; rpd3p, sin3p, ume1p, rco1p and eaf3 in saccharomyces; homologs thereof in other species). [goc:vw, pmid:12773392, pmid:17450151]|a protein complex which deacetylates histones across gene regions. composed of a catalytically conserved protein modification process that marks genes at risk. [goc:vw, pmid:12773392]|30.77404761904765|33.04000000000002|13.604285714285716|10.638333333333335|15.757329885057471|14.99790512820513|24.35785714285715|2.444999999999993|17.633563218390805|10.982179487179486|95.59252899677882|62.58|27.46666666666667|23.200000000000003\n",
      "\n",
      "a eukaryotically conserved histone deacetylase complex which deacetylates histones across gene coding regions. composed of a catalytic histone deacetylase subunit, a chromodomain protein, a sin3 family co-repressor, and a wd repeat protein (clr6p, alp13p, pst2p, and prw1p respectively in schizosaccharomyces; rpd3p, sin3p, ume1p, rco1p and eaf3 in saccharomyces; homologs thereof in other species). [goc:vw, pmid:12773392, pmid:17450151]||30.77404761904765|205.82000000000002|13.604285714285716|-15.2|15.757329885057471|19.476100000000002|24.35785714285715|-290.12|17.633563218390805|-16.22|95.59252899677882|0.0|27.46666666666667|0.4\n",
      "\n",
      "problem associated with freezing and becoming nonfunctional of an application program.|problem unites with the act and becoming nonfunctional of an action program.|8.979772727272717|45.64500000000001|13.373181818181823|8.383333333333333|12.794827272727273|10.810866666666666|-13.192727272727275|-17.483333333333327|16.183636363636367|9.689999999999998|58.53822981607831|54.195869768830164|27.654545454545453|22.400000000000002\n",
      "\n",
      "problem associated with freezing and becoming nonfunctional of an application program.|problem associated with freezing and becoming nonfunctional of a program.|8.979772727272717|24.100000000000023|13.373181818181823|11.14|11.359372727272728|11.086572727272728|-13.192727272727275|-20.979999999999997|16.183636363636367|8.723636363636363|58.53822981607831|54.195869768830164|27.654545454545453|26.0\n",
      "\n",
      "problem associated with freezing and becoming nonfunctional of an application program.| A problem associated with freezing and becoming nonfunctional of an application program|8.979772727272717|24.440000000000026|13.373181818181823|13.080000000000002|11.359372727272728|12.225900000000001|-13.192727272727275|12.05846153846154|16.183636363636367|11.811428571428571|58.53822981607831|82.78555852321104|27.654545454545453|26.738461538461536\n",
      "\n",
      "a chromosome band present on 20q|a body band present on 20q|87.94500000000002|102.045|2.4833333333333343|0.5166666666666693|9.197433333333334|6.565766666666667|-22.873333333333328|-28.75333333333333|2.7650000000000006|-1.9450000000000003|44.250742366654144|44.250742366654144|15.733333333333333|15.733333333333333\n",
      "\n",
      "a chromosome band present on 20q|a chromosome band present on 20q21.3.|87.94500000000002|92.00500000000002|2.4833333333333343|0.9233333333333356|9.197433333333334|10.577242857142856|-22.873333333333328|-115.66|2.7650000000000006|1.8514285714285705|44.250742366654144|25.548178017228544|15.733333333333333|14.133333333333333\n",
      "\n",
      "a chromosome band present on 20q| a chromosome|87.94500000000002|90.99000000000004|2.4833333333333343|1.3133333333333361|9.197433333333334|15.6774|-22.873333333333328|-75.14666666666666|2.7650000000000006|-4.122500000000002|44.250742366654144|31.29|15.733333333333333|14.533333333333331\n",
      "\n",
      "one of a pair of thick-walled tubes that transports urine from the kidney pelvis to the urinary bladder.|one of a pair of thick-walled ride that moves urine from the kidney pelvis to the urine bag.|61.400000000000034|84.90000000000003|6.9311111111111146|3.653333333333336|11.22732105263158|8.734163157894738|-4.468888888888891|-8.388888888888882|9.141052631578948|6.1663157894736855|62.58|49.473833993334296|21.37777777777778|14.711111111111112\n",
      "\n",
      "one of a pair of thick-walled tubes that transports urine from the kidney pelvis to the urinary bladder.|one of a pair of thick-walled tubes that transport urine from the kidney pelvis to the urinary bladder.|61.400000000000034|61.400000000000034|6.9311111111111146|6.9311111111111146|11.22732105263158|11.238|-4.468888888888891|-4.468888888888891|9.141052631578948|3.5874999999999986|62.58|62.58|21.37777777777778|21.37777777777778\n",
      "\n",
      "one of a pair of thick-walled tubes that transports urine from the kidney pelvis to the urinary bladder.| one of a pair of tubes that transports urine from the kidney to the bladder|61.400000000000034|84.845|6.9311111111111146|5.400000000000002|11.22732105263158|10.981464705882354|-4.468888888888891|4.285|9.141052631578948|4.524705882352944|62.58|69.96656701596841|21.37777777777778|18.900000000000002\n",
      "\n",
      "an observation of the above normal incidence of immature neutrophils, including band neutrophils and neutrophil precursors in a biological specimen.|an attention of the above normal incidence of immature neutrophils, including band neutrophils and neutrophil person in a biological sample.|10.564999999999998|23.255000000000024|14.270000000000007|12.499999999999996|13.313|11.734|8.326000000000004|5.974|18.478499999999997|16.594500000000004|76.64453405168562|76.64453405168562|28.0|28.0\n",
      "\n",
      "an observation of the above normal incidence of immature neutrophils, including band neutrophils and neutrophil precursors in a biological specimen.|an observation of the above normal incidence of immature neutrophils, including a normal range of cell types in biological specimens.|10.564999999999998|31.715000000000003|14.270000000000007|11.320000000000004|13.313|13.180157142857144|8.326000000000004|4.210000000000004|18.478499999999997|9.164285714285718|76.64453405168562|69.96656701596841|28.0|24.0\n",
      "\n",
      "an observation of the above normal incidence of immature neutrophils, including band neutrophils and neutrophil precursors in a biological specimen.| an observation of the incidence of immature neutrophils|10.564999999999998|37.900000000000034|14.270000000000007|10.208888888888893|13.313|13.6065|8.326000000000004|-0.8755555555555503|18.478499999999997|7.120000000000001|76.64453405168562|62.58|28.0|21.37777777777778\n",
      "\n",
      "the outermost layer of the renal capsule, which is composed of a single layer of simple squamous epithelium.|the outermost shape of the renal seat, which is a plan of a single shape of simple squamous epithelium.|52.00000000000003|72.51881578947369|8.242222222222225|5.504473684210527|11.547077777777778|7.90311052631579|-3.1622222222222227|-4.852631578947367|10.858333333333334|8.645263157894735|69.96656701596841|54.195869768830164|25.822222222222223|16.431578947368422\n",
      "\n",
      "the outermost layer of the renal capsule, which is composed of a single layer of simple squamous epithelium.|the outermost layer of the renal capsule, which is composed of two layers of simple skin cells.|52.00000000000003|73.79573529411766|8.242222222222225|5.077941176470592|11.547077777777778|10.223455555555555|-3.1622222222222227|-7.152941176470584|10.858333333333334|3.4800000000000004|69.96656701596841|58.53822981607831|25.822222222222223|19.870588235294118\n",
      "\n",
      "the outermost layer of the renal capsule, which is composed of a single layer of simple squamous epithelium.| the capsule, which is composed of a single layer of simple squamous epithelium|52.00000000000003|59.68214285714288|8.242222222222225|8.412857142857145|11.547077777777778|11.749166666666667|-3.1622222222222227|6.997142857142855|10.858333333333334|7.1080000000000005|69.96656701596841|82.78555852321104|25.822222222222223|25.6\n",
      "\n",
      "a pattern of choosing a course of action for meeting short- and long-term health-related goals, which can be strengthened.|a match of choosing a course of action for meeting short- and long-term health-related goals, which can be changed.|72.51881578947369|85.87671052631579|5.504473684210527|3.641315789473687|8.43762380952381|6.933814285714286|1.0273684210526355|-1.1389473684210465|11.49857142857143|9.92857142857143|54.195869768830164|44.250742366654144|16.431578947368422|12.221052631578948\n",
      "\n",
      "a pattern of choosing a course of action for meeting short- and long-term health-related goals, which can be strengthened.|a pattern of choosing a course of action for meeting short- and long-term health goals, which can be strengthened.|72.51881578947369|85.87671052631579|5.504473684210527|3.641315789473687|8.43762380952381|7.91682380952381|1.0273684210526355|-1.1389473684210465|11.49857142857143|4.902857142857144|54.195869768830164|49.473833993334296|16.431578947368422|14.326315789473682\n",
      "\n",
      "a pattern of choosing a course of action for meeting short- and long-term health-related goals, which can be strengthened.| a pattern of choosing a course of action for meeting short- and long-term goals, which can be strengthened|72.51881578947369|80.68684210526318|5.504473684210527|6.725263157894737|8.43762380952381|9.189528571428571|1.0273684210526355|12.273684210526316|11.49857142857143|9.03142857142857|54.195869768830164|69.96656701596841|16.431578947368422|18.126315789473683\n",
      "\n",
      "any cranial somatic dysfunction resulting in abnormal dural membrane tension.|any finding somatic dysfunction happens in abnormal dural sheet stress.|7.180000000000035|32.56000000000003|13.5|9.96|16.7645|13.6065|-19.216|-22.743999999999993|15.127000000000002|12.300999999999995|66.37611354998121|58.53822981607831|38.0|30.0\n",
      "\n",
      "any cranial somatic dysfunction resulting in abnormal dural membrane tension.|any brain abnormality resulting in abnormal dural membrane tension.|7.180000000000035|4.867500000000007|13.5|13.698333333333334|16.7645|14.9375|-19.216|-26.57777777777777|15.127000000000002|8.859000000000002|66.37611354998121|58.53822981607831|38.0|32.91111111111112\n",
      "\n",
      "any cranial somatic dysfunction resulting in abnormal dural membrane tension.| any cranial neuralgia|7.180000000000035|54.72500000000002|13.5|6.620000000000001|16.7645|16.5165|-19.216|-44.6|15.127000000000002|0.8520000000000003|66.37611354998121|54.195869768830164|38.0|31.6\n",
      "\n",
      "life-threatening consequences; urgent operative intervention indicated (e.g., organ resection)|life-threatening result; urgent detective care inform (e.g., organ resection)|-68.80999999999995|6.390000000000015|23.602222222222228|13.113333333333333|16.7645|14.9375|-42.48|-53.58666666666666|21.720999999999997|11.214000000000006|51.09635603445709|47.79626449838941|36.75555555555555|32.31111111111112\n",
      "\n",
      "life-threatening consequences; urgent operative intervention indicated (e.g., organ resection)|life-threatening consequences; urgent operative intervention indicated (e.g., organ removal)|-68.80999999999995|-68.80999999999995|23.602222222222228|23.602222222222228|16.7645|17.10119090909091|-42.48|-43.133333333333326|21.720999999999997|18.32454545454545|51.09635603445709|51.09635603445709|36.75555555555555|36.75555555555555\n",
      "\n",
      "life-threatening consequences; urgent operative intervention indicated (e.g., organ resection)| Life-threatening situation; urgent operation|-68.80999999999995|-52.039999999999964|23.602222222222228|21.76000000000001|16.7645|17.517985714285714|-42.48|-9.807999999999993|21.720999999999997|9.657142857142855|51.09635603445709|62.58|36.75555555555555|34.0\n",
      "\n",
      "polypeptide hormone secreted by thymic epithelial cells; maintains immune system functions and can restore t cell function in thymectomized animals.|peptide hormone hides by thymic epithelial cells; maintains immune system, serve and can change t cell serve in thymectomized animals.|19.025000000000006|44.405|13.09|9.55|14.892000000000001|11.734|8.326000000000004|4.210000000000004|18.478499999999997|14.945999999999998|79.77416029015912|69.96656701596841|30.0|24.0\n",
      "\n",
      "polypeptide hormone secreted by thymic epithelial cells; maintains immune system functions and can restore t cell function in thymectomized animals.|protein hormone secreted by thymic epithelial cells; maintains immune system functions and can restore t cell function.|19.025000000000006|43.93691176470591|13.09|9.242647058823533|14.892000000000001|15.486788888888892|8.326000000000004|1.1482352941176472|18.478499999999997|9.760000000000002|79.77416029015912|73.38155456243756|30.0|29.28235294117647\n",
      "\n",
      "polypeptide hormone secreted by thymic epithelial cells; maintains immune system functions and can restore t cell function in thymectomized animals.| hormone|19.025000000000006|120.20500000000001|13.09|-3.01|14.892000000000001|19.5753|8.326000000000004|-124.48|18.478499999999997|-5.800000000000001|79.77416029015912|31.29|30.0|20.8\n",
      "\n",
      "a therapeutic analogue of the endogenous cxc cytokine macrophage inflammatory protein-2 alpha. macrophage inflammatory protein-2 alpha attracts and activates neutrophils and may play a role in cell proliferation. in experimental models of acute hepatic injury, macrophage inflammatory protein-2 alpha has been shown to promote liver regeneration by stimulating the proliferation of hepatocytes. (nci04)|a medicine analogue of the endogenous cxc protein macrophage inflammatory protein-2 start.  macrophage inflammatory protein-2 alpha attracts and change neutrophils and may play a role in cell increase.  in the experimental shape of a cute bright wrongdoing, macrophage inflammatory protein-2 alpha has been shown to play liver reconstruction by challenge the increase of hepatocytes.  ( nci04)|6.627759433962268|51.34171610169494|15.62655660377359|9.762500000000003|14.125209433962263|12.010966666666667|16.49056603773585|13.318644067796608|15.765566037735852|10.364022988505749|82.78555852321104|73.38155456243756|26.432075471698113|20.815254237288137\n",
      "\n",
      "a therapeutic analogue of the endogenous cxc cytokine macrophage inflammatory protein-2 alpha. macrophage inflammatory protein-2 alpha attracts and activates neutrophils and may play a role in cell proliferation. in experimental models of acute hepatic injury, macrophage inflammatory protein-2 alpha has been shown to promote liver regeneration by stimulating the proliferation of hepatocytes. (nci04)|a therapeutic analogue of the protein complex formed by a protein molecule that activates hepatocytes. (nci04)|6.627759433962268|29.515000000000015|15.62655660377359|11.130000000000003|14.125209433962263|13.346335294117647|16.49056603773585|-1.7199999999999989|15.765566037735852|8.586470588235294|82.78555852321104|62.58|26.432075471698113|23.200000000000003\n",
      "\n",
      "a therapeutic analogue of the endogenous cxc cytokine macrophage inflammatory protein-2 alpha. macrophage inflammatory protein-2 alpha attracts and activates neutrophils and may play a role in cell proliferation. in experimental models of acute hepatic injury, macrophage inflammatory protein-2 alpha has been shown to promote liver regeneration by stimulating the proliferation of hepatocytes. (nci04)| a therapeutic analogue of the endogenous mediator macrophage inflammatory protein-2 alpha|6.627759433962268|4.305000000000007|15.62655660377359|15.64|14.125209433962263|16.427453846153846|16.49056603773585|14.533333333333339|15.765566037735852|14.416923076923077|82.78555852321104|82.78555852321104|26.432075471698113|28.13333333333334\n",
      "\n",
      "a disorder characterized by reduced blood flow to the skin.|a change distinguishes by reducing blood flow to the skin.|57.940000000000026|74.86000000000003|6.420000000000002|4.060000000000002|8.8695|7.2905|-29.799999999999997|-30.387999999999998|6.649000000000001|6.178000000000001|38.32226702584281|31.29|14.0|10.0\n",
      "\n",
      "a disorder characterized by reduced blood flow to the skin.|a disorder characterized by reduced blood flow to the skin.|57.940000000000026|57.940000000000026|6.420000000000002|6.420000000000002|8.8695|9.651118181818184|-29.799999999999997|-29.211999999999996|6.649000000000001|2.7290909090909103|38.32226702584281|38.32226702584281|14.0|14.0\n",
      "\n",
      "a disorder characterized by reduced blood flow to the skin.| a skin disease|57.940000000000026|118.17500000000001|6.420000000000002|-2.2299999999999986|8.8695|13.3585|-29.799999999999997|-54.89|6.649000000000001|-5.742000000000001|38.32226702584281|31.29|14.0|11.600000000000001\n",
      "\n",
      "enables the transfer of short-chain fatty acids from one side of a membrane to the other. short-chain fatty acids are fatty acids with a chain length of less than c6. [goc:mah]|change the shift of short-chain fatty acids from one side of a sheet to the other.  short-chain fatty acids are fatty acids with a chain length of less than c6.  [ goc: mah]|76.26924731182795|98.30761904761907|5.188387096774196|2.445714285714285|9.771574509803923|9.256953333333335|-0.9522580645161263|-2.0194285714285733|3.4922549019607843|-0.298333333333332|65.13532912329528|54.195869768830164|20.907526881720432|14.952380952380953\n",
      "\n",
      "enables the transfer of short-chain fatty acids from one side of a membrane to the other. short-chain fatty acids are fatty acids with a chain length of less than c6. [goc:mah]|enables the transfer of short-chain fatty acids from one side of a membrane to the other side of the membrane is the one with the longest chain length of less than c6. [goc:mah]|76.26924731182795|79.85113636363639|5.188387096774196|6.2207575757575775|9.771574509803923|8.915411111111112|-0.9522580645161263|8.075151515151514|3.4922549019607843|6.017499999999998|65.13532912329528|69.96656701596841|20.907526881720432|18.721212121212123\n",
      "\n",
      "enables the transfer of short-chain fatty acids from one side of a membrane to the other. short-chain fatty acids are fatty acids with a chain length of less than c6. [goc:mah]| enables the transfer of short-chain fatty acids|76.26924731182795|61.24000000000001|5.188387096774196|6.705000000000002|9.771574509803923|13.6065|-0.9522580645161263|-6.130000000000003|3.4922549019607843|3.3520000000000003|65.13532912329528|69.96656701596841|20.907526881720432|28.200000000000003\n",
      "\n",
      "seizures that occur while the affected individual is sleeping. [pmid:22334817, pmid:23385697, pmid:25941204]|attack that occurs while the refer individual is sleeping.  [ pmid: 22334817, pmid: 23385697, pmid: 25941204]|66.79500000000002|98.67808823529413|5.433333333333334|1.6073529411764724|13.045733333333335|13.769783333333333|-1.8033333333333275|-2.656470588235294|16.68|6.552916666666668|49.473833993334296|49.473833993334296|19.06666666666667|15.164705882352942\n",
      "\n",
      "seizures that occur while the affected individual is sleeping. [pmid:22334817, pmid:23385697, pmid:25941204]|seizures that occur while the affected individual is sleeping. [pmid:22334817, pmid =23385697, pmc:25941204]|66.79500000000002|70.08365384615385|5.433333333333334|5.098846153846157|13.144933333333334|14.535166666666669|-1.8033333333333275|-1.664615384615388|17.68|11.208000000000006|49.473833993334296|49.473833993334296|19.06666666666667|17.984615384615388\n",
      "\n",
      "seizures that occur while the affected individual is sleeping. [pmid:22334817, pmid:23385697, pmid:25941204]| seizures|66.79500000000002|77.90500000000002|5.433333333333334|2.890000000000004|13.144933333333334|19.5753|-1.8033333333333275|-121.53999999999999|17.68|-4.229999999999997|49.473833993334296|31.29|19.06666666666667|20.8\n",
      "\n",
      "<p>values for security metadata observation made about the formal declaration by an authority or neutral third party that validates the technical, security, trust, and business practice conformance of trust agents to facilitate security, interoperability, and trust among participants within a security domain or trust framework.</p>|< p > values for security data attention made about the dance document by a book or neutral third party that change the foul, security, trust, and business practice conformance of trusted agents to cause security, ability, and trust among contestant within a security domain or trust framework.  < /p >|-7.762499999999989|45.41038461538463|19.93166666666667|13.384615384615387|14.123022448979594|11.910138461538462|24.60711111111111|16.997692307692304|30.36877551020408|13.851923076923079|112.8176994092682|103.77718969022045|32.11111111111111|27.323076923076925\n",
      "\n",
      "<p>values for security metadata observation made about the formal declaration by an authority or neutral third party that validates the technical, security, trust, and business practice conformance of trust agents to facilitate security, interoperability, and trust among participants within a security domain or trust framework.</p>|a value for security metadata observation made about the formal declaration by an authority or neutral third party that validates the technical, security, trust, and business practice conformance of trust agents to help secure the domain or trust framework.|-7.762499999999989|24.35019230769234|19.93166666666667|14.707307692307694|14.123022448979594|11.33925|24.60711111111111|17.989743589743597|30.36877551020408|14.003999999999998|112.8176994092682|98.94766798666859|32.11111111111111|28.312820512820508\n",
      "\n",
      "<p>values for security metadata observation made about the formal declaration by an authority or neutral third party that validates the technical, security, trust, and business practice conformance of trust agents to facilitate security, interoperability, and trust among participants within a security domain or trust framework.</p>| <p>security metadata consists of information used in the observation of an entity's formal declaration|-7.762499999999989|5.490000000000009|19.93166666666667|16.220000000000006|14.123022448979594|15.382584210526316|24.60711111111111|15.546666666666667|30.36877551020408|10.62842105263158|112.8176994092682|88.50148473330829|32.11111111111111|27.33333333333334\n",
      "\n",
      "functional assessment of cancer therapy-cognitive function version 3 - perceived cognitive impairments: subscale score.|functional act of cancer therapy-cognitive serve version 3 - perceived cognitive damage: subscale score.|18.44428571428574|42.61571428571432|12.425714285714289|9.054285714285715|17.865185714285715|14.481614285714286|2.2342857142857113|-4.065714285714286|19.885714285714286|14.839285714285715|69.96656701596841|62.58|31.371428571428574|25.65714285714286\n",
      "\n",
      "functional assessment of cancer therapy-cognitive function version 3 - perceived cognitive impairments: subscale score.|cancer therapy-cognitive function version 3 - perceived cognitive impairments: subscale score.|18.44428571428574|24.36159090909092|12.425714285714289|11.227727272727272|17.865185714285715|18.40826666666667|2.2342857142857113|-8.381818181818183|19.885714285714286|13.362500000000004|69.96656701596841|62.58|31.371428571428574|31.290909090909096\n",
      "\n",
      "functional assessment of cancer therapy-cognitive function version 3 - perceived cognitive impairments: subscale score.| assessment|18.44428571428574|77.90500000000002|12.425714285714289|2.890000000000004|17.865185714285715|19.5753|2.2342857142857113|-115.66|19.885714285714286|-1.0899999999999999|69.96656701596841|31.29|31.371428571428574|20.8\n",
      "\n",
      "a terminology subset of the cdisc study data tabulation model (sdtm) unit codelist created for clinical data acquisition standards harmonization (cdash) unit for duration of treatment interruption terminology.|a word set of the cdisc study data tabulation model (steam) unit codelist created for clinical data acquiring flag, singing (crash) unit for time of care happening word.|-6.789285714285711|47.59642857142859|17.684285714285718|10.098571428571429|16.867800000000003|11.792442857142857|17.077142857142857|8.677142857142854|22.34392857142857|15.447142857142858|96.44225707644962|79.77416029015912|32.74285714285715|24.171428571428574\n",
      "\n",
      "a terminology subset of the cdisc study data tabulation model (sdtm) unit codelist created for clinical data acquisition standards harmonization (cdash) unit for duration of treatment interruption terminology.|a terminology subset of the cdisc study data tabulation model (sdtm) unit codelist created for clinical data acquisition standards harmonization (cdash) unit for duration of treatment interruption terminology.|-6.789285714285711|-6.789285714285711|17.684285714285718|17.684285714285718|16.867800000000003|16.334320689655172|17.077142857142857|17.287142857142857|22.34392857142857|14.729655172413793|96.44225707644962|96.44225707644962|32.74285714285715|32.74285714285715\n",
      "\n",
      "a terminology subset of the cdisc study data tabulation model (sdtm) unit codelist created for clinical data acquisition standards harmonization (cdash) unit for duration of treatment interruption terminology.| a terminology subset of the Clinical Data Acquisition Standards Harmonization (CDASH) unit for duration of treatment interruption terminology|-6.789285714285711|-12.81842105263155|17.684285714285718|19.767368421052627|16.867800000000003|16.471000000000004|17.077142857142857|23.105263157894736|22.34392857142857|17.772|96.44225707644962|108.39173953766033|32.74285714285715|32.863157894736844\n",
      "\n",
      "simulators designed for training in endoscopic diagnostic and therapeutic procedures performed in the bronchi. these simulators typically include an anatomic model resembling the characteristics of the bronchial tree that is capable of simulating coughing, breathing, and bleeding; the anatomic models are made of plastics, metal, or a combination of these. the equipment simulates the conditions for endoscopic procedures by providing access to entrances in the anatomic model resembling the body natural airways, permitting the use of flexible endoscopes, surgical instruments, cameras as well as the external use of video monitors. the simulator also includes a main control unit with dedicated software that permits both training and recording of the simulated endoscopic procedure in real time. bronchial endoscopic training simulators may include as integral parts or attached modules and/or accessories intended for training in particular procedures, such as diagnostic, emergency, ultrasonic, and other interventional bronchial procedures.|a machine designed for training in endoscopic diagnostic and medicine proceeding re-create in the bronchi.  these machines typically include an anatomic model match the property of the bronchial tree that is capable of dissemble coughing, breathing, and treat; the anatomic shape is made of plastics, metal, or an alliance of these.  the equipment dissemble the shampoo for endoscopic proceeding by providing reach to attract in the anatomic model match the body natural line, permit the use of flexible endoscopes, surgical address, cameras as well as the feature use of video observes.  the machine also includes a main control unit with assigning codes that permits both training and remind of the dissemble endoscopic software in real time.  the bronchial endoscopic training machine may include as integral parts or take modules and/or criminal convey for training in part proceeding, such as diagnostic, brake, ultrasonic, and other interventional bronchial proceeding.|-0.31347701149422846|30.57957505518766|19.306724137931038|15.246192052980135|13.677727586206897|11.74589941520468|24.36993103448276|20.364238410596023|21.849724137931034|12.144773391812862|117.07645963215661|109.88686864225407|32.839080459770116|29.669315673289187\n",
      "\n",
      "simulators designed for training in endoscopic diagnostic and therapeutic procedures performed in the bronchi. these simulators typically include an anatomic model resembling the characteristics of the bronchial tree that is capable of simulating coughing, breathing, and bleeding; the anatomic models are made of plastics, metal, or a combination of these. the equipment simulates the conditions for endoscopic procedures by providing access to entrances in the anatomic model resembling the body natural airways, permitting the use of flexible endoscopes, surgical instruments, cameras as well as the external use of video monitors. the simulator also includes a main control unit with dedicated software that permits both training and recording of the simulated endoscopic procedure in real time. bronchial endoscopic training simulators may include as integral parts or attached modules and/or accessories intended for training in particular procedures, such as diagnostic, emergency, ultrasonic, and other interventional bronchial procedures.|simulators designed for training in specific procedures, such as diagnostic, emergency, ultrasonic, and other interventions. these simulators typically include an anatomic model resembling the characteristics of the bronchial tree that is capable of simulating coughing, breathing and bleeding; the an|-0.31347701149422846|2.530000000000058|19.306724137931038|17.875000000000004|13.677727586206897|13.125982926829268|24.36993103448276|23.861000000000004|21.849724137931034|18.228780487804876|117.07645963215661|106.1095525859948|32.839080459770116|31.0\n",
      "\n",
      "simulators designed for training in endoscopic diagnostic and therapeutic procedures performed in the bronchi. these simulators typically include an anatomic model resembling the characteristics of the bronchial tree that is capable of simulating coughing, breathing, and bleeding; the anatomic models are made of plastics, metal, or a combination of these. the equipment simulates the conditions for endoscopic procedures by providing access to entrances in the anatomic model resembling the body natural airways, permitting the use of flexible endoscopes, surgical instruments, cameras as well as the external use of video monitors. the simulator also includes a main control unit with dedicated software that permits both training and recording of the simulated endoscopic procedure in real time. bronchial endoscopic training simulators may include as integral parts or attached modules and/or accessories intended for training in particular procedures, such as diagnostic, emergency, ultrasonic, and other interventional bronchial procedures.| simulator|-0.31347701149422846|35.60500000000002|19.306724137931038|8.790000000000003|13.677727586206897|19.5753|24.36993103448276|-118.6|21.849724137931034|-2.66|117.07645963215661|31.29|32.839080459770116|20.8\n",
      "\n",
      "a genus known for fibers obtained from their leaves: sisal from a. sisalana, henequen from a. fourcroyoides and a. cantala, or manila-maguey fiber from a. cantala. some species provide a sap that is fermented to an intoxicating drink, called pulque in mexico. some contain agavesides.|a kind known for trait exist from their leaves: sisal from a.  sisalana, henequen from a.  fourcroyoides and a.  agave, or manila-maguey trait from a.  agave.  some kind provide a sap that is converted to a poison drink, called plaque in mexico.  some contain agavesides.|48.84562500000001|82.58790441176471|7.8437500000000036|3.3237009803921573|12.635294202898551|12.121731623931623|-21.262222222222228|-20.95137254901961|9.99144927536232|1.2952350427350439|46.934999999999995|41.39277926160552|18.25|13.530392156862746\n",
      "\n",
      "a genus known for fibers obtained from their leaves: sisal from a. sisalana, henequen from a. fourcroyoides and a. cantala, or manila-maguey fiber from a. cantala. some species provide a sap that is fermented to an intoxicating drink, called pulque in mexico. some contain agavesides.|a genus known for fibers obtained from their leaves: a sap that is fermented to an intoxicating drink, called pulque in mexico. some contain agavesides.|48.84562500000001|56.24866666666668|7.8437500000000036|7.484000000000002|12.635294202898551|10.354376923076924|-21.262222222222228|-5.1791999999999945|9.99144927536232|7.714230769230767|46.934999999999995|51.09635603445709|18.25|16.133333333333336\n",
      "\n",
      "a genus known for fibers obtained from their leaves: sisal from a. sisalana, henequen from a. fourcroyoides and a. cantala, or manila-maguey fiber from a. cantala. some species provide a sap that is fermented to an intoxicating drink, called pulque in mexico. some contain agavesides.| genus|48.84562500000001|120.20500000000001|7.8437500000000036|-3.01|12.635294202898551|19.5753|-21.262222222222228|-130.36|9.99144927536232|-8.94|46.934999999999995|31.29|18.25|20.8\n",
      "\n",
      "transfusion-independent patients: a greater than or equal to 20 g/l increase in hemoglobin level or for transfusion-dependent patients: becoming transfusion-independent (adapted from revised response criteria for myelofibrosis: international working group-myeloproliferative neoplasms research and treatment (iwg-mrt) and european leukemianet (eln) consensus report. blood 22 august 2013 x volume 122 number 8)|transfusion-independent case : a greater than or equal to 20 g/l increase in hemoglobin level or for transfusion-dependent patients : becoming transfusion-independent ( change from revised response ideal for fibrosis : socialism working group-myeloproliferative growth research and care ( iwg-mrt ) and european leukemianet ( eln ) consensus report .  blood 22 august 2013 x volume, 122 number 8)|-6.352000000000004|33.97500000000002|20.356000000000005|15.973333333333333|15.457978571428571|14.191678947368422|30.613599999999995|23.15933333333333|21.67107142857143|19.427368421052627|119.14877024124084|110.62685591663536|33.2|28.66666666666667\n",
      "\n",
      "transfusion-independent patients: a greater than or equal to 20 g/l increase in hemoglobin level or for transfusion-dependent patients: becoming transfusion-independent (adapted from revised response criteria for myelofibrosis: international working group-myeloproliferative neoplasms research and treatment (iwg-mrt) and european leukemianet (eln) consensus report. blood 22 august 2013 x volume 122 number 8)|transfusion-independent patients: a greater than or equal to 20 g/l increase in hemoglobin level or for blood clot disorders: international working group-myelofibrosis research and treatment (iwg-mrt) and european leukemianet (eln|-6.352000000000004|-1.2749999999999773|20.356000000000005|20.890000000000004|15.457978571428571|14.8465|30.613599999999995|29.72533333333333|21.67107142857143|22.04228571428572|119.14877024124084|121.18564890283007|33.2|32.0\n",
      "\n",
      "transfusion-independent patients: a greater than or equal to 20 g/l increase in hemoglobin level or for transfusion-dependent patients: becoming transfusion-independent (adapted from revised response criteria for myelofibrosis: international working group-myeloproliferative neoplasms research and treatment (iwg-mrt) and european leukemianet (eln) consensus report. blood 22 august 2013 x volume 122 number 8)| anemic patient|-6.352000000000004|62.79000000000002|20.356000000000005|5.246666666666666|15.176014285714286|19.6249|30.613599999999995|-71.22666666666666|21.67107142857143|-1.7674999999999983|119.14877024124084|44.250742366654144|33.2|27.866666666666664\n",
      "\n",
      "pediatric quality of life neuromuscular module acute version 3 young adult parent report - in the past 7 days, how much of a problem has this been for your child: my child gets hurt accidentally.|pediatrician quality of life neuromuscular module acute turn 3 young adult parent report - in the past 7 days, how much of a problem has this been for your child: my child gets hurt accidentally.|65.79821428571432|65.79821428571432|8.429285714285715|8.429285714285715|10.89584117647059|10.431429411764706|10.133714285714284|10.133714285714284|17.319117647058825|17.319117647058825|73.38155456243756|69.96656701596841|19.571428571428573|18.428571428571427\n",
      "\n",
      "pediatric quality of life neuromuscular module acute version 3 young adult parent report - in the past 7 days, how much of a problem has this been for your child: my child gets hurt accidentally.|pediatric quality of life module acute version 3 young adult parent report - in the past 7 days, how much of a problem has this been for your child?|65.79821428571432|69.46206896551725|8.429285714285715|10.775172413793104|10.89584117647059|10.519727586206898|10.133714285714284|14.326896551724138|17.319117647058825|12.234827586206897|73.38155456243756|93.86999999999999|19.571428571428573|24.01379310344828\n",
      "\n",
      "pediatric quality of life neuromuscular module acute version 3 young adult parent report - in the past 7 days, how much of a problem has this been for your child: my child gets hurt accidentally.| pediatric quality of life neuromuscular module acute version 3 young adult report - in the last 7 days how often problem is this for your child: my child gets hurt accidentally|65.79821428571432|50.098750000000024|8.429285714285715|14.221250000000001|10.89584117647059|12.131825000000001|10.133714285714284|17.761249999999997|17.319117647058825|16.059374999999996|73.38155456243756|103.77718969022045|19.571428571428573|26.55\n",
      "\n",
      "evaluating and managing a new client in a comprehensive, prolonged, 150-minute, in-facility meeting. this code may be used by providers of services who are able to diagnose.|think and act a new case in a comprehensive, lengthen, 150-minute, in-facility meeting.  this code may be used by providers of services who are able to diagnose.|47.30000000000004|70.46166666666669|8.89777777777778|5.7500000000000036|9.800527586206897|8.343166666666667|-0.8755555555555503|-3.5742857142857147|8.55793103448276|3.6660000000000004|59.91578840339164|51.09635603445709|19.8962962962963|15.161904761904763\n",
      "\n",
      "evaluating and managing a new client in a comprehensive, prolonged, 150-minute, in-facility meeting. this code may be used by providers of services who are able to diagnose.|evaluating and managing a new client in an extensive, prolonged, 150-minute, in-facial meeting. this code may be used by providers of services who are able to diagnose.|47.30000000000004|56.70000000000002|8.89777777777778|7.58666666666667|9.800527586206897|9.922166666666667|-0.8755555555555503|-1.7466666666666661|8.55793103448276|4.922000000000001|59.91578840339164|59.91578840339164|19.8962962962963|19.8962962962963\n",
      "\n",
      "evaluating and managing a new client in a comprehensive, prolonged, 150-minute, in-facility meeting. this code may be used by providers of services who are able to diagnose.| assessing and managing a new client over a prolonged period|47.30000000000004|49.54272727272729|8.89777777777778|9.081818181818182|9.800527586206897|13.442533333333335|-0.8755555555555503|0.35272727272727167|8.55793103448276|4.98|59.91578840339164|76.64453405168562|19.8962962962963|26.218181818181815\n",
      "\n",
      "this gene plays a role in the structure of immunoglobulin light chains.|this gene plays a role in the structure of antibody light chains.|73.84500000000001|87.94500000000002|4.450000000000003|2.4833333333333343|9.495033333333335|9.495033333333335|-19.93333333333333|-22.873333333333328|7.727500000000003|5.372500000000002|31.29|31.29|9.066666666666666|9.066666666666666\n",
      "\n",
      "this gene plays a role in the structure of immunoglobulin light chains.|this gene plays a role in the structure of light chains.|73.84500000000001|108.96159090909092|4.450000000000003|-0.5722727272727273|9.495033333333335|9.197433333333334|-19.93333333333333|-28.694545454545462|7.727500000000003|-0.375|31.29|22.125371183327072|9.066666666666666|5.836363636363637\n",
      "\n",
      "this gene plays a role in the structure of immunoglobulin light chains.| this gene plays a role in the structure of the immunoglobulin protein|73.84500000000001|69.99384615384618|4.450000000000003|6.726153846153846|9.495033333333335|12.225900000000001|-19.93333333333333|3.916923076923073|7.727500000000003|5.755714285714284|31.29|54.195869768830164|9.066666666666666|14.430769230769233\n",
      "\n",
      "inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (dorland, 27th ed)|burning of part or all of the uvea, the middle (vascular) cloak of the eye, and commonly absorb the other cloak (sclera and cornea, and the membrane).  ( dorland, 27th ed)|56.25000000000003|79.5575|9.140000000000004|6.137499999999999|11.222833333333334|10.00820322580645|9.078666666666663|7.224999999999998|7.422000000000001|6.071612903225805|79.77416029015912|73.38155456243756|23.333333333333336|20.150000000000002\n",
      "\n",
      "inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (dorland, 27th ed)|inflammation of part or all the uvea, the middle (vascular) tunic of the eye, and commonly involving other organs. (dorland, 27th ed)|56.25000000000003|57.23363636363638|9.140000000000004|8.009090909090911|11.222833333333334|11.07211739130435|9.078666666666663|3.2927272727272765|7.422000000000001|5.822173913043478|79.77416029015912|69.96656701596841|23.333333333333336|22.581818181818182\n",
      "\n",
      "inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (dorland, 27th ed)| inflammation|56.25000000000003|35.60500000000002|9.140000000000004|8.790000000000003|11.222833333333334|19.5753|9.078666666666663|-109.78|7.422000000000001|2.0500000000000007|79.77416029015912|31.29|23.333333333333336|20.8\n",
      "\n",
      "a radioimmunoconjugate consisting of the iodine 131-radiolabeled murine igg1 monoclonal antibody 8h9 directed against the surface immunomodulatory glycoprotein 4ig-b7-h3 with potential radioimaging and radioimmunotherapeutic uses. iodine i 131 monoclonal antibody 8h9 binds to 4ig-b7-h3 (human b7-h3 with 4 ig-like domains) and may be used to radioimage and/or destroy tumor cells that express tenascin. 4ig-b7-h3 inhibits t-cell activation and the production of effector cytokines such as interferon-gamma and interleukin-4; it is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and is highly expressed on monocyte-derived dendritic cells (mddcs). in vitro, it has been shown that monoclonal antibody-mediated masking of 4ig-b7-h3 on neuroblastoma cells resulted in the enhancement of natural killer (nk)-mediated lysis of target cells.|an immunologic factor be of the iodine 131-radiolabeled murine igg1 monoclonal protein 8h9 directed against the surface immunomodulatory glycoprotein 4ig-b7-h3 with potential radioimaging and radioimmunotherapeutic uses.  iodine i 131 monoclonal protein 8h9 binds to 4ig-b7-h3 (human b7-h3 with 4 egg-like domains) and may be used to radio imaging and/or destroy tumor cells that express tension.  4ig-b7-h3 suppress t-cell beginning and the display of organ protein such as interferon-gamma and interleukin-4; it is mailed on the cell sheet of a wide difference of growth of neuroectodermal, mesenchymal and epithelial source and is highly mail on monocyte-derived dendritic cells (mddcs).  in vitro, it has been shown that a monoclonal antibody-mediated hide of 4ig-b7-h3 on neuroblastoma cells happen in the improvement of natural killer (nk) -mediated lysis of target cells.|12.666000000000025|33.371153846153874|17.604000000000003|15.063846153846157|14.386902898550725|12.722273399014778|25.30308943089431|22.493230769230763|21.55434782608696|12.44466009852217|104.7163689210049|100.90721797770465|28.051382113821138|26.400000000000002\n",
      "\n",
      "a radioimmunoconjugate consisting of the iodine 131-radiolabeled murine igg1 monoclonal antibody 8h9 directed against the surface immunomodulatory glycoprotein 4ig-b7-h3 with potential radioimaging and radioimmunotherapeutic uses. iodine i 131 monoclonal antibody 8h9 binds to 4ig-b7-h3 (human b7-h3 with 4 ig-like domains) and may be used to radioimage and/or destroy tumor cells that express tenascin. 4ig-b7-h3 inhibits t-cell activation and the production of effector cytokines such as interferon-gamma and interleukin-4; it is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and is highly expressed on monocyte-derived dendritic cells (mddcs). in vitro, it has been shown that monoclonal antibody-mediated masking of 4ig-b7-h3 on neuroblastoma cells resulted in the enhancement of natural killer (nk)-mediated lysis of target cells.|a radioimmunoconjugate consisting of the iodine 131-radiolabeled murine igg1 monoclonal antibody 8h9 directed against a protein complex. it is expressed on the skin, the deepest mucusosal tissue|12.666000000000025|30.199166666666713|17.604000000000003|12.400925925925925|14.386902898550725|13.067424137931035|25.30308943089431|14.878518518518518|21.55434782608696|12.780689655172417|104.7163689210049|82.78555852321104|28.051382113821138|26.14074074074074\n",
      "\n",
      "a radioimmunoconjugate consisting of the iodine 131-radiolabeled murine igg1 monoclonal antibody 8h9 directed against the surface immunomodulatory glycoprotein 4ig-b7-h3 with potential radioimaging and radioimmunotherapeutic uses. iodine i 131 monoclonal antibody 8h9 binds to 4ig-b7-h3 (human b7-h3 with 4 ig-like domains) and may be used to radioimage and/or destroy tumor cells that express tenascin. 4ig-b7-h3 inhibits t-cell activation and the production of effector cytokines such as interferon-gamma and interleukin-4; it is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and is highly expressed on monocyte-derived dendritic cells (mddcs). in vitro, it has been shown that monoclonal antibody-mediated masking of 4ig-b7-h3 on neuroblastoma cells resulted in the enhancement of natural killer (nk)-mediated lysis of target cells.| a|12.666000000000025|162.505|17.604000000000003|-8.91|14.386902898550725|14.311966666666669|25.30308943089431|-142.12|21.55434782608696|-15.219999999999999|104.7163689210049|0.0|28.051382113821138|0.8\n",
      "\n",
      "a measurement of the dermatophagoides farinae antigen igg antibody in a biological specimen.|a functional concept of the dermatophagoides farinae substance egg protein in a biological sample.|-8.008653846153834|18.44428571428574|15.99115384615385|12.425714285714289|13.998223076923077|13.353757142857145|-9.353846153846156|-6.585714285714289|13.692307692307686|13.829999999999998|58.53822981607831|62.58|24.13846153846154|25.65714285714286\n",
      "\n",
      "a measurement of the dermatophagoides farinae antigen igg antibody in a biological specimen.|a measurement of the farinae antigen igg antibody in a biological specimen.|-8.008653846153834|17.44500000000002|15.99115384615385|12.316666666666666|13.998223076923077|13.675823076923077|-9.353846153846156|-17.483333333333327|13.692307692307686|5.007692307692309|58.53822981607831|54.195869768830164|24.13846153846154|22.400000000000002\n",
      "\n",
      "a measurement of the dermatophagoides farinae antigen igg antibody in a biological specimen.| a measurement of the molecule antigen of the house dust mite|-8.008653846153834|74.805|15.99115384615385|5.806666666666668|13.998223076923077|11.568992307692309|-9.353846153846156|0.32333333333333414|13.692307692307686|3.91|58.53822981607831|54.195869768830164|24.13846153846154|14.8\n",
      "\n",
      "problem with all or part of an implanted or invasive device moving from its intended location within the body.|the problem with all or part of an attach or invasive device moving from its convey location within the body.|54.70828947368423|65.555|7.988684210526319|6.600000000000005|10.396268421052632|10.155000000000001|-2.6863157894736815|-3.139999999999997|10.62842105263158|9.529500000000002|66.37611354998121|66.37611354998121|22.74736842105263|22.0\n",
      "\n",
      "problem with all or part of an implanted or invasive device moving from its intended location within the body.|problem with all or part of a device moving from its intended location within the body.|54.70828947368423|66.5275|7.988684210526319|5.967500000000001|10.396268421052632|9.631041176470589|-2.6863157894736815|-10.172500000000003|10.62842105263158|2.7682352941176482|66.37611354998121|58.53822981607831|22.74736842105263|20.700000000000003\n",
      "\n",
      "problem with all or part of an implanted or invasive device moving from its intended location within the body.| problem with all or part of an implanted or invasive device moving from its intended location within the body.|54.70828947368423|61.32500000000002|7.988684210526319|7.190000000000001|10.396268421052632|10.924442857142857|-2.6863157894736815|-2.257999999999999|10.62842105263158|4.678571428571431|66.37611354998121|66.37611354998121|22.74736842105263|22.0\n",
      "\n",
      "a congenital lymphatic malformation usually arising from the neck and characterized by cystic dilation of the lymphatic vessels.|a birth defect lymphatic failure usually protest from the neck and distinguish by cystic dilation of the lymphatic craft.|9.700000000000017|50.25565789473683|14.142222222222227|8.609736842105267|11.547077777777778|12.889426315789473|3.3711111111111194|0.717894736842112|16.35333333333333|13.355263157894733|69.96656701596841|66.37611354998121|25.822222222222223|22.74736842105263\n",
      "\n",
      "a congenital lymphatic malformation usually arising from the neck and characterized by cystic dilation of the lymphatic vessels.|a congenital lymphatic malformation usually arising from the neck and characterized by cystic dilation of the lymph vessel.|9.700000000000017|19.100000000000023|14.142222222222227|12.831111111111113|11.547077777777778|11.587173684210526|3.3711111111111194|2.0644444444444474|16.35333333333333|9.596842105263157|69.96656701596841|66.37611354998121|25.822222222222223|23.6\n",
      "\n",
      "a congenital lymphatic malformation usually arising from the neck and characterized by cystic dilation of the lymphatic vessels.| a malformation|9.700000000000017|62.79000000000002|14.142222222222227|5.246666666666666|11.547077777777778|15.6774|3.3711111111111194|-71.22666666666666|16.35333333333333|-1.7674999999999983|69.96656701596841|31.29|25.822222222222223|14.533333333333331\n",
      "\n",
      "an elevated concentration of phosphohydroxylysine in the urine. [hpo:probinson, pmid:23242558]|a change diligence of phosphohydroxylysine in the urine.  [ hop: probinson, pmid: 23242558]|-9.73999999999998|66.7871428571429|15.86|5.682857142857145|13.957481818181819|12.300007692307693|-9.219999999999999|-9.525714285714287|15.57454545454545|6.643461538461537|49.473833993334296|44.250742366654144|22.0|14.228571428571428\n",
      "\n",
      "an elevated concentration of phosphohydroxylysine in the urine. [hpo:probinson, pmid:23242558]|an elevated concentration of a chemical in the urine. [hpo:probinson, pmid:23242558]|-9.73999999999998|32.05250000000001|15.86|10.155000000000001|13.957481818181819|13.675823076923077|-9.219999999999999|-13.727272727272734|15.57454545454545|7.181538461538462|49.473833993334296|49.473833993334296|22.0|20.381818181818183\n",
      "\n",
      "an elevated concentration of phosphohydroxylysine in the urine. [hpo:probinson, pmid:23242558]| an elevated concentration of phosphorylated amino acid in the urine.|-9.73999999999998|16.670681818181833|15.86|12.300454545454546|13.957481818181819|14.460766666666668|-9.219999999999999|-21.74545454545455|15.57454545454545|5.120000000000001|49.473833993334296|54.195869768830164|22.0|24.018181818181816\n",
      "\n",
      "a radioactive isotope of cesium with an atomic mass of 139 and potential application in radiotherapy. cesium cs 137 is prevalent due to its spontaneous production, which occurs as a result of nuclear fission of other radioactive materials, such as uranium and plutonium. this radionuclide has a relatively long half-life, 30 years, and decays by emitting beta particles. both cs 137 and its metastable nuclear isomer, barium-137m, emit gamma radiation of moderate energy and so are used in sterilization procedures in the food industry or in hospital environments. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c68812\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c68812\" nci thesaurus)|an atom atom of cesium with an atomic mass of 139 and potential action in therapy.  cesium, cs 137 is prevalent due to its spontaneous display, which occurs as a result of nuclear fission of the other radioactive applicant, such as uranium and plutonium.  this radionuclide has a relatively long half-life, 30 years, and change of exhaust beta body.  both cs 137 and its metastable nuclear isomer, barium-137m, emit gamma therapy of change good_health and so are used in cleaning proceeding in the food industry or in hospital environments.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c68812 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c68812 '' nice wordbook)|46.096666666666664|65.248574929972|8.900000000000002|6.622037815126053|12.839111764705882|13.639600593723495|6.286800000000007|4.097142857142856|19.07029411764706|9.541594571670906|59.91578840339164|61.26237874911485|20.933333333333337|19.42885154061625\n",
      "\n",
      "a radioactive isotope of cesium with an atomic mass of 139 and potential application in radiotherapy. cesium cs 137 is prevalent due to its spontaneous production, which occurs as a result of nuclear fission of other radioactive materials, such as uranium and plutonium. this radionuclide has a relatively long half-life, 30 years, and decays by emitting beta particles. both cs 137 and its metastable nuclear isomer, barium-137m, emit gamma radiation of moderate energy and so are used in sterilization procedures in the food industry or in hospital environments. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c68812\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c68812\" nci thesaurus)|a radioactive isotope of cesium with an atomic mass of 139 atoms and potential application in radiotherapy. cesium cs 137 is prevalent due to its spontaneous production, which occurs as a result of nuclear fission of other types of materials. this radionu|46.096666666666664|41.553571428571445|8.900000000000002|10.941428571428574|12.839111764705882|13.160456589147287|6.286800000000007|8.957142857142856|19.07029411764706|8.958062015503877|59.91578840339164|78.74477315987392|20.933333333333337|23.695238095238096\n",
      "\n",
      "a radioactive isotope of cesium with an atomic mass of 139 and potential application in radiotherapy. cesium cs 137 is prevalent due to its spontaneous production, which occurs as a result of nuclear fission of other radioactive materials, such as uranium and plutonium. this radionuclide has a relatively long half-life, 30 years, and decays by emitting beta particles. both cs 137 and its metastable nuclear isomer, barium-137m, emit gamma radiation of moderate energy and so are used in sterilization procedures in the food industry or in hospital environments. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c68812\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c68812\" nci thesaurus)| Ces|46.096666666666664|162.505|8.900000000000002|-8.91|12.839111764705882|19.5753|6.286800000000007|-136.24|19.07029411764706|-12.079999999999998|59.91578840339164|0.0|20.933333333333337|0.8\n",
      "\n",
      "ureter urothelial carcinoma that has spread to another anatomical site.|ureter neoplastic process cancer that has spread to another saying site.|-1.2799999999999727|47.434318181818185|14.68|8.009545454545457|12.0275|11.359372727272728|-22.743999999999993|-20.67636363636364|12.300999999999995|10.189090909090911|49.473833993334296|54.195869768830164|22.0|24.018181818181816\n",
      "\n",
      "ureter urothelial carcinoma that has spread to another anatomical site.|ureter cancer that has spread to another body site.|-1.2799999999999727|61.26750000000001|14.68|5.831666666666667|12.0275|10.200500000000002|-22.743999999999993|-37.0311111111111|12.300999999999995|1.3230000000000004|49.473833993334296|44.250742366654144|22.0|19.57777777777778\n",
      "\n",
      "ureter urothelial carcinoma that has spread to another anatomical site.| Cancer|-1.2799999999999727|120.20500000000001|14.68|-3.01|12.0275|19.5753|-22.743999999999993|-127.42|12.300999999999995|-7.370000000000001|49.473833993334296|31.29|22.0|20.8\n",
      "\n",
      "an orally administered non-steroidal antiinflammatory agent. acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. this agent exhibits analgesic, antipyretic, and anticoagulant properties.|an orally direct non-steroidal antiinflammatory agent.  acetylsalicylic acid binds to and change serine parts in enzyme, happen in change synthesis of autacoid, platelet grouping, and burning.  this agent walks, medicine, medicine, and medicine properties.|-53.10426470588234|26.150000000000034|22.777941176470588|11.847777777777779|15.493738095238097|11.350164864864865|12.389411764705883|3.2077777777777783|19.930190476190475|10.309324324324326|76.64453405168562|69.96656701596841|31.635294117647064|25.822222222222223\n",
      "\n",
      "an orally administered non-steroidal antiinflammatory agent. acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. this agent exhibits analgesic, antipyretic, and anticoagulant properties.|an orally administered non-steroidal antiinflammatory agent. acetylsalicylic acid binds to and acylates protein building blocks in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation|-53.10426470588234|-45.000833333333304|22.777941176470588|22.889814814814816|15.493738095238097|14.700872413793105|12.389411764705883|24.242962962962963|19.930190476190475|19.439655172413794|76.64453405168562|93.86999999999999|31.635294117647064|32.06666666666666\n",
      "\n",
      "an orally administered non-steroidal antiinflammatory agent. acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. this agent exhibits analgesic, antipyretic, and anticoagulant properties.| a nonsteroidal anti-inflammatory|-53.10426470588234|-51.02499999999998|22.777941176470588|21.370000000000008|15.493738095238097|17.092433333333332|12.389411764705883|-28.43|19.930190476190475|5.905000000000001|76.64453405168562|44.250742366654144|31.635294117647064|21.6\n",
      "\n",
      "carbetimer (carboxyimamidate) is a low molecular weight derivatized copolymer of ethylene and maleic anhydride. it has demonstrated antitumor activity against several animal models. it has calcium chelation activity but seems to inhibit growth of sensitive cells by disrupting nucleoside uptake and metabolism.|carbetimer (carboxyimamidate) is a low molecular weight derivatized polymer of alkene and maleic compound.  it has protested antitumor activity against several animal shapes.  it has calcium process activity but seems to suppress growth of psychic cells by break nucleoside uptake and metabolism.|-1.2224999999999966|24.54727272727274|16.038333333333334|12.56818181818182|12.977804761904762|12.326843636363636|9.469523809523807|6.900909090909092|15.175714285714285|9.731363636363639|76.64453405168562|75.03078418222748|27.057142857142857|25.309090909090912\n",
      "\n",
      "carbetimer (carboxyimamidate) is a low molecular weight derivatized copolymer of ethylene and maleic anhydride. it has demonstrated antitumor activity against several animal models. it has calcium chelation activity but seems to inhibit growth of sensitive cells by disrupting nucleoside uptake and metabolism.|carbetimer (carboxyimamidate) is a low molecular weight derivatized copolymer of ethylene and maleic anhydride. it has demonstrated antitumor activity against several animal models, it has anticancer potential, and inhibits growth of|-1.2224999999999966|-16.303951612903205|16.038333333333334|19.38403225806452|12.977804761904762|13.311975|9.469523809523807|19.597419354838713|15.175714285714285|15.8603125|76.64453405168562|93.86999999999999|27.057142857142857|29.425806451612903\n",
      "\n",
      "carbetimer (carboxyimamidate) is a low molecular weight derivatized copolymer of ethylene and maleic anhydride. it has demonstrated antitumor activity against several animal models. it has calcium chelation activity but seems to inhibit growth of sensitive cells by disrupting nucleoside uptake and metabolism.| carbomer is a low molecular weight polymer|-1.2224999999999966|50.66500000000002|16.038333333333334|8.180000000000003|12.977804761904762|14.60956666666667|9.469523809523807|-9.805000000000003|15.175714285714285|2.956666666666667|76.64453405168562|54.195869768830164|27.057142857142857|18.2\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of 2,4-dichlorophenoxyacetic acid, a chlorinated phenoxy compound which functions as a systemic herbicide and is used to control many types of broadleaf weeds. [goc:ai]|the process force and path happen in the breakdown of 2,4-dichlorophenoxyacetic acid, a disinfect phenoxy mix which serves as a systemic herbicide and is used to control many types of broadleaf weeds.  [ goc: ai]|49.087500000000006|75.76500000000001|10.511666666666667|7.163333333333334|13.076214285714286|11.249477777777777|17.518787878787876|12.46555555555556|13.292285714285718|7.073333333333334|88.50148473330829|73.38155456243756|25.993939393939396|19.422222222222224\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of 2,4-dichlorophenoxyacetic acid, a chlorinated phenoxy compound which functions as a systemic herbicide and is used to control many types of broadleaf weeds. [goc:ai]|the chemical reactions and pathways resulting in the breakdown of 2,4-dichlorophenoxyacetic acid, a chlorinated molecule used to control many types of broadleaf weeds. [goc:ai]|49.087500000000006|53.655|10.511666666666667|8.756666666666668|13.076214285714286|13.663137037037037|17.518787878787876|13.06333333333334|13.292285714285718|11.137777777777778|88.50148473330829|76.64453405168562|25.993939393939396|24.8\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of 2,4-dichlorophenoxyacetic acid, a chlorinated phenoxy compound which functions as a systemic herbicide and is used to control many types of broadleaf weeds. [goc:ai]| The chemical reaction resulting in the breakdown of dichlorophenoxy acid|49.087500000000006|18.77909090909094|10.511666666666667|13.372727272727271|13.076214285714286|14.758366666666669|17.518787878787876|7.301818181818181|13.292285714285718|10.082500000000003|88.50148473330829|76.64453405168562|25.993939393939396|26.218181818181815\n",
      "\n",
      "benign and malignant neoplasms arising from one or more of the cervical, thoracic, lumbar, sacral, or coccygeal nerve roots. the majority of these tumors are benign. clinical manifestations may include pain, weakness and loss of sensation along the course of the involved nerve root. large tumors may cause spinal cord compression.|benign and malignant growth protest from one or more of the cervical, thoracic, lumbar, sacral, or coccygeal nerve roots.  the age of these growths is benign.  clinical protest may include pain, weakness and loss of stir along the course of the involved nerve root.  large growth may cause spinal cord press.|53.82317647058824|83.07300000000004|8.286039215686277|4.355333333333334|10.151449019607844|10.159684126984127|3.3780392156862717|0.3592592592592574|10.064999999999998|4.145476190476188|65.6344577184881|55.973253612774734|21.334901960784318|16.17185185185185\n",
      "\n",
      "benign and malignant neoplasms arising from one or more of the cervical, thoracic, lumbar, sacral, or coccygeal nerve roots. the majority of these tumors are benign. clinical manifestations may include pain, weakness and loss of sensation along the course of the involved nerve root. large tumors may cause spinal cord compression.|benign and malignant neoplasms arising from one or more of the cervical, thoracic, spine and lumbar, sacral, or coccygeal nerve roots. the majority of these tumors are benign. clinical manifestations may include pain, weakness and|53.82317647058824|45.1304761904762|8.286039215686277|9.862857142857145|10.151449019607844|11.249477777777777|3.3780392156862717|7.72457142857143|10.064999999999998|9.428333333333335|65.6344577184881|72.26115969177356|21.334901960784318|22.952380952380953\n",
      "\n",
      "benign and malignant neoplasms arising from one or more of the cervical, thoracic, lumbar, sacral, or coccygeal nerve roots. the majority of these tumors are benign. clinical manifestations may include pain, weakness and loss of sensation along the course of the involved nerve root. large tumors may cause spinal cord compression.| tumors|53.82317647058824|120.20500000000001|8.286039215686277|-3.01|10.151449019607844|19.5753|3.3780392156862717|-127.42|10.064999999999998|-7.370000000000001|65.6344577184881|31.29|21.334901960784318|20.8\n",
      "\n",
      "enables the transfer of a negatively charged ion from one side of a membrane to the other. [goc:dgf, goc:mtg_transport, isbn:0815340729]|change the shift of a negatively charged ion from one side of a sheet to the other.  [ goc : dgf , goc : mtg_transport , isbn:0815340729 ]|69.78500000000001|113.35198275862071|6.010000000000002|1.0512068965517258|11.359372727272728|10.19546231884058|4.797999999999998|1.8896551724137929|7.620000000000001|3.700724637681155|54.195869768830164|38.32226702584281|16.0|9.937931034482759\n",
      "\n",
      "enables the transfer of a negatively charged ion from one side of a membrane to the other. [goc:dgf, goc:mtg_transport, isbn:0815340729]|enables the transfer of negatively charged ions from one side of a membrane to the other. [goc:dgf, goc:mtg_transport, isbn:0815340729]|69.78500000000001|68.0661842105263|6.010000000000002|6.125526315789475|11.359372727272728|12.0771|4.797999999999998|5.359999999999999|7.620000000000001|7.834090909090911|54.195869768830164|54.195869768830164|16.0|16.431578947368422\n",
      "\n",
      "enables the transfer of a negatively charged ion from one side of a membrane to the other. [goc:dgf, goc:mtg_transport, isbn:0815340729]| enables the transfer of a negatively charged ion from one side of a cell membrane to the other|69.78500000000001|67.32894736842107|6.010000000000002|8.588421052631581|11.359372727272728|10.155000000000001|4.797999999999998|8.560000000000002|7.620000000000001|7.174500000000002|54.195869768830164|69.96656701596841|16.0|18.126315789473683\n",
      "\n",
      "facial angiofibroma in tuberous sclerosis|facial neoplastic process in tuberous sclerosis|-35.11999999999995|3.344999999999999|19.400000000000002|14.283333333333335|16.5165|17.092433333333332|-15.687999999999995|-8.173333333333332|15.924|14.54|62.58|69.96656701596841|34.0|35.73333333333334\n",
      "\n",
      "facial angiofibroma in tuberous sclerosis|facial angiofibroma|-35.11999999999995|-91.29499999999996|19.400000000000002|26.490000000000006|16.5165|19.5753|-15.687999999999995|-92.14|15.924|9.899999999999999|62.58|44.250742366654144|34.0|40.800000000000004\n",
      "\n",
      "facial angiofibroma in tuberous sclerosis| angioma|-35.11999999999995|77.90500000000002|19.400000000000002|2.890000000000004|16.5165|19.5753|-15.687999999999995|-124.48|15.924|-5.800000000000001|62.58|31.29|34.0|20.8\n",
      "\n",
      "catalysis of the reaction: n5,n10-methenyltetrahydromethanopterin + h2 = n5,n10-methylenetetrahydromethanopterin. [um-bbd_reactionid:r0353]|catalysis of the reaction: n5, n10-methenyltetrahydromethanopterin + h2 = n5, n10-methylenetetrahydromethanopterin.  [ um-bbd_reactionid: r0353]|125.62000000000002|125.9025|-3.0199999999999996|-2.438333333333331|17.517985714285714|17.99045294117647|17.240000000000002|11.493333333333325|23.114285714285714|16.344117647058823|31.29|38.32226702584281|10.0|11.0\n",
      "\n",
      "catalysis of the reaction: n5,n10-methenyltetrahydromethanopterin + h2 = n5,n10-methylenetetrahydromethanopterin. [um-bbd_reactionid:r0353]|starts the reaction: n5,n10-methenyltetrahydromethanopterin + hydrogen ion. [um-bbd_reactionid:r0353]|125.62000000000002|107.60000000000001|-3.0199999999999996|-0.754999999999999|17.517985714285714|17.092433333333332|17.240000000000002|-4.175000000000011|23.114285714285714|16.11|31.29|31.29|10.0|11.600000000000001\n",
      "\n",
      "catalysis of the reaction: n5,n10-methenyltetrahydromethanopterin + h2 = n5,n10-methylenetetrahydromethanopterin. [um-bbd_reactionid:r0353]| catalysis|125.62000000000002|35.60500000000002|-3.0199999999999996|8.790000000000003|17.40225238095238|19.5753|17.240000000000002|-118.6|21.94761904761905|-2.66|31.29|31.29|10.0|20.8\n",
      "\n",
      "hours times nanograms per milliliter per milligram per kilogram.|hours times nanograms per milliliter per milligram per kilogram.|33.067500000000024|33.067500000000024|9.765|9.765|16.36401111111111|16.36401111111111|-29.191111111111105|-29.191111111111105|11.853333333333332|11.853333333333332|44.250742366654144|44.250742366654144|19.57777777777778|19.57777777777778\n",
      "\n",
      "hours times nanograms per milliliter per milligram per kilogram.|hours times nanograms/milliliter per milligram per kilogram.|33.067500000000024|-2.1746428571428282|9.765|14.432142857142857|16.36401111111111|16.140811111111113|-29.191111111111105|-38.371428571428574|11.853333333333332|8.556666666666668|44.250742366654144|38.32226702584281|19.57777777777778|18.54285714285714\n",
      "\n",
      "hours times nanograms per milliliter per milligram per kilogram.| hours times nanograms per milliliter per milligram per kilogram.|33.067500000000024|49.48000000000002|9.765|7.600000000000001|16.36401111111111|16.82839090909091|-29.191111111111105|-25.683999999999997|11.853333333333332|5.7263636363636365|44.250742366654144|44.250742366654144|19.57777777777778|18.0\n",
      "\n",
      "a measurement of the cells of nonhematopoietic origin in a biological specimen.|a functional concept of the cells of nonhematopoietic source in a biological sample.|10.39500000000001|31.037500000000023|13.3|10.545000000000002|10.810866666666666|11.568992307692309|-16.01333333333333|-12.972307692307695|10.8675|10.793846153846154|49.473833993334296|49.473833993334296|19.06666666666667|17.984615384615388\n",
      "\n",
      "a measurement of the cells of nonhematopoietic origin in a biological specimen.|a measurement the cells of nonhematopoietic origin in a biological specimen.|10.39500000000001|1.2888636363636294|13.3|14.445909090909094|10.810866666666666|11.8291|-16.01333333333333|-18.003636363636367|10.8675|7.475000000000001|49.473833993334296|49.473833993334296|19.06666666666667|20.381818181818183\n",
      "\n",
      "a measurement of the cells of nonhematopoietic origin in a biological specimen.| a measurement|10.39500000000001|90.99000000000004|13.3|1.3133333333333361|10.810866666666666|15.6774|-16.01333333333333|-73.18666666666667|10.8675|-2.9450000000000003|49.473833993334296|31.29|19.06666666666667|14.533333333333331\n",
      "\n",
      "a person who calls for, activates, or starts a process, procedure, or program.|a person who calls for, change, or starts a walk, software, or program.|63.57596153846157|96.11442307692309|6.006538461538462|1.468076923076925|9.139761538461538|6.710530769230769|-15.68615384615385|-18.852307692307697|7.170769230769231|4.634615384615387|49.473833993334296|38.32226702584281|17.984615384615388|11.830769230769231\n",
      "\n",
      "a person who calls for, activates, or starts a process, procedure, or program.|a person who calls for, activates or starts a process, procedure or program.|63.57596153846157|63.57596153846157|6.006538461538462|6.006538461538462|9.139761538461538|9.622985714285715|-15.68615384615385|-16.13846153846154|7.170769230769231|2.9285714285714306|49.473833993334296|49.473833993334296|17.984615384615388|17.984615384615388\n",
      "\n",
      "a person who calls for, activates, or starts a process, procedure, or program.| a person who initiates, calls for, or activates a process, procedure, or program.|63.57596153846157|54.70142857142861|6.006538461538462|7.368571428571428|9.139761538461538|11.377166666666668|-15.68615384615385|-12.885714285714286|7.170769230769231|3.0440000000000005|49.473833993334296|54.195869768830164|17.984615384615388|19.942857142857143\n",
      "\n",
      "genetically determined classes of human erythrocytes based on specific antigens for which the groups are named.|genetically conclude classes of human blood_cell based on fact substance for which the groups are named.|29.515000000000015|66.5275|11.130000000000003|5.967500000000001|10.35135|9.364474999999999|-1.7199999999999989|-4.292499999999997|14.535625000000003|12.475000000000001|58.53822981607831|54.195869768830164|20.700000000000003|18.2\n",
      "\n",
      "genetically determined classes of human erythrocytes based on specific antigens for which the groups are named.|genetically determined classes of human blood cells based on specific antigens for which the groups are named.|29.515000000000015|53.889852941176486|11.130000000000003|7.854411764705883|10.35135|9.346233333333334|-1.7199999999999989|-1.9647058823529377|14.535625000000003|7.666666666666668|58.53822981607831|54.195869768830164|20.700000000000003|17.51764705882353\n",
      "\n",
      "genetically determined classes of human erythrocytes based on specific antigens for which the groups are named.| A molecular trait|29.515000000000015|75.87500000000001|11.130000000000003|3.6700000000000017|10.35135|16.5165|-1.7199999999999989|-50.480000000000004|14.535625000000003|-2.9160000000000004|58.53822981607831|31.29|20.700000000000003|11.600000000000001\n",
      "\n",
      "exocrine pancreatic cancer in which the regional lymph nodes cannot be assessed. (from ajcc 6th ed.)|a gland neoplastic process cancer in which the regional lymph nodes cannot be charged.  ( from ajcc 6th ed.)|69.23416666666668|98.54833333333333|4.927499999999998|1.1700000000000017|13.346335294117647|12.817|-24.262499999999992|-18.233999999999998|5.261764705882353|3.8230000000000004|44.250742366654144|40.39521630094336|17.133333333333336|12.666666666666668\n",
      "\n",
      "exocrine pancreatic cancer in which the regional lymph nodes cannot be assessed. (from ajcc 6th ed.)|cancer in which the regional lymph node cannot be assessed. (from ajcc 6th ed.)|69.23416666666668|87.28404761904761|4.927499999999998|2.2442857142857164|13.346335294117647|12.915175000000001|-24.262499999999992|-35.28857142857143|5.261764705882353|1.1156250000000014|44.250742366654144|36.13057984588678|17.133333333333336|13.295238095238094\n",
      "\n",
      "exocrine pancreatic cancer in which the regional lymph nodes cannot be assessed. (from ajcc 6th ed.)| exocrine carcinoma|69.23416666666668|6.390000000000015|4.927499999999998|13.113333333333333|13.346335294117647|19.6249|-24.262499999999992|-63.386666666666656|5.261764705882353|2.942499999999999|44.250742366654144|44.250742366654144|17.133333333333336|27.866666666666664\n",
      "\n",
      "world health organization disability assessment schedule 2.0 - 36-item interviewer - in the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?|world health organization unfitness action plan 2.0 - 36-item inquirer - in the past 30 days, not trust the days that you were totally unable, for how many days did you cut back or reduce your usual trait or work because of any health condition?|52.39750000000001|69.31750000000001|11.54055555555556|9.180555555555557|11.201854545454546|10.84299090909091|15.721777777777776|13.108444444444443|23.58477272727273|21.443863636363638|85.69119412168324|76.64453405168562|22.333333333333332|19.66666666666667\n",
      "\n",
      "world health organization disability assessment schedule 2.0 - 36-item interviewer - in the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?|in the past 30 days, not counting the days that you were totally able, for how many days did you cut back or reduce your usual activities or work because of a health condition?|52.39750000000001|55.377941176470614|11.54055555555556|13.981764705882352|10.110654545454546|8.5305|15.721777777777776|16.197647058823527|12.584772727272728|15.044571428571423|85.69119412168324|93.86999999999999|22.333333333333332|24.188235294117646\n",
      "\n",
      "world health organization disability assessment schedule 2.0 - 36-item interviewer - in the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?| world health organization disability assessment schedule 2.0 - item interviewer---in the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?|52.39750000000001|46.06863636363636|11.54055555555556|12.29909090909091|11.201854545454546|11.482722222222222|15.721777777777776|16.079090909090908|23.58477272727273|23.57333333333333|85.69119412168324|88.50148473330829|22.333333333333332|23.345454545454547\n",
      "\n",
      "the volume enclosed by the rhoptry membrane. [goc:rph, pmid:17997128]|the quantity put by the rotary sheet.  [ goc: rph, pmid: 17997128]|80.06750000000002|109.12980769230771|3.2094444444444434|-0.347307692307691|14.9375|13.144933333333334|-25.92444444444444|-21.113846153846154|7.445999999999998|0.8024999999999984|44.250742366654144|31.29|19.57777777777778|8.753846153846155\n",
      "\n",
      "the volume enclosed by the rhoptry membrane. [goc:rph, pmid:17997128]|the volume enclosed by the rhoptry membrane. [goc:rph, pmid:17997128]|80.06750000000002|80.06750000000002|3.2094444444444434|3.2094444444444434|14.9375|15.392936363636366|-25.92444444444444|-25.271111111111104|7.445999999999998|5.7263636363636365|44.250742366654144|44.250742366654144|19.57777777777778|19.57777777777778\n",
      "\n",
      "the volume enclosed by the rhoptry membrane. [goc:rph, pmid:17997128]| the volume enclosed by the rhoptry|80.06750000000002|78.87285714285717|3.2094444444444434|3.997142857142858|14.9375|13.902050000000001|-25.92444444444444|-17.085714285714285|7.445999999999998|0.8212499999999991|44.250742366654144|54.195869768830164|19.57777777777778|19.942857142857143\n",
      "\n",
      "diabetes mellitus in which there are frequent, clinically significant fluctuations in blood glucose levels both above and below levels expected to be achieved by available therapies.|diabetes disease in which there are frequent, clinically significant change in blood glucose levels both above and below levels sees to be achieved by available therapies.|24.440000000000026|37.455384615384645|13.080000000000002|11.264615384615386|10.999176923076924|10.391869230769231|12.736923076923073|10.249230769230767|19.648846153846158|17.65615384615385|85.69119412168324|79.77416029015912|28.276923076923072|25.200000000000003\n",
      "\n",
      "diabetes mellitus in which there are frequent, clinically significant fluctuations in blood glucose levels both above and below levels expected to be achieved by available therapies.|diabetes mellitus in which there are frequent, clinically significant fluctuations in blood sugar levels both above and below levels expected to be achieved by available therapies.|24.440000000000026|24.440000000000026|13.080000000000002|13.080000000000002|10.999176923076924|10.154248148148149|12.736923076923073|12.510769230769231|19.648846153846158|12.184444444444445|85.69119412168324|85.69119412168324|28.276923076923072|28.276923076923072\n",
      "\n",
      "diabetes mellitus in which there are frequent, clinically significant fluctuations in blood glucose levels both above and below levels expected to be achieved by available therapies.| Diabetes mellitus is a metabolic disorder|24.440000000000026|6.35857142857148|13.080000000000002|14.111428571428572|10.999176923076924|15.875800000000002|12.736923076923073|-11.205714285714286|19.648846153846158|4.942499999999999|85.69119412168324|62.58|28.276923076923072|25.65714285714286\n",
      "\n",
      "tubes designed to access the esophagus through the mouth or nose for examination, treatment, or other purposes. these devices typically consist of rubber or polymeric flexible tubes with a diameter, length, and other physical characteristics appropriate for reaching the esophagus. dedicated esophageal tubes are used to facilitate the diagnosis of esophagus diseases, to treat hemorrhage (i.e., tamponade) from esophageal varices, to provide suction of liquids and/or other materials, and to be used as a first step in esophagus reconstruction; they may also be used to assess some stomach diseases. dedicated tubes intended for patient rewarming may be also available.|ride designed to reach the esophagus through the mouth or nose for introspection, chair, or other decide.  these emblems are typically being of rubber or polymeric flexible ride with a straight_line, length, and other physical property assumes for tug the esophagus.  assign esophageal ride are used to cause the diagnosis of esophagus illness , to treat exhaust ( i.e. , tamponade ) from esophageal varices , to provide suction of liquids and/or other applicant , and to be used as a first step in esophagus recall ; they may also be used to charge some stomach illness .  assign ride convey for case warming may be also available.|21.57090909090911|61.934594594594614|13.764098124098126|8.56005148005148|12.041372727272728|10.313403559870551|13.044040404040409|8.985225225225225|17.44469696969697|10.474692556634302|84.45816301577958|75.72660232705545|26.263203463203464|21.11763191763192\n",
      "\n",
      "tubes designed to access the esophagus through the mouth or nose for examination, treatment, or other purposes. these devices typically consist of rubber or polymeric flexible tubes with a diameter, length, and other physical characteristics appropriate for reaching the esophagus. dedicated esophageal tubes are used to facilitate the diagnosis of esophagus diseases, to treat hemorrhage (i.e., tamponade) from esophageal varices, to provide suction of liquids and/or other materials, and to be used as a first step in esophagus reconstruction; they may also be used to assess some stomach diseases. dedicated tubes intended for patient rewarming may be also available.|tubes designed to access the esophagus through the mouth or nose for examination, treatment, or other purposes. these devices typically consist of rubber or polymeric flexible tubes with a diameter, length, and other physical characteristics appropriate for reaching the stomach. they are used to facilitate the diagnosis of|21.57090909090911|23.1575|13.764098124098126|14.004166666666666|12.041372727272728|11.213776190476189|13.044040404040409|15.555|17.44469696969697|12.881972789115643|84.45816301577958|88.50148473330829|26.263203463203464|26.400000000000002\n",
      "\n",
      "tubes designed to access the esophagus through the mouth or nose for examination, treatment, or other purposes. these devices typically consist of rubber or polymeric flexible tubes with a diameter, length, and other physical characteristics appropriate for reaching the esophagus. dedicated esophageal tubes are used to facilitate the diagnosis of esophagus diseases, to treat hemorrhage (i.e., tamponade) from esophageal varices, to provide suction of liquids and/or other materials, and to be used as a first step in esophagus reconstruction; they may also be used to assess some stomach diseases. dedicated tubes intended for patient rewarming may be also available.| tubes|21.57090909090911|120.20500000000001|13.764098124098126|-3.01|12.041372727272728|19.5753|13.044040404040409|-130.36|17.44469696969697|-8.94|84.45816301577958|31.29|26.263203463203464|20.8\n",
      "\n",
      "decrease dietary gluten found in wheat, rye, oats, barley and their derivatives. treatment for celiac disease, dermatitis herpetiformis and gluten sensitivity.|change fare gluten found in wheat, rye, oats, grain and their word.  care for celiac disease, eczema herpetiformis and gluten ability.|18.44428571428574|68.64621212121216|12.425714285714289|5.506363636363638|13.180157142857144|9.742051515151516|-3.36571428571429|-10.161818181818173|13.649999999999999|5.358484848484849|62.58|47.79626449838941|25.65714285714286|15.66060606060606\n",
      "\n",
      "decrease dietary gluten found in wheat, rye, oats, barley and their derivatives. treatment for celiac disease, dermatitis herpetiformis and gluten sensitivity.|decreased gluten found in wheat, rye, barley and their derivatives. treatment for gluten disease, herpetiformis and gluten sensitivity.|18.44428571428574|22.14500000000001|12.425714285714289|11.661111111111111|13.180157142857144|13.092212280701753|-3.36571428571429|-10.459999999999994|13.649999999999999|9.996666666666666|62.58|57.127462747788826|25.65714285714286|24.622222222222224\n",
      "\n",
      "decrease dietary gluten found in wheat, rye, oats, barley and their derivatives. treatment for celiac disease, dermatitis herpetiformis and gluten sensitivity.| decrease|18.44428571428574|120.20500000000001|12.425714285714289|-3.01|13.180157142857144|19.5753|-3.36571428571429|-121.53999999999999|13.649999999999999|-4.229999999999997|62.58|31.29|25.65714285714286|20.8\n",
      "\n",
      "a molecular genetic abnormality indicating the presence of a mutation in exon 18 of the pdgfra gene located within 4q11-q13.|a finding genetic misbehavior informs the presence of a change in exon 18 of the pdgfra gene located within 4q11-q13.|40.17500000000001|69.78500000000001|10.140000000000004|6.010000000000002|15.20476666666667|13.700957142857144|1.2699999999999996|-0.7880000000000003|12.17142857142857|10.60142857142857|66.37611354998121|62.58|22.0|20.0\n",
      "\n",
      "a molecular genetic abnormality indicating the presence of a mutation in exon 18 of the pdgfra gene located within 4q11-q13.|a molecular genetic abnormality indicating the presence of a mutation in the gene region 4q11-q13.|40.17500000000001|30.022500000000008|10.140000000000004|10.935000000000002|15.20476666666667|14.275158823529411|1.2699999999999996|-6.146666666666668|12.17142857142857|5.815882352941177|66.37611354998121|58.53822981607831|22.0|21.666666666666668\n",
      "\n",
      "a molecular genetic abnormality indicating the presence of a mutation in exon 18 of the pdgfra gene located within 4q11-q13.| a mutation|40.17500000000001|90.99000000000004|10.140000000000004|1.3133333333333361|15.20476666666667|15.6774|1.2699999999999996|-79.06666666666666|12.17142857142857|-6.477499999999999|66.37611354998121|31.29|22.0|14.533333333333331\n",
      "\n",
      "a standardized 20-item self-report measure, published in 2013, that is used to assess the 20 diagnostic and statistical manual of mental disorders (dsm-5) symptoms of post-traumatic stress disorder (ptsd), using a 5-point likert-type intensity scale, ranging from zero (not at all) to four (extremely).|a measure 20-item self-report measure , produce in 2013 , that is used to charge the 20 diagnostic and statistical handbook of mental change ( dsm-5 ) symptoms of post-traumatic stress disorder ( ptsd ) , using a 5-point likert-type degree scale , feed from zero ( not at all ) to four ( extremely ) .|44.1459090909091|84.40223684210525|12.567272727272726|8.567105263157895|14.445267346938776|13.156287755102042|21.157272727272726|14.887719298245614|26.235510204081628|24.889795918367348|93.86999999999999|85.69119412168324|25.163636363636368|21.926315789473684\n",
      "\n",
      "a standardized 20-item self-report measure, published in 2013, that is used to assess the 20 diagnostic and statistical manual of mental disorders (dsm-5) symptoms of post-traumatic stress disorder (ptsd), using a 5-point likert-type intensity scale, ranging from zero (not at all) to four (extremely).|a standardized 20-item self-report measure, published in 2013, that is used to assess the 20 diagnostic and statistical manual of mental disorders (dsm-5) symptoms of post-traumatic stress disorder (ptsd), using a 5-point likert-type intensity scale, ranging from|44.1459090909091|25.23135135135138|12.567272727272726|18.93189189189189|14.445267346938776|14.949532558139534|21.157272727272726|28.233513513513515|26.235510204081628|23.619999999999997|93.86999999999999|125.16|25.163636363636368|32.097297297297295\n",
      "\n",
      "a standardized 20-item self-report measure, published in 2013, that is used to assess the 20 diagnostic and statistical manual of mental disorders (dsm-5) symptoms of post-traumatic stress disorder (ptsd), using a 5-point likert-type intensity scale, ranging from zero (not at all) to four (extremely).| a standardized 20-item self-report measure that is used to assess the 20 diagnostic and statistical manual of mental disorders symptoms of post-traumatic stress disorder, using a 5-point likert scale (0-4).|44.1459090909091|54.65088709677423|12.567272727272726|9.48725806451613|14.445267346938776|13.515991891891893|21.157272727272726|14.665806451612902|26.235510204081628|9.460540540540542|93.86999999999999|79.77416029015912|25.163636363636368|22.9741935483871\n",
      "\n",
      "a heterotetrameric transcription factor composed of two distinct proteins. its name refers to the fact it binds to dna sequences rich in guanine and adenine. ga-binding protein integrates a variety of signal transduction pathways and regulates expression of genes involved in cell cycle control, protein biosynthesis, and cellular metabolism.|a bioactive substance transcription factor plan of two distinct proteins.  its name name to the fact it binds to dna rate rich in guanine and purine.  ga-binding protein calculate a difference by telling transduction path and restrict squeeze of genes involved in cell cycle control, protein synthesis, and cellular metabolism.|26.927780612244902|61.859230769230805|12.546683673469389|7.8607692307692325|13.305566666666667|11.312448679245282|11.116734693877554|8.439999999999998|14.032933333333332|8.042075471698112|79.77416029015912|73.38155456243756|26.124489795918368|22.123076923076923\n",
      "\n",
      "a heterotetrameric transcription factor composed of two distinct proteins. its name refers to the fact it binds to dna sequences rich in guanine and adenine. ga-binding protein integrates a variety of signal transduction pathways and regulates expression of genes involved in cell cycle control, protein biosynthesis, and cellular metabolism.|a heterotetrameric transcription factor composed of two distinct proteins. their names refer to the fact that it binds to dna sequences rich in guanine and adenine. ga-binding protein integrates a variety of signal transduction pathways and|26.927780612244902|37.20500000000001|12.546683673469389|11.051111111111112|13.305566666666667|12.159766666666666|11.116734693877554|8.979999999999997|14.032933333333332|10.064649122807015|79.77416029015912|74.48509850970193|26.124489795918368|23.68888888888889\n",
      "\n",
      "a heterotetrameric transcription factor composed of two distinct proteins. its name refers to the fact it binds to dna sequences rich in guanine and adenine. ga-binding protein integrates a variety of signal transduction pathways and regulates expression of genes involved in cell cycle control, protein biosynthesis, and cellular metabolism.| a protein|26.927780612244902|119.19000000000003|12.546683673469389|-2.619999999999999|13.305566666666667|15.6774|11.116734693877554|-81.02666666666666|14.032933333333332|-7.654999999999999|79.77416029015912|31.29|26.124489795918368|14.533333333333331\n",
      "\n",
      "an abnormal pregnancy in which the conception is implanted in the peritoneal cavity or on the abdominal organs.|a finding pregnancy in which the conception is attached to the peritoneal structure or on the abdominal meat.|33.20000000000002|52.00000000000003|10.864444444444448|8.242222222222225|10.669855555555555|9.792633333333335|-2.1822222222222187|-2.8355555555555547|11.905000000000001|11.381666666666668|62.58|58.53822981607831|21.37777777777778|19.15555555555556\n",
      "\n",
      "an abnormal pregnancy in which the conception is implanted in the peritoneal cavity or on the abdominal organs.|an abnormal pregnancy in which the conception is implanted in the peritoneal cavity or on the abdomen.|33.20000000000002|38.960441176470624|10.864444444444448|9.936764705882357|10.669855555555555|11.100677777777777|-2.1822222222222187|-4.731764705882352|11.905000000000001|5.573333333333334|62.58|58.53822981607831|21.37777777777778|19.870588235294118\n",
      "\n",
      "an abnormal pregnancy in which the conception is implanted in the peritoneal cavity or on the abdominal organs.| an abnormal pregnancy where the conception is implanted in the cavity or on the organs|33.20000000000002|53.120000000000005|10.864444444444448|9.825|10.669855555555555|10.981464705882354|-2.1822222222222187|8.327499999999997|11.905000000000001|7.572352941176469|62.58|76.64453405168562|21.37777777777778|21.400000000000002\n",
      "\n",
      "the number of observable tumor nodules in the lungs.|the number of observable growth hunk in the lungs.|51.867500000000035|80.06750000000002|7.142777777777777|3.2094444444444434|11.100677777777777|9.346233333333334|-37.0311111111111|-38.33777777777777|5.573333333333334|4.526666666666667|44.250742366654144|31.29|19.57777777777778|10.68888888888889\n",
      "\n",
      "the number of observable tumor nodules in the lungs.|the number of visible tumor nodules in the lungs.|51.867500000000035|61.26750000000001|7.142777777777777|5.831666666666667|11.100677777777777|11.7795|-37.0311111111111|-38.33777777777777|5.573333333333334|0.3810000000000002|44.250742366654144|44.250742366654144|19.57777777777778|19.57777777777778\n",
      "\n",
      "the number of observable tumor nodules in the lungs.| the number of observable lung cancer|51.867500000000035|66.7871428571429|7.142777777777777|5.682857142857145|11.100677777777777|13.902050000000001|-37.0311111111111|-15.405714285714286|5.573333333333334|1.9987500000000011|44.250742366654144|54.195869768830164|19.57777777777778|19.942857142857143\n",
      "\n",
      "a pathologic finding about one or more characteristics of melanoma of the conjunctiva, following the rules of the tnm ajcc v7 classification system. complete resection of the primary site is indicated. histopathologic evaluation for negative peripheral and deep margins should be performed. to best judge the depth of penetration of the tumor, sections should be made perpendicular to the epithelial surface. (from ajcc 7th ed.)|a finding finding about one or more property of skin_cancer of the conjunctiva, following the rules of the tnm ajcc v7 restriction system.  complete resection of the primary site is informed.  histopathologic appraisal for negative peripheral and deep space should be re-create.  to best judge the depth of depth of the growth, sections should be made face to the epithelial surface.  ( from ajcc 7th ed.)|35.749935897435904|71.71904761904764|10.96423076923077|6.154285714285717|11.326069230769232|11.350785714285715|5.604923076923075|2.8525714285714265|10.793846153846154|5.774285714285714|63.87044504307137|58.53822981607831|19.717948717948723|16.666666666666668\n",
      "\n",
      "a pathologic finding about one or more characteristics of melanoma of the conjunctiva, following the rules of the tnm ajcc v7 classification system. complete resection of the primary site is indicated. histopathologic evaluation for negative peripheral and deep margins should be performed. to best judge the depth of penetration of the tumor, sections should be made perpendicular to the epithelial surface. (from ajcc 7th ed.)|a pathologic finding about one or more characteristics of melanoma of the conjunctiva, following the rules outlined in the classification system of tumor markers for skin tumors. sections should be made perpendicular to the skin's surface. (from ajcc 7th|35.749935897435904|39.624615384615424|10.96423076923077|10.962051282051284|11.326069230769232|9.824333333333334|5.604923076923075|9.947692307692304|10.793846153846154|10.31741666666667|63.87044504307137|72.26115969177356|19.717948717948723|21.61025641025641\n",
      "\n",
      "a pathologic finding about one or more characteristics of melanoma of the conjunctiva, following the rules of the tnm ajcc v7 classification system. complete resection of the primary site is indicated. histopathologic evaluation for negative peripheral and deep margins should be performed. to best judge the depth of penetration of the tumor, sections should be made perpendicular to the epithelial surface. (from ajcc 7th ed.)| a pathological finding about one or more characteristics of conjunctival melanoma|35.749935897435904|4.305000000000007|10.96423076923077|15.64|11.326069230769232|12.783607692307694|5.604923076923075|10.613333333333337|10.793846153846154|11.518461538461537|63.87044504307137|76.64453405168562|19.717948717948723|24.8\n",
      "\n",
      "aspirators designed to provide suction for evacuation of gas, body fluids, or foreign materials that may accumulate between the lung and chest wall (i.e., pleural space). these aspirators typically consist of a powered low-vacuum (> 50 mm hg) and high-volume (> 20 liter/min) pump; collection canisters; plastic tubes connecting the components each other; an overflow protection and/or bacteria filter; and suction tubing (e.g., tubes, catheters, cannulae). the devices can be line-or battery-powered, mobile or portable. thoracic aspirators are intended to evacuate gas and body fluids after thoracic surgery, trauma in the chest, or after cardiac bypass surgery. they are used mainly when suction from a central vacuum system is not available or appropriate.|pump designed to provide suction  discharge of gas, body fluids, or foreign applicant that may increase between the lung and the chest wall (i.e., pleural space).  these pumps typically are of a powered low-vacuum (> 50 mm hg) and high-volume (> 20 liter/min) pump; grouping canisters; plastic ride hit the part each other; a seethe assets and/or bacteria filter; and suction ride (e.g., ride, tube, canola).  the emblem can be line-or battery-powered, mobile or portable.  thoracic pump conveys to excrete gas and body fluids after thoracic room, trauma in the chest, or after cardiac shunt room.  they are used mainly when suction from a central clean system is not available or assume.|37.395588495575225|71.31334615384618|10.850628318584072|6.219153846153844|13.237314237288135|11.686150637522768|7.524247787610616|3.4475213675213716|14.997711864406774|6.426958105646634|76.00314592173142|65.6344577184881|25.40495575221239|19.722735042735042\n",
      "\n",
      "aspirators designed to provide suction for evacuation of gas, body fluids, or foreign materials that may accumulate between the lung and chest wall (i.e., pleural space). these aspirators typically consist of a powered low-vacuum (> 50 mm hg) and high-volume (> 20 liter/min) pump; collection canisters; plastic tubes connecting the components each other; an overflow protection and/or bacteria filter; and suction tubing (e.g., tubes, catheters, cannulae). the devices can be line-or battery-powered, mobile or portable. thoracic aspirators are intended to evacuate gas and body fluids after thoracic surgery, trauma in the chest, or after cardiac bypass surgery. they are used mainly when suction from a central vacuum system is not available or appropriate.|aspirators are intended to evacuate gas and body fluids after thoracic surgery, trauma in the chest, or when suction from a central vacuum system is not available or appropriate.|37.395588495575225|34.58646551724141|10.850628318584072|12.03741379310345|13.237314237288135|11.222833333333334|7.524247787610616|10.202758620689657|14.997711864406774|9.306000000000001|76.00314592173142|82.78555852321104|25.40495575221239|25.110344827586207\n",
      "\n",
      "aspirators designed to provide suction for evacuation of gas, body fluids, or foreign materials that may accumulate between the lung and chest wall (i.e., pleural space). these aspirators typically consist of a powered low-vacuum (> 50 mm hg) and high-volume (> 20 liter/min) pump; collection canisters; plastic tubes connecting the components each other; an overflow protection and/or bacteria filter; and suction tubing (e.g., tubes, catheters, cannulae). the devices can be line-or battery-powered, mobile or portable. thoracic aspirators are intended to evacuate gas and body fluids after thoracic surgery, trauma in the chest, or after cardiac bypass surgery. they are used mainly when suction from a central vacuum system is not available or appropriate.| gas;liquid;vapor|37.395588495575225|-6.694999999999993|10.850628318584072|14.690000000000001|13.042220903954801|19.5753|7.524247787610616|-98.02000000000001|13.031045197740113|8.329999999999998|76.00314592173142|31.29|25.40495575221239|20.8\n",
      "\n",
      "parental actions to provide an infant a safe, nurturing, and positive physical, emotional, spiritual, and social environment from 28 days to first birthday|parental actions to provide a child a safe, provide, and film physical, emotional, spiritual, and social environment for 28 days to first birthday|21.646521739130463|36.35956521739132|15.953913043478263|13.901739130434787|13.015560869565219|11.642517391304349|21.13217391304348|18.831304347826084|16.28217391304348|14.439130434782605|108.39173953766033|98.94766798666859|30.0695652173913|26.59130434782609\n",
      "\n",
      "parental actions to provide an infant a safe, nurturing, and positive physical, emotional, spiritual, and social environment from 28 days to first birthday|parental actions to provide an infant a safe, nurturing environment from 28 days to first birthday.|21.646521739130463|61.24000000000001|15.953913043478263|6.705000000000002|13.015560869565219|11.488688235294118|21.13217391304348|-5.762499999999999|16.28217391304348|5.815882352941177|108.39173953766033|58.53822981607831|30.0695652173913|20.700000000000003\n",
      "\n",
      "parental actions to provide an infant a safe, nurturing, and positive physical, emotional, spiritual, and social environment from 28 days to first birthday| parental actions to provide a child with a safe, nurturing, and positive environment from birth through the first year.|21.646521739130463|69.78500000000001|15.953913043478263|6.010000000000002|13.015560869565219|10.172538095238096|21.13217391304348|0.3880000000000017|16.28217391304348|6.248571428571427|108.39173953766033|54.195869768830164|30.0695652173913|16.0\n",
      "\n",
      "a campus of the university of california located in santa cruz, ca.|a field of the university of california located in santa cruz, ca.|38.595|45.64500000000001|9.366666666666667|8.383333333333333|13.442533333333335|12.1267|-21.893333333333324|-22.383333333333333|5.765000000000001|5.372500000000002|49.473833993334296|44.250742366654144|19.06666666666667|15.733333333333333\n",
      "\n",
      "a campus of the university of california located in santa cruz, ca.|a campus of the university of california located in santa cruz, ca.|38.595|38.595|9.366666666666667|9.366666666666667|13.442533333333335|13.675823076923077|-21.893333333333324|-21.40333333333333|5.765000000000001|1.7469230769230784|49.473833993334296|49.473833993334296|19.06666666666667|19.06666666666667\n",
      "\n",
      "a campus of the university of california located in santa cruz, ca.| a campus of the university of california located in santa cruz, ca.|38.595|50.56057692307695|9.366666666666667|7.821923076923078|12.1267|14.134414285714287|-21.893333333333324|-19.75692307692308|5.765000000000001|0.9100000000000001|49.473833993334296|49.473833993334296|19.06666666666667|17.984615384615388\n",
      "\n",
      "continuing program of rehabilitation designed to reinforce and maintain the effects of treatment and to help clients adjust to their environment after hospital release.|be program of vindication designed to teach and have the effects of care and to help clients change to their environment after hospital release.|36.03|64.22999999999999|11.215|7.28166666666667|12.7219|9.432316666666667|10.858333333333334|4.978333333333335|18.83|14.119999999999997|79.77416029015912|62.58|26.466666666666665|18.133333333333333\n",
      "\n",
      "continuing program of rehabilitation designed to reinforce and maintain the effects of treatment and to help clients adjust to their environment after hospital release.|continuing program of rehabilitation designed to reinforce and maintain the effects of treatment and to help clients adjust to the environment after hospital release.|36.03|36.03|11.215|11.215|12.7219|12.4673|10.858333333333334|10.613333333333337|18.83|11.761199999999995|79.77416029015912|79.77416029015912|26.466666666666665|26.466666666666665\n",
      "\n",
      "continuing program of rehabilitation designed to reinforce and maintain the effects of treatment and to help clients adjust to their environment after hospital release.| a program|36.03|119.19000000000003|11.215|-2.619999999999999|12.7219|15.6774|10.858333333333334|-81.02666666666666|18.83|-7.654999999999999|79.77416029015912|31.29|26.466666666666665|14.533333333333331\n",
      "\n",
      "days times grams per milliliter, divided by grams.|days times grams per milliliter, move by grams.|65.30000000000001|86.45000000000002|5.145|2.1950000000000003|11.9283|11.9283|-42.394999999999996|-44.6|6.708749999999998|4.942499999999999|31.29|22.125371183327072|11.600000000000001|6.6000000000000005\n",
      "\n",
      "days times grams per milliliter, divided by grams.|days times grams per milliliter, divided by gram.|65.30000000000001|65.30000000000001|5.145|5.145|11.9283|12.631922222222224|-42.394999999999996|-42.394999999999996|6.708749999999998|2.2766666666666673|31.29|31.29|11.600000000000001|11.600000000000001\n",
      "\n",
      "days times grams per milliliter, divided by grams.| quantity unit|65.30000000000001|62.79000000000002|5.145|5.246666666666666|11.9283|19.6249|-42.394999999999996|-73.18666666666667|6.708749999999998|-2.9450000000000003|31.29|44.250742366654144|11.600000000000001|27.866666666666664\n",
      "\n",
      "a measurement of the matrix metalloproteinase 1 in a biological specimen.|a functional concept of the mold metalloproteinase 1 in a biological sample.|16.670681818181833|31.545000000000016|12.300454545454546|10.350000000000001|12.794827272727273|13.442533333333335|-20.14181818181818|-17.483333333333327|10.617272727272727|9.689999999999998|49.473833993334296|49.473833993334296|20.381818181818183|19.06666666666667\n",
      "\n",
      "a measurement of the matrix metalloproteinase 1 in a biological specimen.|a measurement of the matrix metalloprotease 1 in a biological specimen.|16.670681818181833|24.36159090909092|12.300454545454546|11.227727272727272|12.794827272727273|13.144933333333334|-20.14181818181818|-20.67636363636364|10.617272727272727|5.512499999999999|49.473833993334296|49.473833993334296|20.381818181818183|20.381818181818183\n",
      "\n",
      "a measurement of the matrix metalloproteinase 1 in a biological specimen.| a measurement of the enzyme matrix metalloproteinase 1|16.670681818181833|47.30000000000004|12.300454545454546|8.89777777777778|12.794827272727273|15.185500000000001|-20.14181818181818|-1.5288888888888863|10.617272727272727|6.649000000000001|49.473833993334296|62.58|20.381818181818183|21.37777777777778\n",
      "\n",
      "a mass spectrometric technique that is used for the analysis of large biomolecules. analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. the matrix absorbs the laser energy, thus inducing a soft disintegration of the sample-matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. in general, only molecular ions of the analyte molecules are produced, and almost no fragmentation occurs. this makes the method well suited for molecular weight determinations and mixture analysis.|a mass spectrometry technique that is used for the calculation of large biomolecules.  analyst unit are grouped in an excess mold of small organic unit that show a high resonant sorption at the laser distance used.  the mold blend the laser good_health, thus produce a soft destruction of the sample-matrix mixture into free (gas phase) mold and analyst unit and molecular ions.  in general, only molecular ions of the analyst unit are produced, and almost no explosion occurs.  this makes the method well match for molecular weight choice and mixture calculus.|25.95951465201466|55.4041666666667|13.40631868131868|9.465000000000003|12.44414|11.962220833333333|13.437362637362636|10.210105263157892|13.316630434782603|7.138750000000002|83.76530337794998|77.70174998029323|24.967765567765568|21.912280701754387\n",
      "\n",
      "a mass spectrometric technique that is used for the analysis of large biomolecules. analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. the matrix absorbs the laser energy, thus inducing a soft disintegration of the sample-matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. in general, only molecular ions of the analyte molecules are produced, and almost no fragmentation occurs. this makes the method well suited for molecular weight determinations and mixture analysis.|a mass spectrometric technique that is used for the analysis of large biomolecules. analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the wavelength used. the matrix absorbs the laser energy, thus inducing|25.95951465201466|32.92387596899229|13.40631868131868|12.227906976744187|12.44414|12.258966666666668|13.437362637362636|11.07348837209302|13.316630434782603|10.416742424242422|83.76530337794998|78.74477315987392|24.967765567765568|23.4077519379845\n",
      "\n",
      "a mass spectrometric technique that is used for the analysis of large biomolecules. analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. the matrix absorbs the laser energy, thus inducing a soft disintegration of the sample-matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. in general, only molecular ions of the analyte molecules are produced, and almost no fragmentation occurs. this makes the method well suited for molecular weight determinations and mixture analysis.| a technique|25.95951465201466|119.19000000000003|13.40631868131868|-2.619999999999999|12.44414|15.6774|13.437362637362636|-77.10666666666665|13.316630434782603|-5.300000000000001|83.76530337794998|31.29|24.967765567765568|14.533333333333331\n",
      "\n",
      "mechanical shields usually made of high-impact transparent plastics attached to or placed on the laboratory benches. these shields are used in clinical laboratories to protect the workers from explosions, flames, spurting liquids, and other physical or chemical reactions.|mechanical manufactured good usually made of high-impact transparent plastics take to or placed on the regional seat.  these shields are used in clinical region to protect the workers from golf_stroke, burn, pour liquids, and other physical or chemical force.|31.457280701754428|51.59666666666669|12.018421052631577|9.375|11.486520512820514|10.476317886178862|12.994736842105265|10.139999999999997|15.976153846153842|10.10211382113821|80.79043260188672|72.26115969177356|26.119298245614033|21.333333333333336\n",
      "\n",
      "mechanical shields usually made of high-impact transparent plastics attached to or placed on the laboratory benches. these shields are used in clinical laboratories to protect the workers from explosions, flames, spurting liquids, and other physical or chemical reactions.|mechanical shields usually made of high-impact transparent plastics attached to or placed on the bench top of a clinical laboratory to protect the workers from explosions, flames and other physical or chemical reactions.|31.457280701754428|33.70568181818183|12.018421052631577|12.657121212121215|11.486520512820514|10.820500000000001|12.994736842105265|15.736969696969702|15.976153846153842|12.350285714285711|80.79043260188672|88.50148473330829|26.119298245614033|25.993939393939396\n",
      "\n",
      "mechanical shields usually made of high-impact transparent plastics attached to or placed on the laboratory benches. these shields are used in clinical laboratories to protect the workers from explosions, flames, spurting liquids, and other physical or chemical reactions.| mechanical shields usually made of transparent plastic materials attached to the laboratory benches.|31.457280701754428|18.44428571428574|12.018421052631577|12.425714285714289|11.486520512820514|14.535166666666669|12.994736842105265|-4.905714285714289|15.976153846153842|10.266000000000002|80.79043260188672|62.58|26.119298245614033|25.65714285714286\n",
      "\n",
      "the act of deceiving or the fact of being deceived.|the act of deceiving or the fact of being deceived.|74.86000000000003|74.86000000000003|4.060000000000002|4.060000000000002|7.2905|7.2905|-34.50399999999999|-34.50399999999999|2.8810000000000002|2.8810000000000002|38.32226702584281|38.32226702584281|14.0|14.0\n",
      "\n",
      "the act of deceiving or the fact of being deceived.|the act of deception or the fact of being deceived.|74.86000000000003|74.86000000000003|4.060000000000002|4.060000000000002|7.2905|8.215663636363637|-34.50399999999999|-33.916|2.8810000000000002|-0.6963636363636354|38.32226702584281|38.32226702584281|14.0|14.0\n",
      "\n",
      "the act of deceiving or the fact of being deceived.| the act of deception or being deceived|74.86000000000003|71.81500000000001|4.060000000000002|5.230000000000004|7.2905|11.100677777777777|-34.50399999999999|-12.745000000000001|2.8810000000000002|0.8633333333333333|38.32226702584281|54.195869768830164|14.0|18.2\n",
      "\n",
      "syndrome is characterized by hematological anomalies (fanconi anemia, leukemia and lymphoma) often appearing during childhood. anomalies of the limbs and hands are also present: bifid or hypoplastic thumbs, cutaneous syndactyly and ulnar and radial defects. the syndrome has been described in several families. transmission is autosomal dominant.|the syndrome is distinguished by hematological position (fanconi symptom, cancer and cancer) often perform during childhood.  the position of the limbs and hands are also present: bifid or hypoplastic thumbs, cutaneous birth_defect and ulnar and radial flee.  the syndrome has been marked in several families.  gear is autosomal allele.|11.894000000000034|46.602076923076936|13.935574468085107|9.342923076923078|10.938448936170213|10.988995604395605|6.042553191489361|3.7653846153846118|13.606914893617024|7.55524725274725|75.35629887408219|71.35217810270406|28.440851063829786|24.16\n",
      "\n",
      "syndrome is characterized by hematological anomalies (fanconi anemia, leukemia and lymphoma) often appearing during childhood. anomalies of the limbs and hands are also present: bifid or hypoplastic thumbs, cutaneous syndactyly and ulnar and radial defects. the syndrome has been described in several families. transmission is autosomal dominant.|syndrome is characterized by hematological anomalies (fanconi anemia, leukemia and lymphoma) often appearing during childhood. anomalies of the limbs and hands are also present: bifid or hypoplastic thumbs, cutaneous synd|11.894000000000034|2.670000000000016|13.935574468085107|16.613333333333333|10.938448936170213|11.536267741935484|6.042553191489361|18.09466666666667|13.606914893617024|14.731935483870963|75.35629887408219|93.86999999999999|28.440851063829786|30.0\n",
      "\n",
      "syndrome is characterized by hematological anomalies (fanconi anemia, leukemia and lymphoma) often appearing during childhood. anomalies of the limbs and hands are also present: bifid or hypoplastic thumbs, cutaneous syndactyly and ulnar and radial defects. the syndrome has been described in several families. transmission is autosomal dominant.| syndrome is syndrome|11.894000000000034|97.025|13.935574468085107|0.7199999999999989|10.938448936170213|16.5165|6.042553191489361|-46.07|13.606914893617024|-0.08999999999999986|75.35629887408219|44.250742366654144|28.440851063829786|21.6\n",
      "\n",
      "optical filter blocking transmission of infrared radiation|optical filter blocking gear of infrared therapy|-17.812857142857126|18.44428571428574|17.482857142857146|12.425714285714289|15.262271428571431|15.262271428571431|1.394285714285715|-7.005714285714284|17.058571428571433|10.329999999999998|76.64453405168562|69.96656701596841|37.08571428571428|31.371428571428574\n",
      "\n",
      "optical filter blocking transmission of infrared radiation|optic filter blocking transmission of infrared radiation|-17.812857142857126|-5.727142857142809|17.482857142857146|15.797142857142859|15.262271428571431|15.875800000000002|1.394285714285715|0.5542857142857187|17.058571428571433|12.596250000000005|76.64453405168562|76.64453405168562|37.08571428571428|37.08571428571428\n",
      "\n",
      "optical filter blocking transmission of infrared radiation| optical filter blocking transmission of infrared radiation|-17.812857142857126|8.365000000000009|17.482857142857146|14.080000000000002|15.262271428571431|16.36401111111111|1.394285714285715|1.9549999999999983|17.058571428571433|11.329999999999998|76.64453405168562|76.64453405168562|37.08571428571428|33.2\n",
      "\n",
      "catalysis of the reaction: bisphenol a + nadh + h+ + o2 = 1,2-bis(4-hydroxyphenyl)-2-propanol + nad+ + h2o. [um-bbd_reactionid:r0860]|the catalysis of the reaction: bisphenol a + nash + h+ + o2 = 1,2-bis (4-hydroxyphenyl) -2-propanol + nad+ + h2o.  [ um-bbd_reactionid: r0860]|125.95039473684211|123.08350000000002|-1.9481578947368412|-0.802999999999999|18.04795|17.633719047619046|4.431578947368415|4.0735999999999954|5.372500000000002|1.4038095238095245|38.32226702584281|44.250742366654144|10.115789473684211|11.4\n",
      "\n",
      "catalysis of the reaction: bisphenol a + nadh + h+ + o2 = 1,2-bis(4-hydroxyphenyl)-2-propanol + nad+ + h2o. [um-bbd_reactionid:r0860]|starting of the reaction: bisphenol a + nadh + water = 1,2-bis(4-hydroxyphenyl)-2-propanol + oxygen. [um-bbd_reactionid:r0860]|125.95039473684211|108.9825|-1.9481578947368412|-0.07833333333333137|18.04795|16.187776190476193|4.431578947368415|4.829333333333331|5.568749999999998|7.145714285714288|38.32226702584281|44.250742366654144|10.115789473684211|13.66666666666667\n",
      "\n",
      "catalysis of the reaction: bisphenol a + nadh + h+ + o2 = 1,2-bis(4-hydroxyphenyl)-2-propanol + nad+ + h2o. [um-bbd_reactionid:r0860]| acceleration|125.95039473684211|-6.694999999999993|-1.9481578947368412|14.690000000000001|18.04795|19.5753|4.431578947368415|-109.78|5.372500000000002|2.0500000000000007|38.32226702584281|31.29|10.115789473684211|20.8\n",
      "\n",
      "paced tapping test (paced tapping) the median intertap interval within the tone-paced tapping phase across all trials (in milliseconds).|paced pierce test (paced pierce) the median entertains distance within the tone-paced pierce phase across all trials (in milliseconds).|27.992500000000007|45.80302631578948|11.715|9.230789473684215|10.155000000000001|12.5235|5.359999999999999|5.050526315789476|14.945999999999998|14.710500000000003|76.64453405168562|66.37611354998121|29.063157894736847|22.74736842105263\n",
      "\n",
      "paced tapping test (paced tapping) the median intertap interval within the tone-paced tapping phase across all trials (in milliseconds).|the median intertap interval within the tonal tapping phase across all trials (in milliseconds).|27.992500000000007|36.572857142857174|11.715|9.89714285714286|12.817|13.4825|5.359999999999999|-7.005714285714284|9.945999999999998|7.754000000000001|76.64453405168562|62.58|29.063157894736847|25.65714285714286\n",
      "\n",
      "paced tapping test (paced tapping) the median intertap interval within the tone-paced tapping phase across all trials (in milliseconds).| beat-to-beat interval within the tapping rhythm|27.992500000000007|54.70142857142861|11.715|7.368571428571428|9.659|12.0275|5.359999999999999|-6.16571428571428|9.945999999999998|3.3520000000000003|76.64453405168562|62.58|29.063157894736847|25.65714285714286\n",
      "\n",
      "a response indicating that something happens or happened a lot of the time.|a phrase informs that something chance or happened a lot of the time.|70.08365384615385|96.11442307692309|5.098846153846157|1.468076923076925|6.710530769230769|6.710530769230769|-17.043076923076928|-19.75692307692308|7.533076923076923|5.35923076923077|49.473833993334296|38.32226702584281|17.984615384615388|11.830769230769231\n",
      "\n",
      "a response indicating that something happens or happened a lot of the time.|a response indicating that something happens/ happened a lot of the time.|70.08365384615385|66.79500000000002|5.098846153846157|5.433333333333334|6.710530769230769|8.817361538461538|-17.043076923076928|-18.46333333333333|7.533076923076923|4.283076923076923|49.473833993334296|49.473833993334296|17.984615384615388|19.06666666666667\n",
      "\n",
      "a response indicating that something happens or happened a lot of the time.| a response indicating that something happens or happens a lot of the time|70.08365384615385|71.76785714285715|5.098846153846157|6.727142857142859|6.710530769230769|8.591166666666666|-17.043076923076928|4.89714285714286|7.533076923076923|5.852|49.473833993334296|69.96656701596841|17.984615384615388|19.885714285714286\n",
      "\n",
      "a substance often found in a person with cancer|a substance often found in a person with cancer|75.50000000000003|75.50000000000003|4.964444444444446|4.964444444444446|7.591788888888889|7.591788888888889|-7.408888888888889|-7.408888888888889|3.4800000000000004|3.4800000000000004|62.58|62.58|21.37777777777778|21.37777777777778\n",
      "\n",
      "a substance often found in a person with cancer|a substance often found in a person with cancer|75.50000000000003|75.50000000000003|4.964444444444446|4.964444444444446|7.591788888888889|8.8695|-7.408888888888889|-6.755555555555549|3.4800000000000004|2.41|62.58|62.58|21.37777777777778|21.37777777777778\n",
      "\n",
      "a substance often found in a person with cancer| a substance often found in a person with cancer|75.50000000000003|86.70500000000001|4.964444444444446|3.650000000000002|7.591788888888889|9.923918181818184|-7.408888888888889|-6.079999999999998|3.4800000000000004|1.625454545454545|62.58|62.58|21.37777777777778|20.0\n",
      "\n",
      "international physical activity questionnaire (november 2002) - long last 7 days telephone format - how much time did you usually spend on one of those days walking as part of your work?: hours and minutes per day.|socialism physical activity form (november 2002) - long last 7 days telephone change - how much time did you usually spend on one of those days walking as part of your work?  : hours and minutes per day.|64.58722972972974|80.75019230769233|8.846621621621622|6.840641025641027|9.015928571428573|8.4768|12.287567567567567|9.6974358974359|10.331714285714288|8.372500000000002|69.96656701596841|62.58|18.210810810810813|16.005128205128205\n",
      "\n",
      "international physical activity questionnaire (november 2002) - long last 7 days telephone format - how much time did you usually spend on one of those days walking as part of your work?: hours and minutes per day.|international physical activity questionnaire (november 2002) - long last 7 days telephone format. how much time did you usually spend on one of those days walking as part of your work?: hours and minutes per day.|64.58722972972974|67.75500000000001|8.846621621621622|6.790000000000003|9.177738095238094|9.346233333333334|12.287567567567567|4.57|7.41504761904762|5.573333333333334|69.96656701596841|57.127462747788826|18.210810810810813|15.911111111111111\n",
      "\n",
      "international physical activity questionnaire (november 2002) - long last 7 days telephone format - how much time did you usually spend on one of those days walking as part of your work?: hours and minutes per day.| international physical activity questionnaire (november 2002) - long last 7 days telephone format - how much time did you usually spend on one of those days walking as part of your work|64.58722972972974|52.84909090909092|8.846621621621622|14.08606060606061|9.883928571428573|10.6515125|12.287567567567567|18.648484848484852|19.08171428571429|16.942500000000003|69.96656701596841|93.86999999999999|18.210810810810813|24.10909090909091\n",
      "\n",
      "milliliters per hour (flow rate), divided by meters squared (surface area).|milliliters per hour (flow rate), move  meter row (surface area).|39.7434090909091|70.50704545454548|9.08227272727273|4.791363636363638|9.923918181818184|11.359372727272728|-19.07272727272727|-24.41818181818182|9.332727272727272|5.47909090909091|54.195869768830164|44.250742366654144|24.018181818181816|16.745454545454546\n",
      "\n",
      "milliliters per hour (flow rate), divided by meters squared (surface area).|milliliters per hour (flow rate) divided by meters squared (surface area).|39.7434090909091|39.7434090909091|9.08227272727273|9.08227272727273|11.359372727272728|11.8291|-19.07272727272727|-19.07272727272727|9.332727272727272|5.120000000000001|54.195869768830164|54.195869768830164|24.018181818181816|24.018181818181816\n",
      "\n",
      "milliliters per hour (flow rate), divided by meters squared (surface area).| cubic centimeter per hour (flow rate), divided by meters squared (surface area).|39.7434090909091|50.56057692307695|9.08227272727273|7.821923076923078|11.359372727272728|13.006557142857146|-19.07272727272727|-13.876923076923077|9.332727272727272|3.937857142857144|54.195869768830164|58.53822981607831|24.018181818181816|24.13846153846154\n",
      "\n",
      "any process that stops, prevents or reduces the frequency, rate or extent of hepatocyte growth factor receptor signaling pathway. [goc:termgenie, pmid:18819921]|any wall that stops, prevents or weaken the ratio, rate or extent of hepatocyte growth factor organ tell path.  [ goc: termgenie, pmid: 18819921]|39.06321428571431|82.47550000000001|10.419285714285714|4.861000000000001|14.230281818181819|11.270383333333335|11.009523809523813|4.779199999999996|12.544090909090912|4.942499999999999|76.64453405168562|66.37611354998121|27.057142857142857|19.400000000000002\n",
      "\n",
      "any process that stops, prevents or reduces the frequency, rate or extent of hepatocyte growth factor receptor signaling pathway. [goc:termgenie, pmid:18819921]|any process that stops, prevents or reduces cell growth factor receptor signaling pathway. [goc:termgenie, pmid:18819921]|39.06321428571431|46.942499999999995|10.419285714285714|8.575000000000003|14.230281818181819|15.203982352941178|11.009523809523813|2.86933333333333|12.544090909090912|11.079999999999998|76.64453405168562|66.37611354998121|27.057142857142857|27.0\n",
      "\n",
      "any process that stops, prevents or reduces the frequency, rate or extent of hepatocyte growth factor receptor signaling pathway. [goc:termgenie, pmid:18819921]| any process that prevents or reduces cell surface molecule exposure on a cell|39.06321428571431|53.639285714285734|10.419285714285714|9.255714285714287|14.230281818181819|11.749166666666667|11.009523809523813|6.5771428571428565|12.544090909090912|7.1080000000000005|76.64453405168562|82.78555852321104|27.057142857142857|25.6\n",
      "\n",
      "a developmental therapist is a person qualified by completion of an approved program in developmental therapy and where applicable credentialed by the state and practicing within the scope of the credential, or credentialed by completion of education experiences as approved by the state and practicing within the scope of that credential or, where state credentialing does not exist, certified by the board of the developmental therapy association. a developmental therapist evaluates children's global development in order to identify areas of developmental delay whether arising from physiological, neurological, or environmental factors, or a combination of factors; and designs, implements, and modifies therapeutic interventions for the child and the family to promote the child's acquisition of skills in a variety of developmental areas, including cognitive processes and social interaction in order to maximize functional independence and developmental homeostasis, and improve the quality of life at home and in the community; and provides consultation for the parents and other professionals working with the family on global development.|a concept expert is a person add by completion of an approved program in developmental therapy and where applicable credentialed by the state and perform within the scope of the credential , or credentialed by completion of upbringing change as approved by the state and perform within the scope of that credential or , where state credentialing does not exist , declare by the board of the developmental therapy group .  a developmental expert think children 's global section in order to recognize areas of developmental change whether protest from physiological , neurological , or environmental lend , or a alliance of factors ; and sketch , complete , and add medicine care for the child and the family to play the child 's acquiring of skills in a difference of developmental areas , including cognitive transform and social action in order to exploit functional victory and developmental homeostasis , and change the quality of life at home and in the community ; and provides action for the parents and other athlete working with the family on global section .|-21.978495934959312|11.451915285451236|29.905609756097565|26.65049723756906|14.732175609756098|13.757409090909091|29.9370731707317|23.941657458563533|47.48536585365853|44.79727272727272|162.58760930649052|151.14505946275582|41.62276422764228|39.602946593001846\n",
      "\n",
      "a developmental therapist is a person qualified by completion of an approved program in developmental therapy and where applicable credentialed by the state and practicing within the scope of the credential, or credentialed by completion of education experiences as approved by the state and practicing within the scope of that credential or, where state credentialing does not exist, certified by the board of the developmental therapy association. a developmental therapist evaluates children's global development in order to identify areas of developmental delay whether arising from physiological, neurological, or environmental factors, or a combination of factors; and designs, implements, and modifies therapeutic interventions for the child and the family to promote the child's acquisition of skills in a variety of developmental areas, including cognitive processes and social interaction in order to maximize functional independence and developmental homeostasis, and improve the quality of life at home and in the community; and provides consultation for the parents and other professionals working with the family on global development.|a developmental therapist is a person qualified by completion of an approved program in developmental therapy and where applicable credentialed by the state and practicing within the scope of the study area. other factors include functional independence and developmental homeostasis, and improve the quality of life at home and in the|-21.978495934959312|20.046617647058866|29.905609756097565|16.798137254901963|14.732175609756098|11.606484615384616|29.9370731707317|21.366274509803915|47.48536585365853|17.293846153846154|162.58760930649052|108.39173953766033|41.62276422764228|29.02352941176471\n",
      "\n",
      "a developmental therapist is a person qualified by completion of an approved program in developmental therapy and where applicable credentialed by the state and practicing within the scope of the credential, or credentialed by completion of education experiences as approved by the state and practicing within the scope of that credential or, where state credentialing does not exist, certified by the board of the developmental therapy association. a developmental therapist evaluates children's global development in order to identify areas of developmental delay whether arising from physiological, neurological, or environmental factors, or a combination of factors; and designs, implements, and modifies therapeutic interventions for the child and the family to promote the child's acquisition of skills in a variety of developmental areas, including cognitive processes and social interaction in order to maximize functional independence and developmental homeostasis, and improve the quality of life at home and in the community; and provides consultation for the parents and other professionals working with the family on global development.| a therapist is a person who has been|-21.978495934959312|94.30000000000001|29.905609756097565|2.342222222222226|14.732175609756098|8.8695|29.9370731707317|-13.288888888888884|47.48536585365853|-1.8290000000000006|162.58760930649052|44.250742366654144|41.62276422764228|12.488888888888889\n",
      "\n",
      "the expanded prostate cancer index composite short form - how big a problem, if any, has each of the following been for you? losing control of your stools.|the change prostate cancer list flower short form - how big a problem, if any, has each of the following been for you?  losing control of your stools.|71.76785714285715|87.0968103448276|6.727142857142859|4.7132758620689685|8.399803703703704|6.919076190476191|5.737142857142857|4.322758620689658|6.776666666666667|3.0859523809523814|69.96656701596841|62.58|19.885714285714286|16.83448275862069\n",
      "\n",
      "the expanded prostate cancer index composite short form - how big a problem, if any, has each of the following been for you? losing control of your stools.|the expanded prostate cancer index composite short form - how big a problem, if any, has each of the following been for you? loss control of your stools.|71.76785714285715|74.78928571428573|6.727142857142859|6.305714285714288|8.399803703703704|8.610861904761904|5.737142857142857|5.527142857142856|6.776666666666667|3.758809523809525|69.96656701596841|66.37611354998121|19.885714285714286|18.45714285714286\n",
      "\n",
      "the expanded prostate cancer index composite short form - how big a problem, if any, has each of the following been for you? losing control of your stools.| the expanded prostate cancer index composite short form - have each of the following been a problem for you? losing control of your stools.|71.76785714285715|75.70750000000002|6.727142857142859|5.805|8.399803703703704|9.734233333333332|5.737142857142857|3.8384|6.776666666666667|4.402666666666665|69.96656701596841|66.37611354998121|19.885714285714286|19.400000000000002\n",
      "\n",
      "the greening response of plants grown in the dark (etiolated) as a result of chloroplast biogenesis and the accumulation of chlorophyll. [goc:lr]|the greening phrase of plants grown in the dark (change) as a result of plastic synthesis and the net_income of pigment.  [ goc: lr]|45.69727272727275|89.24350000000001|9.618181818181817|3.9170000000000016|10.385595652173913|9.855350000000001|6.232727272727271|1.7216000000000022|8.484347826086957|1.7837500000000013|62.58|54.195869768830164|18.94545454545455|14.600000000000001\n",
      "\n",
      "the greening response of plants grown in the dark (etiolated) as a result of chloroplast biogenesis and the accumulation of chlorophyll. [goc:lr]|the greening response of plants grown in the dark (etiolated) as a result of photosynthesis and the accumulation of chlorophyll. [goc:lr]|45.69727272727275|47.12035714285716|9.618181818181817|9.29547619047619|10.385595652173913|10.385595652173913|6.232727272727271|4.849523809523809|8.484347826086957|7.255652173913045|62.58|58.53822981607831|18.94545454545455|17.53333333333333\n",
      "\n",
      "the greening response of plants grown in the dark (etiolated) as a result of chloroplast biogenesis and the accumulation of chlorophyll. [goc:lr]| the greening response of the chloroplast of plants grown in the dark|45.69727272727275|89.51692307692309|9.618181818181817|4.003076923076925|10.385595652173913|8.842328571428572|6.232727272727271|3.4646153846153815|8.484347826086957|5.419285714285714|62.58|54.195869768830164|18.94545454545455|14.430769230769233\n",
      "\n",
      "a blood vessel arising from the popliteal artery that supplies blood to the head of the tibia and the knee joint.|a blood craft protest from the popliteal artery that state blood to the head of the tibia and the knee joint.|75.32035714285716|87.40607142857144|5.362142857142857|3.6764285714285734|8.43762380952381|9.189528571428571|-2.150476190476187|-3.270476190476188|9.704285714285717|8.807142857142857|54.195869768830164|44.250742366654144|15.628571428571428|11.81904761904762\n",
      "\n",
      "a blood vessel arising from the popliteal artery that supplies blood to the head of the tibia and the knee joint.|a blood vessel arising from the popliteal vein that supplies blood to the head of the tibia and the knee joint.|75.32035714285716|83.37750000000003|5.362142857142857|4.238333333333333|8.43762380952381|8.488463636363637|-2.150476190476187|-2.430476190476192|9.704285714285717|3.5522727272727295|54.195869768830164|49.473833993334296|15.628571428571428|13.723809523809525\n",
      "\n",
      "a blood vessel arising from the popliteal artery that supplies blood to the head of the tibia and the knee joint.| an artery arising from the leg artery that supplies blood to the head of the tibia and the knee|75.32035714285716|72.32500000000003|5.362142857142857|8.140000000000004|8.43762380952381|9.189528571428571|-2.150476190476187|8.132|9.704285714285717|6.78857142857143|54.195869768830164|69.96656701596841|15.628571428571428|18.0\n",
      "\n",
      "the period of time that an action is delayed relative to an original schedule. example(s): if a substance administration is delayed 2 days as a result of an adverse event, then the delayduration is 2 days. other name(s): note(s): derived from comparing the dates of the scheduled activity with the corresponding performed activity.|the period of time that an action is a change person to a model plan.  example (s): if a substance justice is change 2 days as a result of an adverse event, then the delay duration is 2 days.  other name (s): note (s): make from inflect the dates of the planned activity with the equal re-create the activity.|43.34096698113211|77.63165983606561|10.505801886792455|6.219795081967213|11.66295534591195|10.51755806451613|8.613584905660382|4.592131147540982|11.30880503144654|4.324354838709677|76.64453405168562|66.37611354998121|23.413207547169815|17.90327868852459\n",
      "\n",
      "the period of time that an action is delayed relative to an original schedule. example(s): if a substance administration is delayed 2 days as a result of an adverse event, then the delayduration is 2 days. other name(s): note(s): derived from comparing the dates of the scheduled activity with the corresponding performed activity.|the period of time that an action is delayed relative to an original schedule. note(s): derived from comparing the dates of the scheduled activity with the performed activity.|43.34096698113211|43.26880952380955|10.505801886792455|9.542857142857144|11.66295534591195|11.194242528735632|8.613584905660382|-0.42428571428571615|11.30880503144654|6.953333333333333|76.64453405168562|65.13532912329528|23.413207547169815|22.304761904761907\n",
      "\n",
      "the period of time that an action is delayed relative to an original schedule. example(s): if a substance administration is delayed 2 days as a result of an adverse event, then the delayduration is 2 days. other name(s): note(s): derived from comparing the dates of the scheduled activity with the corresponding performed activity.| the period of time duration that a drug is administered as a result of an adverse event.|43.34096698113211|66.10000000000002|10.505801886792455|6.2755555555555596|11.66295534591195|11.587173684210526|8.613584905660382|-9.042222222222218|11.30880503144654|1.4163157894736855|76.64453405168562|54.195869768830164|23.413207547169815|16.933333333333334\n",
      "\n",
      "silver staining or gms staining is a technique for demonstrating fungi in tissue sections. it is primarily based on staining the polysaccharides in fungal cell wall (from biogenex).|silver dye or gms dye is a technique for protest fungi in tissue sections.  it is primarily based on dye the carbohydrate in fungal cell wall (from biogenex).|46.290238095238124|71.58195402298851|9.121428571428574|5.6765517241379335|11.66197142857143|11.738725287356322|0.6257142857142846|-4.262068965517241|10.802142857142854|4.029885057471265|65.13532912329528|57.127462747788826|22.304761904761907|17.65977011494253\n",
      "\n",
      "silver staining or gms staining is a technique for demonstrating fungi in tissue sections. it is primarily based on staining the polysaccharides in fungal cell wall (from biogenex).|a technique for demonstrating fungi in tissue sections. it is primarily based on staining the polysaccharides in fungal cell wall.|46.290238095238124|43.55833333333334|9.121428571428574|8.840000000000003|11.66197142857143|11.50274761904762|0.6257142857142846|-11.472000000000001|10.802142857142854|6.741428571428571|65.13532912329528|54.195869768830164|22.304761904761907|20.666666666666668\n",
      "\n",
      "silver staining or gms staining is a technique for demonstrating fungi in tissue sections. it is primarily based on staining the polysaccharides in fungal cell wall (from biogenex).| silver stain is a technique for staining polysaccharides|46.290238095238124|47.30000000000004|9.121428571428574|8.89777777777778|11.66197142857143|13.6065|0.6257142857142846|-0.22222222222222143|10.802142857142854|7.5909999999999975|65.13532912329528|62.58|22.304761904761907|21.37777777777778\n",
      "\n",
      "a series of molecular signals generated as a consequence of a intracellular steroid hormone receptor binding to one of its physiological ligands. [goc:mah, goc:signaling]|a group of molecular tell make as a result of an intracellular steroid hormone organ binding to one of its physiological ligands.  [ goc: mah, god: tell]|11.355000000000018|62.70357142857142|14.656666666666666|7.991428571428575|13.390915384615385|10.739062962962963|11.348333333333336|5.3171428571428585|10.612692307692306|6.427777777777781|82.78555852321104|66.37611354998121|28.13333333333334|18.45714285714286\n",
      "\n",
      "a series of molecular signals generated as a consequence of a intracellular steroid hormone receptor binding to one of its physiological ligands. [goc:mah, goc:signaling]|a series of molecular signals generated as a consequence of an hormone receptor binding to one of its physiological ligands. [goc:mah, goc:signaling]|11.355000000000018|22.624545454545483|14.656666666666666|12.836363636363636|13.390915384615385|13.0989|11.348333333333336|7.569090909090907|10.612692307692306|7.993199999999998|82.78555852321104|76.64453405168562|28.13333333333334|26.218181818181815\n",
      "\n",
      "a series of molecular signals generated as a consequence of a intracellular steroid hormone receptor binding to one of its physiological ligands. [goc:mah, goc:signaling]| a series of molecular signals generated as a consequence of a intracellular protein binding to one of its physiological substrates|11.355000000000018|16.32000000000002|14.656666666666666|16.2|13.390915384615385|12.6227|11.348333333333336|17.264761904761905|10.612692307692306|13.76227272727273|82.78555852321104|98.94766798666859|28.13333333333334|27.44761904761905\n",
      "\n",
      "a plant genus of the family rosaceae. members contain esculetin and quercetin.|a plant kind of the family rosaceae.  members contain escalating and quercetin.|40.625|59.26743589743592|8.586666666666666|6.069230769230771|10.513266666666667|9.924510256410258|-41.17|-38.00307692307693|7.082500000000003|4.64897435897436|47.79626449838941|44.250742366654144|24.933333333333337|20.194871794871798\n",
      "\n",
      "a plant genus of the family rosaceae. members contain esculetin and quercetin.|a plant genus of the family rosaceae. members contain esculetin and quercetin.|40.625|40.625|8.586666666666666|8.586666666666666|10.513266666666667|11.139125641025641|-41.17|-40.68|7.082500000000003|4.64897435897436|47.79626449838941|47.79626449838941|24.933333333333337|24.933333333333337\n",
      "\n",
      "a plant genus of the family rosaceae. members contain esculetin and quercetin.| a genus|40.625|119.19000000000003|8.586666666666666|-2.619999999999999|10.513266666666667|15.6774|-41.17|-84.94666666666666|7.082500000000003|-10.01|47.79626449838941|31.29|24.933333333333337|14.533333333333331\n",
      "\n",
      "powder (including freeze-dried powder) and solvent intended for the preparation of an intravesical suspension by dispersing the powder in the solvent.|powder (including preserve powder) and solvent convey  the harmony of an intravesical support by discharge the powder in the solvent.|26.97750000000002|51.1489285714286|12.105|8.733571428571427|9.751790909090909|12.19714761904762|8.209523809523809|3.4495238095238108|16.545454545454547|13.965714285714284|76.64453405168562|76.64453405168562|27.057142857142857|27.057142857142857\n",
      "\n",
      "powder (including freeze-dried powder) and solvent intended for the preparation of an intravesical suspension by dispersing the powder in the solvent.|powder (including freeze-dried powder) and solvent intended for the preparation of an intravesical suspension by dispersing the powder in solution.|26.97750000000002|19.025000000000006|12.105|13.09|9.751790909090909|9.923918181818184|8.209523809523809|8.326000000000004|16.545454545454547|10.83136363636364|76.64453405168562|76.64453405168562|27.057142857142857|28.0\n",
      "\n",
      "powder (including freeze-dried powder) and solvent intended for the preparation of an intravesical suspension by dispersing the powder in the solvent.| powder and solvent intended for the preparation of an intravesical suspension by dispersing the powder in the solvent|26.97750000000002|31.70789473684212|12.105|13.556842105263158|9.751790909090909|10.944500000000001|8.209523809523809|15.677894736842102|16.545454545454547|12.591000000000001|76.64453405168562|93.86999999999999|27.057142857142857|26.54736842105263\n",
      "\n",
      "refers to the anterior part of the superior semilunar lobule ( madigan-1971 ).|name to the tooth part of the character semilunar lobule (madigan-1971).|70.08365384615385|78.19795454545455|5.098846153846157|3.7186363636363637|12.794827272727273|9.923918181818184|-15.68615384615385|-20.67636363636364|11.045454545454547|9.332727272727272|49.473833993334296|38.32226702584281|17.984615384615388|13.109090909090908\n",
      "\n",
      "refers to the anterior part of the superior semilunar lobule ( madigan-1971 ).|refers to the front part of the superior semilunar body ( madigan-1971 ).|70.08365384615385|83.09903846153848|5.098846153846157|3.283461538461541|12.794827272727273|10.513266666666667|-15.68615384615385|-17.49538461538462|11.045454545454547|4.727500000000003|49.473833993334296|44.250742366654144|17.984615384615388|14.90769230769231\n",
      "\n",
      "refers to the anterior part of the superior semilunar lobule ( madigan-1971 ).| refers to the anterior part of the superior semilunar lobe|70.08365384615385|49.54272727272729|5.098846153846157|9.081818181818182|12.794827272727273|13.442533333333335|-15.68615384615385|-0.18181818181818343|11.045454545454547|4.587499999999999|49.473833993334296|62.58|17.984615384615388|18.94545454545455\n",
      "\n",
      "a heterodimer involved in the recognition and repair of base-base and small insertion/deletion mismatches. in human the complex consists of two subunits, msh2 and msh6. [pmid:11005803]|an immunologic factor have in the appointment and pay of base-base and small insertion/deletion match.  in human the whole be of two subunits, msh2 and msh6.  [ pmid: 11005803]|48.361410256410295|81.727311827957|8.666923076923077|4.427096774193547|11.430504761904762|10.315720833333334|1.8046153846153743|-0.9522580645161263|8.8052380952381|1.8429166666666674|59.91578840339164|47.79626449838941|20.38974358974359|13.165591397849463\n",
      "\n",
      "a heterodimer involved in the recognition and repair of base-base and small insertion/deletion mismatches. in human the complex consists of two subunits, msh2 and msh6. [pmid:11005803]|a heterodimer involved in the recognition and repair of base-base and small insertion/deletion mismatches. in humans the complex consists of two subunits, msh2 and mh6. [pmid:11005803]|48.361410256410295|48.361410256410295|8.666923076923077|8.666923076923077|11.430504761904762|11.738725287356322|1.8046153846153743|2.0307692307692236|8.8052380952381|8.252643678160918|59.91578840339164|59.91578840339164|20.38974358974359|20.38974358974359\n",
      "\n",
      "a heterodimer involved in the recognition and repair of base-base and small insertion/deletion mismatches. in human the complex consists of two subunits, msh2 and msh6. [pmid:11005803]| a complex whose structure is different from person to person|48.361410256410295|72.61545454545457|8.666923076923077|5.863636363636363|11.430504761904762|9.495033333333335|1.8046153846153743|0.8872727272727268|8.8052380952381|5.372500000000002|59.91578840339164|69.96656701596841|20.38974358974359|22.581818181818182\n",
      "\n",
      "transducin beta-like protein 2 (447 aa, ~50 kda) is encoded by the human tbl2 gene. this protein may be involved in signal transduction.|transducin amino acids, protein 2 (447 aa, ~50 code) converts by the human tbl2 gene.  this protein may have in telling transduction.|81.3489855072464|88.70550724637683|3.817391304347826|2.791304347826088|14.758366666666669|15.001114492753624|-9.46434782608696|-10.231304347826086|5.765000000000001|4.1102898550724625|54.195869768830164|54.195869768830164|18.718840579710143|18.718840579710143\n",
      "\n",
      "transducin beta-like protein 2 (447 aa, ~50 kda) is encoded by the human tbl2 gene. this protein may be involved in signal transduction.|transducin beta-like protein 2 (447 amino acids, 50 kilodaltons) is encoded by a human gene tbl2. this protein may be involved in signal transduction.|81.3489855072464|61.24000000000001|3.817391304347826|6.705000000000002|14.758366666666669|14.99790512820513|-9.46434782608696|-5.640000000000001|5.765000000000001|5.004102564102563|54.195869768830164|62.58|18.718840579710143|23.200000000000003\n",
      "\n",
      "transducin beta-like protein 2 (447 aa, ~50 kda) is encoded by the human tbl2 gene. this protein may be involved in signal transduction.| a protein|81.3489855072464|119.19000000000003|3.817391304347826|-2.619999999999999|14.758366666666669|15.6774|-9.46434782608696|-81.02666666666666|5.765000000000001|-7.654999999999999|54.195869768830164|31.29|18.718840579710143|14.533333333333331\n",
      "\n",
      "a non-neoplastic disorder that affects the heart and/or vessels. representative examples include myocardial infarction, endocarditis, arteriosclerosis, thrombosis, and lymphedema.|a disease change, that change the heart and/or craft.  inform examples include myocardial infarction, carditis, sclerosis, thrombosis, and edema.|-26.67754385964909|47.78833333333333|18.553684210526317|8.250000000000004|15.185500000000001|14.230666666666666|3.088421052631574|-7.356000000000002|19.837000000000003|10.16333333333333|65.13532912329528|57.127462747788826|29.90175438596491|22.666666666666668\n",
      "\n",
      "a non-neoplastic disorder that affects the heart and/or vessels. representative examples include myocardial infarction, endocarditis, arteriosclerosis, thrombosis, and lymphedema.|a disorder that affects the heart and/or vessels. representative examples include myocardial infarction, heart rhythm, and lymphedema.|-26.67754385964909|26.906862745098067|18.553684210526317|10.914117647058823|15.185500000000001|13.583544444444446|3.088421052631574|-11.075294117647061|19.837000000000003|11.661666666666669|65.13532912329528|54.195869768830164|29.90175438596491|23.443137254901963\n",
      "\n",
      "a non-neoplastic disorder that affects the heart and/or vessels. representative examples include myocardial infarction, endocarditis, arteriosclerosis, thrombosis, and lymphedema.| a disorder|-26.67754385964909|90.99000000000004|18.553684210526317|1.3133333333333361|15.185500000000001|15.6774|3.088421052631574|-79.06666666666666|19.837000000000003|-6.477499999999999|65.13532912329528|31.29|29.90175438596491|14.533333333333331\n",
      "\n",
      "endonucleolytic cleavage between the 5s rrna and the 4.5s rrna of an rrna molecule originally produced as a tetracistronic rrna transcript that contains the small subunit (ssu) rrna, large subunit (lsu) the 4.5s rrna, and the 5s rrna in that order from 5' to 3' along the primary transcript. note that the use of the word tetracistronic refers only to the number of mature rrna molecules which will be produced from the primary transcript and ignores trnas that may also be present within the primary transcript. [goc:curators]|endonucleolytic state between the 5s rrna and the 4.5s rrna of an rrna unit originally produced as a tetracistronic rrna transcript that contains the small subunit (sue) rrna, large subunit (lsu) the 4.5s rrna, and the 5s rana in that order from 5 ' to 3 ' along the coil transcript.  note that the use of the word tetracistronic name only to the number of draw rrna units which will be produced from the coil transcript and reject trans that may also be present within the coil transcript.  [ goc: curators]|56.92572413793104|75.15600000000003|9.641977011494252|7.397333333333336|13.355036363636364|11.722522222222223|12.794022988505745|10.387956989247307|23.47772727272727|8.765|77.91147168421348|71.35217810270406|21.212873563218395|18.62279569892473\n",
      "\n",
      "endonucleolytic cleavage between the 5s rrna and the 4.5s rrna of an rrna molecule originally produced as a tetracistronic rrna transcript that contains the small subunit (ssu) rrna, large subunit (lsu) the 4.5s rrna, and the 5s rrna in that order from 5' to 3' along the primary transcript. note that the use of the word tetracistronic refers only to the number of mature rrna molecules which will be produced from the primary transcript and ignores trnas that may also be present within the primary transcript. [goc:curators]|endonucleolytic cleavage between the 5s rrna and the 4.5s subunit of a cell's protein maker. note that the use of the word tetracistronic refers only to the number of mature rna molecules that will be produced from|56.92572413793104|61.70045045045046|9.641977011494252|7.717297297297296|12.627569696969697|10.811794736842106|12.794022988505745|4.446486486486478|16.144393939393936|10.132631578947368|77.91147168421348|65.13532912329528|21.212873563218395|18.98738738738739\n",
      "\n",
      "endonucleolytic cleavage between the 5s rrna and the 4.5s rrna of an rrna molecule originally produced as a tetracistronic rrna transcript that contains the small subunit (ssu) rrna, large subunit (lsu) the 4.5s rrna, and the 5s rrna in that order from 5' to 3' along the primary transcript. note that the use of the word tetracistronic refers only to the number of mature rrna molecules which will be produced from the primary transcript and ignores trnas that may also be present within the primary transcript. [goc:curators]| endonucleolytic cleavage|56.92572413793104|-21.809999999999945|9.641977011494252|17.04666666666667|12.627569696969697|19.6249|12.794022988505745|-51.62666666666666|16.144393939393936|10.0075|77.91147168421348|44.250742366654144|21.212873563218395|27.866666666666664\n",
      "\n",
      "an acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors. (who, 2001)|a neoplastic process cancer distinguish by the increase of both neutrophil and monocyte person.  ( who, 2001)|24.382499999999993|70.80000000000003|11.721666666666671|5.6200000000000045|12.305833333333334|12.417511764705882|-2.6186666666666696|-2.8355555555555547|9.329999999999998|7.478235294117649|58.53822981607831|62.58|21.666666666666668|21.37777777777778\n",
      "\n",
      "an acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors. (who, 2001)|acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors. (who, 2001)|24.382499999999993|18.44428571428574|11.721666666666671|12.425714285714289|12.429833333333335|13.4825|-2.6186666666666696|-3.2257142857142824|10.579999999999998|10.266000000000002|58.53822981607831|58.53822981607831|21.666666666666668|22.8\n",
      "\n",
      "an acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors. (who, 2001)| an acute leukemia characterized by the proliferation of neutrophils and monocytes|24.382499999999993|4.305000000000007|11.721666666666671|15.64|12.429833333333335|13.998223076923077|-2.6186666666666696|10.613333333333337|10.579999999999998|11.518461538461537|58.53822981607831|76.64453405168562|21.666666666666668|24.8\n",
      "\n",
      "problem associated with any motion of the system or components that was not initiated by the user.|problem unite with any change of the system or part that was not hash_out by the user.|48.9133823529412|83.74867647058825|8.548529411764708|3.6897058823529427|10.981464705882354|9.123817647058823|-6.461176470588235|-10.611764705882354|9.511764705882353|6.187058823529412|62.58|54.195869768830164|22.223529411764705|17.51764705882353\n",
      "\n",
      "problem associated with any motion of the system or components that was not initiated by the user.|problem associated with any motion of the system or component that was not initiated by the user.|48.9133823529412|48.9133823529412|8.548529411764708|8.548529411764708|10.981464705882354|11.100677777777777|-6.461176470588235|-6.461176470588235|9.511764705882353|4.265000000000001|62.58|62.58|22.223529411764705|22.223529411764705\n",
      "\n",
      "problem associated with any motion of the system or components that was not initiated by the user.| A problem that occurs because of any motion of the system or components that was not initiated by the user.|48.9133823529412|67.2632142857143|8.548529411764708|6.48595238095238|10.981464705882354|10.641645454545454|-6.461176470588235|-3.270476190476188|9.511764705882353|3.12409090909091|62.58|66.37611354998121|22.223529411764705|21.34285714285714\n",
      "\n",
      "administration of a medicinal product directly into the anterior chamber of the eye|justice of a medicinal product directly into the tooth house with the eye|17.932307692307717|56.97846153846157|13.98769230769231|8.541538461538462|11.568992307692309|9.139761538461538|9.344615384615384|4.821538461538459|10.793846153846154|7.170769230769231|82.78555852321104|69.96656701596841|26.738461538461536|20.58461538461539\n",
      "\n",
      "administration of a medicinal product directly into the anterior chamber of the eye|administration of a medical product directly into the front chamber of the eye.|17.932307692307717|44.05288461538464|13.98769230769231|8.729615384615386|11.568992307692309|10.750842857142857|9.344615384615384|-14.781538461538464|10.793846153846154|4.610714285714284|82.78555852321104|54.195869768830164|26.738461538461536|21.06153846153846\n",
      "\n",
      "administration of a medicinal product directly into the anterior chamber of the eye| Administration|17.932307692307717|-6.694999999999993|13.98769230769231|14.690000000000001|11.568992307692309|19.5753|9.344615384615384|-103.9|10.793846153846154|5.189999999999998|82.78555852321104|31.29|26.738461538461536|20.8\n",
      "\n",
      "an incision in the uterus, performed through either the abdomen or the vagina.|a cut in the uterus, re-create through either the abdomen or the duct.|44.05288461538464|76.59134615384617|8.729615384615386|4.191153846153846|10.354376923076924|9.970185714285716|-15.68615384615385|-19.30461538461539|8.25769230769231|4.073571428571427|54.195869768830164|44.250742366654144|21.06153846153846|14.90769230769231\n",
      "\n",
      "an incision in the uterus, performed through either the abdomen or the vagina.|an incision in the uterus, performed through the abdomen or the vagina.|44.05288461538464|45.64500000000001|8.729615384615386|8.383333333333333|10.354376923076924|11.246592307692307|-15.68615384615385|-19.443333333333328|8.25769230769231|3.1961538461538446|54.195869768830164|49.473833993334296|21.06153846153846|19.06666666666667\n",
      "\n",
      "an incision in the uterus, performed through either the abdomen or the vagina.| an incision|44.05288461538464|90.99000000000004|8.729615384615386|1.3133333333333361|10.354376923076924|15.6774|-15.68615384615385|-77.10666666666665|8.25769230769231|-5.300000000000001|54.195869768830164|31.29|21.06153846153846|14.533333333333331\n",
      "\n",
      "a skin spray composed of evaux thermal spring water, the emulsifier polysorbate 20, the preservatives phenoxyethanol and chlorphenesin, zinc gluconate, and the moisturizer caprylyl glycol with prophylactic and calming activity. evaux thermal spring water is rich in mineral elements particularly of lithium, strontium and manganese. when sprayed directly onto the skin or scalp, this topical spray may have a calming, moisturizing, healing and nurturing effect. this agent may prevent or decrease skin rashes associated with the administration of egfr inhibitors or with radiochemotherapy-induced skin reactions.|a skin sprays plan of evaux wind spring water, the emulsifier polysorbate 20, the compound phenoxyethanol and chlorphenesin, zinc gluconate, and the moisturizer caprylyl glycol with remedy and calming activity.  evaux wind spring water is rich in mineral straight_line particularly of lithium, strontium and manganese.  when sprayed directly onto the skin or scalp, this topical spray may have a calming, moisten, help and provide the effect.  this agent may prevent or change skin rashes unite with the justice of egfr substance or with radiochemotherapy-induced skin force.|18.389411764705926|44.28260674157306|14.91764705882353|11.504808988764047|13.87138992248062|12.34465873015873|19.113411764705884|15.545617977528089|21.10856589147287|9.961571428571425|90.68703567765351|83.9598804191621|26.56470588235294|23.299775280898878\n",
      "\n",
      "a skin spray composed of evaux thermal spring water, the emulsifier polysorbate 20, the preservatives phenoxyethanol and chlorphenesin, zinc gluconate, and the moisturizer caprylyl glycol with prophylactic and calming activity. evaux thermal spring water is rich in mineral elements particularly of lithium, strontium and manganese. when sprayed directly onto the skin or scalp, this topical spray may have a calming, moisturizing, healing and nurturing effect. this agent may prevent or decrease skin rashes associated with the administration of egfr inhibitors or with radiochemotherapy-induced skin reactions.|a skin spray composed of evaux thermal spring water, the emulsifier polysorbate 20, the preservatives phenoxyethanol and chlorphenesin, zinc gluconate, and the moisturizer caprylyl glycol with prophylactic and calming effect. this|18.389411764705926|16.44443548387102|14.91764705882353|14.816290322580645|13.515923255813954|13.805412500000001|19.113411764705884|19.028387096774196|17.525232558139535|15.418749999999996|90.68703567765351|88.50148473330829|26.56470588235294|26.84516129032258\n",
      "\n",
      "a skin spray composed of evaux thermal spring water, the emulsifier polysorbate 20, the preservatives phenoxyethanol and chlorphenesin, zinc gluconate, and the moisturizer caprylyl glycol with prophylactic and calming activity. evaux thermal spring water is rich in mineral elements particularly of lithium, strontium and manganese. when sprayed directly onto the skin or scalp, this topical spray may have a calming, moisturizing, healing and nurturing effect. this agent may prevent or decrease skin rashes associated with the administration of egfr inhibitors or with radiochemotherapy-induced skin reactions.| A skin cream composed of evaux thermal spring water, the emulsifier polysorbate 20, the preservatives phenoxyethanol and chlorphenesin, zinc gluconate, and the moisturizer caprylyl glycol with prophylactic and calming activity. evaux|18.389411764705926|13.463750000000005|14.91764705882353|15.35625|13.515923255813954|14.02459696969697|19.113411764705884|18.985|17.525232558139535|15.365454545454547|90.68703567765351|91.22524239485473|26.56470588235294|27.650000000000002\n",
      "\n",
      "an estimation as to the cause of the pathology responsible for the cardiac valve regurgitation.|a judgment as to the cause of the ill_health responsible for the cardiac valve expulsion.|35.662499999999994|69.5025|10.148333333333337|5.428333333333338|10.6965|10.6965|-7.714666666666666|-10.06666666666667|11.189999999999998|9.306000000000001|49.473833993334296|49.473833993334296|16.333333333333332|16.333333333333332\n",
      "\n",
      "an estimation as to the cause of the pathology responsible for the cardiac valve regurgitation.|an estimation as to the cause of the disease responsible for the heart valve regurgitation.|35.662499999999994|52.58250000000001|10.148333333333337|7.7883333333333375|10.6965|9.954550000000001|-7.714666666666666|-8.890666666666672|11.189999999999998|5.236875000000001|49.473833993334296|44.250742366654144|16.333333333333332|13.66666666666667\n",
      "\n",
      "an estimation as to the cause of the pathology responsible for the cardiac valve regurgitation.| an evaluation|35.662499999999994|34.59000000000003|10.148333333333337|9.180000000000003|10.6965|15.6774|-7.714666666666666|-73.18666666666667|11.189999999999998|-2.9450000000000003|49.473833993334296|31.29|16.333333333333332|14.533333333333331\n",
      "\n",
      "human ubqln4 wild-type allele is located in the vicinity of 1q21 and is approximately 18 kb in length. this allele, which encodes ubiquilin-4 protein, may play a role in the regulation of the proteasome.|human ubqln4 wild-type gene is located in the section of 1q21 and is approximately 18 kb in length.  this gene, which convert ubiquilin-4 protein, may play a role in the control of the proteasome.|70.91990196078433|91.05619047619048|6.182941176470592|3.457142857142859|12.173928571428572|12.1267|3.2823529411764696|1.8445714285714274|9.524285714285714|5.241666666666667|59.91578840339164|54.195869768830164|17.47450980392157|14.952380952380953\n",
      "\n",
      "human ubqln4 wild-type allele is located in the vicinity of 1q21 and is approximately 18 kb in length. this allele, which encodes ubiquilin-4 protein, may play a role in the regulation of the proteasome.|normal human ubqln4 gene is located in the vicinity of 1q21 and is about 18 kilobases in length. this gene, which encodes ubiquilin-4 protein, may play a role in regulation of the proteasome.|70.91990196078433|72.61545454545457|6.182941176470592|5.863636363636363|12.173928571428572|12.093633333333333|3.2823529411764696|1.6000000000000014|9.524285714285714|5.847254901960785|59.91578840339164|57.127462747788826|17.47450980392157|16.521212121212123\n",
      "\n",
      "human ubqln4 wild-type allele is located in the vicinity of 1q21 and is approximately 18 kb in length. this allele, which encodes ubiquilin-4 protein, may play a role in the regulation of the proteasome.| human ubiquilin-4 protein locus is located near the long arm of chromosome 1; region q21|70.91990196078433|84.845|6.182941176470592|5.400000000000002|12.173928571428572|14.69675882352941|3.2823529411764696|9.0625|9.524285714285714|7.849411764705884|59.91578840339164|76.64453405168562|17.47450980392157|21.400000000000002\n",
      "\n",
      "glycerol esterified with fatty acids.|glycerol change_state with fatty acids.|1.2575000000000216|18.17750000000001|13.705000000000002|11.345000000000006|16.5165|16.5165|-79.59199999999998|-77.24|11.214000000000006|13.097999999999999|44.250742366654144|44.250742366654144|33.0|33.0\n",
      "\n",
      "glycerol esterified with fatty acids.|gocerol esterified with fatty acids.|1.2575000000000216|1.2575000000000216|13.705000000000002|13.705000000000002|16.5165|16.94363333333333|-79.59199999999998|-79.59199999999998|11.214000000000006|5.189999999999998|44.250742366654144|44.250742366654144|33.0|33.0\n",
      "\n",
      "glycerol esterified with fatty acids.| glycerol ester|1.2575000000000216|62.79000000000002|13.705000000000002|5.246666666666666|16.5165|19.6249|-79.59199999999998|-71.22666666666666|11.214000000000006|-1.7674999999999983|44.250742366654144|44.250742366654144|33.0|27.866666666666664\n",
      "\n",
      "the total body clearance for intravascular administration, calculated using the observed value of the last non-zero concentration.|the total body room for intravascular justice, trust using the check value of the last non-zero diligence.|9.101617647058845|53.889852941176486|14.101470588235298|7.854411764705883|12.4243|9.792633333333335|4.607058823529414|-3.6941176470588246|16.615000000000002|10.334999999999997|69.96656701596841|58.53822981607831|26.929411764705886|19.870588235294118\n",
      "\n",
      "the total body clearance for intravascular administration, calculated using the observed value of the last non-zero concentration.|the total body clearance for blood injection, calculated using the observed value of the last non-zero concentration.|9.101617647058845|38.960441176470624|14.101470588235298|9.936764705882357|12.4243|11.587173684210526|4.607058823529414|0.4564705882352982|16.615000000000002|7.861578947368422|69.96656701596841|66.37611354998121|26.929411764705886|24.576470588235296\n",
      "\n",
      "the total body clearance for intravascular administration, calculated using the observed value of the last non-zero concentration.| the total body clearance, calculated using the observed value of the last non-zero concentration|9.101617647058845|39.33000000000001|14.101470588235298|11.500000000000004|12.4243|12.839111764705882|4.607058823529414|13.194666666666663|16.615000000000002|10.065882352941177|69.96656701596841|88.50148473330829|26.929411764705886|27.33333333333334\n",
      "\n",
      "the number of days from the date of initial cancer diagnosis to the date of death.|the number of days from the date of sign cancer diagnosis to the date of death.|77.1025|87.67750000000001|4.492500000000003|3.017500000000002|7.390725|6.40385|-12.377500000000001|-13.48|5.998750000000001|5.115625000000001|44.250742366654144|38.32226702584281|13.200000000000001|10.700000000000001\n",
      "\n",
      "the number of days from the date of initial cancer diagnosis to the date of death.|the number of days from the initial cancer diagnosis to the date of death.|77.1025|72.83000000000003|4.492500000000003|4.840000000000003|7.390725|8.219166666666666|-12.377500000000001|-16.245714285714282|5.998750000000001|1.4740000000000002|44.250742366654144|44.250742366654144|13.200000000000001|14.228571428571428\n",
      "\n",
      "the number of days from the date of initial cancer diagnosis to the date of death.| the number of days from the date of initial cancer diagnosis to the date of death|77.1025|75.12117647058825|4.492500000000003|7.004705882352944|7.390725|8.915411111111112|-12.377500000000001|5.76235294117647|5.998750000000001|5.363333333333333|44.250742366654144|62.58|13.200000000000001|16.211764705882356\n",
      "\n",
      "st. george's respiratory questionnaire past 4 weeks version (sgrq past 4 weeks version) these are questions about your respiratory treatment: my treatment interferes with my life a lot.|st. george 's respiratory form past 4 week version (sgrq past 4 week version) these are questions about your respiratory treatment: my treatment interact with my life a lot.|58.37595238095241|71.58195402298851|7.435714285714287|5.6765517241379335|11.66197142857143|11.792442857142857|1.465714285714295|-1.2206896551724142|11.306785714285716|16.288214285714282|59.91578840339164|54.195869768830164|19.44761904761905|16.28045977011494\n",
      "\n",
      "st. george's respiratory questionnaire past 4 weeks version (sgrq past 4 weeks version) these are questions about your respiratory treatment: my treatment interferes with my life a lot.|these are questions about your respiratory treatment: my treatment interferes with my life a lot.|58.37595238095241|52.58250000000001|7.435714285714287|7.7883333333333375|12.558361904761906|8.835408333333334|1.465714285714295|-6.538666666666671|9.14166666666667|5.375416666666666|59.91578840339164|54.195869768830164|19.44761904761905|19.0\n",
      "\n",
      "st. george's respiratory questionnaire past 4 weeks version (sgrq past 4 weeks version) these are questions about your respiratory treatment: my treatment interferes with my life a lot.| st. George's respiratory questionnaire past 4 weeks version (sgrq past 4 weeks version) these are questions about your respiratory treatment: my treatment interferes with my life a lot|58.37595238095241|57.92439655172416|7.435714285714287|8.78224137931035|12.35637142857143|12.275500000000001|1.465714285714295|11.62206896551724|18.306785714285716|10.405000000000001|59.91578840339164|73.38155456243756|19.44761904761905|20.97241379310345\n",
      "\n",
      "a doctor who specializes in diagnosing and treating eye problems, including injury and disease.|a treat who evolves in diagnosing and give eye problems, including wrongdoing and disease.|42.61571428571432|66.7871428571429|9.054285714285715|5.682857142857145|11.098042857142858|11.098042857142858|-7.845714285714287|-9.945714285714288|12.484285714285711|10.802142857142854|62.58|54.195869768830164|25.65714285714286|19.942857142857143\n",
      "\n",
      "a doctor who specializes in diagnosing and treating eye problems, including injury and disease.|a doctor who specializes in diagnosis and treating eye problems, including injury and disease.|42.61571428571432|36.572857142857174|9.054285714285715|9.89714285714286|11.098042857142858|11.377166666666668|-7.845714285714287|-7.845714285714287|12.484285714285711|7.439999999999998|62.58|62.58|25.65714285714286|25.65714285714286\n",
      "\n",
      "a doctor who specializes in diagnosing and treating eye problems, including injury and disease.| an eye doctor|42.61571428571432|118.17500000000001|9.054285714285715|-2.2299999999999986|11.098042857142858|10.200500000000002|-7.845714285714287|-56.36|12.484285714285711|-6.683999999999999|62.58|31.29|25.65714285714286|11.600000000000001\n",
      "\n",
      "a route that begins in the regional surrounding a tumor.|a route that acts in the region protect a growth.|66.40000000000003|100.24000000000002|5.240000000000002|0.5199999999999996|8.8695|7.2905|-31.563999999999997|-35.67999999999999|5.235999999999997|1.939|44.250742366654144|31.29|18.0|10.0\n",
      "\n",
      "a route that begins in the regional surrounding a tumor.|a route that begins in the region surrounding a tumor.|66.40000000000003|74.86000000000003|5.240000000000002|4.060000000000002|8.8695|9.651118181818184|-31.563999999999997|-32.152|5.235999999999997|0.5881818181818197|44.250742366654144|44.250742366654144|18.0|18.0\n",
      "\n",
      "a route that begins in the regional surrounding a tumor.| a way that begins|66.40000000000003|117.16000000000003|5.240000000000002|-1.8399999999999999|8.8695|9.197433333333334|-31.563999999999997|-41.559999999999995|5.235999999999997|-5.870000000000001|44.250742366654144|31.29|18.0|10.0\n",
      "\n",
      "membrane-associated transporter protein (530 aa, ~58 kda) is encoded by the human slc45a2 gene. this protein is involved in the modulation of both melanin synthesis and melanocyte differentiation.|membrane-associated belt protein (530 aa, ~58 code) is converted by the human slc45a2 gene.  this protein is having in the revision of both melanin synthesis and melanocyte adaptation.|37.22595238095241|56.99574712643681|10.385714285714286|7.71103448275862|14.700872413793105|13.6065|3.7757142857142902|1.0096551724137903|12.293448275862069|7.277000000000001|62.58|57.127462747788826|20.876190476190477|17.65977011494253\n",
      "\n",
      "membrane-associated transporter protein (530 aa, ~58 kda) is encoded by the human slc45a2 gene. this protein is involved in the modulation of both melanin synthesis and melanocyte differentiation.|this protein is involved in the modulation of both the middle germ-cell layer synthesis and melanocyte differentiation.|37.22595238095241|29.00750000000002|10.385714285714286|11.325000000000003|14.700872413793105|11.587173684210526|3.7757142857142902|1.1482352941176472|12.293448275862069|8.605263157894736|62.58|66.37611354998121|20.876190476190477|24.576470588235296\n",
      "\n",
      "membrane-associated transporter protein (530 aa, ~58 kda) is encoded by the human slc45a2 gene. this protein is involved in the modulation of both melanin synthesis and melanocyte differentiation.| membrane-associated transporter protein is encoded by the human sld45a2 gene|37.22595238095241|34.160909090909115|10.385714285714286|11.22727272727273|14.700872413793105|16.427453846153846|3.7757142857142902|9.440000000000001|12.293448275862069|9.706923076923076|62.58|69.96656701596841|20.876190476190477|22.581818181818182\n",
      "\n",
      "genus in the family felidae comprised of big felines including lions; tigers; jaguars; and the leopard.|kind in the family felidae include of big felines, including lions; tigers; jaguars; and the fur.|50.66500000000002|66.5275|8.180000000000003|5.967500000000001|11.338225000000001|9.364474999999999|-4.660000000000004|-6.864999999999998|11.2975|9.236875000000001|66.37611354998121|58.53822981607831|25.700000000000003|20.700000000000003\n",
      "\n",
      "genus in the family felidae comprised of big felines including lions; tigers; jaguars; and the leopard.|genus in the family felidae comprised of big felines including lion; tigers; jaguars; and the leopard.|50.66500000000002|45.377500000000026|8.180000000000003|8.917500000000004|11.338225000000001|11.488688235294118|-4.660000000000004|-4.660000000000004|11.2975|6.092941176470589|66.37611354998121|69.96656701596841|25.700000000000003|28.200000000000003\n",
      "\n",
      "genus in the family felidae comprised of big felines including lions; tigers; jaguars; and the leopard.| genus of the family felidae composed of big felines including lions; tigers; jaguars; and leopards.|50.66500000000002|61.24000000000001|8.180000000000003|6.705000000000002|11.338225000000001|12.417511764705882|-4.660000000000004|-5.395|11.2975|5.815882352941177|66.37611354998121|66.37611354998121|25.700000000000003|25.700000000000003\n",
      "\n",
      "unified huntington's disease rating scale 1999 version (uhdrs 1999 version) dysarthria.|change huntington 's disease pad scale 1999 version (uhdrs 1999 version) dysarthria.|55.12522727272727|80.89500000000001|6.936818181818182|3.4666666666666686|19.972099999999998|17.10119090909091|-12.658181818181824|-13.563333333333333|15.755454545454548|14.04272727272727|58.53822981607831|49.473833993334296|27.654545454545453|19.06666666666667\n",
      "\n",
      "unified huntington's disease rating scale 1999 version (uhdrs 1999 version) dysarthria.|neurologic disease rating scale 1999 version (uhdrs 1999 version) dysarthria.|55.12522727272727|57.940000000000026|6.936818181818182|6.420000000000002|19.972099999999998|19.6993|-12.658181818181824|-18.627999999999993|15.755454545454548|9.579999999999998|58.53822981607831|54.195869768830164|27.654545454545453|26.0\n",
      "\n",
      "unified huntington's disease rating scale 1999 version (uhdrs 1999 version) dysarthria.| unified huntington's disease rating scale|55.12522727272727|45.64500000000001|6.936818181818182|8.383333333333333|19.972099999999998|19.773699999999998|-12.658181818181824|-12.093333333333334|15.755454545454548|8.311428571428571|58.53822981607831|62.58|27.654545454545453|29.066666666666663\n",
      "\n",
      "an arbitrary unit of substance concentration expressed in milligrams per a volume of hydrogen peroxide. one carratelli unit is equal to 0.8mg substance per liter of hydrogen peroxide.|a quantitative unit of substance concentration mail in milligrams per a volume of hydrogen bleach.  one carratelli unit is equal to 0.8mg substance per liter of hydrogen bleach.|33.5514285714286|56.53142241379314|10.318571428571431|7.175431034482759|14.700872413793105|14.132833333333334|-9.525714285714287|-10.616551724137928|10.83172413793104|6.806000000000001|62.58|56.4088497046341|25.65714285714286|20.831034482758625\n",
      "\n",
      "an arbitrary unit of substance concentration expressed in milligrams per a volume of hydrogen peroxide. one carratelli unit is equal to 0.8mg substance per liter of hydrogen peroxide.|an arbitrary unit of substance concentration expressed in milligrams per a volume of hydrogen peroxide. one carratelli unit is equal to 0.8mg substance in molar proportions.|33.5514285714286|34.29134615384618|10.318571428571431|10.091153846153848|14.700872413793105|14.25014761904762|-9.525714285714287|-11.841538461538462|10.83172413793104|7.964166666666667|62.58|60.592824451415034|25.65714285714286|25.676923076923075\n",
      "\n",
      "an arbitrary unit of substance concentration expressed in milligrams per a volume of hydrogen peroxide. one carratelli unit is equal to 0.8mg substance per liter of hydrogen peroxide.| an arbitrary unit of concentration expressed in grams per milliliter|33.5514285714286|26.470000000000027|10.318571428571431|12.3|14.700872413793105|16.0742|-9.525714285714287|5.1636363636363605|10.83172413793104|8.5125|62.58|69.96656701596841|25.65714285714286|22.581818181818182\n",
      "\n",
      "the chemical reactions and pathways resulting in the formation of oligosaccharides, molecules with between two and (about) 20 monosaccharide residues connected by glycosidic linkages. [isbn:0198506732]|the process force and path happen in the placement of carbohydrate, unit with between two and (about) 20 carbohydrate part connected by glycosidic linkages.  [ isbn: 0198506732]|8.027500000000003|62.70357142857142|15.245000000000005|7.991428571428575|12.4673|11.100677777777777|17.950400000000002|10.35714285714285|17.0364|8.189999999999998|82.78555852321104|73.38155456243756|27.400000000000002|21.314285714285717\n",
      "\n",
      "the chemical reactions and pathways resulting in the formation of oligosaccharides, molecules with between two and (about) 20 monosaccharide residues connected by glycosidic linkages. [isbn:0198506732]|the chemical reactions and pathways resulting in the formation of oligomers, molecules with between two and (about) 20 monosaccharides connected by glycosidic linkages. [isbn:0198506732]|8.027500000000003|18.405|15.245000000000005|13.673333333333336|12.4673|12.4673|17.950400000000002|15.513333333333335|17.0364|14.587200000000003|82.78555852321104|79.77416029015912|27.400000000000002|26.466666666666665\n",
      "\n",
      "the chemical reactions and pathways resulting in the formation of oligosaccharides, molecules with between two and (about) 20 monosaccharide residues connected by glycosidic linkages. [isbn:0198506732]| the chemical processes resulting in the formation of oligosaccharides, molecules with between two and about 20 monosaccharide residues connected by glycosidic linkages|8.027500000000003|-11.457826086956487|15.245000000000005|20.57130434782609|12.4673|13.379816666666667|17.950400000000002|24.711304347826086|17.0364|19.418749999999996|82.78555852321104|112.8176994092682|27.400000000000002|31.808695652173913\n",
      "\n",
      "a subjective score of 9 on a tiredness scale that ranges from 0: no tiredness to 10: worst possible tiredness.|a quality score of 9 on a tiredness scale that feed from 0: no tiredness to 10: worst possible tiredness.|78.24500000000002|82.47500000000001|4.830000000000002|4.240000000000002|11.734|10.944500000000001|-2.8459999999999965|-4.3160000000000025|9.294|8.116500000000002|54.195869768830164|49.473833993334296|16.0|14.0\n",
      "\n",
      "a subjective score of 9 on a tiredness scale that ranges from 0: no tiredness to 10: worst possible tiredness.|a subjective score on a tiredness scale that ranges from 0: no tiredness to 10: worst possible fatigue.|78.24500000000002|75.50000000000003|4.830000000000002|4.964444444444446|11.734|11.587173684210526|-2.8459999999999965|-4.468888888888891|9.294|4.143157894736845|54.195869768830164|54.195869768830164|16.0|16.933333333333334\n",
      "\n",
      "a subjective score of 9 on a tiredness scale that ranges from 0: no tiredness to 10: worst possible tiredness.| a subjective score of 9 on a tiredness scale that ranges from 0: not tiredness to 10: worst possible tiredness.|78.24500000000002|83.37750000000003|4.830000000000002|4.238333333333333|11.734|12.0771|-2.8459999999999965|-2.150476190476187|9.294|3.5522727272727295|54.195869768830164|54.195869768830164|16.0|15.628571428571428\n",
      "\n",
      "the multiplication or reproduction of cells, resulting in the expansion of a cell population. [goc:mah, goc:mb]|the increase or copying of cells, happen in the increase of a cell integer.  [ goc : mah , goc : mb ]|34.80250000000001|110.055|10.392500000000002|0.8900000000000006|11.9779|11.430107017543861|-1.7199999999999989|-5.556666666666665|6.358333333333334|-0.4149122807017527|54.195869768830164|49.473833993334296|18.2|13.133333333333335\n",
      "\n",
      "the multiplication or reproduction of cells, resulting in the expansion of a cell population. [goc:mah, goc:mb]|the multiplication or reproduction of cells, resulting in the expansion of a cell population.|34.80250000000001|30.53000000000003|10.392500000000002|10.740000000000002|11.9779|10.3245|-1.7199999999999989|-8.265714285714282|6.358333333333334|7.126000000000001|54.195869768830164|49.473833993334296|18.2|17.085714285714285\n",
      "\n",
      "the multiplication or reproduction of cells, resulting in the expansion of a cell population. [goc:mah, goc:mb]| the multiplication or reproduction of cells|34.80250000000001|42.61571428571432|10.392500000000002|9.054285714285715|11.9779|11.9283|-1.7199999999999989|-9.525714285714287|6.358333333333334|6.120000000000001|54.195869768830164|44.250742366654144|18.2|14.228571428571428\n",
      "\n",
      "a peptide of 22 amino acids, derived mainly from cells of vascular endothelium. it is also found in the brain, major endocrine glands, and other tissues. it shares structural homology with atrial natriuretic factor. it has vasorelaxant activity thus is important in the regulation of vascular tone and blood flow. several high molecular weight forms containing the 22 amino acids have been identified.|a pharmacologic substance of 22 group acids, make mainly from cells of vascular endothelium.  it is also found in the brain, major gland glands, and other tissues.  it shares structural homology with atrial natriuretic factor.  it has vasorelaxant activity, thus is important in the control of vascular tone and blood flow.  several high molecular weight forms defend the 22 group acids have been recognized.|41.74892857142859|59.72284313725493|10.04468253968254|7.744705882352946|11.279237777777777|10.792070588235294|3.4495238095238108|3.368823529411763|9.616190476190479|6.092941176470589|67.59412548439398|63.87044504307137|21.977777777777778|19.239215686274513\n",
      "\n",
      "a peptide of 22 amino acids, derived mainly from cells of vascular endothelium. it is also found in the brain, major endocrine glands, and other tissues. it shares structural homology with atrial natriuretic factor. it has vasorelaxant activity thus is important in the regulation of vascular tone and blood flow. several high molecular weight forms containing the 22 amino acids have been identified.|a peptide of 22 amino acids, derived mainly from cells of vascular endothelium. it is also found in the brain, major endocrine glands, and other tissues. this protein has vasorelaxant activity thus is important in|41.74892857142859|47.547619047619065|10.04468253968254|9.525714285714287|11.279237777777777|11.249477777777777|3.4495238095238108|4.868571428571428|9.616190476190479|7.465833333333332|67.59412548439398|72.26115969177356|21.977777777777778|22.952380952380953\n",
      "\n",
      "a peptide of 22 amino acids, derived mainly from cells of vascular endothelium. it is also found in the brain, major endocrine glands, and other tissues. it shares structural homology with atrial natriuretic factor. it has vasorelaxant activity thus is important in the regulation of vascular tone and blood flow. several high molecular weight forms containing the 22 amino acids have been identified.| a peptide|41.74892857142859|119.19000000000003|10.04468253968254|-2.619999999999999|11.279237777777777|15.6774|3.4495238095238108|-81.02666666666666|9.616190476190479|-7.654999999999999|67.59412548439398|31.29|21.977777777777778|14.533333333333331\n",
      "\n",
      "trauma symptom checklist for children - scary ideas or pictures just pop into my head.|trauma symptom list for children - scary tune or pictures just pop into my head.|63.86250000000001|80.78250000000001|6.215000000000003|3.8550000000000004|8.842328571428572|7.714471428571429|-11.242666666666668|-13.594666666666669|9.120000000000001|7.1014285714285705|62.58|54.195869768830164|24.333333333333336|19.0\n",
      "\n",
      "trauma symptom checklist for children - scary ideas or pictures just pop into my head.|trauma symptom checklist for children - scary ideas or pictures just pop into my head.|63.86250000000001|63.86250000000001|6.215000000000003|6.215000000000003|8.842328571428572|9.271833333333333|-11.242666666666668|-10.850666666666672|9.120000000000001|4.614000000000001|62.58|62.58|24.333333333333336|24.333333333333336\n",
      "\n",
      "trauma symptom checklist for children - scary ideas or pictures just pop into my head.| trauma symptoms checklist for children - scary thoughts just pop into my head.|63.86250000000001|90.95857142857145|6.215000000000003|2.3114285714285714|8.842328571428572|10.750842857142857|-11.242666666666668|-14.145714285714288|9.120000000000001|4.274285714285714|62.58|54.195869768830164|24.333333333333336|19.942857142857143\n",
      "\n",
      "symbol digit modalities test test name.|symbol intellectual product, treatment test test name.|48.690000000000026|34.08250000000001|7.213333333333335|9.375|11.8291|13.006557142857146|-65.34666666666666|-44.251428571428576|7.475000000000001|13.021428571428565|38.32226702584281|44.250742366654144|21.200000000000003|24.257142857142856\n",
      "\n",
      "symbol digit modalities test test name.|symbol digit modalities test name.|48.690000000000026|35.097500000000025|7.213333333333335|8.985000000000003|11.8291|14.311966666666669|-65.34666666666666|-81.94399999999999|7.475000000000001|3.620000000000001|38.32226702584281|38.32226702584281|21.200000000000003|25.0\n",
      "\n",
      "symbol digit modalities test test name.| symbol digit modalities test|48.690000000000026|49.48000000000002|7.213333333333335|7.600000000000001|11.8291|17.092433333333332|-65.34666666666666|-28.624|7.475000000000001|2.7650000000000006|38.32226702584281|54.195869768830164|21.200000000000003|26.0\n",
      "\n",
      "the developmental process pertaining to the initial formation of a lung lobe from unspecified parts. this process begins with the specific processes that contribute to the appearance of the lobe and ends when the structural rudiment is recognizable. a lung lobe is a projection that extends from the lung. [goc:dph]|the organ function walks pertaining to the sign placement of a lung lobe from unspecified parts.  this walk act with the fact transform that pay to the pretense of the lobe and ends when the structural rudiment is recognizable.  a lung lobe is a structure that use of the lung.  [ goc: dph]|52.01950000000002|85.36428571428573|9.109000000000002|4.830714285714286|11.699488235294119|10.055123376623378|7.601599999999998|3.532142857142855|8.95676470588235|2.3662077922077884|64.5059875127883|51.88859484511023|18.6|13.457142857142856\n",
      "\n",
      "the developmental process pertaining to the initial formation of a lung lobe from unspecified parts. this process begins with the specific processes that contribute to the appearance of the lobe and ends when the structural rudiment is recognizable. a lung lobe is a projection that extends from the lung. [goc:dph]|the developmental process pertaining to the initial formation of a lung lobe from unspecified parts. this process begins with the specific processes that contribute to their appearance and ends when the structural rudiment is recognizable.|52.01950000000002|35.461904761904776|9.109000000000002|11.211428571428574|11.699488235294119|11.688088888888888|7.601599999999998|9.236571428571423|8.95676470588235|11.259999999999998|64.5059875127883|69.96656701596841|18.6|21.80952380952381\n",
      "\n",
      "the developmental process pertaining to the initial formation of a lung lobe from unspecified parts. this process begins with the specific processes that contribute to the appearance of the lobe and ends when the structural rudiment is recognizable. a lung lobe is a projection that extends from the lung. [goc:dph]| the developmental process pertaining to the initial formation of a lobe|52.01950000000002|46.60500000000002|9.109000000000002|9.740000000000002|11.699488235294119|13.998223076923077|7.601599999999998|5.713333333333338|8.95676470588235|7.895384615384614|64.5059875127883|69.96656701596841|18.6|21.46666666666667\n",
      "\n",
      "nutritional condition produced by a deficiency of thiamine in the diet, characterized by anorexia, irritability, and weight loss; later, patients experience weakness, peripheral neuropathy, headache, and tachycardia; in addition to being caused by a poor diet, thiamine deficiency in the united states most commonly occurs as a result of alcoholism, since ethanol interferes with thiamine absorption.|nutritional condition produced by a amount of thiamine in the fast , distinguish by anorexia , ill_nature , and weight loss ; later , case change weakness , peripheral neuropathy , ache , and tachycardia ; in addition to being caused by a poor fast , thiamine amount in the united states most commonly occurs as a result of mania , since ethanol interact with thiamine sorption .|-2.870714285714257|47.91323529411767|20.615714285714287|15.022941176470592|14.591064285714285|12.899278571428571|25.653571428571425|18.27294117647058|34.57767857142857|31.802142857142854|123.18885318891476|112.8176994092682|33.34285714285715|28.894117647058824\n",
      "\n",
      "nutritional condition produced by a deficiency of thiamine in the diet, characterized by anorexia, irritability, and weight loss; later, patients experience weakness, peripheral neuropathy, headache, and tachycardia; in addition to being caused by a poor diet, thiamine deficiency in the united states most commonly occurs as a result of alcoholism, since ethanol interferes with thiamine absorption.|nutrient condition produced by a deficit of thiamine in the diet, characterized by anorexia, nausea, weight loss; later, patients experience weakness, peripheral neuropathy, headache, and rhythm.|-2.870714285714257|11.424615384615407|20.615714285714287|14.895384615384618|14.873028571428572|14.247951851851854|25.653571428571425|15.90307692307692|34.57767857142857|13.579999999999998|123.18885318891476|88.50148473330829|33.34285714285715|29.81538461538462\n",
      "\n",
      "nutritional condition produced by a deficiency of thiamine in the diet, characterized by anorexia, irritability, and weight loss; later, patients experience weakness, peripheral neuropathy, headache, and tachycardia; in addition to being caused by a poor diet, thiamine deficiency in the united states most commonly occurs as a result of alcoholism, since ethanol interferes with thiamine absorption.| condition|-2.870714285714257|77.90500000000002|20.615714285714287|2.890000000000004|14.873028571428572|19.5753|25.653571428571425|-118.6|34.57767857142857|-2.66|123.18885318891476|31.29|33.34285714285715|20.8\n",
      "\n",
      "a standard operating procedure (sop) that is a collection of activities and the rules that describe when each activity is performed to achieve a specific purpose or objective(s). example(s): specimen collection protocol; specimen processing protocol; image acquisition protocol other name(s): note(s): in modeling, often the same term is used to mean different things and a single concept can have more than one name. in the healthcare arena, the term \"protocol\" is somewhat overloaded and must be qualified to provide semantic context. therefore during the early years of the bridg project, the term \"study protocol\" was chosen to disambiguate the concept of the detailed plan for a clinical study (the scope of bridg at that time) from other kinds of protocols such as are common in life sciences. in bridg, the notion of a study protocol is very specific in purpose and includes (but is not limited to) the design, statistical considerations, activities to test a particular hypothesis or answer a particular question that is the basis of the study, characteristics, specifications, objective(s), background, pre-study/study/post-study portions of the plan (including the design, methodology, statistical considerations, organization). for a more complete discussion of the notion of the study protocol see the classes studyprotocol, studyprotocolversion, studyprotocoldocument, studyprotocoldocumentversion, studyconduct and all their associations. with the addition of life sciences to the scope of the bridg model, there came along (with that scope) the need to identify the kind of protocol that represents a more simple or atomic concept, that of a composite activity that serves as a rule that guides how activities should be performed. this concept, represented by the processprotocol class, has a more limited size than the concept of a study protocol does and represents a standardized approach to doing tasks or activities that are not as big as the plan for a whole study. the bridg scc acknowledges that overloaded terms are problematic. the scc recognizes that many different users within the bridg community will have differing opinions on what the meaning of a term is, which term is the best to use for each concept, and how to define them most effectively. given that the real meat of a concept is in the definition, the bridg scc aims to choose the most unambiguous term to use as the class name, to make the class definition as explicit and clear as possible, to provide sufficient examples and other names to illustrate the range of possible instances that could be represented by the class. so the bridg model is maintaining the distinction between a processprotocol and a studyprotocol because there is a distinction in the domain that we're trying to disambiguate - the concepts, attributes and relationships that describe an sop-like, atomic, reusable processprotocol are very different than those of a full-blown clinical trial studyprotocol. linking the classes because they both contain the same overloaded word would create artificial complexity in the model and not serve the ultimate purpose of interoperability across systems that need to exchange biomedical research data.|a standard treat software (sop) that is a grouping of trait and the rules that mark when each trait is re-create to achieve a fact goal or lens (s).  example (s): sample grouping rule; sample walk rule; image acquiring rule other name (s): note (s): in re-create, often the same term is used to mean different things and a single concept can have more than one name.  in the care playing_field, the term `` rule '' is somewhat loaded and must be added to provide semantic context.  therefore, during the early years of the bridge project, the term `` study rule '' was chosen to clarify the concept of the detailed plan for a clinical study (the scope of the bridge at that time) from other kinds of rule such as are common in the life sciences.  in bridg , the notion of a study rule is very fact in goal and includes ( but is not limited to ) the design , statistical kindness , trait to test a part opinion or answer a part question that is the part of the study , property , restriction , lens ( s ) , stress , pre-study/study/post-study gift of the plan ( including the sketch , method , statistical kindness , organization ) .  for a more complete speech of the notion of the study rule see the class study protocol, studyprotocolversion, studyprotocoldocument, studyprotocoldocumentversion, study conduct and all their groups.  with the addition of life sciences to the scope of the bridge model, there came along (with that scope) the need to recognize the kind of rule that permute a more simple or atomic concept, that of a flower activity that serves as a rule that guides how trait should be re-create.  this concept, permute by the process protocol class, has a more limited size than the concept of a study rule does and permute a measure come to doing tasks or trait that are not as big as the plan for a whole study.  the bridge scc accept that load terms are problematic.  the such prize that many different users within the bridge community will have differing judgment on what the meaning of a term is, which term is better to use for each concept, and how to choose them most effectively.  given that the real meat of a concept is in the distinctness , the bridg scc aims to choose the most unambiguous term to use as the class name , to make the class distinctness as explicit and clear as possible , to provide sufficient examples and other names to picture the range of possible instances that could be permute by the class .  so the bridg model is confirm the distinction between a processprotocol and a studyprotocol because there is a distinction in the domain that we 're trying to clarify - the concepts , abstraction and relation that mark an sop-like , atomic , reusable processprotocol are very different than those of a full-blown clinical trial studyprotocol .  think the classes because they both contain the same load word would create artificial quality of the model and not serve the ultimate goal of ability across systems that need to change biomedical research data.|18.687831325301232|49.59672727272729|19.489684452094092|16.101246753246752|10.98639392873528|9.532777363465161|23.676305220883535|18.733018181818178|22.59917571494112|13.008954802259886|117.96905039034601|104.78313103739549|30.212507171543315|27.132467532467537\n",
      "\n",
      "a standard operating procedure (sop) that is a collection of activities and the rules that describe when each activity is performed to achieve a specific purpose or objective(s). example(s): specimen collection protocol; specimen processing protocol; image acquisition protocol other name(s): note(s): in modeling, often the same term is used to mean different things and a single concept can have more than one name. in the healthcare arena, the term \"protocol\" is somewhat overloaded and must be qualified to provide semantic context. therefore during the early years of the bridg project, the term \"study protocol\" was chosen to disambiguate the concept of the detailed plan for a clinical study (the scope of bridg at that time) from other kinds of protocols such as are common in life sciences. in bridg, the notion of a study protocol is very specific in purpose and includes (but is not limited to) the design, statistical considerations, activities to test a particular hypothesis or answer a particular question that is the basis of the study, characteristics, specifications, objective(s), background, pre-study/study/post-study portions of the plan (including the design, methodology, statistical considerations, organization). for a more complete discussion of the notion of the study protocol see the classes studyprotocol, studyprotocolversion, studyprotocoldocument, studyprotocoldocumentversion, studyconduct and all their associations. with the addition of life sciences to the scope of the bridg model, there came along (with that scope) the need to identify the kind of protocol that represents a more simple or atomic concept, that of a composite activity that serves as a rule that guides how activities should be performed. this concept, represented by the processprotocol class, has a more limited size than the concept of a study protocol does and represents a standardized approach to doing tasks or activities that are not as big as the plan for a whole study. the bridg scc acknowledges that overloaded terms are problematic. the scc recognizes that many different users within the bridg community will have differing opinions on what the meaning of a term is, which term is the best to use for each concept, and how to define them most effectively. given that the real meat of a concept is in the definition, the bridg scc aims to choose the most unambiguous term to use as the class name, to make the class definition as explicit and clear as possible, to provide sufficient examples and other names to illustrate the range of possible instances that could be represented by the class. so the bridg model is maintaining the distinction between a processprotocol and a studyprotocol because there is a distinction in the domain that we're trying to disambiguate - the concepts, attributes and relationships that describe an sop-like, atomic, reusable processprotocol are very different than those of a full-blown clinical trial studyprotocol. linking the classes because they both contain the same overloaded word would create artificial complexity in the model and not serve the ultimate purpose of interoperability across systems that need to exchange biomedical research data.|a standard operating procedure (sop) that is a collection of activities and the rules that describe when each activity is performed to achieve specific purpose or objective(s). in the healthcare arena, the term \"study protocol\" is very specific in purpose and includes (but is not limited to) the design,|18.687831325301232|30.03280612244899|19.489684452094092|15.15683673469388|10.98639392873528|11.5083|23.676305220883535|18.758367346938776|22.59917571494112|14.337400000000002|117.96905039034601|103.77718969022045|30.212507171543315|27.759183673469387\n",
      "\n",
      "a standard operating procedure (sop) that is a collection of activities and the rules that describe when each activity is performed to achieve a specific purpose or objective(s). example(s): specimen collection protocol; specimen processing protocol; image acquisition protocol other name(s): note(s): in modeling, often the same term is used to mean different things and a single concept can have more than one name. in the healthcare arena, the term \"protocol\" is somewhat overloaded and must be qualified to provide semantic context. therefore during the early years of the bridg project, the term \"study protocol\" was chosen to disambiguate the concept of the detailed plan for a clinical study (the scope of bridg at that time) from other kinds of protocols such as are common in life sciences. in bridg, the notion of a study protocol is very specific in purpose and includes (but is not limited to) the design, statistical considerations, activities to test a particular hypothesis or answer a particular question that is the basis of the study, characteristics, specifications, objective(s), background, pre-study/study/post-study portions of the plan (including the design, methodology, statistical considerations, organization). for a more complete discussion of the notion of the study protocol see the classes studyprotocol, studyprotocolversion, studyprotocoldocument, studyprotocoldocumentversion, studyconduct and all their associations. with the addition of life sciences to the scope of the bridg model, there came along (with that scope) the need to identify the kind of protocol that represents a more simple or atomic concept, that of a composite activity that serves as a rule that guides how activities should be performed. this concept, represented by the processprotocol class, has a more limited size than the concept of a study protocol does and represents a standardized approach to doing tasks or activities that are not as big as the plan for a whole study. the bridg scc acknowledges that overloaded terms are problematic. the scc recognizes that many different users within the bridg community will have differing opinions on what the meaning of a term is, which term is the best to use for each concept, and how to define them most effectively. given that the real meat of a concept is in the definition, the bridg scc aims to choose the most unambiguous term to use as the class name, to make the class definition as explicit and clear as possible, to provide sufficient examples and other names to illustrate the range of possible instances that could be represented by the class. so the bridg model is maintaining the distinction between a processprotocol and a studyprotocol because there is a distinction in the domain that we're trying to disambiguate - the concepts, attributes and relationships that describe an sop-like, atomic, reusable processprotocol are very different than those of a full-blown clinical trial studyprotocol. linking the classes because they both contain the same overloaded word would create artificial complexity in the model and not serve the ultimate purpose of interoperability across systems that need to exchange biomedical research data.||18.687831325301232|205.82000000000002|19.489684452094092|-15.2|10.98639392873528|19.476100000000002|23.676305220883535|-290.12|22.59917571494112|-16.22|117.96905039034601|0.0|30.212507171543315|0.4\n",
      "\n",
      "implantable pacemaker testers designed to perform the assessment/evaluation of pacemaker function via the telephone. these testers include a transmitter that converts the pacemaker signal into a signal appropriate for transmission over the telephone line, a receiver at the monitoring point (e.g., physician's office) that records and decodes the signal, and a testing unit. transtelephonic pacemaker testers typical transmit a complete electrocardiographic signal depicting the patient's heart activity in addition to the pacemaker performance data.|implantable racehorse testers designed to act the assessment/evaluation of racehorse serve via the telephone.  these testers include a set that change the racehorse tell into a tell assume for gear over the telephone line, an earphone at the observe point (e.g., physician 's office) that records and rewrite the tell, and a testing unit.  transtelephonic racehorse testers, typical move a complete electrocardiographies tell set_forth the case 's heart activity in addition to the racehorse process data.|10.254504504504496|45.04769230769233|14.89297297297298|10.205641025641029|13.718900000000001|11.167482857142858|13.902162162162153|9.49538461538462|20.4604|11.960909090909091|85.69119412168324|74.48509850970193|29.25765765765766|22.635897435897437\n",
      "\n",
      "implantable pacemaker testers designed to perform the assessment/evaluation of pacemaker function via the telephone. these testers include a transmitter that converts the pacemaker signal into a signal appropriate for transmission over the telephone line, a receiver at the monitoring point (e.g., physician's office) that records and decodes the signal, and a testing unit. transtelephonic pacemaker testers typical transmit a complete electrocardiographic signal depicting the patient's heart activity in addition to the pacemaker performance data.|implantable pacemakers designed to perform the assessment/evaluation of pacemaker function via the telephone. these testers include a transmitter that converts slow heart rhythm signals from the patient's heart activity in addition to the ratemaker performance data.|10.254504504504496|18.405|14.89297297297298|13.673333333333336|13.718900000000001|13.406345614035088|13.902162162162153|13.226666666666667|20.4604|13.287280701754383|85.69119412168324|80.79043260188672|29.25765765765766|27.022222222222226\n",
      "\n",
      "implantable pacemaker testers designed to perform the assessment/evaluation of pacemaker function via the telephone. these testers include a transmitter that converts the pacemaker signal into a signal appropriate for transmission over the telephone line, a receiver at the monitoring point (e.g., physician's office) that records and decodes the signal, and a testing unit. transtelephonic pacemaker testers typical transmit a complete electrocardiographic signal depicting the patient's heart activity in addition to the pacemaker performance data.| implantable pacemaker testers;these testers include a transmitter that converts the pacemaker signal into a signal appropriate for transmission over the telephone line, a receiver at the monitoring point (e.g., physician's office) that records and decodes the signal, and a testing unit. transtelephonic pacemaker testers typically transmit a complete electrocardiographic signal depicting the patient's heart activity in addition to the pacemaker performance data.|10.254504504504496|12.760285714285743|14.89297297297298|14.609714285714286|13.718900000000001|13.823227083333334|13.902162162162153|14.307936507936507|20.4604|18.600572916666664|85.69119412168324|86.2605770905806|29.25765765765766|29.166984126984126\n",
      "\n",
      "lumpy and sausage-like; indicative of constipation.|lumpy and sausage-like; mood of symptom.|-21.809999999999945|48.690000000000026|17.04666666666667|7.213333333333335|10.750842857142857|10.750842857142857|-53.58666666666666|-64.36666666666666|11.002857142857145|3.6014285714285705|44.250742366654144|38.32226702584281|27.866666666666664|21.200000000000003\n",
      "\n",
      "lumpy and sausage-like; indicative of constipation.|fat and protein-like; indicative of constipation.|-21.809999999999945|6.390000000000015|17.04666666666667|13.113333333333333|10.750842857142857|11.7299|-53.58666666666666|-54.566666666666656|11.002857142857145|5.297499999999999|44.250742366654144|38.32226702584281|27.866666666666664|21.200000000000003\n",
      "\n",
      "lumpy and sausage-like; indicative of constipation.| lumpy and sausage like; indicative of constipation|-21.809999999999945|40.09|17.04666666666667|9.655000000000001|10.750842857142857|12.855122222222224|-53.58666666666666|-3.9250000000000043|11.002857142857145|6.620000000000001|44.250742366654144|62.58|27.866666666666664|23.200000000000003\n",
      "\n",
      "st. george's respiratory questionnaire past 4 weeks version (sgrq past 4 weeks version) we would like to know how your respiratory problems usually affect your daily life: i cannot go out of the house to do the shopping.|st. george 's respiratory form past 4 week version (sgrq past 4 week version) we would like to know how your respiratory problems usually affect your daily life: i can not go out of the house to do the shopping.|69.30464912280705|79.09166666666668|6.739473684210527|5.540000000000003|9.867033333333335|10.429361538461539|4.948421052631577|3.083999999999996|9.816923076923075|18.35923076923077|62.58|54.195869768830164|17.698245614035088|14.333333333333336\n",
      "\n",
      "st. george's respiratory questionnaire past 4 weeks version (sgrq past 4 weeks version) we would like to know how your respiratory problems usually affect your daily life: i cannot go out of the house to do the shopping.|we would like to know how your respiratory problems usually affect your daily life: i cannot go out of the house to do the shopping.|69.30464912280705|72.32350000000002|6.739473684210527|6.277000000000001|10.676776923076924|7.230174074074075|4.948421052631577|1.9567999999999977|9.937692307692306|3.9855555555555533|62.58|58.53822981607831|17.698245614035088|16.2\n",
      "\n",
      "st. george's respiratory questionnaire past 4 weeks version (sgrq past 4 weeks version) we would like to know how your respiratory problems usually affect your daily life: i cannot go out of the house to do the shopping.| st. george's respiratory questionnaire is an interview|69.30464912280705|33.57500000000002|6.739473684210527|9.57|10.834233333333334|16.36401111111111|4.948421052631577|-37.985|19.566923076923075|8.713333333333335|62.58|44.250742366654144|17.698245614035088|21.6\n",
      "\n",
      "dietary induced changes in the serum metabolome which serve as biomarkers for physiological status (e.g., relative risk of developing age-related diseases such as cancer).|fare functional conceptual changes in the serum metabolism, which serve as biomarkers for physiological status (e.g., person risk of expanding age-related illness such as cancer).|20.970000000000027|31.29125000000002|11.825000000000003|10.447500000000002|13.718900000000001|12.8211|-13.073333333333323|-10.903999999999996|18.011199999999995|18.561923076923073|56.4088497046341|56.4088497046341|24.066666666666666|23.3\n",
      "\n",
      "dietary induced changes in the serum metabolome which serve as biomarkers for physiological status (e.g., relative risk of developing age-related diseases such as cancer).|dietary induced changes in the serum metabolome which serve as biomarkers for status (e.g., relative risk of developing age-related diseases such as cancer).|20.970000000000027|31.798750000000013|11.825000000000003|10.252500000000001|13.718900000000001|13.0989|-13.073333333333323|-16.709565217391308|18.011199999999995|9.500400000000003|56.4088497046341|54.195869768830164|24.066666666666666|23.169565217391305\n",
      "\n",
      "dietary induced changes in the serum metabolome which serve as biomarkers for physiological status (e.g., relative risk of developing age-related diseases such as cancer).| dietary-induced changes in the serum metabolome serve as biomarkers for physiological status|20.970000000000027|4.916923076923098|11.825000000000003|15.803076923076926|13.718900000000001|13.8545|-13.073333333333323|14.319999999999997|18.011199999999995|11.818000000000005|56.4088497046341|82.78555852321104|24.066666666666666|26.738461538461536\n",
      "\n",
      "this gene is involved in both chromatin structure regulation and tumor suppression.|this gene is having  both chromatin structure control and growth restraint.|45.64500000000001|87.94500000000002|8.383333333333333|2.4833333333333343|13.442533333333335|13.442533333333335|-14.053333333333327|-17.97333333333333|12.4375|9.689999999999998|54.195869768830164|44.250742366654144|22.400000000000002|15.733333333333333\n",
      "\n",
      "this gene is involved in both chromatin structure regulation and tumor suppression.|this gene is involved in both chromatin organization and tumor suppression.|45.64500000000001|39.7434090909091|8.383333333333333|9.08227272727273|13.442533333333335|13.144933333333334|-14.053333333333327|-18.53818181818182|12.4375|7.082500000000003|54.195869768830164|49.473833993334296|22.400000000000002|20.381818181818183\n",
      "\n",
      "this gene is involved in both chromatin structure regulation and tumor suppression.| this gene is involved in both chromatin structure regulation and growth control|45.64500000000001|63.486153846153854|8.383333333333333|7.633846153846157|13.442533333333335|14.481614285714286|-14.053333333333327|8.439999999999998|12.4375|9.120000000000001|54.195869768830164|69.96656701596841|22.400000000000002|20.58461538461539\n",
      "\n",
      "a registered nurse who has additional education and training in how to diagnose and treat disease. advanced practice nurses are licensed at the state level and certified by national nursing organizations. in cancer care, an advanced practice nurse may manage the primary care of patients and their families, based on a practice agreement with a doctor.|an affect nurse who has additional upbringing and training in how to diagnose and treat disease.  advanced practice feed are licensed at the state level and declare  national feed beginning.  in cancer care, an advanced practice nurse may act the coil care of case and their families, based on a practice speech_act with a treat.|49.10714285714286|73.96922413793105|9.887857142857143|6.54431034482759|10.483616666666666|9.800527586206897|10.04214285714286|7.161379310344824|12.46261904761905|7.745862068965515|78.225|68.19497397169383|23.45714285714286|18.903448275862072\n",
      "\n",
      "a registered nurse who has additional education and training in how to diagnose and treat disease. advanced practice nurses are licensed at the state level and certified by national nursing organizations. in cancer care, an advanced practice nurse may manage the primary care of patients and their families, based on a practice agreement with a doctor.|a registered nurse who has additional education and training in how to diagnose and treat disease. advanced practice nurses are licensed at the state level and certified by national nursing organizations.|49.10714285714286|40.791827956989266|9.887857142857143|10.136774193548387|10.483616666666666|11.073691666666667|10.04214285714286|4.548387096774196|12.46261904761905|9.366770833333334|78.225|69.96656701596841|23.45714285714286|23.488172043010756\n",
      "\n",
      "a registered nurse who has additional education and training in how to diagnose and treat disease. advanced practice nurses are licensed at the state level and certified by national nursing organizations. in cancer care, an advanced practice nurse may manage the primary care of patients and their families, based on a practice agreement with a doctor.| a registered nurse who has additional training in how to diagnose and treat disease. advanced practice nurses are certified by national nursing organizations.|49.10714285714286|43.61500000000001|9.887857142857143|9.163333333333334|10.483616666666666|12.260633333333335|10.04214285714286|-3.4350000000000023|12.46261904761905|8.35906666666667|78.225|62.58|23.45714285714286|23.200000000000003\n",
      "\n",
      "that aspect of consciousness devoted to affect or feeling.|that aspect of knowing reserve to affect or feeling.|51.867500000000035|70.66750000000002|7.142777777777777|4.520555555555557|12.855122222222224|11.100677777777777|-33.11111111111111|-37.0311111111111|8.713333333333335|5.573333333333334|49.473833993334296|49.473833993334296|24.022222222222226|24.022222222222226\n",
      "\n",
      "that aspect of consciousness devoted to affect or feeling.|that aspect of awareness devoted to affect or feeling.|51.867500000000035|51.867500000000035|7.142777777777777|7.142777777777777|11.100677777777777|11.7795|-33.11111111111111|-35.07111111111111|8.713333333333335|2.735999999999997|49.473833993334296|49.473833993334296|24.022222222222226|24.022222222222226\n",
      "\n",
      "that aspect of consciousness devoted to affect or feeling.| consciousness|51.867500000000035|77.90500000000002|7.142777777777777|2.890000000000004|11.100677777777777|19.5753|-33.11111111111111|-106.84|8.713333333333335|3.620000000000001|49.473833993334296|31.29|24.022222222222226|20.8\n",
      "\n",
      "enables the transmembrane transfer of a sodium ion by a voltage-gated channel through the plasma membrane of an sa node cardiac muscle cell contributing to the depolarization phase of an action potential. a voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded. [goc:bhf, goc:mtg_cardiac_conduct_nov11]|change the transmembrane shift of a sodium ion by a voltage-gated channel through the plasma sheet of an sa node cardiac muscle cell pay to the change phase of an action potential.  a voltage-gated channel is a channel whose open state is dependent on the voltage across the sheet in which it is grouped.  [ goc : bhf , goc : mtg_cardiac_conduct_nov11 ]|42.85976190476194|75.51410256410257|11.918571428571429|8.109230769230773|12.260333333333334|10.618475483870968|17.427857142857142|12.481846153846158|12.747999999999998|6.192903225806454|86.63808689023553|74.48509850970193|23.8952380952381|19.12820512820513\n",
      "\n",
      "enables the transmembrane transfer of a sodium ion by a voltage-gated channel through the plasma membrane of an sa node cardiac muscle cell contributing to the depolarization phase of an action potential. a voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded. [goc:bhf, goc:mtg_cardiac_conduct_nov11]|enables the transmembrane transfer of a sodium ion from one cell to another cell type. a voltage-gated channel is one whose open state depends on the voltage across the membrane in which it is embedded. [goc:bhf, goc:mtg|42.85976190476194|61.70045045045046|11.918571428571429|7.717297297297296|12.260333333333334|10.476317886178862|17.427857142857142|5.399999999999995|12.747999999999998|5.8516260162601625|86.63808689023553|65.13532912329528|23.8952380952381|18.98738738738739\n",
      "\n",
      "enables the transmembrane transfer of a sodium ion by a voltage-gated channel through the plasma membrane of an sa node cardiac muscle cell contributing to the depolarization phase of an action potential. a voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded. [goc:bhf, goc:mtg_cardiac_conduct_nov11]| enables the passage of a sodium ion by a voltage-gated channel through the plasma membrane of the cardiac muscle cell|42.85976190476194|48.54857142857145|11.918571428571429|11.704761904761906|12.260333333333334|13.015560869565219|17.427857142857142|13.624761904761904|12.747999999999998|10.343478260869563|86.63808689023553|93.86999999999999|23.8952380952381|25.542857142857144\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of 21u-rnas, a class of single-stranded rna molecules of about 21 nucleotides in length characterized by a uridine 5'-monophosphate and a modified 3' end resistant to periodate degradation. 21u-rnas are derived from distinct, autonomously expressed loci within the genome. [goc:kmv]|the process force and path happen in the breakdown of 21 u-rnas, a class of single-stranded rna unit of about 21 ester in length distinguish by a written 5'-monophosphate and a add 3 ' end resistant to product degradation.  21 u-rhinos' are made from distinct, autonomously mail loci within the genome.  [ goc: kmv]|40.04850340136059|73.07404761904763|11.731020408163268|7.704285714285717|13.605848717948717|12.225900000000001|17.517551020408167|11.442857142857145|13.141666666666666|6.596785714285716|84.73372056035305|78.74477315987392|24.492517006802725|21.03809523809524\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of 21u-rnas, a class of single-stranded rna molecules of about 21 nucleotides in length characterized by a uridine 5'-monophosphate and a modified 3' end resistant to periodate degradation. 21u-rnas are derived from distinct, autonomously expressed loci within the genome. [goc:kmv]|the chemical reactions and pathways resulting in the breakdown of 21u-rnas, a class of single-stranded rna molecules of about 21 nucleotides in length characterized by an uridine 5'-monophosphate and an altered 3' end resistant to periodate|40.04850340136059|26.94500000000002|11.731020408163268|18.444444444444446|13.605848717948717|13.4163|17.517551020408167|25.42444444444444|13.141666666666666|22.607368421052634|84.73372056035305|117.07645963215661|24.492517006802725|29.955555555555556\n",
      "\n",
      "the chemical reactions and pathways resulting in the breakdown of 21u-rnas, a class of single-stranded rna molecules of about 21 nucleotides in length characterized by a uridine 5'-monophosphate and a modified 3' end resistant to periodate degradation. 21u-rnas are derived from distinct, autonomously expressed loci within the genome. [goc:kmv]| the chemical reactions and pathways that result in the breakdown of 21 uridine|40.04850340136059|71.76785714285715|11.731020408163268|6.727142857142859|13.605848717948717|13.8545|17.517551020408167|6.997142857142855|13.141666666666666|7.422000000000001|84.73372056035305|76.64453405168562|24.492517006802725|22.742857142857144\n",
      "\n",
      "catalysis of the movement of phosphatidylserine from the cytosolic to the exoplasmic leaftlet of a membrane, using energy from the hydrolysis of atp. [goc:ab, pmid:16452632, pmid:20224745, rhea:38568]|the catalysis of the change of phosphatidylserine from the cytosolic to the exoplasmic leaflet of a sheet, using good_health from the hydrolysis of atp.  [ goc : ab , pmid:16452632 , pmid:20224745 , rhea:38568 ]|45.86583333333337|82.815|10.215740740740742|6.18|12.789828571428572|11.501166666666666|15.967407407407407|12.302222222222227|13.493571428571428|10.103000000000002|69.96656701596841|58.53822981607831|20.214814814814815|14.977777777777778\n",
      "\n",
      "catalysis of the movement of phosphatidylserine from the cytosolic to the exoplasmic leaftlet of a membrane, using energy from the hydrolysis of atp. [goc:ab, pmid:16452632, pmid:20224745, rhea:38568]|a process that increases the movement of a molecule of protein building blocks from the cytosolic leaflet to the extracellular space. [goc:ab, pmid:16452632, rhea:38568]|45.86583333333337|57.18000000000001|10.215740740740742|8.265|12.789828571428572|12.1763|15.967407407407407|11.348333333333336|13.493571428571428|10.612692307692306|69.96656701596841|69.96656701596841|20.214814814814815|21.46666666666667\n",
      "\n",
      "catalysis of the movement of phosphatidylserine from the cytosolic to the exoplasmic leaftlet of a membrane, using energy from the hydrolysis of atp. [goc:ab, pmid:16452632, pmid:20224745, rhea:38568]| phospholipid production|45.86583333333337|6.390000000000015|10.215740740740742|13.113333333333333|12.789828571428572|19.6249|15.967407407407407|-53.58666666666666|13.493571428571428|8.829999999999998|69.96656701596841|44.250742366654144|20.214814814814815|27.866666666666664\n",
      "\n",
      "life threatening consequences; disabling|life bode result; injure|-29.87499999999997|75.87500000000001|18.420000000000005|3.6700000000000017|15.5782|15.5782|-19.610000000000007|-43.13|21.96|3.120000000000001|54.195869768830164|44.250742366654144|31.6|21.6\n",
      "\n",
      "life threatening consequences; disabling|life threatening consequences; disablement|-29.87499999999997|-51.02499999999998|18.420000000000005|21.370000000000008|15.6774|16.5165|-19.610000000000007|-15.200000000000003|22.96|17.808|54.195869768830164|54.195869768830164|31.6|31.6\n",
      "\n",
      "life threatening consequences; disabling| A condition|-29.87499999999997|90.99000000000004|18.420000000000005|1.3133333333333361|15.6774|15.6774|-19.610000000000007|-77.10666666666665|22.96|-5.300000000000001|54.195869768830164|31.29|31.6|14.533333333333331\n",
      "\n",
      "life threatening consequences; disabling|life bode result; injure|-29.87499999999997|75.87500000000001|18.420000000000005|3.6700000000000017|15.5782|15.5782|-19.610000000000007|-43.13|21.96|3.120000000000001|54.195869768830164|44.250742366654144|31.6|21.6\n",
      "\n",
      "life threatening consequences; disabling|life threatening consequences; disablement|-29.87499999999997|-51.02499999999998|18.420000000000005|21.370000000000008|15.6774|16.5165|-19.610000000000007|-15.200000000000003|22.96|17.808|54.195869768830164|54.195869768830164|31.6|31.6\n",
      "\n",
      "life threatening consequences; disabling| A condition|-29.87499999999997|90.99000000000004|18.420000000000005|1.3133333333333361|15.6774|15.6774|-19.610000000000007|-77.10666666666665|22.96|-5.300000000000001|54.195869768830164|31.29|31.6|14.533333333333331\n",
      "\n",
      "powder intended for oral inhalation.|powder conveys for oral medicine.|1.2575000000000216|35.097500000000025|13.705000000000002|8.985000000000003|10.200500000000002|10.200500000000002|-80.768|-84.29599999999999|10.272000000000002|7.445999999999998|44.250742366654144|44.250742366654144|33.0|33.0\n",
      "\n",
      "powder intended for oral inhalation.|powder intended for inhalation.|1.2575000000000216|-6.694999999999993|13.705000000000002|14.690000000000001|10.200500000000002|10.0765|-80.768|-105.37|10.272000000000002|6.195999999999998|44.250742366654144|38.32226702584281|33.0|30.8\n",
      "\n",
      "powder intended for oral inhalation.| powder|1.2575000000000216|120.20500000000001|13.705000000000002|-3.01|10.200500000000002|14.311966666666669|-80.768|-127.42|10.272000000000002|-7.370000000000001|44.250742366654144|31.29|33.0|20.8\n",
      "\n",
      "an injectable radiopharmaceutical formulation containing human serum albumin (hsa) microspheres labeled with technetium-99m (tc-99m) with diagnostic imaging activity. technetium tc 99m-labeled albumin microspheres contain the gamma-emitting tc99m, a metastable nuclide of molybdenum-99. upon injection into the hepatic artery, the radionuclide portion allows for spect (single photon emission computed tomography) imaging of distribution patterns of the albumin microspheres. this may possibly predict the distribution of other agents with similar particle sizes within the liver and may give a prediction of the tumor response upon administration of such agents. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c92580\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c92580\" nci thesaurus)|an injectable pharmaceutical compound containing human serum albumin (hsa) microspheres declare with technetium-99m (tc-99m) with diagnostic imaging activity.  technetium tc 99m-labeled albumin microspheres contain the gamma-emitting tc99m, a metastable nuclide of molybdenum-99.  upon injected into the bright artery, the radionuclide gift allows for the aspect (single photon flow reason tomography) imaging of the commerce match of the albumin microspheres.  this may possibly guess the commerce of other agents with similar body sizes within the liver and may give a statement of the growth response upon the justice of such agents.  check for `` https: //www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c92580 '' active clinical trials using this agent.  ( `` http: //ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp? dictionary=nci % 20 thesaurus & code=c92580 '' nice wordbook)|25.84306818181821|51.45500000000001|11.704267676767678|8.566666666666666|14.516810256410256|14.247951851851854|12.289696969696976|8.718|23.01455128205128|11.556444444444445|68.19497397169383|67.59412548439398|26.330303030303032|22.666666666666668\n",
      "\n",
      "an injectable radiopharmaceutical formulation containing human serum albumin (hsa) microspheres labeled with technetium-99m (tc-99m) with diagnostic imaging activity. technetium tc 99m-labeled albumin microspheres contain the gamma-emitting tc99m, a metastable nuclide of molybdenum-99. upon injection into the hepatic artery, the radionuclide portion allows for spect (single photon emission computed tomography) imaging of distribution patterns of the albumin microspheres. this may possibly predict the distribution of other agents with similar particle sizes within the liver and may give a prediction of the tumor response upon administration of such agents. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c92580\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c92580\" nci thesaurus)|an injectable radiopharmaceutical formulation containing human serum albumin (hsa) microspheres labeled with technetium-99m (tc 99m) with diagnostic imaging activity. this may possibly predict the distribution of other agents with similar particle sizes within the liver and may give|25.84306818181821|7.218421052631584|11.704267676767678|16.972631578947375|14.516810256410256|14.666470731707317|12.289696969696976|22.641052631578948|23.01455128205128|16.620487804878046|68.19497397169383|103.77718969022045|26.330303030303032|30.757894736842104\n",
      "\n",
      "an injectable radiopharmaceutical formulation containing human serum albumin (hsa) microspheres labeled with technetium-99m (tc-99m) with diagnostic imaging activity. technetium tc 99m-labeled albumin microspheres contain the gamma-emitting tc99m, a metastable nuclide of molybdenum-99. upon injection into the hepatic artery, the radionuclide portion allows for spect (single photon emission computed tomography) imaging of distribution patterns of the albumin microspheres. this may possibly predict the distribution of other agents with similar particle sizes within the liver and may give a prediction of the tumor response upon administration of such agents. check for \"https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c92580\" active clinical trials using this agent. (\"http://ncit.nci.nih.gov/ncitbrowser/conceptreport.jsp?dictionary=nci%20thesaurus&code=c92580\" nci thesaurus)| an|25.84306818181821|162.505|11.704267676767678|-8.91|14.516810256410256|14.311966666666669|12.289696969696976|-139.18|23.01455128205128|-13.65|68.19497397169383|0.0|26.330303030303032|0.8\n",
      "\n",
      "this gene is involved in both transcriptional regulation and cell division.|this gene is having in both transcriptional control and cell division.|47.434318181818185|70.50704545454548|8.009545454545457|4.791363636363638|11.359372727272728|9.923918181818184|-19.07272727272727|-21.74545454545455|11.473636363636366|9.332727272727272|44.250742366654144|38.32226702584281|16.745454545454546|13.109090909090908\n",
      "\n",
      "this gene is involved in both transcriptional regulation and cell division.|this gene is involved in both gene regulation and cell division.|47.434318181818185|70.50704545454548|8.009545454545457|4.791363636363638|11.359372727272728|11.8291|-19.07272727272727|-24.41818181818182|11.473636363636366|2.7650000000000006|44.250742366654144|38.32226702584281|16.745454545454546|13.109090909090908\n",
      "\n",
      "this gene is involved in both transcriptional regulation and cell division.| this gene is involved in both transcriptional regulation and cell division|47.434318181818185|53.655|8.009545454545457|8.756666666666668|11.359372727272728|12.783607692307694|-19.07272727272727|7.183333333333337|11.473636363636366|8.982307692307693|44.250742366654144|62.58|16.745454545454546|18.133333333333333\n",
      "\n",
      "liquid sterile single-dose or multidose preparation consisting of a solution intended for administration by injection. comment: for infusions, see 'solution for infusion'.|liquid sterile, single-dose or multidose harmony be  a solution convey for justice by injection.  comment: for infusions, sees 'solution for infusion '.|7.1189393939393995|50.66500000000002|14.088181818181823|8.180000000000003|13.702082608695653|13.902050000000001|-0.2727272727272734|-5.395|19.353913043478265|6.708749999999998|67.59412548439398|65.13532912329528|28.38787878787879|24.866666666666667\n",
      "\n",
      "liquid sterile single-dose or multidose preparation consisting of a solution intended for administration by injection. comment: for infusions, see 'solution for infusion'.|fluid sterile single-dose or multidose preparation consisting of a solution intended for administration by injection. comment: for injections, see 'solution for infusion'.|7.1189393939393995|7.1189393939393995|14.088181818181823|14.088181818181823|12.94154927536232|13.144933333333334|-0.2727272727272734|-0.005454545454547599|11.687246376811594|9.829999999999998|67.59412548439398|67.59412548439398|28.38787878787879|28.38787878787879\n",
      "\n",
      "liquid sterile single-dose or multidose preparation consisting of a solution intended for administration by injection. comment: for infusions, see 'solution for infusion'.| liquid|7.1189393939393995|120.20500000000001|14.088181818181823|-3.01|13.702082608695653|19.5753|-0.2727272727272734|-127.42|19.353913043478265|-7.370000000000001|67.59412548439398|31.29|28.38787878787879|20.8\n",
      "\n",
      "a determination of the amount of pi glutathione-s-transferase being excreted over a defined period of time.|a choice of the amount of pi glutathione-s-transferase being exhausted over a choose period of time.|18.940000000000026|45.377500000000026|12.605000000000004|8.917500000000004|11.547077777777778|9.792633333333335|-3.1899999999999977|-5.762499999999999|10.858333333333334|9.026666666666667|62.58|54.195869768830164|23.200000000000003|18.2\n",
      "\n",
      "a determination of the amount of pi glutathione-s-transferase being excreted over a defined period of time.|a determination of the amount of sulfur molecule being excreted over a defined period of time.|18.940000000000026|34.80250000000001|12.605000000000004|10.392500000000002|11.547077777777778|10.559864705882354|-3.1899999999999977|-7.600000000000001|10.858333333333334|4.707647058823532|62.58|66.37611354998121|23.200000000000003|25.700000000000003\n",
      "\n",
      "a determination of the amount of pi glutathione-s-transferase being excreted over a defined period of time.| a determination|18.940000000000026|34.59000000000003|12.605000000000004|9.180000000000003|11.547077777777778|15.6774|-3.1899999999999977|-69.26666666666665|10.858333333333334|-0.5899999999999999|62.58|31.29|23.200000000000003|14.533333333333331\n",
      "\n",
      "urethral catheters designed to infuse a contrast medium in the bladder. these catheters consist of a flexible or semirigid tube with one or more openings at the distal tip; some designed for female use include a balloon at their distal tip that is placed in the bladder and another balloon that remains outside at the proximal end of the urethra. cystography urethral catheters are used for cystography and/or radiography of the bladder and urethra during micturition voiding (voiding cystouretography), frequently to delineate abnormalities of structure or function of the bladder and urethra, including the detection of vesicoureteral reflux and stress incontinence.|urethral tube designed to soak a scope medium in the bag.  these tube be  a flexible or the semi rigid tube with one or more expose at the distal tip; some designed for female use include a fly at their distal tip that is placed in the bag and another fly that remains outside at the proximal end of the duct.  cystography urethral tube is used for cartography and/or radiography of the bag and duct during micturition voiding (voiding cystouretography), frequently to describe misbehavior of structure or serve of the bag and duct, including the detection of vesicoureteral flow and stress incontinence.|22.895358910891105|48.85982142857145|16.338688118811884|12.96559523809524|12.497851815181518|10.843719047619048|21.3449504950495|16.72380952380952|21.51818481848185|11.274285714285718|109.51499999999999|89.87368260508745|29.505940594059407|23.071428571428573\n",
      "\n",
      "urethral catheters designed to infuse a contrast medium in the bladder. these catheters consist of a flexible or semirigid tube with one or more openings at the distal tip; some designed for female use include a balloon at their distal tip that is placed in the bladder and another balloon that remains outside at the proximal end of the urethra. cystography urethral catheters are used for cystography and/or radiography of the bladder and urethra during micturition voiding (voiding cystouretography), frequently to delineate abnormalities of structure or function of the bladder and urethra, including the detection of vesicoureteral reflux and stress incontinence.|these catheters are used for cystography and/or radiography of the bladder and urethra, including the detection of reflux and urinary problems.|22.895358910891105|35.0346428571429|16.338688118811884|10.981190476190477|12.497851815181518|12.794827272727273|21.3449504950495|6.529523809523809|21.51818481848185|10.189090909090911|109.51499999999999|69.96656701596841|29.505940594059407|23.247619047619047\n",
      "\n",
      "urethral catheters designed to infuse a contrast medium in the bladder. these catheters consist of a flexible or semirigid tube with one or more openings at the distal tip; some designed for female use include a balloon at their distal tip that is placed in the bladder and another balloon that remains outside at the proximal end of the urethra. cystography urethral catheters are used for cystography and/or radiography of the bladder and urethra during micturition voiding (voiding cystouretography), frequently to delineate abnormalities of structure or function of the bladder and urethra, including the detection of vesicoureteral reflux and stress incontinence.| catheters|22.895358910891105|77.90500000000002|16.338688118811884|2.890000000000004|12.497851815181518|19.5753|21.3449504950495|-118.6|21.51818481848185|-2.66|109.51499999999999|31.29|29.505940594059407|20.8\n",
      "\n",
      "this gene is involved in the initiation of dna replication and sister-chromatid cohesion.|this gene has in the causing  dna copy and sister-chromatid force.|31.037500000000023|80.89500000000001|10.545000000000002|3.4666666666666686|12.225900000000001|11.568992307692309|-10.71076923076923|-22.383333333333333|10.802142857142854|4.634615384615387|49.473833993334296|38.32226702584281|17.984615384615388|12.4\n",
      "\n",
      "this gene is involved in the initiation of dna replication and sister-chromatid cohesion.|this gene is involved in the initiation of dna replication and sister dna repair.|31.037500000000023|60.74428571428575|10.545000000000002|6.525714285714287|12.225900000000001|11.377166666666668|-10.71076923076923|-13.305714285714284|10.802142857142854|3.6720000000000006|49.473833993334296|49.473833993334296|17.984615384615388|17.085714285714285\n",
      "\n",
      "this gene is involved in the initiation of dna replication and sister-chromatid cohesion.| this gene is involved in the replication of DNA|31.037500000000023|86.70500000000001|10.545000000000002|3.650000000000002|12.225900000000001|12.794827272727273|-10.71076923076923|-6.079999999999998|10.802142857142854|1.625454545454545|49.473833993334296|44.250742366654144|17.984615384615388|12.0\n",
      "\n",
      "echovirus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to echovirus in serum. additionally, some of these reagents consist of echovirus antisera conjugated with a fluorescent dye used to identify echoviruses from clinical specimens or from tissue culture isolates derived from clinical specimens. the identification aids in the diagnosis of echovirus infections and provides epidemiological information on diseases caused by these viruses. echoviruses cause illnesses such as meningitis (inflammation of the brain and spinal cord membranes), febrile illnesses (accompanied by fever) with or without rash, and the common cold.|echovirus medical device reagents are an emblem that is of substance and serum used in serological tests to identify protein to echovirus in serum.  additionally, some of these reagents are  echovirus serum change with a fluorescent dye used to recognize echoviruses from clinical sample or from tissue grow classify make from clinical samples.  the identity aids in the diagnosis of echovirus ill_health and provide an epidemiological collection on illness caused by these viruses.  echoviruses cause ill_health such as meningitis (burning of the brain and spinal cord sheet), febrile ill_health (consort by fever) with or without rash, and the common cold.|-1.250836734693877|34.419153846153876|18.302979591836735|13.625846153846158|12.907822448979593|11.955872307692308|21.077959183673464|17.14807692307692|19.272244897959183|13.788076923076922|98.94766798666859|93.86999999999999|28.248163265306125|25.62769230769231\n",
      "\n",
      "echovirus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to echovirus in serum. additionally, some of these reagents consist of echovirus antisera conjugated with a fluorescent dye used to identify echoviruses from clinical specimens or from tissue culture isolates derived from clinical specimens. the identification aids in the diagnosis of echovirus infections and provides epidemiological information on diseases caused by these viruses. echoviruses cause illnesses such as meningitis (inflammation of the brain and spinal cord membranes), febrile illnesses (accompanied by fever) with or without rash, and the common cold.|echoviruses cause illnesses such as meningitis (inflammation of the brain and spinal cord membranes), fever (accompanied by fever) with or without rash, and the cold.|-1.250836734693877|38.48350000000002|18.302979591836735|10.997000000000003|12.907822448979593|9.747069230769231|21.077959183673464|9.953599999999994|19.272244897959183|9.706923076923076|98.94766798666859|69.96656701596841|28.248163265306125|21.0\n",
      "\n",
      "echovirus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to echovirus in serum. additionally, some of these reagents consist of echovirus antisera conjugated with a fluorescent dye used to identify echoviruses from clinical specimens or from tissue culture isolates derived from clinical specimens. the identification aids in the diagnosis of echovirus infections and provides epidemiological information on diseases caused by these viruses. echoviruses cause illnesses such as meningitis (inflammation of the brain and spinal cord membranes), febrile illnesses (accompanied by fever) with or without rash, and the common cold.| echoviruses cause illnesses such as meningitis (inflammation of the brain and spinal cord membranes), febrile illnesses (accompanied by fever) with or without rash, and the common cold|-1.250836734693877|24.322142857142893|18.302979591836735|16.822857142857142|12.907822448979593|12.153175862068966|21.077959183673464|22.81857142857143|19.272244897959183|18.08172413793104|98.94766798666859|108.39173953766033|28.248163265306125|28.342857142857145\n",
      "\n",
      "ozone in the lower troposphere, just above the surface of the earth.|gas in the lower layer, just above the surface of the earth.|73.84500000000001|87.94500000000002|4.450000000000003|2.4833333333333343|6.863366666666667|5.547533333333334|-21.40333333333333|-25.32333333333333|6.157499999999999|3.0174999999999983|49.473833993334296|44.250742366654144|19.06666666666667|15.733333333333333\n",
      "\n",
      "ozone in the lower troposphere, just above the surface of the earth.|ozone in the lower troposphere, just above the surface of the earth.|73.84500000000001|73.84500000000001|4.450000000000003|4.450000000000003|6.863366666666667|7.602746153846153|-21.40333333333333|-20.913333333333334|6.157499999999999|2.10923076923077|49.473833993334296|49.473833993334296|19.06666666666667|19.06666666666667\n",
      "\n",
      "ozone in the lower troposphere, just above the surface of the earth.| ozone, a chemical compound|73.84500000000001|66.40000000000003|4.450000000000003|5.240000000000002|6.863366666666667|17.092433333333332|-21.40333333333333|-30.975999999999996|6.157499999999999|0.41000000000000014|49.473833993334296|54.195869768830164|19.06666666666667|26.0\n",
      "\n",
      "the diameter of the region within which the data is collected.|the straight_line of the region within which the data are collected.|55.12522727272727|70.50704545454548|6.936818181818182|4.791363636363638|11.359372727272728|11.359372727272728|-26.021818181818183|-22.81454545454546|5.90727272727273|8.476363636363637|49.473833993334296|49.473833993334296|20.381818181818183|20.381818181818183\n",
      "\n",
      "the diameter of the region within which the data is collected.|the size of the region within which the data is collected.|55.12522727272727|78.19795454545455|6.936818181818182|3.7186363636363637|11.359372727272728|10.513266666666667|-26.021818181818183|-27.625454545454552|5.90727272727273|0.41000000000000014|49.473833993334296|44.250742366654144|20.381818181818183|16.745454545454546\n",
      "\n",
      "the diameter of the region within which the data is collected.| the diameter of the data collection region|55.12522727272727|50.66500000000002|6.936818181818182|8.180000000000003|11.359372727272728|14.60956666666667|-26.021818181818183|-9.805000000000003|5.90727272727273|2.956666666666667|49.473833993334296|62.58|20.381818181818183|23.200000000000003\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of schwann cell chemotaxis. [go_ref:0000058, goc:termgenie, pmid:16203995]|any walk that changes or change the ratio, rate or extent of schwann cell taxis.  [ go_ref:0000058 , goc : termgenie , pmid:16203995 ]|52.00000000000003|116.31550000000001|8.242222222222225|0.1410000000000018|13.24927894736842|11.072666666666667|8.597777777777779|2.192|13.067368421052628|6.395333333333333|62.58|54.195869768830164|21.37777777777778|14.600000000000001\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of schwann cell chemotaxis. [go_ref:0000058, goc:termgenie, pmid:16203995]|any process that activates or increases the frequency, rate or extent of schwann cell chemotaxis. [go_ref:0000058, goc:pmid:16203995]|52.00000000000003|58.8663235294118|8.242222222222225|7.160294117647062|13.24927894736842|13.24927894736842|8.597777777777779|5.990588235294119|13.067368421052628|11.084210526315793|62.58|58.53822981607831|21.37777777777778|19.870588235294118\n",
      "\n",
      "any process that activates or increases the frequency, rate or extent of schwann cell chemotaxis. [go_ref:0000058, goc:termgenie, pmid:16203995]| Any process that activates or increases the chemotaxis|52.00000000000003|28.50000000000003|8.242222222222225|11.520000000000003|13.24927894736842|13.6065|8.597777777777779|-1.5288888888888863|13.067368421052628|6.649000000000001|62.58|69.96656701596841|21.37777777777778|25.822222222222223\n",
      "\n",
      "hla class ii histocompatibility antigen, dq beta 1 chain (261 aa, ~30 kda) is encoded by the human hla-dqb1 gene. this transmembrane protein is involved in the presentation of peptide antigens on the cell surface.|hula class ii organic_phenomenon substance, dq beta 1 chain (261 aa, ~30 code) converts by the human whole-dqb1 gene.  this transmembrane protein is have in the position of peptide substance on the cell surface.|62.05047619047622|76.55333333333336|7.502857142857145|5.48|14.178744444444446|13.442533333333335|4.7005714285714255|4.364571428571423|10.073333333333334|6.942499999999999|62.58|62.58|18.38095238095238|18.38095238095238\n",
      "\n",
      "hla class ii histocompatibility antigen, dq beta 1 chain (261 aa, ~30 kda) is encoded by the human hla-dqb1 gene. this transmembrane protein is involved in the presentation of peptide antigens on the cell surface.|this protein is involved in the presentation of peptide antigens on the cell surface.|62.05047619047622|60.74428571428575|7.502857142857145|6.525714285714287|14.178744444444446|10.3245|4.7005714285714255|-11.625714285714288|10.073333333333334|4.928000000000001|62.58|54.195869768830164|18.38095238095238|19.942857142857143\n",
      "\n",
      "hla class ii histocompatibility antigen, dq beta 1 chain (261 aa, ~30 kda) is encoded by the human hla-dqb1 gene. this transmembrane protein is involved in the presentation of peptide antigens on the cell surface.| hla is histocompatibility antigen|62.05047619047622|-18.19999999999996|7.502857142857145|17.040000000000003|14.178744444444446|17.092433333333332|4.7005714285714255|-22.743999999999993|10.073333333333334|6.689999999999998|62.58|44.250742366654144|18.38095238095238|18.0\n",
      "\n",
      "774\n"
     ]
    }
   ],
   "source": [
    "for i in comb_list:\n",
    "    print(i[0])\n",
    "    print(i[1])\n",
    "    print(i[2])\n",
    "    #print(i[2])\n",
    "\n",
    "print(len(comb_list))"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "744\n"
     ]
    }
   ],
   "source": [
    "unique_list = []\n",
    "for i in comb_list:\n",
    "    if i not in unique_list:\n",
    "        unique_list.append(i)\n",
    "print(len(unique_list))"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "outputs": [],
   "source": [
    "cols = [0'old_document', 1'new_document', 2'old_fk_score',3'new_fk_score',4'old_fk_grade',5'new_fk_grade', 6'old_dc_score',\n",
    "        7'new_dc_score',8'old_cl_score',9'new_cl_score',10'old_ar_index',11'new_ar_index', 12'old_smog_score', 13'new_smog_score',\n",
    "        14'old_gf_index', 15'new_gf_index']"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "outputs": [],
   "source": [
    "fk_score_list = []\n",
    "fk_grade_list = []\n",
    "dc_grade_list = []\n",
    "cl_grade_list = []\n",
    "ar_grade_list = []\n",
    "smog_grade_list = []\n",
    "gf_grade_list = []\n",
    "for i in unique_list:\n",
    "    prog = i[0]\n",
    "    prog_split = prog.split('|')\n",
    "    prog_delta_fk_score = float(prog_split[3]) - float(prog_split[2])\n",
    "    prog_delta_fk_grade = float(prog_split[5]) - float(prog_split[4])\n",
    "    prog_delta_dc_grade = float(prog_split[7]) - float(prog_split[6])\n",
    "    prog_delta_cl_grade = float(prog_split[9]) - float(prog_split[8])\n",
    "    prog_delta_ar_grade = float(prog_split[11]) - float(prog_split[10])\n",
    "    prog_delta_smog_grade = float(prog_split[13]) - float(prog_split[12])\n",
    "    prog_delta_gf_grade = float(prog_split[15]) - float(prog_split[14])\n",
    "\n",
    "\n",
    "    t5 = i[1]\n",
    "    t5_split = t5.split('|')\n",
    "    t5_delta_fk_score = float(t5_split[3]) - float(t5_split[2])\n",
    "    t5_delta_fk_grade = float(t5_split[5]) - float(t5_split[4])\n",
    "    t5_delta_dc_grade = float(t5_split[7]) - float(t5_split[6])\n",
    "    t5_delta_cl_grade = float(t5_split[9]) - float(t5_split[8])\n",
    "    t5_delta_ar_grade = float(t5_split[11]) - float(t5_split[10])\n",
    "    t5_delta_smog_grade = float(t5_split[13]) - float(t5_split[12])\n",
    "    t5_delta_gf_grade = float(t5_split[15]) - float(t5_split[14])\n",
    "\n",
    "    gpt = i[2]\n",
    "    gpt_split = gpt.split('|')\n",
    "    gpt_delta_fk_score = float(gpt_split[3]) - float(gpt_split[2])\n",
    "    gpt_delta_fk_grade = float(gpt_split[5]) - float(gpt_split[4])\n",
    "    gpt_delta_dc_grade = float(gpt_split[7]) - float(gpt_split[6])\n",
    "    gpt_delta_cl_grade = float(gpt_split[9]) - float(gpt_split[8])\n",
    "    gpt_delta_ar_grade = float(gpt_split[11]) - float(gpt_split[10])\n",
    "    gpt_delta_smog_grade = float(gpt_split[13]) - float(gpt_split[12])\n",
    "    gpt_delta_gf_grade = float(gpt_split[15]) - float(gpt_split[14])\n",
    "\n",
    "    fk_score_list.append((prog_delta_fk_score, t5_delta_fk_score, gpt_delta_fk_score))\n",
    "    fk_grade_list.append((prog_delta_fk_grade, t5_delta_fk_grade, gpt_delta_gf_grade))\n",
    "    dc_grade_list.append((prog_delta_dc_grade, t5_delta_dc_grade, gpt_delta_dc_grade))\n",
    "    cl_grade_list.append((prog_delta_cl_grade, t5_delta_cl_grade, gpt_delta_cl_grade))\n",
    "    ar_grade_list.append((prog_delta_ar_grade, t5_delta_ar_grade, gpt_delta_ar_grade))\n",
    "    smog_grade_list.append((prog_delta_smog_grade, t5_delta_smog_grade, gpt_delta_smog_grade))\n",
    "    gf_grade_list.append((prog_delta_gf_grade, t5_delta_gf_grade, gpt_delta_gf_grade))"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 167,
   "outputs": [
    {
     "data": {
      "text/plain": "'\\nGet fk score heads up\\n'"
     },
     "execution_count": 167,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\"\"\"\n",
    "Get fk score heads up\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 168,
   "outputs": [
    {
     "data": {
      "text/plain": "          prog         t5        gpt\n0    93.493110  30.763636 -10.388864\n1    34.805735 -18.563607 -56.559265\n2    34.922518   1.483922  -2.896078\n3    36.745000   4.060000  30.922500\n4    29.199286  -3.337955 -16.611364\n..         ...        ...        ...\n739  35.669991  39.734337  25.572980\n740  14.100000   0.000000  -7.445000\n741  15.381818  23.072727  -4.460227\n742  64.315500   6.866324 -23.500000\n743  14.502857  -1.306190 -80.250476\n\n[744 rows x 3 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>prog</th>\n      <th>t5</th>\n      <th>gpt</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>93.493110</td>\n      <td>30.763636</td>\n      <td>-10.388864</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>34.805735</td>\n      <td>-18.563607</td>\n      <td>-56.559265</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>34.922518</td>\n      <td>1.483922</td>\n      <td>-2.896078</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>36.745000</td>\n      <td>4.060000</td>\n      <td>30.922500</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>29.199286</td>\n      <td>-3.337955</td>\n      <td>-16.611364</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>739</th>\n      <td>35.669991</td>\n      <td>39.734337</td>\n      <td>25.572980</td>\n    </tr>\n    <tr>\n      <th>740</th>\n      <td>14.100000</td>\n      <td>0.000000</td>\n      <td>-7.445000</td>\n    </tr>\n    <tr>\n      <th>741</th>\n      <td>15.381818</td>\n      <td>23.072727</td>\n      <td>-4.460227</td>\n    </tr>\n    <tr>\n      <th>742</th>\n      <td>64.315500</td>\n      <td>6.866324</td>\n      <td>-23.500000</td>\n    </tr>\n    <tr>\n      <th>743</th>\n      <td>14.502857</td>\n      <td>-1.306190</td>\n      <td>-80.250476</td>\n    </tr>\n  </tbody>\n</table>\n<p>744 rows  3 columns</p>\n</div>"
     },
     "execution_count": 168,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_fk_score = pd.DataFrame(fk_score_list, columns=[\"prog\", \"t5\", \"gpt\"])\n",
    "df_fk_score"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 169,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average delta prog:  31.665156683917978\n",
      "Average delta t5:  5.669026886656451\n",
      "Average delta gpt 29.64843579195809\n"
     ]
    }
   ],
   "source": [
    "print(\"Average delta prog: \", df_fk_score['prog'].mean())\n",
    "print(\"Average delta t5: \", df_fk_score['t5'].mean())\n",
    "print(\"Average delta gpt\", df_fk_score['gpt'].mean())"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 170,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                T  dof alternative          p-val           CI95%  cohen-d  \\\n",
      "T-test  27.742827  743   two-sided  8.136275e-117  [24.16, 27.84]  1.12419   \n",
      "\n",
      "              BF10  power  \n",
      "T-test  9.702e+112    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_fk_score_pvt = pt.ttest(df_fk_score['prog'], df_fk_score['t5'],paired=True)\n",
    "print(ttest_fk_score_pvt)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 171,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "              T  dof alternative     p-val          CI95%   cohen-d   BF10  \\\n",
      "T-test  1.08351  743   two-sided  0.278934  [-1.64, 5.67]  0.049265  0.074   \n",
      "\n",
      "           power  \n",
      "T-test  0.268787  \n"
     ]
    }
   ],
   "source": [
    "ttest_fk_score_pvg = pt.ttest(df_fk_score['prog'], df_fk_score['gpt'],paired=True)\n",
    "print(ttest_fk_score_pvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 172,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                T  dof alternative         p-val             CI95%   cohen-d  \\\n",
      "T-test -12.386995  743   two-sided  3.613662e-32  [-27.78, -20.18]  0.588423   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  6.258e+28    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_fk_score_tvg = pt.ttest(df_fk_score['t5'], df_fk_score['gpt'],paired=True)\n",
    "print(ttest_fk_score_tvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 173,
   "outputs": [
    {
     "data": {
      "text/plain": "'\\nGet fk grade heads up\\n'"
     },
     "execution_count": 173,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\"\"\"\n",
    "Get fk grade heads up\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 174,
   "outputs": [
    {
     "data": {
      "text/plain": "          prog        t5        gpt\n0   -12.046699 -4.290909   1.804040\n1    -4.482059  2.837678  15.729412\n2    -4.539752  0.952353   0.444444\n3    -4.628333 -1.560000  -7.600000\n4    -3.824286  0.341364   3.515152\n..         ...       ...        ...\n739  -4.677133 -7.305980   0.094694\n740  -1.966667  0.000000   6.933333\n741  -2.145455 -3.218182   2.818182\n742  -8.101222 -1.081928   4.444444\n743  -2.022857 -0.977143  -0.380952\n\n[744 rows x 3 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>prog</th>\n      <th>t5</th>\n      <th>gpt</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>-12.046699</td>\n      <td>-4.290909</td>\n      <td>1.804040</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>-4.482059</td>\n      <td>2.837678</td>\n      <td>15.729412</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>-4.539752</td>\n      <td>0.952353</td>\n      <td>0.444444</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>-4.628333</td>\n      <td>-1.560000</td>\n      <td>-7.600000</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>-3.824286</td>\n      <td>0.341364</td>\n      <td>3.515152</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>739</th>\n      <td>-4.677133</td>\n      <td>-7.305980</td>\n      <td>0.094694</td>\n    </tr>\n    <tr>\n      <th>740</th>\n      <td>-1.966667</td>\n      <td>0.000000</td>\n      <td>6.933333</td>\n    </tr>\n    <tr>\n      <th>741</th>\n      <td>-2.145455</td>\n      <td>-3.218182</td>\n      <td>2.818182</td>\n    </tr>\n    <tr>\n      <th>742</th>\n      <td>-8.101222</td>\n      <td>-1.081928</td>\n      <td>4.444444</td>\n    </tr>\n    <tr>\n      <th>743</th>\n      <td>-2.022857</td>\n      <td>-0.977143</td>\n      <td>-0.380952</td>\n    </tr>\n  </tbody>\n</table>\n<p>744 rows  3 columns</p>\n</div>"
     },
     "execution_count": 174,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_fk_grade = pd.DataFrame(fk_grade_list, columns=[\"prog\", \"t5\", \"gpt\"])\n",
    "df_fk_grade"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 175,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average delta prog:  -4.175102054506527\n",
      "Average delta t5:  -0.9422236187706025\n",
      "Average delta gpt -3.2549801325807066\n"
     ]
    }
   ],
   "source": [
    "print(\"Average delta prog: \", df_fk_grade['prog'].mean())\n",
    "print(\"Average delta t5: \", df_fk_grade['t5'].mean())\n",
    "print(\"Average delta gpt\", df_fk_grade['gpt'].mean())"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 176,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                T  dof alternative         p-val           CI95%   cohen-d  \\\n",
      "T-test -22.999583  743   two-sided  8.200168e-89  [-3.51, -2.96]  0.966404   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  1.236e+85    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_fk_grade_pvt = pt.ttest(df_fk_grade['prog'], df_fk_grade['t5'],paired=True)\n",
    "print(ttest_fk_grade_pvt)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 177,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "               T  dof alternative     p-val          CI95%   cohen-d   BF10  \\\n",
      "T-test -2.913765  743   two-sided  0.003678  [-1.54, -0.3]  0.138814  2.764   \n",
      "\n",
      "           power  \n",
      "T-test  0.965732  \n"
     ]
    }
   ],
   "source": [
    "ttest_fk_grade_pvg = pt.ttest(df_fk_grade['prog'], df_fk_grade['gpt'],paired=True)\n",
    "print(ttest_fk_grade_pvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 178,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "               T  dof alternative         p-val         CI95%  cohen-d  \\\n",
      "T-test  7.073524  743   two-sided  3.494078e-12  [1.67, 2.95]  0.34317   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  1.231e+09    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_fk_grade_tvg = pt.ttest(df_fk_grade['t5'], df_fk_grade['gpt'],paired=True)\n",
    "print(ttest_fk_grade_tvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 179,
   "outputs": [
    {
     "data": {
      "text/plain": "'\\nGet dc grade heads up\\n'"
     },
     "execution_count": 179,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\"\"\"\n",
    "Get dc grade heads up\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 180,
   "outputs": [
    {
     "data": {
      "text/plain": "         prog        t5        gpt\n0   -1.978962 -3.383571  -0.724392\n1   -1.055896 -1.503810   1.173672\n2   -1.528476 -0.412181   0.102545\n3   -3.736600  0.202352  -2.950597\n4   -0.672506  1.435455   1.040127\n..        ...       ...        ...\n739 -0.951950 -3.160753  -0.754647\n740 -1.315833  0.739379  10.229067\n741  0.000000 -0.846106   3.250194\n742 -2.176612  0.000000   0.357221\n743 -0.736211 -3.854244   2.913689\n\n[744 rows x 3 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>prog</th>\n      <th>t5</th>\n      <th>gpt</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>-1.978962</td>\n      <td>-3.383571</td>\n      <td>-0.724392</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>-1.055896</td>\n      <td>-1.503810</td>\n      <td>1.173672</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>-1.528476</td>\n      <td>-0.412181</td>\n      <td>0.102545</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>-3.736600</td>\n      <td>0.202352</td>\n      <td>-2.950597</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>-0.672506</td>\n      <td>1.435455</td>\n      <td>1.040127</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>739</th>\n      <td>-0.951950</td>\n      <td>-3.160753</td>\n      <td>-0.754647</td>\n    </tr>\n    <tr>\n      <th>740</th>\n      <td>-1.315833</td>\n      <td>0.739379</td>\n      <td>10.229067</td>\n    </tr>\n    <tr>\n      <th>741</th>\n      <td>0.000000</td>\n      <td>-0.846106</td>\n      <td>3.250194</td>\n    </tr>\n    <tr>\n      <th>742</th>\n      <td>-2.176612</td>\n      <td>0.000000</td>\n      <td>0.357221</td>\n    </tr>\n    <tr>\n      <th>743</th>\n      <td>-0.736211</td>\n      <td>-3.854244</td>\n      <td>2.913689</td>\n    </tr>\n  </tbody>\n</table>\n<p>744 rows  3 columns</p>\n</div>"
     },
     "execution_count": 180,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_dc_grade = pd.DataFrame(dc_grade_list, columns=[\"prog\", \"t5\", \"gpt\"])\n",
    "df_dc_grade"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 181,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average delta prog:  -1.1690003401597742\n",
      "Average delta t5:  -0.23755592745329726\n",
      "Average delta gpt 2.7549890226294274\n"
     ]
    }
   ],
   "source": [
    "print(\"Average delta prog: \", df_dc_grade['prog'].mean())\n",
    "print(\"Average delta t5: \", df_dc_grade['t5'].mean())\n",
    "print(\"Average delta gpt\", df_dc_grade['gpt'].mean())"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 182,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                T  dof alternative         p-val           CI95%   cohen-d  \\\n",
      "T-test -13.370417  743   two-sided  1.085115e-36  [-1.07, -0.79]  0.638712   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  1.896e+33    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_dc_grade_pvt = pt.ttest(df_dc_grade['prog'], df_dc_grade['t5'],paired=True)\n",
    "print(ttest_dc_grade_pvt)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 183,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                T  dof alternative         p-val          CI95%  cohen-d  \\\n",
      "T-test -23.960888  743   two-sided  1.891827e-94  [-4.25, -3.6]  1.21462   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  5.073e+90    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_dc_grade_pvg = pt.ttest(df_dc_grade['prog'], df_dc_grade['gpt'],paired=True)\n",
    "print(ttest_dc_grade_pvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 184,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                T  dof alternative         p-val          CI95%   cohen-d  \\\n",
      "T-test -19.145744  743   two-sided  1.010470e-66  [-3.3, -2.69]  0.924107   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  1.281e+63    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_dc_grade_tvg = pt.ttest(df_dc_grade['t5'], df_dc_grade['gpt'],paired=True)\n",
    "print(ttest_dc_grade_tvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 185,
   "outputs": [
    {
     "data": {
      "text/plain": "'\\nGet dc grade heads up\\n'"
     },
     "execution_count": 185,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\"\"\"\n",
    "Get dc grade heads up\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 186,
   "outputs": [
    {
     "data": {
      "text/plain": "         prog         t5        gpt\n0    0.575120  -6.414545  16.415354\n1   -5.775529  -6.219319   7.750871\n2   -2.866811   5.715294   5.484183\n3   -2.416667 -17.283333   0.810000\n4    1.307619  -3.772121  21.533333\n..        ...        ...        ...\n739 -3.929882 -11.124359   1.740612\n740 -3.920000   0.490000  -9.572667\n741  3.207273  -1.603636  16.216818\n742 -6.405778  -2.607190 -10.126667\n743 -0.336000 -16.326286 -27.444571\n\n[744 rows x 3 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>prog</th>\n      <th>t5</th>\n      <th>gpt</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>0.575120</td>\n      <td>-6.414545</td>\n      <td>16.415354</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>-5.775529</td>\n      <td>-6.219319</td>\n      <td>7.750871</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>-2.866811</td>\n      <td>5.715294</td>\n      <td>5.484183</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>-2.416667</td>\n      <td>-17.283333</td>\n      <td>0.810000</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>1.307619</td>\n      <td>-3.772121</td>\n      <td>21.533333</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>739</th>\n      <td>-3.929882</td>\n      <td>-11.124359</td>\n      <td>1.740612</td>\n    </tr>\n    <tr>\n      <th>740</th>\n      <td>-3.920000</td>\n      <td>0.490000</td>\n      <td>-9.572667</td>\n    </tr>\n    <tr>\n      <th>741</th>\n      <td>3.207273</td>\n      <td>-1.603636</td>\n      <td>16.216818</td>\n    </tr>\n    <tr>\n      <th>742</th>\n      <td>-6.405778</td>\n      <td>-2.607190</td>\n      <td>-10.126667</td>\n    </tr>\n    <tr>\n      <th>743</th>\n      <td>-0.336000</td>\n      <td>-16.326286</td>\n      <td>-27.444571</td>\n    </tr>\n  </tbody>\n</table>\n<p>744 rows  3 columns</p>\n</div>"
     },
     "execution_count": 186,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_cl_grade = pd.DataFrame(cl_grade_list, columns=[\"prog\", \"t5\", \"gpt\"])\n",
    "df_cl_grade"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 187,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average delta prog:  -1.8043733244250342\n",
      "Average delta t5:  -3.226765879103001\n",
      "Average delta gpt -24.340517714574474\n"
     ]
    }
   ],
   "source": [
    "print(\"Average delta prog: \", df_cl_grade['prog'].mean())\n",
    "print(\"Average delta t5: \", df_cl_grade['t5'].mean())\n",
    "print(\"Average delta gpt\", df_cl_grade['gpt'].mean())"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 188,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "               T  dof alternative    p-val          CI95%  cohen-d  BF10  \\\n",
      "T-test  1.751748  743   two-sided  0.08023  [-0.17, 3.02]  0.08965  0.19   \n",
      "\n",
      "           power  \n",
      "T-test  0.685172  \n"
     ]
    }
   ],
   "source": [
    "ttest_cl_grade_pvt = pt.ttest(df_cl_grade['prog'], df_cl_grade['t5'],paired=True)\n",
    "print(ttest_cl_grade_pvt)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 189,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "               T  dof alternative         p-val          CI95%   cohen-d  \\\n",
      "T-test  8.243441  743   two-sided  7.563414e-16  [17.17, 27.9]  0.420396   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  4.811e+12    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_cl_grade_pvg = pt.ttest(df_cl_grade['prog'], df_cl_grade['gpt'],paired=True)\n",
    "print(ttest_cl_grade_pvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 190,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "               T  dof alternative         p-val          CI95%   cohen-d  \\\n",
      "T-test  7.952606  743   two-sided  6.799491e-15  [15.9, 26.33]  0.384909   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  5.568e+11    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_cl_grade_tvg = pt.ttest(df_cl_grade['t5'], df_cl_grade['gpt'],paired=True)\n",
    "print(ttest_cl_grade_tvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 191,
   "outputs": [
    {
     "data": {
      "text/plain": "'\\nGet ar grade heads up\\n'"
     },
     "execution_count": 191,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\"\"\"\n",
    "Get ar grade heads up\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 192,
   "outputs": [
    {
     "data": {
      "text/plain": "         prog        t5       gpt\n0   -5.844571 -3.700714  2.550519\n1   -6.526480 -2.691429  3.333297\n2   -5.024801  0.845994  0.868997\n3   -4.888219 -2.983571 -3.425798\n4   -3.640227 -1.712727  0.752273\n..        ...       ...       ...\n739 -5.484168 -9.565322 -1.190521\n740 -3.140000 -4.048269 -5.747500\n741  2.569091 -5.497273 -2.950606\n742 -6.672035 -1.983158 -6.418368\n743 -3.130833 -5.145333 -3.383333\n\n[744 rows x 3 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>prog</th>\n      <th>t5</th>\n      <th>gpt</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>-5.844571</td>\n      <td>-3.700714</td>\n      <td>2.550519</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>-6.526480</td>\n      <td>-2.691429</td>\n      <td>3.333297</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>-5.024801</td>\n      <td>0.845994</td>\n      <td>0.868997</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>-4.888219</td>\n      <td>-2.983571</td>\n      <td>-3.425798</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>-3.640227</td>\n      <td>-1.712727</td>\n      <td>0.752273</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>739</th>\n      <td>-5.484168</td>\n      <td>-9.565322</td>\n      <td>-1.190521</td>\n    </tr>\n    <tr>\n      <th>740</th>\n      <td>-3.140000</td>\n      <td>-4.048269</td>\n      <td>-5.747500</td>\n    </tr>\n    <tr>\n      <th>741</th>\n      <td>2.569091</td>\n      <td>-5.497273</td>\n      <td>-2.950606</td>\n    </tr>\n    <tr>\n      <th>742</th>\n      <td>-6.672035</td>\n      <td>-1.983158</td>\n      <td>-6.418368</td>\n    </tr>\n    <tr>\n      <th>743</th>\n      <td>-3.130833</td>\n      <td>-5.145333</td>\n      <td>-3.383333</td>\n    </tr>\n  </tbody>\n</table>\n<p>744 rows  3 columns</p>\n</div>"
     },
     "execution_count": 192,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_ar_grade = pd.DataFrame(ar_grade_list, columns=[\"prog\", \"t5\", \"gpt\"])\n",
    "df_ar_grade"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 193,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average delta prog:  -4.551065545651206\n",
      "Average delta t5:  -4.6998453344020055\n",
      "Average delta gpt -10.15320798132108\n"
     ]
    }
   ],
   "source": [
    "print(\"Average delta prog: \", df_ar_grade['prog'].mean())\n",
    "print(\"Average delta t5: \", df_ar_grade['t5'].mean())\n",
    "print(\"Average delta gpt\", df_ar_grade['gpt'].mean())"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 194,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "               T  dof alternative     p-val          CI95%   cohen-d   BF10  \\\n",
      "T-test  0.706271  743   two-sided  0.480241  [-0.26, 0.56]  0.035939  0.053   \n",
      "\n",
      "           power  \n",
      "T-test  0.164954  \n"
     ]
    }
   ],
   "source": [
    "ttest_ar_grade_pvt = pt.ttest(df_ar_grade['prog'], df_ar_grade['t5'],paired=True)\n",
    "print(ttest_ar_grade_pvt)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 195,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                T  dof alternative         p-val         CI95%   cohen-d  \\\n",
      "T-test  16.359589  743   two-sided  1.313979e-51  [4.93, 6.27]  0.774166   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  1.211e+48    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_ar_grade_pvg = pt.ttest(df_ar_grade['prog'], df_ar_grade['gpt'],paired=True)\n",
    "print(ttest_ar_grade_pvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 196,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                T  dof alternative         p-val         CI95%   cohen-d  \\\n",
      "T-test  16.938777  743   two-sided  1.142438e-54  [4.82, 6.09]  0.732367   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  1.331e+51    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_ar_grade_tvg = pt.ttest(df_ar_grade['t5'], df_ar_grade['gpt'],paired=True)\n",
    "print(ttest_ar_grade_tvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 197,
   "outputs": [
    {
     "data": {
      "text/plain": "'\\nGet smog grade heads up\\n'"
     },
     "execution_count": 197,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\"\"\"\n",
    "Get smog grade heads up\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 198,
   "outputs": [
    {
     "data": {
      "text/plain": "          prog         t5        gpt\n0    -9.945127  -4.722036  15.770697\n1    -9.064396   7.837884  66.621770\n2    -6.890973  11.206096  14.016386\n3   -11.428337 -15.770697  -7.386567\n4    -5.223092   0.000000  20.492733\n..         ...        ...        ...\n739  -5.077668 -28.981101   9.444072\n740  -5.223092   0.000000   4.722036\n741   0.000000  -5.223092  13.106166\n742  -8.384130  -4.041770   7.386567\n743   0.000000  -8.384130 -18.329258\n\n[744 rows x 3 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>prog</th>\n      <th>t5</th>\n      <th>gpt</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>-9.945127</td>\n      <td>-4.722036</td>\n      <td>15.770697</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>-9.064396</td>\n      <td>7.837884</td>\n      <td>66.621770</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>-6.890973</td>\n      <td>11.206096</td>\n      <td>14.016386</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>-11.428337</td>\n      <td>-15.770697</td>\n      <td>-7.386567</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>-5.223092</td>\n      <td>0.000000</td>\n      <td>20.492733</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>739</th>\n      <td>-5.077668</td>\n      <td>-28.981101</td>\n      <td>9.444072</td>\n    </tr>\n    <tr>\n      <th>740</th>\n      <td>-5.223092</td>\n      <td>0.000000</td>\n      <td>4.722036</td>\n    </tr>\n    <tr>\n      <th>741</th>\n      <td>0.000000</td>\n      <td>-5.223092</td>\n      <td>13.106166</td>\n    </tr>\n    <tr>\n      <th>742</th>\n      <td>-8.384130</td>\n      <td>-4.041770</td>\n      <td>7.386567</td>\n    </tr>\n    <tr>\n      <th>743</th>\n      <td>0.000000</td>\n      <td>-8.384130</td>\n      <td>-18.329258</td>\n    </tr>\n  </tbody>\n</table>\n<p>744 rows  3 columns</p>\n</div>"
     },
     "execution_count": 198,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_smog_grade = pd.DataFrame(smog_grade_list, columns=[\"prog\", \"t5\", \"gpt\"])\n",
    "df_smog_grade"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 199,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average delta prog:  -6.521380725625623\n",
      "Average delta t5:  -2.8997578857227224\n",
      "Average delta gpt -12.10094738834315\n"
     ]
    }
   ],
   "source": [
    "print(\"Average delta prog: \", df_smog_grade['prog'].mean())\n",
    "print(\"Average delta t5: \", df_smog_grade['t5'].mean())\n",
    "print(\"Average delta gpt\", df_smog_grade['gpt'].mean())"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 200,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "               T  dof alternative         p-val           CI95%   cohen-d  \\\n",
      "T-test -7.563531  743   two-sided  1.160328e-13  [-4.56, -2.68]  0.371961   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  3.447e+10    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_smog_grade_pvt = pt.ttest(df_smog_grade['prog'], df_smog_grade['t5'],paired=True)\n",
    "print(ttest_smog_grade_pvt)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 201,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "               T  dof alternative         p-val         CI95%   cohen-d  \\\n",
      "T-test  5.147532  743   two-sided  3.382327e-07  [3.45, 7.71]  0.263403   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  1.767e+04    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_smog_grade_pvg = pt.ttest(df_smog_grade['prog'], df_smog_grade['gpt'],paired=True)\n",
    "print(ttest_smog_grade_pvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 202,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "               T  dof alternative         p-val          CI95%   cohen-d  \\\n",
      "T-test  8.364311  743   two-sided  2.980072e-16  [7.04, 11.36]  0.407719   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  1.201e+13    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_smog_grade_tvg = pt.ttest(df_smog_grade['t5'], df_smog_grade['gpt'],paired=True)\n",
    "print(ttest_smog_grade_tvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 203,
   "outputs": [
    {
     "data": {
      "text/plain": "'\\nGet smog grade heads up\\n'"
     },
     "execution_count": 203,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\"\"\"\n",
    "Get smog grade heads up\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 204,
   "outputs": [
    {
     "data": {
      "text/plain": "          prog        t5        gpt\n0   -11.797129 -3.636364   1.804040\n1    -5.870588  2.876780  15.729412\n2    -4.729825  0.616667   0.444444\n3    -7.533333 -1.600000  -7.600000\n4    -4.838095  1.315152   3.515152\n..         ...       ...        ...\n739  -2.620471 -7.248163   0.094694\n740  -3.333333  0.000000   6.933333\n741   0.000000 -3.636364   2.818182\n742  -6.777778 -1.507190   4.444444\n743   0.000000  1.561905  -0.380952\n\n[744 rows x 3 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>prog</th>\n      <th>t5</th>\n      <th>gpt</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>-11.797129</td>\n      <td>-3.636364</td>\n      <td>1.804040</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>-5.870588</td>\n      <td>2.876780</td>\n      <td>15.729412</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>-4.729825</td>\n      <td>0.616667</td>\n      <td>0.444444</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>-7.533333</td>\n      <td>-1.600000</td>\n      <td>-7.600000</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>-4.838095</td>\n      <td>1.315152</td>\n      <td>3.515152</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>739</th>\n      <td>-2.620471</td>\n      <td>-7.248163</td>\n      <td>0.094694</td>\n    </tr>\n    <tr>\n      <th>740</th>\n      <td>-3.333333</td>\n      <td>0.000000</td>\n      <td>6.933333</td>\n    </tr>\n    <tr>\n      <th>741</th>\n      <td>0.000000</td>\n      <td>-3.636364</td>\n      <td>2.818182</td>\n    </tr>\n    <tr>\n      <th>742</th>\n      <td>-6.777778</td>\n      <td>-1.507190</td>\n      <td>4.444444</td>\n    </tr>\n    <tr>\n      <th>743</th>\n      <td>0.000000</td>\n      <td>1.561905</td>\n      <td>-0.380952</td>\n    </tr>\n  </tbody>\n</table>\n<p>744 rows  3 columns</p>\n</div>"
     },
     "execution_count": 204,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_gf_grade = pd.DataFrame(gf_grade_list, columns=[\"prog\", \"t5\", \"gpt\"])\n",
    "df_gf_grade"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 205,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average delta prog:  -4.305759301224711\n",
      "Average delta t5:  -0.6712921426166036\n",
      "Average delta gpt -3.2549801325807066\n"
     ]
    }
   ],
   "source": [
    "print(\"Average delta prog: \", df_gf_grade['prog'].mean())\n",
    "print(\"Average delta t5: \", df_gf_grade['t5'].mean())\n",
    "print(\"Average delta gpt\", df_gf_grade['gpt'].mean())"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 206,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                T  dof alternative         p-val          CI95%   cohen-d  \\\n",
      "T-test -19.775107  743   two-sided  2.966091e-70  [-4.0, -3.27]  0.946718   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  4.181e+66    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_gf_grade_pvt = pt.ttest(df_gf_grade['prog'], df_gf_grade['t5'],paired=True)\n",
    "print(ttest_gf_grade_pvt)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 207,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "               T  dof alternative     p-val           CI95%   cohen-d   BF10  \\\n",
      "T-test -3.202757  743   two-sided  0.001419  [-1.69, -0.41]  0.156068  6.593   \n",
      "\n",
      "           power  \n",
      "T-test  0.989032  \n"
     ]
    }
   ],
   "source": [
    "ttest_gf_grade_pvg = pt.ttest(df_gf_grade['prog'], df_gf_grade['gpt'],paired=True)\n",
    "print(ttest_gf_grade_pvg)"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 208,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "               T  dof alternative         p-val         CI95%   cohen-d  \\\n",
      "T-test  7.728436  743   two-sided  3.536341e-14  [1.93, 3.24]  0.374596   \n",
      "\n",
      "             BF10  power  \n",
      "T-test  1.105e+11    1.0  \n"
     ]
    }
   ],
   "source": [
    "ttest_gf_grade_tvg = pt.ttest(df_gf_grade['t5'], df_gf_grade['gpt'],paired=True)\n",
    "print(ttest_gf_grade_tvg)\n",
    "\n",
    "\n",
    "\n"
   ],
   "metadata": {
    "collapsed": false,
    "pycharm": {
     "name": "#%%\n"
    }
   }
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}